<SEC-DOCUMENT>0001193125-23-239121.txt : 20230921
<SEC-HEADER>0001193125-23-239121.hdr.sgml : 20230921
<ACCEPTANCE-DATETIME>20230921080053
ACCESSION NUMBER:		0001193125-23-239121
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230921
DATE AS OF CHANGE:		20230921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Benitec Biopharma Inc.
		CENTRAL INDEX KEY:			0001808898
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39267
		FILM NUMBER:		231267770

	BUSINESS ADDRESS:	
		STREET 1:		3940 TRUST WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 780-0819

	MAIL ADDRESS:	
		STREET 1:		3940 TRUST WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d549728d10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:bntc="http://www.benitecbiopharmainc.com/20230630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-K</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P07_01_2022To06_30_2023">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="hidden88517285" contextRef="P07_01_2022To06_30_2023">84-4620206</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P07_01_2022To06_30_2023">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P07_01_2022To06_30_2023">0001808898</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bntc-20230630.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn06_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_16_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_15_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2022To03_31_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-02</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bntc:PeriodAxis" >bntc:NOLpreJanuaryOneTwoThousandEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bntc:PeriodAxis" >bntc:NolFromTwoThousandEighteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:Series2WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >bntc:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_BenitecIpHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecIpHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:BenitecLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_LicenseMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:LicenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bntc:PeriodAxis" >bntc:NolFromTwoThousandEighteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyOneMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >bntc:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bntc:PeriodAxis" >bntc:NOLpreJanuaryOneTwoThousandEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyFourMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >bntc:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bntc:PeriodAxis" >bntc:NOLpreJanuaryOneTwoThousandEighteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2022MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:TaxYear2022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2016MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:TaxYear2016Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2019MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:TaxYear2019Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2014MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:TaxYear2014Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2011MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:TaxYear2011Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2022MemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >us-gaap:TaxYear2022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:SeriesTwoWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis" >bntc:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis_SuspensionOfAnnualDeductionLimitationMemberBNTCEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis" >bntc:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bntc:EventAxis" >bntc:SuspensionOfAnnualDeductionLimitationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_CaliforniaAssemblyBillEightyFiveMemberBNTCUnexpectedEventAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis" >bntc:CaliforniaAssemblyBillEightyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bntc:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PurchaseWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-22</xbrli:startDate> <xbrli:endDate>2020-04-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-15</xbrli:startDate> <xbrli:endDate>2022-09-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-15</xbrli:startDate> <xbrli:endDate>2022-09-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:Series2WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_17_2022To10_17_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-17</xbrli:startDate> <xbrli:endDate>2022-10-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_27_2022To10_27_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-27</xbrli:startDate> <xbrli:endDate>2022-10-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_27_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_26_2023To07_26_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-26</xbrli:startDate> <xbrli:endDate>2023-07-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_11_2023To08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-11</xbrli:startDate> <xbrli:endDate>2023-08-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-11</xbrli:startDate> <xbrli:endDate>2023-08-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-11</xbrli:startDate> <xbrli:endDate>2023-08-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_11_2023To08_11_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-11</xbrli:startDate> <xbrli:endDate>2023-08-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:Series2WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:PreFundedWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2023_CommonWarrantsMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >bntc:CommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_15_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_15_2023_CommonWarrantsMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >bntc:CommonWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_09_2022To02_09_2022_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMemberBNTCEventAxis_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023MemberusgaapTaxPeriodAxis_CaliforniaFranchiseTaxBoardMemberusgaapIncomeTaxAuthorityNameAxis_SB113MemberBNTCLegislationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >bntc:BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bntc:EventAxis" >bntc:ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bntc:LegislationAxis" >bntc:SB113Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis" >us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-09</xbrli:startDate> <xbrli:endDate>2022-02-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_01_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_31_2023_RevisionInTheExercisePriceOfPrefundedWarrantsMemberBNTCEventAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >bntc:Series2WarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="bntc:EventAxis" >bntc:RevisionInTheExercisePriceOfPrefundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_08_2021_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bntc:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_09_2020To12_09_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >bntc:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-09</xbrli:startDate> <xbrli:endDate>2020-12-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_13_2023_Dr.JerelBanksMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ExecutiveChairmanAndChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >bntc:Dr.JerelBanksMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >bntc:ExecutiveChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_13_2023_ExecutiveDirectorMembersrtTitleOfIndividualAxis_MeganBostonMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >bntc:ExecutiveDirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >bntc:MeganBostonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_01_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-10-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_USD_per_unit" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>bntc:per_unit</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_AUD_per_unit" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:AUD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>bntc:per_unit</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 17pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 17pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 17pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM&#160;<ix:nonNumeric name="dei:DocumentType" contextRef="P07_01_2022To06_30_2023">10-K</ix:nonNumeric> </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">(Mark One) </div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P07_01_2022To06_30_2023" format="ixt:fixed-true">&#9746;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Annual Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 </div></div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P07_01_2022To06_30_2023" format="ixt:date-monthname-day-year-en"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P07_01_2022To06_30_2023" format="ixt:date-monthname-day-en">June 30</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P07_01_2022To06_30_2023">2023</ix:nonNumeric></ix:nonNumeric> </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P07_01_2022To06_30_2023" format="ixt:fixed-false">&#9744;</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 11pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Transition Report under Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 </div></div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="P07_01_2022To06_30_2023">001-39267</ix:nonNumeric> </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 23pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P07_01_2022To06_30_2023">Benitec Biopharma Inc.</ix:nonNumeric> </div></div><div style="margin-top: 2pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of registrant as specified in its charter) </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><span style="-sec-ix-hidden:hidden88517285">84-462-0206</span></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(I.R.S. Em<div style="display:inline;">ployer</div></div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Identification No.)</div></div></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td colspan="2" style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P07_01_2022To06_30_2023">3940 Trust Way</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P07_01_2022To06_30_2023">Hayward</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P07_01_2022To06_30_2023" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P07_01_2022To06_30_2023">94545</ix:nonNumeric></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip Code)</div></div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Registrant&#8217;s telephone number, including area code </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P07_01_2022To06_30_2023">510</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P07_01_2022To06_30_2023">780-0819</ix:nonNumeric> </div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Title of each class</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Trading Symbol(s)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Name of each exchange on which registered</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P07_01_2022To06_30_2023">Common Stock, par value $0.0001</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P07_01_2022To06_30_2023">BNTC</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P07_01_2022To06_30_2023" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div></div></td></tr></table><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Act: </div></div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">None </div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P07_01_2022To06_30_2023">No</ix:nonNumeric>&#160;&#160; &#9746; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P07_01_2022To06_30_2023">No</ix:nonNumeric>&#160;&#160; &#9746; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P07_01_2022To06_30_2023">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P07_01_2022To06_30_2023">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160; &#9744; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:18%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:22%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom">Large&#160;Accelerated&#160;Filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Accelerated Filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P07_01_2022To06_30_2023" format="ixt-sec:entityfilercategoryen">Non-Accelerated Filer</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Smaller&#160;Reporting&#160;Company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P07_01_2022To06_30_2023" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td>
<td colspan="2" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Emerging Growth Company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P07_01_2022To06_30_2023" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td></tr></table><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P07_01_2022To06_30_2023" format="ixt:fixed-false">&#9744;</ix:nonNumeric> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#160;<ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="P07_01_2022To06_30_2023" format="ixt:fixed-false">&#9744;</ix:nonNumeric> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#160;&#9744; </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P07_01_2022To06_30_2023" format="ixt:fixed-false">&#9746;</ix:nonNumeric> </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">The aggregate market value of the Registrant&#8217;s common equity held by non-affiliates, based upon the closing price of the Registrant&#8217;s securities on the Nasdaq Capital Market of $2.89 on December 31, 2022 was approximately $<ix:nonFraction name="dei:EntityPublicFloat" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,756,798</ix:nonFraction>. </div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">There were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn08_16_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,547,434</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.0001 par value per share, outstanding on August 16, 2023. </div><div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">DOCUMENTS INCORPORATED BY REFERENCE </div></div><div style="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">None </div><div style="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">BENITEC BIOPHARMA INC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ANNUAL REPORT ON FORM 10-K </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:9%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:84%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">PART I</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_1">Business</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;1A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_2">Risk Factors</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1B.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_3">Unresolved Staff Comments</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_4">Properties</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_5">Legal Proceedings</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_6">Mine Safety Disclosures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">PART II</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 5.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_7">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 6.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_8">RESERVED</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_9">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;7A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_10">Quantitative and Qualitative Disclosures about Market Risk</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 8.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_11">Financial Statements and Supplementary Data</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">F-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_12">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;9A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_13">Controls and Procedures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9B.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_14">Other Information</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&#160;9C.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_15">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">PART III</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 10.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_16">Directors, Executive Officers and Corporate Governance</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">III-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 11.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_17">Executive Compensation</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">III-5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 12.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_18">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">III-12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 13.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_19">Certain Relationships and Related Transactions, and Director Independence</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">III-13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 14.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_20">Principal Accountant Fees and Services</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">III-14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="font-weight:bold">PART IV</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 15.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_21">Exhibits and Financial Statement Schedules</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">IV-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 16.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_22">Form 10-K Summary</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">IV-3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><a href="#toc549728_23">Signatures</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">IV-4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART I </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ABOUT THIS ANNUAL REPORT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, the terms &#8220;Benitec,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms used in this Annual Report on Form 10-K refer (i), prior to the Re-domiciliation (as defined herein) to Benitec Biopharma Limited (BBL), an Australian corporation, and its subsidiaries, and (ii), following the Re-domiciliation, to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including Benitec Limited). Any references to &#8220;Benitec Limited&#8221; or &#8220;BBL&#8221; refer to Benitec Biopharma Limited, an Australian corporation. On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references to &#8220;$&#8221; in this Annual Report refer to U.S. dollars. All references to &#8220;A$&#8221; in this Annual Report mean Australian dollars. As of June&#160;30, 2023, the rate of exchange of U.S. dollars to Australian dollars was 1.5063 AUD. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our fiscal year-end is June&#160;30. References to a particular &#8220;fiscal year&#8221; are to our fiscal year ended June&#160;30 of that calendar year. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise stated, all share and earnings per share amounts presented in this Annual Report reflect the impact of the 1-for-17 reverse stock split of the Company&#8217;s common stock effective July 26, 2023. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INDUSTRY AND MARKET DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Annual Report includes information with respect to market and industry conditions and market share from third-party sources or based upon estimates using such sources when available. We believe that such information and estimates are reasonable and reliable. We also believe the information extracted from publications of third- party sources has been accurately reproduced. However, we have not independently verified any of the data from third-party sources. Similarly, our internal research is based upon our understanding of industry conditions, and such information has not been verified by any independent sources. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TRADEMARKS AND TRADENAMES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have proprietary and licensed rights to trademarks used in this Annual Report which are important to our business, many of which are registered under applicable intellectual property laws. Our trademarks include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BENITEC BIOPHARMA<sup style="font-size:75%; vertical-align:top">&#174;</sup> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">BENITEC<sup style="font-size:75%; vertical-align:top">&#174;</sup> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">GIVING DISEASE THE SILENT TREATMENT<sup style="font-size:75%; vertical-align:top">&#174;</sup> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">SILENCING GENES FOR LIFE<sup style="font-size:75%; vertical-align:top">&#174;</sup> </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solely for convenience, trademarks and trade names referred to in this Annual Report appear without the &#8220;<sup style="font-size:75%; vertical-align:top">&#174;</sup>&#8221; or &#8220;&#8482;&#8221; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent possible under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Each trademark, trade name or service mark of any other company appearing in this Annual Report is the property of its respective holder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Annual Report contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. All statements, other than statements of historical fact included in this Annual Report, regarding our strategy, future operations, financial position, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this Annual Report, the words &#8220;could,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;continue,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; or the negative of these terms, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and factors include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of our plans to develop and potentially commercialize our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of the initiation and completion of preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and sufficiency of patient enrollment and dosing in any future clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of the availability of data from clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and outcome of regulatory filings and approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unanticipated delays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales, marketing, manufacturing and distribution requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market competition and the acceptance of our products in the marketplace; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory developments in the United States, France and Canada; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the development of novel AAV vectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the plans of licensees of our technology; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a &#8220;one shot&#8221; cure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our dependence on our relationships with collaborators and other third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors, including our capital structure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to continue as a going concern; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our intellectual property position and the duration of our patent portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of local, regional, and national and international economic conditions and events; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of the COVID-19 pandemic, the disease caused by the SARS-CoV-2 virus, which may adversely impact our business and preclinical and future clinical trials; </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as well as other risks detailed under the caption &#8220;Risk Factors&#8221; in this Annual Report and in other reports filed with the SEC. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and important factors currently known by us and our expectations of the future, about which we cannot be certain. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based the forward-looking statements included in this Annual Report on information available to us on the date of this Annual Report or on the date thereof. Except as required by law we undertake no obligation to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All forward-looking statements included herein or in documents incorporated herein by reference are expressly qualified in their entirety by the cautionary statements contained or referred to elsewhere in this Annual Report. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left" id="toc549728_1"><span style="font-weight:bold">Item&#160;1.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Business. <span style="text-decoration:underline"> </span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Company Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (&#8220;Benitec&#8221; or the &#8220;Company&#8221; or in the third person, &#8220;we&#8221; or &#8220;our&#8221;) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called <span style="white-space:nowrap">DNA-directed</span> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The unique therapeutic constructs also enable the simultaneous delivery of wildtype replacement genes, facilitating the proprietary &#8220;silence and replace&#8221; approach to the treatment of genetically defined diseases. The Company is developing a silence and replace-based therapeutic <span style="white-space:nowrap">(BB-301)</span> for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> is a silence and replace-based genetic medicine currently under development by Benitec. <span style="white-space:nowrap">BB-301</span> is an <span style="white-space:nowrap">AAV-based</span> gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells). This fundamental therapeutic approach to disease management is called &#8220;silence and replace.&#8221; The silence and replace mechanism offers the potential to restore the normative physiology of diseased cells and tissues and to improve treatment outcomes for patients suffering from the chronic, and potentially fatal, effects of OPMD. <span style="white-space:nowrap">BB-301</span> has been granted Orphan Drug Designation in the United States and the European Union. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The targeted gene silencing effects of RNAi, in conjunction with the durable transgene expression achievable via the use of modified viral vectors, imbues the silence and replace approach with the potential to produce permanent silencing of disease-causing genes along with simultaneous replacement of the wild type gene function following a single administration of the proprietary genetic medicine. We believe that this novel mechanistic profile of the current and future investigational agents developed by Benitec could facilitate the achievement of robust and durable clinical activity while greatly reducing the frequency of drug administration traditionally expected for medicines employed for the management of chronic diseases. Additionally, the achievement of permanent gene silencing and gene replacement may significantly reduce the risk of patient <span style="white-space:nowrap">non-compliance</span> during the course of medical management of potentially fatal clinical disorders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will require additional financing to progress our product candidates through to key inflection points. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proprietary technology platforms are designated as <span style="white-space:nowrap">DNA-directed</span> RNA interference, or &#8220;ddRNAi&#8221;, and &#8220;silence and replace.&#8221; ddRNAi is designed to produce permanent silencing of disease-causing genes, by combining RNA interference, or RNAi, with viral delivery agents typically associated with the field of gene therapy (i.e., viral vectors). Modified AAV vectors are employed to deliver genetic constructs which encode short hairpin RNAs that are, then, serially expressed and processed to produce siRNA molecules within the transduced cell for the duration of the life of the target cell. These newly introduced siRNA molecules drive </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permanent silencing of the expression of the disease-causing gene. The silence and replace approach further bolsters the biological benefits of permanent silencing of disease-causing genes by incorporating multifunctional genetic constructs within the modified AAV vectors to create an <span style="white-space:nowrap">AAV-based</span> gene therapy agent that is designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, &#8220;wildtype&#8221; genes (to drive restoration of function in diseased cells). This fundamentally distinct therapeutic approach to disease management offers the potential to restore the underlying physiology of the treated tissues and, in the process, improve treatment outcomes for patients suffering from the chronic and, potentially, fatal effects of diseases like Oculopharyngeal Muscular Dystrophy (OPMD). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Traditional gene therapy is defined by the introduction of an engineered transgene to correct the pathophysiological derangements derived from mutated or malfunctioning genes. Mutated genes can facilitate the intracellular production of disease-causing proteins or hamper the production of critical, life-sustaining, proteins. The introduction of a new transgene can facilitate the restoration of production of normal proteins within the diseased cell, thus, restoring natural biological function. Critically, the implementation of this traditional method of gene therapy cannot eliminate the expression, or the potential deleterious effects of, the underlying mutant gene (as mutant proteins may be continually expressed and aggregate or drive the aggregation of other native proteins within the diseased cell). In this regard, the dual capabilities of the proprietary silence and replace approach to silence a disease-causing gene via ddRNAi and simultaneously replace the wild type activity of a mutant gene via the delivery of an engineered transgene could facilitate the development of differentially efficacious treatments for a range of genetic disorders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Overview of RNAi and the siRNA Approach </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mutation of a single gene can cause a chronic disease via the resulting intracellular production of a disease-causing protein (i.e., an abnormal form of the protein of interest), and many chronic and/or fatal disorders are known to result from the inappropriate expression of a single gene or multiple genes. In some cases, genetic disorders of this type can be treated exclusively by &#8220;silencing&#8221; the intracellular production of the disease-causing protein through well-validated biological approaches like RNA interference (&#8220;RNAi&#8221;). RNAi employs small nucleic acid molecules to activate an intracellular enzyme complex, and this biological pathway temporarily reduces the production of the disease-causing protein. In the absence of the disease-causing protein, normal cellular function is restored and the chronic disease that initially resulted from the presence of the mutant protein is partially or completely resolved. RNAi is potentially applicable to over 20,000 human genes and a large number of disease-causing <span style="white-space:nowrap">microorganism-specific</span> genes. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 1 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g07a03.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A small double stranded RNA, or dsRNA, molecule (A, Figure 1), comprising one strand known as the sense strand and another strand known as the antisense strand, which are complementary to each other, is synthesized in the laboratory. These small dsRNAs are called small interfering RNAs, or siRNAs. The sequence of the sense strand corresponds to a short region of the target gene mRNA. The siRNA is delivered to the target cell (B, Figure 1), where a group of enzymes, referred to as the <span style="white-space:nowrap">RNA-Induced</span> Silencing Complex, or RISC, process the siRNA (C, Figure 1), where one of the strands (usually the sense strand) is released (D, Figure 1). RISC uses the antisense strand to find the mRNA that has a complementary sequence (E, Figure 1) leading to the cleavage of the target mRNA (F, Figure 1). As a consequence, the output of the mRNA (protein production) does not occur (G, Figure 1). Several companies, including Alnylam Pharmaceuticals Inc. (&#8220;Alnylam&#8221;), utilize this approach in their RNAi product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Importantly, many genetic disorders are not amenable to the traditional gene silencing approach outlined in Figure 1, as the diseased cells may produce a mixture of the wild type protein of interest and the disease-causing mutant variant of the protein, and the underlying genetic mutation may be too small to allow for selective targeting of the disease-causing variant of the protein through the use of siRNA-based approaches exclusively. In these cases, it is extraordinarily difficult to selectively silence the disease-causing protein without simultaneously silencing the wild type intracellular protein of interest whose presence is vital to the conduct of normal cellular functions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proprietary silence and replace technology utilizes the unique specificity and robust gene silencing capabilities of RNAi while overcoming many of the key limitations of siRNA-based approaches to disease management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the standard RNAi approach, double-stranded siRNA is produced synthetically and, subsequently, introduced into the target cell via chemical modification of the RNA or alternative methods of delivery. While efficacy has been demonstrated in several clinical indications through the use of this approach, siRNA-based approaches maintain a number of limitations, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Clinical management requires repeat administration of the siRNA-based therapeutic agent for multiple cycles to maintain efficacy; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Long-term patient compliance challenges due to dosing frequencies and treatment durations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Therapeutic concentrations of siRNA are not stably maintained because the levels of synthetic siRNA in the target cells decrease over time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Novel chemical modifications or novel delivery materials are typically required to introduce the siRNA into the target cells, making it complicated to develop a broad range of therapeutics agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Potential adverse immune responses, resulting in serious adverse effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Requirement for specialized delivery formulations for genetic disorders caused by mutations of multiple genes; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">siRNA acts only to silence genes and cannot be used to replace defective genes with normally functioning genes. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Approach to the Treatment of Genetic Diseases&#8212;ddRNAi and Silence and Replace </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proprietary silence and replace approach to the treatment of genetic diseases combines RNAi with wild type gene replacement to drive permanent silencing of disease-causing genes and concomitant restoration of functional wild type genes following a single administration of the therapeutic agent. Benitec employs ddRNAi in combination with classical gene therapy (i.e., transgene delivery via viral vectors) to overcome several of the fundamental limitations of RNAi. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The silence and replace approach to the treatment of genetic disorders employs adeno-associated viral vectors (&#8220;AAVs&#8221;) to deliver genetic constructs which may, after a single administration to the target tissues: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Chronically express RNAi molecules inside of the target, diseased, cells (to serially silence the intracellular production of mutant, disease- causing, protein and the wild type protein of interest); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Simultaneously drive the expression of a wild type variant of the protein of interest (to restore native intracellular biological processes); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">AAV vectors can accommodate the multi-functional DNA expression cassettes containing the engineered wild type transgenes and the novel genes encoding short hairpinRNA/microRNA molecules (shRNA/miRNA) that are required to support the development of therapeutic agents capable of the achievement of the goals of the silence and replace approach to therapy. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our silence and replace technology utilizes proprietary DNA expression cassettes to foster continuous production of gene silencing shRNAs and wild type proteins (via expression of the wild type transgene). A range of viral and <span style="white-space:nowrap">non-viral</span> gene therapy vectors can be used to deliver the DNA construct into the nucleus of the target cell and, upon delivery, shRNA molecules are expressed and subsequently processed by intracellular enzymes into siRNA molecules that silence the expression of the mutant, disease-causing protein (Figure 2). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the silence and replace approach (Figure 2): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A DNA construct is delivered to the nucleus of the target cell by a gene therapy vector (A)&#160;such as an AAV vector; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Once inside of the nucleus, the DNA construct drives the continuous production of shRNA molecules (B)&#160;which are processed by an enzyme called Dicer into siRNAs (C); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The processed siRNA is incorporated into RISC and silences the target gene using the same mechanism shown in Figure 1; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">When the DNA expression cassette is additionally comprised of a wild type transgene, upon entry of the DNA construct into the nucleus of the target cell via the use of the AAV vector, the DNA construct also drives the continuous production of wild type protein (to restore native intracellular biological processes). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 2 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g09b03.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy is to discover, develop and commercialize treatments that leverage the capabilities of ddRNAi and the silence and replace approach to disease management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For selected product candidates, at the appropriate stage, we may collaborate with large biopharmaceutical companies to further <span style="white-space:nowrap">co-develop</span> and, if approved, commercialize our ddRNAi-based and silence and replace-based products to achieve broad clinical and commercial distribution. For specific clinical indications that we deem to be outside of our immediate areas of focus, we will continue to <span style="white-space:nowrap">out-license,</span> where appropriate, applications of our ddRNAi and silence and replace technology to facilitate the development of differentiated therapeutics, which could provide further validation of our proprietary technology and approach to disease management. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cash and cash equivalents will be deployed for the advancement of our product candidate <span style="white-space:nowrap">BB-301</span> for the treatment of OPMD-derived dysphagia, including the natural history <span style="white-space:nowrap">lead-in</span> study and the Phase 1b/2a <span style="white-space:nowrap">BB-301</span> treatment study, for the continued advancement of development activities for other existing and new product candidates, for general corporate purposes and for strategic growth opportunities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Oculopharyngeal Muscular Dystrophy&#8212;OPMD </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OPMD is an insidious, autosomal-dominant, late-onset degenerative muscle disorder that typically presents in patients at <span style="white-space:nowrap">40-to-50</span> years of age. The disease is characterized by progressive swallowing difficulties (dysphagia) and eyelid drooping (ptosis). OPMD is caused by a specific mutation in the poly(A)-binding protein nuclear 1, or PABPN1, gene. OPMD is a rare disease; however, patients have been diagnosed with OPMD in at least 33 countries. Patient populations suffering from OPMD are well-identified, and significant geographical clustering has been noted for patients with this disorder, which could simplify clinical development and global commercialization efforts. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> is an <span style="white-space:nowrap">AAV-based</span> gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, &#8220;wildtype&#8221; genes (to drive restoration of function in diseased cells). This fundamental therapeutic approach to disease management is called &#8220;silence and replace&#8221; and this biological mechanism offers the potential to restore the underlying physiology of the treated tissues and, in the process, improve treatment </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outcomes for patients suffering from the chronic and, potentially, fatal effects of Oculopharyngeal Muscular Dystrophy (OPMD). <span style="white-space:nowrap">BB-301</span> has been granted Orphan Drug Designation in the United States and the European Union. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strengths </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the combination of our proprietary ddRNAi and silence and replace technology, and our deep expertise in the design and development of genetic medicines, will enable us to achieve and maintain a leading position in gene silencing and gene therapy for the treatment of human disease. Our key strengths include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A first mover advantage for silence and replace-based therapeutics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A proprietary ddRNAi-based silence and replace technology platform that may potentially enable the serial development of single-administration therapeutics capable of facilitating sustained, long-term silencing of disease-causing genes and concomitant replacement of wild type gene function; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A proprietary AAV vector technology which improves the endosomal escape capability of virus produced in insect cells using a baculovirus system. This technology has broad application in <span style="white-space:nowrap">AAV-based</span> gene therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The capabilities to drive the development of a pipeline of programs focused on chronic diseases with either large patient populations, or rare diseases, which may potentially support the receipt of Orphan Drug Designation, including OPMD; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A growing portfolio of patents protecting improvements to our ddRNAi, and silence and replace, technology and product candidates through at least 2036, with additional patent life anticipated through at least 2040. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We endeavor to become the leader in discovery, development, and commercialization of silence and replace-based therapeutic agents. We apply the following general strategy to drive the Company towards these goals: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Selectively develop proprietary and partnered programs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Continue to explore and secure research and development partnerships with global biopharmaceutical companies supported by the differentiated nature of our scientific platform and intellectual property portfolio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our senior leadership team will continue to explore partnership opportunities with global biopharmaceutical companies, as we expect that the unique attributes of the proprietary ddRNAi and silence and replace approaches, and the breadth of potential clinical indications amenable to our proprietary methods, to support the formation of collaborations over a broad range of diseases with significant unmet medical need. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We seek to actively protect our intellectual property and proprietary technology. These efforts are central to the growth of our business and include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Seeking and maintaining patents claiming our ddRNAi and silence and replace technologies and other inventions relating to our specific products in development or that are otherwise commercially and/or strategically important to the development of our business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Protecting and enforcing our intellectual property rights; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Strategically licensing intellectual property from third parties to advance development of our product candidates. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Pipeline </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our current product candidate and the development status: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Table 1. Pipeline: Oculopharyngeal Muscular Dystrophy </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g11c03.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">BB-301</span> for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). The Investigational New Drug (IND) application for <span style="white-space:nowrap">BB-301</span> was approved to proceed by the U.S. Food and Drug Administration in June 2023. <span style="white-space:nowrap">BB-301</span> is the lead investigational agent under development by Benitec, and the key attributes of <span style="white-space:nowrap">BB-301</span> are outlined in Figure 3. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 3 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g12d03.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> is a <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-class</span></span> genetic medicine employing the &#8220;silence and replace&#8221; approach for the treatment of OPMD. OPMD is an insidious, autosomal-dominant, late-onset, degenerative muscle disorder that typically </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
presents in patients at <span style="white-space:nowrap"><span style="white-space:nowrap">40-to-50</span></span> years of age. The disease is characterized by progressive swallowing difficulties (dysphagia) and eyelid drooping (ptosis). OPMD is caused by a specific mutation in the poly(A)-binding protein nuclear 1 gene (PABPN1). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OPMD is a rare disease, however, patients have been diagnosed with OPMD in at least 33 countries. Patient populations suffering from OPMD are well-identified, and significant geographical clustering has been noted for patients with this disorder. Each of these attributes could facilitate efficient clinical development and global commercialization of <span style="white-space:nowrap">BB-301.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PABPN1 is a ubiquitous factor that promotes the interaction between the poly(A) polymerase and CPSF (cleavage and polyadenylation specificity factor) and, thus, controls the length of mRNA poly(A) tails, mRNA export from the nucleus, and alternative poly(A) site usage. The characteristic genetic mutation underlying OPMD results in trinucleotide repeat expansion(s) within exon 1 of PABPN1 and results in an expanded poly-alanine tract at the <span style="white-space:nowrap">N-terminal</span> end of PABPN1. The mutation generates a protein with an <span style="white-space:nowrap">N-terminal</span> expanded poly-alanine tract of up to 18 contiguous alanine residues, and the mutant protein is prone to the formation of intranuclear aggregates designated as intranuclear inclusions (INIs). The INIs that sequester wildtype PABPN1 may contribute to the &#8220;loss of function&#8221; phenotype associated with OPMD. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No therapeutic agents are approved for the treatment of OPMD. Additionally, there are no surgical interventions available to OPMD patients that modify the natural history of the disease, which is principally comprised of chronic deterioration of swallowing function. <span style="white-space:nowrap">BB-301</span> has received Orphan Drug Designation in the United States and the European Union and, upon achievement of regulatory approval for <span style="white-space:nowrap">BB-301</span> in these respective jurisdictions, the Orphan Drug Designations would provide commercial exclusivity independent of intellectual property protection. While OPMD is a rare medical disorder, we believe the commercial opportunity for a safe and efficacious therapeutic agent in this clinical indication exceeds $1&#160;billion over the course of the commercial life of the product. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investigational therapies that have been explored, unsuccessfully, in the past include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Intravenous administration of trehalose; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The use of autologous myoblast transplant. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">BB-301</span> is our Lead, Silence and Replace-Based, OPMD Therapeutic Agent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> is composed of a modified AAV serotype 9 (AAV9) capsid that expresses a bifunctional construct under the control of a single muscle specific <span style="white-space:nowrap">Spc5-12</span> promoter to achieve <span style="white-space:nowrap">co-expression</span> of both the codon-optimized PABPN1 mRNA and two shmiR molecules directed against wild type and mutant PABPN1. <span style="white-space:nowrap">BB-301</span> is designed to correct the genetic defect underlying OPMD following a single localized administration. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">BB-301&#8212;Design</span> and Mechanism of Action </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> is designed to target two distinct regions of the PABPN1 mRNA to accomplish gene silencing via the concomitant expression of two distinct shmiRs from a single DNA construct (Figure 4). <span style="white-space:nowrap">BB-301</span> is also engineered to drive the simultaneous expression of a codon-optimized, siRNA-resistant, version of the wild type PABPN1 gene (Figure 4). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 4 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g13e03.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In collaboration with researchers at the Royal Holloway University of London and the Institut de Myologie in Paris, we developed a ddRNAi construct expressing three shRNAs against three distinct regions of PABPN1 mRNA and observed effective silencing of the PABPN1 gene in vitro using this ddRNAi construct. Furthermore, as part of this collaboration, we have generated a gene expression construct that produces a <span style="white-space:nowrap">siRNA-resistant</span> version of the wild type PABPN1 gene. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In subsequent studies undertaken exclusively by Benitec, a second set of target regions within PABPN1 were identified for therapeutic development and shmiRs designed against these regions. Additional shmiRs have also been designed for the original shRNA developed in collaboration with Royal Holloway University of London and the Institut de Myologie. The &#8216;silence and replace&#8217; construct, designated <span style="white-space:nowrap">BB-301,</span> incorporates the two best performing shmiRs, and the gene expression construct that produces a siRNA-resistant version of the wild type PABPN1 gene, under the control of a muscle-specific promoter. The mechanism of action of <span style="white-space:nowrap">BB-301</span> is shown in Figure 5. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 5 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g14f03.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In initial in vivo studies evaluating the use of direct intramuscular injection of AAV-based constructs with the potential to facilitate the desired silence and replace approach in the A17 transgenic mouse model of OPMD at </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Royal Holloway University of London and the Institut de Myologie, we observed decreases in muscle fibrosis, increases in cross sectional area of the treated muscles, decreases in intranuclear inclusions, and normalization of muscle strength. These nonclinical results were published in Nature Communications in April 2017. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In subsequent studies, Benitec demonstrated in a key nonclinical model (the A17 mouse model) that a single intramuscular injection of <span style="white-space:nowrap">BB-301</span> results in robust intracellular silencing of PABPN1 protein production and concomitant expression of the normal, biologically functional PABPN1 protein. In the A17 mouse model, the treatment restores muscle strength and muscle weight to wild type levels and improves other physiological hallmarks of the disease (Figure 6a, Figure 6b, Figure 6c, Figure 6d): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Multiple A17 animal cohorts received single doses of <span style="white-space:nowrap">BB-301</span> (over a range of doses spanning 4x10<sup style="font-size:75%; vertical-align:top">8</sup> <span style="white-space:nowrap"><span style="white-space:nowrap">vg/muscle-to-7.5x10</span></span><sup style="font-size:75%; vertical-align:top">11</sup> vg/muscle) and, following <span style="white-space:nowrap">BB-301</span> administration, each cohort was observed for <span style="white-space:nowrap">14-weeks</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">BB-301</span> was injected into the Tibialis Anterior (TA) muscle of 10 week <span style="white-space:nowrap"><span style="white-space:nowrap">old-to-12</span></span> week old animals and, <span style="white-space:nowrap">14-weeks</span> post administration, each A17 cohort was anesthetized and the contractile properties of the injected TA muscles were analyzed via <span style="white-space:nowrap">in-situ</span> muscle electrophysiology </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Intermediate doses of <span style="white-space:nowrap">BB-301</span> resulted in 75% silencing of PABPN1 and 26% replacement of wild type PABPN1 activity, leading to full restoration of muscle strength, clearance of INIs, and a reduction of fibrosis </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">An additional experiment conducted over the course of <span style="white-space:nowrap">20-weeks</span> demonstrated that more modest doses of <span style="white-space:nowrap">BB-301</span> (which supported only partial resolution of the disease phenotype at <span style="white-space:nowrap">week-14)</span> were, surprisingly, able to facilitate significant benefit at <span style="white-space:nowrap">20-weeks,</span> as evidenced by restoration of parameters relating to muscle strength, weight and INI formation </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 6a. Dose-Dependent shRNA Expression </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g15g03.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 6b. Dose-Dependent PABPN1 Inhibition and Transgene Expression </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g15h04.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 6c. Dose-Dependent Decreases in Intranuclear Inclusions </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g16p01.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 6d. Dose-Dependent Increases in Muscle Force </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g16p02.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center">Restoration of muscle strength was assessed by muscle contractility measurements in response to a series of induced impulses that ranged from 10 to 180 Hz </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ongoing Development Activities for <span style="white-space:nowrap">BB-301</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 8, 2020, Benitec announced the initiation of the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study in large animal subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study was the first of two planned <span style="white-space:nowrap">CTA-enabling</span> and <span style="white-space:nowrap">IND-enabling</span> studies that were designed to be conducted in large animals. The <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study was carried out under the guidance of the scientific team at Benitec, with key elements of the study design and execution conducted in close collaboration with a team of leading experts in both medicine and surgery that have been deeply engaged in the treatment of OPMD patients for several decades. The <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study, along with the subsequent GLP Toxicology and Biodistribution Study, were conducted in canine subjects and were carried out to support the validation and optimization of the newly designed method of BB-301 administration, confirm the efficiency of vector transduction and transgene expression in the key tissue compartments underlying the natural history of OPMD, confirm the optimal drug doses in advance of initiation of human clinical studies, and facilitate observation of key toxicological data-points. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study was designed as an <span style="white-space:nowrap">8-week</span> study in Beagle dogs to confirm the transduction efficiency of <span style="white-space:nowrap">BB-301</span> upon administration via direct intramuscular injection into specific anatomical regions of the pharynx through the use of an open surgical procedure. This new route of BB-301 administration was developed in collaboration with key surgical experts in the field of Otolaryngology, and this novel method of <span style="white-space:nowrap">BB-301</span> dosing was implemented to significantly enhance the ability of a treating physician to accurately administer the AAV-based investigational agent to the muscles that underlie the characteristic deficits associated with the progression of OPMD. It is important to note that prior nonclinical studies of <span style="white-space:nowrap">BB-301</span> have reproducibly validated the robust biological activity achieved following direct intramuscular injection. As an example, direct injection of <span style="white-space:nowrap">BB-301</span> into the tibialis anterior muscles of A17 mice facilitated robust transduction of the targeted skeletal muscle cells and supported complete remission of the OPMD disease phenotype in this animal model. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec conducted the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study in Beagle dog subjects to demonstrate that direct intramuscular injection of BB-301 via the use of a proprietary dosing device in an open surgical procedure could safely achieve the following goals: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Biologically significant and dose-dependent levels of <span style="white-space:nowrap">BB-301</span> tissue transduction (i.e., delivery of the multi-functional BB-301 genetic construct into the target pharyngeal muscle cells); </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Broad-based and dose-dependent expression of the three distinct genes comprising the <span style="white-space:nowrap">BB-301</span> gene construct within the pharyngeal muscle cells; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Durable and biologically significant levels of target gene knock-down (i.e., inhibition of the expression of the gene of interest) within the pharyngeal muscle cells. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Pilot Dosing Study evaluated the safety and biological activity of two concentrations of <span style="white-space:nowrap">BB-301</span> (1.0+E13 vg/mL and 3.0+E13 vg/mL) across three distinct doses (1.0+E13 vg/mL, 3.0+E13 vg/mL with a low injection volume, and 3.0+E13 vg/mL with a high injection volume) following direct intramuscular injection into the Hypopharyngeal (HP) muscles and the Thyropharyngeal (TP) muscles of Beagle dogs via the use of a proprietary delivery device employed in an open surgical procedure. The HP muscle in Beagle dogs corresponds to the Middle Pharyngeal Constrictor muscle in human subjects, and the TP muscle in Beagle dogs corresponds to the Inferior Pharyngeal Constrictor muscle in human subjects. Atrophy, fibrosis, and the presence of intranuclear inclusions characterize the Middle Pharyngeal Constrictor muscles and the Inferior Pharyngeal Constrictor muscles of human subjects diagnosed with OPMD. <span style="white-space:nowrap">BB-301</span> was injected into the pharyngeal muscles of the Beagle dog subjects only on Day 1 of the Pilot Dosing Study, and the corresponding canine pharyngeal muscles were harvested for analysis after 8 weeks of observation post-dosing. BB-301 dosing was carried out independently by both a veterinary surgeon and a practicing Otolaryngologist who has extensive experience with the provision of palliative surgical care for OPMD patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The key results are summarized here: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 7. Pharyngeal Muscle Tissue Transduction Levels for <span style="white-space:nowrap">BB-301</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g18p03.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regarding Gene Expression Levels Observed for <span style="white-space:nowrap">BB-301</span> Within the Pharyngeal Muscle Tissues (Figure 8, Figure 9, Figure 10): </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">BB-301</span> encodes two distinct siRNA species (i.e., siRNA13 and siRNA17) which are each, independently, capable of inhibiting (i.e., &#8220;silencing&#8221;) the expression of the mutant form of the PABPN1 protein and the wild type (i.e., endogenous) form of the PABPN1 protein (importantly, the mutant form of the PABPN1 protein underlies the development and progression of OPMD). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">BB-301</span> also codes for a wild type version of the PABPN1 protein whose intracellular expression is unaffected by the inhibitory activities of siRNA13 and siRNA17, and this codon optimized PABPN1 </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
protein (i.e., coPABPN1) serves to replenish the endogenous form of the PABPN1 protein and to replace the mutant form of PABPN1 that underlies the development and progression of OPMD in diseased tissues. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For comparative purposes, it should be noted that the average range of expression for wild type PABPN1 within the pharyngeal muscle cells of Beagle dogs is 4.5 copies per <span style="white-space:nowrap"><span style="white-space:nowrap">cell-to-7.8</span></span> copies per cell. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 8. siRNA13 Expression Levels for <span style="white-space:nowrap">BB-301</span> within Pharyngeal Muscle Tissues </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g19p04.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 9. siRNA17 Expression Levels for <span style="white-space:nowrap">BB-301</span> within Pharyngeal Muscle Tissues </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g20p05.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 10. coPABPN1 Expression Levels for <span style="white-space:nowrap">BB-301</span> within Pharyngeal Muscle Tissues </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g21p06.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding Wild Type PABPN1 Silencing (i.e. target &#8220;knock-down&#8221;) Observed for <span style="white-space:nowrap">BB-301</span> Within the Pharyngeal Muscle Tissues (Figure 11): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As noted above, <span style="white-space:nowrap">BB-301</span> encodes two distinct siRNA species (i.e., siRNA13 and siRNA17) which are each, independently, capable of inhibiting (i.e., &#8220;silencing&#8221;) the expression of all forms of the PABPN1 protein (siRNA13 and siRNA17 silence the expression of both wild type PABPN1 [wtPABPN1] and mutant PABPN1). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">While the Beagle dog subjects treated in the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study did not express mutant PABPN1, the level of <span style="white-space:nowrap"><span style="white-space:nowrap">BB-301-driven</span></span> gene silencing for the PABPN1 target can be accurately assessed due to the equivalent inhibitory effects of siRNA13 and siRNA17 on both wtPABPN1 and mutant PABPN1. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Thus, the wtPABPN1 silencing activity observed in the <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study served as a surrogate for the activity that would be anticipated in the presence of mutant PABPN1. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">BB-301</span> has been evaluated in prior nonclinical studies in animals that express mutant PABPN1 and manifest the key signs and symptoms of OPMD and, in these animal models of OPMD, the achievement of PABPN1 silencing levels of 31% inhibition or higher led to resolution of OPMD disease symptoms and correction of the histological hallmarks of OPMD. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 11. PABPN1 Silencing (i.e., &#8220;target knock-down&#8221;) within Pharyngeal Muscle Tissues </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g22p07.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, it is critical to highlight the key methodological distinctions between the recently completed <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study in Beagle dogs conducted by Benitec (i.e., the study described above) and the prior Beagle dog dosing study carried out independently by the previous <span style="white-space:nowrap">BB-301</span> licensee of Benitec. The <span style="white-space:nowrap">BB-301</span> dosing study conducted by the prior <span style="white-space:nowrap">BB-301</span> licensee employed <span style="white-space:nowrap">non-ideal</span> routes and methods of <span style="white-space:nowrap">BB-301</span> administration to the target pharyngeal muscle tissues and employed similarly limited analytical methods at the completion of the dosing phase of the study. The Benitec team worked to optimize the route and method of administration of <span style="white-space:nowrap">BB-301</span> and to refine the core analytical methods employed following the completion of dosing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the implementation of these methodological modifications, Benitec demonstrated a <span style="white-space:nowrap">248-fold</span> improvement (+24,650%) in <span style="white-space:nowrap">BB-301</span> transduction of the HP muscle and a <span style="white-space:nowrap">111-fold</span> improvement (+11,027%) in <span style="white-space:nowrap">BB-301</span> transduction of the TP muscle relative to the levels of <span style="white-space:nowrap">BB-301</span> transduction observed by the previous <span style="white-space:nowrap">BB-301</span> licensee (Figure 12). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 12. Impact of Benitec-Initiated Methodological Improvements on the Relative Pharyngeal Muscle Tissue Transduction Levels Achieved for <span style="white-space:nowrap">BB-301</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g549728g23p08.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the disclosure of the positive interim <span style="white-space:nowrap">BB-301</span> Pilot Dosing Study results, Benitec completed <span style="white-space:nowrap">pre-CTA</span> and <span style="white-space:nowrap">pre-IND</span> meetings with regulatory agencies in France, Canada, and the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Summary of Regulatory Interactions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In June 2023 the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for <span style="white-space:nowrap">BB-301</span> which allows dosing of <span style="white-space:nowrap">BB-301</span> to begin for OPMD subjects that are eligible for enrollment into the Phase 1b/2a treatment study (described below). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operational Updates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key milestones related to the development of <span style="white-space:nowrap">BB-301</span> for the treatment of OPMD, along with other corporate updates, are outlined below: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">BB-301</span> Clinical Development Program Overview: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The <span style="white-space:nowrap">BB-301</span> clinical development program will be conducted in the United States and Canada, and the primary elements of the program are summarized below: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The program will comprise approximately 76 weeks of <span style="white-space:nowrap">follow-up</span> which we anticipate will consist of: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">The OPMD Natural History (NH) Study: </span><span style="white-space:nowrap">6-month</span> <span style="white-space:nowrap">pre-treatment</span> observation periods for the evaluation of baseline disposition and natural history of OPMD-derived dysphagia (swallowing impairment) in each study participant. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Dosing with <span style="white-space:nowrap">BB-301:</span> </span><span style="white-space:nowrap">1-day</span> of <span style="white-space:nowrap">BB-301</span> dosing to initiate participation in the Phase 1b/2a <span style="white-space:nowrap">single-arm,</span> open-label, sequential, dose-escalation cohort study. <span style="white-space:nowrap">BB-301</span> will be delivered directly to the pharyngeal muscles of each study subject. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Phase 1b/2a Treatment Evaluation: </span><span style="white-space:nowrap">52-weeks</span> of post-dosing <span style="white-space:nowrap">follow-up</span> for conclusive evaluation of the primary and secondary endpoints of the <span style="white-space:nowrap">BB-301</span> Phase 1b/2a treatment study, with interim safety and efficacy results expected to be available at the end of each <span style="white-space:nowrap">90-day</span> period following the administration of <span style="white-space:nowrap">BB-301.</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The OPMD NH Study will characterize the level of dysphagia borne by each OPMD subject at baseline and assess subsequent progression of dysphagia via the use of the following quantitative radiographic measures (i.e., videofluoroscopic swallowing studies or &#8220;VFSS&#8221;). The VFSS outlined below collectively provide objective assessments of global swallowing function and the function of the pharyngeal constrictor muscles (i.e., the muscles whose functional deterioration drives disease progression in OPMD): </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Total Pharyngeal Residue <span style="white-space:nowrap">%(C2-4)</span><sup style="font-size:75%; vertical-align:top">2</sup> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Pharyngeal Area at Maximum Constriction (PhAMPC) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Dynamic Imaging Grade of Swallowing Toxicity Scale (DIGEST) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Vallecular Residue <span style="white-space:nowrap">%(C2-4)</span><sup style="font-size:75%; vertical-align:top">2</sup>, Pyriform Sinus Residue <span style="white-space:nowrap">%(C2-4)</span><sup style="font-size:75%; vertical-align:top">2,</sup> and Other Pharyngeal Residue <span style="white-space:nowrap">%(C2-4)</span><sup style="font-size:75%; vertical-align:top">2</sup> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Normalized Residue Ratio Scale (NRRS<sub style="font-size:75%; vertical-align:bottom">v</sub>, NRRS<sub style="font-size:75%; vertical-align:bottom">p</sub>) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Pharyngeal Construction Ratio (PCR) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The NH study will also employ clinical measures of global swallowing capacity and oropharyngeal dysphagia, along with two distinct patient-reported outcome instruments targeting the assessment of oropharyngeal dysphagia. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Upon the achievement of <span style="white-space:nowrap">6-months</span> of <span style="white-space:nowrap">follow-up</span> in the NH Study, participants will, potentially, be eligible for enrollment into the <span style="white-space:nowrap">BB-301</span> Phase 1b/2a treatment study. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">BB-301</span> Phase 1b/2a Treatment Study: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">This <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> (FIH) study will evaluate the safety and clinical activity of intramuscular doses of <span style="white-space:nowrap">BB-301</span> administered to subjects with OPMD. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The primary endpoint of the FIH study will be safety. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Secondary endpoints are designed to determine the impact of <span style="white-space:nowrap">BB-301</span> on swallowing efficiency, swallowing safety, and pharyngeal constrictor muscle function in subjects diagnosed with OPMD with dysphagia via the use of serial clinical and videofluoroscopic assessments. Critically, each of the clinical and videofluoroscopic assessments employed in the FIH study will be equivalent to those employed for the NH study to facilitate comparative clinical and statistical analyses for each study subject. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The primary and secondary endpoints will be evaluated during each <span style="white-space:nowrap">90-day</span> period following <span style="white-space:nowrap">BB-301</span> intramuscular injection (Day 1). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:14%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The NH of dysphagia observed for each OPMD study participant, as characterized by the VFSS and clinical swallowing assessments carried out during the NH Study, will serve as the baseline for comparative assessments of safety and efficacy of <span style="white-space:nowrap">BB-301</span> upon rollover from the NH Study onto the <span style="white-space:nowrap">BB-301</span> Phase 1b/2a Treatment Study. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In December 2022, Benitec began screening OPMD subjects at the lead clinical study site in the United States. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In January 2023, Benitec announced the enrollment of the first OPMD subject into the NH Study in the United States. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As of September 2023, 15 subjects have been enrolled into the NH study in the United States. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The pace of enrollment of OPMD subjects into the NH Study at the U.S. clinical study site supports our central clinical development goals of: (1)&#160;administering <span style="white-space:nowrap">BB-301</span> to OPMD subjects in 2H2023, and (2)&#160;disclosing the initial interim safety and efficacy data over the next 12 months for subjects that have received <span style="white-space:nowrap">BB-301.</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Regulatory Updates for the Clinical Development Program: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">North America: </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Formal submission of the comprehensive NH Study trial package to the Research Ethics Board (REB) for the lead clinical study site in Canada was completed, and Benitec awaits the formal response from the REB. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Approval of the NH Study trial package by the REB is required for clinical study site activation and OPMD patient screening and enrollment to begin in Canada. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec seeks to actively procure rights to and protect the intellectual property and proprietary technology that it believes is important to its business. Such intellectual property rights include patents claiming our ddRNAi and silence and replace technologies, as well as <span style="white-space:nowrap">know-how</span> and trade secrets related to our product candidates and proprietary technology. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ddRNAi-based treatment for OPMD </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec&#8217;s patent portfolio for OPMD includes five patent families relating to shRNA and shmiRs targeting PABPN1 (the causative gene for OPMD), as well as &#8216;silence and replace&#8217; therapeutics and treatment strategies for OPMD. These five families cover the OPMD therapeutic candidate, <span style="white-space:nowrap">BB-301,</span> under development at Benitec, treatment strategies for OPMD that silence PABPN1 which is causative for OPMD and replace with functional PABPN1, and Benitec&#8217;s AAV patent family which covers the delivery system for <span style="white-space:nowrap">BB-301.</span> <span style="white-space:nowrap">BB-301</span> is a &#8216;silence and replace&#8217; construct encoding two shmiRs targeting the endogenous PABPN1 (including variants causative of OPMD) internally designated <span style="white-space:nowrap">shmiR-13</span> and <span style="white-space:nowrap">shmiR-17,</span> as well as a <span style="white-space:nowrap">codon-optimized</span> PABPN1 replacement construct, the transcript of which is not targeted by <span style="white-space:nowrap">shmiR-13</span> and <span style="white-space:nowrap">shmiR-17.</span> Both shmiRs and the codon- optimized PABPN1 replacement construct are under the control of a muscle-specific promoter. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first patent family, entitled &#8220;Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof (OPMD family #1)&#8221;, arose out of a collaboration with Royal Holloway University of London (RHUL) and relates to three shRNA target regions within PABPN1. RHUL assigned its ownership interests in this patent family to Benitec, and the PCT application and the related U.S. priority document were filed solely in the name of Benitec. This patent family is directed to RNAi agents targeting specific regions within mutant PABPN1 variants causative of OPMD, as well as use of those RNAi agents in combination with PABPN1 replacement constructs to treat OPMD. More specifically, this family includes claims covering shmiR17 of <span style="white-space:nowrap">BB-301</span> This patent family entered the national/regional phase in October/November 2018. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second patent family, entitled &#8220;Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof (OPMD family #2)&#8221; relates to a second set of target gene sequences within PABPN1 as well as &#8216;silence and replace&#8217; construct <span style="white-space:nowrap">BB-301</span> under development at Benitec. The PCT application and the related U.S. priority document were filed solely in the name of Benitec, and this family entered the national/regional phase in June/July 2019. This patent family is directed to RNAi agents targeting specific regions within mutant PABPN1 variants causative of OPMD, as well as &#8216;silence and replace&#8217; constructs and use of same for treatment of OPMD. More specifically, this family includes claims covering shmiR13 and shmiR17 of <span style="white-space:nowrap">BB-301</span> separately, as well as the full <span style="white-space:nowrap">BB-301</span> &#8216;knockdown and replacement&#8217; construct. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A third patent family, entitled &#8220;Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD) (OPMD family #3)&#8221; has been filed to pursue claims which are broadly directed to the &#8216;silence and replace&#8217; treatment concept for OPMD, relying on RNAi agents to knockdown PABPN1 and replacement with functional PABPN1 which is not targeted by the RNAi agents. The claims in this application are not limited to <span style="white-space:nowrap">BB-301.</span> This patent family exists as a PCT application and was filed solely in the name of Benitec. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A fourth patent family, entitled &#8220;Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD) (OPMD family #4)&#8221; has been filed to specifically claim the OPMD therapeutic candidate developed by Benitec, <span style="white-space:nowrap">BB-301</span> (described herein). This patent family exists as a PCT application and was filed solely in the name of Benitec. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">AAV with modified phospholipase domain </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Benitec patent portfolio includes a single patent family, entitled &#8220;Adeno-associated virus (AAV) with modified phospholipase domain,&#8221; which relates to an AAV having a modified phospholipase (PLA2) domain in the capsid. The modified AAV will be used as the delivery system for the OPMD therapeutic. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware of a third party patent directed to AAV vectors that expires in 2026. In the event we receive regulatory marketing approval before the expiration date it may be necessary for us to obtain a license to the patent in order to commercialize. We cannot guarantee the availability of the license or that it can be obtained on commercially reasonable terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Know-How</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patent protection of ddRNAi and other technology and our product candidates, we also rely on proprietary <span style="white-space:nowrap">know-how</span> that is not patentable or that we elect not to patent, as valuable intellectual property for our business. This <span style="white-space:nowrap">know-how</span> is related to the areas of, among others, identifying nucleic acid targets for ddRNAi technology and designing ddRNAi constructs for targeting preferred genes. We have implemented a number of security measures designed to safeguard our <span style="white-space:nowrap">know-how</span> including limiting access to our research facilities, databases and networks. We also seek to protect our <span style="white-space:nowrap">know-how</span> by way of confidentiality agreements when engaging with external providers for progressing our pipeline of therapeutic candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Laws and Regulations Regarding Patent Terms </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal terms of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a <span style="white-space:nowrap">non-provisional</span> patent application. In the United States, a patent term may be shortened if a patent is terminally disclaimed over another patent or as a result of delays in patent prosecution by the patentee. A patent&#8217;s term may be lengthened by a patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent. The patent term of a European patent is 20 years from its filing date, which, unlike in the United States, is not subject to patent term adjustments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of a patent that covers an <span style="white-space:nowrap">FDA-approved</span> biologic may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the biologic is under clinical testing regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved biologic may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved biologic although the eligibility requirements for any duration of such extension vary. In the future, if and when our products receive FDA approval, or approval from an equivalent regulatory body in another jurisdiction in which patent protection is sought or obtained, we expect to apply for patent term extensions on patents covering those products. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trademarks </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our trademarks include registrations for company branding and product names for our pipeline in development. The trademarks that we use in connection with our business include the following: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:26%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:23%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:23%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:22%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Application or</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Country or Territory</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trademark (program)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registration number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Status</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BENITEC BIOPHARMA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">86190065</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">SILENCING GENES FOR LIFE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">86488147</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">SILENCING GENES FOR LIFE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">1448041</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BENITEC BIOPHARMA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1448046</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">BENITEC&#8212;logo


<img src="g549728g28p24.jpg" alt="LOGO" />
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">1448052</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Nervarna</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1526478</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">TRIBETARNA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1526479</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">HEPBARNA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1526483</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International Bureau (WIPO) &#8211;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">designating EU; UK and US</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">GIVING DISEASE THE SILENT TREATMENT</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">1389399</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BENITEC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">86795296</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">USA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">GIVING DISEASE THE SILENT TREATMENT</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">79226988</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">European Union</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BENITEC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">14680003</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BENITEC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1728797</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BENITEC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1103049</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BENITEC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">1103300</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Australia</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">GIVING DISEASE THE SILENT TREATMENT</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">1851660</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">Registered</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">United Kingdom</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">BENITEC</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">3238275</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">Registered</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacture of the biological products required for gene therapy is complex and difficult. We do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any of our product candidates. We are exploring long-term manufacturing alliances with a number of potential partners to investigate manufacturing processes in order to produce materials at reasonable scale and cost of goods to support future commercialization efforts. We do not have a long-term agreement with any third- party manufacturer, but we plan to establish such a relationship with an appropriate manufacturer to serve our long-term needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Our contract manufacturing organizations manufacture our product candidates under cGMP conditions. cGMP is a regulatory standard for the production of pharmaceuticals that will be used in humans. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sales and Marketing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet established sales, marketing or product distribution operations because our product candidates are in preclinical or clinical development. If we receive marketing and commercialization approval for any of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates, we intend to market the product through strategic alliances and distribution agreements with third parties. In certain cases, we may market an approved product directly worldwide or in selected geographical segments. The ultimate implementation of our strategy for realizing the financial value of our product candidates is dependent on the results of clinical trials for our product candidates, the availability of funds and the ability to negotiate acceptable commercial terms with third parties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our proprietary technology and scientific expertise in gene silencing using ddRNAi provide us with competitive advantages, we face potential competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions and governmental agencies and public and private research institutions that may develop potentially competitive products or technologies. We are aware of several companies focused on developing gene therapy or gene silencing product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not aware of any companies developing a gene therapy or gene silencing approach for OPMD. Our product candidates, if approved, would also compete with treatments that have already been approved and accepted by the medical community, patients and third-party payers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors and potential competitors, alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and subject registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that we will face intense and increasing competition as new products enter the market and advanced technologies become available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of competition and the availability of reimbursement from government and other third party-payers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that our therapeutic products, if approved, will be priced at a significant premium over competitive products and our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of competitive products including biosimilar or generic products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This increasingly competitive landscape may compromise the development of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a pharmaceutical and biological product company that wishes to conduct clinical trials and ultimately obtain marketing approval in the United States, we are subject to extensive regulation by the FDA, and other federal, state, and local regulatory agencies. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, the Public Health Service Act, or PHS Act, and their implementing regulations set forth, among other things, requirements for the research, testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record keeping, reporting, distribution, import, export, advertising and promotion of our products. A failure to comply explicitly with any requirements during the product development, approval, or post-approval periods, may lead to administrative or judicial sanctions. These sanctions could include the imposition by the FDA or an IRB, of a suspension on clinical trials, refusal to approve pending marketing applications or supplements, withdrawal of approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the discussion below focuses on regulation in the United States, we anticipate seeking approval for the testing and marketing of our products in other countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the European Union are addressed in a centralized way through the EMA, but country-specific regulation remains essential in many respects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government regulation may delay or prevent testing or marketing of our products and impose costly procedures upon our activities. The testing and marketing approval process, and the subsequent compliance with appropriate statutes and regulations, requires substantial time, effort, and financial resources, and we cannot be certain that the FDA or any other regulatory agency will grant marketing approvals for our products or any future products on a timely basis, if at all. The FDA&#8217;s or any other regulatory agency&#8217;s policies may change and additional governmental regulations may be enacted that could prevent or delay regulatory approval of our products or any future products or approval of new indications or label changes. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative, judicial, or administrative action, either in the United States or abroad. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Recent Developments in Regulation of Gene Therapy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Government Regulation in the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has provided guidance for the development of gene therapy products. For example, the FDA has established the Office of Tissues and Advanced Therapies (formerly Office of Cellular, Tissue and Gene Therapies) within the Center for Biologics Evaluation and Research (CBER), to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews. In addition, the FDA has issued a growing body of clinical guidelines, chemical, manufacturing and control, or CMC, guidelines, regenerative medicine guidelines and other guidelines, all of which are intended to facilitate industry&#8217;s development of gene therapy products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2016, Section&#160;3033 of the 21st Century Cures Act created a new product category called &#8220;regenerative medicine advanced therapy&#8221;, or the RMAT designation. The RMAT designation gives the sponsor of a new investigational biologic access to increased meeting opportunities with the FDA, in a manner comparable to those offered to sponsors of therapies designated as &#8220;breakthrough therapies&#8221; by the FDA. Because the designated products meet the criteria for unmet medical need in the treatment of a serious condition, they may be eligible for priority review, in which the initial assessment of the BLA is reduced from 12 months to eight months, and accelerated approval, which bases approval on an effect on a predictive surrogate endpoint or an intermediate clinical endpoint. RMATs qualifying for such accelerated approval may be able to satisfy licensing requirements through commitment to post-approval clinical studies as well as real-world data such as patient registries and health record analysis. The eligibility of the RMAT-designated product for these expedited </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs can be discussed with the FDA at specific development meetings, but we do not know whether any of our current or future product candidates will be eligible for RMAT designation. We believe the increased access to the FDA during early development is a benefit for sponsors, because the typical Type B development meetings are normally restricted to one each at the stages of <span style="white-space:nowrap">pre-IND,</span> end of Phase <span style="white-space:nowrap">II/pre-Phase</span> III and <span style="white-space:nowrap">pre-BLA</span> submission. In addition, the option to qualify for a fast-track program, also based on the potential to serve an unmet medical need in the treatment of a serious condition, allows for a <span style="white-space:nowrap">so-called</span> &#8220;rolling review&#8221; of parts of the BLA, which can be submitted for assessment following agreement of a review timetable with CBER. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA plans to include certain gene therapy products that permanently alter tissue and produce a sustained therapeutic benefit as part of the products that will meet the definition of being eligible to come under the pathway enabled by RMAT designation. RMAT designation enables gene therapy products to access the FDA&#8217;s existing expedited programs to help foster the development and approval of gene therapy products. Our product candidates may not be eligible for RMAT designation now or in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, the EMA approved a second gene therapy product called Strimvelis, the first approved ex vivo stem cell gene therapy, to treat patients with a very rare disease called <span style="white-space:nowrap">ADA-SCID</span> (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2017, the FDA approved the first gene therapy product in the United States. The FDA approved Kymriah (tisagenlecleucel) for the treatment of certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Kymriah is a genetically-modified autologous T-cell immunotherapy. Because of the risk of cytokine release syndrome and neurological events, Kymriah is being approved with a REMS. In December 2017, the FDA approved Luxturna (voretigene <span style="white-space:nowrap">neparvovec-rzyl),</span> a gene therapy to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the United States that targets a disease caused by mutations in a specific gene. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Marketing Approval </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, for premarket approval purposes, the FDA regulates gene therapy products as biologics under the FDC Act, the PHS Act and related regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The steps required before a new biologic may be marketed in the United States generally include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">nonclinical pharmacology and toxicology laboratory and animal tests according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission of an IND application which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adequate and well-controlled human clinical trials according to GCPs and any additional requirements for the protection of human research subjects and their health information to establish the safety and efficacy of the investigational product for each targeted indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission of a biologics license application, or BLA, to the FDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA&#8217;s <span style="white-space:nowrap">pre-approval</span> inspection of manufacturing facilities to assess compliance with cGMPs and, if applicable, the FDA&#8217;s good tissue practices, or GTPs, for the use of human cellular and tissue products to prevent the introduction, transmission, or spread of communicable diseases; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA&#8217;s audit of clinical trial sites that generated data in support of the BLA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA approval of a BLA, which must occur before a product can be marketed or sold. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Product Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before testing any biologic in humans, the product enters the nonclinical, or preclinical, testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity, and formulation, as well as animal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies to assess the potential safety and activity of the product. The conduct of nonclinical tests must comply with federal regulations and requirements including GLPs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a gene therapy trial is conducted at, or sponsored by, institutions receiving NIH funding for recombinant DNA research, prior to the submission of an IND to the FDA, a protocol and related documentation is submitted to and the trial is registered with the NIH Office of Science Policy, or OSP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The product sponsor then submits the results of the nonclinical testing, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical protocol, to the FDA in an IND, which is a request for authorization from the FDA to administer an investigational product to humans. Some nonclinical testing may continue even after the IND application is submitted. IND authorization is required before interstate shipping and administration of any new product to humans that is not the subject of an approved BLA. The IND automatically becomes effective 30 days after receipt by the FDA unless the FDA, within the <span style="white-space:nowrap">30-day</span> time period, raises concerns or questions about the conduct of the clinical trial and places the clinical trial on a clinical hold. In such case, the IND sponsor must resolve any outstanding concerns with the FDA before the clinical trial may begin. Further, an IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that site. If the site has an IBC, it may also have to review and approve the proposed clinical trial. Clinical trials involve the administration of the investigational product to patients under the supervision of qualified investigators following GCPs, requirements meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, investigators, and monitors. Clinical trials are conducted under protocols that detail, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur, and the efficacy criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. The informed written consent of each participating subject is required and the form and content of the informed consent must be approved by each IRB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical investigation of an investigational product is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined in some cases. The three phases of an investigation are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase I includes the initial introduction of an investigational product into humans. Phase I clinical trials may be conducted in patients with the target disease or condition or on healthy volunteers. These studies are designed to evaluate the safety, metabolism, pharmacokinetics and pharmacologic actions of the investigational product in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. During Phase I clinical trials, sufficient information about the investigational product&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of Phase II clinical trials. The total number of participants included in Phase I clinical trials varies, but is generally in the range of 20 to 80. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase II includes the controlled clinical trials conducted to evaluate the effectiveness of the investigational product for a particular indication(s) in patients with the disease or condition under study, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks associated with the product. Phase II clinical trials are typically well- controlled, closely monitored, and conducted in a limited patient population, usually involving no more than several hundred participants. Phase IIa trials provide information on the impact of dose ranging on safety, biomarkers and proof of concept, while Phase IIb trials are patient dose-ranging efficacy trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase III clinical trials are controlled clinical trials conducted in an expanded patient population at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the investigational product has been obtained, and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the product, and to provide an adequate basis for product approval. Phase III clinical trials usually involve several </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
hundred to several thousand participants. In most cases, the FDA requires two adequate and well controlled Phase III clinical trials to demonstrate the efficacy of the product. FDA may accept a single Phase III trial with other confirmatory evidence in rare instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events; any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects; or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA typically recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a <span style="white-space:nowrap">15-year</span> period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire, of trial subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decision to terminate a clinical trial of an investigational biologic may be made by the FDA or other regulatory authority, an IRB, an IBC, or institutional ethics committee, or by a company for various reasons. The FDA may place a clinical hold and order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. If the FDA imposes a clinical hold, trials may not recommence without FDA and IRB authorization and then only under terms authorized by the FDA and IRB. In some cases, clinical trials are overseen by an independent group of qualified experts organized by the trial sponsor, or the clinical monitoring board or DSMB. This group provides authorization for whether or not a trial may move forward at designated check points. These decisions are based on the limited access to data from the ongoing trial. The suspension or termination of a clinical trial can occur during any phase of clinical trials if it is determined that the participants or patients are being exposed to an unacceptable health risk. In addition, there are requirements for the registration of ongoing clinical trials of drugs and biologics on public registries and the disclosure of certain information pertaining to the trials as well as clinical trial results after completion. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational product information is submitted to the FDA in the form of a BLA for a biologic to request marketing approval for the product in specified indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human gene therapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of human gene therapy products, or that the data generated in these trials will be acceptable to the FDA to support marketing approval. The NIH and the FDA have a publicly accessible database, the Genetic Modification Clinical Research Information System, which includes information on gene transfer trials and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these trials. Over the last several years the FDA has issued helpful guidance on development of gene therapy products and shown a willingness to work closely with developers, especially with those working in orphan disease areas. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biologics License Application Approval Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to obtain approval to market a biologic in the United States, a BLA must be submitted to the FDA that provides data from nonclinical studies and clinical trials and manufacturing information establishing to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FDA&#8217;s satisfaction the safety, purity, and potency or efficacy of the investigational product for the proposed indication. The BLA must be accompanied by a substantial user fee payment unless a waiver or exemption applies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA will initially review the BLA for completeness before it accepts it for filing. Under the FDA&#8217;s procedures, the agency has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, which includes determining whether it is effective for its intended use, and whether the product is being manufactured in accordance with cGMP, to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity, and in accordance with biological product standards. The FDA will inspect the facilities at which the product is manufactured to ensure the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. For a human cellular or tissue product, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. Additionally, before approving a BLA, the FDA may inspect one or more clinical sites to assure compliance with GCP. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information, or corrective action for a manufacturing facility. This may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses provided in the BLA. Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. The FDA also may determine a REMS is necessary to assure the safe use of the biologic, in which case the BLA sponsor must submit a proposed REMS. The REMS may include, but is not limited to, a Medication Guide, a communications plan, and other elements to assure safe use, such as restrictions on distribution, prescribing, and dispensing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA completes its initial review of a BLA, it will either license, or approve, the product, or issue a complete response letter to communicate that it will not approve the BLA in its current form and to inform the sponsor of changes that the sponsor must make or additional clinical, nonclinical or manufacturing data that must be received before the FDA can approve the application, with no implication regarding the ultimate approvability of the application. If a complete response letter is issued, the sponsor may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The testing and approval process for both a drug and biologic requires substantial time, effort and financial resources and this process may take several years to complete. Data obtained from clinical trials is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing our products. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan Drug Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product candidate. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product candidate that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication than the one for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same biological product as defined by the FDA or if our product candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the European Union has similar, but not identical, benefits. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic or drug may request the FDA to designate the biologic or drug as a fast track product at any time during the clinical development of the product. Unique to a fast track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it would, if approved, be a significant improvement in the safety, effectiveness, treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new biological or drug product designated for priority review in an effort to reduce the review period from 12 to eight months. Additionally, a product may be eligible for accelerated approval. Biological or drug products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint. As a condition of approval, the FDA may require that a sponsor of a biological or drug product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently requires as a condition for accelerated approval <span style="white-space:nowrap">pre-approval</span> of promotional materials, which could adversely impact the timing of the commercial launch of the product. Lastly, under the provisions of the new Food and Drug Administration Safety and Innovation Act, enacted in 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug or biological that is intended, alone or in combination with one or more other drugs or biological, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biological may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs and biologicals designated as breakthrough therapies receive the same benefits as drugs and biologicals with Fast Track designation. In addition, the FDA must take certain additional actions, such as intensive guidance on an efficient drug development program (beginning as early as Phase 1), and organizational commitment involving senior managers, intended to expedite the development and review of an application for approval of a breakthrough therapy. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fast Track designation and breakthrough therapy designation may expedite the product development and approval process, and priority review may expedite the approval process. However, these three paths do not change the standards for approval. Accelerated approval designation changes the standards for product approval and thus may expedite the development and/or approval process. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Additional Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These <span style="white-space:nowrap">so-called</span> Phase 4 clinical trials may be made a condition to be satisfied for continuing drug and biologic approval. The results of Phase 4 clinical trials can confirm the efficacy of a product candidate and can provide important safety information. In addition, the FDA has expressed statutory authority to require sponsors to conduct post- market studies to specifically address safety issues identified by the agency. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of an onerous REMS, restrictions on distribution, or post- marketing study requirements. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. In addition, we cannot predict what adverse governmental regulations may arise from future U.S. or foreign governmental action. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Medical Device Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our contemplated diagnostics, for use with certain of our therapeutic products, are regulated by FDA as in vitro diagnostic, or IVD, medical devices. Such IVD devices must comply with applicable FDA <span style="white-space:nowrap">IVD-specific</span> regulations as well as FDA regulations applicable more broadly to medical devices. These FDA regulations include requirements for registering establishments with FDA; listing IVD devices with FDA; reporting certain adverse events related to IVD devices to FDA; complying with the Quality System Regulation (current good manufacturing practices for devices); labeling IVD devices; and obtaining premarket approval or clearance prior to marketing IVD devices (unless exempt). There are also regulations covering the requirements for investigational devices and the conduct of clinical investigations of devices. Like drugs and biologics, failure to comply with applicable device/IVD requirements can result in legal or administrative enforcement actions against an IVD device firm, its officers or employees, and/or its products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us or on our behalf pursuant to FDA approvals are subject to continuing regulation by the FDA, including requirements for record-keeping, reporting of adverse experiences </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the biologic or drug, and submitting biological product deviation reports to notify the FDA of unanticipated changes in distributed products. Manufacturers are required to register their facilities with the FDA and certain state agencies, and are subject to periodic announced or unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose certain quality processes, manufacturing controls and documentation requirements upon us and our <span style="white-space:nowrap">third-party</span> manufacturers in order to ensure that the product is safe, has the identity and strength, and meets the quality, purity and potency characteristics that it purports to have. In November 2013, the Drug Quality and Security Act, or DQSA, became law and establishes requirements to facilitate the tracing of prescription drug and biological products through the supply distribution chain. This law includes a number of new requirements that are being implemented over time and require us to devote additional resources to satisfy these requirements, including serializing the product and using new technology and data storage to electronically trace the product from manufacturer to dispenser. If our products are not covered by the serialization and tracing requirements of the DQSA, they may be subject to state pedigree and traceability requirements. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP and other FDA regulatory requirements. If our present or future suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, refuse to approve any BLA, force us to recall a product from distribution, shut down manufacturing operations or withdraw approval of the applicable BLA. Noncompliance with cGMP or other requirements can result in issuance of warning or untitled letters, civil and criminal penalties, seizures, and injunctive action. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and other federal and state agencies closely regulate the labeling, marketing and promotion of drugs and biologics. Government regulators, including the Department of Justice and the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities, recently have increased their scrutiny of the promotion and marketing of drugs and biologics. While doctors are free to prescribe any product approved by the FDA for any use, a company can only make claims relating to safety and efficacy of a product that are consistent with FDA approval, and the company is allowed to market a product only for the particular use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion must, among other things, be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these requirements can result in adverse publicity, warning or untitled letters, corrective advertising, injunctions, potential civil and criminal penalties, criminal prosecution, and agreements with governmental agencies that materially restrict the manner in which a company promotes or distributes products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pediatric Research Equity Act </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, as amended, a BLA or supplement must contain data to assess the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Manufacturers must submit a pediatric study plan to the IND not later than 60 days after the <span style="white-space:nowrap"><span style="white-space:nowrap">end-of-phase</span></span> 2 meeting with the FDA; if there is no such meeting, before the initiation of any phase 3 studies or a combined phase 2 and phase 3 study; or if no such study will be conducted, no later than 210 days before a marketing application or supplement is submitted. The intent of PREA is to compel sponsors whose products have pediatric applicability to study those products in pediatric populations, rather than ignoring pediatric indications for adult indications that could be more economically desirable. The FDA may grant deferrals for submission of data or full or partial waivers. By its terms, PREA does not apply to any product for an indication for which orphan designation has been granted, unless the FDA issues regulations stating otherwise. Because the FDA has not issued any such regulations, submission of a pediatric assessment is not required for an application to market a product for an orphan-designated indication. In a July 2018 guidance, the FDA announced that it does not expect to grant any additional orphan drug designations to drugs for pediatric subpopulations of common diseases (i.e., diseases or conditions with an overall prevalence of 200,000 or greater). Pediatric subpopulation orphan designations that have already been granted will not be affected by this change. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent Term Restoration and Marketing Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending on the timing, duration and specifics of FDA marketing approval of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally <span style="white-space:nowrap">one-half</span> the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent and within sixty days of approval of the biological product. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Biologics Price Competition and Innovation Act of 2009, which was included within the Patient Protection and Affordable Care Act, created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an <span style="white-space:nowrap">FDA-licensed</span> reference biological product, and grants a reference biologic twelve years of exclusivity from the time of first licensure. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of exclusivity in the United States. Pediatric exclusivity, if granted, provides an additional six months of exclusivity to be attached to any existing marketing exclusivity, e.g., twelve year exclusivity, or patent protection for a drug. This six month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric trial in accordance with an <span style="white-space:nowrap">FDA-issued</span> &#8220;Written Request&#8221; for such a trial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Government regulation outside the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a request for a clinical trial authorization, or CTA, must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials, product approval or licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of a biological product under European Union regulatory systems, we must submit a marketing authorization application. The application required in the European Union is similar to a BLA in the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States, with the exception of, among other things, country-specific document requirements. The European Union also provides opportunities for market exclusivity. For example, in the European Union, upon receiving marketing authorization, a new biological generally receives eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a biosimilar application. During the additional <span style="white-space:nowrap">two-year</span> period of market exclusivity, a biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no biosimilar product can be marketed until the expiration of the market exclusivity. The innovator may obtain an additional one year of market exclusivity if the innovator obtains an additional authorization during the initial eight year period for one or more new indications that demonstrate significant clinical benefit over existing therapies. This data and market exclusivity regime in the European Union of a total of 10 or 11 years protects against generic competition, but does not protect against the launch of a competing product if the competitor, rather than referencing the clinical data of the originator, has conducted its own clinical trials to support its marketing authorization application. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan drugs in the European Union are eligible for <span style="white-space:nowrap">10-year</span> market exclusivity. This <span style="white-space:nowrap">10-year</span> market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the applicant consents to a second orphan medicinal product application; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the applicant cannot supply enough orphan medicinal product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pharmaceutical Coverage, Pricing and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our products, when and if approved for marketing, will depend, in part, on the extent to which our products will be covered by third-party payers, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations. These third-party payers are increasingly reducing reimbursements for medical products, biologicals, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of interchangeable products. Adoption of price controls and cost containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payer not to cover our product candidates could reduce physician usage of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state and foreign governments. Third-party payers are increasingly challenging the prices charged for drug products and medical services, examining the medical necessity and reviewing the cost effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payers do not consider our products to be <span style="white-space:nowrap">cost-effective</span> compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the availability of healthcare and containing or lowering the cost of healthcare. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, was enacted. The ACA includes measures that have significantly changed, and are expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. In January 2013, former President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, in August, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes, in part, provisions to lower certain products&#8217; costs for Medicare beneficiaries. Beginning in 2023, if a manufacturer of any of our products increases the prices for the products faster than inflation for such products used by Medicare beneficiaries, then the manufacturer would be required to pay rebates to Medicare. If we establish any relationships with manufacturers for our products, and if our products are used by Medicare beneficiaries, manufacturers would be required to pay rebates to Medicare or else face a penalty fine representing the difference between the actual and the inflated price. Depending on the financial aspects of our relationships with manufacturers for such products, we may incur additional compliance costs which could impact our financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Healthcare Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we currently do not have any products on the market, we may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and other countries in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine and open payment laws and regulations, many of which may become more applicable to us if our product candidates are approved and we begin commercialization. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, we had 18 full-time employees, 7 of whom have a Ph.D., 4 have Masters Degrees and 2 have Biotechnology Certificates, for a total of 13 with post-graduate degrees. Of these full-time employees, 13 are engaged in research and development activities and 5 are engaged in finance, legal, human resources, facilities and general management. None of our employees is represented by any labor union. As of June 30, 2023, 17 employees were located in the United States of America, and 1 employee was located in Australia. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated as a Delaware corporation on November 22, 2019 and completed the <span style="white-space:nowrap">Re-domiciliation</span> April 15, 2020. Our predecessor, Benitec Limited, was incorporated under the laws of Australia in 1995. Our principal executive offices are located at 3940 Trust Way, Hayward, California 94545. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Re-domiciliation</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 15, 2020, or the Implementation Date, the <span style="white-space:nowrap">re-domiciliation,</span> or the <span style="white-space:nowrap">Re-domiciliation,</span> of Benitec Biopharma Limited, a public company incorporated under the laws of the State of Western Australia, or Benitec Limited, was completed in accordance with the Scheme Implementation Agreement, as amended and restated as of January 30, 2020, between Benitec Limited and us. As a result of the <span style="white-space:nowrap">Re-domiciliation,</span> our jurisdiction of incorporation was changed from Australia to Delaware, and Benitec Limited became our wholly owned subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">Re-domiciliation</span> was effected pursuant to a statutory scheme of arrangement under Australian law, or the Scheme, whereby on the Implementation Date, all of the issued and outstanding ordinary shares of Benitec Limited were exchanged for newly issued shares of our common stock, on the basis of one share of our common stock, par value $0.0001 per share, for every 300 ordinary shares of Benitec Limited issued and outstanding. Holders of Benitec Limited&#8217;s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of our common stock for every three ADSs held. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock began trading on The Nasdaq Capital Market, or Nasdaq, at the start of trading on the Implementation Date under the symbol &#8220;BNTC.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Reverse Stock Split </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;26, 2023, the Company effected a <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-17</span></span> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its common stock. In accordance with the Reverse Stock Split, 17 <span style="white-space:nowrap">pre-split</span> shares of the Company&#8217;s common stock were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, <span style="white-space:nowrap">pre-funded</span> warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#8217;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. All share and earnings per share amounts presented in this Form <span style="white-space:nowrap">10-K</span> reflect the impact of this reverse split. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Available Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our telephone number is (510) <span style="white-space:nowrap">780-0819,</span> and our Internet website is www.benitec.com. The information on, or that can be accessed through, our website is not part of this Annual Report and is not incorporated by reference herein. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_2">Item&#160;1A. Risk Factors. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report, including our consolidated financial statements and the related notes, before deciding to invest in our securities. The risks and uncertainties described below and in the documents incorporated by reference herein are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks actually occurs, our business, financial condition, results of operations and prospects could be materially and adversely affected, and the trading price of our common stock could decline. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risk Factor Summary </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the risks and uncertainties that could cause our business, financial condition or operating results to be harmed. We encourage you to carefully review the full risk factors contained in this report in their entirety for additional information regarding these risks and uncertainties. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. If we are unable to achieve or sustain profitability, the market value of our common stock will likely decline; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have never generated any revenue from product sales and may never be profitable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will need to continue our efforts to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain capital when needed may negatively impact our ability to continue as a going concern; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our product candidates are based on ddRNAi and silence and replace technology. Currently, no product candidates utilizing ddRNAi technology or silence and replace technology have been approved for commercial sale and our approach to the development of ddRNAi technology and silence and replace technology may not result in safe, effective or marketable products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are early in our product development efforts and our current product candidate is in early clinical stage. We may not be able to obtain regulatory approvals for the commercialization of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Issues that may impact delivery of our therapeutics to the cell could adversely affect or limit our ability to develop and commercialize product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We face competition from entities that have developed or may develop product candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to obtain or protect sufficient intellectual property rights related to our product candidates, we may not be able to obtain exclusivity for our product candidates or prevent others from developing similar competitive products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Condition, Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. If we are unable to achieve or sustain profitability, the market value of our common stock will likely decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023, we had accumulated losses of $167.9 million. We have devoted most of our financial resources to research and development, including our clinical and preclinical development activities. To date, we and our predecessor have financed our operations primarily through the issuance of equity securities, research and development grants from the Australian government and payments from our collaboration partners. We do </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not expect to generate any significant revenue for the foreseeable future, and we expect to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials and the regulatory approval process for product candidates. The amount of our future net losses is uncertain and will depend, in part, on the rate of our future expenditures. Our ability to continue operations will depend on, among other things, our ability to obtain funding through equity or debt financings, strategic collaborations or additional grants. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses, and we may incur operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continue our research and preclinical development of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expand the scope of our current preclinical studies for our product candidates or initiate clinical, additional preclinical or other studies for product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">further develop the manufacturing process for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">change or add additional manufacturers or suppliers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek to identify and validate additional product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acquire or in-license other product candidates and technologies, which may or may not include those related to our ddRNAi technology and delivery vectors for our therapeutic candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain, protect and expand our intellectual property portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">create additional infrastructure to support our operations as a public company in the United States and our product development and future commercialization efforts; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience any delays or encounter issues with any of the above. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause the price of our common stock to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have never generated any revenue from product sales and may never be profitable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate significant revenue and achieve profitability depends on our ability to, alone or with strategic collaboration partners, successfully complete the development of and obtain the regulatory approvals for our product candidates, to manufacture sufficient supply of our product candidates, to establish a sales and marketing organization or suitable third-party alternative for the marketing of any approved products and to successfully commercialize any approved products on commercially reasonable terms. All of these activities will require us to raise sufficient funds to finance business activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past we received milestone payments from our collaborative partners. However, we do not anticipate generating revenue from commercializing product candidates for the foreseeable future, if ever. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate future revenues from commercializing product candidates depends heavily on our success in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing proof of concept in preclinical studies and clinical trials for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully initiating and completing clinical trials of our product candidates; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining regulatory and marketing approvals for product candidates for which we complete clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintaining, protecting and expanding our intellectual property portfolio, and avoiding infringing on intellectual property of third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and maintaining successful licenses, collaborations and alliances with third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing a sustainable, scalable, reproducible and transferable manufacturing process for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and maintaining supply and manufacturing relationships with third parties that can provide products and services adequate, in amount and quality, to support clinical development and commercialization of our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launching and commercializing any product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining market acceptance of any product candidates that receive regulatory approval as viable treatment options; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining favorable coverage and reimbursement rates for our products from third-party payers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">addressing any competing technological and market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying and validating new product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of developing product candidates for ddRNAi-based and antisense RNA-based therapeutics contains a number of inherent risks and uncertainties. For example, with regard to ddRNAi, it may not be possible to identify a target region of a disease-associated gene that has not been previously identified and/or patented by others, resulting in restrictions on freedom to operate for that target sequence. Silencing the target gene may not ultimately result in curing the disease as there may be more factors contributing to the development of the disease than the target gene. Silencing the target gene using ddRNAi may lead to short-term or long-term adverse effects that were not predicted or observed in preclinical studies. The delivery of the DNA construct to the target cells may not be possible, or complete or adequate to provide sufficient therapeutic benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if one or more of our product candidates is approved for commercial sale, we may incur significant costs associated with commercializing any approved product candidate. As one example, our expenses could increase beyond expectations if we are required by the United States Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations, which could have an adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to continue our efforts to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain capital when needed may negatively impact our ability to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Developing ddRNAi products is expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates in preclinical studies and clinical trials and as we undertake preclinical studies of new product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;11, 2023 we closed an underwritten public offering in which we sold 875,949 shares of common stock, 15,126,226 pre-funded warrants to purchase 15,126,226 shares of common stock, and 16,002,175 common warrants to purchase up to 16,002,175 shares of common stock. The combined purchase price for each share of common stock and accompanying common warrant was $1.93, which was allocated as $1.9299 per share of common stock and $0.0001 per common warrant. Each pre-funded warrant was sold together with one common warrant at a combined price of $1.9299, which was allocated as $1.9298 per pre-funded warrant and $0.0001 per common warrant. In addition, the Company granted the underwriter an option to purchase up to 2,331,606 additional shares of common stock and/or up to 2,331,606 additional common warrants. As of August&#160;15, 2023 the underwriter had partially exercised this option and purchased 458,134 additional shares of common stock and 458,134 additional common warrants. Net proceeds from the offering, including the impact of the underwriter&#8217;s partial exercise of its option and net of underwriting discounts, commissions, and other offering expenses, totaled $28.6 million. We estimate that our cash and cash equivalents will be sufficient to fund the Company&#8217;s operations for at least the next twelve months after the date that this Annual Report is filed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the length of time and activities associated with successful development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. In any event, we will require additional capital to obtain regulatory approval for our product candidates and to commercialize any product candidates that receive regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their day-to-day activities, which may compromise our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. If we incur indebtedness we may be required to agree to restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could compromise our ability to conduct our business. We could also seek financing through arrangements with collaborative partners at an earlier stage than would otherwise be desirable and we may be required to relinquish rights to some or all of our technologies or product candidates or otherwise agree to terms unfavorable to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any approved product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will continue to seek to raise additional working capital through public equity, private equity or debt financings. If we fail to raise additional working capital, or do so on commercially unfavorable terms, it may materially and adversely affect our business, prospects, financial condition and results of operations, and we may be unable to continue as a going concern. Future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, if at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be unable to conduct and conclude clinical trials for our product candidate for OPMD if we are unable to raise additional financing. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to raise additional funds, and thus unable to continue our studies, our business operations may be adversely affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Product Development and Regulatory Approval of Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates are based on ddRNAi and silence and replace technology. Currently, no product candidates utilizing ddRNAi technology or silence and replace technology have been approved for commercial sale and our approach to the development of ddRNAi technology and silence and replace technology may not result in safe, effective or marketable products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have concentrated our product research and development efforts on our ddRNAi technology and silence and replace technology, and our future success depends on successful clinical development of these technologies. We plan to progress our product candidates using our ddRNAi technology and our silence and replace technology for the treatment of the life-threatening conditions of OPMD. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scientific research that forms the basis of our efforts to develop product candidates is based on the therapeutic use of ddRNAi, and the identification, optimization and delivery of ddRNAi-based product candidates is relatively new. The scientific evidence to support the feasibility of successfully developing therapeutic treatments based on ddRNAi is preliminary and limited. There can be no assurance that any development and technical problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may be unable to reach agreement on favorable terms, or at all, with providers of vectors needed to optimize delivery of our product candidates to target disease cells and we may also experience unanticipated problems or delays in expanding our manufacturing capacity or transferring our manufacturing process to commercial partners, any of which may prevent us from completing our preclinical trials, initiating clinical trials or commercializing our products on a timely or profitable basis, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only a few product candidates based on ddRNAi have been tested in either animals or humans, and a number of clinical trials conducted by other companies using other forms of RNAi technologies have not been successful. We may discover that application of ddRNAi does not possess properties required for a therapeutic benefit, such as the ability to continually express shRNAs for the period of time required to be maximally effective or the ability of viral vectors or other technologies to effectively deliver ddRNAi constructs to target cells in therapeutically relevant concentrations. In addition, application of ddRNAi-based products in humans may result in safety issues. We currently have only limited data, and no conclusive evidence, to suggest that we can effectively produce effective therapeutic treatments using our ddRNAi technology. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are early in our product development efforts and our current product candidates are still in preclinical development. We may not be able to obtain regulatory approvals for the commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of biologics is subject to extensive regulation by the FDA and other regulatory authorities, and these regulations differ from country to country. We do not have any products on the market and are early in our development efforts. All of our ddRNAi product candidates and our silence and replace product candidates are in preclinical development. Our current product candidates are subject to the risks of failure typical for development of biologics. The development and approval process is expensive and can take many years to complete, and its outcome is inherently uncertain. In addition, the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not submitted a marketing application, or received marketing approval, for any of our product candidates and will not submit any applications for marketing approval for several years. We have limited experience in conducting and managing clinical trials necessary to obtain regulatory approvals, including marketing approval by the FDA. To receive marketing approval, we must, among other things, demonstrate with evidence from clinical trials that the product candidate is both safe and effective for each indication for which approval is sought, and failure can occur in any stage of development. Satisfaction of the marketing approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the type, complexity and novelty of the biopharmaceutical product. We cannot predict if or when we might receive regulatory approvals for any of our product candidates currently under development. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA and foreign regulatory authorities also have substantial discretion in the biopharmaceutical product approval process. The numbers, types and sizes of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain marketing approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, and there may be varying interpretations of data obtained from preclinical studies or clinical trials, any of which may cause delays or limitations in the marketing approval or the decision not to approve an application. Regulatory agencies can delay, limit or deny marketing approval of a product candidate for many reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of any future clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the results of any future clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable foreign regulatory authorities for approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patients recruited for a particular clinical program may not be sufficiently broad or representative to assure safety and effectiveness in the full population for which we seek approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the results of any future clinical trials may not confirm the positive results from earlier preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the data collected from any future clinical trials of our product candidates may not be sufficient to the satisfaction of FDA or comparable foreign regulatory authorities to support the submission of a biologics license application, or BLA, or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or comparable foreign regulatory authorities may only agree to approve a product candidate under conditions that are so restrictive that the product is not commercially viable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory agencies may change their approval policies or adopt new regulations in a manner rendering our clinical data insufficient for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any delay in obtaining or failure to obtain required approvals could materially and adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact the price of our common stock. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a BLA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. If we fail to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain FDA approval to market our product candidates, we will be unable to sell our product candidates in the United States, which will significantly impair our ability to generate revenues. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject us to administrative or judicially imposed sanctions, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the products, manufacturers, or manufacturing process; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">warning letters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">civil and criminal penalties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or withdrawal of regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizures, detentions or import bans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">voluntary or mandatory product recalls and publicity requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">total or partial suspension of production; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of restrictions on operations, including costly new manufacturing requirements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to approve pending BLAs or supplements to approved BLAs. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we do receive regulatory approval to market a product candidate, any such approval may be subject to limitations on the indicated uses for which we may market the product. It is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because our ddRNAi and silence and replace product candidates are considered gene therapies, it is difficult to predict the time and cost of product candidate development as well as subsequently obtaining regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other pharmaceutical product candidates. The FDA and comparable foreign regulatory authorities have relatively limited experience with ddRNAi-based and silence and replace- based therapeutics, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States or other countries. We and our current collaborators, or any future collaborators, may never receive approval to market and commercialize any product candidate. Even if we or a collaborator obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired and may require labeling that includes significant use or distribution restrictions or safety warnings. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. Also, before a clinical trial can begin at any institution, that institution&#8217;s institutional review board, or IRB, and its institutional biosafety committee, or IBC, if it has one, have to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or comparable foreign regulatory bodies to change the requirements for approval of any of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These committees and advisory groups and the new guidelines they promulgate and new requirements they may impose may lengthen the clinical development and regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory committees and advisory groups, and comply with applicable guidelines and requirements as they may change from time to time. If we fail to do so, we may be required to delay or discontinue development of our product candidates. These additional processes may result in a development, review and approval process that is longer than we otherwise would have expected for our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market would delay or prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Positive results from preclinical studies of our product candidates are not necessarily predictive of the results of our planned clinical trials of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Positive results in preclinical proof of concept and animal studies of our product candidates may not result in positive results in clinical trials in humans. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results in preclinical development or early stage clinical trials, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory authority approval. If we fail to produce positive results in our clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be negatively impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Issues that may impact delivery of our therapeutics to the cell could adversely affect or limit our ability to develop and commercialize product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Successful clinical development of ddRNAi-based therapeutics and silence and replace-based therapeutics is largely dependent on using the appropriate delivery methodologies, including viral vectors, to obtain therapeutically relevant concentrations of the DNA constructs that express the shRNAs and engineered transgenes in the appropriate target cells. To develop effective product candidates, we will need to license delivery technologies from third parties or develop delivery technologies with research collaborators. Although delivery technologies, including AAV vectors, have been identified and are well defined for specific tissue types, we continue to seek vectors with ideal delivery properties for indications we are pursuing, including OPMD. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tissue tropism and other physical properties of AAV vectors are limited and may not be effective for other product candidates or delivery into a wide array of tissues types. AAV vectors can also trigger immune responses in some patients, and those patients will not derive clinical benefit from administration of a product candidate unless steps are taken to clinically address the issue. If we or our collaborators are not successful in identifying effective delivery methodologies to achieve a therapeutically relevant concentration for our product candidates in the target tissues, we may not succeed in developing marketable products. In addition, if we are unable to reach agreement on favorable terms, or at all, with providers of any effective vectors that we do identify, we may not succeed in completing our clinical trials or commercializing our products on a timely or profitable basis, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use AAV vectors as part of our ddRNAi and silence and replace approaches for several indications. As such, we require licenses and the ability to manufacture large quantities of AAV particles under the FDA&#8217;s current good manufacturing practices, or cGMP, requirements and those of comparable foreign regulatory authorities in order to commercialize a product candidate using an AAV vector. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may find it difficult to enroll patients in any future clinical trials, and patients could discontinue their participation in our current and any future clinical trials, which could delay or prevent our current and any future clinical trials of our product candidates and make those trials more expensive to undertake. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in current and any future clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates. Patients may be unwilling to participate in any future clinical trials because of negative publicity from adverse events in the biotechnology, RNAi or gene therapy industries. Patients may be unavailable for other reasons, including competitive clinical trials for similar patient populations, and the timeline for recruiting patients, conducting trials and obtaining regulatory approval of potential products may be delayed. If we have difficulty enrolling a sufficient number of patients to conduct any future clinical trials as planned, we may need to delay, limit or discontinue those clinical trials. Clinical trial delays could result in increased costs, slower product development, setbacks in testing the safety and effectiveness of our technology or discontinuation of the clinical trials altogether. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial, to complete any future clinical trials in a timely manner. Patient enrollment is affected by factors including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">finding and diagnosing patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">severity of the disease under investigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">design of the clinical trial protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">size and nature of the patient population; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">eligibility criteria for the trial in question; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">perceived risks and benefits of the product candidate under study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">proximity and availability of clinical trial sites for prospective patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">availability of competing therapies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and patients&#8217; perceptions of the potential advantages of the product being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patient referral practices of physicians; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to monitor patients adequately during and after treatment; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the COVID-19 pandemic. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or any potential collaborators plan to seek initial marketing approval for our product candidates in the United States, Canada, Europe and Israel. We may not be able to initiate or continue any future clinical trials in a timely manner if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory agencies. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulty in establishing or managing relationships with contract research organizations, or CROs, clinical sites and physicians; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">different standards for the conduct of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to locate and engage qualified local consultants, physicians and partners; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of biopharmaceutical and biotechnology products and treatments. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, patients enrolled in current and any future clinical trials may discontinue their participation at any time during the trial as a result of a number of factors, including experiencing adverse events, which may or may not be judged related to our product candidates under evaluation. The discontinuation of patients in any one of our trials may cause us to delay or discontinue our clinical trial, or cause the results from that trial not to be positive or sufficient to support either partnering with a pharmaceutical or biotechnology company to further develop and commercialize the product candidate or filing for regulatory approval of the product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may encounter substantial delays in any future clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of any of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical trials are expensive and time-consuming, and their outcome is uncertain. We may experience delays in initiating and completing any clinical trials that we are conducting or intend to conduct as a result of the COVID-19 pandemic, and we do not know whether our ongoing or planned clinical trials will begin or progress on schedule, need to be redesigned, enroll patients on time or be completed on schedule, or at all. We cannot guarantee that any clinical trials will be initiated or conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to generate sufficient preclinical, toxicology or other data to support the initiation of human clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching consensus with regulatory agencies on trial design; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, recruiting and training suitable clinical investigators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining required IRB or IBC approval at each clinical trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in recruiting suitable patients to participate in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold by regulatory agencies, including after an inspection of our clinical trial operations or trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by our CROs, other third parties or us to adhere to clinical trial requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to perform in accordance with the FDA&#8217;s good clinical practices, or GCP, or applicable regulatory requirements in other countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to manufacture, test, release, import or export for use sufficient quantities of our product candidates for use in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to manufacture our product candidate in accordance with cGMP requirements or applicable regulatory guidelines in other countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in the testing, validation and manufacturing of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in the delivery of our product candidates to the clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in having patients complete participation in a trial or return for post-treatment follow-up; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements and guidance that require amending or submitting new clinical trial protocols; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or discontinue product development programs; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the severity, duration and impact of the COVID-19 pandemic. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, a clinical trial may be suspended or discontinued by us, our collaborators, the IRBs or the IBCs at the sites in which such trials are being conducted, the data safety monitoring board, or DSMB, for such trial, or by the FDA or comparable foreign regulatory authorities due to a number of factors, including the imposition of a clinical hold or termination of a trial due to failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, unforeseen safety issues or adverse side effects of our product candidate, or a product candidate from another company that shares similar properties, failure to demonstrate adequate benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience discontinuation of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates may be eliminated or delayed. Furthermore, many of the factors that lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if we or our third-party collaborators make significant manufacturing or formulation changes to our product candidates, we or they may need to conduct additional studies to bridge the modified product candidates to earlier versions to ensure comparability, safety and efficacy of the two different product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to commercialize our programs and product candidates. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the results of our current or any future clinical trials are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fail to obtain, or be delayed in obtaining, marketing approval for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval for indications or patient populations that are not as broad as intended or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">need to change the way the product is administered; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be required to perform additional clinical trials to support approval or be subject to additional post- marketing testing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have regulatory authorities withdraw their marketing approval of the product after granting it; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have regulatory authorities impose restrictions on distribution of the product in the form of a risk evaluation and mitigation strategy, or REMS, or modified REMS, that limit our ability to commercialize the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to the addition of labeling statements, such as warnings or contraindications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be sued and held liable for harm caused to patients; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience damage to our reputation. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of any particular study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any BLA we submit to the FDA or any comparable foreign regulating authorities. Any such delay or rejection could prevent us from commercializing our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates and the process for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment with our product candidates may produce undesirable side effects or adverse reactions or events. For example, the AAV vector and related capsid protein, which we are currently using to deliver many of our ddRNAi and silence and replace product candidates, could cause adverse immunological side effects due to preexisting and/or recall responses to the naturally occurring virus from which the vector is engineered, or to the DNA construct product itself. These responses may also interfere with therapeutic efficacy if not identified and managed optimally. Preexisting immune responses to AAV manifesting as neutralizing antibodies are common within the general population and may be a limitation to the enrollment of patients in gene therapy clinical trials using AAV vectors, the successful use of AAV vectors in gene therapy clinical trials and the market acceptance of product candidates, if approved, that are delivered using AAV vectors. Patients with neutralizing antibodies to AAV will not derive clinical benefit from administration of such a product candidate unless steps are taken to clinically address the issue and those treatments themselves may cause adverse effects. In previous clinical trials undertaken by other companies involving systemic administration of AAV viral vectors for gene therapy, some subjects experienced adverse events, including the development of a negative T cell response against the AAV capsid protein. If our vectors cause similar adverse events, we may be required to delay or discontinue further clinical development of our product candidates. It is also possible that we may discover new adverse events related to AAV or other vectors, which could potentially enhance the risk to patients who use our product candidates delivered with that vector. Additionally, the procedure used to administer the treatment could result in undesirable health effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any such adverse events occur, our current and any future clinical trials could be suspended or discontinued and the FDA or comparable foreign regulatory authorities could order us to cease further development or deny approval of our product candidates for any or all targeted indications. The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial. If we elect or are required to delay, suspend or discontinue any clinical trial of any of our product candidates, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if any of our biopharmaceutical product candidates receive marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of the product outweigh its risks, which may include, among other things, a medication guide outlining the risks of gene therapies for distribution to patients and a communication plan to patients and healthcare practitioners. Other elements to assure safe use in a mandated REMS could include, but are not limited to, restrictions upon distribution and prescribing, additional prescriber training, establishment of patient registries and other measures that could limit commercialization of the product. Comparable foreign regulating authorities might require adoption of measures similar to a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
REMS. Furthermore, if we or others later identify undesirable side effects caused by our product candidate, a number of potentially significant negative consequences could result, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may withdraw approvals of such product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require additional warnings on the label; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to change the way a product candidate is administered or conduct additional clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we could be sued and held liable for harm caused to patients; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reputation may suffer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly harm our business, prospects, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to successfully develop related diagnostics for our therapeutic product candidates, or experience significant delays in doing so, we may not achieve marketing approval or realize the full commercial potential of our therapeutic product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may develop related diagnostics for some of our therapeutic product candidates. Such related diagnostics are subject to regulation by the FDA and typically to comparable foreign regulatory authorities as medical devices and typically require separate regulatory approval or clearance prior to commercialization. Marketing approval or clearance of the diagnostic will require sufficient data to support its safety and efficacy. In addition, at least in some cases, the FDA and comparable foreign regulatory authorities may require the development and regulatory approval or clearance of a related diagnostic as a condition to approving our therapeutic product candidates. While we have some limited experience in developing diagnostics, we plan to rely in large part on third parties to perform these functions. We may seek to enter into arrangements with one or more third parties to create a related diagnostic for use with our current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or any third parties that we engage to assist us are unable to successfully develop or obtain marketing approval or clearance for related diagnostics for our therapeutic product candidates, or experience delays in doing so: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the development of relevant product candidates may be delayed or impaired altogether if we are unable to appropriately select patients for enrollment in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our relevant therapeutic product candidate may not receive marketing approval if its effective use depends on a related diagnostic in the regulatory authority&#8217;s judgment; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not realize the full commercial potential of any therapeutic product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations targeted by our therapeutic product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of these events were to occur, our business would be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate or the approval may be for a narrower indication than we expect. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or comparable foreign regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. Regulatory agencies may also approve a treatment candidate for fewer or more limited indications than requested, may not approve the price we intend to charge for our product candidate, may limit our ability to promote the product, may impose significant limitations upon the approval of the product, including, but not limited to, narrow indications, significant warnings, precautions or contraindications with respect to conditions of use, or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. The FDA or comparable foreign regulatory authorities may impose a REMS or other conditions upon our approval that limit our ability to commercialize the product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA, had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of foreign manufacturing facilities and products, postponed routine surveillance inspections of domestic manufacturing facilities and is conducting only teleconference meetings. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report to the FDA adverse events and any failure of a product to meet the specifications in the BLA. FDA guidance advises that patients treated with some types of gene therapy undergo follow-up observations for potential adverse events for as long as 15 years. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable foreign, federal and state laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, product manufacturers and their establishments, products and applications are subject to payment of user fees/or and continual review and periodic inspections by the FDA and comparable foreign regulatory authorities for compliance with cGMP and comparable foreign requirements, and adherence to commitments made in the BLA. If we or a regulatory agency discover previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issue a warning letter asserting that we are in violation of the law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek an injunction or impose civil or criminal penalties or monetary fines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspend or withdraw regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspend any ongoing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refuse to permit government reimbursement of our product by government-sponsored third-party payers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refuse to approve a pending BLA or supplements to a BLA submitted by us for other indications or new product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seize our product; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refuse to allow us to enter into or continue supply contracts, including government contracts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable regulatory authorities of foreign countries must also approve the manufacturing and marketing of the product candidates in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Even if a product candidate is approved, the FDA or comparable regulatory authorities in other countries, as the case may be, may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States also have requirements for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Regulatory approval of a product candidate in one country does not ensure approval in any other country, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in other countries. Also, regulatory approval for any of our product candidates may be withdrawn based on adverse events reported or regulatory decisions made in other countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced, our ability to realize the full market potential of our product candidates will be compromised and our business may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future prospects may also depend on our collaborators&#8217; ability to successfully develop a pipeline of additional product candidates, and we and our collaborators may not be successful in efforts to use our platform technologies to identify or discover additional product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. We do not have any products on the market and are early in our development efforts. All of our product candidates are in preclinical development. Our product candidates derived from our platform technology may not successfully complete investigational new drug, or IND, enabling studies, and our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. Our and our collaborators&#8217; research methodology may be unsuccessful in identifying potential product candidates, our potential product candidates may not demonstrate the necessary preclinical outcomes to progress to clinical studies, or our product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to discontinue our development efforts for a program or programs. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to obtain orphan drug exclusivity, where relevant, in all markets for our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of our current pipeline product candidates, only our silence and replace therapeutic for the treatment of OPMD has been designated with orphan drug status. In January 2018, the FDA granted such designation after our candidate for the treatment of OPMD had been designated an orphan drug in January 2017 by the European Commission. Regulatory authorities in some jurisdictions, including the United States, may designate drugs or biological products for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a product intended to treat a &#8220;rare disease or condition&#8221;, which is generally defined as any disease or condition which affects less than 200,000 individuals in the United States. The FDA may also designate a product as an orphan drug if it is intended to treat a disease or condition which affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product candidate. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for such indication for that time period. The applicable period is seven years in the United States. Orphan drug exclusivity may be lost if the FDA or the European Medicines Agency, or the EMA, determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. While there is no guarantee, FDA orphan drug designation may provide a range of benefits, including a potential fast track process for clinical regulatory approval, potential tax credits for qualified clinical trials and an exemption from FDA application user fees. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product in the United States or for additional products in the European Union, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition, and the same drug could be approved for a different condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug, made by a competitor, for the same condition if the FDA concludes that the competitive product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, the EMA can approve a competitive product if the orphan drug no longer meets the criteria for orphan designation (including sufficient profitability), if the competitive product is safer, more effective or otherwise clinically superior, or if the orphan drug cannot be supplied in sufficient quantities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Reliance on Third Parties </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our prospects for successful development and commercialization of our products are dependent to varying degrees upon the research, development, commercialization, and marketing efforts of any potential collaborators. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third parties for certain aspects of the research, development, commercialization and marketing of our current and any future product candidates. Other than as provided for in our collaboration agreements, we have no control over the resources, time and effort that our collaborators may devote to the development of product candidates. We are dependent on our collaborators to conduct some aspects of the research and development of each of our product candidates, and expect to need access to them to facilitate and/or to complete the regulatory process. We will likely rely on a pharmaceutical company for the successful marketing and commercialization of any such product candidates for which they/we receive approval, if any. There can be no guarantee at this stage that we will conclude a partnership with such a company on favorable terms, or at all, nor even if we do so, that success will be achieved. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to recognize revenues from successful potential collaborations may be impaired by multiple factors including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may cease development in an area that is the subject of a collaboration agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may change the success criteria for a particular program or product candidate in development, thereby delaying or ceasing development of such program or product candidate in development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator with development or commercialization obligations may not commit sufficient financial or human resources to the development, marketing, distribution or sale of a product, or may otherwise fail in development or commercialization efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator could independently develop, or develop with unrelated parties, products that compete directly or indirectly with our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may exercise its rights under the agreement to discontinue our collaboration; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a dispute may arise between us and a collaborator concerning the development or commercialization of a product candidate, resulting in a delay in milestones, royalty payments, or discontinuation of a program and possibly resulting in costly litigation or arbitration that may divert management attention and resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may not adequately protect the intellectual property rights associated with a product candidate; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may use our proprietary information or intellectual property in such a way as to expose us actual or threatened litigation from a third party, patent office proceedings or other risks that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator may own or co-own, or have a license to use, intellectual property rights associated with a product candidate that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property rights. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our potential collaborators do not perform in the manner we expect or fulfill their responsibilities in a timely manner, or at all, the development, regulatory and commercialization process could be delayed or discontinued or otherwise be unsuccessful. Conflicts between us and our collaborators may arise. In the event of discontinuation of one or more of our collaboration agreements, it may become necessary for us to assume the responsibility for any such product candidates at our own expense or seek new collaborators. In that event, we likely would be required to limit the size and scope of one or more of our independent programs or increase our expenditures and seek additional funding, which may not be available on acceptable terms or at all, and our business may be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct our preclinical studies and clinical trials. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have the ability to conduct all aspects of our preclinical testing or any future clinical trials ourselves. We are dependent on third parties to conduct the preclinical studies for our product candidates and will depend on third parties to conduct any future clinical trials for our product candidates, and therefore the timing of the initiation and completion of these trials and studies is reliant on third parties and may occur at times substantially </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">different from our estimates or expectations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of clinical trials, we expect to rely on CROs and third-party collaborators to conduct any future clinical trials in accordance with our clinical protocols and regulatory requirements. We expect our CROs, investigators and third-party collaborators will play a significant role in the conduct of these trials and subsequent collection and analysis of data. There is no guarantee that any CROs, investigators or the other third-party collaborators on which we rely for administration and conduct of our future clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements or otherwise performs in a substandard manner, any future clinical trials may be extended, delayed or terminated. If our current or any of our future clinical trial sites terminates for any reason, we may lose all of the information on subjects enrolled in any such clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot contract with acceptable third parties on commercially reasonable terms, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed or discontinued. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In all events, we are responsible for ensuring that each of our preclinical studies, and our future clinical trials are conducted in accordance with the general investigational plan and protocols for the study or trial. The FDA requires clinical trials to be conducted in accordance with current GCP, including for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements, and any failure to satisfy these responsibilities and requirements, whether caused by us or by third parties upon whom we rely, could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third-party supply and manufacturing partners to manufacture and supply the materials for our research and development and preclinical and clinical study supplies. We do not own manufacturing facilities or supply sources for such materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that our supply of research and development, preclinical and clinical development biologics and other materials will not be limited, interrupted or restricted in certain geographic regions, be of satisfactory quality or continue to be available at acceptable prices. Replacement of a third-party manufacturer could require significant effort, cost and expertise because there may be a limited number of qualified replacements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves or enter into an agreement with another third party, which would be costly and delay any future clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party. These factors increase our reliance on our manufacturers and may require us to obtain a license from a manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines of the FDA and comparable foreign regulatory authorities. The delays and costs associated with the verification of a new manufacturer could increase our costs and delay the development of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to rely on third-party manufacturers for preclinical and clinical grade product candidates and if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements could adversely affect our business in a number of ways, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an inability to conduct necessary preclinical studies to progress our product candidates to clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an inability to initiate or continue any future clinical trials of product candidates under development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of the cooperation of a collaborator; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subjecting our product candidates to additional inspections by regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requirements to cease distribution or to recall batches of our product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our third-party manufacturers may be subject to damage or interruption from, among other things, events such as the COVID-19 pandemic, fire, natural or man-made disaster, power loss, telecommunications failure, unauthorized entry, computer viruses, denial-of-service attacks, acts of terrorism, human error, vandalism or sabotage, financial insolvency, bankruptcy and similar events. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and our licensees or collaborators may disagree over our right to receive payments under any potential collaboration agreements with them, potentially resulting in costly litigation and loss of reputation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to receive payments under any out-license and collaboration agreements depends on our ability to clearly delineate our rights under those agreements. We have licensed and may license additional portions of our intellectual property to our collaborators with the intent that our collaborators will develop product candidates based on our ddRNAi or other technology to address specific conditions. However, a collaborator may use our intellectual property without our permission, dispute our ownership of intellectual property rights, or argue that our intellectual property does not cover, or add value to, any product candidates they develop. If a dispute arises, it may result in costly patent office procedures and litigation, and our collaborator may refuse to pay us while the dispute is ongoing. Furthermore, regardless of any resort to legal action, a dispute with a collaborator over intellectual property rights may damage our relationship with that collaborator and may also harm our reputation in the industry. Even if we are entitled to payments from our collaborators, we may not actually receive these payments, or we may experience difficulties in collecting the payments to which we believe we are entitled. After our collaborators launch commercial products containing our licensed traits, we will need to rely on the good faith of our collaborators to report to us the sales they earn from these products and to accurately calculate the payments we are entitled to, a process that will involve complicated and difficult calculations. Although we seek to address these concerns in our license and collaboration agreements by reserving our right to audit financial records, such provisions may not be effective. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have only limited experience in regulatory affairs and intend to rely on consultants and other third parties for regulatory matters, which may affect our ability or the time we require to obtain necessary regulatory approvals. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited experience in filing and prosecuting the applications necessary to gain regulatory approvals for gene therapy or ddRNAi product candidates. Moreover, the product candidates that are likely to result from our development programs are based on novel technologies that have not been extensively tested in humans. The regulatory requirements governing these types of product candidates may be less well defined or more rigorous than for conventional products. As a result, we may experience a longer regulatory process in connection with obtaining regulatory approvals of any products that we develop. We intend to rely on independent consultants for purposes of our regulatory compliance and product development and approvals in the United States and elsewhere. Any failure by our consultants to properly advise us regarding, or properly perform tasks related to, regulatory compliance requirements could compromise our ability to develop and seek regulatory approval of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to manufacture our product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our technology and product candidates, we may, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite these contractual provisions, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by potential competitors, are inadvertently incorporated into the technology of others, or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, discovery by a third party of our trade secrets or other unauthorized use or disclosure would impair our intellectual property rights and protections in our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us or we may share these rights with other parties. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Commercialization of Our Product Candidates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have not entered into agreements with any third-party manufacturers to support commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet secured manufacturing capabilities for commercial quantities of our product candidates or established facilities in the desired locations to support commercialization of our product candidates. We intend to rely on third-party manufacturers for commercialization, but have not entered into any agreements with such manufacturers to support our product candidates currently in development. We may be unable to negotiate agreements with third-party manufacturers to support our commercialization activities on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may encounter technical or scientific issues related to manufacturing or development that we may be unable to resolve in a timely manner or with available funds. Currently, we do not have the capacity to manufacture our product candidates on a commercial scale. In addition, our product candidates are novel, and only one manufacturer currently has experience producing our product candidates on a large scale. If we are unable to engage manufacturing partners to produce our product candidates on a larger scale on reasonable terms, our commercialization efforts will be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we timely develop a manufacturing process and successfully transfer it to the third-party manufacturers of our product candidates, if such third-party manufacturers are unable to produce the necessary quantities of our product candidates, or do so in compliance with cGMP or with pertinent foreign regulatory requirements, and within our planned time frame and cost parameters, the development and sales of our product candidates, if approved, may be impaired. In some jurisdictions, approval of the manufacturer may be required. There is no guarantee such approval can be obtained. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to enter into agreements with third parties to commercialize our product candidates or establish sales and marketing capabilities to market and sell our product candidates, we may be unable to generate any revenues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have no sales and marketing organization and have no experience selling and marketing pharmaceutical products. To successfully commercialize any product candidates that may be approved, we will need to develop these capabilities, either through our relationships with collaborators or our own. We may seek to enter into collaborations with other entities to utilize their marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our future collaborators do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. The establishment and development of our own sales force or the establishment of a contract sales force to market any products we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be competing with many companies that currently have extensive and well- funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Physicians, patients, third-party payers or others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue from the sale or licensing of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain approval for a product candidate, we may not generate or sustain revenue from sales of the product if the product cannot be sold at a competitive cost or if it fails to achieve market acceptance by physicians, patients, third-party payers or others in the medical community. These market participants may be hesitant to adopt a novel treatment based on ddRNAi or silence and replace technology, and we may not be able to convince the medical community and third-party payers to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on, among other factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the safety and efficacy of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to offer our products for sale at competitive prices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative convenience and ease of administration of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any adverse side effects associated with our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms of any approvals and the countries in which approvals are obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations or warnings contained in any labeling approved by the FDA or comparable foreign regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conditions upon the approval imposed by FDA or comparable foreign regulatory authorities, including, but not limited to, a REMS; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of patients to try new treatments and of physicians to prescribe these treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of government and other third-party payer coverage and adequate reimbursement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since we are focused on the emerging therapeutic modality of ddRNAi, and silence and replace these risks may increase if new competitors are able to market ddRNAi-based therapeutics or silence and replace-based therapeutics or if these treatments become less favored in the commercial marketplace. In addition, we believe that one of the benefits of our ddRNAi and silence and replace technologies is the expected length of time of the effects. If our treatments do not have a long-term effect after administration, such a development would likely significantly and adversely affect market acceptance of our product candidates, if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional risks apply in relation to any disease indications we pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the United States or European Union. If pricing is not approved or accepted in the market at an appropriate level for any approved product for which we pursue and receive an orphan drug designation, such product may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, for a period of time. Orphan exclusivity could temporarily delay or block approval of one of our products if a competitor obtains orphan drug designation for its product first. However, even if we obtain orphan exclusivity for one of our products upon approval, our exclusivity may not block the subsequent approval of a competitive product that is shown to be clinically superior to our product. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market size is also a variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a product, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Events such as the COVID-19 pandemic and other public health crises may materially and adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of our products is dependent on the efforts of our third-party collaborators, as we rely on third parties to conduct our preclinical studies and clinical trials, and for our supply of research and development, preclinical and clinical development biologics and other materials. Accordingly, our operations and supply chain could be subject to significant disruptions to the extent that our third-party partners are impacted by the COVID-19 pandemic or the associated governmental actions. There may be related restrictions or delays with respect to clinical trials and preclinical studies, as well as the export, import or shipment of raw materials, drug substance or drug product that could materially delay our business or clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, certain of our research and development efforts are conducted globally, including our ongoing development of our silence and replace therapeutic for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), and will be dependent upon our ability to initiate clinical sites and enroll patients despite the ongoing COVID-19 pandemic. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We had also implemented work-from-home measures for the majority of our employees between March 2020 and June 2021, resulting in a reduction of laboratory work and a halt of non-essential business travel. As we transition our employees back to our premises, there is a risk that COVID-19 infections occur at our offices or laboratory facilities and significantly affect our operations. Additionally, if any of our critical vendors are impacted, our business could be affected if we become unable to timely procure essential equipment, supplies or services in adequate quantities and at acceptable prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the COVID-19 outbreak has caused significant disruption to the global economy and in the global and U.S. financial markets. This could impact our ability to raise additional funding, which may not be available on acceptable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. In addition, due to the speed with which the COVID-19 situation is developing and evolving, there is uncertainty around its ultimate impact on public health, business operations and the overall economy; therefore, the negative impact on our financial position, operating results and liquidity cannot be reasonably estimated at this time, but the impact may be material. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face competition from entities that have developed or may develop product candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of pharmaceutical products is highly competitive. We compete with a variety of multinational pharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or could develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community, patients and third-party payers, and any new treatments that enter the market. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be a significant number of products that are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing, and may in the future try to develop, product candidates. This increasingly competitive landscape may compromise the development of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware of multiple companies that are working in the field of RNAi therapeutics, including Alnylam, Arbutus, Arrowhead. Some of our current product candidates, if approved, would compete with approved and currently marketed treatments. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our ddRNAi-based product candidates would compete with antisense and other RNA-based pharmaceutical products currently under development. Like RNAi therapeutics, antisense products target mRNA with the objective of suppressing the activity of specific genes. The development of antisense products is more advanced than that of RNAi therapeutics, and antisense technology may become the preferred technology for products that target mRNAs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources and experience than we have. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or non-competitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A variety of risks outside of our control associated with international operations could adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved for commercialization, it is our current intention to market them on a worldwide basis, either alone or in collaboration with others. In addition, we conduct development activities in various jurisdictions throughout the world. We expect that we will be subject to additional risks related to engaging in international operations, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">different regulatory requirements for approval of biopharmaceutical products in foreign countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced protection for intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unexpected changes in tariffs, trade barriers and regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">economic weakness, including inflation, or political instability in particular foreign economies and markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">workforce uncertainty in countries where labor unrest is more common than in Australia or the United States; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business interruptions resulting from geopolitical actions, including war and terrorism, natural disasters, including earthquakes, typhoons, floods and fires and disease pandemics and epidemics. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The insurance coverage and reimbursement status of newly approved products is uncertain. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The availability of coverage and adequate reimbursement by governmental and private payers is essential for most patients to be able to afford expensive treatments. Sales of our product candidates will depend substantially, both in the United States and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by third-party payers, and there have been increasing efforts by governmental and other third-party payers, in the United States and abroad, to cap or reduce healthcare costs. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the reimbursement amounts approved by third-party payers may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intended use of a biopharmaceutical product by a physician can also affect pricing. For example, CMS could initiate a National Coverage Determination administrative procedure, by which the agency determines which uses of a therapeutic product would and would not be reimbursable under Medicare. This determination process can be lengthy, thereby creating a long period during which the future reimbursement for a particular product may be uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries is likely to put pressure on the pricing and usage of any of our product candidates that may be approved for marketing in the future. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems can be substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, each enacted in March 2010, as amended, or the ACA, greatly expanded health insurance coverage in the United States, but has also been the target of litigation and Congressional reform efforts since its adoption, including unsuccessful efforts to seek repeal of the entire ACA. While efforts to strike down the ACA in the courts currently seem stalled, uncertainty regarding the future of the ACA remains, including with respect to legislative efforts. Any significant efforts at the federal or state levels to reform the healthcare system by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changing the way healthcare is provided or funded&#8212;including through the expansion of Medicare to larger sections of the population&#8212;could have a material impact on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the ACA, and similar laws, may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. For example, other legislative changes adopted since the ACA was enacted ACA may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. In addition, other legislative changes have been adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year effective April 2013 that, due to subsequent legislative amendments to the statute, will stay in effect through 2029 unless additional Congressional action is taken. Note, however, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), which was signed into law on March&#160;27, 2020, designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May&#160;1, 2020 through December&#160;31, 2020, and extended the sequester by one year, through 2030. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the 2017 Cuts and Jobs Act (the &#8220;Tax Act&#8221;). Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&#160;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, although it is unclear when the Supreme Court will make a decision. It is also unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In January 2013, former President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. This law may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and accordingly, our financial operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, value and risk-based payment arrangements that put healthcare providers at direct financial risk for the healthcare resources used to care for patient populations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription pharmaceutical products and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. We cannot predict what healthcare reform initiatives may be adopted in the future. It is possible that additional governmental action is taken to address the COVID-19 pandemic. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on biopharmaceutical product pricing. Such reforms could depress pricing for any product candidates that we may successfully develop and for which we may obtain regulatory approval and may negatively affect our overall financial condition and ability to develop additional product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in U.S. tax law may materially adversely affect our financial condition, results of operations and cash flows. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock, warrants and pre-funded warrants. In recent years, many such changes have been made and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes are likely to continue to occur in the future. Future changes in U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge our investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. tax laws on an investment in our common stock, warrants and pre-funded warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our relationships with third-party payers, healthcare professionals and customers in the United States and elsewhere may be subject to anti- kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to significant penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our relationships with third-party payers, healthcare professionals and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we sell, market and distribute any biopharmaceutical products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by the federal government and by the U.S. states and foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Open Payments program, created under the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the CMS information related to payments or other transfers of value made to physicians, and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members by the 90th day of each subsequent calendar year, and disclosure of such information will be made by CMS on a publicly available website; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers; state and foreign laws that require biopharmaceutical or biotechnology companies to comply with the industry voluntary </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require biopharmaceutical or biotechnology manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or compromise our ability to conduct our business or obtain regulatory approvals for our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gene therapy remains a novel technology and no gene therapy product utilizing ddRNAi or silence and replace has been approved to date in the United States. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Our product candidates, including our viral delivery systems, could produce adverse events. Adverse events in our clinical trials or following approval of any of our product candidates, even if not ultimately attributable to our product candidates, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Business Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not successfully engage in strategic transactions or enter into new collaborations, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may consider additional strategic transactions, such as collaborations, acquisitions, asset purchases or sales and out- or in- licensing of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or pharmaceutical companies. The competition for collaborators is significant, and the negotiation process is time- consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new or existing collaboration if, for example, development or approval of a product </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator discontinues the collaboration. Any such collaboration, or other strategic transaction, may require us to incur non- recurring or other charges, increase our expenditures, pose significant integration or implementation challenges or disrupt our management or business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay and make more expensive the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success largely depends on the continued service of key management and other specialized personnel, including Dr.&#160;Jerel Banks (Chief Executive Officer) and Ms.&#160;Megan Boston (Executive Director). The loss of one or more members of our management team or other key employees or advisors, if not adequately replaced, could delay or increase the cost of our research and development programs and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our product candidates and the specialized nature of the regulatory approval process for our product candidates. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our collaborations with outside scientists and consultants may be subject to restriction and change. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We work with medical experts, chemists, biologists and other scientists at academic and other institutions, and consultants who assist us in our research, development and regulatory efforts, including the members of our scientific advisory board. In addition, these scientists and consultants have provided, and we expect that they will continue to provide, valuable advice regarding our programs and regulatory approval processes. These scientists and consultants are not our employees and may have other commitments that would limit their future availability to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, we are limited in our ability to prevent them from establishing competing businesses or developing competing products. For example, if a key scientist acting as a principal investigator in any of our future clinical </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials identifies a potential product or compound that is more scientifically interesting to his or her professional interests, his or her availability to remain involved in any future clinical trials could be restricted or eliminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may experience difficulties in managing our growth and expanding our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited experience in development and commercialization of pharmaceutical products. As our product candidates continue to advance through preclinical studies and any future clinical trials and potentially toward regulatory approval and commercial sale, we will need to expand our development, regulatory, manufacturing and sales capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and insider trading. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, principal investigators, CROs, consultants, commercial partners and vendors. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and comparable foreign regulators, provide accurate information to the FDA and comparable foreign regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of any future clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We could face potential product liability and, if successful claims are brought against us, we may incur substantial liability and costs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of our product candidates in clinical trials and the sale of any products for which we may in the future obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impairment of our business reputation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs due to related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">distraction of management&#8217;s attention from our primary business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to patients or other claimants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our product candidates, if approved for commercial sale; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased cost, or impairment of our ability, to obtain or maintain product liability insurance coverage. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We carry combined general public and products liability (including human clinical trials extension) insurance of $20 million (per any one occurrence) and $10 million (per any one occurrence and in the aggregate), respectively. We believe our product liability insurance coverage is sufficient in light of our current clinical programs. However, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidates, we intend to expand our insurance coverage to include the sale of commercial products, but we may not be able to obtain or maintain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded against other pharmaceutical companies in class action lawsuits based on pharmaceutical products, or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the price of our common stock to decline and, if judgments exceed our insurance coverage, could materially and adversely affect our financial position. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or discontinue our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our product candidate, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may harm our reputation, delay our regulatory approval process, limit the type of regulatory approvals our product candidates receive or maintain, and compromise the market acceptance of any of our product candidates that may in the future receive regulatory approval. As a result of these factors, a product liability claim, even if successfully defended, could hurt our business and impair our ability to generate revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and our development partners, third-party manufacturers and suppliers use biological materials and may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our development partners, third-party manufacturers and suppliers may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. National, state and local laws and regulations in the United States and other countries govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development and commercialization efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and any future clinical trials, regulatory approvals or product commercialization progress could be suspended. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may use our limited financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal computer and information technology systems, or those of our collaborators and other development partners, third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our product development programs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer and information technology systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cyber-attacks, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. While we have not experienced any material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. For example, the loss of clinical trial data from ongoing or future clinical trials or data from preclinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to manufacture our product candidates and will rely on third parties to conduct future clinical trials, and similar events relating to their computer systems could also have similar consequences to our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed and become more expensive. As a result of COVID-19, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees that are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyber-attacks, breaches, interruptions or other data security incidents could result in legal claims or proceedings, liability under federal or state laws that protect the privacy of personal information, regulatory penalties, significant remediation costs, disrupt key business operations and divert attention of management and key information technology resources. In the United States, notice of breaches must be made to affected individuals, the U.S. Secretary of the Department of Health and Human Services, or HHS, and for extensive breaches, notice may need to be made to the media or U.S. state attorneys general. Such a notice could harm our reputation and our ability to compete. HHS has the discretion to impose penalties without attempting to resolve violations through informal means. In addition, U.S. state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. There can be no assurance that we, our collaborators, CROs, vendors, and any other business counterparties will be successful in efforts to detect, prevent, protect against or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches of systems. In addition, we do not maintain standalone cyber-security insurance and have limited insurance coverage in the event of any breach or disruption of our or our collaborators&#8217;, CROs&#8217;, or vendors&#8217; systems, including any unauthorized access or loss of any personal data that we may collect, store or otherwise process. The costs related to significant security breaches or disruptions could be material and exceed </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the limits of any insurance coverage we may have. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary information, including data related to our personnel, we could incur liability and the further development and commercialization of our product candidates could be delayed and our business and operations could be adversely affected and/or could result in the loss or disclosure of critical or sensitive data, which could result in financial, legal, business or reputational harm to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our current laboratory operations are concentrated in one location and any events affecting this location may seriously compromise our ability to operate our business and continue the development of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current laboratory operations are located in our facility situated in Hayward, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics and pandemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize the facility, may compromise our ability to operate our business, particularly on a daily basis, cause us financial losses and inhibit or delay our continued development of our product candidates. Loss of access to this facility may result in increased costs, delays in the development of our product candidates or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at this facility, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facility is unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The investment of our cash and cash equivalents is subject to risks which may cause losses and affect the liquidity of these investments. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023, we had $2.5 million in cash and cash equivalents. We historically have invested substantially all of our available cash and cash equivalents in cash deposits meeting the criteria of our investment policy, which is focused on the preservation of our capital. These investments are subject to general credit, liquidity, market and interest rate risks. We may realize losses in the fair value of these investments, which would have a negative effect on our financial results. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain or protect sufficient intellectual property rights related to our product candidates, we may not be able to obtain exclusivity for our product candidates or prevent others from developing similar competitive products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, know-how, trade secret protection and confidentiality agreements&#8212;both that we own or possess or that are owned or controlled by our licensors and licensed to us&#8212;to protect the intellectual property related to our technology and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file, and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current licensors or licensees, or any future licensors or licensees, will fail to identify or obtain sufficient protection for patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, our patents and patent applications may not be prosecuted </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, patent term adjustments, etc., although we are unaware of any such defects. If we or our current licensors or licensees, or any future licensors or licensees, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our current licensors or licensees, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable in circumstances where it is not possible to remedy those material defects. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or other jurisdictions. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate opposition, interference, re-examination, post-grant review, inter parties review, nullification or derivation action in court or before patent offices or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Furthermore, even if our patents and patent applications are unchallenged, they may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue, or are revoked, if the breadth or strength of our patent protection is threatened, or if our patent portfolio fails to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates and threaten our ability to commercialize future products. Any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time (up to 18 months) after filing, we cannot be certain that we or our licensors were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications before March&#160;16, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications on or after March&#160;16, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, and in most other jurisdictions with a patent system, the natural expiration of a patent is generally 20 years after its filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. This risk is material in light of the length of the development process of our products and lifespan of our current patent portfolio. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. What constitutes a trade secret and what protections are available for trade secrets varies from state to state in the United States and country by country worldwide. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by measures designed to maintain the physical security of our premises and physical and electronic security of our information technology systems. Security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known to or be independently discovered by competitors. Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets can be difficult to detect, could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, the laws of some foreign countries such as India and China do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our markets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on license relationships with a number of third parties for portions of our intellectual property, including platform technology patents relating to our ddRNAi technology. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have in-licensed certain intellectual property from third parties, including technology related to ddRNAi and antisense RNA. In some cases, our licenses to intellectual property are non-exclusive and the licensors may license the technology to our competitors in the same field, which may result is significant competition for us. In other cases, our licenses to intellectual property are exclusive only for a specific field of use (such as human therapeutics), and the licensors retain rights to practice the licensed intellectual property themselves and to grant licenses to third parties in other fields. Such third parties may develop improvements to the licensed intellectual property that are not licensed to us, which could block our ability to continue developing the product candidate covered by the licensed intellectual property, unless we negotiate a license. Such third parties may also disclose competitively sensitive information about the licensed intellectual property that diminishes its value. In other cases, our licenses are for research purposes only. Upon regulatory marketing approval of our product candidates it may be necessary for us to obtain a broader license in order to commercialize. We cannot guarantee the availability of the broader license or that it can be obtained on commercially reasonable terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on some of these third party licensors to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights we license, and therefore cannot guarantee that these patents and applications will be prosecuted or enforced in a manner consistent with the best interests of our business. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. Additionally, we may not be able to control the publication or other disclosures of research carried out by our licensors relating to technology that could otherwise prove patentable. Pursuant to the terms of some of our license agreements with third parties, some of our third-party licensors have the right, but not the obligation, to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents. Even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors, and cannot guarantee that we would receive it and on what terms. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our prosecution or enforcement of such patents or defense of such claims to protect our interests in the licensed patents. If we cannot obtain patent protection, or enforce existing or future patents against third parties, our competitive position and our financial condition could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hold rights under license or sublicense agreements with third parties that are important to our business. Under our existing license and sublicense agreements, we are subject to various obligations, including diligence obligations with respect to development and commercialization activities and payment obligations. In spite of our efforts, our licensors may conclude that we have materially breached our obligations under such license agreements and terminate the license agreements, thereby removing or limiting our ability to develop and commercialize product candidates and technology covered by these license agreements. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may need to obtain additional licenses from third parties to advance our research or allow commercialization of our product candidates, such as if we identify new technology that would advance our programs or if an existing license agreement is terminated. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In many cases, patent prosecution of our in-licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In some cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners and the value of the licensed patents may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which our technology and processes infringe on intellectual property of a licensor that is not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sublicensing of patent and other rights under any collaborative relationships we might enter into in the future; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the priority of invention of patented technology. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our results of operations will be affected by the level of royalty payments that we are required to pay to third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a party to license agreements that require us to remit royalty payments and other payments related to in-licensed intellectual property. Under our in-license agreements, we may pay up-front fees and milestone payments and be subject to future royalties. We cannot precisely predict the amount, if any, of royalties we will owe in the future, and if our calculations of royalty payments are incorrect, we may owe additional royalties, which could negatively affect our results of operations. As our product sales increase, we may, from time to time, disagree with our third-party collaborators as to the appropriate royalties owed, and the resolution of such disputes may be costly, may consume management&#8217;s time, and may damage our relationship with our collaborators. Furthermore, we may enter into additional license agreements in the future, which may also include royalty, milestone and other payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The licenses we may grant to our collaborators and other licensees to use our ddRNAi and other technology may be exclusive to the development of product candidates for certain conditions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the out-licenses we may grant to our collaborators to use our ddRNAi and other technology may be exclusive to the development of product candidates for certain conditions, so long as our collaborators comply with certain requirements. That means that once our ddRNAi technology is licensed to a collaborator for a specified condition, we are generally prohibited from developing product candidates for that condition and from licensing the ddRNAi to any third party for that condition. The limitations imposed by these exclusive licenses could prevent us from expanding our business and increasing our development of product candidates with new collaborators, both of which could adversely affect our business and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter parties review proceedings before the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may be accused of infringing. In addition, third parties may obtain patents in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process, methods of use or formulations of any of our product candidates, any DNA constructs formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. In either case, such a license may not be available on commercially reasonable terms or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to gene therapy product components and processes for our development pipeline through acquisitions and in-licenses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently, we have certain rights to intellectual property to develop our current gene therapy product candidates. However, our product candidates may require specific formulations to work effectively and efficiently and rights to such formulations may be held by others. In addition, we may need additional intellectual property rights as we develop future product candidates. In particular, we are aware of a third party patent directed to AAV vectors that expires in 2026. In the event we receive regulatory marketing approval before the expiration date it may be necessary for us to obtain a license to the patent in order to commercialize. We cannot guarantee the availability of the license or that it can be obtained on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify on terms that we find acceptable, or at all. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third- party intellectual property rights, our business, financial condition and prospects for growth could suffer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful, and issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non- enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. Such proceedings could result in revocation, amendments to our patent claims or statements being made on the record such that our claims may no longer be construed to cover our product candidates. Outcomes or statements on the record in one country could have a disadvantageous effect on prosecution or enforcement of a patent or patent application in another country. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that no invalidating prior art exists or that the patent examiner was aware of all material prior art during prosecution. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce or defend the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted, enforced and defended in a manner consistent with the best interests of our business. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, enforcement of a favorable decision by a court can depend on cooperation of a governmental authority which may or may not be available in every jurisdiction. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our patents and patent applications filed in the United States before March&#160;16, 2013, interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could cause the trading price of our common stock to fall. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our key employees and personnel are or were previously employed at universities, medical institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. Furthermore, universities or medical institutions who employ some of our key employees and personnel in parallel to their engagement by us may claim that intellectual property developed by such person is owned by the respective academic or medical institution under the respective institution intellectual property policy or applicable law. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs, be a distraction to management and other employees, and damage our relationships with the academic and medical institutions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may in the future have ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various corresponding governmental patent agencies outside of the United States require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and it therefore is costly, time-consuming and inherently uncertain. In addition, on September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An important change introduced by the Leahy-Smith Act is that, as of March&#160;16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. It is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the Leahy-Smith Act are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent U.S. Supreme Court rulings such as Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad I); BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litig. (Myriad II); and Promega Corp. v. Life Technologies Corp. have also narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in some situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our success depends, in part, on our ability to protect our intellectual property and our technologies outside the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on our ability to obtain and maintain patent and trade secret protection for our technologies, our traits, and their uses, as well as our ability to operate without infringing upon the proprietary rights of others outside the United States. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries around the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. In addition, we may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at times in- license third-party technologies for which limited international patent protection exists and for which the time period for filing international patent applications has passed. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Potential competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, if approved, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to an Investment in Our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price and trading volume of our common stock may be volatile and may be affected by economic conditions beyond our control. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be highly volatile and subject to wide fluctuations. In addition, the trading volume of our common stock may fluctuate and cause significant price variations to occur. If the market price of our common stock declines significantly, you may be unable to resell your shares of our common stock at or above your purchase price, if at all. We cannot assure you that the market price of our common stock will not fluctuate or significantly decline in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some specific factors that could negatively affect the price of our common stock or result in fluctuations in its price and trading volume include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory actions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or expected fluctuations in our operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in our key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in financial estimates or recommendations by securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">strategic decisions by us or our competitors, such as acquisitions, collaborations, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the passage of legislation or other regulatory developments in the United States and other countries affecting us or our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in trading volume of our common stock on Nasdaq; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our common stock by us, our executive officers or our shareholders in the future; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conditions in the financial markets or changes in general economic conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the stock market has experienced and is currently experiencing significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">An active trading market for our common stock may not continue to develop or may not be liquid enough for you to sell your shares of our common stock quickly or at market price. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although our common stock is listed on Nasdaq, if an active public market in the United States for our common stock does not continue to develop, the market price and liquidity of our common stock may be adversely affected. The price of our common stock may decline, which means you may experience a decrease in the value of your shares of our common stock regardless of our operating performance or prospects. In the past, following periods of volatility in the market price of a company&#8217;s securities, shareholders often instituted securities class action litigation against that company. If we were involved in a class action suit, it could divert the attention of senior management and, if adversely determined, could cause us significant financial harm. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not continue to publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If no additional securities or industry analysts commence coverage of us, our stock price could be negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to establish and maintain proper internal financial reporting controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;404(a) of the Sarbanes-Oxley Act requires that our management assess and report annually on the effectiveness of our internal controls over financial reporting and identify any material weaknesses in our internal controls over financial reporting. Although Section&#160;404(b) of the Sarbanes- Oxley Act requires our independent registered public accounting firm to issue an annual report that addresses the effectiveness of our internal controls over financial reporting, we rely on the exemption provided for non-accelerated filers, and consequently will not be required to comply with SEC rules that implement Section&#160;404(b) of the Sarbanes-Oxley Act until such time as we are an accelerated or large accelerated filer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presence of any material weaknesses in our internal control over financial reporting could result in financial statement errors which, in turn, could lead to errors in our financial reports and/or delays in our financial reporting, which could require us to restate our operating results. We might not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section&#160;404(a) of the Sarbanes- Oxley Act. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal controls over financial reporting, we will need to expend significant resources and provide significant management oversight. Implementing any appropriate changes to our internal controls may require specific compliance training of our directors and employees, entail substantial costs in order to modify </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our existing accounting systems, take a significant period of time to complete and divert management&#8217;s attention from other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to conclude that we have effective internal controls over financial reporting, investors may lose confidence in our operating results, the price of our common stock could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section&#160;404 of the Sarbanes-Oxley Act, our common stock may not be able to remain listed on Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have never declared or paid dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. For the foreseeable future, we currently intend to retain all available funds and any future earnings to support our operations and to finance the growth and development of our business. Any future determination to declare cash dividends will be made at the discretion of our Board, subject to compliance with applicable laws and covenants under current or future credit facilities, which may restrict or limit our ability to pay dividends, and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our Board may deem relevant. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. As a result, a return on your investment in our securities will only occur if the price of our common stock appreciates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales and issuances of our common stock or rights to purchase common stock could result in substantial dilution to the percentage ownership of our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock or other securities convertible into or exchanged for our common stock in one or more transactions, and in a manner we determine from time to time and at prices that may not be the same as the price per share paid by other investors, and dilution to our stockholders could result. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by other investors. New investors could also receive rights, preferences and privileges senior to those of existing holders of our common stock. In addition, in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock, we may be required to proportionally adjust the conversion price, exercise price or number of shares issuable upon exercise of any outstanding warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our corporate governance structure may prevent our acquisition by another company at a premium over the public trading price of our shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that the acquisition of a majority of our outstanding voting stock by another company could result in our stockholders receiving a premium over the public trading price for our shares. Provisions of our restated certificate of incorporation and our amended and restated bylaws, each as amended, and of Delaware corporate law could delay or make more difficult an acquisition of our company by merger, tender offer or proxy contest, even if it would create an immediate benefit to our stockholders. Furthermore, our certificate of incorporation also provides for a classified board of directors with directors divided into three classes serving staggered terms. These provisions may have the effect of delaying or preventing a change in control of us without action by our stockholders and, therefore, could adversely affect the price of our stock or the possibility of sale of shares to an acquiring person. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a limited number of unreserved, authorized shares. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we seek equity financing we may need to use a significant percentage of our unreserved authorized shares of common stock in such an offering, and would therefore need stockholder approval to implement an increase in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our authorized shares of common stock or a reverse stock split in order to issue additional shares of common stock in the future. Our certificate of incorporation and the Delaware General Corporation Law, or the DGCL, currently require the approval of stockholders holding not less than a majority of all outstanding shares of capital stock entitled to vote in order to approve an increase in our authorized shares of common stock or a reverse stock split. There are no assurances that stockholder approval will be obtained, in which event we will be unable to raise additional capital through the issuance of shares of common stock to fund our future operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Although we are required to use our reasonable best efforts to have an effective registration statement covering the issuance of shares of common stock underlying certain of our outstanding warrants at the time that holders of our warrants exercise their warrants, we cannot guarantee that a registration statement will be effective, in which case holders of our warrants are entitled to a cashless exercise of their warrants. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of certain of our warrants, we are obligated to have an effective registration statement covering the resale of the shares of common stock underlying such warrants. If no registration is effective at the time a warrant holder seeks to exercise their warrants, we would be obligated to issue shares to such warrant holder in a &#8220;cashless exercise&#8221; in exchange for such holder&#8217;s warrants, in which case we would not receive the cash that we would otherwise receive in an exercise of warrants for cash. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_3">Item&#160;1B. Unresolved Staff Comments. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_4">Item&#160;2. Properties. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate headquarters and our research and development facility is located in Hayward, California, and consists of approximately 7,295 square feet of leased office space under a lease that expires in June 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management believes that these facilities are suitable and adequate to meet our anticipated needs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_5">Item&#160;3. Legal Proceedings. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not currently a party to any material legal proceedings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_6">Item&#160;4. Mine Safety Disclosures. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_7">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market Information </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock trades on Nasdaq under the symbol &#8220;BNTC.&#8221; On August 15, 2023, the closing sale price of our common stock as reported on Nasdaq was $2.69 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September 10, 2023, we had approximately 3,318 record holders of our common stock. The number of record holders is based on the actual number of holders registered on the books of our transfer agent and does not reflect holders of shares in &#8220;street name&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividends </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We never have declared or paid any cash dividends on our capital stock. Currently, we anticipate that we will retain all available funds for use in the operation and expansion of our business and do not anticipate paying any cash dividends for the foreseeable future. Any future determination relating to dividend policy will be made at the discretion of our Board and will depend on our future earnings, capital requirements, financial condition, prospects, applicable Delaware law, which provides that dividends are only payable out of surplus or current net profits, and other factors that our Board deems relevant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Sales of Unregistered Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Use of Proceeds </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Purchases of Equity Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_8">Item&#160;6. Reserved. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_9">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion and analysis of financial condition and operating results together with our consolidated financial statements and the related notes and other financial information included in Item 8 in this Annual Report. This discussion contains <span style="white-space:nowrap">forward-looking</span> statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section of the Annual Report captioned &#8220;Risk Factors&#8221; and elsewhere in this Annual Report, our actual results may differ materially from those anticipated in these forward- looking statements. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (&#8220;Benitec&#8221; or the &#8220;Company&#8221; or in the third person, &#8220;we&#8221; or &#8220;our&#8221;) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called <span style="white-space:nowrap">DNA-directed</span> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The unique therapeutic constructs also enable the simultaneous delivery of wildtype replacement genes, facilitating the proprietary &#8220;silence and replace&#8221; approach to the treatment of genetically defined diseases. The Company is developing a silence and replace-based therapeutic <span style="white-space:nowrap">(BB-301)</span> for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">BB-301</span> is a silence and replace-based genetic medicine currently under development by Benitec. <span style="white-space:nowrap">BB-301</span> is an <span style="white-space:nowrap">AAV-based</span> gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells). This fundamental therapeutic approach to disease management is called &#8220;silence and replace.&#8221; The silence and replace mechanism offers the potential to restore the normative physiology of diseased cells and tissues and to improve treatment outcomes for patients suffering from the chronic, and potentially fatal, effects of OPMD. <span style="white-space:nowrap">BB-301</span> has been granted Orphan Drug Designation in the United States and the European Union. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The targeted gene silencing effects of RNAi, in conjunction with the durable transgene expression achievable via the use of modified viral vectors, imbues the silence and replace approach with the potential to produce permanent silencing of disease-causing genes along with simultaneous replacement of the wild type gene function following a single administration of the proprietary genetic medicine. We believe that this novel mechanistic profile of the current and future investigational agents developed by Benitec could facilitate the achievement of robust and durable clinical activity while greatly reducing the frequency of drug administration traditionally expected for medicines employed for the management of chronic diseases. Additionally, the achievement of permanent gene silencing and gene replacement may significantly reduce the risk of patient <span style="white-space:nowrap">non-compliance</span> during the course of medical management of potentially fatal clinical disorders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline"><span style="white-space:nowrap">Re-domiciliation</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 15, 2020, or the Implementation Date, the <span style="white-space:nowrap">Re-domiciliation</span> of Benitec Limited, a public company incorporated under the laws of the State of Western Australia, or Benitec Limited, was completed in accordance with the Scheme Implementation Agreement, as amended and restated as of January 30, 2020, between Benitec Limited and us. As a result of the <span style="white-space:nowrap">Re-domiciliation,</span> the jurisdiction of incorporation was changed from Australia to Delaware, and Benitec Limited became our wholly owned subsidiary. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">Re-domiciliation</span> was effected pursuant to a statutory scheme of arrangement under Australian law, or the Scheme, whereby on the Implementation Date, all of the issued and outstanding ordinary shares of Benitec Limited were exchanged for newly issued shares of our common stock, on the basis of one share of our common stock, par value $0.0001 per share, for every 300 ordinary shares of Benitec Limited issued and outstanding. Holders of Benitec Limited&#8217;s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of our common stock for every three ADSs held. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline"><span style="white-space:nowrap">COVID-19</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">COVID-19</span> has been declared a pandemic by the World Health Organization and has spread to nearly every country, including Australia and the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to businesses and capital markets around the world. The extent to which the coronavirus impacts us will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and its variants, and the actions to contain the coronavirus or treat its impact, including the effectiveness and adoption of vaccines for the virus, among others. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our research and development efforts are conducted globally, including the ongoing development of our silence and replace therapeutic for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), and will be dependent upon our ability to continue our preclinical and clinical studies and related work despite the <span style="white-space:nowrap">COVID-19</span> pandemic and any similar events. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Royalties, milestone payments and other license fees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to pay royalties, milestone payments and other license fees in connection with our licensing of intellectual property from third parties, including as discussed below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have collaborated with Biomics Biotechnologies Co., Ltd., or Biomics, pursuant to several collaboration agreements in relation to single-stranded RNA and shRNA sequences for treatment of hepatitis B. In July 2015, we entered into an <span style="white-space:nowrap">earn-out</span> agreement with Biomics which confirmed Benitec&#8217;s ownership of certain patents resulting from the collaboration in exchange for an upfront payment and equity issuance to Biomics and a share of certain future licensing revenue received by Benitec. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Foreign Currency Translation and Other Comprehensive Income (Loss) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive income (loss).&#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">April 2021 Capital Raise </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April 30, 2021, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents (the &#8220;April 2021 Capital Raise&#8221;). The Company received gross proceeds of approximately $14.3&#160;million and net proceeds of approximately $12.7&#160;million from the offering. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">September 2022 Capital Raise </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;15, 2022, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents (the September 2022 Capital Raise&#8221;). The Company received gross proceeds of approximately $17.9&#160;million and net proceeds of approximately $16.0&#160;million from the offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">August 2023 Capital Raise </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;11, 2023, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents (the &#8220;August 2023 Capital Raise&#8221;). The Company received gross proceeds of approximately $30.9&#160;million and net proceeds of approximately $28.6&#160;million from the offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Results of Operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenues from customers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the fiscal year ended June 30, 2023, the Company generated funds primarily from capital raising activities. The Company has not generated any revenues from the sales of products. Revenues from licensing fees and interest income are included in the revenue from customers line item on our statements of operations and comprehensive income (loss). Our licensing fees have been generated through the licensing of our ddRNAi technology to biopharmaceutical companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our revenues for each of the periods set forth below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;June<span style="text-decoration:underline"></span>&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(US$&#8217;000)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues from customers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June 30, 2023, the Company recognized $75&#160;thousand in customer revenues, as compared to $73&#160;thousand for the comparable year ended June 30, 2022. The slight increase in revenues from customers is due to the increase in licensing revenue in the current year. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Royalties and license fees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties and license fees consist primarily of payments we are required to remit for royalties and other payments related to <span style="white-space:nowrap">in-licensed</span> intellectual property. Under our <span style="white-space:nowrap">in-license</span> agreements, we may pay <span style="white-space:nowrap">up-front</span> fees and milestone payments and be subject to future royalties. We cannot precisely predict the amount, if any, of royalties we will owe in the future, and if our calculations of royalty payments are incorrect, we may owe additional royalties, which could negatively affect our results of operations. As our product sales increase, we may, from time to time, disagree with our third-party collaborators as to the appropriate royalties owed, and the resolution of such disputes may be costly, may consume management&#8217;s time, and may damage our relationship with our collaborators. Furthermore, we may enter into additional license agreements in the future, which may also include royalty, milestone and other payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and <span style="white-space:nowrap">pre-clinical</span> trials. <span style="white-space:nowrap">Pre-clinical</span> and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries, related benefits, travel, and equity-based compensation expense. General and administrative expenses also include facility expenses, professional fees for legal, consulting, accounting and audit services and other related costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses may increase as the Company focuses on the continued development of the <span style="white-space:nowrap">pre-clinical</span> OPMD program. The Company also anticipates an increase in expenses relating to accounting, legal and regulatory-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and other costs associated with being a domestic public company after the <span style="white-space:nowrap">Re-domiciliation.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our expenses for each of the periods set forth below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;June&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(US$&#8217;000)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalties and license fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,646</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June 30, 2023, we did not incur any royalties and license fees, as compared to $9&#160;thousand for the year ended June 30, 2022. The change is primarily due to a decrease in license fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June 30, 2023, we incurred $12.774&#160;million in research and development expenses, as compared to $11.272&#160;million for the comparable year ended June 30, 2022. The increase in research and development expenses relates primarily to the OPMD project. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense was $6.382&#160;million and $6.646&#160;million for the years ended June 30, 2023 and 2022, respectively. The year-over-year decrease relates primarily to lower listing and filing fees and stock-based compensation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Income (Loss) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our other income (loss) for each of the periods set forth below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year&#160;Ended&#160;June&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(US$&#8217;000)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Loss:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency transaction loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(415</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(32</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on investment</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other loss, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(481</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The other loss, net during the year ended June 30, 2023 totaled $481&#160;thousand, which consists of foreign currency transaction loss, interest expense, other expense, net, and unrealized loss on investment. During the year ended June 30, 2022, other loss, net, totaled $354&#160;thousand. Foreign currency transaction loss has increased due to a change in foreign exchange rates. Interest expense was essentially unchanged year-over-year. The decrease in other expense, net relates to recognition of a tax refund. Unrealized loss on investment was due to lower fair market values of the Company&#8217;s investments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. For the years ended June&#160;30, 2023, and 2022, the Company incurred net losses of $19.56&#160;million and&#160;$18.21&#160;million, and used net cash of $18.01&#160;million and $15.90&#160;million in operations, respectively. The Company expects to continue to incur additional operating losses in the foreseeable future. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred cumulative losses and negative cash flows from operations since our predecessor&#8217;s inception in 1995, except for the year ended June 30, 2019 where we had net income of $2.609&#160;million and generated positive cash flows of $4.790&#160;million from operating activities. The Company had accumulated losses of $167.9&#160;million as of June 30, 2023. We expect that our research and development expenses may increase due to the continued development of the OPMD program. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We had no borrowings for the years ended June 30, 2023 and 2022 and do not currently have a credit facility. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, we had cash and cash equivalents of $2.5&#160;million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the net cash flow activity for each of the periods set forth below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended June&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(US$&#8217;000)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,012</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,899</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(13</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate changes on cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash, cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,586</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(15,708</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Operating activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended June 30, 2023 was $18.012&#160;million. Net cash used in operating activities for the year ended June 30, 202 was $15.899&#160;million. Net cash used in operating activities was primarily the result of our net loss, change in working capital, depreciation and amortization, and share-based compensation expense. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the years ended June 30, 2023 and 2022 was $1&#160;thousand and $13&#160;thousand, respectively, and primarily related to purchases of equipment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Financing activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $16.015&#160;million and zero for the years ended June 30, 2023 and 2022, respectively. For the year ended June 30, 2023, cash from financing activities related to the issuance of ordinary shares and <span style="white-space:nowrap">pre-funded</span> warrants, and common warrants; including $17.884&#160;million in gross proceeds from the September 2022 Capital Raise, partially offset by $1.869&#160;million of shares and warrant issuance costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future of the Company as an operating business will depend on its ability to keep operating costs and budgeted amounts and obtain adequate financing. While we continue to progress discussions and advance opportunities to engage with pharmaceutical companies and continue to seek licensing partners for ddRNAi in disease areas that are not our focus, there can be no assurance as to whether we will enter into such arrangements or what the terms of any such arrangement could be. On August&#160;11, 2023, the Company closed an underwritten public offering resulting in $28.6&#160;million in net proceeds to the Company. We estimate that our cash and cash equivalents will be sufficient to fund the Company&#8217;s operations for at least the next twelve months after the date that this Annual Report is filed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have established some licensing arrangements, we do not have any products approved for sale and have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless and until we establish significant revenues from licensing programs, strategic alliances or collaboration arrangements with pharmaceutical companies, or from product sales, we anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of product candidates and begin to prepare to commercialize any product that receives regulatory approval. We are subject to the risks inherent in the development of new gene therapy products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. On August&#160;11, 2023, the Company announced the closing of an underwritten public offering of common stock and common stock equivalents. The Company received gross proceeds of approximately $30.9&#160;million and net proceeds of approximately $28.6&#160;million from the offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and costs of our planned clinical trials for our ddRNAi and silence and replace product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and costs of our planned preclinical studies for our ddRNAi and silence and replace product candidates; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and characteristics of product candidates that we pursue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome, timing and costs of seeking regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">revenue received from commercial sales of any of our product candidates that may receive regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which we need to <span style="white-space:nowrap">in-license</span> or acquire other products and technologies. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations and Commercial Commitments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 1, 2016, the Company entered into an operating lease for office space in Hayward, California that originally expired in April 2018. The Company has entered into lease amendments that extend the lease commitment through June 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Significant Accounting Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of Notes to the consolidated financial statements included in Item&#160;8 in this Annual Report describes the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A critical accounting policy is defined as one that is both material to the presentation of the Company&#8217;s consolidated financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on the Company&#8217;s financial condition or results of operations. Specifically, these policies have the following attributes: (1)&#160;the Company is required to make assumptions about matters that are highly uncertain at the time of the estimate; and (2)&#160;different estimates the Company could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on the Company&#8217;s financial condition or results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimates and assumptions about future events and their effects cannot be determined with certainty. The Company bases its estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as the Company&#8217;s operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, management is periodically faced with uncertainties, the outcomes of which are not within its control and will not be known for prolonged periods of time. These uncertainties are discussed in the section above entitled &#8220;Risk Factors.&#8221; Based on a critical assessment of its accounting policies and the underlying judgments </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and uncertainties affecting the application of those policies, management believes that the Company&#8217;s consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the United States of America, and provide a meaningful presentation of the Company&#8217;s financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management believes that the following are critical accounting policies: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and <span style="white-space:nowrap">pre-clinical</span> trials. Pre- clinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, &#8220;<span style="font-style:italic">Stock Compensation</span>&#8221;. ASC 718 requires the fair value of all share- based employee compensation awarded to employees and <span style="white-space:nowrap">non-employees</span> to be recorded as an expense over the related requisite service period. The Company values employee and <span style="white-space:nowrap">non-employee</span> share-based compensation at fair value using the Black-Scholes Option Pricing Model. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Accounting Standards recently adopted </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Accounting Standards and Interpretations not yet mandatory or early adopted </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">ASU <span style="white-space:nowrap">2016-13</span></span>&#8212;In June 2016, the FASB issued ASU <span style="white-space:nowrap">No.&#160;2016-13:</span> &#8220;<span style="font-style:italic">Financial Instruments&#8212;Credit Losses</span> (Topic 326)&#8221;. This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU <span style="white-space:nowrap">2019-10:</span> &#8220;<span style="font-style:italic">Financial <span style="white-space:nowrap">Instruments-Credit</span> Losses, Derivatives and Hedging, and Leases: Effective Dates</span>&#8221; amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU effective July 1, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_10">Item&#160;7A. Quantitative and Qualitative Disclosures about Market Risk. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company and not required to provide this information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="bntc-20230630.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="toc549728_11" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Item 8. Financial Statements and Supplementary Data. </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:96%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#otv_fin549728_1">Report of Independent Registered Public Accounting Firm Baker Tilly (PCAOB Firm ID No.&#160;<ix:nonNumeric name="dei:AuditorFirmId" contextRef="P07_01_2022To06_30_2023">23</ix:nonNumeric>)</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#otv_fin549728_2">Consolidated Balance Sheets</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#otv_fin549728_3">Consolidated Statements of Operations and Comprehensive Loss</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#otv_fin549728_4">Consolidated Statements of Stockholders&#8217; Equity</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#otv_fin549728_5">Consolidated Statements of Cash Flows</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#otv_fin549728_6">Notes to Consolidated Financial Statements</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-8</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-1 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="otv_fin549728_1" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of Benitec Biopharma Inc. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Opinion on the Financial Statements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Benitec Biopharma Inc. and its subsidiaries (the &#8220;Company&#8221;) as of June&#160;30, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June&#160;30, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis for Opinion </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Critical Audit Matter </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1)&#160;relates to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-2 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">ACCRUED RESEARCH AND DEVELOPMENT COSTS </div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Critical Audit Matter Description </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As discussed in Notes 2 and 8 to the financial statements, the Company records expenses for research and development activities based on management&#8217;s estimates of services received and efforts expended pursuant to contracts with vendors that conduct research and development on the Company&#8217;s behalf. The financial terms vary from contract to contract and may result in uneven payment flows as compared with services performed. As a result, the Company is required to estimate research and development expenses incurred during the period, which impacts the amount of accrued expenses related to such costs as of each balance sheet date. Management makes significant judgments and estimates in determining the accrued balance at the end of each reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">We identified the evaluation of research and development accrued costs as a critical audit matter. The Company&#8217;s estimates are based on a number of factors, including the Company&#8217;s knowledge of the status of each of the research and development project milestones, and contract terms together with related executed change orders. Higher degree of auditor judgment was required in evaluating the results of our audit procedures regarding the Company&#8217;s estimates, because of the subjectivity and estimation uncertainty in the significant assumptions used in the calculation. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">How We Addressed the Matter in Our Audit</div></div> </div><div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The primary procedures we performed to address this critical audit matter included: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Obtaining an understanding of the Company&#8217;s process for estimating the amount of accrued costs incurred by the contract research organizations and contract manufacturing organizations (the &#8220;R&amp;D service providers&#8221;). </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Inquiring with Company personnel responsible for overseeing the research and development activities to understand progress of the activities completed to date for selected R&amp;D service providers. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Obtaining external confirmations for select R&amp;D service providers as to the completion status for billed and unbilled services and comparing responses to management&#8217;s accrual estimates. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Performing an analysis of the accuracy of the calculation of estimated accrual and R&amp;D expenses by comparing totals at year end to the actual amounts that were invoiced by the third-party R&amp;D service providers and paid by the Company for selected R&amp;D service providers. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>Comparing the Company&#8217;s estimate of costs incurred as of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> to a selection of cash disbursements and third-party invoices received after <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> but prior to the issuance of the Company&#8217;s financial statements. </div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="P07_01_2022To06_30_2023">BAKER TILLY US, LLP</ix:nonNumeric> </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s auditor <div style="display:inline;">since</div> 2020. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="dei:AuditorLocation" contextRef="P07_01_2022To06_30_2023">Mountain View, California</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 21, 2023 </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="otv_fin549728_2" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Balance Sheets </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except par value and share amounts) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,062</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted <div style="letter-spacing: 0px; top: 0px;;display:inline;">c</div>ash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid and other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,729</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,820</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deposits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Prepaid and other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">526</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">771</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and Stockholders&#8217; Equity</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefits</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">472</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,532</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, less current portion</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,091</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies (Note 12)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn06_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn06_30_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value&#8212;<ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">160,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,645,951</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">480,688</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2023 and 2022, respectively</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,454</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">167,889</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">148,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">830</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,882</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equity</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:150pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="otv_fin549728_3" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Operations and Comprehensive Loss </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share and per share amounts) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenues from customers</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Royalties and license fees</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:RoyaltiesAndLicenseFees" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:RoyaltiesAndLicenseFees" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,774</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,382</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,646</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,156</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,081</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,854</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other loss:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency transaction loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other expense, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">79</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on investment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other loss, net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss):</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized foreign currency translation gain</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,998</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">14.12</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">37.88</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares outstanding:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,385,818</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">480,688</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="otv_fin549728_4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Stockholders&#8217; Equity</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands, except share amounts)</div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/> Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Comprehensive<br/> Loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;<br/> Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June&#160;30, 2021</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">480,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,584</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">130,119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,455</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2021To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation gain</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June&#160;30, 2022</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">480,688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,454</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">148,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,882</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants sold for cash, net of offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,869</ix:nonFraction></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrants" contextRef="P07_01_2022To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,037,520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" contextRef="P07_01_2022To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" contextRef="P07_01_2022To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,015</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,015</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WarrantsExercisedDuringThePeriod" contextRef="P07_01_2022To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">127,743</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2022To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation gain</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,645,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">167,889</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">830</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div> </div> </div> </div> <div></div> </div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="otv_fin549728_5" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Cash Flows </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(in thousands) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from operating activities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash from operating activities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AmortizationOfRightOfUseAssets" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AmortizationOfRightOfUseAssets" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on investment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:UnrealizedGainLossOnInvestment" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:UnrealizedGainLossOnInvestment" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other receivables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid and other assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">414</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade and other payables</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IncreasedecreaseInAccountsAndOtherPayables" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:IncreasedecreaseInAccountsAndOtherPayables" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee benefit payable</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:IncreaseDecreaseInLeaseLiabilities" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:IncreaseDecreaseInLeaseLiabilities" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,012</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,899</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from investing activities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in investing activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from financing activities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issues of shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,884</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share issue transaction costs</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,869</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,015</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">412</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">204</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net decrease in cash, cash equivalents, and restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,586</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,708</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash at beginning of year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,784</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents, and restricted cash at end of year</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,490</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,062</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total cash, cash equivalents, and restricted cash</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,490</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosure of cash flow information:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="otv_fin549728_6" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> <ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Business </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (the &#8220;Company&#8221;) is a corporation incorporated in the state of Delaware on <ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P07_01_2022To06_30_2023" format="ixt:date-monthname-day-year-en">November 22, 2019</ix:nonNumeric> and listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BNTC&#8221;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#8220;BBL&#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April&#160;15, 2020. On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#8217;s business focuses on the development of novel genetic medicines. Our proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;27, 2019, BBL announced its intention to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domicile</div> from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of effecting the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> (&#8220;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-</div> domiciliation&#8221;), acquired all BBL shares and BBL became a wholly owned subsidiary of Benitec Biopharma Inc. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms used herein refer (i), prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> to BBL, an Australian corporation, and its subsidiaries, and (ii), following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL). On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June&#160;30, 2021, the Company completed an organization restructure as part of the commercial desire to provide a more efficient structure for the future as the Company continues to transition its operations to the US. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s fiscal year end is June 30. References to a particular &#8220;fiscal year&#8221; and the &#8220;year ended June 30&#8221; are to our fiscal year end June&#160;30 of that calendar year. </div> <ix:nonNumeric name="bntc:ScheduleOfEntitiesInControlTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and the following wholly owned subsidiaries: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal&#160;place&#160;of<br/>business/country&#160;of<br/>incorporation</div></div></div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">Australia</ix:nonNumeric></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Australia Proprietary Limited</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">Australia</ix:nonNumeric></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Limited</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">United Kingdom</ix:nonNumeric></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec LLC</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">RNAi Therapeutics, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tacere Therapeutics, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec IP Holdings, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P07_01_2022To06_30_2023_BenitecIpHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" format="ixt-sec:edgarprovcountryen">USA</ix:nonNumeric></td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517163"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517379"> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-8</ix:exclude> </div> </ix:nonNumeric></ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_88517379" continuedAt="TextSelectionAppend_88517379_1"><ix:continuation id="TextSelection_88517163" continuedAt="TextSelectionAppend_88517163_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_88517163_1" continuedAt="TextSelectionAppend_88517163_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517163_2" continuedAt="TextSelectionAppend_88517163_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517163_3" continuedAt="TextSelectionAppend_88517163_4"><ix:continuation id="TextSelectionAppend_88517379_1"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> </ix:exclude> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">consummation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation.</div> As a result, the financial statements included in this report reflect (i)&#160;the historical operating results of BBL and subsidiaries prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> (ii)&#160;the combined results of the Company, BBL, and subsidiaries following the completion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> and (iii)&#160;the Company&#8217;s equity structure for all periods presented. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P07_26_2023To07_26_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">On July&#160;26, 2023, the Company effected a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-17</div></div> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its common stock. In accordance with the Reverse Stock Split, 17 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-split</div> shares of the Company&#8217;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#8217;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.</ix:nonNumeric> All share and earnings per share amounts presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">10-K</div> reflect the impact of this reverse split<div style="null;text-indent: 0px;;display:inline;">&#160;as if it had taken effect on June 30, 2021.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div> </ix:continuation><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-9</ix:exclude> </div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_88517163_4" continuedAt="TextSelectionAppend_88517163_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_88517163_5" continuedAt="TextSelectionAppend_88517163_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517163_6" continuedAt="TextSelectionAppend_88517163_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> </div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517163_7" continuedAt="TextSelectionAppend_88517163_8"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="bntc:RisksAndUncertainitiesPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and any similar events, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the Company&#8217;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#8217;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#8217;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). </div><ix:nonNumeric name="bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exchange rate on balance sheet dates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">USD: AUD Exchange Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="PAsOn06_30_2023" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.6639</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="PAsOn06_30_2022" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.6891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Average exchange rate for the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">USD: AUD Exchange Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AverageForeignExchangeRateForThePeriod" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.6730</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AverageForeignExchangeRateForThePeriod" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal">0.7254</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_88517163_8" continuedAt="TextSelectionAppend_88517163_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517163_9" continuedAt="TextSelectionAppend_88517163_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517163_10" continuedAt="TextSelectionAppend_88517163_11"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517163_11" continuedAt="TextSelectionAppend_88517163_12"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> </ix:exclude> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, the carrying amounts approximate fair value due to their short maturities. ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;1:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;2:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;3:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions, which reflect those that a market participant would use. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023 and 2022, the Company had <ix:nonFraction name="bntc:FinancialAssetsAtFairValue" contextRef="PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="bntc:FinancialAssetsAtFairValue" contextRef="PAsOn06_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn06_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> financial assets or liabilities measured at fair value on a recurring basis. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash balances of $<ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction>&#160;thousand and $<ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction>&#160;thousand as of June&#160;30, 2023 and June&#160;30, 2022, respectively, secure the Company&#8217;s credit cards. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Trade and Other Receivables </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517174"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude> </div> </ix:nonNumeric></ix:continuation></div></div> <ix:continuation id="TextSelection_88517174" continuedAt="TextSelectionAppend_88517174_1"><ix:continuation id="TextSelectionAppend_88517163_12" continuedAt="TextSelectionAppend_88517163_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_88517163_13" continuedAt="TextSelectionAppend_88517163_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517163_14" continuedAt="TextSelectionAppend_88517163_15"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div></div></div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517163_15" continuedAt="TextSelectionAppend_88517163_16"><ix:continuation id="TextSelectionAppend_88517174_1"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> </ix:exclude> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn06_30_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn06_30_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">4</ix:nonNumeric> years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Computer hardware</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn06_30_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric> years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="bntc:DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P07_01_2022To06_30_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">shorter of the lease term or estimated useful lives</ix:nonNumeric></td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div> </ix:nonNumeric><ix:nonNumeric name="bntc:TradeAndOtherPayablesPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and other payables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517170"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and Diluted Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted- average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude> </div> </ix:nonNumeric></ix:continuation></div> </div> <ix:continuation id="TextSelection_88517170" continuedAt="TextSelectionAppend_88517170_1"><ix:continuation id="TextSelectionAppend_88517163_16" continuedAt="TextSelectionAppend_88517163_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_88517163_17" continuedAt="TextSelectionAppend_88517163_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517163_18" continuedAt="TextSelectionAppend_88517163_19"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517163_19" continuedAt="TextSelectionAppend_88517163_20"><ix:continuation id="TextSelectionAppend_88517170_1"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> </ix:exclude> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of June&#160;30, 2023 and 2022, there were <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,456,032</ix:nonFraction> and <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">49,716</ix:nonFraction> potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div> </ix:continuation><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517166"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue by applying the following steps: </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude> </div> </ix:nonNumeric></ix:continuation></div> </div> <ix:continuation id="TextSelection_88517166" continuedAt="TextSelectionAppend_88517166_1"><ix:continuation id="TextSelectionAppend_88517163_20" continuedAt="TextSelectionAppend_88517163_21"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_88517163_21" continuedAt="TextSelectionAppend_88517163_22"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517163_22" continuedAt="TextSelectionAppend_88517163_23"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div> </div> </div> <div> <div> <div style="line-height:normal;background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517163_23" continuedAt="TextSelectionAppend_88517163_24"><ix:continuation id="TextSelectionAppend_88517166_1"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> </ix:exclude> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Services revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div> </ix:continuation><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-</div> clinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-based Compensation Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based employee compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the related requisite service period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is governed by Australia and United States income tax laws. The Company follows ASC 740, Accounting for Income Taxes, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude> </div> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_88517163_24" continuedAt="TextSelectionAppend_88517163_25"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_88517163_25" continuedAt="TextSelectionAppend_88517163_26"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517163_26" continuedAt="TextSelectionAppend_88517163_27"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517163_27"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> </ix:exclude> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive income (loss). </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">No</div>.&#160;2016-13:</div> Financial Instruments&#8212;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> Financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Instruments-Credit</div> Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> effective July 1, 2023. </div> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="bntc:LiquidityDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Liquidity </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in conformity with US&#160;GAAP, which contemplate continuation of the Company as a going concern. For the fiscal years ended June 30, 2023 and 2022, the Company had a net loss of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">19.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">18.2</ix:nonFraction>&#160;million, respectively, and net cash used in operations of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">18.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">15.9</ix:nonFraction>&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, the Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>&#160;million in cash and cash equivalents. The Company has incurred operating losses and negative cash flows from operations since inception, except for the year ended June 30, 2019. On August&#160;11, 2023 we closed an underwritten public offering. Net proceeds from the offering, including the impact of the underwriter&#8217;s partial exercise of its option and net of underwriting discounts, commissions, and other offering expenses, totaled $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P08_11_2023To08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.6</ix:nonFraction>&#160;million. We estimate that our cash and cash equivalents will be sufficient to fund the Company&#8217;s operations for at least the next twelve months after the date that this Annual Report is filed. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Revenue </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues from customers (US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/> ended<br/> June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/> ended<br/> June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2022To06_30_2023_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2021To06_30_2022_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized licensing revenue over time as the performance obligations were satisfied. </div> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-15 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Cash, cash equivalents, and restricted cash </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at bank</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DueFromBanks" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DueFromBanks" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,062</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Restricted cash</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,490</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,076</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:OtherAssetsDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Prepaid and other assets </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">871</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:MarketValueOfListedShares" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:MarketValueOfListedShares" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Property and equipment, net </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2023_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,404</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,318</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,182</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">136</ix:nonFraction>,000 and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">167</ix:nonFraction>,000 for the years ended June 30, 2023 and 2022, respectively. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Trade and other payables </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">422</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedLicenceFeesCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">109</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedLicenceFeesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued OPMD project costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedOpmdProjectCostsCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedOpmdProjectCostsCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued consultant fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedConsultantFeesCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:AccruedConsultantFeesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-16 </div></div></div></div><div></div></div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517303"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 1, 2019, the Company adopted ASC 842, Leases (&#8220;ASC 842&#8221;). ASC 842 requires lessees to recognize at the lease commencement date a lease liability, which is the lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis, and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into an operating lease for office space under an agreement that expires in 2025. The lease requires the Company to pay utilities, insurance, taxes, and other operating expenses. The Company&#8217;s lease does not contain any residual value guarantees or material restrictive covenants. </div><ix:nonNumeric name="bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below show the changes during the years ended June 30, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> right-of-<br/> use assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Initial measurement at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2021_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">771</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">245</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">526</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Initial measurement at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn06_30_2021_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:RemeasurementOfLeaseLiabilitiesDuringThePeriod" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">811</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">252</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, the Company&#8217;s operating lease has a remaining lease term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn06_30_2023" format="ixt-sec:duryear">1.96</ix:nonNumeric> years and a discount rate of <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="PAsOn06_30_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.67</ix:nonFraction>%. The maturities of the operating lease liabilities are as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="null;text-indent: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">586</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-17 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_88517303" continuedAt="TextSelectionAppend_88517303_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517303_1" continuedAt="TextSelectionAppend_88517303_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517303_2" continuedAt="TextSelectionAppend_88517303_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517303_3"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div></ix:exclude> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the fiscal years ended June 30, 2023 and 2022, total lease expense under operating leases was approximately $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2022To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">277,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P07_01_2021To06_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">260,000</ix:nonFraction>, respectively, and was recorded in general and administrative expenses. </div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517367"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stockholders&#8217; equity </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 6, 2019, the Investors were issued <ix:nonFraction name="bntc:NumberOfSeriesWarrantsIssued" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4</ix:nonFraction> Purchase Warrants that were exercisable into <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">12,600</ix:nonFraction> fully paid shares of common stock should the Purchase Warrants be exercised in full (&#8220;Purchase Warrants&#8221;). The exercise price for the Purchase Warrants is US$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">178.50</ix:nonFraction> per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (<ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en">December 6, 2024</ix:nonNumeric>). On April 22, 2020, the Company issued <ix:nonFraction name="bntc:CashlessExerciseOfPurchaseWarrants" contextRef="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,201</ix:nonFraction> shares of common stock in connection with a cashless exercise of Purchase Warrants exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,300</ix:nonFraction> shares of common stock. The Company did not have an effective registration statement registering the resale of the Warrant Shares by the Holder at the time the Holder wanted to exercise the warrant; therefore, the Holder carried out a cashless exercise. The formula for conducting a cashless exercise was outlined in the Warrant agreement. Based on this formula, the Holder would have been entitled to receive 6,300 shares of common stock if they had exercised the Purchase Warrants for cash. Because of the cashless exercise, the holder received 2,201 shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 15, 2022, we closed an underwritten public offering in which we issued and sold (i) <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,037,521</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) <ix:nonFraction name="bntc:ClassOfWarrantOrRightsIssuedDuringPeriod" contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">715,978</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, with each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant immediately exercisable for one share of common stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0017</ix:nonFraction> per share until exercised in full and (iii) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">29,809,471</ix:nonFraction> outstanding&#160;Series 2 warrants (the &#8220;Series 2 Warrants&#8221;) which are currently exercisable into <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,753,503</ix:nonFraction>&#160;shares of common stock after giving effect to the Reverse Stock Split at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_15_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">11.22</ix:nonFraction> per share. The Series 2 warrants sold in the offering became exercisable commencing December 9, 2022, the date on which the Company had both (a)&#160;received approval from its stockholders to increase the number of shares of common stock it is authorized to issue and (b)&#160;effected such stockholder approval by filing with the Secretary of State of the State of Delaware a certificate of amendment to its Amended and Restated Certificate of Incorporation, and will expire on the fifth anniversary of such initial exercise date. The combined purchase price for each share of common stock and accompanying common warrant was $<ix:nonFraction name="bntc:IssueOfCommonStockAndWarrantPricePerShare" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">10.20</ix:nonFraction>, which was allocated as $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.03</ix:nonFraction> per share of common stock and $<ix:nonFraction name="bntc:ClassOfWarrantsOrRightsIssuePricePerUnit" contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.17</ix:nonFraction> per common warrant. The Series 2 Warrants contain an exercise price adjustment mechanism providing that certain issuances of common stock (or common stock equivalents), if made at a price lower than the then existing exercise price of such Series 2 Warrants, would reset the exercise price to such lower price. As a result of the August&#160;11, 2023 public offering, the exercise price of the Series 2 Warrants has been automatically reset as of the closing time of such public offering to $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">1.9299</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 17, 2022 and October 27, 2022, investors exercised <ix:nonFraction name="bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod" contextRef="P10_17_2022To10_17_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">117,939</ix:nonFraction> and <ix:nonFraction name="bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod" contextRef="P10_27_2022To10_27_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">9,804</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, respectively, at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn10_27_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0017</ix:nonFraction> per share. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,348,039</ix:nonFraction> warrants outstanding. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_88517367" continuedAt="TextSelectionAppend_88517367_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517367_1" continuedAt="TextSelectionAppend_88517367_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517367_2" continuedAt="TextSelectionAppend_88517367_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517367_3" continuedAt="TextSelectionAppend_88517367_4"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></ix:exclude><ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The activity related to warrants during for the fiscal years ended June 30, 2023 and 2022, is summarized as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common<br/> Stock from<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price&#160;(per<br/> share)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" contextRef="PAsOn06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">178.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pre-funded warrants issued September 15, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P07_01_2022To06_30_2023_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">715,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfPreFundedWarrantsIssued" contextRef="P07_01_2022To06_30_2023_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series 2 warrants issued September 16, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:ClassOfWarrantOrRightsIssuedDuringPeriod" contextRef="P07_01_2022To06_30_2023_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,753,503</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" contextRef="P07_01_2022To06_30_2023_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pre-funded warrants exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:ClassOfWarrantOrRightsExercised" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">127,743</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,348,039</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" contextRef="PAsOn06_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:ClassOfWarrantsOrRightsExcercisable" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,348,039</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;">Effective as of the closing of the August 2023 underwritten public offering conducted by the Company, the exercise price of the Series </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">2 warrants issued</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"> September 16, 2022 was automatically adjusted to $<ix:nonFraction name="bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" contextRef="P08_01_2023To08_31_2023_RevisionInTheExercisePriceOfPrefundedWarrantsMemberBNTCEventAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">1.9299</ix:nonFraction> as required by the terms of such warrants. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">Equity Incentive Plan</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Employee Share Option Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> the Company assumed BBL&#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-</div> domiciliation pursuant to the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (the &#8220;Plan&#8221;). This includes the Company&#8217;s assumptions of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances . Employee options vest one third <div style="letter-spacing: 0px; top: 0px;;display:inline;">on</div> each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the organization, and certain other conditions have been satisfied, generally the employee has 12 months to exercise their options, or the options are cancelled. After the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> no new options have been or will be issued under the Plan. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Equity and Incentive Compensation Plan </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On December 9, 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2020 Equity and Incentive Compensation Plan (the &#8220;2020 Plan&#8221;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#8217;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date over three years. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> director options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on the day prior to each of the Company&#8217;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan), the option holder generally has 12 months to exercise their vested options, or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan), the option holder generally has 90 days to exercise their vested options, or the options are cancelled. The maximum contractual term of options granted under the 2020 Plan is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P12_09_2020To12_09_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. Upon the consummation of a Change in Control (as defined in the 2020 Plan), all unvested stock options will immediately vest as of immediately prior to the Change in Control. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>F-19</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_88517367_4" continuedAt="TextSelectionAppend_88517367_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517367_5" continuedAt="TextSelectionAppend_88517367_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517367_6" continuedAt="TextSelectionAppend_88517367_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div></ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517367_7" continuedAt="TextSelectionAppend_88517367_8"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> </ix:exclude> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December 8, 2021, the Company&#8217;s stockholders approved an amendment to the 2020 Plan, which increased the number of shares of the Company&#8217;s common stock reserved under the 2020 Plan to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_08_2021_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,850,000</ix:nonFraction>. For the fiscal year ended June 30, 2023, our named executive officers (&#8220;NEO&#8217;s&#8221;) were each granted equity incentive awards under the 2020 Plan. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;">Equity Awards</div></div> <ix:nonNumeric name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activity related equity awards, which are comprised of stock options, during the fiscal years ended June&#160;30, 2023 and 2022, respectively, is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">41,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">121.72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P07_01_2021To07_01_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">8.07</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,118</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">50.83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">9.45</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">43,416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">118.15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">7.18</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">66,868</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">9.94</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">848.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">107,993</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">31.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">8.96</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">27,135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">88.79</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">7.22</ix:nonNumeric> years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Equity-based Compensation Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of stock options granted during the years ended June 30, 2023 and June 30, 2022 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.34</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">44.20</ix:nonFraction>, respectively. </div> <ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">115.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">122.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P07_01_2022To06_30_2023" format="ixt-sec:duryear">6</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P07_01_2021To06_30_2022" format="ixt-sec:duryear">6</ix:nonNumeric>&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.96</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected Volatility. Due to the lack of Company-specific historical or implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies in the life sciences industry. The Company selected the peer group based on comparable characteristics, including development stage, product pipeline and enterprise value. The Company computed historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the equity-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own share price becomes available. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected Term. The expected term represents the period that the equity awards are expected to be outstanding. For stock options with service conditions, it is based on the &#8220;simplified method&#8221; for developing the estimate of the expected life. Under this approach, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude> </div> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_88517367_8" continuedAt="TextSelectionAppend_88517367_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517367_9" continuedAt="TextSelectionAppend_88517367_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517367_10" continuedAt="TextSelectionAppend_88517367_11"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517367_11"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> </ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> Interest Rate. The Company bases the risk-free interest rate assumption on U.S. Treasury constant maturities with maturities similar to those of the expected term of the equity award being valued. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Expected Dividend Yield. The Company bases the expected dividend yield assumption on the fact that it has never paid dividends and does not expect to pay dividends in the foreseeable future. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In addition to assumptions used in the Black-Scholes option-pricing model, the Company estimates a forfeiture rate to calculate the equity-based compensation expense for equity awards. The forfeiture rate is based on an analysis of actual and estimated forfeitures. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based</div> Compensation Expense </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The classification of share-based compensation expense for the years ended: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To06_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To06_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">613</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of June 30, 2023 and 2022, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">350,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">522,000</ix:nonFraction>, <div style="letter-spacing: 0px; top: 0px;;display:inline;">respectively, of unrecognized share-based compensation expense related to stock options granted under the Plan and 2020 Plan. Unrecognized expense as of June 30, 2023 is expected to be recognized over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">2.11</ix:nonNumeric> years.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Employee option awards-related stock-based compensation expense for the years ended June&#160;30, 2021 and 2022, and the nine months ended March&#160;31, 2023 was understated by a total of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P07_01_2020To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P07_02_2022To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;thousand. The Company determined that this understatement is immaterial to the previously issued consolidated financial statements for the years ended June&#160;30, 2021 and 2022, and the nine months ended March&#160;31, 2023, and corrected it as of June&#160;30, 2023. </div> </ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517413"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">11. Income taxes </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Loss before provision for income taxes consisted of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,369</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">International</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"><ix:exclude>F-21</ix:exclude> </div> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_88517413" continuedAt="TextSelectionAppend_88517413_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_88517413_1" continuedAt="TextSelectionAppend_88517413_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517413_2" continuedAt="TextSelectionAppend_88517413_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517413_3" continuedAt="TextSelectionAppend_88517413_4"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></ix:exclude><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax effects of significant items comprising the Company&#8217;s deferred taxes are as follows: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,348</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">221</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">348</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">117</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">170</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">263</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Section&#160;174 Capitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="bntc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,070</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,321</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,923</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,965</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">356</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. As of June 30, 2023 and 2022, the Company established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The valuation allowance increased $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="6" format="ixt:num-dot-decimal">3.958</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million&#160;</div>during the year ended June 30, 2023. <ix:nonNumeric name="bntc:DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517431">Net operating losses and tax credit carryforwards as of June 30, 2023 are as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_88517431"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration<br/> Years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses, federal (post-December 31, 2017)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis">Do&#160;not&#160;expire</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net operating losses, state</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,632</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="bntc:YearOfExpiryOfOperatingLossesCarryForwards" contextRef="P07_01_2022To06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyOneMemberusgaapTaxPeriodAxis">2031</ix:nonNumeric>-<ix:nonNumeric name="bntc:YearOfExpiryOfOperatingLossesCarryForwards" contextRef="P07_01_2022To06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyFourMemberusgaapTaxPeriodAxis">2042</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses, Australia</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,640</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="P07_01_2022To06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">Do not expire</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-22</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_88517413_4" continuedAt="TextSelectionAppend_88517413_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517413_5" continuedAt="TextSelectionAppend_88517413_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517413_6" continuedAt="TextSelectionAppend_88517413_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517413_7" continuedAt="TextSelectionAppend_88517413_8"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></ix:exclude><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effective rate of the Company&#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">20.92</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">20.55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign tax rate differential</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the U.S., various state jurisdictions and Australia. The Company&#8217;s tax returns for the tax years <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2014MemberusgaapTaxPeriodAxis">2014</ix:nonNumeric>, <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2016MemberusgaapTaxPeriodAxis">2016</ix:nonNumeric>, and <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2019MemberusgaapTaxPeriodAxis">2019</ix:nonNumeric> through <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2022MemberusgaapTaxPeriodAxis">2022</ix:nonNumeric> are open and are subject to examination by federal taxing authorities and the Company&#8217;s tax returns for tax years <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P07_01_2022To06_30_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2011MemberusgaapTaxPeriodAxis">2011</ix:nonNumeric> through <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P07_01_2022To06_30_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2022MemberusgaapTaxPeriodAxis">2022</ix:nonNumeric> are subject to examination by state taxing authorities. The Company is not currently undergoing a tax audit in any federal, state, or Australian jurisdiction. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The entire amount of the Company&#8217;s unrecognized tax benefits would not impact its effective tax rate if recognized. The Company has elected to include interest and penalties as a component of tax expense. During the year ended June&#160;30, 2023, the Company did <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&#160;382 places a limitation (&#8220;Section&#160;382 Limitation&#8221;) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than <ix:nonFraction name="bntc:PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" contextRef="PAsOn06_30_2023_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% change in ownership within a <ix:nonNumeric name="bntc:PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" contextRef="P07_01_2022To06_30_2023_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> period) of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section&#160;382 Limitation. Due to these &#8220;change in ownership&#8221; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Australian income tax legislation, losses can be utilized by the Company if it satisfies firstly the Continuity of Ownership Test (&#8220;COT&#8221;) or if failing that, the Similar Business Test (&#8220;SBT&#8221;). Broadly, the COT requires a company to show that it maintained continuity of majority beneficial ownership from the beginning of the year in which a loss is incurred to the end of an income year in which a tax loss is sought to be recouped. The SBT requires a company to demonstrate that a &#8220;similar business&#8221; has been maintained from the time when the COT is failed and throughout the period until the end of the income year that the losses are being recouped. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act was enacted and signed into law and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities, and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses in the CARES Act include a <ix:nonNumeric name="bntc:NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" contextRef="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> net operating loss carryback for certain net operating losses, suspension of the annual deduction limitation of <ix:nonFraction name="bntc:PercentageOfAnnualTaxableIncomeEligibleForDeduction" contextRef="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis_SuspensionOfAnnualDeductionLimitationMemberBNTCEventAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>% of taxable income for certain net operating losses, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_88517413_8" continuedAt="TextSelectionAppend_88517413_9"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_88517413_9" continuedAt="TextSelectionAppend_88517413_10"><div><div style="line-height:normal;background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div style="line-height:normal;background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517413_10"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CARES Act also provides other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-tax</div> benefits to assist those impacted by the pandemic. The Company evaluated the impact of the CARES Act and determined that there is <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> material impact to the income tax provision for the fiscal year ended June 30, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of net operating losses and limits the use of research tax credits for 2020, 2021 and 2022, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 9, 2022, Governor Gavin Newsom signed CA SB 113 (SB 113) into law. The legislation shortens the suspension period for deducting net operating losses (NOL) The suspension of deductions of California NOLs applied to California taxpayers with net business income of $<ix:nonFraction name="bntc:MinimumNetBusinessIncome" contextRef="P02_09_2022To02_09_2022_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMemberBNTCEventAxis_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023MemberusgaapTaxPeriodAxis_CaliforniaFranchiseTaxBoardMemberusgaapIncomeTaxAuthorityNameAxis_SB113MemberBNTCLegislationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;million or more for tax years beginning on or after January 1, 2020, and before January 1, 2023. SB 113 decreases that suspension period by one year, making the suspension applicable for tax years beginning on or after January 1, 2020, and before January 1, 2022. The Company evaluated the impact of SB 113 and determined that the legislation did <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2022To06_30_2023_CaliforniaAssemblyBillEightyFiveMemberBNTCUnexpectedEventAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction>t materially impact the Company&#8217;s income tax provision for the fiscal year ended June 30, 2023. </div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Commitments and contingencies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract commitments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>no contingent liabilities as of June 30, 2023 and 2022, respectively. See Note 9 above for lease commitments. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Related party transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June 30, 2023, the Company did not enter into any related party transactions. During the year ended June&#160;30, 2022, the Company had entered into related party transactions with Francis Abourizk Lightowlers for legal fees totaling $<ix:nonFraction name="us-gaap:LegalFees" contextRef="P07_01_2022To06_30_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction>&#160;thousand. Peter Francis, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director of the Company is a partner at Francis Abourizk Lightowlers. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true" continuedAt="TextSelection_88517183"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Loss per share </div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders (US$&#8217;000)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares used in calculating basic and diluted earnings per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,385,818</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">480,688</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To06_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">14.12</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To06_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">37.88</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-24</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_88517183" continuedAt="TextSelectionAppend_88517183_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517183_1" continuedAt="TextSelectionAppend_88517183_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_88517183_2" continuedAt="TextSelectionAppend_88517183_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_88517183_3"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">BENITEC BIOPHARMA INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">June&#160;30, 2023 and 2022 </div></div></ix:exclude><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Outstanding warrants and options amounting to <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2022To06_30_2023_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2021To06_30_2022_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,456,032</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">49,716</ix:nonFraction></ix:nonFraction> to acquire common stock are considered anti-dilutive for the fiscal years ended June 30, 2023 and June 30, 2022, respectively. </div></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P07_01_2022To06_30_2023" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15. Subsequent events</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="P07_26_2023To07_26_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">On July&#160;26, 2023, the Company effected a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-17</div></div> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its common stock. In accordance with the Reverse Stock Split, 17 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-split</div> shares of the Company&#8217;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#8217;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">All share and earnings per share amounts presented in this Form 10-K reflect the impact of the Reverse Stock Split.&#160;</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On August&#160;11, 2023 we closed an underwritten public offering in which we sold <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">875,949</ix:nonFraction> shares of common stock, <ix:nonFraction name="bntc:ClassOfWarrantOrRightsIssuedDuringPeriod" contextRef="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P08_11_2023To08_11_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,126,226</ix:nonFraction></ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,126,226</ix:nonFraction> shares of common stock, and <ix:nonFraction name="bntc:ClassOfWarrantOrRightsIssuedDuringPeriod" contextRef="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">16,002,175</ix:nonFraction> common warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">16,002,175</ix:nonFraction> shares of common stock. The combined purchase price for each share of common stock and accompanying common warrant was $<ix:nonFraction name="bntc:IssueOfCommonStockAndWarrantPricePerShare" contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.93</ix:nonFraction>, which was allocated as $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">1.9299</ix:nonFraction> per share of common stock and $<ix:nonFraction name="bntc:ClassOfWarrantsOrRightsIssuePricePerUnit" contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per common warrant. Each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant was sold together with one common warrant at a combined price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">1.9299</ix:nonFraction>, which was allocated as $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_11_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">1.9298</ix:nonFraction> per <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant and $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per common warrant. In addition, the Company granted the underwriter an option to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_11_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,331,606</ix:nonFraction> additional shares of common stock and/or up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_11_2023_CommonWarrantsMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,331,606</ix:nonFraction> additional common warrants. As of August&#160;15, 2023 the underwriter had partially exercised this option and purchased <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_15_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">458,134</ix:nonFraction> additional shares of common stock and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_15_2023_CommonWarrantsMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">458,134</ix:nonFraction> additional common warrants. Net proceeds from the offering, including the impact of the underwriter&#8217;s partial exercise of its option and net of underwriting discounts, commissions, and other offering expenses, totaled $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P08_11_2023To08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.6</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company has <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn06_30_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">29,809,471</ix:nonFraction> outstanding&#160;Series 2 warrants (the &#8220;Series 2 Warrants&#8221;) which are currently exercisable into <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn06_30_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,753,503</ix:nonFraction>&#160;shares of common stock after giving effect to the Reverse Stock Split. The Series 2 Warrants contain an exercise price adjustment mechanism providing that certain issuances of common stock (or common stock equivalents) if made at a price lower than the existing exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn06_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.22</ix:nonFraction> of such Series 2 Warrants, would reset the exercise price to such lower price. As a result of the August&#160;11, 2023 public offering, the exercise price of the Series 2 Warrants has been automatically reset as of the closing time of such public offering to $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">1.9299</ix:nonFraction>.<br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September 13, 2023, the Compensation Committee (the &#8220;Compensation Committee&#8221;) of the Company&#8217;s Board of Directors approved increases of the base salaries of Dr. Jerel Banks, the Company&#8217;s Executive Chairman and Chief Executive Officer, and Megan Boston, the Company&#8217;s Executive Director, to $<ix:nonFraction name="bntc:AnnualBaseSalaryCompensation" contextRef="PAsOn09_13_2023_Dr.JerelBanksMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ExecutiveChairmanAndChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">655,200</ix:nonFraction> and $<ix:nonFraction name="bntc:AnnualBaseSalaryCompensation" contextRef="PAsOn09_13_2023_ExecutiveDirectorMembersrtTitleOfIndividualAxis_MeganBostonMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">350,784</ix:nonFraction> (Ms.&#160;Boston&#8217;s salary as noted has been converted from AUD $<ix:nonFraction name="bntc:ForeignCurrencyExchangeRateConversion" contextRef="PAsOn10_01_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_AUD_per_unit" decimals="2" scale="0" format="ixt:num-dot-decimal">1.00</ix:nonFraction> to USD $<ix:nonFraction name="bntc:ForeignCurrencyExchangeRateConversion" contextRef="PAsOn10_01_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_unit" decimals="2" scale="0" format="ixt:num-dot-decimal">0.64</ix:nonFraction>, which was the conversion rate as of September 13, 2023) respectively, each adjustment being effective as of October 1, 2023. </div></div></div></ix:nonNumeric><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;">F-25 </div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_12">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_13">Item 9A. Controls and Procedures. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Evaluation of Disclosure Controls and Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule <span style="white-space:nowrap">13a-15</span> under the Securities Exchange Act of 1934, as of June 30, 2023. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applied its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Changes in Internal Control Over Financial Reporting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, including our principal executive and principal financial officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2023, and has concluded that there was no change that occurred during that period that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Management&#8217;s Report on Internal Control over Financial Reporting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule <span style="white-space:nowrap">13a-15(f)</span> under the Exchange Act. Our management, with the participation of our principal executive and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <span style="font-style:italic">Internal Control &#8211; Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management has concluded that our internal control over financial reporting was effective as of June 30, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitations on Effectiveness of Controls and Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a <span style="white-space:nowrap">non-accelerated</span> filer, and therefore our independent registered public accounting firm has not and is not required to issue a report on the effectiveness of internal control over financial reporting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_14">Item&#160;9B. Other Information. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three-month period ended June&#160;30, 2023, none of our directors or officers&#160;adopted, modified or&#160;terminated&#160;a &#8220;Rule <span style="white-space:nowrap">10b5-1</span> trading arrangement&#8221; or a <span style="white-space:nowrap">&#8220;non-Rule</span> <span style="white-space:nowrap">10b5-1</span> trading arrangement&#8221; as such terms are defined under Item 408 of Regulation S-K. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 13, 2023, the Compensation Committee (the &#8220;Compensation Committee&#8221;) of the Company&#8217;s Board of Directors approved increases of the base salaries of Dr. Jerel Banks, the Company&#8217;s Executive Chairman and Chief Executive Officer, and Megan Boston, the Company&#8217;s Executive Director, to $655,200 and $350,784 (Ms.&#160;Boston&#8217;s salary as noted has been converted from AUD $1.00 to USD $0.64, which was the conversion rate as of September&#160;13, 2023) respectively, each adjustment being effective as of October&#160;1, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_15">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART III </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_16">Item&#160;10. Directors, Executive Officers and Corporate Governance. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors, Executive Officers and Corporate Governance. Directors and Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information covering our current directors and executive officers. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:63%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerel Banks</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">48</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Megan Boston</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">51</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Director, Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Kevin Buchi(1)(2)(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">68</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Francis(1)(2)(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">67</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Smith (1)(2)(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">52</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the audit committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the compensation committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the nominating and corporate governance committee. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dr.&#160;Jerel Banks</span></span> has been a Director since October 2016, Chairman of our Board since October 2017 and Chief Executive Officer since June 2018. Dr.&#160;Banks was formerly the Chief Investment Officer of Nant Capital, LLC . Prior to joining Nant Capital, LLC, Dr.&#160;Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011, Dr.&#160;Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr.&#160;Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr.&#160;Banks earned an M.D. from Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&#160;Banks&#8217; experience in the healthcare industry and finance provides valuable experience and guidance to the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Megan Boston</span></span> has previously been Chief Executive Officer and Managing Director of several companies, including entities listed on the Australian Stock Exchange. With over 13 years of experience, Ms.&#160;Boston has been a director across a range of industries where she chaired company boards as well as board <span style="white-space:nowrap">sub-committees</span> particularly in the area of finance and risk management. Specifically, Ms.&#160;Boston has been a Director of Benitec since August 2016 and Executive Director since June 2018. From 2014 until joining Benitec, Ms.&#160;Boston was CEO of listed companies on the Australian Stock Exchange, Omni Market Tide Ltd and Rision Ltd. Previously, Ms.&#160;Boston held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers. Ms.&#160;Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms.&#160;Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Ms.&#160;Boston&#8217;s operational and financial infrastructure experience gives her the necessary skills and qualifications to serve as a member of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">J. Kevin Buch</span></span>i has been a Director since April 2013. Mr.&#160;Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr.&#160;Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr.&#160;Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr.&#160;Buchi joined Cephalon in 1991 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and held various positions, including Chief Operating Officer, from January 2010 to December 2010, Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr.&#160;Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Novo Nordisk (NYSE:NVO), formerly Dicerna Pharmaceuticals, Inc. and Ampio Pharmaceuticals (NYSE:AMPE). Mr.&#160;Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on his broad executive experience in the biotechnology industry, we believe Mr.&#160;Buchi has the appropriate skills and qualifications to serve on the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Peter Francis</span></span> has been a director since February 2006 and was previously Chairman of the Board until October 2017. Since 1993, Mr.&#160;Francis has been a partner at Francis Abourizk Lightowlers, a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to corporations and research bodies. Mr.&#160;Francis completed his studies in law and jurisprudence at Monash University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on his substantive intellectual property background and experience with our company, we believe Mr.&#160;Francis has the appropriate skills and qualifications to serve on the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Edward Smith</span></span> has been a director since April 2020. Edward brings more than 20 years of experience in executive finance and operations leadership in the biotechnology industry to our Board. Edward presently serves as Chief Financial Officer of Reunion Neuroscience, a private, clinical stage pharmaceutical company focused on developing novel therapeutics for depressive disorders. Prior to that, he served as Chief Financial Officer and took public LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage pharmaceutical company focused on developing novel immuno-oncology therapeutics, and prior to that served as Chief Financial Officer at Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a clinical-stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders and of PolyMedix, Inc. (Nasdaq: PYMX), a clinical stage pharmaceutical company focused on developing a novel class of antibiotics for the treatment of infectious diseases. Prior to that, he was executive director of finance at InKine Pharmaceutical Company, Inc. (Nasdaq: PYMX), where he assisted with its acquisition by Salix Pharmaceuticals, Inc. Earlier in his career, he held various positions in public accounting, most recently in the audit practice at Deloitte. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on his extensive finance and operations background in the biotechnology industry, we believe Mr.&#160;Smith has the appropriate skill and qualifications to serve on the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers and no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our directors or members of senior management was selected as such, except Dr.&#160;Banks was appointed by Nant Capital as a Director in October 2016 following the acquisition by Nant Capital, LLC of a significant percentage of Benitec&#8217;s then- outstanding ordinary shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The business addresses for each of our directors and executive officers is 3940 Trust Way, Hayward, California 9454. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Classified Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s business and affairs are managed under the direction of the Board. The Board currently consists of five directors, comprising the Company&#8217;s Chief Executive Officer, Executive Director and three outside directors. The Board has determined that five directors, three of whom are independent, is the appropriate size for the Company. The number of directors is fixed from time to time by resolution of the Board pursuant to the Company&#8217;s amended and restated certificate of incorporation (the &#8220;Certificate&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Company&#8217;s current directors will continue to serve as a director until the election and qualification of his or her successor, or until his or her earlier death, resignation, or removal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Certificate provides that the Board is divided into three classes with staggered three-year terms. Only one class of directors is elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective terms. The Board is designated as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Mr.&#160;Smith is a Class&#160;I director, and his current term will expire at the annual meeting of stockholders to be held in 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Messrs. Buchi and Francis are Class&#160;II directors, and their current terms will expire at the annual meeting of stockholders to be held in 2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Mr.&#160;Banks and Ms.&#160;Boston are Class&#160;III directors, and their current terms will expire at the annual meeting of stockholders to be held in 2025. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <span style="white-space:nowrap">one-third</span> of the Company&#8217;s directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Committees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board currently has, and appoints the members of, a standing Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. Each of those committees has a written charter approved by the Board. The current charter for each standing Board committee is posted under &#8220;Governance&#8221; in the Investor Relations section of the Company&#8217;s website, www.benitec.com. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board determined that each of Messrs. Buchi, Francis and Smith is independent under the Nasdaq listing standards, and Rule <span style="white-space:nowrap">10A-3</span> under the Exchange Act. Pursuant to Rule <span style="white-space:nowrap">10A-3(b)(1)(iv)(A)(2)</span> under the Exchange Act, the Company&#8217;s audit committee consists entirely of independent directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Audit Committee</span>: Messrs. Buchi (Chairman), Francis and Smith. The purpose of the Audit Committee is to assist the board in fulfilling its oversight responsibilities with respect to (i)&#160;the integrity of the Company&#8217;s financial statements, (ii)&#160;the Company&#8217;s compliance with legal and regulatory requirements, and (iii)&#160;the independent auditors&#8217; qualifications, independence and performance. The Audit Committee is also responsible for preparing a report to be included in the Company&#8217;s annual proxy statement, advising and consulting the management and the Board regarding the Company&#8217;s financial affairs, and appointing, overseeing and approving compensation for the work of the Company&#8217;s independent auditors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has determined that Messrs. Buchi, Francis and Smith each meet the independence requirements of Rule <span style="white-space:nowrap">10A-3</span> under the Exchange Act and the applicable Nasdaq rules. Our Board has determined that Mr.&#160;Smith is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Compensation Committee:</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee establishes and administers the Company&#8217;s policies, programs and procedures for compensating and providing benefits to its executives and Board. The Compensation Committee&#8217;s responsibilities and duties are set forth in the Compensation Committee Charter (a copy of the Compensation Committee Charter is available on the Company&#8217;s website at <span style="text-decoration:underline">https://ir.benitec.com/corporate-governance/ governance-documents).</span> The Compensation Committee&#8217;s responsibilities specifically include reviewing and approving the goals and objectives relevant to the chief executive officer&#8217;s and other executive officers&#8217; compensation, evaluating the performance of the chief executive officer and other executive officers in light of those goals and objectives, and making recommendations to the Board with respect to <span style="white-space:nowrap">non-employee</span> director compensation. The Compensation Committee is also responsible for making recommendations to the Board with respect to incentive compensation plans and equity-based incentive compensation plans. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee met four times during the last fiscal year. The current members of our Compensation Committee are Messrs. Francis (Chairman), Buchi and Smith. Our Board has determined that all members of our Compensation Committee are &#8220;independent&#8221; as defined under the rules of the SEC and the listing standards of Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No member of our Compensation Committee is or has been our current or former officer or employee. None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of our Compensation Committee during the fiscal year ended June 30, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of Compensation Consultant </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, the Compensation Committee retained Radford (AON) (&#8220;Radford&#8221;) to provide advice to the Compensation Committee with respect to the compensation of our <span style="white-space:nowrap">non-employee</span> directors and executive officers. Radford also provided advice with respect to the amendment of the Company&#8217;s 2020 Equity and Incentive Compensation Plan, the Company&#8217;s peer group, certain governance matters, and market trends. In March 2023, Radford (AON) (&#8220;Radford&#8221;) undertook a review of the executive equity compensation program. Radford provided advice on the methodology and prepared a competitive assessment with regards to executive compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Nominating and Corporate Governance Committee</span>: Messrs. Francis (Chairman), Buchi and Smith. The Nominating and Corporate Governance Committee manages all aspects of the governance of the Company&#8217;s Board. The Committee&#8217;s responsibilities include identifying individuals qualified to become members of the Board, recommending candidates to fill Board vacancies and newly created director positions, recommending whether incumbent directors should be nominated for <span style="white-space:nowrap">re-election</span> upon the expiration of their terms, recommending corporate governance guidelines applicable to the Board and to the Company&#8217;s employees, overseeing the evaluation of the Board and its committees, and assessing and recommending Board members to the Board for committee membership. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Ethics and Business Conduct </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established a Code of Ethics and Business Conduct as of April 14, 2020, which sets out the standards of behavior that apply to every aspect of our dealings and relationships, both within and outside the company. The following standards of behavior apply to all directors, executive officers and employees of the company: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">comply with all laws that govern us and our operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">act honestly and with integrity and fairness in all dealings with others and each other; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">avoid or manage conflicts of interest; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">use our assets responsibly and in the best interests of the company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be responsible and accountable for our actions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Code of Ethics and Business Conduct is available on our website at www.benitec.com. Any amendments made to the Code of Ethics and Business Conduct will also be available on our website, within four business days of any such amendment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Hedging and Pledging Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employees (including officers) and directors of the Company are prohibited from entering into hedging transactions with respect to the Company&#8217;s securities, or engaging in transactions with respect to the Company&#8217;s securities that are of a speculative nature, including, but not limited to, put or call options, margining Company securities, or otherwise pledging Company securities as collateral. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_17">Item 11. Executive Compensation. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a &#8220;smaller reporting company&#8221; we have opted to comply with the scaled executive compensation disclosure rules applicable to &#8220;smaller reporting companies&#8221; (as such term is defined under applicable securities laws). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers, or our &#8220;NEOs&#8221;, for the fiscal year ended June&#160;30, 2023 were Dr.&#160;Jerel&#160;A. Banks, our Executive Chairman and Chief Executive Officer, and Megan Boston, our Executive Director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s named executive officer compensation program is designed to incentivize our named executive officers to grow our business and further link the interests of our named executive officers with our stockholders. We provide our named executive officers with an annual base salary as a fixed, stable form of compensation, certain cash incentive opportunities as noted below to reward achievement of short-term goals, and, in prior fiscal years, we have granted our named executive officers stock options with multi-year vesting schedules to further align their compensation with our stockholders&#8217; long-term interests. We have also entered into employment agreements with our named executive officers that provide for a fixed notice period in connection with certain terminations of employment. The employment agreements and our named executive officer compensation program generally are described in greater detail below under the heading &#8220;<span style="font-style:italic">Narrative Disclosure to Summary Compensation Table</span>&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion of our compensation program prior to the completion <span style="white-space:nowrap">of&#160;the&#160;re-domiciliation&#160;of&#160;Benitec</span> Limited (&#8220;<span style="font-weight:bold">Limited</span>&#8221;), resulting in the Company becoming the ultimate parent company of the Benitec group of companies (the &#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Re-Domiciliation</span></span>&#8221;) reflects the compensation program of Limited, and of the Company for periods following the completion <span style="white-space:nowrap">of&#160;the&#160;Re-Domiciliation.&#160;This&#160;discussion</span> may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation earned by our NEOs during the fiscal year ended June&#160;30, 2023 and the fiscal year ended June&#160;30, 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:54%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Named Executive Officer and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fiscal<br />Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br />($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bonus<br />($)(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />($)(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&#160;Jerel&#160;A. Banks, M.D. Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">539,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,568</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Chairman and Chief Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">505,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">260,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,282</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">799,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Megan Boston</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">303,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,289</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,507</td>
<td style="white-space:nowrap;vertical-align:bottom">(6)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">352,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Director</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">309,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127,020</td>
<td style="white-space:nowrap;vertical-align:bottom">(4)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,074</td>
<td style="white-space:nowrap;vertical-align:bottom">(6)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">456,476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Boston&#8217;s salary was paid in Australian dollars and has been converted to U.S. dollars using a conversion rate of A$1.00 to $0.673, and A$1.00 to $0.73, for the fiscal years ended June&#160;30, 2023 and June&#160;30, 2022, respectively. From July&#160;1, 2022 through September&#160;30, 2022, Dr.&#160;Banks&#8217;s and Ms.&#160;Boston&#8217;s salary was $520,000 and $333,427.50 (Ms.&#160;Boston&#8217;s salary was converted using a conversion rate of A$1.00 to $0.73), respectively. As of October&#160;1, 2022,&#160;Dr.&#160;Banks&#8217;s and Ms.&#160;Boston&#8217;s annual base salary rate was increased to $546,000 and $A456,750 ($333,427.50, converted using a conversion rate of A$1.00 to $0.73), respectively. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In respect of the fiscal year ended June&#160;30, 2022, the Compensation Committee paid discretionary annual bonuses to Dr.&#160;Banks and Ms.&#160;Boston. The amount of such bonuses was paid in the fiscal year ended June&#160;30, 2023. The amount of cash bonuses earned in respect of the fiscal year ended June&#160;30, 2023 is not calculable through the latest practicable date. The Compensation Committee expects to determine such bonuses in October 2023, and the amounts of these bonuses will be disclosed in a filing by the Company in a Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;under</span> Item&#160;5.02(f) once the amounts are determined. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount represents the aggregate grant date fair value of stock and option awards granted by the Company in the fiscal year ended June&#160;30, 2023, computed in accordance with FASB ASC Topic 718. For further information on how we account for stock-based compensation, see Note 10 to the Company&#8217;s consolidated financial statements for the year ended June&#160;30, 2023, included in this Annual Report. These amounts reflect the Company&#8217;s accounting expense for these awards and do not correspond to the actual amounts, if any, that will be recognized by the NEOs. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Boston&#8217;s discretionary annual bonus was paid in Australian dollars and has been converted to U.S.&#160;dollars using a conversion rate of A$1.00 to $0.673 and A$1.00 to $0.73, for the fiscal years ended June&#160;30, 2023 and June&#160;30, 2022, respectively. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reflect company-paid health and life insurance premiums. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reflect the Company&#8217;s compulsory contributions to Ms.&#160;Boston&#8217;s superannuation account. The superannuation contributions were paid in Australian dollars and were converted to U.S. dollars using a conversion rate of A$1.00 to $0.673, and A$1.00 to $0.73, for the fiscal years ended June&#160;30, 2023 and June&#160;30, 2022. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative Disclosure to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Annual Base Salary </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use base salaries to recognize the experience, skills, and responsibilities required of all of our employees, including our NEOs. Base salaries are reviewed annually by our Board. On October&#160;12, 2022, the Compensation Committee approved increases of Dr.&#160;Banks&#8217; and Ms.&#160;Boston&#8217;s annual base salaries to $546,000 and $333,427.50, respectively, each effective as of October&#160;1, 2022 (Ms.&#160;Boston&#8217;s salary as reported on <span style="white-space:nowrap">Form&#160;8-K&#160;has</span> been converted from AUD $1.00 to USD $0.73, and is $287,752.50 using a conversion rate of AUD $1.00 to USD $0.63, which was the conversion rate as of October&#160;12, 2022). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Bonus Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically awarded our NEOs annual discretionary bonuses. For the fiscal year ended June&#160;30, 2022, the Compensation Committee paid discretionary bonuses to our NEOs which were based on a target of 50% and 40% of base salary for each of Dr.&#160;Banks and Ms.&#160;Boston, respectively. The actual annual cash bonuses awarded to our NEOs for fiscal year ended June&#160;30, 2022 performance are set forth above in the &#8220;Summary Compensation Table&#8221; in the column titled &#8220;Bonus.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In respect of the fiscal year ended June&#160;30, 2023, target annual bonuses for each of Dr.&#160;Banks and Ms.&#160;Boston remained unchanged, at 50% and 40% of annual base salary, respectively. The actual amount of annual discretionary bonuses for the fiscal year ended June&#160;30, 2023 is not calculable through the latest practicable date. The Compensation Committee expects to determine such bonuses in October 2023, and the amounts of these bonuses will be disclosed in a filing by the Company in a Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;under</span> Item&#160;5.02(f) once the amounts are determined. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Equity or Equity-Linked Incentive Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not have a formal policy with respect to the grant of equity incentive awards to our NEOs, we believe that equity grants provide our NEOs with a strong link to our long-term performance, create an ownership culture and help to align the interests of our NEOs and our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;9, 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2020 Equity and Incentive Compensation Plan (the &#8220;2020 Plan&#8221;). Our Compensation Committee has granted stock options to our NEOs, which have historically been subject to time-based vesting, vesting in increments <span style="white-space:nowrap">of&#160;one-third&#160;on</span> each of the first, second and third anniversaries of the applicable grant date, generally subject to the applicable NEO&#8217;s continued employment through the vesting date. We believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our NEOs to remain in our employment during the vesting period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;13, 2023, the Compensation Committee approved the grant to each of Dr.&#160;Banks and Ms.&#160;Boston, of nonqualified stock options to purchase 20,994 and 9,000 shares (reflective of the Reverse Stock Split), respectively, of the Company&#8217;s common stock pursuant to the 2020 Plan. The stock options vest in <span style="white-space:nowrap">increments&#160;of&#160;one-third&#160;on&#160;each</span> of the first, second and third anniversaries of the applicable grant date. If an NEO dies or terminates employment or service due to Disability (as defined in the 2020 Plan), the NEO generally has 12 months to exercise their vested options or the options are cancelled. If an NEO otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan), the NEO generally has 90 days to exercise their vested options or the options are cancelled. Upon the consummation of a Change in Control (as defined in the 2020 Plan), all unvested stock options will immediately vest as of immediately prior to the Change in Control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreements with our NEOs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to employment agreements with each of our NEOs. These employment agreements provide for &#8220;at will&#8221; employment and may be terminated at any time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreement with Dr.&#160;Jerel&#160;A. Banks, M.D. Ph.D. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, Tacere Therapeutics, Inc., a subsidiary of the Company, entered into an employment agreement with Dr.&#160;Banks setting forth the terms of his employment as Executive Chairman and Chief Executive Officer of Limited. In connection <span style="white-space:nowrap">with&#160;the&#160;Re-Domiciliation,&#160;Dr.&#160;Banks&#160;was</span> appointed Executive Chairman and Chief Executive Officer of the Company. The agreement provides for Dr.&#160;Banks&#8217; employment and sets forth his (i)&#160;annual base salary, (ii)&#160;discretionary annual bonus, (iii)&#160;eligibility to participate in employee benefit plans, (iv)&#160;eligibility for accrued paid vacation, (v)&#160;expense reimbursements in accordance with Company policy, (vi)&#160;eligibility to participate in the Company&#8217;s Share Option Plan (as defined below), (vii) post-employment obligations to refrain from soliciting our employees for one year following the end of employment, <span style="white-space:nowrap">and&#160;(viii)&#160;certain&#160;non-disparagement&#160;obligations.&#160;Dr.&#160;Banks&#8217;</span> employment agreement also provides for confidentiality of information and ownership of proprietary property restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreement, Dr.&#160;Banks&#8217; employment is &#8220;at will&#8221; and can be terminated at any time. However, the Company must provide Dr.&#160;Banks with at least six months&#8217; prior notice (or pay in lieu of notice) prior to any termination. Dr.&#160;Banks may terminate his employment on no fewer than six months&#8217; prior written notice to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any provisions in the employment agreement, the Company may terminate Dr.&#160;Banks&#8217; employment immediately without prior notice to Dr.&#160;Banks if he (a)&#160;commits any serious or persistent breach of any of the provisions of the employment agreement, (b)&#160;commits any act of willful or serious misconduct or negligence in the discharge of his duties, (c)&#160;becomes of unsound mind or under the control of any committee or officer under any law relating to mental health, (d)&#160;is convicted of a felony, which in our reasonable opinion affects Dr.&#160;Banks&#8217; position, or (e)&#160;becomes permanently incapacitated by accident or illness from performing duties under the employment agreement for a period aggregating more than three months <span style="white-space:nowrap">in&#160;any&#160;six-month&#160;period,&#160;or</span> for any period beyond three consecutive months. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreement with Megan Boston </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2018, Limited entered into an employment agreement with Megan Boston for the position of Executive Director. In connection with entering into the employment agreement, Ms.&#160;Boston ceased serving <span style="white-space:nowrap">as&#160;a&#160;Non-Executive&#160;Director&#160;of</span> the Company. Ms.&#160;Boston remains on the Board as an Executive Director. The employment agreement provides for Ms.&#160;Boston&#8217;s employment and sets forth her (i)&#160;annual base salary, (ii)&#160;discretionary annual bonus, (iii)&#160;superannuation contribution, (iv)&#160;eligibility for accrued paid vacation, (v)&#160;expense reimbursements in accordance with Company policy, and (vi)&#160;post-employment obligations to refrain from soliciting our employees for one year following the end of employment. Ms.&#160;Boston&#8217;s employment agreement also provides for confidentiality of information and ownership of proprietary property restrictions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreement, Ms.&#160;Boston&#8217;s employment is &#8220;at will&#8221; and can be terminated at any time. However, the Company must provide Ms.&#160;Boston with at least six months&#8217; prior notice (or pay in lieu of notice) prior to any termination. Ms.&#160;Boston may terminate her employment on no fewer than six months&#8217; prior written notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any provisions in the employment agreement, the Company may terminate Ms.&#160;Boston&#8217;s employment immediately without prior notice to Ms.&#160;Boston if she (a)&#160;commits any serious or persistent breach of any of the provisions of the employment agreement, (b)&#160;commits any act of willful or serious misconduct or negligence in the discharge of her duties, (c)&#160;becomes bankrupt or makes any arrangement or composition with her creditors, (d)&#160;becomes of unsound mind or under the control of any committee or officer under any law relating to mental health, (e)&#160;is convicted of any criminal offense other than an offense which in our reasonable opinion does not affect Ms.&#160;Boston&#8217;s position, or (f)&#160;becomes permanently incapacitated by accident or illness from performing her duties under the employment agreement for a period aggregating more than three months <span style="white-space:nowrap">in&#160;any&#160;six-month&#160;period,&#160;or</span> any period beyond three consecutive months. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards <span style="white-space:nowrap">at&#160;Fiscal&#160;Year-End</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding outstanding equity or equity-linked awards for each of our NEOs as of June&#160;30, 2023. All amounts are reflective of the Company&#8217;s <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-17</span></span> reverse stock split of the shares of Common Stock, effective July&#160;26, 2023 (the &#8220;Reverse Stock Split&#8221;). </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:14%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Named Executive Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Grant Date</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options<br />(#)&#8212;<br />Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options<br />(#)&#8212;<br />Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Exercise<br />Price<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Expiration<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&#160;Jerel&#160;A. Banks, M.D. Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">6/13/2023(1)(2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,994</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/13/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Executive Chairman and Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">12/9/2020(1)(2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,576</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50.66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/9/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Megan Boston</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">6/13/2023(1)(2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/13/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Executive Director</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">12/9/2020(1)(2)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,788</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50.66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/9/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="right">3/12/2019(2)(3)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">721.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/12/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The option awards were granted under the 2020 Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares subject to each of the option awards vest in substantially equal installments on each of the first, second and third anniversaries of the grant date, generally subject to continued employment through the applicable vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The option awards were granted under the Benitec Officers&#8217; and Employees&#8217; Share Option Plan prior <span style="white-space:nowrap">to&#160;the&#160;Re-Domiciliation&#160;(the&#160;&#8220;</span><span style="font-weight:bold">Share Option Plan</span>&#8221;). The share amounts and exercise prices of the awards shown in this table have been adjusted to reflect the terms <span style="white-space:nowrap">of&#160;the&#160;Re-Domiciliation.</span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Elements of Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Benefits and Perquisites </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer participation in broad-based retirement, health and welfare plans to all of our colleagues, including our NEOs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We <span style="white-space:nowrap">maintain&#160;a&#160;tax-qualified&#160;defined&#160;contribution</span> retirement plan that provides eligible U.S. employees (including Dr.&#160;Banks) with an opportunity to save for retirement <span style="white-space:nowrap">on&#160;a&#160;tax-advantaged&#160;basis.&#160;Plan</span> participants are eligible to defer eligible compensation subject to applicable annual Internal Revenue Code limits. The 401(k) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
plan is intended to be qualified under Section&#160;401(a) of the Internal Revenue Code with the 401(k) plan&#8217;s related trust intended to be tax exempt under Section&#160;501(a) of the Internal Revenue Code. As a <span style="white-space:nowrap">tax-qualified</span> retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We contribute to the Australian superannuation scheme that provides eligible Australian employees (including Ms.&#160;Boston) with an opportunity to save for retirement <span style="white-space:nowrap">on&#160;a&#160;tax-advantaged&#160;basis.&#160;We</span> pay superannuation in accordance with legislative requirements and our minimum contribution is set by legislation. We offer flexibility for salary sacrifice to be added to the superannuation scheme and any actual increase in our contribution to the superannuation scheme is subject to legislative rules at the time. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination or Change in Control Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment agreements with our NEOs provide for specified notice periods (or pay in lieu of notice) if the Company terminates the employment of our NEOs under certain circumstances, as described above in the &#8220;Employment Agreements with our NEOs&#8221; section. Upon the consummation of a Change in Control (as defined in the 2020 Plan), all unvested stock options granted pursuant to the 2020 Plan will immediately vest as of immediately prior to the Change in Control. Our NEOs are not eligible to receive any additional payments or benefits in connection with their termination of employment or in connection with the Company&#8217;s change in control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Pay Versus Performance Disclosure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by Item 402(v) of Regulation <span style="white-space:nowrap">S-K,</span> which was mandated by Section&#160;953(a) of the Dodd-Frank Act, we are providing the following information about the relationship between &#8220;compensation actually paid&#8221; to our principal executive officer (&#8220;PEO&#8221;) and average &#8220;compensation actually paid&#8221; (&#8220;CAP&#8221;) to each of our NEOs and the financial performance of the Company for the Company&#8217;s fiscal years ended June&#160;30, 2023 (&#8220;Fiscal 2023&#8221;) and June&#160;30, 2022 (&#8220;Fiscal 2022&#8221;), in each case calculated in a manner consistent with SEC rules. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="2" rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Year</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Summary<br />Compensation<br />Table Total<br />for PEO(1)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Compensation<br />Actually Paid<br />to PEO(1)(2)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Average<br />Summary<br />Compensation<br />Table Total<br />for <span style="white-space:nowrap">Non-PEO</span><br />NEOs (2)(3)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Average<br />Compensation<br />Actually Paid<br />to <span style="white-space:nowrap">Non-PEO</span><br />NEOs (2)(3)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Value of<br />Initial Fixed<br />$100<br />Investment<br />Based<br />On(4):</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Net<br />Income<br />(loss)</span><span style="font-weight:bold"><span style="font-style:italic">&#160;(in</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><br /></span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">thousands)</span></span><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />Shareholder<br />Return</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">428,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">352,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">243,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(79.44</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,901</td>
<td style="white-space:nowrap;vertical-align:bottom">)(5)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">799,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(176,698</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">456,476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39,270</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(71.36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The PEO reflected in these columns for Fiscal 2023 and Fiscal 2022 is Dr.&#160;Jerel&#160;A. Banks, M.D. Ph.D. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">CAP to our PEO and <span style="white-space:nowrap">Non-PEO</span> NEO (Megan Boston, our Executive Director) is calculated based on the &#8220;Total Compensation&#8221; reported in the Summary Compensation Table (&#8220;SCT&#8221;) for each of the applicable fiscal years, adjusted to exclude and include certain items in accordance with Item 402(v) of Regulation <span style="white-space:nowrap">S-K</span> as follows. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PEO SCT Total to CAP Reconciliation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="2" rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Fiscal<br />Year</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">SCT Total</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Deductions<br />from SCT<br />Total (i)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Additions to SCT Total (ii)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">CAP</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fair&#160;Value&#160;of<br />Current&#160;Year<br />Equity&#160;Awards<br />for Fiscal<br />Year&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change in Value<br />of Prior&#160;Years&#8217;<br />Awards&#160;Unvested<br />for Fiscal<br />Year&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change&#160;in&#160;Value<br />of Prior&#160;Years&#8217;<br />Awards that<br />Vested in Fiscal<br />Year 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">645,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70,657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74,271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(230,188</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">428,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">799,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(867,266</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(109,396</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(176,698</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Average <span style="white-space:nowrap">Non-PEO</span> NEOs SCT Total to CAP Reconciliation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="2" rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Fiscal<br />Year</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Summary<br />Compensation<br />Table<br />(&#8220;SCT&#8221;)&#160;Total</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Deductions<br />from&#160;SCT(i)</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Additions to SCT(ii)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">CAP</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fair&#160;Value&#160;of<br />Current&#160;Year<br />Equity&#160;Awards<br />for Fiscal<br />Year&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change&#160;in&#160;Value<br />of Prior Years&#8217;<br />Awards&#160;Unvested<br />for Fiscal<br />Year&#160;2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change&#160;in&#160;Value<br />of Prior Years&#8217;<br />Awards that<br />Vested in Fiscal<br />Year 2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">352,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,289</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(114,972</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">243,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">456,476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(435,106</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(60,640</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39,270</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the grant date fair value of equity-based awards granted each year as reported in the Summary Compensation Table for the applicable fiscal year. The fair values of equity compensation, including such amounts described in the tables above, are calculated in accordance with FASB ASC Topic 718. All assumptions made in the valuations are contained and described in Note 10 to the Company&#8217;s consolidated financial statements for the year ended June&#160;30, 2023 included in this Annual Report. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">We did not report a change in pension value for any of the years reflected in this table because the Company does not maintain a defined benefit or actuarial pension plan and therefore a deduction from SCT related to such pension plans is not needed. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the value of equity calculated in accordance with the SEC methodology for determining CAP for each year shown. The fair values of equity compensation, including such amounts described in the tables below, are calculated in accordance with FASB ASC Topic 718. The amounts shown in the table reflect the total fair value on the applicable date(s) listed in the table above, and do not necessarily reflect the actual value, if any, that may be realized by the PEO. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The <span style="white-space:nowrap">non-PEO</span> NEO reflected in these columns, and our only <span style="white-space:nowrap">non-PEO</span> for the covered fiscal years, is Megan Boston (Executive Director) </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents cumulative total return to holders of our common stock from June&#160;30, 2021 (the last trading day before Fiscal 2022) through June&#160;30, 2023 (the last trading day of the covered period), calculated from the market close on the last trading day before Fiscal 2022 through and including the end of each applicable fiscal year in the table above for which the total shareholder return is being calculated. The total shareholder return for each investment assumes that $100 was invested in our common stock and the respective index on June&#160;30, 2021 through June&#160;30, 2023, including reinvestment of any dividends (of which none were paid during this period). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Relationship Between Financial Performance Measures and CAP </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Fiscal 2023, there was an inverse relationship between our total shareholder return compared to our PEO CAP and our average <span style="white-space:nowrap">non-PEO</span> NEO CAP, and there was a direct relationship between our net income compared to our PEO CAP and our average <span style="white-space:nowrap">non-PEO</span> NEO CAP. Our total shareholder return decreased by approximately 11% as compared to Fiscal 2022. Our net income<span style="font-weight:bold"></span>&#160;between Fiscal 2022 and Fiscal 2023 decreased&#160;by approximately 5%. Our PEO CAP increased by approximately 343% and our average <span style="white-space:nowrap">non-PEO</span> NEO CAP increased<span style="font-weight:bold"></span>&#160;by approximately 721%, in each case as compared to Fiscal 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Fiscal 2022, there was a direct relationship between our total shareholder return and net income, compared to our PEO CAP and average <span style="white-space:nowrap">non-PEO</span> NEO CAP, all of which were negative in Fiscal 2022. Our total shareholder return decreased by approximately 42% as compared to Fiscal 2021. Our net income between Fiscal 2021 and Fiscal 2022 decreased by approximately 31%. And our PEO CAP and average <span style="white-space:nowrap">non-PEO</span> NEO CAP each decreased by approximately 110% and 104%, respectively, as compared to Fiscal 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the total compensation paid to the Company&#8217;s directors (other than any such directors who are also NEOs) for the fiscal year ended June&#160;30, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:66%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees<br />Earned<br />or&#160;Paid&#160;in<br />Cash<br />($)(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />($)(3)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation<br />($)(4)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Kevin Buchi</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Francis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,066</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward F. Smith</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For information regarding the compensation of Dr.&#160;Banks and Ms.&#160;Boston, see &#8220;Summary Compensation Table.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Fees paid to Mr.&#160;Francis were paid in Australian dollars and have been converted to U.S. dollars using a conversion rate of A$1.00 to $0.673 for the fiscal year ended June&#160;30, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount represents the aggregate grant date fair value of stock and option awards granted by the Company in the fiscal year ended June&#160;30, 2023, computed in accordance with FASB ASC Topic&#160;718. For further information on how we account for stock-based compensation, see Note 10 to the Company&#8217;s consolidated financial statements for the year ended June&#160;30, 2023 included in this Annual Report. These amounts reflect the Company&#8217;s accounting expense for these awards and do not correspond to the actual amounts, if any, that will be recognized by the directors. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For information regarding other compensation of all directors, see &#8220;Narrative Disclosure to Director Compensation Table.&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each director, the aggregate number of option awards outstanding <span style="white-space:nowrap">at&#160;fiscal&#160;year-end&#160;for&#160;the</span> fiscal year ended June&#160;30, 2023 is set forth below. All amounts below are reflective of the Reverse Stock Split: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:86%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Kevin Buchi</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Francis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward F. Smith</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative Disclosure to Director Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon their appointment as executive officers and employees, Dr.&#160;Banks and Ms.&#160;Boston no longer receive annual fees with respect to their service on the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual fees for the fiscal year ended June&#160;30, 2023 paid <span style="white-space:nowrap">to&#160;our&#160;non-employee&#160;directors&#160;were:</span> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an annual cash retainer of $40,000; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an additional annual cash retainer of $15,000 to the chair of the Audit Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an additional annual cash retainer of $10,000 to the chair of the Compensation Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an additional annual cash retainer of $7,500 to the chair of the Nominating Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an additional annual cash retainer of $7,500 <span style="white-space:nowrap">to&#160;a&#160;non-chair&#160;member&#160;of</span> the Audit Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an additional annual cash retainer of $5,000 <span style="white-space:nowrap">to&#160;a&#160;non-chair&#160;member&#160;of</span> the Compensation Committee; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an additional annual cash retainer of $4,000 <span style="white-space:nowrap">to&#160;a&#160;non-chair&#160;member&#160;of</span> the Nominating Committee. </p></td></tr></table> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the cash fees paid to <span style="white-space:nowrap">our&#160;non-employee&#160;directors,</span> the Board granted each of Messrs. Buchi, Francis and Smith seven hundred five (705)&#160;option awards (reflective of the Reverse Stock Split) on December&#160;7, 2022. The option awards vest in three substantially equal installments on the day prior to each of the Company&#8217;s next three annual stockholder meetings occurring immediately following December&#160;7, 2022. In addition, the Company makes a superannuation contribution on Mr.&#160;Francis&#8217; behalf in the amount of $5,460. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We never have declared or paid any cash dividends on our capital stock. Currently, we anticipate that we will retain all available funds for use in the operation and expansion of our business and do not anticipate paying any cash dividends for the foreseeable future. Any future determination relating to our dividend policy will be made at the discretion of our Board and will depend on our future earnings, capital requirements, financial condition, prospects, applicable Delaware law, which provides that dividends are only payable out of surplus or current net profits, and other factors that our Board deems relevant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_18">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PRINCIPAL STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding the beneficial ownership of the Company&#8217;s common stock as of August&#160;25, 2023 (after giving effect to the Reverse Stock Split) by (i)&#160;each person or group of persons known by us to beneficially own at least five percent of our common stock, (ii)&#160;each of our named executive officers, (iii)&#160;each of our directors and (iv)&#160;all of our directors and executive officers as a group. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table gives effect to the shares of common stock issuable within 60 days of August&#160;25, 2023 upon the exercise of all options and other rights beneficially owned by the indicated stockholders on that date. Beneficial ownership is determined in accordance <span style="white-space:nowrap">with&#160;Rule&#160;13d-3&#160;promulgated&#160;under</span> Section&#160;13(d) of the Securities Exchange Act and includes voting and investment power with respect to shares. Percentage of beneficial ownership is based on 2,547,434 shares of common stock outstanding at the close of business on August&#160;25, 2023. Except as otherwise noted below, each person or entity named in the following table has sole voting and investment power with respect to all shares of our common stock that he, she or it beneficially owns. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated below, the address for each beneficial owner listed is c/o 3940 Trust Way, Hayward, California 94545. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owner</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Shares<br />Beneficially<br />Owned</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage&#160;of&#160;Shares<br />Beneficially&#160;Owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">5% or Greater Stockholders:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Suvretta Capital Management, LLC(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">177,660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Franklin Resources Inc.(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">588,236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Janus Henderson Group plc (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">206,170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Citadel Securities LLC (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">180,030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Named Executive Officers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jerel A. Banks(5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Megan Boston(6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Kevin Buchi(7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Francis(8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Smith(9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">All Executive Officers and Directors As a Group </span><span style="font-weight:bold"><br /></span>(5 persons)(10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99,506</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than one percent of the Company&#8217;s outstanding common stock. </p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on the information included in the amended Schedule 13G filed by Suvretta Capital Management, LLC (&#8220;Suvretta&#8221;), Averill Master Fund, Ltd. (&#8220;Averill&#8221;) and Aaron Cowen on April&#160;18, 2023, entities affiliated with Suvretta collectively beneficially owned <span style="white-space:nowrap">pre-funded</span> warrants exercisable for 177,660 shares of common stock (after giving effect to the Reverse Stock Split). The <span style="white-space:nowrap">pre-funded</span> warrants are only exercisable to the extent that after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section&#160;13(d) group with the holders or their affiliates would beneficially own in the aggregate, for purposes of Rule <span style="white-space:nowrap">13d-3</span> under the Exchange Act, no more than 9.99% of the outstanding common stock. The address of the principal business office of Suvretta and Mr.&#160;Cowen is c/o Suvretta Capital Management, LLC, 540 Madison Avenue, 7th Floor, New York, New York 10022. The address of the principal business office of Averill is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman <span style="white-space:nowrap">KY1-1104,</span> Cayman Islands. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on information included in the Schedule 13G filed by Franklin Resources Inc. (&#8220;Franklin Resources&#8221;), Charles B. Johnson, Rupert H. Johnson, Jr. and Franklin Advisers, Inc. (&#8220;Franklin Advisers&#8221;) on October&#160;11, 2022. The address of the principal business office of Franklin Resources, Mr.&#160;C. Johnson, Mr.&#160;R. Johnson and Franklin Advisers is One Franklin Parkway, San Mateo, CA 94403-1906. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on the information included in the Schedule 13G filed by Janus Henderson Group plc and Janus Henderson Biotech Innovation Master Fund Ltd on August&#160;18, 2023. The address of the principal business office of Janus Henderson Group plc is 201 Bishopgate, EC2M 3AE, United Kingdom, and the address of the principal business office of Janus Henderson Biotech Innovation Master Fund Ltd is 151 Detroit Street, Denver, Colorado 80206. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on the information included in the Schedule 13G filed by Citadel Securities LLC, Citadel Advisors LLC, Citadel Securities Group LP, Citadel Advisors Holdings LP, Citadel Securities GP LLC, Citadel GP LLC, and Kenneth Griffin on August&#160;21, 2023. The address of the principal business office of each of the forgoing is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents stock options to acquire 11,150 shares of common stock that have vested or will vest within 60&#160;days of August&#160;25, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 20 shares of common stock held by Boston Super Invest Pty A/C Boston Family Super and 25,907 shares that are held by Megan Boston that Megan Boston has sole voting power over and stock options to acquire 6,555 shares of common stock that have vested or will vest within 60 days of August&#160;25, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 52,097 shares of common stock held directly by Mr.&#160;Buchi and stock options to acquire 1,160 shares of common stock that have vested or will vest within 60 days of August&#160;25, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 279 shares of common stock held by the Francis Family Superannuation Fund, 18 shares of common stock held directly by Mr.&#160;Francis, and stock options to acquire 1,160 shares of common stock that have vested or will vest within 60 days of August&#160;25, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents stock options to acquire 1,160 shares of common stock that have vested or will vest within 60&#160;days of August&#160;25, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 78,321 shares of common stock and stock options to acquire 21,185 shares of common stock that have vested or will vest within 60 days of August&#160;25, 2023. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_19">Item 13. Certain Relationships and Related Transactions, and Director Independence. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not had been a participant since July 1, 2021 in a transaction in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of the Company&#8217;s total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;Executive and Director Compensation.&#8221; We also describe below certain other transactions with our directors, executive officers and stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Review and approval of related party transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our related parties include our directors, director nominees, executive officers, holders of more than five percent of the outstanding shares of our common stock and the foregoing persons&#8217; immediate family members. We review relationships and transactions in which the Company and our related parties are participants to determine whether such related persons have a direct or indirect material interest. As required under SEC rules, transactions that are determined to be directly or indirectly material to a related party are disclosed in the appropriate SEC filing. In addition, the Audit Committee reviews and approves any related party transaction that is required to be disclosed. Set forth below is information concerning transactions with our related parties that is required to be disclosed under SEC rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indemnification and Severance Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our directors and executive officers which require us to indemnify such individuals to the fullest extent permitted by Delaware law. Our indemnification obligations under such agreements are not limited in amount or duration. Certain costs incurred in connection with such indemnities may be recovered under certain circumstances under various insurance policies. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed against a director or executive officer, we are unable to determine the maximum amount of losses that we could incur relating to such indemnities. Historically, any amounts payable pursuant to such director and officer indemnities have not had a material negative effect on our business, financial condition or results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_20">Item 14. Principal Accountant Fees and Services. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate fees billed to the Company for services during the fiscal years ended June 30, 2023 and 2022 by our independent registered public accounting firm, Baker Tilly US, LLP (&#8220;Baker Tilly&#8221;): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Fee Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">251,640</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">222,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Related Fees(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 64,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 16,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 28,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 65,735</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">345,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">304,631</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Audit Fees consist of fees billed for professional services rendered for the audit of the Company&#8217;s consolidated annual financial statements included in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> and review of the interim consolidated financial statements included in the Company&#8217;s Quarterly Reports on Form <span style="white-space:nowrap">10-Q,</span> and services that are normally provided by independent registered public accounting firms in connection with statutory and regulatory filings or engagements. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Audit-Related Fees consist of fees billed for assurance and related services rendered that are reasonably related to the performance of the audit or review of the Company&#8217;s consolidated financial statements and are not reported under &#8220;Audit Fees.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Tax Fees were billed for professional services including assistance with tax compliance and the preparation of tax returns, tax consultation services, assistance in connection with tax audits and tax advice related to mergers, acquisitions and dispositions. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-Approval</span> Policies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee, or a designated member thereof, <span style="white-space:nowrap">pre-approves</span> 100% of all audit, audit-related, tax and other services rendered by the independent registered public accounting firm to the Company or its subsidiaries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">III-14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART IV </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_21">Item&#160;15. Exhibits and Financial Statement Schedules. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the Index to the Consolidated Financial Statements included in Item&#160;8 of this report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Statement Schedules </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Required information is included in the notes to the consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exhibit Index </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:88%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="2" style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.1</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td style="vertical-align:top" rowspan="2"><a href="http://www.sec.gov/Archives/edgar/data/1552795/000156459020011511/bntc-ex994_10.htm">Amended and Restated Scheme Implementation Agreement (incorporated by reference to Exhibit&#160;99.4 of the Current Report on Form 6-K of Benitec Biopharma Limited (File No. 001-37518) furnished on March 18, 2020) </a></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000156459020016820/bntc-ex31_43.htm">Amended and Restated Certificate of Incorporation of Benitec Biopharma Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K filed on April 15, 2020) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312521363633/d26967dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Benitec Biopharma Inc., effective December 17, 2021 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K filed on December 21, 2021) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312522302288/d429664dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Benitec Biopharma Inc., effective December 9, 2022 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K filed on December 12, 2022) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312523193295/d512923dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Benitec Biopharma Inc., effective July 26, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K filed on July 25, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="2" style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.5</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td style="vertical-align:top" rowspan="2"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000156459020016820/bntc-ex32_42.htm">Amended and Restated Bylaws of Benitec Biopharma Inc. (incorporated by reference to Exhibit&#160;3.2 to the Registrant&#8217;s Form 8-K filed on April 15, 2020) </a></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000156459020016820/bntc-ex41_105.htm">Form of common stock certificate of Benitec Biopharma Inc. (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form 8-K filed on April 15, 2020) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1552795/000119312519258712/d812687dex994.htm">Form of Purchase Warrant (incorporated by reference to Exhibit 99.4 of the Current Report on Form 6-K of Benitec Biopharma Limited (File No. 001-37518) furnished on September 30, 2019) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312522246077/d360011dex41.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form 8-K filed on September 16, 2022) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312522246077/d360011dex42.htm">Form of Common Warrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Form 8-K filed on September 16, 2022) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312523210679/d518652dex41.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form 8-K filed on August 11, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312523210679/d518652dex42.htm">Form of Common Warrant (incorporated by reference to 4.2 to the Registrant&#8217;s Form 8-K on August 11, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312522246077/d360011dex43.htm">Warrant Agency Agreement, dated September 15, 2022, by and between Benitec Biopharma Inc. and Computershare Trust Company, N.A. (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Form 8-K filed on September 16, 2022) </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">IV-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312523210679/d518652dex43.htm">Warrant Agency Agreement, dated August 11, 2023, by and between Benitec Biopharma Inc. and Computershare Trust Company, N.A. (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Form 8-K filed on August 11, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312521276758/d182332dex43.htm">Description of Registrant&#8217;s Securities (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Form 10-K filed on September 20, 2021) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1552795/000119312517190236/d406425dex101.htm">Share Subscription Agreement, dated October 24, 2016, between Nant Capital, LLC and Benitec Biopharma Limited (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form F-3 of Benitec Biopharma Limited (File No. 333-218400) filed with the SEC on June 1, 2017) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1552795/000119312515230004/d907977dex105.htm">Commercial Lease Agreement between Hayward Point Eden I Limited Partnership and Benitec Biopharma Limited (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form F-1 of Benitec Biopharma Limited (File No. 333-205135) filed with the SEC on June 22, 2015) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.3&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312520220358/d11440dex103.htm">Employment agreement between Megan Boston and Benitec Biopharma Limited dated July 11, 2018 (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 of the Registrant. (File No. 333-39267) filed with the SEC on August 14, 2020) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.4&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312520220358/d11440dex104.htm">Employment agreement between Dr. Jerel A. Banks and Tacere Therapeutics, Inc. dated September 11, 2018 (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 of the Registrant. (File No. 333-39267) filed with the SEC on August 14, 2020) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1552795/000119312517190236/d406425dex103.htm">Research Collaboration Agreement, dated January 27, 2017, between Benitec Biopharma Limited and Nant Capital, LLC (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form F-3 of the Registrant filed with the SEC on June&#160;1, 2017) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1552795/000119312519258712/d812687dex992.htm">Form of Securities Purchase Agreement, dated September 30, 2019, between Benitec Biopharma Limited and the Purchasers (incorporated by reference to Exhibit 99.2 to Form 6-K of Benitec Biopharma Limited (File No. 001-37518) filed with the SEC on September 30, 2019) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.7&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000156459020016820/bntc-ex101_41.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Form 8-K filed on April 15, 2020) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.8&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1552795/000119312516450930/d131177dex42.htm">Benitec Officers&#8217; and Employees&#8217; Share Option Plan (incorporated by reference to Exhibit 4.2 of the Registration Statement on Form S-8 of Benitec Biopharma Limited (File No. 333-209398) filed on February 3, 2016)) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.9&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312520220358/d11440dex109.htm">Form of Option Award Agreement under the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 of the Registrant. (File No. 333-39267) filed on August 14, 2020) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.10&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312520317105/d223910dex101.htm">Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Form 8-K filed on December 14, 2020) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.10.1&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312520274452/d140459ddef14a.htm#rom140459_51">First Amendment to Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan, dated as of December 8, 2021 (incorporated by reference to Appendix A to the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A filed on October 22, 2021) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.11&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312520318182/d811104dex101.htm">Form of Evidence of Award of Option Right Pursuant to the Benitec Biopharma Inc. 2020 Equity Incentive and Compensation Plan (Executives) (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Form 8-K filed on December 15, 2020) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.12&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312520318182/d811104dex102.htm">Form of Evidence of Award of Option Right Pursuant to the Benitec Biopharma Inc. 2020 Equity Incentive and Compensation Plan (Non-Employee Directors) (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Form 8-K filed on December 15, 2020) </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">IV-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.13</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312522246077/d360011dex11.htm">Underwriting Agreement, dated September 12, 2022, by and between Benitec Biopharma Inc. and Citizens JMP Securities, LLC (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Form 8-K filed on September 16, 2022) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.14</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1808898/000119312523210679/d518652dex11.htm">Underwriting Agreement, dated August 8, 2023, by and between Benitec Biopharma Inc. and Citizens JMP Securities, LLC (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Form 8-K filed on August 11, 2023) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;21.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d549728dex21.htm">List of significant subsidiaries </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d549728dex231.htm">Consent of Baker Tilly US, LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;31.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d549728dex311.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;31.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d549728dex312.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;32.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d549728dex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;32.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d549728dex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Instance Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File &#8211; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates a management contract or compensatory plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed or furnished herewith </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Statements and Schedules of Subsidiaries and Affiliates </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc549728_22">Item&#160;16. Form 10-K Summary. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">IV-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc549728_23">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, in the city of Hayward, State of California, on the 21st day of September 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">BENITEC BIOPHARMA INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dr.&#160;Jerel Banks</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Dr.&#160;Jerel Banks</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Executive Officer</td></tr>
</table></div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BY THESE PRESENTS, each person whose signature appears below constitutes and appoints Dr.&#160;Jerel Banks and Megan Boston his true and lawful attorney-in-fact and agents, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities to sign any and all amendments to this annual report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dr.&#160;Jerel Banks</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Dr.&#160;Jerel Banks</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, Director</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(principal executive officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">September&#160;21,&#160;2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Megan Boston</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Director, Director</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(principal accounting and financial officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">September&#160;21,&#160;2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J. Kevin Buchi</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">J. Kevin Buchi</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">September&#160;21,&#160;2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Francis</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Peter Francis</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">September&#160;21,&#160;2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward Smith</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Edward Smith</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">September&#160;21,&#160;2023</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">IV-4 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>d549728dex21.htm
<DESCRIPTION>EX-21
<TEXT>
<HTML><HEAD>
<TITLE>EX-21</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSIDIARIES OF THE REGISTRANT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Subsidiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Jurisdiction of Incorporation or
Organization</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Proprietary Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Australia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Australia Proprietary Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Australia</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">United Kingdom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RNAi Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tacere Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec IP Holdings, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Delaware</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d549728dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTERED PUBLIC ACCOUNTING FIRM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
consent to the incorporation by reference in the registration statements (No. <FONT STYLE="white-space:nowrap">333-261874</FONT> and <FONT STYLE="white-space:nowrap">333-253258)</FONT> on Form <FONT STYLE="white-space:nowrap">S-8,</FONT>
registration statement <FONT STYLE="white-space:nowrap">(No.&nbsp;333-253259)</FONT> on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> and registration statements <FONT STYLE="white-space:nowrap">(No.333-273177,</FONT> 333-268763 and 333-266417)
on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Benitec Biopharma Inc. of our report dated September 21, 2023, relating to the consolidated financial statements of Benitec Biopharma Inc., appearing in this Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma Inc. for the year ended June&nbsp;30, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ BAKER TILLY&nbsp;US, LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mountain View, California</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">September 21, 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>d549728dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Executive Officer Pursuant </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to SEC Rule <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">13a-14(a)/15d-14(a)</FONT></FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">I, Dr.&nbsp;Jerel Banks, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma
Inc. for the year ended June&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: September&nbsp;21, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dr.&nbsp;Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Dr.&nbsp;Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chief Executive Officer (principal executive officer)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>d549728dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Financial Officer Pursuant </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to SEC Rule <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">13a-14(a)/15d-14(a)</FONT></FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Megan Boston, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma
Inc. for the year ended June&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: September&nbsp;21, 2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Megan Boston</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Megan Boston</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Executive Director (principal financial officer)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>d549728dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to Section&nbsp;1350 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of Chapter 63 of Title 18 of the United States Code </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma Inc. (the &#147;Company&#148;) for the year
ended June&nbsp;30, 2023, as filed with the Securities and Exchange Commission (the &#147;Report&#148;), I, Dr.&nbsp;Jerel Banks, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act
of 1934. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Dr.&nbsp;Jerel Banks </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Jerel Banks </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 21, 2023 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A signed original of this written statement
required by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification is being furnished pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>d549728dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to Section&nbsp;1350 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of Chapter 63 of Title 18 of the United States Code </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Benitec Biopharma Inc. (the &#147;Company&#148;) for the year
ended June&nbsp;30, 2023, as filed with the Securities and Exchange Commission (the &#147;Report&#148;), I, Megan Boston, Executive Director of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of
the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act
of 1934. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Megan Boston</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Megan Boston </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Director (principal financial officer)
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 21, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A signed original of this written
statement required by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification is being furnished pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bntc-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 20-September-2023 [11:13:39] {AM}-->
<schema targetNamespace="http://www.benitecbiopharmainc.com/20230630" elementFormDefault="qualified" xmlns:bntc="http://www.benitecbiopharmainc.com/20230630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" id="ConsolidatedStatementsOfStockholdersEquityParenthetical">
<link:definition>1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Business" id="Business">
<link:definition>1008 - Disclosure - Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Liquidity" id="Liquidity">
<link:definition>1010 - Disclosure - Liquidity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Revenue" id="Revenue">
<link:definition>1011 - Disclosure - Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash" id="CashCashEquivalentsAndRestrictedCash">
<link:definition>1012 - Disclosure - Cash, cash equivalents, and restricted cash</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" id="PrepaidAndOtherAssets">
<link:definition>1013 - Disclosure - Prepaid and other assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1014 - Disclosure - Property and equipment, net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
<link:definition>1015 - Disclosure - Trade and other payables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Leases" id="Leases">
<link:definition>1016 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1017 - Disclosure - Stockholders' equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1018 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1019 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1020 - Disclosure - Related party transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LossPerShare" id="LossPerShare">
<link:definition>1021 - Disclosure -  Loss per share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1022 - Disclosure - Subsequent events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" id="BusinessTables">
<link:definition>1024 - Disclosure - Business (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<link:definition>1025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" id="RevenueTables">
<link:definition>1026 - Disclosure - Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables" id="CashCashEquivalentsAndRestrictedCashTables">
<link:definition>1027 - Disclosure - Cash, cash equivalents, and restricted cash (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" id="PrepaidAndOtherAssetsTables">
<link:definition>1028 - Disclosure - Prepaid and other assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1029 - Disclosure - Property and equipment, net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
<link:definition>1030 - Disclosure - Trade and other payables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" id="LeasesTables">
<link:definition>1031 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1032 - Disclosure - Stockholders' equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1033 - Disclosure - Income taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareTables" id="LossPerShareTables">
<link:definition>1034 - Disclosure - Loss per share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" id="BusinessSummaryOfEntitiesInControlDetail">
<link:definition>1035 - Disclosure - Business - Summary of entities in control (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" id="BusinessAdditionalInformationDetail">
<link:definition>1036 - Disclosure - Business - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<link:definition>1037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail">
<link:definition>1039 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail" id="LiquidityAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Liquidity - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" id="RevenueSummaryOfRevenueFromCustomersDetail">
<link:definition>1041 - Disclosure - Revenue - Summary of revenue from customers (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" id="CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail">
<link:definition>1042 - Disclosure - Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" id="PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<link:definition>1043 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<link:definition>1044 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition>1045 - Disclosure - Property and equipment, net - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" id="TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<link:definition>1046 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" id="LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<link:definition>1047 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1048 - Disclosure - Leases - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" id="LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<link:definition>1049 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" id="StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<link:definition>1050 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" id="StockholdersEquityScheduleOfEquityAwardsDetail">
<link:definition>1051 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" id="StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail">
<link:definition>1052 - Disclosure - Stockholders' equity - Summary of equity-based compensation expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" id="StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<link:definition>1053 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1054 - Disclosure - Stockholders' equity - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" id="IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail">
<link:definition>1055 - Disclosure - Income taxes - Summary of income (loss) before provision for income taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" id="IncomeTaxesSummaryOfCompanySDeferredTaxesDetail">
<link:definition>1056 - Disclosure - Income taxes - Summary of company's deferred taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" id="IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail">
<link:definition>1057 - Disclosure - Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" id="IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail">
<link:definition>1058 - Disclosure - Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1059 - Disclosure - Income taxes - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1060 - Disclosure - Commitments and contingencies - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1061 - Disclosure - Related party transactions - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail" id="LossPerShareSummaryOfLossPerShareDetail">
<link:definition>1062 - Disclosure - Loss per share - Summary of Loss per share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail" id="LossPerShareAdditionalInformationDetail">
<link:definition>1063 - Disclosure - Loss per share - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
<link:definition>1064 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
<import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
<import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
<import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
<import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="BasicAndDilutedEarningsPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BasicAndDilutedEarningsPerShareAbstract" substitutionGroup="xbrli:item" />
<element name="RoyaltiesAndLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RoyaltiesAndLicenseFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceAndExerciseOfPrefundedAndCommonWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" substitutionGroup="xbrli:item" />
<element name="WarrantsExercisedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WarrantsExercisedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreasedecreaseInAccountsAndOtherPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreasedecreaseInAccountsAndOtherPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreaseDecreaseInLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmortizationOfRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_AmortizationOfRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnrealizedGainLossOnInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_UnrealizedGainLossOnInvestment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScheduleOfEntitiesInControlAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlAbstract" substitutionGroup="xbrli:item" />
<element name="LiquidityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LiquidityAbstract" substitutionGroup="xbrli:item" />
<element name="LiquidityDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_LiquidityDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherPayablesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_TradeAndOtherPayablesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RisksAndUncertainitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RisksAndUncertainitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BenitecLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecAustraliaProprietaryLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecAustraliaProprietaryLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLlcMember" substitutionGroup="xbrli:item" />
<element name="TacereTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_TacereTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="BenitecBiopharmaProprietaryLimitedBblMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecBiopharmaProprietaryLimitedBblMember" substitutionGroup="xbrli:item" />
<element name="BenitecIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecIncMember" substitutionGroup="xbrli:item" />
<element name="RnaiTherapeuticsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_RnaiTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="BenitecIpHoldingsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecIpHoldingsIncMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlLineItems" substitutionGroup="xbrli:item" />
<element name="LabEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="FinancialAssetsAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_FinancialAssetsAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AverageForeignExchangeRateForThePeriod" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_AverageForeignExchangeRateForThePeriod" substitutionGroup="xbrli:item" />
<element name="MarketValueOfListedShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_MarketValueOfListedShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedOpmdProjectCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedOpmdProjectCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedConsultantFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedConsultantFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedLicenceFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedLicenceFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RemeasurementOfLeaseLiabilitiesDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreFundedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PreFundedWarrantsMember" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfPreFundedWarrantsIssued" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantOrRightsExercised" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightsIssuedDuringPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsExcercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsExcercisable" substitutionGroup="xbrli:item" />
<element name="Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" substitutionGroup="xbrli:item" />
<element name="SeriesTwoWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SeriesTwoWarrantsMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
<element name="Series2WarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_Series2WarrantsMember" substitutionGroup="xbrli:item" />
<element name="PurchaseWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PurchaseWarrantsMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSeriesWarrantsIssued" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_NumberOfSeriesWarrantsIssued" substitutionGroup="xbrli:item" />
<element name="IssueOfCommonStockAndWarrantPricePerShare" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_IssueOfCommonStockAndWarrantPricePerShare" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsIssuePricePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" substitutionGroup="xbrli:item" />
<element name="CashlessExerciseOfPurchaseWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_CashlessExerciseOfPurchaseWarrants" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsExcercisedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_TwoThousandAndTwentyEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_EventDomain" substitutionGroup="xbrli:item" />
<element name="RevisionInTheExercisePriceOfPrefundedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_DeferredTaxAssetsLeaseLiabilities" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" substitutionGroup="xbrli:item" />
<element name="YearOfExpiryOfOperatingLossesCarryForwards" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_YearOfExpiryOfOperatingLossesCarryForwards" substitutionGroup="xbrli:item" />
<element name="PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PeriodDomain" substitutionGroup="xbrli:item" />
<element name="NolFromTwoThousandEighteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_NolFromTwoThousandEighteenMember" substitutionGroup="xbrli:item" />
<element name="NOLpreJanuaryOneTwoThousandEighteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_NOLpreJanuaryOneTwoThousandEighteenMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_YearTwoThousandAndThirtyOneMember" substitutionGroup="xbrli:item" />
<element name="YearTwoThousandAndThirtyFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_YearTwoThousandAndThirtyFourMember" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" substitutionGroup="xbrli:item" />
<element name="SuspensionOfAnnualDeductionLimitationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SuspensionOfAnnualDeductionLimitationMember" substitutionGroup="xbrli:item" />
<element name="ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" substitutionGroup="xbrli:item" />
<element name="UnexpectedEventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_UnexpectedEventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="UnexpectedEventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_UnexpectedEventDomain" substitutionGroup="xbrli:item" />
<element name="CoronavirusAidReliefAndEconomicSecurityActMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CoronavirusAidReliefAndEconomicSecurityActMember" substitutionGroup="xbrli:item" />
<element name="CaliforniaAssemblyBillEightyFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CaliforniaAssemblyBillEightyFiveMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfAnnualTaxableIncomeEligibleForDeduction" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" substitutionGroup="xbrli:item" />
<element name="NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" substitutionGroup="xbrli:item" />
<element name="PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" substitutionGroup="xbrli:item" />
<element name="PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" substitutionGroup="xbrli:item" />
<element name="MinimumNetBusinessIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_MinimumNetBusinessIncome" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LegislationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LegislationAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="LegislationDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LegislationDomain" substitutionGroup="xbrli:item" />
<element name="SB113Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SB113Member" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CommitmentsAndContingenciesDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CommitmentsAndContingenciesDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="FrancisAbourizkLightowlersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_FrancisAbourizkLightowlersMember" substitutionGroup="xbrli:item" />
<element name="Dr.JerelBanksMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_Dr.JerelBanksMember" substitutionGroup="xbrli:item" />
<element name="MeganBostonMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_MeganBostonMember" substitutionGroup="xbrli:item" />
<element name="ExecutiveChairmanAndChiefExecutiveOfficerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" substitutionGroup="xbrli:item" />
<element name="ExecutiveDirectorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ExecutiveDirectorMember" substitutionGroup="xbrli:item" />
<element name="CommonWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_CommonWarrantsMember" substitutionGroup="xbrli:item" />
<element name="AnnualBaseSalaryCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AnnualBaseSalaryCompensation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ForeignCurrencyExchangeRateConversion" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_ForeignCurrencyExchangeRateConversion" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bntc-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 20-September-2023 [11:13:39] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DepositAssets" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_BNTC_RoyaltiesAndLicenseFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_BNTC_RoyaltiesAndLicenseFees" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="loc_us-gaap_DueFromBanks" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_BNTC_AccruedLicenceFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedLicenceFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_BNTC_AccruedOpmdProjectCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedOpmdProjectCostsCurrent" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedConsultantFeesCurrent" xlink:label="loc_BNTC_AccruedConsultantFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedConsultantFeesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_BNTC_AmortizationOfRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_AmortizationOfRightOfUseAssets" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnrealizedGainLossOnInvestment" xlink:label="loc_BNTC_UnrealizedGainLossOnInvestment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_UnrealizedGainLossOnInvestment" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="19" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_BNTC_DeferredTaxAssetsLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_BNTC_DeferredTaxAssetsLeaseLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_BNTC_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_BNTC_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_BNTC_MarketValueOfListedShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_BNTC_MarketValueOfListedShares" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssets" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:label="loc_BNTC_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_BNTC_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bntc-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 20-September-2023 [11:13:39] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LiquidityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#RevenueSummaryOfRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LossPerShareAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BusinessAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#Revenue" roleURI="http://www.benitecbiopharmainc.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#RevenueTables" roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CashCashEquivalentsAndRestrictedCash" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CashCashEquivalentsAndRestrictedCashTables" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PrepaidAndOtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PrepaidAndOtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#SubsequentEvents" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LossPerShare" roleURI="http://www.benitecbiopharmainc.com/role/LossPerShare" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LossPerShareTables" roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#RelatedPartyTransactions" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesTables" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LossPerShareSummaryOfLossPerShareDetail" roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#Liquidity" roleURI="http://www.benitecbiopharmainc.com/role/Liquidity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1701632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1701632" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1701631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasic_1701631" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1701634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1701634" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1701635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1701635" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_StatementTable_747523" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees_747072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_bntc_RoyaltiesAndLicenseFees_747072" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants_747181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants_747181" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WarrantsExercisedDuringThePeriod" xlink:label="loc_bntc_WarrantsExercisedDuringThePeriod_814197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_WarrantsExercisedDuringThePeriod_814197" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StatementTable_747147" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts_748442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts_748442" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecIpHoldingsIncMember" xlink:label="loc_bntc_BenitecIpHoldingsIncMember_1701733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIpHoldingsIncMember_1701733" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_2147469002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_2147469002" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_2147469001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_2147469001" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2147469000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_2147469000" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives_2147468991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives_2147468991" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2147468990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2147468990" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2147469066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2147469066" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469066" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469065" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469066" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469065_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2147469064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2147469065" xlink:to="loc_us-gaap_SubsequentEventMember_2147469064" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue_747932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_FinancialAssetsAtFairValue_747932" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2147469063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_2147469063" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_2147469061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_RestrictedCashCurrent_2147469061" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2147469026" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_NetIncomeLoss_747276" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2147469028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2147469028" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2147469027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_StatementTable_2147469027" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2147469025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2147469027" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2147469025" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469025" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469024" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469024_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469025" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469024_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2147469023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2147469024" xlink:to="loc_us-gaap_SubsequentEventMember_2147469023" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_srt_ProductOrServiceAxis_747412" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_LicenseMember_747416" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847_default" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748515" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_StatementTable_748512" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_748518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_748517" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_748518" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xlink:label="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod_1170859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod_1170859" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747597" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xlink:label="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod_1170856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod_1170856" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_747598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeasePayments_747598" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_747654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseExpense_747654" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_StatementTable_748057" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_748065" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062_default" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1701200" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xlink:label="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued_1701297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued_1701297" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsExercised" xlink:label="loc_bntc_ClassOfWarrantOrRightsExercised_2147469089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantOrRightsExercised_2147469089" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_1701945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_1701945" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1701189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1701189" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1701197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_StatementTable_1701197" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" xlink:to="loc_bntc_PreFundedWarrantsMember_1701203" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1701198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1701198" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701198" xlink:to="loc_us-gaap_ClassOfStockDomain_1701199" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701199_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701198" xlink:to="loc_us-gaap_ClassOfStockDomain_1701199_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SeriesTwoWarrantsMember" xlink:label="loc_bntc_SeriesTwoWarrantsMember_1701944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" xlink:to="loc_bntc_SeriesTwoWarrantsMember_1701944" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable_1701946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable_1701946" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701940" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisable_1701941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisable_1701941" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xlink:label="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised_2147469103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised_2147469103" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1701289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1701289" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2147469107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2147469107" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm_1420382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm_1420382" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1701288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1701288" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_768328" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1283076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1283076" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701168" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1282101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1282101" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued_1282100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_NumberOfSeriesWarrantsIssued_1282100" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_768325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_StatementTable_768325" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Series2WarrantsMember" xlink:label="loc_bntc_Series2WarrantsMember_1701170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_Series2WarrantsMember_1701170" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_770074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_bntc_PreFundedWarrantsMember_770074" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_PreFundedWarrantsMember_1701949" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember_1282099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_PurchaseWarrantsMember_1282099" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1282103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1282103" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1282104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1282103" xlink:to="loc_us-gaap_EquityComponentDomain_1282104" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1282104_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1282103" xlink:to="loc_us-gaap_EquityComponentDomain_1282104_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1282105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1282104" xlink:to="loc_us-gaap_CommonStockMember_1282105" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_770071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_IPOMember_770071" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1282937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_srt_RangeAxis_1282937" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1282938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1282937" xlink:to="loc_srt_RangeMember_1282938" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1282938_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1282937" xlink:to="loc_srt_RangeMember_1282938_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1282968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_PlanNameAxis_1282968" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1282970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1282968" xlink:to="loc_us-gaap_PlanNameDomain_1282970" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1282970_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1282968" xlink:to="loc_us-gaap_PlanNameDomain_1282970_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="loc_bntc_TwoThousandAndTwentyEquityIncentivePlanMember_2147468987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1282970" xlink:to="loc_bntc_TwoThousandAndTwentyEquityIncentivePlanMember_2147468987" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2147469007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2147469007" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469007" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469006" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469006_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469007" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469006_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2147469005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2147469006" xlink:to="loc_us-gaap_SubsequentEventMember_2147469005" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventAxis" xlink:label="loc_bntc_EventAxis_2147468997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_bntc_EventAxis_2147468997" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_2147468996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_EventAxis_2147468997" xlink:to="loc_bntc_EventDomain_2147468996" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_2147468996_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_EventAxis_2147468997" xlink:to="loc_bntc_EventDomain_2147468996_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" xlink:label="loc_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember_2147468995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_EventDomain_2147468996" xlink:to="loc_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember_2147468995" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2147468984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_AwardTypeAxis_2147468984" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2147468983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2147468984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2147468983" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2147468983_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2147468984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2147468983_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2147468982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2147468983" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2147468982" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:label="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_1701953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_1701953" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_1701955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_1701955" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants_1282102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_CashlessExerciseOfPurchaseWarrants_1282102" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1282096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1282096" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_770079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_770079" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_2147469104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_2147469104" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2147469062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2147469062" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2147469004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2147469004" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_2147468998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_2147468998" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2147468988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2147468988" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2147468981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2147468981" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2147468980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2147468980" use="optional" order="54" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_747822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_747822" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747822" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747823" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747822" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747823_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_747825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_DomesticCountryMember_747825" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_747827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_ForeignCountryMember_747827" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_747824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_747824" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis_747818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_bntc_PeriodAxis_747818" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_PeriodAxis_747818" xlink:to="loc_bntc_PeriodDomain_747819" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747819_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_PeriodAxis_747818" xlink:to="loc_bntc_PeriodDomain_747819_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NolFromTwoThousandEighteenMember" xlink:label="loc_bntc_NolFromTwoThousandEighteenMember_747820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_PeriodDomain_747819" xlink:to="loc_bntc_NolFromTwoThousandEighteenMember_747820" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NOLpreJanuaryOneTwoThousandEighteenMember" xlink:label="loc_bntc_NOLpreJanuaryOneTwoThousandEighteenMember_2147469018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_PeriodDomain_747819" xlink:to="loc_bntc_NOLpreJanuaryOneTwoThousandEighteenMember_2147469018" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_747828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_us-gaap_TaxPeriodAxis_747828" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_747828" xlink:to="loc_us-gaap_TaxPeriodDomain_747829" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747829_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_747828" xlink:to="loc_us-gaap_TaxPeriodDomain_747829_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearTwoThousandAndThirtyOneMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyOneMember_747832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtyOneMember_747832" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearTwoThousandAndThirtyFourMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyFourMember_747830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtyFourMember_747830" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_747837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_747837" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:label="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards_747838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards_747838" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_747834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_us-gaap_OperatingLossCarryforwards_747834" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncomeTaxDisclosureLineItems" xlink:label="loc_bntc_IncomeTaxDisclosureLineItems_747872" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_747874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_OpenTaxYear_747874" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:label="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction_748282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction_748282" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:label="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack_748281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack_748281" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_748283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_748283" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards_747875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards_747875" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncomeTaxDisclosureTable" xlink:label="loc_bntc_IncomeTaxDisclosureTable_747855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_IncomeTaxDisclosureTable_747855" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_748278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_srt_StatementGeographicalAxis_748278" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_748279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_748278" xlink:to="loc_srt_SegmentGeographicalDomain_748279" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_748279_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_748278" xlink:to="loc_srt_SegmentGeographicalDomain_748279_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_747860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_TaxPeriodAxis_747860" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_747860" xlink:to="loc_us-gaap_TaxPeriodDomain_747861" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747861_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_747860" xlink:to="loc_us-gaap_TaxPeriodDomain_747861_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2014Member" xlink:label="loc_us-gaap_TaxYear2014Member_747862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2014Member_747862" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2019Member" xlink:label="loc_us-gaap_TaxYear2019Member_747863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2019Member_747863" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2011Member" xlink:label="loc_us-gaap_TaxYear2011Member_747864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2011Member_747864" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" xlink:label="loc_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member_2147469011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member_2147469011" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2016Member" xlink:label="loc_us-gaap_TaxYear2016Member_2147469009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2016Member_2147469009" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2022Member" xlink:label="loc_us-gaap_TaxYear2022Member_2147469008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2022Member_2147469008" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventAxis" xlink:label="loc_bntc_EventAxis_748284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_EventAxis_748284" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_748285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_EventAxis_748284" xlink:to="loc_bntc_EventDomain_748285" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_748285_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_EventAxis_748284" xlink:to="loc_bntc_EventDomain_748285_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:label="loc_bntc_SuspensionOfAnnualDeductionLimitationMember_748286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_EventDomain_748285" xlink:to="loc_bntc_SuspensionOfAnnualDeductionLimitationMember_748286" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" xlink:label="loc_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember_2147469013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_EventDomain_748285" xlink:to="loc_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember_2147469013" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnexpectedEventAxis" xlink:label="loc_bntc_UnexpectedEventAxis_748287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_UnexpectedEventAxis_748287" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnexpectedEventDomain" xlink:label="loc_bntc_UnexpectedEventDomain_748288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_UnexpectedEventAxis_748287" xlink:to="loc_bntc_UnexpectedEventDomain_748288" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnexpectedEventDomain" xlink:label="loc_bntc_UnexpectedEventDomain_748288_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_UnexpectedEventAxis_748287" xlink:to="loc_bntc_UnexpectedEventDomain_748288_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember_748289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_UnexpectedEventDomain_748288" xlink:to="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember_748289" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:label="loc_bntc_CaliforniaAssemblyBillEightyFiveMember_748363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_UnexpectedEventDomain_748288" xlink:to="loc_bntc_CaliforniaAssemblyBillEightyFiveMember_748363" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_747856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_747856" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747856" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747857" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747857_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747856" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747857_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_747859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747857" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_747859" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_747858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747857" xlink:to="loc_us-gaap_DomesticCountryMember_747858" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_747867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_747867" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2147469003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2147469003" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_srt_RangeAxis_747868" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_747868" xlink:to="loc_srt_RangeMember_747869" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747869_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_747868" xlink:to="loc_srt_RangeMember_747869_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747869" xlink:to="loc_srt_MinimumMember_747871" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LegislationAxis" xlink:label="loc_bntc_LegislationAxis_2147469016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_LegislationAxis_2147469016" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LegislationDomain" xlink:label="loc_bntc_LegislationDomain_2147469015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_LegislationAxis_2147469016" xlink:to="loc_bntc_LegislationDomain_2147469015" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LegislationDomain" xlink:label="loc_bntc_LegislationDomain_2147469015_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_LegislationAxis_2147469016" xlink:to="loc_bntc_LegislationDomain_2147469015_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SB113Member" xlink:label="loc_bntc_SB113Member_2147469014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_LegislationDomain_2147469015" xlink:to="loc_bntc_SB113Member_2147469014" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards_747876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards_747876" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_747873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_747873" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MinimumNetBusinessIncome" xlink:label="loc_bntc_MinimumNetBusinessIncome_2147469017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_MinimumNetBusinessIncome_2147469017" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2147469010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2147469010" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747710" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" xlink:to="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis_747705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" xlink:to="loc_bntc_PeriodAxis_747705" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntc_PeriodAxis_747705" xlink:to="loc_bntc_PeriodDomain_747706" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747706_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntc_PeriodAxis_747705" xlink:to="loc_bntc_PeriodDomain_747706_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1170879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_LegalFees_1170879" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember_1170883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_747692" xlink:to="loc_bntc_FrancisAbourizkLightowlersMember_1170883" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2147469032" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2147469037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2147469032" xlink:to="loc_us-gaap_StatementTable_2147469037" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2147469036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2147469037" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2147469036" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2147469036" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2147469036" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2147469034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035" xlink:to="loc_us-gaap_WarrantMember_2147469034" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2147469033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2147469033" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2147469031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2147469032" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2147469031" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_925654" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1701153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1701153" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2147469060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_2147469060" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AnnualBaseSalaryCompensation" xlink:label="loc_bntc_AnnualBaseSalaryCompensation_2147468976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_AnnualBaseSalaryCompensation_2147468976" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ForeignCurrencyExchangeRateConversion" xlink:label="loc_bntc_ForeignCurrencyExchangeRateConversion_2147468966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_ForeignCurrencyExchangeRateConversion_2147468966" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_925649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_SubsequentEventTable_925649" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2147468974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2147468974" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2147468973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2147468974" xlink:to="loc_us-gaap_RelatedPartyDomain_2147468973" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2147468973_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2147468974" xlink:to="loc_us-gaap_RelatedPartyDomain_2147468973_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Dr.JerelBanksMember" xlink:label="loc_bntc_Dr.JerelBanksMember_2147468972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2147468973" xlink:to="loc_bntc_Dr.JerelBanksMember_2147468972" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MeganBostonMember" xlink:label="loc_bntc_MeganBostonMember_2147468971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2147468973" xlink:to="loc_bntc_MeganBostonMember_2147468971" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2147468970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_srt_TitleOfIndividualAxis_2147468970" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2147468970" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2147468970" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember_2147468968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969" xlink:to="loc_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember_2147468968" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ExecutiveDirectorMember" xlink:label="loc_bntc_ExecutiveDirectorMember_2147468967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969" xlink:to="loc_bntc_ExecutiveDirectorMember_2147468967" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_925650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_925650" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_925651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_925650" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_925651" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_925651_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_925650" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_925651_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_925652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_925651" xlink:to="loc_us-gaap_IPOMember_925652" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_941619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_941619" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_941620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_941619" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_941620" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_941620_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_941619" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_941620_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_941621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_941620" xlink:to="loc_us-gaap_SubsequentEventMember_941621" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2147469057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2147469057" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2147469057" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2147469057" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056" xlink:to="loc_bntc_PreFundedWarrantsMember_1701155" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Series2WarrantsMember" xlink:label="loc_bntc_Series2WarrantsMember_2147469046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056" xlink:to="loc_bntc_Series2WarrantsMember_2147469046" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2147469050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2147469050" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2147469049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2147469050" xlink:to="loc_us-gaap_EquityComponentDomain_2147469049" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2147469049_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2147469050" xlink:to="loc_us-gaap_EquityComponentDomain_2147469049_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2147469048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2147469049" xlink:to="loc_us-gaap_CommonStockMember_2147469048" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommonWarrantsMember" xlink:label="loc_bntc_CommonWarrantsMember_2147469047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2147469049" xlink:to="loc_bntc_CommonWarrantsMember_2147469047" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_941623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_941623" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_925656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_925656" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2147469059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2147469059" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2147469054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2147469054" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:label="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_2147469053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_2147469053" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_2147469051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_2147469051" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2147469045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2147469045" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_2147469058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_2147469058" use="optional" order="41" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bntc-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 20-September-2023 [11:13:39] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Principal place of business/country of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right-of-use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Initial measurement at July 1, 2021</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset at June 30, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositAssets" xml:lang="en-US">Deposit Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepositAssets" xml:lang="en-US">Deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities, less current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Less: non-current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at end</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 12)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Contingent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value&#8212;160,000,000 shares authorized; 1,645,951 and 480,688 shares issued and outstanding at June 30, 2023 and 2022, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Trade and other payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Accrued employee benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Lease liabilities, current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion at June 30, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock Par Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss attributable to common stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Total comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized loss on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign currency transaction loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other loss, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_bntc_BasicAndDilutedEarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BasicAndDilutedEarningsPerShareAbstract" xml:lang="en-US">Basic and Diluted Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_BasicAndDilutedEarningsPerShareAbstract" xml:lang="en-US">Weighted-average shares outstanding:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_bntc_BasicAndDilutedEarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_BasicAndDilutedEarningsPerShareAbstract" xml:lang="en-US">Basic and diluted earnings per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of shares used in calculating basic earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of shares used in calculating diluted earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive income (loss):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized foreign currency translation gain</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Foreign currency translation gain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Total other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xml:lang="en-US">Royalties And License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xml:lang="en-US">Royalties and license fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RoyaltiesAndLicenseFees" xlink:to="lab_bntc_RoyaltiesAndLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xml:lang="en-US">Royalties and license fees</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenues from customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenues from customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xml:lang="en-US">Issuance and exercise of prefunded and common warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xml:lang="en-US">Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $1,869, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xlink:to="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xml:lang="en-US">Issuance and exercise of pre-funded and common warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at end (In shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at the beginning (In shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WarrantsExercisedDuringThePeriod" xlink:label="loc_bntc_WarrantsExercisedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WarrantsExercisedDuringThePeriod" xml:lang="en-US">Warrants Exercised During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_WarrantsExercisedDuringThePeriod" xml:lang="en-US">Exercise of&#160;pre-funded&#160;warrants, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WarrantsExercisedDuringThePeriod" xlink:to="lab_bntc_WarrantsExercisedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WarrantsExercisedDuringThePeriod" xml:lang="en-US">Warrants exercised during the period.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xml:lang="en-US">Issuance And Exercise Of Prefunded and Common Warrants Net Of Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xml:lang="en-US">Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $1,869</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xlink:to="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xml:lang="en-US">Issuance and exercise of pre-funded and common warrants, net of transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments For Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Share issue transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Increase Decrease in Accounts and Other Payables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:to="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xml:lang="en-US">Increase (decrease) in accounts and other payables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Trade and other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Accrued employee benefit payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Increase Decrease In Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_bntc_IncreaseDecreaseInLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xml:lang="en-US">Increase decrease In lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in provided by operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of Right of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AmortizationOfRightOfUseAssets" xlink:to="lab_bntc_AmortizationOfRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xml:lang="en-US">Amortization of right-of-use assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnrealizedGainLossOnInvestment" xlink:label="loc_bntc_UnrealizedGainLossOnInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_UnrealizedGainLossOnInvestment" xml:lang="en-US">Unrealized Gain Loss On Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_bntc_UnrealizedGainLossOnInvestment" xml:lang="en-US">Unrealized loss on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_UnrealizedGainLossOnInvestment" xlink:to="lab_bntc_UnrealizedGainLossOnInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_UnrealizedGainLossOnInvestment" xml:lang="en-US">Unrealized (gain) loss on investment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Re-measurement of operating lease right-of-use assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issues of shares and pre-funded warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlAbstract" xml:lang="en-US">Schedule Of Entities In Control [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract" xlink:to="lab_bntc_ScheduleOfEntitiesInControlAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LiquidityAbstract" xlink:label="loc_bntc_LiquidityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_LiquidityAbstract" xml:lang="en-US">Liquidity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LiquidityAbstract" xlink:to="lab_bntc_LiquidityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_LiquidityAbstract" xml:lang="en-US">Liquidity.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LiquidityDisclosureTextBlock" xlink:label="loc_bntc_LiquidityDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_LiquidityDisclosureTextBlock" xml:lang="en-US">Liquidity Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_LiquidityDisclosureTextBlock" xml:lang="en-US">Liquidity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LiquidityDisclosureTextBlock" xlink:to="lab_bntc_LiquidityDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_LiquidityDisclosureTextBlock" xml:lang="en-US">Liquidity disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsAbstract" xml:lang="en-US">Other Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract" xlink:to="lab_us-gaap_OtherAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xml:lang="en-US">Other Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related party transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Translation and Other Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Basic and Diluted Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations of Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:to="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xml:lang="en-US">Trade and other payables.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xml:lang="en-US">Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xml:lang="en-US">Trade and Other Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Equity-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:label="loc_bntc_RisksAndUncertainitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks And Uncertainities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks and Uncertainties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:to="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_RisksAndUncertainitiesPolicyTextBlock" xml:lang="en-US">Risks and uncertainities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Schedule Of Entities In Control [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Summary of entities in control</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xml:lang="en-US">Schedule of entities in control.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Schedule of property plant and equipment useful lives.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:label="loc_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xml:lang="en-US">Schedule Of Foreign Currency Translation Rates [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xml:lang="en-US">Summary of foreign currency translation and other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:to="lab_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xml:lang="en-US">Schedule of foreign currency translation rates.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xml:lang="en-US">Summary of revenue from customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xml:lang="en-US">Summary of other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of trade and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Summary of supplemental balance sheet information related to leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule of supplemental balance sheet information related to leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of maturities of the operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of equity-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Schedule of equity awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of warrants or rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Summary of income (loss) before provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary of company's deferred taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Summary reconciliation of effective rate of the company's provision (benefit) for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xml:lang="en-US">Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xml:lang="en-US">Summary of net operating losses and tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:to="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xml:lang="en-US">Disclosure details of operating loss carry forwards and tax credits.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Summary of Loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlTable" xml:lang="en-US">Schedule Of Entities In Control [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecLimitedMember" xml:lang="en-US">Benitec Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecLimitedMember" xml:lang="en-US">Benitec Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLimitedMember" xlink:to="lab_bntc_BenitecLimitedMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:to="lab_bntc_BenitecAustraliaProprietaryLimitedMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecLlcMember" xml:lang="en-US">Benitec LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecLlcMember" xml:lang="en-US">Benitec LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLlcMember" xlink:to="lab_bntc_BenitecLlcMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_TacereTherapeuticsIncMember" xml:lang="en-US">Tacere Therapeutics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_TacereTherapeuticsIncMember" xml:lang="en-US">Tacere Therapeutics, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TacereTherapeuticsIncMember" xlink:to="lab_bntc_TacereTherapeuticsIncMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xml:lang="en-US">Benitec Biopharma Proprietary Limited BBL [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xml:lang="en-US">Benitec Biopharma Proprietary Limited ("BBL") [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:to="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecIncMember" xml:lang="en-US">Benitec Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_BenitecIncMember" xml:lang="en-US">Benitec, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecIncMember" xlink:to="lab_bntc_BenitecIncMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xml:lang="en-US">RNAi Therapeutics Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xml:lang="en-US">RNAi Therapeutics, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RnaiTherapeuticsIncMember" xlink:to="lab_bntc_RnaiTherapeuticsIncMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecIpHoldingsIncMember" xlink:label="loc_bntc_BenitecIpHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BenitecIpHoldingsIncMember" xml:lang="en-US">Benitec IP Holdings Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_BenitecIpHoldingsIncMember" xml:lang="en-US">Benitec IP Holdings, Inc.[Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecIpHoldingsIncMember" xlink:to="lab_bntc_BenitecIpHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_BenitecIpHoldingsIncMember" xml:lang="en-US">Benitec IP Holdings, Inc.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ScheduleOfEntitiesInControlLineItems" xml:lang="en-US">Schedule Of Entities In Control [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems" xlink:to="lab_bntc_ScheduleOfEntitiesInControlLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation Date Of Incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LabEquipmentMember" xlink:to="lab_bntc_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_LabEquipmentMember" xml:lang="en-US">Lab equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer hardware [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Description of Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Description of Property, Plant and Equipment, Estimated Useful Lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary of significant accounting policies [Table].</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary of significant accounting policies [Line Items].</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_FinancialAssetsAtFairValue" xml:lang="en-US">Financial Assets At Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_FinancialAssetsAtFairValue" xml:lang="en-US">Financial assets at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_FinancialAssetsAtFairValue" xlink:to="lab_bntc_FinancialAssetsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_FinancialAssetsAtFairValue" xml:lang="en-US">Financial assets at fair value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' equity, reverse stock split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AverageForeignExchangeRateForThePeriod" xlink:label="loc_bntc_AverageForeignExchangeRateForThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AverageForeignExchangeRateForThePeriod" xml:lang="en-US">Average Foreign Exchange Rate For The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_AverageForeignExchangeRateForThePeriod" xml:lang="en-US">Average exchange rate for the period, USD: AUD Exchange Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AverageForeignExchangeRateForThePeriod" xlink:to="lab_bntc_AverageForeignExchangeRateForThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AverageForeignExchangeRateForThePeriod" xml:lang="en-US">Average foreign exchange rate for the period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xml:lang="en-US">Exchange rate on balance sheet dates, USD: AUD Exchange Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Net proceeds from public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">License [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicenseMember" xml:lang="en-US">Licensing revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xml:lang="en-US">Revenue from External Customer [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromBanks" xml:lang="en-US">Due from Banks</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueFromBanks" xml:lang="en-US">Cash at bank</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromBanks" xlink:to="lab_us-gaap_DueFromBanks" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value Of listed shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value of listed shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MarketValueOfListedShares" xlink:to="lab_bntc_MarketValueOfListedShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_MarketValueOfListedShares" xml:lang="en-US">Market value of listed shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Less:&#160;non-current&#160;portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssets" xml:lang="en-US">Total other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_bntc_AccruedOpmdProjectCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AccruedOpmdProjectCostsCurrent" xml:lang="en-US">Accrued Opmd Project Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_bntc_AccruedOpmdProjectCostsCurrent" xml:lang="en-US">Accrued OPMD project costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedOpmdProjectCostsCurrent" xlink:to="lab_bntc_AccruedOpmdProjectCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AccruedOpmdProjectCostsCurrent" xml:lang="en-US">Accrued Opmd Project Costs Current.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedConsultantFeesCurrent" xlink:label="loc_bntc_AccruedConsultantFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AccruedConsultantFeesCurrent" xml:lang="en-US">Accrued Consultant Fees Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_AccruedConsultantFeesCurrent" xml:lang="en-US">Accrued consultant fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedConsultantFeesCurrent" xlink:to="lab_bntc_AccruedConsultantFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AccruedConsultantFeesCurrent" xml:lang="en-US">Accrued offering costs current.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued Licence Fees Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued license fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedLicenceFeesCurrent" xlink:to="lab_bntc_AccruedLicenceFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xml:lang="en-US">Accrued licence fees current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Trade payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xlink:label="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xml:lang="en-US">Remeasurement Of Lease Liabilities During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xml:lang="en-US">Re-measurement during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xlink:to="lab_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xml:lang="en-US">Remeasurement of lease liabilities during the period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities at June 30, 2023</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Initial measurement at July 1, 2021</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Amortization of right of use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xlink:label="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xml:lang="en-US">Operating Lease Right Of Use Asset Remasurement During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xml:lang="en-US">Re-measurement during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xlink:to="lab_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xml:lang="en-US">Operating lease right of use asset remasurement during the period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Principal payments on operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xml:lang="en-US">Operating lease discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Operating lease has a remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total operating lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PreFundedWarrantsMember" xml:lang="en-US">Pre funded Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PreFundedWarrantsMember" xml:lang="en-US">Pre-funded warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PreFundedWarrantsMember" xlink:to="lab_bntc_PreFundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_PreFundedWarrantsMember" xml:lang="en-US">Pre funded warrants .</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xlink:label="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xml:lang="en-US">Weighted Average Exercise Price Of Pre Funded Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xml:lang="en-US">Pre-funded warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xlink:to="lab_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xml:lang="en-US">Weighted average exercise price of pre funded warrants issued.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsExercised" xlink:label="loc_bntc_ClassOfWarrantOrRightsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantOrRightsExercised" xml:lang="en-US">Class Of Warrant Or Rights Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ClassOfWarrantOrRightsExercised" xml:lang="en-US">Pre-funded warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantOrRightsExercised" xlink:to="lab_bntc_ClassOfWarrantOrRightsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantOrRightsExercised" xml:lang="en-US">Class of warrant or rights exercised.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Weighted Average Exercise Price Of Class Of Warrants Or Rights Issued During The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Series 2 Warrants issued September 16, 2022</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Class of warrants or rights weighted average exercise price of class of warrants or rights issued during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xml:lang="en-US">Weighted average exercise price of class of warrants or rights issued during the period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Pre-funded warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of stock number of shares issued in the transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Exercise price of class of warrants or rights outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Exercise price of class of warrants or rights outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xml:lang="en-US">Weighted-average exercise price of class of warrants or rights outstanding.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Exercisable at June 30, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Weighted average exercise price of class of warrants or rights excercisable.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xml:lang="en-US">Class Of Warrant Or Rights Issued During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xml:lang="en-US">Series 2 Warrants issued September 16, 2022</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xml:lang="en-US">Class of warrant or rights issued during period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:to="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xml:lang="en-US">Class of warrant or rights issued during period.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Class Of Warrants Or Rights Excercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Exercisable at June 30, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsExcercisable" xlink:to="lab_bntc_ClassOfWarrantsOrRightsExcercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisable" xml:lang="en-US">Class of warrants or rights excercisable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Outstanding, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Outstanding, ending of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of warrants or rights outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xlink:label="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xml:lang="en-US">WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xml:lang="en-US">Pre-funded warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xlink:to="lab_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xml:lang="en-US">Weighted average exercise price of class of warrants or rights exercised.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SeriesTwoWarrantsMember" xlink:label="loc_bntc_SeriesTwoWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SeriesTwoWarrantsMember" xml:lang="en-US">Series Two Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_SeriesTwoWarrantsMember" xml:lang="en-US">Series 2 Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SeriesTwoWarrantsMember" xlink:to="lab_bntc_SeriesTwoWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SeriesTwoWarrantsMember" xml:lang="en-US">Series 2 Warrants [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at June 30, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Stock Options, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock Options, Outstanding, end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock Options,Outstanding, beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted During Period Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted-average Remaining Contractual Term, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share based compensation arrangement by share based payment award options granted during period weighted average remaining contractual term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted-average Remaining Contractual Term, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Stock Options, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-average Remaining Contractual Term, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise price, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Exercise price, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted-average Exercise Price, Exercisable, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Stock Options, Exercisable, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee stock option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Expected volatility, Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Series2WarrantsMember" xlink:label="loc_bntc_Series2WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_Series2WarrantsMember" xml:lang="en-US">Series 2 Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_Series2WarrantsMember" xlink:to="lab_bntc_Series2WarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_Series2WarrantsMember" xml:lang="en-US">Series 2 warrants.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PurchaseWarrantsMember" xml:lang="en-US">Purchase Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PurchaseWarrantsMember" xml:lang="en-US">Purchase warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PurchaseWarrantsMember" xlink:to="lab_bntc_PurchaseWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_PurchaseWarrantsMember" xml:lang="en-US">Purchase warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognised share based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Expiry date of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xml:lang="en-US">Number Of Series Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xml:lang="en-US">Number of series of warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NumberOfSeriesWarrantsIssued" xlink:to="lab_bntc_NumberOfSeriesWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_NumberOfSeriesWarrantsIssued" xml:lang="en-US">Number of series warrants issued.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:label="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IssueOfCommonStockAndWarrantPricePerShare" xml:lang="en-US">Issue Of Common Stock And Warrant Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_IssueOfCommonStockAndWarrantPricePerShare" xml:lang="en-US">Issue of common stock and warrant price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:to="lab_bntc_IssueOfCommonStockAndWarrantPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IssueOfCommonStockAndWarrantPricePerShare" xml:lang="en-US">Issue of common stock and warrant price per share.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xml:lang="en-US">Class Of Warrants Or Rights Issue Price Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xml:lang="en-US">Class of warrants or rights issue price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:to="lab_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xml:lang="en-US">Class of warrants or rights issue price per unit.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xml:lang="en-US">Cashless exercise of purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xml:lang="en-US">Cashless exercise of purchase warrants (In shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CashlessExerciseOfPurchaseWarrants" xlink:to="lab_bntc_CashlessExerciseOfPurchaseWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_CashlessExerciseOfPurchaseWarrants" xml:lang="en-US">Cashless exercise of purchase warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants convertible into shares of common stock on exercise</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants convertible into shares of common stock on exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock issue price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xml:lang="en-US">Class Of Warrants Or Rights Excercised During The Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:to="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xml:lang="en-US">Class of warrants or rights excercised during the period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xml:lang="en-US">Employee option awards related stock based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share based compensation by share based award contractual term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock shares reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share based compensation by share based award unrecognized expense remaining period of recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="loc_bntc_TwoThousandAndTwentyEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_TwoThousandAndTwentyEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Twenty Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_TwoThousandAndTwentyEquityIncentivePlanMember" xml:lang="en-US">Two Thousand And Twenty Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="lab_bntc_TwoThousandAndTwentyEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_TwoThousandAndTwentyEquityIncentivePlanMember" xml:lang="en-US">Two thousand and twenty equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventAxis" xlink:label="loc_bntc_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_EventAxis" xml:lang="en-US">Event [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_EventAxis" xlink:to="lab_bntc_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_EventAxis" xml:lang="en-US">Event</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_EventDomain" xml:lang="en-US">Event [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_EventDomain" xlink:to="lab_bntc_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_EventDomain" xml:lang="en-US">Event</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" xlink:label="loc_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" xml:lang="en-US">Revision In The Exercise Price Of Prefunded Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" xml:lang="en-US">Revision In The Exercise Price Of Prefunded Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" xlink:to="lab_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" xml:lang="en-US">Revision in the exercise price of prefunded warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">International</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">United States</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_bntc_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_bntc_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred tax assets lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Gross deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xml:lang="en-US">Deferred Tax Assets Capitalized Research and Development Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xml:lang="en-US">Section&#160;174 Capitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xml:lang="en-US">Deferred tax assets capitalized research and development costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xml:lang="en-US">Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:to="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xml:lang="en-US">Disclosure details of operating loss carry forwards and tax credits [Table ].</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xml:lang="en-US">Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xml:lang="en-US">Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:to="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xml:lang="en-US">Disclosure details of operating loss carry forwards and tax credits [Line Items].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xml:lang="en-US">Operating loss carryforwards, expiration years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:label="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xml:lang="en-US">Year Of Expiry Of Operating Losses Carry Forwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xml:lang="en-US">Year of expiry of operating losses carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:to="lab_bntc_YearOfExpiryOfOperatingLossesCarryForwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_YearOfExpiryOfOperatingLossesCarryForwards" xml:lang="en-US">Year of expiry of operating losses carry forwards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PeriodAxis" xlink:to="lab_bntc_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PeriodDomain" xml:lang="en-US">Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PeriodDomain" xml:lang="en-US">Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PeriodDomain" xlink:to="lab_bntc_PeriodDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NolFromTwoThousandEighteenMember" xlink:label="loc_bntc_NolFromTwoThousandEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_NolFromTwoThousandEighteenMember" xml:lang="en-US">NOL From Two Thousand Eighteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_NolFromTwoThousandEighteenMember" xml:lang="en-US">NOL From Two Thousand Eighteen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NolFromTwoThousandEighteenMember" xlink:to="lab_bntc_NolFromTwoThousandEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_NolFromTwoThousandEighteenMember" xml:lang="en-US">NOL from two thousand eighteen.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NOLpreJanuaryOneTwoThousandEighteenMember" xlink:label="loc_bntc_NOLpreJanuaryOneTwoThousandEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_NOLpreJanuaryOneTwoThousandEighteenMember" xml:lang="en-US">NOL pre January One Two Thousand Eighteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_NOLpreJanuaryOneTwoThousandEighteenMember" xml:lang="en-US">NOL pre January One Two Thousand Eighteen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NOLpreJanuaryOneTwoThousandEighteenMember" xlink:to="lab_bntc_NOLpreJanuaryOneTwoThousandEighteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_NOLpreJanuaryOneTwoThousandEighteenMember" xml:lang="en-US">NOL pre january one two thousand eighteen.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearTwoThousandAndThirtyOneMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_YearTwoThousandAndThirtyOneMember" xml:lang="en-US">Year Two Thousand And Thirty One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_YearTwoThousandAndThirtyOneMember" xml:lang="en-US">Year Two Thousand And Thirty One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_YearTwoThousandAndThirtyOneMember" xlink:to="lab_bntc_YearTwoThousandAndThirtyOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_YearTwoThousandAndThirtyOneMember" xml:lang="en-US">Year two thousand and thirty one [Member].</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearTwoThousandAndThirtyFourMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_YearTwoThousandAndThirtyFourMember" xml:lang="en-US">Year Two Thousand And Thirty Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_YearTwoThousandAndThirtyFourMember" xml:lang="en-US">Year Two Thousand And Thirty Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_YearTwoThousandAndThirtyFourMember" xlink:to="lab_bntc_YearTwoThousandAndThirtyFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_YearTwoThousandAndThirtyFourMember" xml:lang="en-US">Year two thousand and thirty four [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign tax rate differential</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:label="loc_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xml:lang="en-US">Effective Income Tax Reconciliation Percentage Permanent Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xml:lang="en-US">Permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:to="lab_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xml:lang="en-US">Effective income tax reconciliation percentage permanent differences.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xml:lang="en-US">Share-based payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncomeTaxDisclosureTable" xlink:label="loc_bntc_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncomeTaxDisclosureTable" xlink:to="lab_bntc_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IncomeTaxDisclosureTable" xml:lang="en-US">Income tax disclosure [Table].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2014Member" xlink:label="loc_us-gaap_TaxYear2014Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxYear2014Member" xml:lang="en-US">Tax Year 2014 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxYear2014Member" xml:lang="en-US">Tax Year 2014 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2014Member" xlink:to="lab_us-gaap_TaxYear2014Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2019Member" xlink:label="loc_us-gaap_TaxYear2019Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxYear2019Member" xml:lang="en-US">Tax Year 2019 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxYear2019Member" xml:lang="en-US">Tax Year 2019 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2019Member" xlink:to="lab_us-gaap_TaxYear2019Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2011Member" xlink:label="loc_us-gaap_TaxYear2011Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxYear2011Member" xml:lang="en-US">Tax Year 2011 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxYear2011Member" xml:lang="en-US">Tax Year 2011 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2011Member" xlink:to="lab_us-gaap_TaxYear2011Member" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" xlink:label="loc_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" xml:lang="en-US">Beginning On Or After January 1, 2020, And Before January 1, 2023 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" xml:lang="en-US">Beginning on or After January 1, 2020, and Before January 1, 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" xlink:to="lab_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" xml:lang="en-US">Beginning on or after January 1, 2020, and before January 1, 2023.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2016Member" xlink:label="loc_us-gaap_TaxYear2016Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxYear2016Member" xml:lang="en-US">Tax Year 2016 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2016Member" xlink:to="lab_us-gaap_TaxYear2016Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2022Member" xlink:label="loc_us-gaap_TaxYear2022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxYear2022Member" xml:lang="en-US">Tax Year 2022 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2022Member" xlink:to="lab_us-gaap_TaxYear2022Member" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:label="loc_bntc_SuspensionOfAnnualDeductionLimitationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SuspensionOfAnnualDeductionLimitationMember" xml:lang="en-US">Suspension Of Annual Deduction Limitation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_SuspensionOfAnnualDeductionLimitationMember" xml:lang="en-US">Suspension Of Annual Deduction Limitation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:to="lab_bntc_SuspensionOfAnnualDeductionLimitationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_SuspensionOfAnnualDeductionLimitationMember" xml:lang="en-US">Suspension Of Annual Deduction Limitation</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" xlink:label="loc_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" xml:lang="en-US">Applicability Of Suspension Of Deductions Of California NOLs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" xml:lang="en-US">Applicability of Suspension of Deductions of California NOLs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" xlink:to="lab_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" xml:lang="en-US">Applicability of suspension of deductions of California NOLs.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnexpectedEventAxis" xlink:label="loc_bntc_UnexpectedEventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_UnexpectedEventAxis" xml:lang="en-US">Unexpected Event [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_UnexpectedEventAxis" xml:lang="en-US">Unexpected Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_UnexpectedEventAxis" xlink:to="lab_bntc_UnexpectedEventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_UnexpectedEventAxis" xml:lang="en-US">Unexpected Event</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnexpectedEventDomain" xlink:label="loc_bntc_UnexpectedEventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_UnexpectedEventDomain" xml:lang="en-US">Unexpected Event [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_UnexpectedEventDomain" xml:lang="en-US">Unexpected Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_UnexpectedEventDomain" xlink:to="lab_bntc_UnexpectedEventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_UnexpectedEventDomain" xml:lang="en-US">Unexpected Event</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:to="lab_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xml:lang="en-US">Coronavirus Aid Relief And Economic Security Act</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:label="loc_bntc_CaliforniaAssemblyBillEightyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_CaliforniaAssemblyBillEightyFiveMember" xml:lang="en-US">California Assembly Bill Eighty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_CaliforniaAssemblyBillEightyFiveMember" xml:lang="en-US">California Assembly Bill Eighty Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:to="lab_bntc_CaliforniaAssemblyBillEightyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_CaliforniaAssemblyBillEightyFiveMember" xml:lang="en-US">California assembly bill eighty five [member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xml:lang="en-US">California Franchise Tax Board [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xml:lang="en-US">California Franchise Tax Board [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncomeTaxDisclosureLineItems" xlink:label="loc_bntc_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems" xlink:to="lab_bntc_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income tax disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open Tax Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Tax year subject to examination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:label="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xml:lang="en-US">Percentage Of Annual Taxable Income Eligible For Deduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xml:lang="en-US">Percentage of annual Taxable income eligible for deduction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:to="lab_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xml:lang="en-US">Percentage of annual taxable income eligible for deduction.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:label="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xml:lang="en-US">Number Of Years Of Certain Operating Losses That Can Be Carried Back</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xml:lang="en-US">Number of years of certain operating losses that can be carried back</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:to="lab_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xml:lang="en-US">Number of years of certain operating losses that can be carried back.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xml:lang="en-US">Percentage Of Total Owneship Control To Be Maintained By The Current Shareholders For Availing Operating Loss Carry Forwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xml:lang="en-US">Percentage of total owneship control to be maintained by the current shareholders for availing operating loss carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:to="lab_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xml:lang="en-US">Percentage of total ownership control to be maintained by the current shareholders for availing operating loss carry forwards.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xml:lang="en-US">Period Of Ownership Control For Which The Shareholders Are To Sustain Their Holding For Availing Operating Loss Carry Forwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xml:lang="en-US">Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:to="lab_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xml:lang="en-US">Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Deferred tax assets increase in valuation allowance during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MinimumNetBusinessIncome" xlink:label="loc_bntc_MinimumNetBusinessIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_MinimumNetBusinessIncome" xml:lang="en-US">Minimum Net Business Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_MinimumNetBusinessIncome" xml:lang="en-US">Minimum net business income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MinimumNetBusinessIncome" xlink:to="lab_bntc_MinimumNetBusinessIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_MinimumNetBusinessIncome" xml:lang="en-US">Minimum net business income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xml:lang="en-US">Unrecognized tax benefits, accrued interest and penalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LegislationAxis" xlink:label="loc_bntc_LegislationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_LegislationAxis" xml:lang="en-US">Legislation [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LegislationAxis" xlink:to="lab_bntc_LegislationAxis" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LegislationDomain" xlink:label="loc_bntc_LegislationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_LegislationDomain" xml:lang="en-US">Legislation [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LegislationDomain" xlink:to="lab_bntc_LegislationDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SB113Member" xlink:label="loc_bntc_SB113Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_SB113Member" xml:lang="en-US">SB 113 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_SB113Member" xml:lang="en-US">SB 113 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SB113Member" xlink:to="lab_bntc_SB113Member" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_CommitmentsAndContingenciesDisclosureTable" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureTable" xlink:to="lab_bntc_CommitmentsAndContingenciesDisclosureTable" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_CommitmentsAndContingenciesDisclosureLineItems" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="lab_bntc_CommitmentsAndContingenciesDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_CommitmentsAndContingenciesDisclosureLineItems" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_FrancisAbourizkLightowlersMember" xml:lang="en-US">Francis Abourizk Lightowlers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_FrancisAbourizkLightowlersMember" xlink:to="lab_bntc_FrancisAbourizkLightowlersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_FrancisAbourizkLightowlersMember" xml:lang="en-US">Francis abourizk lightowlers.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Dr.JerelBanksMember" xlink:label="loc_bntc_Dr.JerelBanksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_Dr.JerelBanksMember" xml:lang="en-US">Dr. Jerel Banks [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_Dr.JerelBanksMember" xlink:to="lab_bntc_Dr.JerelBanksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_Dr.JerelBanksMember" xml:lang="en-US">Dr. Jerel Banks.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MeganBostonMember" xlink:label="loc_bntc_MeganBostonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_MeganBostonMember" xml:lang="en-US">Megan Boston [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MeganBostonMember" xlink:to="lab_bntc_MeganBostonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_MeganBostonMember" xml:lang="en-US">Megan Boston.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" xml:lang="en-US">Executive Chairman and Chief Executive Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" xlink:to="lab_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" xml:lang="en-US">Executive chairman and chief executive officer.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ExecutiveDirectorMember" xlink:label="loc_bntc_ExecutiveDirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ExecutiveDirectorMember" xml:lang="en-US">Executive Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ExecutiveDirectorMember" xlink:to="lab_bntc_ExecutiveDirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ExecutiveDirectorMember" xml:lang="en-US">Executive director.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommonWarrantsMember" xlink:label="loc_bntc_CommonWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_CommonWarrantsMember" xml:lang="en-US">Common Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CommonWarrantsMember" xlink:to="lab_bntc_CommonWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_CommonWarrantsMember" xml:lang="en-US">Common warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AnnualBaseSalaryCompensation" xlink:label="loc_bntc_AnnualBaseSalaryCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_AnnualBaseSalaryCompensation" xml:lang="en-US">Annual Base Salary Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_AnnualBaseSalaryCompensation" xml:lang="en-US">Annual base salary compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AnnualBaseSalaryCompensation" xlink:to="lab_bntc_AnnualBaseSalaryCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_AnnualBaseSalaryCompensation" xml:lang="en-US">Annual base salary compensation.</label>
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ForeignCurrencyExchangeRateConversion" xlink:label="loc_bntc_ForeignCurrencyExchangeRateConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_bntc_ForeignCurrencyExchangeRateConversion" xml:lang="en-US">Foreign Currency Exchange Rate Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_bntc_ForeignCurrencyExchangeRateConversion" xml:lang="en-US">Conversion Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ForeignCurrencyExchangeRateConversion" xlink:to="lab_bntc_ForeignCurrencyExchangeRateConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_bntc_ForeignCurrencyExchangeRateConversion" xml:lang="en-US">Foreign currency exchange rate conversion.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bntc-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 20-September-2023 [11:13:39] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#Liquidity" roleURI="http://www.benitecbiopharmainc.com/role/Liquidity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#Revenue" roleURI="http://www.benitecbiopharmainc.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CashCashEquivalentsAndRestrictedCash" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PrepaidAndOtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#RelatedPartyTransactions" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LossPerShare" roleURI="http://www.benitecbiopharmainc.com/role/LossPerShare" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#SubsequentEvents" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#RevenueTables" roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CashCashEquivalentsAndRestrictedCashTables" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PrepaidAndOtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesTables" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LossPerShareTables" roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BusinessAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LiquidityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#RevenueSummaryOfRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LossPerShareSummaryOfLossPerShareDetail" roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#LossPerShareAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20230630.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_747112" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_747113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentType_747113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_747125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_AmendmentFlag_747125" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_747114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentAnnualReport_747114" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_747252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentTransitionReport_747252" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_747133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFileNumber_747133" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_747131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityRegistrantName_747131" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_748326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityTaxIdentificationNumber_748326" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_747126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentPeriodEndDate_747126" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_747127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalYearFocus_747127" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_747128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalPeriodFocus_747128" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_747132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCentralIndexKey_747132" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_747136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CurrentFiscalYearEndDate_747136" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_747137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_747137" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_747139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityVoluntaryFilers_747139" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_747140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCurrentReportingStatus_747140" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_747120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityInteractiveDataCurrent_747120" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_747142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFilerCategory_747142" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_747143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntitySmallBusiness_747143" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_747144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityEmergingGrowthCompany_747144" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_747141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityShellCompany_747141" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_748327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityIncorporationStateCountryCode_748327" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_748405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressAddressLine1_748405" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_1171705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressCityOrTown_1171705" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_747160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressStateOrProvince_747160" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_747162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressPostalZipCode_747162" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_748406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CityAreaCode_748406" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_748407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_LocalPhoneNumber_748407" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_747163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_Security12bTitle_747163" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_747165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_TradingSymbol_747165" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_747166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_SecurityExchangeName_747166" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_747167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_747167" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_747177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityPublicFloat_747177" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_2147468993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_2147468993" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_2147468999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_IcfrAuditorAttestationFlag_2147468999" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_2147469074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_AuditorName_2147469074" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_2147469072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_AuditorFirmId_2147469072" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_2147469073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_AuditorLocation_2147469073" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_746977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_AssetsAbstract_746977" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_746978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrentAbstract_746978" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_1701133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_RestrictedCashCurrent_1701133" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1170841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1170841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_746983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrent_746983" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_746986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_DepositAssets_746986" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_813025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_813025" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_746988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_Assets_746988" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_746991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_746991" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_746995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrent_746995" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_747001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_Liabilities_747001" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747005" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_747013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquityAbstract_747013" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_747014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_CommonStockValue_747014" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquity_747018" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_747045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_747045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_747047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesIssued_747047" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_747049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_747049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_747061" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_747061" xlink:to="loc_us-gaap_StatementTable_747523" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_us-gaap_StatementLineItems_747526" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees_747072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_bntc_RoyaltiesAndLicenseFees_747072" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1701631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasic_1701631" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1701632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1701632" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1701634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1701634" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1701635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_BasicAndDilutedEarningsPerShareAbstract_1701633" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1701635" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747109" xlink:to="loc_us-gaap_StatementTable_747147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_813480" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_813481" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementLineItems_747150" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts_748442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts_748442" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants_747181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants_747181" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WarrantsExercisedDuringThePeriod" xlink:label="loc_bntc_WarrantsExercisedDuringThePeriod_814197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_WarrantsExercisedDuringThePeriod_814197" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747184" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747185" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747220" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_747223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747220" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_747223" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_747054" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetIncomeLoss_747025" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_747028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_747028" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets_747029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_bntc_AmortizationOfRightOfUseAssets_747029" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnrealizedGainLossOnInvestment" xlink:label="loc_bntc_UnrealizedGainLossOnInvestment_2147468989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_bntc_UnrealizedGainLossOnInvestment_2147468989" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_747033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_ShareBasedCompensation_747033" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2147469667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2147469667" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2147469075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2147469075" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_747043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_747043" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_747046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_747046" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_747048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_747048" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_747050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_747050" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_747051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_747051" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_747056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_747056" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_747053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_747053" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_747055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_747055" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_747057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_747057" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2147469070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2147469070" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2147469069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2147469070" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2147469069" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_2147469068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2147469070" xlink:to="loc_us-gaap_RestrictedCashCurrent_2147469068" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2147469067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2147469070" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2147469067" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Business">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747291" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Liquidity">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LiquidityAbstract" xlink:label="loc_bntc_LiquidityAbstract_2147469030" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LiquidityDisclosureTextBlock" xlink:label="loc_bntc_LiquidityDisclosureTextBlock_2147469029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_LiquidityAbstract_2147469030" xlink:to="loc_bntc_LiquidityDisclosureTextBlock_2147469029" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Revenue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747296" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_747298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747296" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_747298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747424" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747424" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747548" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747548" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747580" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747580" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747939" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747939" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747674" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747674" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_747675" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747505" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_747506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747505" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_747506" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_747496" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_747497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_747496" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_747497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747292" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_813075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_813075" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_747299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_747299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_813076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_UseOfEstimates_813076" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RisksAndUncertainitiesPolicyTextBlock" xlink:label="loc_bntc_RisksAndUncertainitiesPolicyTextBlock_1170843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_RisksAndUncertainitiesPolicyTextBlock_1170843" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_747305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_747305" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_747322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_747322" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_747323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_747323" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessTables">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747293" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock" xlink:label="loc_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock_747891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747293" xlink:to="loc_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock_747891" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_747892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747293" xlink:to="loc_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_747892" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747316" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_747330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747316" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_747330" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747437" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747437" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747553" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747553" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747587" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_747588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_747588" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747942" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_747947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_747947" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_747946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_747946" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_747774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_747774" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_747778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_747778" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock_747779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" xlink:to="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock_747779" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_747780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747770" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_747780" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747510" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_747512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747510" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_747512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BenitecIpHoldingsIncMember" xlink:label="loc_bntc_BenitecIpHoldingsIncMember_1701733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIpHoldingsIncMember_1701733" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_747257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_747257" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747899" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747899" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_2147469002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_2147469002" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_2147469001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_2147469001" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2147469000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_2147469000" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2147468990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2147468990" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives_2147468991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives_2147468991" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747924" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747924" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2147469066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2147469066" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469066" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469065" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2147469064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2147469065" xlink:to="loc_us-gaap_SubsequentEventMember_2147469064" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue_747932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_FinancialAssetsAtFairValue_747932" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_2147469061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_RestrictedCashCurrent_2147469061" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2147469063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_2147469063" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747895" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_747896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747895" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_747896" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AverageForeignExchangeRateForThePeriod" xlink:label="loc_bntc_AverageForeignExchangeRateForThePeriod_747897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747895" xlink:to="loc_bntc_AverageForeignExchangeRateForThePeriod_747897" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LiquidityAbstract" xlink:label="loc_bntc_LiquidityAbstract_747274" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2147469027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_LiquidityAbstract_747274" xlink:to="loc_us-gaap_StatementTable_2147469027" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2147469025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2147469027" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2147469025" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469025" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469024" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2147469023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2147469024" xlink:to="loc_us-gaap_SubsequentEventMember_2147469023" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2147469026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2147469027" xlink:to="loc_us-gaap_StatementLineItems_2147469026" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_NetIncomeLoss_747276" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747280" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2147469028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2147469026" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2147469028" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_747399" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_747399" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_srt_ProductOrServiceAxis_747412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_LicenseMember_747416" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1170846" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1170847" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks_747364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_DueFromBanks_747364" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_747365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_RestrictedCashCurrent_747365" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_747366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_747366" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747453" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_747454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_747454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares_747458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_bntc_MarketValueOfListedShares_747458" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_747459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssets_747459" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_813108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_813108" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_813109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssetsCurrent_813109" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2147470769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2147470769" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747565" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_747566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_747566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent_747567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedLicenceFeesCurrent_747567" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedOpmdProjectCostsCurrent" xlink:label="loc_bntc_AccruedOpmdProjectCostsCurrent_1701136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedOpmdProjectCostsCurrent_1701136" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AccruedConsultantFeesCurrent" xlink:label="loc_bntc_AccruedConsultantFeesCurrent_1701921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedConsultantFeesCurrent_1701921" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_747593" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_747593" xlink:to="loc_us-gaap_StatementTable_748512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748516" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748517" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_748518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_748517" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_748518" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748512" xlink:to="loc_us-gaap_StatementLineItems_748515" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747594" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod" xlink:label="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod_1170856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod_1170856" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_747595" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_747596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_747596" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747597" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod" xlink:label="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod_1170859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod_1170859" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_747598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeasePayments_747598" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiability_747599" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_747600" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748515" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_747601" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747645" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747645" xlink:to="loc_us-gaap_StatementTable_748057" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_748065" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_748066" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_StatementLineItems_748060" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_747654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeaseExpense_747654" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747631" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_OperatingLeaseLiability_747638" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747978" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1701197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_us-gaap_StatementTable_1701197" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1701201" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1701202" xlink:to="loc_bntc_PreFundedWarrantsMember_1701203" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1701198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1701198" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1701199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1701198" xlink:to="loc_us-gaap_ClassOfStockDomain_1701199" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1701942" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SeriesTwoWarrantsMember" xlink:label="loc_bntc_SeriesTwoWarrantsMember_1701944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1701943" xlink:to="loc_bntc_SeriesTwoWarrantsMember_1701944" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1701200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1701197" xlink:to="loc_us-gaap_StatementLineItems_1701200" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1701189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1701189" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701940" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsExercised" xlink:label="loc_bntc_ClassOfWarrantOrRightsExercised_2147469089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantOrRightsExercised_2147469089" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisable_1701941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisable_1701941" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued" xlink:label="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued_1701297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued_1701297" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_1701945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_1701945" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised" xlink:label="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised_2147469103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised_2147469103" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable_1701946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1701200" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable_1701946" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747990" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_747997" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1701288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1701288" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_748003" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1701289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1701289" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm_1420382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm_1420382" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2147469107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2147469107" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747949" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_747950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_747950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_747953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747949" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_747953" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_747954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747949" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_747954" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747962" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747962" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_768322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_768325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_768322" xlink:to="loc_us-gaap_StatementTable_768325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_770071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_IPOMember_770071" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_770074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_bntc_PreFundedWarrantsMember_770074" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1282097" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PurchaseWarrantsMember" xlink:label="loc_bntc_PurchaseWarrantsMember_1282099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_PurchaseWarrantsMember_1282099" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Series2WarrantsMember" xlink:label="loc_bntc_Series2WarrantsMember_1701170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_Series2WarrantsMember_1701170" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1282098" xlink:to="loc_bntc_PreFundedWarrantsMember_1701949" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1282103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1282103" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1282104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1282103" xlink:to="loc_us-gaap_EquityComponentDomain_1282104" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1282105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1282104" xlink:to="loc_us-gaap_CommonStockMember_1282105" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1282937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_srt_RangeAxis_1282937" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1282938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1282937" xlink:to="loc_srt_RangeMember_1282938" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1282968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_PlanNameAxis_1282968" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1282970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1282968" xlink:to="loc_us-gaap_PlanNameDomain_1282970" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="loc_bntc_TwoThousandAndTwentyEquityIncentivePlanMember_2147468987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1282970" xlink:to="loc_bntc_TwoThousandAndTwentyEquityIncentivePlanMember_2147468987" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2147469007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2147469007" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2147469006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2147469007" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2147469006" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2147469005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2147469006" xlink:to="loc_us-gaap_SubsequentEventMember_2147469005" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2147468984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_AwardTypeAxis_2147468984" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2147468983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2147468984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2147468983" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2147468982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2147468983" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2147468982" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventAxis" xlink:label="loc_bntc_EventAxis_2147468997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_bntc_EventAxis_2147468997" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_2147468996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_EventAxis_2147468997" xlink:to="loc_bntc_EventDomain_2147468996" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember" xlink:label="loc_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember_2147468995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_EventDomain_2147468996" xlink:to="loc_bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember_2147468995" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_768328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_StatementLineItems_768328" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_770079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_770079" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_814004" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1282096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1282096" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NumberOfSeriesWarrantsIssued" xlink:label="loc_bntc_NumberOfSeriesWarrantsIssued_1282100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_NumberOfSeriesWarrantsIssued_1282100" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1282101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_1282101" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CashlessExerciseOfPurchaseWarrants" xlink:label="loc_bntc_CashlessExerciseOfPurchaseWarrants_1282102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_CashlessExerciseOfPurchaseWarrants_1282102" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1283076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1283076" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_1701168" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:label="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_1701953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_1701953" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_1701955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_1701955" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2147468980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2147468980" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2147468981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2147468981" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2147468988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2147468988" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_2147468998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod_2147468998" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2147469004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_2147469004" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2147469062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2147469062" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_2147469104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_2147469104" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747784" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_747785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747784" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_747785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_747786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747784" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_747786" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747784" xlink:to="loc_us-gaap_NetIncomeLoss_747787" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_747804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_747804" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_747806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_747806" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_bntc_DeferredTaxAssetsLeaseLiabilities_747807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_bntc_DeferredTaxAssetsLeaseLiabilities_747807" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2147469022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2147469022" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2147469021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2147469021" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2147469020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2147469020" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_747808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_747803" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_747808" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_747813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_747813" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_747810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_747810" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_747811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_747811" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2147469019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2147469019" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_747812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_747809" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_747812" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_747814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747802" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_747814" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747816" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747816" xlink:to="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis_747818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_bntc_PeriodAxis_747818" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_PeriodAxis_747818" xlink:to="loc_bntc_PeriodDomain_747819" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NolFromTwoThousandEighteenMember" xlink:label="loc_bntc_NolFromTwoThousandEighteenMember_747820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_PeriodDomain_747819" xlink:to="loc_bntc_NolFromTwoThousandEighteenMember_747820" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NOLpreJanuaryOneTwoThousandEighteenMember" xlink:label="loc_bntc_NOLpreJanuaryOneTwoThousandEighteenMember_2147469018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_PeriodDomain_747819" xlink:to="loc_bntc_NOLpreJanuaryOneTwoThousandEighteenMember_2147469018" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_747822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_747822" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747822" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747823" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_747824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_747824" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_747825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_DomesticCountryMember_747825" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_747827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747823" xlink:to="loc_us-gaap_ForeignCountryMember_747827" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_747828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_us-gaap_TaxPeriodAxis_747828" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_747828" xlink:to="loc_us-gaap_TaxPeriodDomain_747829" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearTwoThousandAndThirtyFourMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyFourMember_747830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtyFourMember_747830" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearTwoThousandAndThirtyOneMember" xlink:label="loc_bntc_YearTwoThousandAndThirtyOneMember_747832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747829" xlink:to="loc_bntc_YearTwoThousandAndThirtyOneMember_747832" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems" xlink:label="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable_747817" xlink:to="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_747834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_us-gaap_OperatingLossCarryforwards_747834" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_747837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_747837" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_YearOfExpiryOfOperatingLossesCarryForwards" xlink:label="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards_747838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems_747833" xlink:to="loc_bntc_YearOfExpiryOfOperatingLossesCarryForwards_747838" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_747842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_747842" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences" xlink:label="loc_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences_747844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences_747844" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_747847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_747847" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_747849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_747849" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_747850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_747850" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_747851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747841" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_747851" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747854" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncomeTaxDisclosureTable" xlink:label="loc_bntc_IncomeTaxDisclosureTable_747855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747854" xlink:to="loc_bntc_IncomeTaxDisclosureTable_747855" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_747856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_747856" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_747857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_747856" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_747857" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_747858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747857" xlink:to="loc_us-gaap_DomesticCountryMember_747858" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_747859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_747857" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_747859" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_747860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_TaxPeriodAxis_747860" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_747861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_747860" xlink:to="loc_us-gaap_TaxPeriodDomain_747861" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2014Member" xlink:label="loc_us-gaap_TaxYear2014Member_747862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2014Member_747862" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2016Member" xlink:label="loc_us-gaap_TaxYear2016Member_2147469009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2016Member_2147469009" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2019Member" xlink:label="loc_us-gaap_TaxYear2019Member_747863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2019Member_747863" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2011Member" xlink:label="loc_us-gaap_TaxYear2011Member_747864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2011Member_747864" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2022Member" xlink:label="loc_us-gaap_TaxYear2022Member_2147469008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_us-gaap_TaxYear2022Member_2147469008" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member" xlink:label="loc_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member_2147469011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_747861" xlink:to="loc_bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member_2147469011" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_747865" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_747867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_747867" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2147469003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_747866" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2147469003" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_srt_RangeAxis_747868" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_747868" xlink:to="loc_srt_RangeMember_747869" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747869" xlink:to="loc_srt_MinimumMember_747871" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_748278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_srt_StatementGeographicalAxis_748278" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_748279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_748278" xlink:to="loc_srt_SegmentGeographicalDomain_748279" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventAxis" xlink:label="loc_bntc_EventAxis_748284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_EventAxis_748284" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_EventDomain" xlink:label="loc_bntc_EventDomain_748285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_EventAxis_748284" xlink:to="loc_bntc_EventDomain_748285" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SuspensionOfAnnualDeductionLimitationMember" xlink:label="loc_bntc_SuspensionOfAnnualDeductionLimitationMember_748286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_EventDomain_748285" xlink:to="loc_bntc_SuspensionOfAnnualDeductionLimitationMember_748286" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember" xlink:label="loc_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember_2147469013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_EventDomain_748285" xlink:to="loc_bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember_2147469013" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnexpectedEventAxis" xlink:label="loc_bntc_UnexpectedEventAxis_748287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_UnexpectedEventAxis_748287" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_UnexpectedEventDomain" xlink:label="loc_bntc_UnexpectedEventDomain_748288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_UnexpectedEventAxis_748287" xlink:to="loc_bntc_UnexpectedEventDomain_748288" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember_748289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_UnexpectedEventDomain_748288" xlink:to="loc_bntc_CoronavirusAidReliefAndEconomicSecurityActMember_748289" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CaliforniaAssemblyBillEightyFiveMember" xlink:label="loc_bntc_CaliforniaAssemblyBillEightyFiveMember_748363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_UnexpectedEventDomain_748288" xlink:to="loc_bntc_CaliforniaAssemblyBillEightyFiveMember_748363" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LegislationAxis" xlink:label="loc_bntc_LegislationAxis_2147469016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_LegislationAxis_2147469016" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_LegislationDomain" xlink:label="loc_bntc_LegislationDomain_2147469015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_LegislationAxis_2147469016" xlink:to="loc_bntc_LegislationDomain_2147469015" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_SB113Member" xlink:label="loc_bntc_SB113Member_2147469014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_LegislationDomain_2147469015" xlink:to="loc_bntc_SB113Member_2147469014" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IncomeTaxDisclosureLineItems" xlink:label="loc_bntc_IncomeTaxDisclosureLineItems_747872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureTable_747855" xlink:to="loc_bntc_IncomeTaxDisclosureLineItems_747872" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_747873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_747873" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_747874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_OpenTaxYear_747874" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards_747875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards_747875" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards" xlink:label="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards_747876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards_747876" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack" xlink:label="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack_748281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack_748281" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction" xlink:label="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction_748282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction_748282" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_748283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_748283" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2147469010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2147469010" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MinimumNetBusinessIncome" xlink:label="loc_bntc_MinimumNetBusinessIncome_2147469017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_IncomeTaxDisclosureLineItems_747872" xlink:to="loc_bntc_MinimumNetBusinessIncome_2147469017" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747703" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommitmentsAndContingenciesDisclosureTable" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747703" xlink:to="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodAxis" xlink:label="loc_bntc_PeriodAxis_747705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" xlink:to="loc_bntc_PeriodAxis_747705" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PeriodDomain" xlink:label="loc_bntc_PeriodDomain_747706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_PeriodAxis_747705" xlink:to="loc_bntc_PeriodDomain_747706" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureTable_747704" xlink:to="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_CommitmentsAndContingenciesDisclosureLineItems_747708" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747710" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_747689" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_747689" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_747692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_747691" xlink:to="loc_us-gaap_RelatedPartyDomain_747692" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_FrancisAbourizkLightowlersMember" xlink:label="loc_bntc_FrancisAbourizkLightowlersMember_1170883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_747692" xlink:to="loc_bntc_FrancisAbourizkLightowlersMember_1170883" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_747694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_747690" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_747694" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_1170879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_747694" xlink:to="loc_us-gaap_LegalFees_1170879" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_748047" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_748048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_748047" xlink:to="loc_us-gaap_NetIncomeLoss_748048" use="optional" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2147469044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_748047" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2147469044" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2147469042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_748047" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2147469042" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_2147469043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_748047" xlink:to="loc_us-gaap_EarningsPerShareBasic_2147469043" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2147469041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_748047" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2147469041" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2147469039" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2147469037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2147469039" xlink:to="loc_us-gaap_StatementTable_2147469037" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2147469036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2147469037" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2147469036" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2147469036" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2147469034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035" xlink:to="loc_us-gaap_WarrantMember_2147469034" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2147469033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2147469035" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2147469033" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2147469032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2147469037" xlink:to="loc_us-gaap_StatementLineItems_2147469032" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2147469031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2147469032" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2147469031" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_925648" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_925649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_925648" xlink:to="loc_us-gaap_SubsequentEventTable_925649" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_925650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_925650" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_925651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_925650" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_925651" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_925652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_925651" xlink:to="loc_us-gaap_IPOMember_925652" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_941619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_941619" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_941620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_941619" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_941620" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_941621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_941620" xlink:to="loc_us-gaap_SubsequentEventMember_941621" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2147469057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2147469057" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2147469057" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_1701155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056" xlink:to="loc_bntc_PreFundedWarrantsMember_1701155" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Series2WarrantsMember" xlink:label="loc_bntc_Series2WarrantsMember_2147469046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2147469056" xlink:to="loc_bntc_Series2WarrantsMember_2147469046" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2147469050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2147469050" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2147469049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2147469050" xlink:to="loc_us-gaap_EquityComponentDomain_2147469049" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_CommonWarrantsMember" xlink:label="loc_bntc_CommonWarrantsMember_2147469047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2147469049" xlink:to="loc_bntc_CommonWarrantsMember_2147469047" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2147469048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2147469049" xlink:to="loc_us-gaap_CommonStockMember_2147469048" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2147468974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2147468974" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2147468973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2147468974" xlink:to="loc_us-gaap_RelatedPartyDomain_2147468973" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_Dr.JerelBanksMember" xlink:label="loc_bntc_Dr.JerelBanksMember_2147468972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2147468973" xlink:to="loc_bntc_Dr.JerelBanksMember_2147468972" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_MeganBostonMember" xlink:label="loc_bntc_MeganBostonMember_2147468971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2147468973" xlink:to="loc_bntc_MeganBostonMember_2147468971" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2147468970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_srt_TitleOfIndividualAxis_2147468970" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2147468970" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ExecutiveDirectorMember" xlink:label="loc_bntc_ExecutiveDirectorMember_2147468967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969" xlink:to="loc_bntc_ExecutiveDirectorMember_2147468967" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember_2147468968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2147468969" xlink:to="loc_bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember_2147468968" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_925654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_925649" xlink:to="loc_us-gaap_SubsequentEventLineItems_925654" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_925656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_925656" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_941623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_941623" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1701153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1701153" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ForeignCurrencyExchangeRateConversion" xlink:label="loc_bntc_ForeignCurrencyExchangeRateConversion_2147468966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_ForeignCurrencyExchangeRateConversion_2147468966" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2147469045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_2147469045" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantsOrRightsIssuePricePerUnit" xlink:label="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_2147469051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit_2147469051" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_IssueOfCommonStockAndWarrantPricePerShare" xlink:label="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_2147469053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_IssueOfCommonStockAndWarrantPricePerShare_2147469053" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2147469054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2147469054" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_ClassOfWarrantOrRightsIssuedDuringPeriod" xlink:label="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_2147469058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod_2147469058" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2147469059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2147469059" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_2147469060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_2147469060" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20230630.xsd#bntc_AnnualBaseSalaryCompensation" xlink:label="loc_bntc_AnnualBaseSalaryCompensation_2147468976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_925654" xlink:to="loc_bntc_AnnualBaseSalaryCompensation_2147468976" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g549728g07a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g07a03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1TT4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!9            "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]
M    $@ U     0 M    !@       3A"24T#]P      '   ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #00    8              3X
M  '%    !@!G #  -P!A #  ,P    $                          0
M           !Q0   3X                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   3X     4F=H=&QO;F<   '%    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $^
M     %)G:'1L;VYG   !Q0    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     CA"24T$#      3(P    $   "@    <    >
M -(    3!P 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ < "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M_O6?]NV?^E$(=8Z4?^U=/^>%-G4NGO\ H9-+CX"QI_[\DIE]DK_>L_[=L_\
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M:*Q_VFR^?@V^L;?_  .I9;\O)Z=D,9U*BWIN3ILLF:W$Z_HLFG<Q
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     /_A0#QH='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC
M,# R(#<Y+C$V-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @(CX*
M(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P
M=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIX
M;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @
M(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIP:&]T
M;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @
M(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O
M9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E9&ET<R!-4R P.3 W,C,Q
M+F1O8W@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(V,#,W,C@\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C
M.F-R96%T;W(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(S+3 Y+3 X
M5# X.C U.C$X*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM
M<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,RTP
M.2TP.%0P.#HR-#HP-BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,C,M,#DM,#A4,#@Z,C0Z,#8K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R
M;V)A="!$:7-T:6QL97(@,C N," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S
M:&]P.C1A-3DX-S$Y+64Q,&$M8S0T-BUA.#(U+6)F8S0Q,6$Q-S U,#PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#HT838R,60W9"TS,3%B+3@Q-#(M.&4X92UF-S V-CDQ-#5D,S0\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO<&1F
M('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A
M<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C9A-3EB.#EE+3%E93DM-S0T,BUA-#@X+3EE83<W.38Q8C5E,CPO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R
M,RTP.2TP.%0P.#HR,CHU-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P
M(#(R+C @*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP-S(V.#1E,BTX
M,F8Y+6,W-&(M86$P.2TU,V,R,6(T.&$Y,C(\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#DM,#A4,#@Z
M,C0Z,#8K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HT838R,60W9"TS,3%B+3@Q-#(M.&4X92UF-S V-CDQ-#5D
M,S0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C,M,#DM,#A4,#@Z,C0Z,#8K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z830R934T9#,M9&(T
M-RTT8SDX+6(S.&,M.#8X-F(T8C(S-6%C/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$
M/GAM<"YI:60Z,#<R-C@T93(M.#)F.2UC-S1B+6%A,#DM-3-C,C%B-#AA.3(R
M/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE
M;G1)1#YX;7 N9&ED.C9A-3EB.#EE+3%E93DM-S0T,BUA-#@X+3EE83<W.38Q
M8C5E,CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.F$T,F4U-&0S+61B-#<M-&,Y."UB,SAC
M+3@V.#9B-&(R,S5A8SPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \<&AO=&]S:&]P
M.D-O;&]R36]D93XQ/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB
M=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( 3$!LP$!$0#_Q  ?
M   ! @<! 0              " D! @,$!0<*!@O_Q !@$  ! P,# @,$!00+
M"P@(! <! @,$!081  <2""$3,4$)%")1%3)A<8$7(Y&A"A88)S0X0K'!T? D
M,S='4E5B=YC7\24H5%=G<K?A)D-$18>7LK1&4V22:'1X@I.BI__:  @! 0
M/P#KPZIM^-V=N-R>G/:_:=BQXM:WPOV9:4BNWQ1Z[7*52(L:U[DN$340*1<%
MNRYE2<- 2%ON'S4DXR ->U1!ZY7$!0W*Z:<8[XVMW-QD_:+]\\$>1\]132^N
M3(SN;TV@9'^*[<X_IS?P&/GD]QGOJM]%=<9['<WIK.>V$[6[E@G/8X(W!!!^
M1!S]VH.4;KE4 $[E=-*4GZQ>VOW+X@?Z7/<+CC/S3G/S.-4FZ-UR *6=S.F4
MJ!P.&U^XV,$X[!O<$+& <DYSY@DIR .4OKF=(;.Y73&$J [':S<LD\>^<+W
M6@DD=\@_8 <'51%%ZY$#D=S.FC.,93M9N.!^E-^)/X9QJ<TOKC/<;F]-(_\
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M+*77+6>7X:BW'CR'5";3T)44I;<+\M2$=\*]6!NH/V5_6ETR27ZA7-N*C<-
MA.+<9O#;^4JK1W? <4VITB%_=X#G#Q,/1T/<5#FVE?).DYVKU';F[>3$V_<3
M,JI1&%AM^D5Z*[$JS(*BKPDMO.MR6%I *?$F./-J5D^[)!XA9EC]1^WEZH9B
MKG&VJH0QX\&KDI83^=#90S*6D,..I)"O#0H*(R4H]-;\C.H>;3(C-1'6U!#3
M<EM+$AB0TL92Z,GX9([9;4 M([@?#WRU'J]8MVHQZQ;U5FT>J0W$N1ZC DNL
M36GDGG^;DMN(6 E0!"<*2HC!SIVCIS]J/<UK)BV[OHP_7Z13_=H[%U4MA3M5
M98>*&>=49;:Q*<0VI:C\1<RGL.1.GM-N]Y=OMVJ#'N#;J[X%?@N!!?-.<2Z[
M'6II#I9FLG#D9UOEP4TX@.!1/P^6=E19;Y<67W2%D )XJ"FU)/KA!5AP Y *
M1@9[ZOE*G^(4-J:6  <DXRDCR&<=QGY#RUD&?%" 'L<\^8\B,#^G/X8\_/57
M1HU(Z"4* \^W\XTD7K5_P*R?/_")LWY?/\J%K]_Z_LTHMHGP(O<C^XH7;)'_
M +*SIN/K"_C=^SYQY_EPK/Z/R8WW_P">G0:?_!4?CYG/EVU>Z-04>()P3CT'
MF<]NVK5YWDCB .2N./C3Q40L? A7DM9P0$_/L=:(WIWJV_V4H*[IOJNBATP
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MOLIZL1F5)2IV,H?#S*9"#Q3P4XMS'F4A*2E [+4X4I*1D'5TF<A;@;26R>2
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MVN"L5SW:"EXB0XBM1:>AV']>/(!4^PJ*42#TBPG64.)0RK+;2&4I#1\9P("
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MG4X:Z;"CQ)QBMQ)*H+!'C1B58?6RKX75=FF^."V@CE$]MM[7/J!M?J^3T%]
M,J#M3=MC-XW7W5B4VW(55DUOW5VX)+-(K"8\Z9;MN42C*<=J,YDQZA.9+U-;
MA/QVT*<T[[(;VW75K:G6=9'2+U@[Q47J0L7>"?%I-J;B4:YH-V2+=K-6C_\
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M_5:CJ(Z8)]"KR6H6Y5J;A[*Q:[ <4&G:LP-S+/:8J<7)P^T0^VZXZ@G'AJR
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M;T%Z+*(*C"DQ9#:' \A*D++B\%06D* "1G;2HS+R$E*6E<,_ E(#2U9 S@
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MU.ETN/&G2 AF;<,17NOO+[;B?!BLEYQ02HJ3Q;*QO*,LJ0@84 &TDJ4 .2E
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MXA2N^,X^_6I?93T]F3O[=;[B$+]VL"2MI12%!*I54CMK2V5=TAQ("5+'QX!
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M2,*(*L'.$C![>@5G&?O_ %:QJ8)P$EL?$6PXO\V5.)0A2 E9R24IY93QP4@
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M=EJ</C\6VVL)%W%ZKZFRT^WOY>,F=&8>G2G8FW>W#$1N%S4%RG6ET1SQ&%*
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MI#0'!2@ODM*DXTD+=;?RS[KO"B42SHD^Y=Q'*8PT_9EJTI51J<JL-5&4IO\
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MJ5Z>+KI\BE7-:6\=?I,C)-,K72)U-5*GI66PT%MLS-G'VV5(!4I/P+3E9RG
MTB[<K:/H(W#6F5&MOJ?VWD)<E2%.[8=.75?:@EN27$*4F4W$V@5&=;04J#*$
M1FDLAYTI!*@4Z)>Z/NAQQ*%(W(]H6QGXG&AM3U:>&H<E'B5+V84<84!CCGB
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+E.JA\_P3_,-?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g549728g09b03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g09b03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1X(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '>R^=F X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R-C S
M-S(X' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !#)UP7-OLM%:8MBYS];
M(!5-.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/T       2 #4    ! "T    &       !.$))30/W       <  #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      -!    !@
M       !,0   ;L    & &< ,  Y &( ,  S     0
M       !              &[   !,0                     !
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M;&]N9P   3$     4F=H=&QO;F<   &[     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    ".$))300,     !/O     0   *
M  !N   !X   SD   !/3 !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !N * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MMUD1/MV_27'L:0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$!_\  "P@!)0&I 0$1 /_$ !\   $"!P$!
M       ("0$" P0%!PH&"__$ %$0  $# P,# @0"!@<$!@8+ 0$" P0%!A$
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M,$C(SC/OY\8'N3GP 2=8V5,_1*4D93P2[QY-\^(2A?)(YX\<Q\P[@!2KY5I
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M?1:I$?L[=&7N->%G6KM=47K@N:B6;3'9LF[PZDQ68$F%';?D3VSW$\V8R!P
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M]M4X-:AU%EN53W(LZ&Z4@2XDI$N,E9;[KJ5/,J+8#(P%'EW,G!: \G.MR&W
M"%(&?NL9_P /?_/54JQ]#^7M_G_RU+W/R_G_ .6CN?\ =/[CY_GC_'4X)/\
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M95Y/I4I"BZXTI6(#)0A3+:5(!*1R2KVTV<VAM*T-AK"DI[7PS1[*6T+4.;B
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M'MJ.H$9R#['6'D4EIQ:G4Y#G;*$+"CR:_P!KY03G((=4"VK+?MX'G3%'J?\
MI$V]U@+5NGM%4*'8N^D*(W'E2*JXN+;UZ16 M"8=9^&B/.197<6EJ-/:8<9;
M>*&E.'RL<@M4HV\G1CO5.LK<FV:I;UVT JBW%:\UQ;,6ITQYP-(G4N6A0;GT
M^<D+3%G*6EX+*0TQW0 7$=N-U;5W)HBJO;LT-NQ^(J%!G1BS5:2>(R[,BH24
M,M%P*#;Q6/B$C*F\GSM6F5RK4&J4^MT&<]3*O2I+<NGU1ATQWHDQ#A4E!1S3
MQ8<P%*XD-D$@().#TO\ 0OUG4WJ)@*L6OPJC3MS+1M]B=75%IO\ !ZS$;=1
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MM#M)@H:"N3;;,/M H=Y+"BX!P^5"5>, *:P#DI/'D2#RXDC.0 #G!.0D ^/
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MV.I(4H.!(7X!TLZS-QK'OE'*RKNMRZ&83*TN*HM39EOMM)90ML+CH</9;22
M24^P 'G&MH1G0AI(&5J5Y)!'LKR%Y. 0,_-C/GV)U?@C&<Y&/<?7\_&HZ-&C
M1HT:-&I5)"P <X"DJ\?4I4% '\B0,CZC5(QVR .(P.600/91*C]/N?KD?EJ@
MJ$SDX0/F&"0!D?,%?;B/*00<#'M]M3NM(2H.(PA6>;A QS0DY5[?4E8\_GY!
MQI*/4K0[3M>V5[X';-G<3<':N$]4[08C1G':T''G$LAF,&?TKX"'EJ4TD@8'
M(I( &MM;37;/O6PK;NRIT&5;%1N"D1)\NWIB2B12WY2 3&6P<*0H+RI05C&<
M'SG6VFG$K3D*20#QR",92 % '/G"^0)^X(^FJF1]Q_$:E*QG&1@>YR/W?Z^N
MIL9.<Y\8QXQ@_P"O]#7FZPU\KP8[C3KC992\R 7$_(M0PA0PH-D\T@?4C\@4
M4;#OL[/[E7+LW?&\56O[<:^*E5;]H-+GQ58M^ANJ6?@(SY0A@\&FUH[(62G*
M5) P!I=4902$E"D$+2%-@$K' CY"I601X.3G./8GV.LB,X&<9P,X]L_E^7VU
M'1J"DA0P?(UA9\) :?X-)67VW$$%.>14@I"5#SR2$J+8'N$+4 <G(8X]8;TU
MJ=U>;:IW<VTBL4K?';B!/J3*XL;#M_T*.EI2[<J+P9+RY/8CI<B=U1*&TML-
MJ#8XGC6VGW)K^R5[RZ-7:=4:; 8J4BD7;;M3BKAN4F6A9:>+\?" S);2D_*1
MR4VA/ *SKJU]'JM4FN[^W#4Z/+9DTVH;429%-EQU ]Z(JOP%<5(&5M<%)P4O
M!*RH>,>!KI5P?N?Y?Y:UEO%:50OW:S<6RJ4\(]1NJT:[0(;[AXH:D52FNQ6G
M>6#A+:GO/RJ /N/&DM]$'1OM]T;[+6OMM95*IZZ]'@L2[UNHQH3E6N2X7T(5
M4G),YIH2'8:'D\(J0YVF^R?T:5$G2Y&8Z4NH=2C!X*Y*'L5+<+BL?8J623@8
MQX^^K[ ^PT:-&C1HT:,9_P#^D?X:I*:2H*P""4D9!/[C^W6L[TL:V;UITFBW
M1;E&N6FRV5L285<I\:I1D,K26UO=J4TXEM92>(>:XOI/E*AIE'>_T%NG#<:I
MU>X]N[JOC:BJ5)]YY=)@RA5K="))4MU42%*$JI(;4Z2I&'D--! 2TA&%%6F[
M&_H[VP\.J)G[J[QW_>\6*H#\"I2H]";G(2$E:9,EQ+4EQLI)#C492'0D E9S
M@/:;"=,>Q_3M;='M+9RP[>M6BTV*6#.B,,OUBIJ1C!J-96A=0?=01GMO25]M
M1S]1K:>Y=]TS;:SY]PS%MJ=94TU38RBC^U5!UL-M(3_?4PDGD\\,J0X"G R
M6_ZC:MV[KNR;CN*HRICLGFXB#\1*:A1F71R0RB*AL,J2E!2$J4A2E?KGR3A$
M>^.R<.GQ7W%P&TD]I ?#122G](I324AD!8&,A6.7OD^--$;F2:]8-636;7K]
M?M>H4ZJ.U*'+I%2G4MUN<P>:/BS&>92N,TA#;Z8[J5L20H(<;4D$#H!]+#U"
MW^J*WJIM#NU6HIWUL&([4WW TB W<UI$L,Q:H&4A+;E1CN%QNK!MA+*%#NH
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MUY;;HK%-@7?4Z.IQ-*J,"X68:EU.U:@VMMZ;3!Q?3);6D*2H'74G_17N@#J
MV-F;T=5&[UM5';^W-YK5@6S8EIU1B8W<50C1:D*G*J]0@RV$@4];#P:A=]]N
M4'4+D!+J"$Z=X]6&FU*U;UV@W-=@M2K4J5*G69-9D4]N:W3JO'FKJ5,ESA(;
M$>.RT7J?)I7-Q<H3(<C+)9/'7.SOGU!;Y5O<IL;<;5WS3[2HE(MZBO2:?#L]
M%+K$ZC5>36:S6*:WW XQ2ZRF3';CI> D=U"WW<=U2 GR7O%U/1G(CU5VTO\
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MALCIPLMVMUMYFHUN8PH42V69+#<^J/$E*74,O)7B*ASBEYTC !(0.7G7-3U
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ME"<)Y\5.A+A0D9Y+2/U? )Q]AJ9%405N)6VM*DI2"/E61R2%C/D$'BI"L$>
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MOK,I8I5$I]&I52?2'W9#S]9EM=Z7*6^]E;CC[ZDN!96K"$!@A*/(4.]&[R7
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M$72K4D!;]8J+*5I[K<GBEI:</1TH!SMG:W:F+8=#I4>HU.9>]W1J:(-<O^Z
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M%K>E.K_2EQQ1XCMMHW[S/V'_ !#4^C1HT:-&C1HT:-&@@'W /[=0\#Z8'O\
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MN)JK/R%-*I%3@5*(TE'Q"#%*4J&[ND?KJN[JPW@B;*6!?]_4*/'M:=="[DW
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..\5_[Z?\ A7__ &Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g549728g11c03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g11c03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1P$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &^B^<40X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  (<G(V,#,W,C@< @4 .4UI8W)O<V]F="!7;W)D("T@,3 M2R!$<F%F="!W
M:71H($I"(&5D:71S($U3(# Y,#<R,S$N9&]C>#A"24T$)0      $.9$5>9)
MC!DU_2@:S8 D;^TX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q =V1>,         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@             $ P  "3@
M   & &< ,0 Q &, ,  S     0                         !
M      DX   $ P                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   $ P    !29VAT;&]N9P  "3@    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  ! ,
M4F=H=&QO;F<   DX     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    &.$))300,     !%#     0   *    !&   !X   @T
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M-R0-[@!ZUG9Q_EJ/[3ZG_P!S<G_MZS_R:)358_[2YM#;VMM?ND@.[D >TO\
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M]-UU3_2_PG_"IVY9(#6=1S6-KK<^S0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB+?23:Q%G:/33;7.^VN,X\F96N47T5I>SPS']$^NJ/W;JJ_H=#K&QQ<PPL%
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M?O\ CW_H]\/:<._X0^\UO]GK_P#F?O\ CW_H]\/:<._X0^\UO]GK_P#F?O\
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M6]5:HBA8-Z1[FO-QQ0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0BP@?\
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MT*UJL#)S5:5$?_)^IN^&56WA$<L^YGJY3B'R6^UIE:8GJ3VJ#9[%V(Y\XB[
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M&,!%8N?V4-?:78X+.,QKL=>IM-! I(+7ZFM0OMX1BJ7N7ZKWZQ>]#W?G<-
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M5+^?J^,B:UBHY)MZF6+8I"+H]P4R%._/290EB\S':P>A?5B.8VU((AE5MX1
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M) 8FU!'J7>_(GT57=KO,.7=,0_9=84"SET9BB##M Q+G)^[3 "S@^D7L%:;
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MBILQ#354I^40+ ')2C15'K3W4E#CEG'ZPSG=0:%E[[ Q6^H/,R<HO2SV9-7
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MK5J#;UVQ/:GKSPKD$)'H@%>(K\Z5R<XE"K5IOZ&SA$M KKZW6*TE5--,IE=
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M>"&8!W&ZV=#K]/Y,)K*-T"5X^D"*P"P/N\XZ$2^.4;RDC2 LUMGIOL;J+*6
MJ!*NI<ACS%6Z]-?K8&)G&Q[O5HDK'Z)]!6^F(SAR*VE#E!'ZX#Z(-4[["1S0
M#AXUGUQ&/L8E*,H#***O3G?XZY7Q[*(>N3G1YYXO'#+L8'N725IAE6+T8&I+
MOS IP?NJ1#.#0OKV5VX4BQ_8WUO[?[-K7'VR,N"Y"^">-& W0D.)@A*C;3"Z
M=6]4.JL_,)VJ9(<P9-(NC^&N7/V$V01V<:3A."[%Q&:ERT9 SDN0^YWY>NRC
M&,A0#BIJ2/#A&M!7Y/;V@(W$F(9UY25JRPFOP.%EJLTUMR#TWE.[R*_)K 76
M>'<[8RJ( 9.HI\R_:5G3DBX 5$<4- \?%LJ\L-E.EM "=GVL>=@]Q&LZ=CW>
M<26E\GGT8J]'V&_1XORA :W1$,'.,<L;>A%U#=:6.A>J[&?$;VK26AT[>6U>
MXCT*@1'4E9?"RRO^*%ZO?P4:S9!6E-+TIPTIRB9PVK\6[VBNNG>N/2D7HJTA
MK2E9Z'*0Z3RXGS4_$J=RD%^OG-:GNAT#J%M;YN]+JE?Y6KC*W%3H92? #:\<
MO^I+ZD+71T/6%B932QD+$'2K%V!) IU@Z.!X17!!JUQHYIKQV8Z1M3UST[9F
M/MCCU!31^&,P)O9N=N#:KO1MB5\=6^ZW/GGGU_GW1MP'.FVO851Y(\H]6 $R
M$;A4N-Z4-#DD2GO7%N0T'+%CKMJ07J^CTJ=.)R%  "M!P/CY>$1WM7IW[!O7
M#^"\N5^B),S!S968ZAUM8[UZ$J"=K65N5%9D5C.\^ZDRS4>>PT3H2C)!;0ND
MDH-ULU'U(1/08 [* +DLUK-UN'/.FFKFM"D@DL:\O/=XE_L_ZF=#[3TJRRAJ
M_+CPDI^0S8,P=!8W<6V<0WY5TNT[.&_, J^N&PYC;J8J6H(-[3FT>26:C!6;
MY7U8@&+HN@-WVUVO\3Q9XB5 !F-]/CZI>-6%+Y-WN2P=2F%N(<J[YJE7J>C
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M5K2\Z8O'K$_/Y=3D=0AUM!KB'!V H=2-.8?LIL6BY4UTWK8OQWX]4?MKV_\
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MU9"PCUTG2%2W>'M63[;ROI%HJK<;ZT5%[\6+& ,-^"Q-T1<'*O2@/<E?6O\
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MIAU5%8*$C8/<NOT&10G.[V-:@!D%'A=O2$HXJ=$,8U9R2:U8D"@V8:OU5>(
MDI=J\VM<UIQCM==]IO9E.2?5$N$Y&3KOG2T]0<.P)>W)N@LXL7>N&.5CW!$I
MF0!&V91FD91<&PI2%,B^0UJ#U\@=/GQU%,-C6&,HE[M8@M?;1[.^FAI$"4^]
M6@H"_?IY<XUM'^]'MO,UG4L]2$K9T.D=><PDM+TZ]B&H+T-G4MN7QH_-T_,3
M@#;XJY2XVGQQV\V)2JQZ%X*JT-H2WQ-XL3I!W-P-F#5/,\/&VB@: G2]N//A
M;A%HP=_]OP8/IIJ=%V0@J\?FJ!5ZQR'IO3C$S1T3V^]CDBZ:*-I#HD6=$52Y
MHC(C+/95E\R*$PO8]G" ]$"163)8 '%2]7HP:MFL'K=NMH$))#EZ;@, .&[O
M\ T5,O\ LQ[Q6@H]^8$,P<="9] 9:'-,<([B%'<Q73GJ$^7W!OC#4&(8=> X
MKJ8@A!ORUD@ML]PWIE7%QCWPJF$P^F#N];._F]6]6BLGAL:[5(/'O#7%(V _
M+_[E%/OE=3QZT=3^<K_5&T*W$?7/J@.][ 5$:IPPDO+ZVMDWP??2KAT@Z=<0
M]">*S+(SD.?T752#X S6AMB!W8DN6-Z"_P!=&+BPJT99.K:@^]:]?JKWQ*^T
M^S/<E3V'=^:<\KB3=9/$>NY!:Y[%P_IS>7Z/+U-V90G1-+76%YAKIB-"FJH:
M%BJ2E ^= <>M@ZS[W5_;6*.!SJ6!.M@VYJ>NW"($@@$]9<4^^GJ^OK#[6?*#
M)R_SO4SSY1(6G;C/*NLL#T/]?>Q;!$!Y>E%[($.#D$L,WM#'<)4&-1HZ3GY;
M50K4B(UTVV"I-KFE6_*"^O(5J X<\2;GD-:Z"4GOH^CD/O%J$_:_VI,7T_GJ
MSS2->Z;><&L)T6X5XCV1A1T %+[7\#YJA&JYN>=,%L.A'@71GSHN/H&Z6Y'=
M4E8[M1:# 6 1JN')(M8[L-*&NW8\0H2 [EFW%?5A\8\<]Z]TU? &H\TEC8.S
M,SD#8.E+_KAU*[3Y"N<_ZT[<\JNA-)&= /EF[3J04.DF1VL-P6-2/O==>KGW
M@YX$M1Q5WI5PU* F@-:4V[GK#*DVN*L]^'>SCMB%6_8?WE8.=]&:2?.A4X*D
M1>>>!$NCQ'LRBX/P#_P_="<EGKU"YKT&!P2:;>VB4;4<GQ4(V51PT%D0BS8>
MZPLJ,4)%?I5-F(KI>M;#2D E(+"]W<4((#-YCX7=RWV<[JP=<]@%YBYLS;\Y
MYZC=//)6T7&7L,Y;,?,W>TK4E>#[28+*ST&V_!-(&=(J"&H<<:PNPMEEJJH]
MLH#!<- G*:.V[N7WZNXF!2FC:D:Z'[HH!0]K/?%S67\R/1UZEIS=([_T(=:)
M>O'78+'6IN;\Z]7WCG?.P0^^W!-@Q=S8>J]=19B(;[Y9N6N>[TU:,V17F$I<
M%AJ=!<Z]IH*[&!2CO9GWWNS7ZHN7A72>U=.]JN?$NBU;X^L*X)[(QM*96X9U
M)$%\A<;_ %OUYJ@$8OU-H)WTKII6\O "]D21 5QNYVJ&,O "#*8S!ZH\0S7-
M16^SD[4IXO1A "2!N-7>Q?[N=H]FWFXXX>(180/^Y=7_ $_^\S>06ZU>)CG3
M8<AX1\3GN;_A:^R7^>OH_P#S22\_0?0/]2=$_P"GX3^2B/+XK\YG_P"*O_D8
MUH\^M'!#Q"'B$/$(>(0\0AXA#Q"'B$/_ -O_ ,__ *__ /O_ -?FQ_\ 3Q"'
MB$/$(>(1VY+]Z6G7'2W;<@^I-8LU:.]B;>G6L6]8=;5BO5VWS!#/9UKU];$L
M>FLDVL$.LFVV(H\:S*D**@D!2@ I3#,0E\H)N0ERP)8.6O!RP&@L.=XZGEA#
M_P#5_P#S^;'S_P#Z_P"W\WZ<_H_M>(/1M+P\0AXA'W!\U_O<\_\ \B%/_@ _
MS\X8W\\Q?^9G_P U<>F1^0G^ZGP$37SK1J'B$=(D0J"!U\K?DVBHC*5HA<EU
MCWEVBJ4H)+-B36*+7:23;2&+?;$<>NV^^<?1TUSMG&,PEN[O+0%2!O&H"C[Y
M\!=+X^B'CZW#DG3H7Z5HMPWK(BG/ =YX7ZLI:137E&+::\[(8 V95!E>.8D2
MLC\+\M2JRD! <CA1-10ACU5UK?ZS2T:*#HQ]5[-8J-']Z?7E?VXXB\KJ'"7*
MB"ZV\Q35Y42G=L?*71>83*-$/SRL(H:EK7U*)+M%#%DT3WGH1TZHPA=8JU62
MQOO1F )+.]784;A];4IM&B@ER35^IFY1;3G[W\'6.*GNWB+K0Z+XNE:W%!U]
M09-#[$6C]:<>VM(+4H$1=2<=+;XKO"Q6;QB*E0#6,V Y>:H8I6Z$5"GI1^="
MSOH6M8Q A1?8:];?7%-M7N+Z])+"\=/"<D=S#)M'3K=$O6^0] %= ,F^<W%A
M9#KZQ(<5<4#$7,]>GS;LD50M1H*]MILX'8O'"S5'4R7H11O>H=W-*;:D,] -
MZ 2",UK,=[OSX^%[&-^VOKH[*K G=3C)$5V^8,I?0XZ:'TDFCJT-_K+=R907
M.E'Y%89 L'&]B4I@%H(3SI5T,2XBWM3K!E>-G:,P LHT(M9JU?OXZO292"XT
M9K;5[.($7IP?O/+>W@IY.80,0T:OB$^[6#,R$S\ZM:*+>!T,(9T.": X6SNK
MG@L,OV+9K5=(HMAUX98@IWA]FI#01;7K/.]>UMA:,D$7J[U\8OCS42'B$/$(
MCQ-57S)M98R8Z.T:3K!2VM7MIK,>XNP:%SA2<D<4,T=>?-L99GJ[:VXK&D>N
M_P 2'6.;7637)2Y>U0_%K<O6T'-1O?JB0^:A%1IG ^+<\*DSB3R]*6BY:6M)
M;OC -**Q'K2O7B=*H.VVBWP'&TR9,D2J"A&*(VL1(7KT%2.W;GFDC=W$@=EH
MI42&>)R#45U;)N!D(-CH$GYBJMC=:TGM2[&6&DJ+*/6)2QV)Y8:TD2JG+0G$
M-&.M5VC%QV-X-KD]NS8 ,27=_#;JB;</,GZXD?EA#Q"'B$/$(>(0\0AXA#Q"
M'B$/$(ZT=*G#:LWHJE:*[=CK17+D<$6EJW%3^-]4CLV-=,33QU?K%CZMI+OO
MK!\>;X6-?B[_ $HP!)WO]UH1V?+".D2'4BXZ^))0:VAY2E:'7ZVVTFFMBE=@
MDK6H-MXMXY=-9H)9(\[1[Z2:XV^?3?7;&,XA (8PM'7!!!2R##+8*IJ/"+XH
M<##T-))IM*0L33AH#ZFDMF2:Q+K6J5X8=9)YI9M\:8VEDWWSMMD P VA>,KY
M80\0AXA$4KHRA5<R/1(%X9J\%05-8NM&T&)#$B[0M;WJX2*W+G?>H,S=WQ<L
M4ZGP(;MN&M8N:3S5*N\,8;:OUQ7+-H(E?EB0\0AXA#Q"'B$/$(>(1'Y%5?E:
MJ;O(-CV::"\25:A?XUG$L( N2%%R([%?$V*>VEDB$%V=IMZ^UG3:IKI%-'%)
M/'+DIJ[Z@LVU+^KF#EFT=^N)!YJ$/$(>(1'1ZFO"V1B;J V.NQME0!182>L]
MK>0E45]"<8&'>"2?>I!@?H8)8TWJP023?6L_6=ILQQ9TR$L27N^F[>4/7KLB
M1>:A#Q"'B$/$(>(0\0AXA#Q"'B$6$#_N75_T_P#O,WD%NM7B8YTV'(>$?$Y[
MF_X6OLE_GKZ/_P TDO/T'T#_ %)T3_I^$_DHCR^*_.9_^*O_ )&-://K1P0\
M0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(^X/FO][GG_P#D
M0I_\ '^?G#&_GF+_ ,S/_FKCTR/R$_W4^ B:^=:-0\0CI$A]4L.OBKT>9J1.
ME:'W(L;[QYEJW()*UB/$D6VDL>=X9-]<;Q[Z;Z?/]+3;7;&,XAKZ>%HUT9O4
M#U_<4PSS]C2[1%38 (=8,#/O2U5-K@0#S(YQ\93^O43-8A7V@0&0P'VLUK4-
MJ6:UJ5EFW*UZ]V+(2VM68%K=_IZO&@HC;7O+F.DE>FO!D-F5G0.!9+K<GM3$
M[!V)B?75C)?>=K51Z6=(W-S)RW#<CLK@JB.JC)H,AQ$4$>@8>/CCCCTK'<<V
MKXM%SJX1&Y/0CUIF^JUI5ENW!U =H'HI8ZCTF-.FQ>X-=]8[QNXKPM,8:ZT6
M^%W<\^W9+524M".K5;]2S7-1[DI0!% 1?;NN/"&<\+^A$NN>HG%"2I(HE1C2
M4JS4'NE.9(/CC8:9['2;JT3;3,K)L9P5W.WBJ@O%*I7-CZP+O4,2C<U=9[&D
MICOSI1@]+\:U/5$SEWIIW/3OC"R^D7KU//M).OMDM6\5C/,X?;I?0M0#X?J]
M!8^JB3G0 43)&*<2P+H+6:91%TW5M2U[.XVI-FP- @:0TQU(-]&(<-<'X\89
MSPX4MP'I^,7@D<I1N=69[BB)E&SV5!"1)MY"1*_])9YE1*CDVA]&_:LZXD&4
MS9&.6YKC%PAF?$A">S)%%MI0&^H;.7.O+LI$)?O[[Q8OEB0\0AXA#Q"'B$/$
M(>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA
M#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"+"!_W+
MJ_Z?_>9O(+=:O$QSIL.0\(^)SW-_PM?9+_/7T?\ YI)>?H/H'^I.B?\ 3\)_
M)1'E\5^<S_\ %7_R,:T>?6C@AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AX
MA#Q"'B$/$(>(1]P?-?[W//\ _(A3_P" #_/SAC?SS%_YF?\ S5QZ9'Y"?[J?
M 1-?.J2P=GX1J(4BG&L\-(V6]2^YU^L<(T:-#[3KE?KPFO\ !^IE?CU]=-8_
MK6V\T7P=L?/GZO\ 'U_]E/'C7R?R/Z7^4G3. QV(^4WR;_HQC)'2^.P>$P?S
MA)Z1_"NCI'LOP;I#VLE"$R_PA2YLOV9#J]@9Z<LJ=+2/2?*?HSH+HK&8.1T!
MT]_2##3NC,)B<5BOP*;@OP;'SO:?A&!]G-4HK]B$RUYQ;VPE*)F2EDRN]+O7
MI7)X\XQ)!5L3:9SCY\8WBAWDUSG']K/Z=<?HS_;_ +7GK%6YD#M(CS8N'MK'
MI<YQ\HGU)96/6(%W@>/*=:=T=;<C@]/$#@(WN"MUY36L<7<4J4Y>A%*,<716
MND@=9BG*Q#D9D#DSI#6DBGTZT4RP- ;$'=N_1GK]<<I0"[<!R:_<UXW;9_:!
MYJ\T86!9Y./FZ2B^R'(_7EZ1CCQ5T 4271W?DP:0LO.HL79T.4I5KK:U?%SV
M0HFW0)79ZYX+!9!D!-B%34=Z.X' TX:%_ 1C*'8FC."WU1KJB?*#MJ[S7D(_
MJ?'W4_U;I*US&5+F7<Q,=?HMAR!==,WV(L+YFJ,)E,AK"^(-['L-$IK)OD29
M4M/@42%ID%JE -6+!^M]6&G6_*L:R DL:/M8[>K6C-,_RF%!<3VM_L>OW1Z2
MVHT:1 @)/V)A_3;-:EP3G_L*_P"U?F0)>:CXV'GJKTA;7SAMKW65*!NLZUC#
M( 7[(]BMO>_2[O(%GJWG9[/CW?&) [_*, ^<B++8U<:=ON67Z[T[@W-RBV;7
MVUA=NI<TZ(9YM*-N)0+:R=60#*8!$9@IO;4U=K0U):YT$)ND%BNR4$O?F +.
M^HNQI3KUB9.-=:;^,2Y3]Z*#2#;-Y.0O"LZ*S)R%,^YSKI>3)#;+V7JSER58
MD$2-@$&P?=;)1-M,&ATDJ#R%A=LYDW7ZI4:3%5H,V[\6:Q9K4)ZVVU-R5%:<
MOCKZ$5]Q#WF>NF7.:+,_))2?4NE<&2>^WDX8WK 9-5$VRKH1=IM!6XWK"2.E
M[ECIR?L%6B-&&*"6U>K%F@30%RF+AC?-75@]BU/NW?@*-C9]*\+>-^JUH*GN
MR-9^(NG6;7-6%38U)V5T+?DC3,8IOV&%VT39U@*87J2B0;*;!;@=*6<AEU2<
M,F_JDU[G=SH"^0!'"[WG()O8L.#TZV[XF2H#W>OP?T_ Q6('Y2@$PJ-_I-3B
MKC!SA8L<5#NYJ\S*]-C!-'=[H, I!AZ1:D@-EJHEN/T0S21NY 3U:4V"0 6R
MV:ID0'>]OJUG[? L['7:^SX]WQCIG?E)]5=64F _Z_M=:\[<]7^T Q(]_1C4
M-?CAKD7<.T6F4X7&SS04F4*J\#;:EE4&5S=0P9*KE=69S]/9DO+3WC96K'W;
M'DWBS0R/8VO3E3SK$\9??6ASHL36NH\A8U9JK!:]L.)#-BNX4FEL;E(ZW\>Y
MF",CY:E:9\ZI72NA@A@RS%6JCV52AJQWBP=K53I6^]NY-!1F/97ZPY ,3)L=
M=F]?7$=Y]\HC'U.VH!TSU^ZA@SU:\*CXY:;J1E$26\806^DN-BZ8>&E3'C0]
MZ@K\N-FMQ"Q5?I+M8PN1#K5FWLS5E:$%JFFK#0W[.0I6*4-5^[XQ*N:^U3H2
MY'QLI.BWWWJ?7;/<3E)=LLZ,I40RIRUT.QDX";54DM*EHF$#6%A;$UU_!:)C
M(2;F+!:NNTV!L'P.*6J*L6J!0O;B;UMM"D9B+ -N:F,WSSW9"]'YT\=D%<W9
M!G*E>YR*@#/&C(.N?;)^LJW+'*"SJLU9+F  Q;"]=6XBEDL8UMV"X]@IU1V:
M%*B6*4Y@14E]DCU\'@4!P'J>'"_KZHP1CWR$#^@NBD/Y4RF5GF3@C*71'BJQ
M -(0DW0>\GO7D).(7=<V"S%8K.0.P6,#H<T9**U6*213VF&J/73 YA7,PNS!
M^3:MK7G#)058G3ZO/X11Y;Y1=E$='Y-/;Y(WY4N\<?6&SC"2$O"7@HUVNA3E
M6M896S7G@!P=$ZP)YXE-UA@$A0CL%Q8G&50!%HOX*R@,LIR:N]V+64^E=K<!
M%R!KU>['L9^^-A5?W<KL'.NS=;)<7Z$HHG&02I,3@:;(8*^FG1JY=S3J6B/
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MH2A LE$A;I2VZ>P@7FM+%D?4^"RNU33COW_5!E]CZC6_K32*L'>A/#!+"_-
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MK&Q!F2"@G D.J&M!C.+HR-<C6UZE6RN058PLEJR7)2T=R!LK9MP)[!:IUO\
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M\J'Y\I]_B_*'\MS/_8O'XO,-_:<_^'E_]D/G69^J1^\J'Y\I]_B_*'\MS/\
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M[_A&%H]*#$BYT!0MC;9I8V&:L(R"W].V'V,T_M 5K?B^C]*#-^E_[S6QM_\
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ME_9(_P 7;]WQ#VG#O^$/O/+^R1_B[?N^(>TX=_PA]YY?V2/\7;]WQ#VG#O\
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MO$QSIL.0\(^)SW-_PM?9+_/7T?\ YI)>?H/H'^I.B?\ 3\)_)1'E\5^<S_\
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MG38<AX1\3GN;_A:^R7^>OH__ #22\_0?0/\ 4G1/^GX3^2B/+XK\YG_XJ_\
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M126M-,$;$ZTH*%<)62["YG0PJ-"U*.^[]S$M<[U,3.-CZ/CZXQ5C#Z8OS#U
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MJ% *'?CU/6ST9PU >6GKJBOE7Y.Q\Z K=75643PWEMBVZ=5"1O25R5E5F]B
M&O7R[PFDHAM[IW?>OPR>P:U;1 F L1I5AP,:J5!\Y<?KT',%;58"A-*UJX)?
M6^S%C%S ,:U',>-XL5G^2ZCNM/4;@ KSJ%1:2I0TI@\KEQ5M4:-]N0&D/SDU
M,EPCH;J0AY2HJ*=1.ZNB=I1&HXLMRZ\(5RU%M *#:TO3K%:U:]*\+0+#!P7;
MT;]<1]*^2ZZ2 B(4K79N?KNA97-BC1SGW*AR\9+LIK@/6^*TVBIN.W#%%.BL
M?E+ANU$!?9=>>S0B]YDA:Y-]. 9'ISMKJ0[4ZM]8OM!L8G1'Y-"JV7NBGF"+
MB*I99N-]J0>>H_.N;V!_.N.]"Z(L\37UGL:4-NWM-AKV'M\GM&"!\)17R\.A
M0*-$W([P4HQLN2[6N7-J5J+@,>_4.28F<:/</06>U^ST8]M6?[>?F_\ KYH4
M Y"../SRPAXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0
MAXA#Q"+"!_W+J_Z?_>9O(+=:O$QSIL.0\(^)SW-_PM?9+_/7T?\ YI)>?H/H
M'^I.B?\ 3\)_)1'E\5^<S_\ %7_R,3;Y/ZSI2]JD.[N0OB-*BQV2UL6%:?%*
M"]:_$>C3;$1L?UFG\2_2QI]9IZ?7*GT[,46OUF#Y_BZ=?Y3)*^AL2D(1,*IW
M1Z1+F%I:R>D<( A9RJ9"C11RJ8$EC:-X.D])<I9,WWA<?_C-+BH#AG%1:XC?
MA69Z_3)?1MS"]$>.UC53W0&)Q[IG8QN0_3:!IBB6#X=*'5=";3%:2(QH4B9S
M:D<R]J(W/O#)0%ULT])?,3Y)P:?E%AIN%P_1ZY_0"YZ,'@5^TP:I<HSI<R>L
MY)*AB"N8E 'L$#(!E6LN!VTD+.$6E:I@3B@DKF#+,"B$$)%5>ZR20RBQ+$!Q
M$#Z\0T[WZ^]+7%CLK;UN^D>PZ7<9&?V.D'(T/*1;3][%$/03#Y-B:AVJZ8-[
M:P,U@DVAXZ%08,M1+>NDMJ]#V\#+/1G2F$FS\!(P*<1T7B$R9/16?$'&KD^P
MQ"UXB6F5(7[9$L$R B1,"RN8@S7 1&)JA.E3$B:J84SD9E3@$>S"BI*0E3J!
M25?ENH90 0F-3>2%G;@#<;5#'9FSGG*B9E7P_P#3_6VP!Z%!,8IT+1Q5"5WM
M>*TZ6_\ 83W][X>HR2_#S!<FM+Y>8;FKK]K'2\/TGAY<]& D8K&(1._!L'TL
M)F%(EJ6)<Z8<--0I52E(3,5*8@I"9LK/F/7EE4E129JD(40%KDLMZ$I 4"FE
M:@*YI-HW0]GG3J'$QC^Y\EFSSUU>O=!BRV$N>6+,=DH,J<T0&_E"\4M1#Q-Z
MY38ZC4::RZY?'U:I)BO%]+8R3-?,>GP.A\/@ND5X:1C4C%8?#] 2?8(Q20R%
MJQ>*P^-FH3FF)"I2I$N2B<A:BB4F6$K]YSVIZIDH+5+]Q:\4K,4&X$M"I8+!
M+@YRH@@ J/O Z="JRTT?VL]X.1I2^GB5MDYU[(F3Q"B%JR'Z]FGQ)B+$$H:6
MWVDU#JPQREO7-Q(FO3VDO4:L-N>6K1KTXM+D'$]"_)['8B;.F3I6*Z)ERTJF
M'V2@K'RD)GK0#_\ I.7(RISS"H!*E%*0I2C$2H(Q&*EH"64B>HJ ]\$2RHH!
MT 5< 7H2U!Z9_/>Q\R'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA'W!\U_O<\__
M ,B%/_@ _P _.&-_/,7_ )F?_-7'ID?D)_NI\!$U\ZI+;GE>-1$DYY6'ZA>)
MJA+!2D-+W =R;%:W5^$2H:P26(<:7(()-]<168)=)M-=H9-)=<Z;YS]+&/-_
M)?Y7_)_Y98/&8_Y.X[YPPN Z2Q/1.*F_@^)P_L\?A$RESI(3B94E:PF7/DS$
MS$)5+6F8DI42X'WOE#\F>FODMBL-@^G,'^!8G&8##])8>7[;#S\^#Q)F)E3"
MK#S9J$*SRIB%RUJ3,0I!"D@$$R>S/K5KV+.^D\FE>&6?>.K7FMV9-8=-I-M*
M]6OI)8LS[XUSK%7@CWFFDSK'%IMOMKKGTA]>O7"/@QZ[@WRBB7CJ5+FO0$C;
MELF;R^%9)''I'/!S<@%BWK8N^S9F^\\WO%J#2&14I3/2+K@^5XR(D S"262T
M%$#4N&JD=7#BW($B_&C.-VC>38OM1GZ_#?E&Q-GW ]6:, RS?]@>34(B^A66
MGK?=0E*?6L!F'P'KU^M:M161(X#(6$8.$BL-.@'T,")25BM$5'[V6:E [V^J
MC@MY$VB9%;=X\XZ*?[:<;.?6J#:ZIG.V>%U[RL5UIE;Q5>Y8$<)ZKUOFY%KE
ML7=1L%&@<&\<;'6"M;^AM3#"F'$=DE65C!.-F+L14;6L^K-U]L,AJU6\@?KB
M0#/:?UQ,VE^@*[9S@@0:;N@X -JLXV4F1OV+E<=0IQ#L3?78[!DC=H#UZ*Q!
M#LQ7R0RF"^T+)*C%/7X&OK?PV>S&&13V\/.)QR_H=;I2D,/;B;:JQ?9R_(XH
M!FQ4E:^<,1]5 .6$ITJTY)-!;4,",P6P3&[[?3K_ %V';7.\4D<FYS6U+'JV
MJ?.(H,=^/K:-9.:^[:H]BV%R- @*)S((WM2K,YG^M<WQ< [HU'I!-QUZ2HR%
MZ1OGC"NB>;WSY-1NX*F**W?P6(_4=P;+2$1U,]+&FKBAU+@'M[CK)QJVWUQ:
MP+VY]8&8A() =\Y26)1?3Q+2IN@62S%+I;H4OJTD>;6NT=V3<L)LP4ML8MV1
M9849KPRB"=&]89N!XTLVO'J>(4J%6\(C9_W&XPJ=LQQ9C91 ^_=PAB0AR(I'
M>J$'IRN]V@O)5ZM6K[:A+JU6X9?ENW+EW?6:\QC!>]6E-%K+=.;Z4HU:\RS6
MJ-X!!(<7VMWQF9?<?U4@@I6;'L)R6O"0O%AU/:=U"P;33@JJR0-38CEM:2:C
MA0ET43M\OOIJ*JKS,"89KN@4I3OS5_HGNY;^KVAE5MX1([WLQZ]C+#?3(=HY
MM4MH=G%%LJ3-H?2R(OY8*RE]G;P?6OBVR.K?<II\@^AI:N1-]NLJR0Z,%B$=
MO,W [:7ZS]^CPRJV]>NW2,G5]@.&W5R5PJ]>YQ,IP:#Y+++HX@?L*KJ4B(S4
M,VRNU[%&IF>,06S]&S/%M%L+(Z38CWHV=8F85#%QHU?NYM$RFS'U3ZXKQ:]O
MN&LSBVKU/H2/$!6>9CNH0.$[<,@'% 5<IT,:_P"V:UO6KL-AYEA"Q:;+5JSM
MFA"8TVOUQT=&26P<T<7+4TJ '/&*4D-Q[MG-JQ,V_P!D^!()S19<^O(*XR2+
M@9MT7RC%0@-[K;(1L!EHMJ*^+F_FJS&*=P.L_P#L/B,):G;&AH[UZK/!&S<#
M3EIUQ DEV%BUQ>(S9]O/705+C=@['S "*)35]E W;Z&GV1[F(V54=MOL(C[/
M+VIJX4,-Z"LV"UXG%3@I"R@UBL21KY0>2L,QJ6]WA=]7KI7[HN0\]^'GU??A
MQ7O#ZG%=[T&>Z\^$WAQU^7[0P^?I!2FEGF;&25&V_P#4+\L-C[#J&QN:=8WG
M34=>G(@ZE>QM?-BZEHYJX/!J[>NT7NR*V\/..KTKW9]=T%!L.E'J7.FJ[8#W
MB:RL47@/5),EJB;L*V1.N<?79Q%Z9MIW$Z.$G1BL;.%2RJZ5I&"&4;J=[#M9
MCNQ!/=8W@$%V(8:^O31:AWV$X8M"*)TYUE"'"2@A=/"+<[*,^8R(;IBM=7O!
MH([&]@O$PS C>@; V&U(1^QR>]7272A:VB [BO :<[=_)Z.RJLWH;_4_5$:L
M^VWK#4^T\R]\Y1M@15J7;F:SL"N8S7NVA%*':CFI<FP5WTN, "K<A%YN3#[!
MT-#?CK2%:&MAFJP!/&C=KPR*V[QYQ*CW?N(JY].56'JZ"'8N@U@5Y)#WF<5#
M>9Q[05K@5LF'AS9SFV+/L%P>OAR>F?J!$^5#@ZEB4J7&5+;-1V/=RL[Q,IVM
MZM>(K)[;>L4>MW;/>>5R9HG1BS+' Y!;,]@^:W.0A10VO7M2SF+1JTL,U /H
M)CNZE":X>&4-K! .1K5F:]#3A\>NM(N56WA'4#>XOJFPEJ0,'[#\@*E2,E>.
ME3I/:_/M8UN?%THV-)-;OP<42%NM;%#R&\FM&^=HD %2Q,;H7*$%?@>ZO?K#
M(K;O'G&74?8KG?1']33N=&PKP+9$_K#+;:0!J"U6 D^5F^*B[*T1':0;6-+Y
MFAVD.>JR6)Z>T0>O0(05;X]A'WH\E1%6/72M;]S==8A21<:@#B[^4:4KWRJ7
M.C2,>;->9LA@O06N9. -+YRXH?36 ^'Z/LV$90MBNN%];"OT5)2T%X?VOG[+
M4H%=E=9)3KM@_;J7JM*N=&UT[-0-0+L7I2-9./=\:CB/NM(O\H'SX7W.[QNL
MOP,$&AL>O"3Z_P!"1KQXY9*< J>Q5)D'<UW(UW&]SC=/MZC)WP57*#Z)O63>
M]4KA:]XO3.6%0YX$V+$AKTL.^&3C7D=]_3]\5-S_ .5?Y0VLO/%TZB&05)VR
MIV3+TM.R%TSG/.A#Z$BNJ=UY9U Q/(#NQ'K@58>@EX75)<YW9EML9XZZ$3V:
M*QSHV^IH;,SOKY"!0P-7ZHVN"^TXLYT3FZ#6YT[:5^C=#]A>;0.V^X'"D$8?
M7UFZ4N7Z5Z38KH9N76[7ES"9#5Q8>Y7%B\U,L%\=;NCJMXZN!V ??>UG[MX%
M#!W[HL$]['<"5G6QSAE[+S5?>:GQ=;BR9< @PG3GKJ]EXL4KD5RY#I4(UDBG
M9=+(RQ)&0KJ$6S/-6T!_-?R<!Z'F&K5MW+&GWB,Y2SM2(Y_XO?5S'V%C?OW*
M(]V6_?&!8)G0+#:N714RQ 3CS4EM:6:L8_9W2I+MFY#7JU:KBJ7)YM*C&'GN
MLP-G/JU3<;==HN56WA$Q'=ZXP8V?X@O34PU9Y;2*D7^H'/4"5M9H@YR=,Q:(
M5JDTLN*XLB%,A[\\6LD-,X'+!+&\989>IUQ4U&8Z/;37@]8F4TI>WK3KB)<Y
M]LO73JV$*%*ZZE$BW2U\2QJ"W*<HTV4A4-!K+#0H2!+$VEVJ>F"4"975?GTT
M+R#!)8G!3F'#+MN&ON&H[Z>NJ*4D5(H([!SVM]:EDX?6F#N?,0YU4+?83.-(
M-PBO873&E3[0MCSGT[&(Q5D6,S$7.:7MX, 0]JB7-9H#2%&U8F;@3R;E9WOX
M0RJ.G>/.,#9]S?5^LVA4K\M*+8-FR#>+BS4.TK P?;11^2;+DT7TF^SA-2A4
MTGS]HW+$8^62K<CCM9VIVO@TDW;M:O)B:^,,BMO _7Z[HR&WM_ZM:41Y&7V!
MY+!3)V3]6G-8=P=?.\BL+"GF626*>W'-4J 5UD7F4M?MQP4:"P>#,EFQ&#)T
MK\\S6H:E@:$=Q,,BMN\><2>;V*X370X^GV.LHL"#(>@4]&B9@H1#<MMJWK0J
M*6<[RZSZM=R_)#0IK.T.#EN_8JTJU"6S:KQ25^![+\O5-6B92[-7UU1BY/:;
MUMBE"PR=UY7INQ+-9R";9=P'P2"Q>%D3@XQ#8^N_5\52@8.:*BL22Z3%!X0W
M;'Q68 Y+>J?@>[MO\>$7*K;PB*:^[_J#OI'O'['\AE^/C7-72%T$32W?C5-2
M5+6A!%/O,0D+",[G045*.>0^NP6V$+K?"4K=^$_ ]W=7U3<0RJV\(RK3[4<?
M$V:(96=$]\;+C-QL1E7 -8V:_@!U[J',.;P-]22KK?B)"U^/K"HQ7]:/Q==J
M9A=KVK(W1H#W98YHP[:=6[T]"L,IN0P8GLX7CH+?M.@G>R]RY3;-I *#A@^M
M9/D23OI"R6MZ:HN.CB6E4YP5>F,24X,WKM<BTR-5J?[9F(T[H(72JT2945,Q
MN#2E:]OIN-&4L#6NC=FNO+A$AC]K/6J65L@C[KRW>5%Q<^]NFKF$SD)*.9Z2
M40J6OFM_-L0H.10.IW1L&9K]1D.@ D]:,D>#UKM)9N.FO'LX/#*K;PB$A?=_
MUJ9CK )7NJI%\<EW;U5Y9[;:N UY8KTN?T^C2%-[ILG1^UQT(6]'7)SA]+F0
M5^J3A-:4=!EN32.7T8VY4J[\:4/%KQ<A;CMZI$QK^V7K-:NK0V#NW+MB;?=B
M&KPS9P$1D[Q"9@A4HZ,@Z6SI=H6\MEJBJ;0$H*DD;.3$KTFNA@L-IVJ_ Z]W
M!W[!J(F56WA&PG_[?_M\WE%0#O&8>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"+"!_
MW+J_Z?\ WF;R"W6KQ,<Z;#D/"/B<]S?\+7V2_P ]?1_^:27GZ#Z!_J3HG_3\
M)_)1'E\5^<S_ /%7_P C%-\_Z"X\L;13T@FYEUL"8(:BS%>O2MRU="HNZ%(Z
M8K$:URE-I;%D;M*72Q6EU^%8WSKC7?&N^O?Q.%P^,D+PV*EB;(F9<\LE20K(
MM,Q!)20H%*T)4&4*B.)"U2U!:%%*@[$<00;TJ"1R)BRF+VB[ZU'TIE.]+.6R
M?.3,#"CZ1PBJ(E;.U[$5J,P-7AP^HOQD<SP1;2W)!<D\^L>L<^\L6/H>=25T
M/T9)E8B3*PDM*,7+,K$56I<Z601D7-6I4PHJ63G87 >.16(FJ4E16IT',@49
M)W   ?BS\8Z72O9+N'70M=<Z#T,P=7:Q'[8T 10"P@24OB.2'4I<$K] 50OD
M8XI9HX;MZO8LPZ33:Q2Z8EDQMK"=%='8%9FX7"RY4U2/9F8ZYDP(<$H2N8I:
MDI) )2D@%@XI$7/FS RUDAW:@#VL  8QO+>]=;XMJ9BYHYW%RHP;4)3([8>%
M-B;]D5))*+ORAV(:7%ZDQLDTNP\K%3T(T<RR?5;47TL_/<;T9@.D#+.,PZ9R
MI04):\TR7,2E8 6@3)*Y<S(L 9D9LJF#@Q)<V9*?V:RG,SA@06L64"'&A9QI
M&?4?:/OZ.=;F5=Z>P0''PI =;KY/0:Q;FCU26::D>FA8Z!:M ='[V)OLXU3A
MK%!VDFT5&W7C^;7&)_0_1F)ER),[!RE2\,@RY"49Y/LY1 "I0,E4M1E*89I:
MB4*9U))K&DXB<E2U"8IUEU&A<Z*J"RAH0Q&A$5N%Z,[KY\^U"F0E QM(MJ#,
M1F>32^0,#G>A>&-<-^P0CM;SR'*1*]#=M;9^M[;699M)])\XDQVYF%PTV5+D
MS)*#)DKDS)4L H1+5AUI7(*0@I $M2$Y4CW6#,T<86L**@HA2@H$N22% A0)
M+FH)!UB%><\9AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(1]P?-?[W//_\ (A3_
M . #_/SAC?SS%_YF?_-7'ID?D)_NI\!$U\ZT:CK5:=2EIO'3JUJD<DTMB2.K
M!%7TDL3[?3FGWUBUTUWFFWSG>67;&=Y-L_2WVSG]/G7P^$PN#2M&$PTC"HF3
M9D^8C#RI<E"YTU17-G*3+2E*ILU9*IDP@J6HNHDUCFGXG$8E25XF?.Q"T2T2
M4*GS5S5(E2DA,N4E2U**9<M("4(!"4@, !'9\[$<,:4=;]$.0=D(=)+L19T%
M%^J,#03:2RY?"42$RZZ<(0."LW/M)K0"_I92R(SEZ(_ZC2L1&:OTI7"'M+.1
MX^(-G+:WH:6>KWKV6ZJ1L+9@P811U#Y/.\%>"P]=ZR[K"&[<CZ G].8U=5X$
M",O%I]))8D@OWA=3E.*]':NE)U"F,;: [0[4QI+5L&+->()2$Y8NS $-9N+%
MN#@MRWBE8(=J@T#]AX\HR+?\EAQ-V)V/MSH'6)E*Q:ZA;T2=KB1<'B-NM,?<
MV%HK*IPJDD6I0I39[VQ4IH5LV.F,:+*798[)FR,);F-U[G>E2]FY??#VAVBR
M#'H@MM_3E?K_ $7K+ST=Z":(% R1:DKA-BHS .5/!CH7/0NPZKR:M46\@F5B
M9+5@XKQB6(C]OVY?M6I=#I]M8S75(UJXUOIVM\(F?0#>]7/&W7\&C=@:.OTK
MA^S</DC-<L6B("Q]ZL%@JJU",*(&;@@\HL4/NW!TY$=?8I++%;-F-29XC5B)
MQA*P<2,H2 &WN?A41B-%73Y/M/Z<==&CIW6NE.;&W*[&B:'=@O)%@I02V%+Z
MPC_9%^=/YL!A;+@@5UXU]B%VJL5M"\!@T-+2#2^X9:@#4T8 5OQI8[[]4;S[
M  >N$6!T_P!+^>=2D;[1%H=P))KZS8[5J2 3K>ED$]_D+6N$";@N,JME*D],
M&(4@C52I&*Y.*RSUMHRF;ZY)L!\!-W+T [.;O6M;0"R-'L.S>(@$]$004X2=
M-.V]?M=%,N(=V(O4NG.:I+[4H7>\;D(!XX6A4 HRF2#>Q+XO0YK#_KX>C46;
MPV]$:%6B9(02+-0AGY:VI\(9[,*,0SOZ:(:A?)F<H2!_2:LO1>ELE_J?&.J<
M19C1.OS<<0D7^MJG+T]D8_IKJ 'U)NVP_DX C*R,/VU:,'B1XD=U)161],68
MD#3LV(T;G K.@;T;QE*/R</*PCB5?%EW=%MGB<#[WSXS07N26#'-6)LZ'#TI
MH^RSQ/FU\\RA#9B+<3; .9,^-RORQZ9AW8A"VR!!S<*5I1ZBFK:ZZCC#VAV'
M'UIWQR3?)Y*4GUBO%VKK<0L^>LO/0!-D5Q@T/Z'TN^Q=/:BCNQ46'DY<;#@J
M>ZRQWB":)H#T*?4:MCONUJ&IEAAQ7;2]+W87Y$G:T,YV#Z<O7**J._)J"*=7
MG:>O-;<V )NF)K#T5C<V8.-U7>9),_6+!KE"2EK2?1&2)?65KL;CR(XF06 B
MXO)128T-SH;&TX""I-:!B+O7?[Q%SWT+4U=^K3SC:WN?I_SSO)0VP,9EB%L!
M&7DUP9?'PK1*H"*<?L]3W W(@K( -"2\1@=V%T",%$[6(UMZ%JK:"8!G*5<Q
M'6(MQIOK<F_'C:,A9'&_?Z/;$ "_)\<A!+SBNU&)PTK/'&NK\6-35*: #TT#
M]E0^,H;FPCA*VD!5\8PSP<3!':VM(1""T.G6*>P%LU)Q]0<9V<L1J.(-GBE;
MM2Q?QX=\9J?TB4+!!^);=)Z-':;&'[U*\T&B-K)S0_!WZ#V='7UK,R9/&9^S
M.RPY/PU'6)F'VA.^JZ2J71T?T=E:VX<?*OK6&?@./'?U6(A:^3Y6YI.CW*W<
M^QCB_<]1/Y?RM2IR;>;K.ZZTL+0N;6JM[F5R@E:!L,Y98CC0:JY]>59(82FU
MUDKQ,^L#THPYV\WT9FBY^%-*QYB/0$. 8EQP#=[['49^<4U4-QDA)0Y';K<L
M6U"AV$ , #QECF6U1LKVE'N+LIE2#OA@,V!T8 A4(T&$3]LVE:T!M=O>IW=<
M3/\ 1''B?7.(>1^2^Y20M-UZ3H;A8NM9-G8]R)GG_KTP&1[>^/8KI;TT4SQ;
MC-@W2(G7<=98*&H8@'A5KA>SHM8&U R=56#$.0'+#5G;N$/:'8<?6G?&SQ+U
M?3R]*C5*M+V5L4N>\7YU*9,%Z!9@*C^(/L?1 1LT8O"IK9)E8SD6,-Q2;;YB
M<>V]BK!0O[9M^,M3Q)+-OS?CV[1 HC35^YF&S"*^0_2%,27'C3?:Z1TEPSZ\
M4X5[B81A^XM<6C(T"<WI$2;M*N)((JRU_L=H'Z2'68B59-]DI7WP5UGG;+#2
MJ2=!6H-]!V>AMK/L._UPCE(>CW.+J#L@5G+I(.MCE_K)RNJQKI@*';!8OU5?
MF7HO/SX@S67\;#6D@>:+N3A2M#K'''6I3@:H2_%)<EI!N.) XLWKA38A[0[1
MVO77TN1?7)ALM2^W-;(<OR] L7Y"XQ#!#9Y^BKOKHLF)M Z.GJ]*.:"CZSI=
MF&WOK.1OE3;:4/7C%TE4F'Y*7'Z/"]@P[HRI68,S1RY](N,7P/ U1DV:F55]
M=4,BFI("P=D TKY4@$65?\H;%.HPKQ"\\T58"47*%VK=HB8A3LY0RB)]RE>2
MC<M#4UUV:H]>$,QJVK<6OOS^$5*F?)L<X2=/L =UKKMOFM=X!OHCF9#7F5D6
M$)I:4(YSS<4-;]N<_E,K+?/$I94E\()A=8LE1RS3HMUIC'E&6F<K?5QV\KQ<
MYVKS+=GKZHV0U]7N92A^2KA6K8.K/)>7-G(:JV8K!;0)Q4'5374QBKN@[ K2
MN2D(AER#2S'3U'TK&]XAK9J30310PQN.Q[R>/H1,QKQ((X,7M&!Y/ZD)'(EW
MBRX(;^B,D'#7WKW05HJYG:1]A.%.QR](D.5F\W(*ANG8A6G3"\0LAOO"<M;#
MQEH^5,W<D;) 0="Q8"E+/V"OWP*B7I< =A?SC6+LGI4]=L[(Q+QZY="^L#H_
M-/0'T%1Z*MWM&:PX>M+'PPU8$KLO$*SXKM=P@PZV-A^>Q&$2F.&2-%>O.;+8
M5!( @6#LSO6_736_!HT%  ;@-;U3QV$6>H_)\<O5Q+U1D;6HF1Z)S[J7.&0Y
M67>5*5NP'ZJ.Y0)*D,5$CGBX/M'!5'CRUJ*)EJI.37>X4@LZS"(5X2 ,;NU;
M7T(ZP:'3MK$*SH/35??A$YX7Z7\SX&U.;*JDBI*-H%L"^*&E@2!!845MH9YV
MPT#&M@1.$O)BG.2R-KQX9V4UG-!?!;W<7C56R:NB";Z;/6H-GHS<;O K)'CQ
MVY=L13F/HHM<TW3J4?7^I,RHK-'.WVZG&ZW-JXMJ?N2\]6N6<\:#1((@BV6I
ML$2T9 K6PR^;# S1=+&%R%"3<JV5F(Q-PU"Q=V<6:GKM@5N]!4,_ QQ];^3_
M .4]=MRDRC&SBRUEFZT;MW<!N;M56P*[9&E:O:UN!?D5K79*,LG/56T'OV1-
M@K0EH35+5LD&(DQ5P 0&OOHSDN=]8!9&E@WQ\_JB*0_)M<TBJM0O\IO3(5]Q
M(NV"RN(I\S6%2NK]$4&A.<EP$JJW/@JTMW6.FS?7C;@ $#FDL3!@[A C8FKV
M][MK1AJW5OU;? Q?:<.^)6;]"$1XMOASJG2^F=)<.C\T=.5,;:6CYX"NX6&K
M/+Y1VXT.I(8)7JD5(ARL4:$2S@[E0D5/,FC-2.!)0P0)*\F)8;W\7ZO"9[,&
M8[WN[\_&L3]!]1DA%2P"A&>+$]PO9@W<[1J)>YZK6CC@ K#APJ$J.3$U>#V!
M]82'#B_K,E&1ADIBZ4,AW:*K5C@F7BU"&NSZ:6\:[O"IR2UPW(15)CY.[G19
M;;D+7IW5!_-.A'!SB^H=/;G^P]F>UZ:&PJ-FYRVB66L/,OV!"9/J%!'1R^3E
M0EW4D,L5B#I6;*Q?1F ?7CN>T[78O<YV#[^O.+U'>L**,: C9 48MKX#JX[K
MU*"20/\ 5-CXSU@G]4JXZ7701I-]C90K$AK>**>*[]Z/FFTNZ!?G#9F0V?1K
M:.^\0J)[^\N?+E&N2+\FIS!&<4]PCZ=U5AF0PO.%]8J,/Y/;D]03S5N]?74.
M,M,D*'7;;8;)CUS4HJR]]NPKX,>?;H00NA9OC[@N@&V@L;Z%]>-C]U*W%KW^
M TBT^P>F:[U8H_GJ74NF<W/=+@=0[273=$*Y8W4>B<KYYR=O6!L#DDM-(?%?
M%<N3SE(SI6D.BF&G8EJW_LNY,+R+A@!2G4Q'K?6 6P9G;[XZA'T=Y]:#)@\:
MZOX$OSLWU=J2F<=(HSDPS5UCV)1?9<B:DI%%0@"*?8;P@"A(D>2%61\ZK>*T
MR\! K+3,T3,"P>U+#0-W?56&<UH"]^QCV^A&$9O0]?>#)!@=>U=;8#! R#=\
MD?JG+!-FEU-=35I,$='HQ".;TQNI ;52$@I26[8^XG;$UJ/[4 E*!4S1OQB+
M49VK=^%@VG$6K#/L._3;UV1FQOI"DQ7^IL3%T#H+<[]IL)-_HS@3T2QMTN20
M#ZR56[5 2O*(D %BIB$M34MJE ;I%8"@X;MS-IFMDC]R@&FC: O2VH>WG0Q,
MUF  %AU??]<;J^:C,/$(>(0\0AXA#Q"'B$/$(>(0\0AXA%A _P"Y=7_3_P"\
MS>06ZU>)CG38<AX1\3GN;_A:^R7^>OH__-)+S]!] _U)T3_I^$_DHCR^*_.9
M_P#BK_Y&-://K1P0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B
M$/$(^X/FO][GG_\ D0I_\ '^?G#&_GF+_P S/_FKCTR/R$_W4^ B:^=4E@YT
MC5XA**^">@C2)0/2-48!APDOSQG!V1MB2X,S#B>:"+,LWQ*F_P ?3$<F=M),
M2:RPSPPSPR1Z^3^1_P L>COEK@<?TAT9A>E,))Z/Z7QW0TV7TM@C@9Z\3@/8
M^VFR99F3/:897MDA$PE*PM,V5-ERITJ8@>D^5'R7QWR3QF#P72&)Z/Q,W&]&
M83I64OHW%?A<E$C&9_9RYLP(EY)Z3+45H 4@H,N;+F3)<Q*C+[4WU:K9L?1^
MG]7KS3_0^?Z/TO@Q[2?1^E\V?F^?Z/S?/\V?F_M_-G^UYZPVNU@_,M'FX]5J
MI\IGDLM=(,L_(=%2P"Y?S_H'+)977ZZ"ZJ<-^NG&/8#HO.X2>5RI,O-?/179
MP<E2G-2(SNBG3,-@6M'$KMX\#GWG;,:T=K<@+78DM<;/')DM7G]5/C%W\]]K
M.CF27*BK[RI0"<R[9U!^Y*EM2CT<LQLP!K5;O1-5[1Y3C* LU( S:/YJ;C^V
M%IJ/V ;!="#+@6P(N7F04!8D$DM5F\"YTT.\9*;@&H#EQX=T3IH]V?7I.=37
M.#YYXK/H8S0 1J%;C78R3 QDR5N]0IX2A@Y$M6G8?O<H2:;G%>,J"@KV!I.<
ME&(*C;]H%$V -'9ZWIOHWGI#*;Z,[^?HQU1'O/ZUGC,(,2W-=FSK=71)J_+R
M+L%)>23C6WEN? %[I#-?1*J_S=BN/H(PF6 +R2 %Q3*.LB3%.A:TUTV.;4!<
M<7!U&[7X"\,AX=M^7Q:(EQ7WB1>@J'/K+56O1] <UKGINVF\J2.O]6LKNK?R
MCC/0"-]MA6><W?N8&HE.Q!Q=0I?OEER<9O5OY:I"--O$*:H-W#AWN*;T'H;Q
M5(:UN) C#&?E'.":DIU]3P[F#E81T6\4F8^5=H3UU,O\Z$H1Z\/Z/=L<Q*,:
M?"3#=% $*)&12(P18WDHWM*Q7>"A*.8T<#E=MZD:_76SLAU/97RBR[_O#ZWC
ML6MK#4V[Z_7JH]?VI\BZ]?UZ)-;?0G+HY^3;44:SKUD=&_LJTM6RW.LLHRE8
M9%V_;MPA3X8G>N:A+68W&O'POX/,AV\#]<1KK_N6FI*QZ].BZ0EKI':>E,"Z
M<=V7F?3[X[GRASSG/4.B]%N-H&@.!%TUB&9Y@04KE-VF RJ%B1B:C(@J-0&,
M1M')+/47#L^S,Y87[*;4)J0;@6>YTZNS2)XO>X/#VAT6N;"KW0]>AM5PO6HH
MQ?B?9EUJ&4P5-/($F)L#,"$,N)2=%2?5.6!R;HPJQ=G*Y&42MDN/*#Z5!(_*
M# #G];^+[V>%)%= .'9ZO&FKG\I::3VKJ*Y)S9%NZIU_OXP#G/0'2D5S9X9T
M<(@YLM=2QR3["Q0:8"T[!'616ET:1%:CM'E5)THS!4%&-LQML';0[G4&KNU&
MC61P*_7&SO%O:,QVKEO1F "!YM7Z8DNKRA!5B?HS# I-Y).H"BGVU$1(\V']
M*!"):):.2_2(\IW+P;T[%L- ?6"*\TF3D4KH2H@VY"UJN7<]<0I8@$TU/KCV
M/%%)/R@+>\A[#2'Y6FVE#GVZW/V$[%T)AK3?8+;[']2]?!1_F00CSNJ6)24*
M_(V7HQ]<?:Z.9I4;0E0JZ72D]DO4:T5<T!J+/?:HMO H#@ FKMU#7[HVOY-W
M@PY N\&>A<_M<^FX?T]I2KX0&1O]/,DEX&BI?0AAW0>HK^]ZVQDU]SJ8M)BM
M3:9JI>"40&+,LFT%FPS,6=WJ+W)8#D.KZHA39B[MWOY1 1/R@/JT<WWT%N;=
M<TH#,&FFW#QWLD@SG@7#BSH,ACIY?1"V%<V$P-*:R5+))UN!*5<6*M-,L^BE
M%(=T9C6EM0Y%GX:<15J0R*X=OHQS:^^_K/N/J$M&+H6U<UM5U3XOR$=VUO=&
M^M-P1!UWYB/WYQK>Z-#7<V5=7R%A.@,P#+)\'<(RU11@9?M 55H"U*'5QQ+=
MD,BJVIQ]=\9]=]UO6YE,K0*J\DQ%IVUGLI%UOY_T5'7W</6 ,[-,T)S2X*@1
M;9D[0,H&;6&\,5N+>_Q%_2,GOLXIWV_7+U8 7KV'@\"DUH]6T\XCHOY0'U1-
M:R;"^BE[FNU"I;&9BYCU;.S-?N&55;U5$V/*3B5R?JK.[+*J0Y\L1E70>TW[
M2U<!PFP;#0$QU:@"E]*'G0-U][,BOBX;G&($^[ZCE(9.B&U#HTRY5]GQ'K>O
MT%[E72[+IH0.VU +5)MR-<7(6Q=R./L!"F2^O!J>MC%,?3#0$BAD15)P*+[N
M'J6 '?U\>LEET=CE?<:Z_?K%N*GM3Q!TB9K()G,XHK":6Z-(3,H705H2S<\!
M32UBSYSLJQJXH?TU/ISZ0Z[L//K#(,W@*+MZ&Q(.:EBV8TY JSFPXUIMMKNT
M"DAK;,]B;/%<S^_WJ]2J#;11N=06Q;41=H4&/BO:UHM(M'%IQ<Q[_8$G^?#2
M([F65+GKXPW>E$JU1'$CTYC^UCM&R)MUXSG0 TI76NSOVCG%""=O5^L1G8?=
M?@5BQ&+@O=/F:I=<6]>>Q< [U+U+ #8? 4PZ;\NCYMMT"-"VIV:\6KONN:K&
MQF>)5P4RV[X!>0J.@%[N".0L7B9#PYOKMS>D8;3W]]5)HKDE3HA:_-&2'C M
M ?S;J%TH]2%-V76G?YF,K)LE[I@/,2<T$+#"BP'P=$$'E9;Q"LN6QI6[74=
M+<>=CV==89%;=XCH5_>/DCDZ\*5>1$2;\-Z_T:--W=*_/^EP<_AI[\4>>O[U
MA'1[*O20K#G3JKP.$FI3G]C8S6X=&7Q5<\O&:(D2:FP#B_813N>]*1<A#DZ
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MT$Q>N%\M&<Z;S4*-&G$/ES+:WEL019$EVJ -BQ+BG,Q$I=[T:S<=X[TGNIP
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M(>(1]P?-?[W//_\ (A3_ . #_/SAC?SS%_YF?_-7'ID?D)_NI\!$U\ZT:AY
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M3AK,I"Q]3U'T-.:*V1=>M3KZ5;7VZ6D^.::&,D3CAA6Q>B2+5-!SO J)#,
M=/OBJY_3?U^ZA0M,]JQTHN";R[IT=<&6WIV$!U!JZO:(&&ET4E2W(/PMM)/)
MTU%7NDALI('1.G!8V,;4*DJUA2@< TIE+ZMKQWXB+F(HP# #?3T8E<_K-PQ+
M6FJU?K-GWC<VRB<.]@W8VTMVS9R/QIZ(*,"^C#Y++D!Q",7TY7UH IQRK45A
M,8LN+^[&3,-@6( >E?\ Y(<!B:..9;D.+,HD -LVA[8PG_@QX"M2X;+]ISI?
M4;M-OZ,:,=)8*]+IEI5Z 7[&',=CFGOP4&0>IOA<ZS#:UK \(*H$2*YO4^Y<
MD@#%#%B[@/H==+V8A@QX0SFS#A3JI$SI<[X;UY.]C4D;K>,K76G1J =HT@OF
MZ&UQLLHB>E'8A-^3-?:M7PIA5B."<+)((FETEL1;S[V+F-U'>Q#FQJESIQ?G
MM$)((T8#Z_,@_=&FK3Z@^OGK^V/CR_-/2:'&.JJ?,^7$4I;.]8;CG5'>]T/M
MKDYKCB@\\72UIB6&N%W!UQ858H11T1=9Q6M: %(OW!AB.7H 3<<@[4TN6<TL
MUHT%$B@!(/4 W.]3$E]/N#>OK@B\]/4GI@["T\/RO!*Q;9R?KZ>ALUN5![.5
M"HXUFI@YJ0\B5@1[YL60&[W 4@:!"E@ U0%M7HTWK344=V%7;;2L%*(-J>//
MN:T744]!O7!@4R"*S 6QG3Y5T*E+P Z^MEVESY# LXAMHHO/-\$XK2HLRE (
M2H2K4[&UTLNAQ*D1OV5<0+$4PJ0Q%1^B:BU:BS<.^,YSPXTOSB+=3]8O3_DX
MKJO<^BW;?+U3>]/T1I887(PM!4]RLOJUT'+RLZBMXR-9R)=*7UXT''UI"D=Q
MIMW!J^O[3N9\<>$T9PI[!C6O.C;TM%"E%@&/EL=&B9HG&^$-22_<R469_-:4
M^O)_66]KO-;/9<]>KVJG.^S++-69SD.<;ZV*.$PO&+%P96:%*>1;KBA].M((
MJ0 V_)<$#5[OK1N.O"D"2&+"Q' @:7]<HH?6CZCKL[MQCFO03LW0V'G;WZU<
M\IL]CJC/S?D-=C+LB?4Y6*:=@!5(YT(*]%1[*P*$DS&IIA(<\I)*QDM&F"%\
M?/>H6H[EC=NO1O.L7WF!-@02S.1=^H#PB\%7T;XK2&"_OU2:.EL$2#3YN5(O
MKRT-V+"3%S]\YU,BQ[D[<6\ZEH ZET*&/6U#DR2LL<Q8X3(E*U*S5T*))"J6
M=CRH'WJ3J>49SFK !R^K^/K9HC2_ZZ>O)?IC'&$=>US]Q3,V$1DZ1CHG2(G^
MLJ44_F3/8YC,]S8T'V$_5?Z5SX]$/KV,DK+*1LM]0E,^B& ]0@)(K07=C<:T
M(Y[.(TZF!8-W.[N:\.6\=8;Z!>J$T)Q5"+;#2^Z;."*@X(RA?6OS4K5#,,XR
MNCX+TIP]JALO=%81%F,A$U5\!"L2K9EB'KX84&KV]X5-*'LO38^=89U!BPK;
MT\243ZT>N_*>C\7I#B/0@Y"FVGF_EB#L^/1%%WZ 'Y494&APN!Y;=L?8.7T,
MF;G*2,-S<838B11JAH;N9<D7NRI)#YM"6 ()+<SX5B.H@E@18[L=*:><8?J?
MIYS<L*>A2X2VMN/2+'9F-/1^J=#;BW+Q+UV<&RJO67T,A5B6MR>WA.Z&X5=@
MPB6N*IPL).$?LKW&@PQ2' !J#H:$%V(%7X:0"C2E P) JV@?B8E3WZU</!>L
M2AS)YO-E3EWKNDW27W@&&R]=HE"@>3.?/7DP<O#=+9-@ON'/'!]JM>VT-PH7
MMLA$I5DT8<TB$%+AB+FA ZVZP-;=3O HN2&KOW;6CE>_3#UY[ :TZ :!G,,!
M?XM[[Q"6(L+)3ASJ;S].*AXL[;;_ &:/-KG,T3%F6A#1.#B0&L9"%0YG:>[O
M06%P"27!8ZE]O0BYE!V%G?5JDZ>J1^>SG*>#7 [!T_L)AY5EB'G9!*Z;JDEF
MNH*?^3+]=A<K20_!5:F0M%ED?6W;9X=Z40PKI3/L8& OBBT$!A&$,:-N VVK
M]?4]&H02558 ZU\=(Q+ H<&Z=>YX7.]#ZP=!GNZLZ&$3[CF^[I#9UOA_6NH]
M-R'.+5N/,%6GSCH'*W'*_=@R$!F%Y*55*]>95 >HB,YJ!8 TK1VIJ..[N_ P
M<N: $!W8$V%7&]SP)9Z"-C:G*U>N8YPR6)#YEAY:K,">LGCS 4,%IAC5"M0G
MIS]V[/)*?+$L*0::<J3S/<S8BLSZR:[V[&=Z  IG#N*,6?2I)WI6_9&7O05^
MKK]:1K\?]0. $F:I6+XZ!L3O%F]ZY\-A=G; ?F;80Z(M=7;''GF:T^1J>PV^
MATP;#7VNV9=88=RBXO4H$\HS+]U1R<UJ%T\=;<!O2*%*8VHSG4Z '>,45]*_
M7L=:K5K5OJ="WT5D$[.>PSHCYIMU]L6V1H[ '*]/L#;$D=VS0.[L5_6Y-("$
MW!61_/[NMM4JKBG!JC @BE'+ZC=W';PNT4*)L!3A;2E>IA'2]D?5[U8+&&#O
MW;X6J#YX1(XO@*7;[,94L65F'BR_7'*R?5(,["P%0?2B:B 5@58A&1-FZEX8
MN3M>\!'.0*44X=@XUNS]AXD6-B256 =GH?0]'E$!<$'T@[2$[_U*5[< @IFY
MF;;?90LIMG2D&Z1Y,0"FN=G@;^'AK#C@RL&QP9R!W5F(<->4T\OO0B: /;8F
M$:65H' H" 1J]JN=;CCL8.H,&&P#<F/> "_.L</6F;TC>'MWW<.H=3HG9U,)
MQ!Q3D2?NX"OV);YL^N03[DJ0U$ US/:Y%-UZ0W+#S6XY=9;8B4S= NVU:K'M
M7CGO#34FK4-:U/>?OOO &@N35J'>[1%VT3\GB[BJ:+$],:^NLJ/UBUB;G-SJ
M2THFN?\ <DD;UCI/,)6U>!ZJE.PRH7-1#U!R6L7'=#HJJEI9# :H.4E7OZ!(
M9[UIJ=-"YH+L1K6#KV=F%>&M^^T27U@XR-9.NW^Z+#QI^3M/QWU)4D,=CN:L
M36C?8WE1>V*(]RGLMN&SQTZ%KAZ=J0'5#V-&*5EKM"WHC)4P=/L/RG%C1]C]
MS-<<;-!1#,S$L=/$=D6]8^3W]3=!O-ZJ[RP<A&>4ZBLJ+USRQ,E]%VL!81NP
MZZT/(/ZJPO%O0R$ M=V1SNG=#34$H&3D1*;ZWI:T02*MV<^.QT(^J,YS6Q?0
MVB7)_IWQ9+V8[%*LX&"K@S\X=&DZTO#(Q&SK1ROKQKNBD6N7R-Z7:/-;I+ 4
M+6*%+2J*D'30+L-&NOT:(VODHM5F?0ZWUMZ+P*B6H* BG$-'F-].N$"#+,?H
MKA6,FW!^D@CDN[*;ECL#>LE31IUBBADN;1UY+Y!@)RU9H<:R#M)HXJ6T,<,>
MN+EY=AXMJ;/P-JTBYSPB&L?H#ZWMDE74Z#:KHZE1Z?4K!=G9@U&5I^P"^@!'
MDG0UQ:^NB")81T]PH32!KH^O;BM"-RE8A.KK$H>L:5YTOWT]6%(%9TIZ[.[?
M>.TT^B/!76NIQ-$+N6M*EIVNZEIG0I$7.V>B.R]T=OF.W:V(<R;F796!F[.X
MJ,3MOI5G![;96B1,-<,=QV?$^M(9SP[_ #([HS7_ (,^/Q%R+(.M= #-5AKG
M< C2(>"],XF$[9WL;#;JJ=C7.T%,-;O=_P"N16A!"L4HST6Z6G)%F(4"P,C%
MF<'F'[:Q,Y9B >;^<2CG_JOQ7E\2Q E+=\7"H=#TZF$TG8SQ231WQQ&3U\F,
MW[16_<NEI[O-I[%4CL4LW-R1VQ89KV]@Y/+=W%+EWT8T^/= J?06;Z_'T8Y!
MGJ]QT1<8+U($1CLL[^N]-,;['BTFL[>J]E=.]A;T>F]G.L%>OTM_92TM&+&M
M2Q1M0")HMA].O!H8[BS6/78Z_<T,QX6([0!OP\8CS5ZA\P<VDTZ,!WJ=YEN6
MH[JJ3FZ4RS2<NL9?4SIU_P#)G'9LSQ+M0N\\\2S)(58T)A]ZB_36:P^LI9G
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MG7C -&*@%4+D-'!7I.9(D">%DP/BL7ZY9F5U)X=G=:C:P*QHX[#QW]6O'?\
M6'TM]B.7]NK]1Z@VH%X+'8@,6UQ0,7[M.PY75;IBZYN D37Y%S>F)W;]V5+W
ME@8B#X[8&K,=1JZ>\7!HXE8$N",JK4H>IWU]5N8I0(8'3AP/;P&_"*C,?)N]
MN)OG1W#67D<]AAE[I41#S$Y-!U^2[/9UQ\I2]!PW#.*JM^^1 %22-"#33&S
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M0SY1?L2/XO"?]T/G#"?K#^XO[,/SL7H]_"@9_FYZ%_5KQ_0SY1?L2/XO"?\
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M,:O+;+\I,V+R^195HM1>!Y5:@W-EN9(Y5AYHVGE5F&]3^Y]DMRU$#S)PB6V
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M]Z'B2Z\P%M:IU98&H#0*@"^E$R-GM3TS5$24H7!T0T8Y1=F KJUBU?A6(4D
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M.638I97-Z]K>GQO\O@2GI%::ZL@R%NYA<7+X(P?R($:,#8O*A:X.+6;&E0Q
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MM$Z8)TQ").'5BR9N&Q,GVF&00%3Y FRD&?*2Z75)"V"DG_Z#CAYP(&4$J4$
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MMDW)5'\HZ$RDKS.F\SJ\U&:\YHN0CI5[J?=>4M0JL2O=-^H/-427X<[,):V
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M]=R#'>&%5M@8P,H8MS+M$4-(G:MCBPN[O:FLCQ=RA%MB9G( :H/&K.-!Z=Q
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M"'B$/$(>(0\0AXA#Q"'B$/$(>(0\0AXA#Q"'B$/$(^X/FO\ >YY__D0I_P#
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FSOB3X?T_[+&OT?G^G)OO_:^?/]KZ7_U__P!> &]:ZQL!@!M'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g549728g12d03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g12d03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &2*^9#0X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R-C S
M-S(X' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !#)UP7-OLM%:8MBYS];
M(!5-.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M           $.P  "4H    & &< ,0 R &0 ,  S     0
M           !              E*   $.P                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   $.P    !29VAT;&]N9P  "4H    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P  !#L     4F=H=&QO;F<   E*     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    &.$))300,      Z;     0
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MU?U6N76)(6IY8.:'4N?=U9FZ75-#B\N<VPU>
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU=<C,S1!57-TD9.RL]+3U!HD4UAAUN(*,C=2<;8E.4)W@29XL49R=H31_\0
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MJX%*O4ADZ:'#EQ34A;AN<R&4%JP $DD<3.Q2-7W$L5<HQ)56"J'!4,W!(..
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M$!ED+YMDTN+^"1WF79CL&IM2I<O(B1)T_C<.P;JKOCVJJER63+8*@@ YIN!
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MBL?-ZGAC/BZO/FQ]MGQQC.<X0CRX>AVQ!'3."H0CJ2XV@R$8&_ .9'\PPQ!
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MM700=J(P$)LQLM8S@$NFOQB(V&HEFOHK@OU'CB"/T]SEMK.1N 7:A)!7#$X
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MK:Y]F/;=#5W52^O/:NQ:UV=0-7V;2EFOY74M*NXG9&M36U+AMP"P7H,Z>+%
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MF?(Q((P"<D U)7)&#C&/4#V]A-;4]C>MMAW1=-#[)HVU7-47O1-FMY$:2?I
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M8'.?9SZC[.^;%Z>=-6.K#VP#,^S:\M-GOZ:Y"DO:SZZ:BZZU<2'JZ"?N,6*
MUN+67*SR,HO+G&2%FMAR.J0B*@$, 1VY#,JD\_6V@!@%R1OEDE8EL9RSGU8
M& ..Y8\T"XS\_L ';Z*Z)/HZ():^N-!5L(BTQ;^Z87N2Z237XRG8)4-NRH[H
M11&X^2F$/CWYE3: *.J=;DMQ9BYV!JG64QG)$Y#A]HR(#!W/(,31;CZ\X8G'
MM]?-3CC'SY__ ';OW_?54(]FX20F/JKZXZV?6<Q-QIW;'ZT8H=43/2=1LQ6Y
MFZ(YN'#ORC=U(C9RE6'%4R#2>5 \M:7<5@TXB\OZ5W?I+U^GTNJ&(&WI]/=T
M\;>IL\N[./7MR34;?5GRYSC'L.?LSZJLP/T3#B-7:JUDG8I%^/J[N,>[>QBZ
MJ[%0\8*'=V[%W2NCOQ,%5(AP(TO83X!)MM]^0Y&&-3\CD.REQF:-<,SL^T O
M"(2,GL(ECW?.<*#C@#Z!0*  /8<_MXS^[ZJY6[HH'MM:WK7'=BDH2-X=N-0=
ML)DINNQ7EU\GJ0QH@O%I4=I11M)" ;7HV$Q(,NKBR(6+#*<;'R,CVDRBW#*T
M9V@].%X0,GD.)!N[<$=3MZ]O?GACOSW.>W;&,?9@5KCKWV3,.@;SIFV6-YLD
M0>OMY;<WB K^='Z]'7ZPF=R =EA#P_:.[84A-ZV+D C9,INI3I^![4 6,C#2
MHTT\V+(A=7O"T;)T\%HTC8]1]H"%2-B9PF=HW<G)R05R14;!G/SY' ]A]?<]
M\C/;[,;=@NEU$9Z-!NBEO/&;30X.CQVD2-KAM,UVQ38 T*R)BV@<TVX4C!SL
M.3&C&1N,K(1X9&-'RXF4RA2',FN'-R;D *YD,F.X!)SCGN/5[?KJP "A>X Q
M](QBM>MC^SJV-OO72:5V1[83=S$:;:J%=]*$RW7W4$.M46VT%BQCV[!=Z).B
M'Q6VY5R!V@G7KX,-S0M7)"E-O5^O5@VS',,W2Y6)MT4.P,K+(!+)EE?:<*P*
ME-I4,A&2& )+#(,%<]SGG(X'!_CQP?F)^K.ZI]G %URO3I:5?ZN_9]8=CY'8
MHF]KS0>K=*5&P3,Z7OFEAM(%4_7,0;@( %B[S)L#92P&KS87S+9#"R*(95+
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MJ;40Z@P&<^^&KBK.:L.!.<2Y:Y#%W$*B:1=KS;V.=P =@AX#2 >8EB.3A0"
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M#_C/_3Q\./"/]H--_3C[J?!+Q+^1;[]%_P!:?54UY]+0_P",_P#3Q\./"/\
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M4IQ2O##VY7_A?HC_ /SVT?\ MZ+S]%]SO_M>I?\ XT7_ (Y*\C5OD0_GG_\
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M?O6N?/4K&OZ:/8>?^ FW_P#[R+_]C5'GY-[H7_ZE8?\ X'_]F>O<TK_A2_\
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M<<,TQ2/T^U@CO8-D$NZXLY9HT8('P)$)[EKW0U2[C!K]@J!:#72)% B'<7"
M+,>206'EFENQ@+9!9Y\-$C0I#$XQ[FAJ)+;6A;&6$YD<Z=<]T1/#GB"UTK5M
M!O[72+NZ6P@\0O>:88I;HZ?/J320Z4ETVJRZ;!#;RQ76H^CK';W",CQF->J<
M-(\$MKFB7.HZ;K-E<:E:VS7L^B+;:@)8K87T5@B2ZBULNFQWT\LR26UCUR\\
M+!E?J'I5A@O82 1ASY1&AW,0[FI0;W6!K<*&<+6ZJ$Y[(R%,'00DN:N#.]]E
MP$3QY147 R.0BS9LIJ)B4[%\[3?=7M;RWNI[SPQXCT]SH-MXHT2S6WM]3O\
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M_']_<B__ &-4<?\ \XSS\F]T+_\ 4K'_ / __LSU[FE?\*7_ .X/_"*]K^?
M5ZE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE:FD=$;!)5
M:[:^<N=58IUKM-FMC#C%=.HLD287M;MP@1)$]JT1X4B"T2Q'B$4,P8LB2-]X
M;C/Q9*VY+?X7>>YCXJO-#\2>%'\1Z'%X?UW7-9UV)XM(U1-8M[C4-=?Q#:V\
MMU'K45O+:QW@BM[M8K:&6>SZRQ2PS,DJ?KUM[H'AVUU?0?$BZ%J\NMZ/I.E:
M/(DFIZ<VES066CIHEQ-%;OI$D\=P]J9)[9I)YHXKH1-)%+$KQ/')O6*WR@K\
M)NYC(LHT4L,ZRL(D; ?AD5%J\*KXV6Z1DW9VPS)8=@<^IR(X1B!S+$QJ$1@J
M;',..^1<>XQKT^FRVR^(K*"?4K[5KK68EF\626UV;_2;+2;.X>[F\2OJUS<:
M?%:2,]O)=P:?J,5PEO>6S):1L_I0>ZIH\-]',VA74T-A::9;Z5(T?AN.>U%E
MJ5WJ5U"EK%H":9!#>RW,869+66]L9(&GM9U:YD1.]CK59XS2!,.SU-X--L&L
MK47FE*M+F6ELKKV!5QRX08LDPVS%%D6:TER-[Q%>D#4SY\1'K-2W'D]*^X[K
M-O&FGVVMZ%)IMQJO@O7-0N;[0Y[C7$O?"5KHEHUKIU^-06.&QO$T8/#U8))K
M(75S G5CG=TYS[I^ES.UY/I.L1WT&G>*](LH+35X8=):S\2W&KW*SWUF;%I)
MKRU?5"LO3FCCNS;6\S=-XE0W3=*)9Y%O&;#H!D,+M$,#*JI.#9ATTB!. 7YS
M1..T]D=.@D!\\:00Z_$F1EO(<:E28TF,XE;3C/Z+XB\,ZU-K]CXL\+:CIUEK
M5MI<^AWEKK-I<7FE:GI<MRM["DGH=Q;75I=65XK36]Q"TBNDTL,T+J4:/XC1
M-?TJ/1KOPWXBL;Z[TF;48M7M)]*N8+74=/U&.W>TE=/2H+BWN;:[MF2*>"58
MV5X89HI59662I[IHC9=\G"I]BV&%E.,QP&9K4,18 P^+,!VR19,J&BQMG;B$
MFI,5<,2VJT9,9@_#TDHK2)DMW+?PWB/W,?&/BBZL;G5O%NFSM'%I1NDM].U7
M3K6"XTW79=8)L[&SUM+>]CF@:WL%;7/?!K7T47EO&+B>0K]=H7C_ ,,>'H+R
M#3?#5]$LDNHB!I[S3;^XFM]0T6+2L75W=Z4\UJ\4RSWK#2/01<>DFUF=H((P
MW$IUAR3KPT)\H($%Z,.VS$FD8H;&72#^Q+5!LPYR4TJ2CWN(*S :@$X<AU6"
MD53K2'8J%^":7WN+>FZ39Z:-6M;66&T\>075Y;Z<-]Y+XMUNVUFS:=#.O7M[
M)K:.VO;>9V%] 7C5X%:K6GNJ&TU*YOQIMQ<))<^#9H+::_(2WC\,:1<:5=+"
MXA/1FO!<O/:SQH#9S!799BO/''7>TE[ 1L=EL=5A22IRD$I,2EUZ<$C,1:A7
M;O7EHC.2RLY_)&:W;&9+4]S/A$]P3&2RMM+*TV'N3:S?ZM=ZQK.L:';SW^J>
M&KV>#PYI%SIL,4&@:-XDT=DA>:]N9#=W":['-'<M@0>BB$1L@C98/ND:79:9
M;:7I>F:O/#:6&O6L4VO:G;W\KS:UJ>@ZD&E6*S@C]&@;1Y(WMU ,QN6E,BMO
M#8AOK9?41X3#5SIPIP!KC.MP,VO5&<)G3!R+%5S.9A^2DV\YF20@U^2-D*%Y
MB.CY!247&OHEN92GSD]Q_P 4+#;Q)XC\/6+:5X/^!VEW&D^'[BQN+JS35]$U
M'TC5IEU&1^M=VVE364QL3 ]I)?7%_9RK<, .UO=.\/F6>1]"UJ\74O$X\4:C
M!J6LV]Y;P71TS5['H:;";!$Z5M<:E%=1"\$R7$=I#9W4;0KDY6N]<+  D@IZ
M;*%>E1+-?R17#L,[,7D+L(>"ASHXPH4.3S&38=89;PTJ4F34O/R\R9+*5(RT
MONT?W(=5TJ;2[H:UITL\&M>*[R_#6VJ3L=-\6VFEVUS#8WU[J=WJ'OEIS:<\
MEG?7T]T)99S--&&0QMR:I[IFGZC%J%N=*O8XIM*\.6UH4GTZ!1?^&KG4)K>6
MZM+33[>Q] O5O5CNK.U@@Z<<72B<@AUDVD]#S]6E5$2AR&;5 J46E!7XSMKP
M^H1&FIFY=FQ3-G+B(67%LQU-CPXZ-%AO^]NQ'FF)BXB?8]S?W,+KP3>F[OM3
MM]2:UT*W\.Z=)"^NB4V$%P+C?<0ZCK>H:?;EBD9%II]G#!!*9W@D2*=H!YGC
MOW0+?Q;:BVM-/FL%N-7GUR^CE31NF+V: P;()K'2+*]G"AY0US>W4LLT?169
M'DA$QC8_K86C7%RQ*,4Z$RF^7:[(*AZB_$O9%JVN&U(K)NT9,Y;E@(J3.$R8
MOPY6)2(;#;>(^<8<1Y%I[C]]#XA?5CJ/AZVB7Q5XE\3+?:=H$MOXHNTU]M2(
MT74M;.H%)]*B&H!9X!:?'K;QJO2X9?2N?=.M9=$3318ZW.Y\/:#H+6=[K44_
MAZV?1AIX.K6.DBP5X=1E-B3%,;H=%IW9NJ/*>.N.LDNJNBTESX8=%%4O%/=<
MU@+,:_.6=29@J8V;MEA'V!R<1)QEBO!AR,F*O.2))+KRF)3L=<>#_<9FT%K!
M+[5=.LX+#PVOAZ1_!5A?^$]3UMEN+&X34]>U:TU1[F[O(38D1-"MNW],O \C
M1SR1/;Q/[J4.L+=FSTZ^N9;S7#K2KXLN['Q+8:2#!>PM8:-IMSIJ6]M:RB\!
MD$QG']%M2D:R1)(L@MNB#UOL@51*R!7:H EQ'!DYT)+?V9'"M!'1)&I.71XJ
MXX0#'G)$F68E$H\F;+Q*?8>PZK+<A'K:][F6I^(-8TTWNKZ:^AZ7/ UG=OIM
MQ)XTATU-->PO- ?Q')?,]WINJ/++<:A->137%QUI(I%D)69?-T?Q]8:+IE^+
M32[Y-7U&*=;NV6_@C\*2WSWZWEMK2:#'9JMK?:<L<,-C%:RQ00]&.1"@W1-E
M]>Z@L]<)1R5KM(LZ\ UTSJ^J?"@\@7AL"W(9D/%3>)!&?B2:G9@"FGDPO=H4
M=$)Q3+:E2E8:[O"?@'6-'O(KS7-;L=3DTKPC'X)T(V.G36.W2TGCGDO]3ZMW
M<B;4KDVMBDBVW1MHEMW,:DSMLX_$?C+2]3MI;71](N]/34O$S^+=7]+OHKS=
MJ+1211V=@8[6W,5A!Z3>.K3]6XE:=1(VV%=UG:UJ3U#H%/IDB:V1?K%?&A79
M[3*H[4M<",AA4AMA;CJFD.Y1YDMJ<7E.,^&59S\_/LO!^A2>&/"WA_P[+<)=
MR:+I-EIKW4<;1)<-:0K$94B9G:-7*[@A=BN<%CWKY?Q/K">(/$6M:Y' UJFJ
MZC=7R6[N)7A6XE:01M(JH'*;L%@B@XSM':IOSZ2O"IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*CU@7&0U&S)@0YZ<N+\J)C"'TM
MY\N/%2,+2K"59Q\V<X^?./FXW,N-I(R<'!(X.?94-@ DC./546]87]'0?X@Q
M_A\MO?\ &;^\?OK/</Q!^S[J>L+^CH/\08_P^-[_ (S?WC]]-P_$'[/NIZPO
MZ.@_Q!C_  ^-[_C-_>/WTW#\0?L^ZGK"_HZ#_$&/\/C>_P",W]X_?3</Q!^S
M[J>L+^CH/\08_P /C>_XS?WC]]-P_$'[/NIZPOZ.@_Q!C_#XWO\ C-_>/WTW
M#\0?L^ZGK"_HZ#_$&/\ #XWO^,W]X_?3</Q!^S[J>L+^CH/\08_P^-[_ (S?
MWC]]-P_$'[/NIZPOZ.@_Q!C_  ^-[_C-_>/WTW#\0?L^ZGK"_HZ#_$&/\/C>
M_P",W]X_?3</Q!^S[J>L+^CH/\08_P /C>_XS?WC]]-P_$'[/NIZPOZ.@_Q!
MC_#XWO\ C-_>/WTW#\0?L^ZGK"_HZ#_$&/\ #XWO^,W]X_?3</Q!^S[J>L+^
MCH/\08_P^-[_ (S?WC]]-P_$'[/NIZPOZ.@_Q!C_  ^-[_C-_>/WTW#\0?L^
MZGK"_HZ#_$&/\/C>_P",W]X_?3</Q!^S[J>L+^CH/\08_P /C>_XS?WC]]-P
M_$'[/NIZPOZ.@_Q!C_#XWO\ C-_>/WTW#\0?L^ZGK"_HZ#_$&/\ #XWO^,W]
MX_?3</Q!^S[JEP'W945U<:#$@IR]G"FX;*&$+SAMO/G4E&,84OPSA/FSCQ\J
M<8^YCE=Q;DDG:2HR2>.#Z^W-77!&< 9]GTFLYQ5J<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*C%G_ &B+_&N?U,<JWX/YP_C57^2?J_>*AW+5C3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI4XKG[B=_E&?[%GE5_"_./\ "MD^2/K_
M 'FI!RU6IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*A-\V-2=9!L'KQ88(" [(1"@HD9=?(F2;V%9C!P >$U)+6 Y,\J
MDP0H6%/*SEXRW%B/+^;FL4,DV\H %BC:6:61TB@MX4Y>>YN)62"W@3\.:>2.
M).-SC(IZP "22 JJ"S,3V 4 DD^P FO-+>_93>^T"^-1:55*T<Z7A-3K#:R,
M(:8VA4*9.RXTU82HU]!&LZ[,6!M#J:-5IR[%>3*/>"Q:)KM@'+<?_.?'/NP^
M#?<UT.77IXHO$]XTDMIH5@TDEMIVMZK"H+QV@!AOK[2M.9D?6-7VVUC 3'9V
M7OG<7D/3][2?#MYJMR(23;Q* \[@!FAC)P-QP56609Z,6&9N7<QJA!I)%NWO
MT\,Q[C1=@V/9NBIK<1N_T+<MD/W1VI&,)].7?1]_GX-W6N@[ _Y9-OE)^40"
MK%'95D?J#P,D7)5/\&]SO_:GU7Q%#)I'C/0;36?$4=U=W>GS>'[:RT;5=:TV
M>0S'1-+LU-OH]YK6D*7&B:5="SD\0V2QZ3!K-KJ]M86^N?5ZIX)M(V$ME</:
M0LD:,9RTT$$JC;UKAN98[>;@W%PA?T:4]9X7@>1K?U"TSV@UQN-UH"R[+I>P
MTQ<RY.NK<J'$/OQ6TH4\5K4J+)E!KK7L86A>#E4(%(L9#S+)= H@MR U_2GA
M#QIX4\?Z/[^^#=<M-=TZ-ECO!;[X=1TBX?(]"US2KA8]0T>\#!D$=[!''.4=
M[.:Z@ F;XC4](U+1I_1]1M7MW89C?AX)TP"'MYT)CF0@@Y5MR@@.J-Q6QW/I
MJ\VG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4J,6?]HB_QKG]3'*M^#^</XU5_DGZOWBH=RU8TXI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5.*Y^XG?Y1G^Q9Y5?POSC_"M
MD^2/K_>:D'+5:G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4K^?O8^VMPZ5JIGL!E%<W?>]EV6\5JID[C&GQKIJ(9")VZ>
M2<KC<'$ZM$]9TRI5.8>GU$$'UV4*N!X^#5AN-@*-/\_,O%OBO0]:\2:]X7UV
M;5-!TCP<\!CM-,G@DTOQ->32V.G:/ILD$[6UQ:^(M=UC4K338-3N;K5K:+TI
MY4M=*L;:4CZ?3-,G]'M)[98I9;U0SO(K"2UC57EGN"R[@\%O#&\K(J1L0N 9
M'90:QZY=KA=ZKUNSJS7)&WN@+N7$; ME@OC44]:;]AF(^8L).>1IXUHVHBRY
M$S"GB&< 8PQJ$( L00PV /B_P7[NOH^A^)='U#W3_$^JZ5?>)_#=AKOAW2[#
MPG97=CI7AB>6XAT_3+:UL/&%V=)%E)%/'-I]^R:H+DSW6I=:]NI[F;];\-Z7
M=7EI<1Z+!9SQ6-Y+:74KW<\;RWB*C2REYK&+KAPRE)8@T)0!8B$546]C/8"X
MB1!4J:T[#CAA@V<0+2)&QQ+L=@9"BNR9[S[2:XZIQEJ(TZMU"6W,K0E2<(7G
M.$Y_'M.U?W-M1U"PT_3?&/B2;4;Z]M;.PAA\#M'+->W4\<%I%$Y\3H$DDGDC
M1&+H%9@2RCD>]+H&OQ12RRVE@L44;R2L=0.%C12SL0+4D@*"2 "<#@5YL!^S
M0ZX+&T[4E6KI#6EL7@SK.R'+!89C6E[/ D6?#P $D>*J%M8D,YK!TI1@C!FI
M&:6P-G1(Y^)79%-&M_TAXB\&/X%U:?W3[OQ'XV\(>Z;X3N([?Q7H^@V6CZ%J
M7C_3KJ+06@\2R:@FL>)=$BM&?Q#HNG^*]3;3=>T[Q/<:C:2^]%UJ\/BB_7QM
M*BFUJVCT@6^EW^AWN5M;VY:YNH-.G47;>@"%H+.X:8I874]I"9[:2UC@<-/'
M"]E$W](W0^WW2\]6=;']A6DA=K:B9L"OD;469ALE33%0V5<*D*EDL0&(T=Z=
MD.$@-RI66O>)CS:Y<QV1,>?D._W_ *'K#^(O#_AKQ%+:V]E-X@\+^&==N;2T
M#BU@NM8T'3M1ND@61F98A<7,A1 0B A41$"HOX3K%E'INL:KIT3.\5AJ5[91
MO)C>T=M<R1(SX &XJHSC//K/>MO>>G7G4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI48L_[1%_C7/ZF.5;\'\X?
MQJK_ "3]7[Q4.Y:L:I*E[A)WFSEQ(O5%ZC50+;;I39>R"!76[5944HQ4J"*N
MM"6+W(O.8<@T(D#H+JZDVM:G&94AN/!RY);WD@6-%9IHR[(D@B"S%\2 ,N3T
MNGG:03Y_F[\5FKEB<(V S*6)3&5)4\;]_<?B_/4_:V#0GP\FPL7BGO5^%*?@
MS#K5F".!HLV*RJ1*AR2B)V8+$J-'0M^1'=?2\PTA3CJ$H3G.,S'(&"F.0,0"
M%*/N(/8A<;B">,@=^/55]RX+;EP.YW+C]_<>L=QZZR<ZRUL7(#1"=A!CI5B?
MQ&KT:>7'PY!Z2I#:\1PS,B0VX4?RAUI>&H*7W,I<;5Y?!:<YJ%9@Q"N0G+D(
MV$'/+'&%['OCL:9&0"0-W;) S]&3S771<:BY+-P&[56G)U:0ERR0D'1:Y=?;
M7C*D+.1DR\O"4+3C*D*((CX5C&<ISG')VOA3L?#G"'8V'/KV\>;'KQG%-R\C
M<N5^4,C*_G#/'LYQSQWKKB[Y1C<J!!"W2I%YI1F9(&0Q=D#$)9*..><CD'X$
M>)->>F,P)#3K$UV.AQ$5YIQI]3:T*3@R.H)9)%"XW%D<!=W*[LCC<#Y<XSZL
MT#*>S*2<\ @GC@\ YX/'TUDA=CKQR25AA3P4Q,!2_AYN(**P2$D-/^W_ -2*
ML1'WG1TO]C<_U:8AE[]C7]I]HKPAE90"RLH8;E+*P#+QRI(PPY'(SWH""2 0
M2.X!!Q\QQV/S&O@U;:H^<?K#-GKSUEBY;3*KK1H:X=C*>BO3FDR!").2#.78
M4=^6WAR.G+D5EU]'BTVM>&UMH?8^P]GV-M/('#8P>2!P:9&<97/LR-WK]6<^
MH^JNFW?:*\,FFFKK4G0XV9)'$2S=D#.#8!"&RN1,@39R)N8L6;$CMN/R8K[K
M;[#+;CKK:$(4K$E) P4QR!B,A3&^XC.,@;<D9(&>V33<O/F7 X)W# /L)S@8
M]>>WKKL/W.GQ8H.;*ME:C0K.\Q&K4M\\*9BV*1*2E<5@%(<EI:+O24*2N.T/
M7(6\E25-I5A6,Y;')8!')3E@$;*CVN "5 [$L  >#SQ0LHQEE&>!EAS]'//U
M9_:*BX3;M$M)V57JB;A6H@(N,ZC6A(8@)7\E#L"N3+(XV78F$8<V1'=CQ<0&
M'0<4PM1%Y;;C3<4::EC+/#+&H:1"@:-94W;LNC-M\N%*Y')(9EX'!)*@P'4G
M ()#%6P1Y2!N]N3[..,^O@XF0:R5VQXG9KI\(>P+FN#2>0I: 5P.(L_MT"?F
M!(D>YS6O''J19'IOH_\ J;QRC!DP'5DW#*[U9=P]H+  CYQP:D$'."#@X."#
M@^PX[&JP)[SJ$:[0*0$<C7&=)K]E-D'JQ8*S+^"/UFY:UITT041++P8\0AA_
M9,0FY'E3H\M,,//CQHDTE(@PG]1;R&,R,#& RJ!(D@+AXY9 RX4G Z)7.""6
M!R "17J+NVCS>5B=I4XVLBD') !\^>2.Q'<C-A9NU,PS8)&;?5\1ZF[EBU/Y
ML G#-9>QX^+-@=S+\@5W[57[&25&7\V?M?FSS/8^5&Q\N,H-C9<<<H,98<CD
M9JVY>?,..#R./IYX^NN;MSI[&*_E^V5EG%LRVFK>J>%-_*53J6EM8K_GEX^,
MY=0^PMO [WG+B7FE(\<.(RIL<[\(YZ?R_*WD_/X\OUXIN7CS+YOD\CGZ.>?J
MKCF[4Q+=@>S;JOAFI+]*U.YL GTJRY]MGT["Y[WY KG@A><H)*C*\$JSX>&,
MYXV/Y/BY/C/D>1_/QGR<>;COMSCUTW+SYE\ORN1Q]//'UUS^6-1]0 U\JJWZ
MMK;]6K-?'1?J65K#:7LN5]'O7F,MX96AW*QV)*<-+2YX^16,Y;'\QV280X?R
M/Y#VP_'E/S-@T!!QAEYY'F'/T<\_5WJ1\KWJ:<4J<5S]Q._RC/\ 8L\JOX7Y
MQ_A6R?)'U_O-2#EJM3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI6%-V2O5F$X2LAT/7QS6,Y=GFR<(5";PGYU97*G/,,(QC'SY
MRIS&,<4K4ZX>T+Z4TF8L82[(ZQ,&FUJ;R HIO.R;#EU/W64@M>L6<KEWQ^U]
M/W3"O/X(\/-GPXI7BSJKL<(VYLRK"ZSKK;UCI]'%6JG0[:K7Y(/3Q-KV)<Y]
MIN)&S2[0L*_';@54=KYD6AD=**)CV,ZE4-,>7A3O\._[6-JMO:Z[%'XC\/:7
M=ZWXGD\7WFEWNHR0:]J.E:+:'2_"\.E6$,$D["XU"\\3SW;7+6ML+C3[ ]8W
M%NR1_KWN>29EAD:QO;A([1+!+B.'=:0R3$37CS2NRKY4BM@FS<^'D\N&K0WI
M1L09ILQNRC#*CM&^8L.S;2>"A*%2 ;@.N- B3@:<!B$IIP*J7*&!7JE*D,84
MY'C0"0[W?/O&2*4>!_M@^YY>^Z%;^YCXUN?$/@3PE#IG@K1M&U?5O%_BC5TU
M/5[S5H'U:UU*>SM=*U58+?4+^/Q#';R[8YIKNROUG^)6R9_J/<[UF/23K.F+
M:ZG?M-J$]S;P6%E;F&". K;O$LCS0%GBB-KO7+*$DB*^<R@;(=C^S4T/I38.
M']&]A0/QH#+K+9254J4VF-FQHR(=<:3)N4]M]YN++D.I9Q"D*\C;CWD2AE;B
M/YR]Q3W"X-3]U#P=Z/[JGN-:P=+U>WUZ6PA\1^*6Z\>AM[YA)7@\+VC0QO+;
M11]0W4 :1XX0Y>5$?[/Q'XGEBT6_"Z!XCC>X@:T1O0[(,&N08LH'O) S*K,Q
M'3<!59R %)'G=UXV2$K?5$4R]2=D1K**O5JOT2TQ=;F)5?LIX+L$N\J.Z<K[
M9>%$DDZ]%<IA!<UUE@>V\_'R_F/'2\K^N_=N\+7^L_[1VH-\)_![^&]2\&^&
M_!<V@W/C33X]5T#1-8\#Z6D4RZ;JK:;<W<.F:Y=1^*K:.TBEFOIX(YA )YS&
MOB>%=9LK'W.(K:31]>BO[?4]0U>/48] NY;&]OK75YFV-=V2W<4;SV<9TR5I
M6580S('VH&K^G'V<W<SJ@YUQHM(D]AM2AKDQ8MJ2W*K9KJ$JMAQ'.[;O)P0X
MD38Y0N:[B<*)09C.&67,Y1(2A7E=2M"?ZR\'V5SIG@SP5I=]$;>^TOP7X0TN
M^MRRNUO?:=X;TRRO;=G1F1F@N8)8F9&9&*$JS*03_//B&XBN]?UV[MWZEO=:
MOJ-S!( P#PSW4LD3X8*R[D8'#*K#." :]8!)L,>B-$ 98:9@/IPIF:*G12,1
MU.<>.%-R8CKS*TYQ\^,I7G&<?/CGT->/63XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI48L_[1%_C7/ZF.5;\'\X
M?QJK_)/U?O%0[EJQK4;/4VH2J9N<>\+IPO9&UI^\\L[4&5B$]:1 W;1>T/#F
MI)1;4$Q-R)"G8HLA";)L,RH\5Z%&E-QUMNIZ_39>I;G,C0P"WS 7.QFA"9(&
M0!EE+*Q!P><'M6/14K(, .YD^, \P$F?7P> <8! QQ\]14=U?/V&ZB;M?06G
M0,8?8=42']>42 0(T^:/U.(VHR,L,A9>O@D/V>44V&-2,A+!I8K86J#8B3IE
M_$=<2YO%5&CB-PQ*3@32D+(K3/ 2@*L?B\1$L=V6=V8* :J(26#,L8P4\B_)
M(028)!4 G+]CV ')Q4WWIHZV[$V%JRYTQ^IAY%,D0XY(V:ESWID0(S<ZE:IX
M]BGRJ]9:A;8Q!JLI:A)G)J9^M&403H&W176EQLTM[A(HIHY!(XD&0J@<MTY$
M!Z@=)8R"^3_Q4=<JT9)R;21EV0KM&TCDYSC<"1@JRD$+C\$@\AO55%D.F%S.
M5-K7Q2;K**%J])VO3Q%R@13#]UVLWL]EZ+)>VVTZ'BQ8C*L/YL%MCPB=M^65
MXC#;,E=?3"R-?Z/3T63J@3,\DD#O&<"*'H'.(.20?P(V(CV1DKA@<C/H,0%.
MP*JR*IP2S]08)DR!W[M\K<^&X(P;B5U:'1KQ9+@#9J5>D&=_U3:\&:'$('F1
M=9!:0#ZJF HLN+!1[L0?(LGBD9+*L#_=##_KJ]YDRVU<_ICM''&_48+:O"=S
M95G:X:<,02<@#8IR"P*C' !K3HC<6&T9E60$#:0JQ=/;P.Y.3WQ@]\YQA.KG
M6&RZ,+1I%D* S"*SKN-K($;%F#DHG:AC):$3</6())#AA-?GOK&LRE#DS;Q*
M:*E#LJ):(L<A,BD+7MTER"$5ANE,SJR*%1BI&Q&#.[ 9P"!&-H V;E4K$,)B
M/)!PH4'))/(.2"J@<\D>;DGG!K6E_4IRY;*K&H@D)N$/KNR.SQP[MAG5>Q*K
MM,(.VSK/=U:0;,7"Q 1E-FN1[)L,%&#D:Y;#\G8C$(#8(HRNP@!%MCL,ZQPR
M3L22\5FBPF>*2%C!+;L%"*S2 E87W!HT$>7#,Y=2<NGN=8A@*&FS((V60!TD
M&2V,$[I."KDM@' P35T:ZZ=&1<NO3;TQK^3@!:M4S7A8^<<L0<R&U0%V#%#R
M_AQ6O !0><V8ND6>"#-B2;U>8&J9?N1W"1C0W";4 0XC$HWI,-Q"HRM,T)89
M621BN(R&;<N[=D1CD5=(",%L$AD)&=P(0/C *J 06RHQQ@#=ZZCERZ0VPHEM
MD,<J4\40#;BI4^LE2!T !KE5V/NJ\[.%$*ZD0 *3),B,$MT*N6>KQ7JDV776
M*TX+N 9L(PX_:/44&<QNK*8) X =I'BMXX2'+.H&6C+HY$H7J.&C.<55K<MQ
ME2")%()("AY&?( 4D\,%8 KG:ISD5:"NK]C=LMN;CEZ[7:P:V;:K\,LU??(L
M[ ;8NO7:RZ:GQY+*Q#4&.8KI\PQ9PI5)XAB>V_.<DQQTYK&)^/IB[8R4=I%@
MCC9'P8OBKI)Q@@G(=%V,H1<<8)';3HD,V" I=G!'#>:%H_Q<94G(.3GU^VK(
MUEJ>U!-;V#7]D$:QH[TFA#-<";)IQDC$*2AXL 2!Q[)-41"A%B)<14_W^OUM
MAX\S7'W)V$V4IF9EUO&656F29&FE(D,Q6XQM!9@Q0 ,X8' 5V."P \JX JR(
M0A5@B^78&CX. "-QX&""20.<'NS9J@AO4[8<HM6912#HVH1J5JNOZJ'/Z^'G
MV)]HC5W;6F]@L'#29(0>@/$6.UJ5C"ZFU(L6 !0Z^Y\J"[$U]V+U->Q!9 #<
MR&6=ISU6!"%X;B+:HW$L<S*6<!-P3_AJ0,Y=!\CB)0J*@V@@LHD1_-Q@#"L
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MZ_6B5@DUT%:[N_8B0R>< "QQZ>R8FP/?_=IK[+D^EW$@"B0N45#D)&&V0 %
MSA S1Q[58(Q905'E)&*@Q1+DD  DC!)VYD)#84G:"Y8@X )SBIKC26LT6V%=
MV:X[%L$'(=S"H1^S0@TZ971N U?*G*M$,LU>PG08E+0T0?/AB1H;"CPX\2>R
MW"AI8IZ3)TS&9 R'</,$+ .VYE5]N]49LLR*P0DDD<FK=-"V_'FX]; $@8!*
M@[20  "02!P.*[=PU!KJ_$W"]NKB34N16Y51G-NE3D8:5KLJ0Y,2.-!H).*'
M-8'3GGB(*46@3)M=)/O$@$D;/=7(4CGDCXC?&'#C"J2' QE6*EER  P5@'
M<$#%&C1SEAGR[2,G!&<X*@X;!Y!()![$5W:;K&DT(89%UH0^TU8Y;LZQSS)H
M_:C]BF.06!F)!^SVHH:L9IQ@7&C#(>2965[B-C1H$/#$1AEE%9)FE*L[#* !
M J(BQ@-G"1HJJHW$L<*,L2QY.:E4500!WSDDEB<C&2S$DG' )/ QCL*A0GK;
MI8-'*1XM,5*R:%&0)68:LMOL16:#/@(M5(!'35@/DR^!":Y"C!A@U$Y,,'!;
MRT$9'9<>4YHUW,VS,N K*ZA4C1=Z.7#;40)NWDLS8RY^66XJHB0 X7U$$DL3
M@@*1DDD#&!C. .  .*R<O0NIYMC(6F1559)EFGD%([-@M$6ODI<BO.5)TU/J
M44VS5)=G56'% <6M\*NRH%81";*I8::0@+F8*(^IPIRN53>//U JR%>H$WC=
MTP_3W<E<DFIZ:;BV.3WY.W.-N=N=N['&[&[Y^U=TYI76%BB/PR]4COH>"4NO
M(D,$#(\E &ZZ(&"M&4&+#B,0H"*58F>+S@YX-,@G8LF8MS!+.6V?3JEQ*K92
M0Y#2.00K*6F"K*64J5<2!%#(P9#@>6I*(1@J.RC.2#A22N"#E2I)P5P>>]89
MKKQJ%DD",-UF<DF :&--3,W"[J=.)"&I=C#+O'GL:D[%>$6"?/-BW[\FROCR
MDZ9.B.,R94AQRYN9R&7J85RQ*A(@%W*%;I83,.Y553TBF5 7L *KTH\@[>5Q
M@EF.<'(W9/GP22"^X@DD'DYNOF%:4XI3BE3BN?N)W^49_L6>57\+\X_PK9/D
MCZ_WFI!RU6IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2J?%%]FV9P[+#D**
M-&#[39:_#C$J\?(SLL@#$L2F1)E1;0.86Y)]UR_E+41I+?GPWCS>7SJ_/['4
M/&FLOJ<^GW7A>SL[36]8TJWAO-*U6[NC'I6H3V(EFG@UJTB9YNCU"$@14W;>
M<;C]G=V7A;2UL(;VWU^YNKG2=+U&:6UU+3K:W#ZC90WACBBETFYD58NMTP7F
M<MMW9&<#+>Y[@^D&M_S1LW_.O._H>Z!^5/!WZBUO_P#R.N/K>#/R=XG_ %SI
M7_D5,Q-P>&?_ -0:W^Y]$;-_SKQT/= _*G@[]0ZU_P#Y'3K>#/R?XG_7.E?^
M15C-01-Q1 <I&X2=7(E<S'LC<U^&^Q):@9<<]))9_#B1[\GR>GA"($1M#+>/
M!Z3,>4IW')X!@]T"#2Y5]T&]T2\OS.YLSI5O)%/':EW*+J,H=;.6<+L %I;J
MJ '?/.Y+#I\93>"YM0B;P5:ZO:V8A070U.:.2-[D*N]K*/8;F.'=N)-Q,Q=C
MF.*! $JW>?>5\?3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI48L_[1%_C7
M/ZF.5;\'\X?QJK_)/U?O%0['W<>/W/W^2<D''?\ U[*QKS!,:_W:8OU ESZK
MN^??:QN7;UGM=U>V#"<TPJDD->[K ZN=I]7?NBAP^5%:L=!%#F@-)"V4/,;-
MOVLE(7*?(F_662W6*0*]L(WMX$2+ID7(D$UL\W4<1EB"5E8F20HR[ @!  Y-
MLF]"1*7$DC,P?XO;LE6,JI< '#*,!,@\L2?-72+U7M\T7N**:WLJ58R^F8T&
M"<M5F>@@*I9XNM*!%?C51MK;9"CVHH<LXNS,CY9>A4RVUZWDS)PO<I-8=%/2
M0>PV1]7H[%N-S+&@+NAFEPSY@65%5"F[$LL;H%54# U)$P9MH?)B W.WE4[5
M'"B3:S,P)Y164G); %)%;['LZ\<$Q0NYB@HSL9YZ&A\E>@UPIXR+KSW=O,-A
MKMT]L&P5ZQ7)S+&%VG<(P56#C$DW\G9E6>'S8\AK0RAB]LK+$ 3MC:.1FE/!
M)L>DKQQ8_P"' 2ZX7>) 5-2LH7 60@N> 7W ;1[;C>0S9Y,@P1G;M(-8TI6N
MZ3K[+]?:V3)O1K10*"4)V&P-B*M3KJUI0*V>55VP^V7*%9S!C8D0D,CQK!KN
MOV4)=B\NT(OJZ(.%H7(;3QD/T>DMPQ4(A9WC](;;O+0"6-5B*LQ25XVB CZ8
ME+&A%QW&_>T2@DL BMTAG"JX0DOG@H"K'=OV@"MCM USL /$&5/V.:%$/70;
M(BA=S4JU6$RU7600ED]'JY"=V6V#;(*2!9$U;4NX6(G%BE$3I 6NK 2(+TKD
MNC:L5P@=A&P+6\D: MN.SJ!;.-&*KCB-06!&]]X.-8A)C);:-PXD1F.W'FP>
MNS#)];,<'Y*[2*J&4)WA"HI.%)H?8(WM6:;@P=GVM>S3[M D#UW;WV38]656
MJ[FI9%^ V+:C_!ZQ2GM=S&:C*E"[60=-1G1!7HWVQE!ZUHL 4]!!"HE#;-H6
M=Y+>4<,26:3K O@H-AW+3$@7E92Y($AWDI\H^9%$R>KLJ]/R\-SG.,@X[<5_
M6943/J.WK%;[;H]%-JSPZSU]$NF7D!M;;GIF[*0)[()."BDO6=AUY*2?8LEM
M*FFZ[D;,/%SL6*J=8FP>52)+=$CN.H^48B2-H8/+$JPKN F68;2D85FSM52<
M0.L%P5D8M$%&&4;9!(X+,2^1\64((+$[<$Y[R>L5[L=%V%?(Z8&U)=>G;;U\
M>;M=KM$D4\W6V-_?%+#5Q59:VE=*C.K,75\I]/QVFB: U/J4$77+#5"%I42Q
M'S=K0Q18,(98)5*1H&&\VNU79NA'*LAF'R)&DQ(6='$>TFPZP=\ARID4[F8@
M[>IDJ%ZC J$/RE$9*C:RELXPDN@[^H&L@$UFW[*26/:2J&=NR;;M_#Q%6P&-
MD:TS8*]2SEPLZP-$O5CHI;8U1JI4%("!'#>:\[/*-E(H\LFXEM99F4QPX6XD
M]'V6XQTC#,%>55CWRPI(L3R!@[[ Y P66JA)50>9P3&F_<_=@Z!@F6VHY4N%
M(P,[1G/(MGK:8L4\OV<'#E;& B:Y8JR+I C<EX3L A4"#VM!1B<Q**9MMZ?A
MP'"Q)@Y)#D+,1*QX4]AR2B#'D0AL/GO%119,PB=G61I6MXS$) )2JD+TX@6"
MKMW*BJ2IP2<FM(<DS ;P-RA [[R,H3W+-@$X."Q(! .*U7'S=YE50:MK>;N>
M'?RO6:;9+?)M>X0^P E\LK&U-(-VNTZO0*VI+&AY9^G/[#A40V,(:J /_&X,
M>KO5A\<2F@NTBU&7F6W,0O0D8CMS&\49AN-B3!H?,$D$1D4B9AR7W9"MA\;G
M:G4W='+;I-X8B2+<R'J$ LN\(1L4@@*1SB[Z%J?<=I57AUULN[!E#1,V\0:@
M(MELUP='M2J_K&#21<XG&W9LG8Q4;\I&+[8@*[/=UE1\MR0.D0(-7P*'3.:6
M:W3<T:6[2XMP6")*C8>?J,%-M#"#L,2,(X\$<YW[RNJI(<!C(%S(0-S(>0@4
M$]61R-VYE#.=O;&T8J+5:K=O)&P]>D+L4V)$D)C:,F.S@K+92M10@ZAU-O<5
M>ML9K>-4H31@O<F;RT5FD]4W,]ALT"*4@M-^%,0Z]H[V BE6,18S<C:^5D+&
M1S;O'_1I)BHC,6T">- 597"Y#-11<;D+[@?BLE>5 "KU PZHCR6W GIN>5*G
M&0+VZAB=N A][%;0@;!=98FUMT';-EFY[]GL\YP9*9LV)E7>V1L\+7GQLJ*/
M7.(TDV'HEEGDY,BK5,&/'X3(Y[UH7:)H6BQM<.D*KL4 CIXDZ,#MD%L+(AE0
M* [L6XUA#C=O#8R,%B<D\[LJ7D"^KE2$8DE5&.=Q^<5;TXI3BE.*5.*Y^XG?
MY1G^Q9Y5?POSC_"MD^2/K_>:D'+5:G%*T;]H)WQUQ[.S1D#?6T:=>;Q7"-_
M:\9#:^:K[IU)2PB["6BS%ILIROCL0&&*Y+1(5B>J3AUZ/AJ.XE3BF]K>![B0
M1(5#$$Y8D# &3V!J"0!DUXK?Z5ETU_W<NT?XGJ+]:'.[WIN?;'_>/W57>/8?
MV??3_2LNFO\ NY=H_P 3U%^M#CWIN?;'_>/W4WCV']GWT_TK+IK_ +N7:/\
M$]1?K0X]Z;GVQ_WC]U-X]A_9]]/]*RZ:_P"[EVC_ !/47ZT./>FY]L?]X_=3
M>/8?V??7N5*[JZR&=0-?]SRP"ZQM;;"H>L[^/K\:"%F7,>-VE'!O@X,Z%DZP
M%S/A9/1&RF(QQZ,WEI]45^6E+?J5L-+N-1OUTZW:)9V,H#2LRQ_$HSMEE1VY
M"D#"')QG YJDLRPQ&5PQ48R% +>8@#NP'KYYK4;[-9U.^B>\OS3IOZP^?3?
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M$K__ #3R/][;W,_R9XP_5FE?^>4_W;/'GY0\,?\ ?]1_\HJ24_O)J*[6JOU
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MT[6R&ER&X!/XJ=F.RX-KJ/6:=9/.5"*'>$E4+7[2%3MV"1Q);<$&(N%+ILC
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MJJY) KKLK"]U*YCLM.L[J_O)M_2M;."6YN)>FC2R=.&%7D?9&CR/M4[45F.
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M%N]ODYSYE6-9N/\ XJPJD(/8(HXR2:P-O&6W98'J"3N/5D[#P,J7)<CUMSR
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M(6AGU4O/J<6PZXO,937S>"E=+-A-Y<R[DG+RYG*<Y7ZGVV<IP.PG.<^'[V!
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MB[<I4C84.&F.B4J7+I;3*[)&BIBN(D*D/#4-886EWS^FK"LO]U'W+OZWQ/\
MK6T_\LI_O&^Z%_5^'_U;/_/U=M2Z2:9I=G VT,_<\E:X5A&!V)AV(_%S,@/H
MD1_>&4"&5N,^HA/J(2ZWE2?''GQX^//7T#_9L]SKPWK>E:_ITGB$WVCW]MJ-
MH+C4K:6 W%K(LL0FC73XV>,LHW*'0D=F!YKS-:]W?QQKNDZCHUZFB"SU2SGL
M;DP:?-',(+B,QR=)VO'5'VL=K%& /)4]JE&\^J6KNPI8$9O[MG1,KHZ2,'X
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MMYV0TXMU24J6I6<8SRV]MP;<VX=FW'<,=@#G( ]@Q48&",#![C'!^D5]D5X
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M&V@<Y'JZ-XDUGPI?+J^A/+'?I#/;*T73W=*[B:&4_&2PKY%;J(>H"LJ1MM8
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MB?36I?G&'_SG'PH\,_VBT+];Z?\ S%/@]K_Y#UC]67O^13Y?43Z:U+\XP_\
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M &,.6W<%2*BMT5V&ONKK4+#W'M2<&Q];T&Z[,DVC5N*5;*]N(7LNE.G*=K*
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M.2PC7;S@M\F87K8?<<9;>P0ZD.;8L\5-@R^/-_(L\!!Z_H#&W00F9 I]?*:
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ML^JWH4@LR[V(E)10%#$X.-X&.#@WV*HT(YK ?9:1UXBB+8JLD+=::=<6;S6
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M5))QXDAV#F0EES*>3T6XVLXMI"J,RNQC8;64@,K>4\@D ^S//>MNI'D#>F6
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M(JU+=$[7FFX,1)RQ6S48.;))UY(MDF]+IX2S5ZR#GIGP,KB0.6A[1].A0O\
MTG*Q+.9 HA>3= %)*(D[ *^[ ZC(R,,.O.:HMRS 8BY8QA<EU7#[AR[1+RI7
M)*JP8'"Y*G/QL7M ;J):B!A6CW+!>:X*VH9V6*$2]A'@33.IMHVG512'23=3
MU=9''5GRU1)E81B^P:2"!098>.;FX>GNO0Y73$.7:Y"Q.T*PLPB5OCX4G!E5
MYT^0C@,L1E<D-M4[<&3<L,#IEF <OC>1Y)'C.PJC$\J3E@@ (SC.:V%['=DK
M-I2M:_MH+7>#5>L;!(W=#EG?M@V!K>MB10\J]*M,"ETJ_P!E&X>1.<BSCLL
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M,DI.3+(?(T?+$_%NS,Z'L=C,S,RY&69CW)-6V*.RJ,$-V'RE "M\Q   (Q@
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MAR<B:Q&6-B,$(_O4QEQ?DQ8*2T:J-S2H\B!2#E([9KMV.#Y0MNID.[&,;/\
MB$*8/"-(>$3;N8\#SW7H28SRVZY!C7;G(!D'Q0WU*QFY-2&0,RTB]G:_G5H>
M3+AIY^/<*^X'A%@)"8*-#99'!#W2--%DATZ%/C/.H>C28DAIU"5-+QBH(948
M$%719$8<AD94=74C@J5DC8$<8=#^$,R59696!#*Q5E((*L"RD$=P0R.,>U6]
MAQ,1EA &I!&('.!RTL.[&9+Q1A.%/D"WIL1J?#9(L17W78+LN"^S,C-R4M+?
MB/-2&L+9<0O-L'DX. S(3['0@.A]C(2 R]U)&0,U'L^=58?.K9VL/:K8.T]C
M@X)K,<BE.*5J )ZZVL5V8D[H4<HT^O2I]C+.R)]29D[/PR<JH>MPZ8S;I+;\
MB#4@$H6Z7&M"YPZ&MF<\,FUZ3/\ 6L<CZR3Q!:R>&UT;H7L=PL<$(6.\9-,)
MAO9;M[U[12JR7<Z2B"0RI(XZ4<B7"QCT8<;6S&Z6X#1D"0/YHP9446HM^C&Y
MSMC+@SG&W+2S!E=F61-E[L*)GJ;;081^%',&:T>%"I!%TBT/8)$!4J)!=G.B
M)$0LU$;E/,KE.#)44@AC"U0I#,G#3B?F[22.&[M9I@[117$$DJQB,R&-)5:0
M()5>(N4!"B16C+8#J5R*[.?5W]6>V?5G&#]AJG^M&G2VDJ*5K!G-':?)6B2>
M8A4"NL5T&/C. P(9$9Q+,0=DM/=<"NSGRTD?'G*9F1Q\Z07ECW3I3V/$FKQ:
MU?17,/II6*U6!GO[@W$TC"XN)]RY>00QJ)Q&L*2&,,C21I"D@@BY;2!K='5A
M$-SA@(E*KQ%%'DD^9F)C)W,6?! 9W(+'!]I-$6+>==!CZZ2IB9 99]*P.QZX
MW:J606>$*%1S<@/(CSX:[#5UY5) R)XLG%2Q.,14,P)\R"<$Z^&M;@T6YGDG
MCN]LRP#TC3[@VM[&()UF:%)E:-Q!=!>G<".:%SMB;<Z*\,LW,!G15!7RN7*2
M+NCDS%+& X.0=C2+*FY77?& R'(*[&5X>^' A!,R4S,EC!(X?*EL1FX+,J1#
MALQWI+,)K*FH;3[C:G6XK:E-QT*PTA64HQG/@7,BS7$\R*466:6149R[*KNS
M*K2$9<J" 7(RQ!8C)K:)#''&A()1$0E1M4E5 )"Y. <<#)P.,FM7P'6A43M/
M=NQ!:2%CLDH09FJCZY&@#BKTMBHXJAF9=B*:PP?,H?C>'P\1\L)%70N*+)R:
MZLZ*'%(OTDWB/=X7L_#T2S,4DF:ZDN&DDB5&NQ=PI91^DF"$JZCJ3>AK<D/-
M$MP(9I8Y.9K4/>"Z8@!$0* %#EU26/+MLW,NR4@('"^2-F5BB;-B=@UB7=J'
M=*<//D*K.M=5L%<B683E6"E>E&A4H<P;'92ZPO$X6Y)3-B^1]A?KLH\KS*O!
MQ/S]C<+9WMG=O!'=):W5O</;3?\ "N%AE21H9.&\DH4HW!X8\&NMAE64,5+*
MRAE^4I8$;ESQN7.Y<Y&0,@CBJ=ZU:<L.F:_=!9_&N(GRENSUE&AM75*/4:T'
M@YKX$(EA<=N+%D$2,AT.N2]/GXDSDQ'(4*81,38DDR1]?Q%J]OJ\]G+![XL;
M:S%O+-J=XUY<S/UYYLABS)'&@F"JD>Q"V]UBA1DACYK:!H.IGI8<H0(H^GDJ
M@5G8Y)9G(SYBS <%W.6,2[=]:)O9L'0:]%)UT&Q5K%9#LPR6%ME"K'Q.@6FJ
M#HP9MT?+2VSDP>'EBRX\P,5PR%C+!&@QMH>9&]?A/Q&GAN>^N6CN)VN;:"!(
M8I3%$3'?VMV[3,LB$GI6\D$>5ECS.W6AFA,D,E;VU-U'&@95VR[RS('PIBEB
M)4,"NY3('4$8)3&5)#+M6%9G1@XJ.4]TP28&P6IZ8+TN1"3-;C--RL0WY_\
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M\EB?">OP^'KZXNIXIYDF@MH@D#E?-#J=C?%GVSP,<):.L6'P)75G5D#*VMW
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MBORCUIH00" W0],,C[FPJ+ML+EU25HYF*B$1=?,:P!P"2 .C%,>=Q'66W:-
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M$)\O)D)6R^F(XBK*'5U;)$O_ !,$@M@8!)!!R 3@YR,D@@\U*DJR,O!C.4R
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M.&:T^F/:XY9^96)4NMAK,&*B2LF(_C##@C;-@*V?D9CL9P\BXW+$+;4()Y'
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M@4R$NIN/K,32?JKT^K$,L82^2TF0Q@ZL8*W'3!V7'0$C(;=983(^7*A%C?Y
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MQE)ZXVFI6D-99G;/L_?(@B4N1(J5T-:;E58VG+#K/NAEFNZ6KAE<9"G,/I3
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MN(M[,^_V*JR )T00CQ<C'1S>)4:3V)J4T;LQB0L[S2X8R@$W#QNV0)!OC^+
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M848*O4C6-XU*JR")T/.2S*Q*%B3MK,V,15%W,=FX$L$<N&.2&WJPR, !@,@
M $5LGNGK+4MW3PL@Y8[57A\#7.S-2F0U96#CQ+-0MIMU)9T3,D$@A.>*E0"E
M&JY<*5K\H5.B2ARX[SDJ!+DQ%\L%T]N&"JCDRQ3*S[B4EAW[6&& ;(D<,'#
M@\8(!&TD"RE<EAA'C(&/,K[<@\9&"JD$8/&,X-2#3VD(FJ)]WL<^[V_95YV)
M*K[MKNMS168A.9"J0CX'6!,893:]5J[!@B8"Y*_/'#IG3IT^=,GS)&7&6X]9
MY^L(U6-(8X@P2.,N5!=MSL6D9W))P/E8   %6CBZ99B[.SD;F8 ' &%'E &
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M]Q/-<2! \\TLSB-%CC#RNTC!(T 5$#,0J* JK@ 8%;1H(T2-22J(J L2S$*
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DQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g549728g13e03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g13e03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@V4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!9            "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M *$   %W    !@!G #$ ,P!E #  ,P    $
M 0             !=P   *$                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   *$     4F=H=&QO;F<   %W    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      -G     $   "@    10
M >   (%@   -@  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 10"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MR(MZ/[+E_P#<VS_,J_\ 2:7V7+_[FV?YE7_I-%Q+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF:WG_P! TG][ZMDY^[[P<[GS,3#C-I?YFMY?OH-,_95\:@I +/\ #YJ$2_\
MQ*'=_P#ZB'URZ4>O\#V]8^";=HQ ^PJK.2/MZZH:18!1#@@]Y5[V-]X?7.I@
MZ#9G><@= 30:0"?B0*J0">Y&3CWG4L=CY&,@L/7QB/USJ9^9G>?_ $#2/WKJ
M(1#ZYU,_,UO1_H"C?O34L=CY&$/KD4[\S>]G]'J/^]M7ZI6Z?^H1@S'<^<2_
M7+IGELUO1_H*E'_^XU/4$584K8?6)SJW]P^T3)XRJ;GKLYO5CWFWJ0<#WD)J
MX/3SQGH/NU7(0"7L']$MYPS'N\5:^,5?KDTGSV?WGQYXMVF?MJX'SU1CM[T_
M)1, 22 YJ1J?K#ZY=&_,]O3_ $>I7[XTC)E._P#-_5#ZY=&_,]O3_1ZE?OC2
M&4[_ ,W]4/KET;\SV]/]'J5^^-(93O\ S?U0^N51SVV?WHS\;=I9_55R=/5P
M/B0(JIP'?7GSW48?7(I1(QL_O+_EV_34CYBK=_@?CYXU*4DEK>*3\"3%0H[G
MX_'[1(.,FG J/\#F\ZL>0H-&P.O<9JW-\P1CSSG5B@@4+^[YQ9*JL3W.3RYM
M%-7&=2\==FMZOCB@4@8Q\15,G_;OJK'8^496UIYCX.\3HXR:4HC&SV]0Z@$"
M@T=7?^<%57/D>B>O?.I"5'1N9]?VY10]IF4*.[/Y%F.E-.;17/&/2$YSM!O(
M<J/:@TLD 'S!JV$G.>B>G[)R'<>?VB6.X#;YJ^1\GM$GURJ,/^9_>C[K>I1'
MS^EQJI#:@]U8C*=_YOZH?7+HWYGMZ?Z/4K]\:B&4[_S?U137QDTK.4[.[UD'
ML10*0!GKY&K$Y^_5A+S!Z%]]/=X^,5)4*,X&K'ZF)?KF4P=/X&MZ#C^=0:3G
M[_[KZL)?-NX?VBN=6[<F^KF(_7.IH_YF=YC_ /H5)_;53^LZJ4D$T)\(R@N
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MZ??J<QW/G$,-AY")A#AD9]49/^0L?LU&8[J_]T&&P\A%00(I (8 !\DG 'P
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MN0A5%360"0"'VD+22 H)/32$9E@5^DU1E+]-J$.HLJSR/4Z5'FL+\_XV.MQ
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M6VZVGF#3(3#:9#26PG * @'E[#.L12220'O[SIN+&D3ZY^@T9-2Z0$I'*K
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M%NJ0@HY>;JJVDJ) 4".Q(.1D G4CVM<%- '+M_%?8=GS=_"*#\(?M#$T*SR
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M,MJ<%*4A!8R LK."#CD23G617M\P&3,C#)&9:969E,E:_P!-A6X/O.HC%+Z
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M&NJA2'5M4RJ*IS C,0DJKJ"->0LP-#74/JSQ*IY2E*4RT]AR5AG(<DA[\K5
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ME<C#!BP9</P4M.9=(<&1?0CH\JG[12$YA434E5@[U RZ&@;O#Q17M?\ :4)
MF'H].5<NF5BY22SEDYT+6"Q 95"3F #M'#*X:=I)83%INZL6I4MJCUJX'[PD
MUFSH4ZFQ8U CU*DPJU3ZA6FX50];J,EZFQ'6U>L,MQD*7+3S(=.(]"> $@)X
M@A64$E0G %B' JP(T (=Z"K/$WVQ=/D</7.5T?QR5E;,D3EEP2'2$H*R&[7Z
M: .2FJH[C1^$S82DWG!CU??6BW31F[8_")RD0JG9U&>G-2$5F,BL/3JG<=(8
M>HT>HP(Z)M,H\.N7'3ZA)C0Y$>0R':FR1T0Z/2Y@4OB**5*3-#J%0*FC.&)
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MN/,B,E#O"9.B85,DS,5,+*ZL@RL2$DOD*4KZAR"I#$!:DYKL[DT\,=:U&2P
M(N6%+4+"P>-7[EW1XV-M=LX+VXU)I\G;*\+EAV6T]=MPT:X5UR\+8K35U*5,
M?9NYN:Q59\V6U"EU)3T>-4(3+41F07(\@0MR7(Z+S<6)<J<>NEH!RA$] 2E0
M 2:RNK4V@).78&,4[\R " 654D%.E6%0H/J6+BQLW==N*MQH6=OQOS=5$X>]
MNJ\G?39>VZ_NS-H&X5A5&CV?MM5[]72YU_V>:9N366:_48\A%8D5*W6:M5YS
M,^$(L:A/--)]:\H]JT[@*^ 3Y<F=,F2T8;$R2I<J>E944D)!2N4A1<M7*QI8
M-'.<#3BSB)*EN 31E)4+L!V5$U<%GY&,"<1E*WXJ5V\2ZK+J>[$%FE[=;'U3
M:U%H7%=E&I;M?$BH0+KC4UN@NPF:I*>2\:C*9DQI(9=<\;Q4QT)83^>7 >)=
M"\+(X6<5)P'6?M''R^(IG_EYW4RER\'U2E)4#V23.ZLHS *2NJ2YCZ;QHXM,
MPK2!-(.&E)1E3,0ZPN83<)>@#@@68U:.M1Z3Q3T/BBI+,29NT[LC2KDLF%.J
MTR[[[N+U:GRK36Y.I=0MVI2Q3JS1Y%=4H5FY9D:1,ITD-QR\PTA:1N\2XKT*
MG]',0,/*P8Q\TS9J)?589*T*$Q 04S$K!2L)+RY>5B IOT@'1P:>,(G!.)1-
M3)=()(H4L7=(S B^8JK8O4Q]6WHYRES;2]0CDZ[EW(,IY0V2VY$YD("23^2T
M%)R.56 4D@$CVOV+J"^%%25$C*UB&)K5P"]_J1'FW3A"?SJNK(858. P)M2N
M@^HMZ)NJ!D)(\VW5C_J_B4Y^;:NGP^(U[A'28NY"/$96@I"PI)2I*@"E22""
M%!04D@@X(*5 CH4D=-(1B^A;0[8VU/>JEN[:6#;]6F-OQYE5H5G6]1ZA*CRB
MA<R/*GTVG1)K[$YU/B/I6\H.J(,AM8Y@4(N+3VFV[L%<B19&WEBV:_*0VU,>
MM*TK>MM^:RSR):;F+H].C![P@TA:"04(2?!;;;2.;2'KP_OZUBE5MI=M;@N.
M#=]?V\L>NW;2^04NZJY:=!JUQTU+;A=:3 KM0ITVK1?!6I99#,QMM@GF:;23
MD(1=-[8;?BZ95[HL2SVKVG1'H,F\4VU1C=;T)YA49R$[<)A(JJH98Y4%@S5,
MO J#K(Z80BPMG97:FRJNY7;,VLVZL^KOLR&7ZM:UF6Q;]5<9E.(>D,.SZ12H
MDMQIY\+>?;5)6AUU1<65*Z:@LU;>?F-:MO\ ,(R%*8PV$(64E("@.;D!(&<%
M0!.#U'3)\QCKK">T15JBKZ;'<-]XA272;VYBOH^BT>:_$_PA[B[P;OQ-QK/N
M.SZ?#794&V9D&XOID2E2($VI267&7*9%EM.,J3-0AQJ1'6E:$G'M@:\;]IGL
MJE]-\7)Q!Q,R6496"5$=H(*15PZ6+&E=16O<>C729?!L+,3U843F#;N<SN 2
M[IMSJ]8P%_N>N_KC#8<OW:]8;0 XRHWFMAE10UXB6D/10XX/$0I; "H985T;
M;\+F0KRW&_AFE3CAU?MB?^Z6A12M2UA 2Y) "_U#0IW.A:.YR?:O,3A)DD8&
M6I1#.4!+VY5T=]:&ENQ61P*[U42[[8K]<O;;E5*HE?IU7J#-.5=4JHS6($M,
ME+*(\R!3H)<6H$!R07U1NS*G 3GM/13V%X;H_P 8PW'CCE3YN#2A.=E!1R%B
M"2<Q')F,<'Q'V@XWB'#)N"3AT2>LS/E  926(-='9R7$;)6S:_$K9<:H4FD[
M5;<UZ"*_<U2A5E[=F;2Y,Z'5JQ4:E#8<IZ[&?$)+29##90'WE)(5API .OHU
M4E$Q*%?J(2+UU-"_)FV<ZV\ZPZUIE--6ZRI18.<H)I4#>K4OM2-7^*C@JW/X
MP+AVAJV\&R]B2J#M%5KYJ\>U(&]M7A4RZ%7Q9%1M233ZRNE692Y\N# 7.9DB
MGNU!BG5=N,J#54OT]U;3F,RLM!0W&M+ .Y9FO?YW*@;&M=Q0!]O0UK&J%3]$
MCNI/I4>VZ7;-BVQ;BK>C4NL,TFZZ$BNUBI-UN15ITQVZ&+$;J#5+K;$DTZNT
M!Z+/B5:.PPY/=E.,,XH4*)<C5[B]]^?UC'<^OG'3K3]#-NW:TE+L!='^C)9M
MM%=H$V_X-7A3&Z),MF34*K0U2+'C&U+[GL6S'IM*W%IK:KCMN!)EQJ4$0Y;\
M(QU5SEJ0_>014Z6!MM7:#$?"]*A^[5]MXH;;>A7W%VYFT%35*HU9M^W;1J%D
MTZTZAN6Y H;5M2+VO.[:=1U4^A4.F6_(A(8O*9 N=JJ6[6(ER2(U-J+5.ILN
M AQ=A*+4%=P0')+L/BQ.II>,IR% <N=FYFG(::Q[2,-\3<1I$6'L;M-%@0VF
MF8$6)O!.BQ(,!M ;:AQH+6VSD..Q':0F.TQ':#:6T@(!3G,IE*!/9J[W 'C>
MMMGJ7BDM00IVTL.<:P<3'"GQ%\3&V.XMOS*=MCM[7Z_-V>3;<%^]*_<%"EP]
MO[UJEV5XUFHTRS(53IGTHS4ETR.8%*G%IM(7';B.J7(UQ/2C@ZN.\.&#"LHR
M!)(5E-.;@>/<12_=_9]TYF= .E&$Z1IP:<6<.H$2E93F3F!%PHV2 SBYN6;S
M:C^AJXS76V%_A[PZ(?\ ""B6ZUN)'4EY92M:R&;"*&BKE2/Q!)5@^(3G7D)]
MD&*F=K\ZE%+LQ )=B4J#N;U#U<AX^P/]=?/.S?Z,2U!891*@D$$DEGE$Y6(>
MI-FH(G<]#%QF!?,N^^&]7.K*R]7=Q7EKYL I*U;>+YPD)0E*UE1;25(0TI*U
M:'V,3B/]J3*#1BWF3:P%0QI%9OXS\.E2>KZ(R>T>W^]E@-N'D:@.PI>CDL3Z
M&CC(>;0VN_>&I2 E*5)^F]Q^0@!T.8;_ (-VVPD^.X UCP@YS+_E=<)]AZE9
M@>*SA9^UJ"10)6 &)%FK6-J7^..9+DRTCH%A%YR4J;%E#@%Q0R2'(N6HYW8P
M/H9.,;U9$8[@<."(CDH2S#1<&YS<93[(<$=Y<1%@>K>.A3KCB9"FUOM..*6A
MSQ%*UE1[&IZ0QXM/W+$D%M*KW<TJ7?F>-7^,CAYG=?\ Z!X'-3L#$D!P*M^Z
M87=K@VBJCT+W&&UE2+XX<&E(4IQ 37MR$^&XIS(<:6C;M)0O\KFQD*2X4+=(
M!&K?X/31_P!XSF )_4:>_P V%79[QRB_QL80I2A/03",""/_ (JB6U(,HA@Q
M#,"33N@?0P<8G,5&^.&I_.""NL;B/+PT$E"</;<JRGQ4A:1E/A!(#9&!JTOV
M.*(_VE-LU2;/6ZBYU )H3%%?C9S252?]#,&@D@A0G).4?Y@GJF)#Y@"*T&D%
M>AAXQBKPSN!PZ+4E;/B>-<6Y#@>4RE08<= VZ/.XV25-K4E;H?(?\1#B,C',
M]C2E!0_:DX."E1S5L0.37LQN3>-69^-$+E2Y Z*R5&6I*BDS4!+#F9+.!8D-
M<N8IJ]#%QC%391?O#>.11 2FN;D) 2HGFYT)V^!YDX2HKYB%)RGER#K71[%)
MJ1_M2=0E@Y(KHJK^(.U(SK_&VI<]$\=$))6E!E$F>@LD @#_ +)ZOH6Y->!]
M#!QF(0DHOSAK;(*BA;5:W*BE"RA+*E-^JV$TMA#J  IJ-X02CQT^(/6%YR'V
M.SR C]J30*'0AQRS!+<J,Y;GB_UU.KEI0.AF&F-,2O*J>A*2<V8&DI@0]P I
MP*L8KCT-G&HT9"F-Q.'.*J8PF/+$6Y-SFERH22E::=(6WM^A3\)LI ,>0M<9
M:DI*F%%"7AFE>QJ=+"BGBL])51NL4.R?X2\S,0+540P%"0\5QOXT4XK$HG+Z
M"</4R7*EXG,H%(+*#R7<D7U%@8@KT,_&2\\[+EW_ ,-[\Z2]XDF8]<>YLAUY
M26TM(>6\]MRJ5XW@H#(4EWV$)2E*N1( A7L;7,5E7Q7$$$@G,HDYK/59(ILU
M*.U(Q8/\9TG!F;.3T"P(*Y@6R,3E4%U90/4WK6 ]#)QEDG%^\-_7E!"+@W)0
MZ4GE0XDNHV["BI;?,V'"HNI0I:0XWSJ.M<^Q-*9G9XBLI<$B8YKN[N=F9V*@
M341RL_\ '-BYTO*.@\@IV/$*;&AEEJ4T'NB ]"YQ@)2CFO;AO\5L) +5P;D-
MA'*I3H+8&W* T<K4@+;1SAO\4E*65!EO:/L92M(2.(*1EKFE@@Z\]:/<TV$:
M2/QHX:8E*9_03" E0+C%)55G8 (2P</MR%Q:K]#-QA+"D)OKAL4A&$EI-9W'
M2$M<N%M@#;T!M).%<B0&2H9\/VB=:R?8@!,SJXE-6*,,S, 7:ION.;/M:;^-
MP3P<.GH5ATRY*5% _,Y@2 R1E9A6@9V ;<'G;0]#9Q94F]K#JU8O_AZ71Z!>
M%G7'5!3ZK?LB6:70[GIE8J+5+8J%B"*B>_&@N>K!UQ*DSG65"?&C*>0CM/!_
M9?*X5B),Y.-F*4A:" M9+95/V0[.3?5R*@4'3>EGXJATFZ/<0X:OHQ)P<W'8
M:;)5-1,2OMJ24@FE&S%C0>31ZN<5^P&^FX&[NUNZ>S],L>OL6?:ES4.JT*\;
MJG6OZRY<'J_@/19D6@W&HJ890XE\KCM+?<*_Q[)4R^SZ)C\"N>):$_O& ';.
M@.ZB0:;OYM'PIQCA,WB<T8J6D*8)[)* $]I1(8TJ#H VF4TC#J=G>/1FFQJ?
M#L'A]AOPUPFH\A[=*XZC(@4UD1DR8D)4O;I7@^LI0^,MN)<94X76'VWL+-4\
M'DY$$H *0V6X&[ BGAWTC&."39<J6B3-2A*4!(EJ964D58DD 4%BX;D\2,[+
M<>;,<-?P=<-KTVEMEFT*S,W+N9V5;G-29--;4M;6W'BS8\=J;45!EPJ=:1)?
M5'=]9=4Z:+X;*#@(2HM<T+%DL"Q]XU)9ZG2G<$XHL]B?+)LDE*,R01E9)<)M
M9P6-4D*J>@79PG\9=R4O=N$_M9PZQ9.YUNU.W5/4W=BXJ9&I2ZDA+LJKN0XN
MU8=JJGIZ4R(RZC4G)T)AM%/94F,I]3U)?"@DJF) 22[I30"K <F/C7O 8;H[
M-$Q4R?DZU?ZBA*<H[>=*4_J(": .2;5H(WDO#A>N6^N!61PK2;@H]!NVJ;'T
MK;!^YT1G:K2(-5@V[3Z3)J$1A+=*=DQ''8?.T%(BN!M0P$*! [%PO$G!3)3)
M+RZW#D@%GI8/8$]^_;)&%3)EI!T#&@85VUV^6_F99GHM^.FQ-OK7V\MSB7X?
M(5*M.-/ATVK#;;<YRX!3ZM*8F5&CN5!>X_-&I$M<-EJ52H!9IDH.*6Y!#R?6
M==KG=)IDP$=54A(423VL@ !(_P PL"2]+L (E6%02U=6M5W!+-0%]P^E;Y'K
M? ]Z2FJMTQ'UHN&FE3+;-.:MNITC:S<>%.MNGQ'+84FFTPKO22TIM\VA2Y$O
MZ3348DQR5,B(A1822)'&_M1*BM2Y9*UDDM8]IVNP?,HN*OX1 PLMA1S4U9VI
M<GNY#5KMUB]O1V^D-OJG.TNL\2W## ITF>BHHATS8^MNB++2]/>DF+(J-0DR
M_P"Z2ZA(CU+UZ3/1ZBM3-/;@.(2XJ\OC*I<\S0E7Z$I!*JT '?4BKWISC%-P
MJ%-E3;5P#NWFVM#4V:,U;!^COWRLJO[TU_<[<+9#UO<;8>E;*6K3]F[#N^U+
M=M2)1JA-J$&:FC5V[*E'C1VURUK=IUNMT:--G..SI2?6'5/#@.D2$\<P<_#3
M5*"9B69O/SYF@V:NY@3^57*4'(0H$O4WO4[;Q%'HW=VFVXZ4;U6*%,(Y?9VY
MK" ISD:9\5)3=N6UF.@H0!T0K! ZDGY>G?ASP"ILV<G%2TE<]4P)""!E+U+*
M8*K:_/6/74^UC'@2T_E494 .&%VL.3UHP#D Q%/HX-WD 8WKLAL)6M0#&WM<
M8(6X%EYXAB^F$>(^58D+"2N025O%?GK_ .KY*P\P34XZ6M(5FZOJU"@(-\S:
M 6O>)F>U+$XA*D' RTY@0X9P5!G<"FIO77:-YN%38&N;!V=5;;K]T4^[*G6+
MIJERNU&F4MZCQ6/I!:4MQ!%EU*J.J+++8;YTNC*EE04,:]XZ&]&I71S "0D
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M#,3PN;,PN+EF5-"B"E6E=VU#U[[".[);23@H"@!G\@ ],D@8&<X'3'V:N7N
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MLM86>4C&,^?<],#IK',T\?E#UZ]?.)"VK ]DDX[Y\O=U'ZM8X1;N)45]U)4
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MT(LPI4/IO0=U_'E42D)=T)(<BS=WN'.D;#;;;=6MM/:%"L2QJ2S1;9M^$F)
MA,*SD!Q;S\J4\XI;TBIU&2X[.J,MYQR149S[\N4XMQU1$N]1K7S@X%F JPV
M^0M&2QX9"24*3S>1(!Z_#R^S/36/K.7O^T6;U7Z>/=SI%WK)$0TA#2$6)_CV
M_P#%T_ZQTA%]I"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI",3[KWK
M4[ M*JW/1[3JMZU.F*9<AVW1IU+AU"JI>ELL2Q'>JDB/&3ZG$=?E*2\I(6&_
M#:)4KGU"!+*SF+5<F]N]AXNXKX%*86>WN>]-M;4#QJ2KC#O\J"4<,NYI2C*0
M3<%A94D= I2%U]"AS8&0M"5C.%!)! Y!,K!,'G.P!(ZNQ&@[?]QS,:,U<T52
MAV=G6_=0I)T^\3CC!W"P/^+!N6?C^$-@=?\ ]PZV!A.'$ _G%!P"W5$L^GZ]
M(Q=;C-)8;3M__P Q)]<>_O\ T9MQOOKUAY^_^[VI_)\._P#'*_\ QS_^Z)Z[
M&_[I/_4/Z(I)XQ[\)(^K/N6<K*$%-?L,A7XM#@!YK@24J]ISF21[*4 GVU%M
M-3@^$_\ CE?^BK<C28=*^[F;];CS_P#;T_S@:/\ Y1SKR\HIXQ+Y(*CPS[EE
ML<B2M-;L-0YW$DH3A5Q)R<I4%'J@  A:P<:H,#PEP!CEW%>H.]2.V[ZAS]#!
MF<09DRW)LG.')T#Z T!-@\0^N+>H!2>&#<U*$E2^;Z>L$!)4DAQ2FQ7\J]@G
MIDJ\DD:+X=PE18X];.03^76 QN[3B;EV(-+"L4Z[C,IBKAX) ?\ ^IED=FH#
M%%GT=FIJ8J*XP+W;4H*X7MSDGF=0$"X+&4TVIMU?,MP)N-3KJW%("6ELM.,I
M1A:U) (U9/#>$ .GB9+/;#+)!U%5@#>IW8-%TX_C"U 'AJ<I(S$SY='J6_=N
M1R#>#Q+]<*]%*0ZKA;W&4>51;<5<%@*2 %%M20I-QG!"@0$Y)4I*P>7EP;CA
M_"FKQ-0;0X93"M;3?A4TWB)N+XH#_LY+%@YQ,NPU+(4:<W/.T3JXQK[2E83P
MS;E#"2L<]PV"&D!(*BI2S<94AI"<K<4@.+#:5%#;B@&U5. X0"W[3SD73^67
M47/\;%A6ITB!B.)K&56$0A)'ZDSP2&J&'4I<$LEWL2:LT2KXQ+_!]CAFW*Z@
ME 77;'25#F(2 &[A=(<*0'2WU4$= "Y[&I&!X2'/YTBSMASRTZR@KRY[Q&;'
M?Y/_ '#XY?EX:137QD7Y_%GAGW*!!ZCZ>L8<J@"2DA=P)4%#H2 "G!'M9) '
M!<)37\\IR;G#DUMK,#C:M["D7?'90<ESJ0!YA+@W85 J]8F1QB7]Y\,^YGVB
MO6+_ /=<6/EJ@PO#!48Q]OW"AY$+,'QNJ1_U>^Q/OB<\8E_^7#-N<L@$\OT_
M80SY8_\ *%1Z@G'*E1!\L9(+DX(#]SB.L67#9%!@SO56A H-X9L2&ZQ("3J%
M/7:U'#U8^^-F]G-RJWN9;DFMUK;ZO;=RHU27#;H5PSZ1/FNMI2DB<E^CRID=
M#:N;"6BOQ!@DZXY;/2N_]M.?-^4;J"2D>XW<=^O?&<$@]#TSTR>W,, _HR1]
MV?LP+T\?E%XQONMN/$VMLNKWI,H5P7'&H_JH>I-KPFJC69+<R9'A<T2&\]&;
M=+"WTNN@OH*64.K&2G!R2@9A"10\]8D DMK&H X\[67E2-EM^%E 2I:4VI Y
M %]0HK%74VE..8K4MQ 0EM9)'+C7(HX6J8DKSHN1^JM+6Y4IKIK&K-GF6O*Q
M- 7IKI5S\FYQ*KCSM-(*SLYOJI("UY1:D/E2AMM;BU+S5!RIY4=#U"U+2VG+
MN4"XX.K5<L?\Q^GAI7E6,1Q1&A/_ $C;4\^40^OQ:G,>39??7*4(64_@9$6X
M.=/B!"TFL I=:1CQF5E#J%9;2A:T+"7[&7_FED'_ (P'T(K<T:QTC&>(Y24M
M,!'(,_>X$53Q[VV,E6S&^*",$@V7 "@.B@,?3F1D$$ X.",C3]C&W[O_ -0;
M<PU;OJ]#I$?M*K-,L]D_U4Y/YQ2/'Q;"L$;-[XIZ>5E4_K\>M<U<<)F , FE
M!V]J: 0_.E50%AP]QK6Q=NYWW,5$\>ELJ /\#>^>  #FSJ8G)QY'Z5) SY$J
M]V3WUB5P=9/ZY3EZ$@D,:BI+U?3OC*G%D@.%NP%@IZ?#T6BV5Q\6FASD7LWO
MFG/=!LN&M:^8*++@;16>=PNE*T1W6T%!6DI  2I21P"DZHI2BJ 5#_0TI9Z1
M/6$U8UW8'O-*<P/*D9HV8XBJ1O55JM3:98>XMJR*+&8E/OWG0H]+C34NN!M3
M41V//EA3K8)*D+"<X[)/4Z:Y"45)!>IH.6I],00XK&4+4S %Z-IX CEN/(F-
MJ]88V(:0AI"+$_Q[?^+I_P!8Z0B^TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0
MTA#2$-(0TA%L[%:>Y@X XE9',VM*5-D9&?9(SE2?9SS=,YQTU&4.[5A7?N]<
MW]5>GZBS_-223G)2#_5HPLP;9H4U /?#U!GW#_,1_5HPV'D(1#U%KW-_]E_^
M6C#8>0A&FW%OO)NSLK8U"K>R^RUP[V7;5[F5&E4&@,QRNG42'3*K7JE,E!Z0
MP!)F-TDT&GJ*L/UNH175X86X4C8OXTT_M_;2)=5 "SGN?X-;N T://2_O2G;
MD;&WW;&W>Y6RUO5:Y6-O=F;EORV:'=L>-N?+K^[E2?@?@]M_8<@N.W NR7&S
M]/QVEJ=#$>0^POPT<VI+[[^>_J\'55E$5?Z[4-?3-O@QQ^\+KMX5&S#>J_I2
MCR[FI-4J*;<KCEL-7/9=!F71==H,W0B(:)*N>@T:GSGI]+CRG5^/&=BLN/2$
M.-(@.-:BKZW[_+;W14A[L;O3?:M(U3XC/2L;16_L#NI>_#I6Z?=>Z5D6GMY?
MM#M6]K<N2WT7!M_>U[6W9[-Z4F/58-.DUNW2:T['34(12A%5Y(CS>5!2[9E5
M[2G(-7^U0*%M]=( "KI27T8MY/Z\WW88XN-DH=]3]MZS5:K;UQ4VE5FKNR[@
MM>KT2VJB+7@1IURQ:+7ZA$:@U.31X<E,Z2S%4H>KK4IE;ZDN<D.=R'U%WW.G
MN^,1E2[LD-9A8<J^A2,<H](YPL2*!2:U&N*YGW+JK;MOV)11MW=;-Q[@SFZ8
MJL^-8]$E4IJ1<-/12VGI\BH1^6+&C,ER2MKQHX>@O_F47I4N-ZCPTK%CX#S]
M]?@T=67Q6[E;J;D;4+X9;#;OO8B^K?LBJ3]U*G2IT&D0W[AOEAROMM&4J'.C
M/V785LWVQ68DR$U+@7U5+-H[J/%E2$,B^FOBU#]O$F'::A^+<]=:?>/1J+&9
M=!!0V5 J3DI"R$ Y3D*/.,JYNBCS!0)/0IT(>]1\]_LS1.96Y\S%\(+(&.1O
M_L\?J5HPV'D(.K_,>YZ?7WP,%@]"AO'7(\,$'((Z\Q5VSGI@Y\\9!-M3N =M
MH@UO76M8G;B,M!0:0VV%J4HAMM*!E7<\J  3_A$$_'RU #:D_P!@/7AJ'A%5
M8*6U#F).!C)Z]",^>I(<$;AHK0%R;TY<O'QWTM8.L(?96VXVEY"@ MMQ"5H(
MY@1S)4DH5^3YCI^G54@I4X+=W]W#:7[XN_>^[_;YQBK=1JM47;V\JEMY:]/N
M"_(=MUEZT*,N-";3/N$P7A1XCSCH9;;B&>J,[(YGFTJ996.89R,PFS!9:AXG
M2F^O]]HQ+"7JD$,*V]VI'?K>QCQWX@N(;C,V M+;9F\ALM;-4W1W:OVWYFZV
MYEC7)5]L]L;$LVWDIMAR\U6,BHR(=0W,JT>I7$S7ZBIB@4.,_P"JU H<C>(J
M,\W_ 'JP-G+,'M5_>SWY5 EDGL#G77T7.I H'I%Y<O'!N1%WQVWV[5<&T,R@
M3=]^'NR+W7:UMS)]*:MW<'AUN;<FY)-+N^8\*?<$1ZN4A-2H-6IZ.6FT8%$\
M*==;*QF3J-.78"IO<D-W[]XY $L?W0(K4W#?!]:,]'C*#OI>^"2%2;WK:H->
MDT>TJ4;BI\R!:,6I.7W;C=WP[(FUBS($*5(J,]N)7ZA';5#FQ:?,>BNMRF&5
M-+!U)FSB3^_F?]1%--?[UK$@!JRDW.GU3ZY4C*E.](?L!4+0KU<_@JW1@WE1
M=Q:'M9'V=G;:+C;IUV\+JHZ+BMB'0[:<<2)D.KV^XJM(J'K:(T:%'D*DK:4C
M&IZV=_O9A-!^I5=+9O/?0/$,@L<@ .KMWMOX=PM'6MSO2C<(^T5PVY;5]T"[
M*%-J=H61>MU^O63&A.;8TO<28Y3K8C7S"ERF:E#JK\ME8G0*=#J#U/C<LV2$
M,DE+K9G^\7<ZESYDGR-XEDBN1MZT<4(H*AP6?>MXR!L'4.*RZ=Z;IG[K63:E
MJ[$"%=E4MADPJ2[7I_KU?B0K%@H=@R7'&E1:# GUFK2'&?">-9IT?F"V74I&
M:LBYL [DGQ<GU[[%";BU^7-F]<H]"(5/B-8+,=B,ISF*U,,M,E9SS)\0M!/.
M$D8"2<>??&L*B34S-=:[&Y-:$<FOK%F&P]/]?#2.>U:)AI"&D(LL*+R3CHEA
M(S\">_?WG'_<=(1>Z0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI
M"&D(:0AI".%=A%OF<YVR0$Y2I*^124*'A9QD)*4I4V#Y)4L]22=(1XW<5GHV
M[IWNWYW+XE+#K]B6KOC!M;:!OANOJIP)TFN[<W?M[5JC*N1<M^,$K70[JI%5
MF4F6U&+9DLO)+J"M"%"&]>?F.4/7K;YQKV/1W[D[(6;Q&W)?+FW&X%C,#B<W
MXH%PIK-]4^ZK.JUY[<7C-DQ*19#[_P""TBO4BNU>J4ZE7.IY#<NB2W@:<W*<
M+RI#M7GHWIH<A\O0'TC&[7HU^*;B[VNMW<_=/<C9ZEU^K<$NQNP.V-,L^@W3
M%I4BC0KPV\W?JM[7TN8[)6S6YL*BL41BAT9V1284QHRV)2'G7FV4-?OZ]=\;
M57/Z/[BDW*W?J=R[C[NVQ6;-0C>:%0:@:I><ZO1:#N%:C=NVO;T"V)R!;E I
M5H.E]Q]5-;>D50J4XF9%2\MK2$=6OC@+XVMST<*-Q7Q>&P+-Q\(->FL6I;=H
M.;DVQ3;YM6JV4Q;-5GU"XXLXU"U+B3.@P:A ,&',IK* [!FB6.1QJ*_#[CUO
M VIZ/KNCUAX8MGSLOLG9.VKM&MJW)E&36IM3I5H3:S4[>:JEPW#5;GK)IU4N
M'Q*S4F9U4JTB5*FSEH>E2E.N^&E"@!,(V,8C!DI/.M7*D@ G(&>_4^T1T]D$
MX3Y#STA%SI"&D(:0B122K';S[_'2*+!+-H_RBD$*;.>='7R4< X[?+/^V=(L
M'U#-S=XMWXX<0K*QA9 /*>APK)'7H<C*59[ Z0(?5J-86^/O^L:,<;FP_$=O
MO8\C;S8[=#:JQ[8O.U+SL/=*@;I;8/;BTVO6_>5.BTU$^CF'6Z'*I%5HL=-2
M\%IUV;3J@JH!4J&Z8C02]5]>M8KD'/1N7G<?(1HUMKZ'MG;*H[;TBC[LJK.W
M^VMV;$U.#!KE)=E7)5[?VCV"N/9:J0*C64U!B%]-W5(KYK*JA$@MM18D*-3S
M#<:#3JT9*,:EZM9N6AMY;F,*6AZ#.395L;@V#;%Q</5M4NMLTR!:VX=N;,52
M#O+)I$#<NAWUX%]W8[=[T:M2$0J(BCK>I=,HT>2^&9TM#ZVELN&%?+PK]84Y
MCD:U]-I&Z^\? #N9=-[WEO!MCN];%I;M1MV]JMX=J:I<]G.W';5O5.PMMSMA
M6Z3=M(:K%*?K],N>CRZDMM4*329%.DN-.L25\O*I%"D$DUW'(_"NM(UIWJ]$
M#?>\F\]O;Z7=>O#?N1?E;VYVRMC=JK[O[ .W7RWQM^N457KM3#A732$V:W4H
M#[<2-;]2%>AMJ;349*7YRU++UZ]>4,M&<\CJ.0IR'>8]XZ;1HT2,Q&CH2Q'C
M1HT9EAH<K3;49(2TE#9SR\J<I!(RE!*.VL650);5]1[^?.+O;EOYGU?X#G?#
M5E)'(.7L #^GK^K&F4TH?,>[;WQ$5M980TA#2$6_F/\ W*?]8:0BXTA#2$-(
M0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$6I)Z))40IY2""H
M_DX[9SD=_(@]CY#2$<>XA(46QDHYFDD%2E*4E14"%K42M>0D?EJ4>@TA%JIM
M#CKC:TA;9<DL%"NJ%,IC<_AK2>BTK*CXH4#XR<)>YT@ (18-*Y/5E)0T%*2I
MDJ\%DGPHZ4I8;!*#RH:2XX$!. D..8_+5E".1Z%Y*2E!07)"2@MH*2$)*DY2
M4\N0KKG&2<DDY.D(Y!#+:W<$'V0C!2M:2.9#A)RE0)/4X))*02$D D:0BZ:9
M;;7E"<%7B<QR25$+ "E$D\R@"1SJRK!(SC2$7&D(:0AI"&D(:0BW?_D?Y7_V
MZ0B@.I'VC2$3/H27F04@A6 <CK@<V,'NDIZE*@0I)*BD@J.4(M"D);;( &7D
ML^\>$4 \@!Z 9/3 R E !PA 3(J1WB*.776P#<J&)U$@'J24%(25$J(!4T#U
M5DDGF/4DGMUZ#$1!IG;1FY/?SBB?9<RG .7^P _);:('3RRM1([$DD@G2,D5
MT=77@<$-.!IOH,I;5X1*2<95U.<J)(."""!A".10 $I( R4C)\ST\SW/WZ0B
+?2$-(0TA#2$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g549728g14f03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g14f03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1TJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '0Z^=#@X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R-C S
M-S(X' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !#)UP7-OLM%:8MBYS];
M(!5-.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M           !2@   <     & &< ,0 T &8 ,  S     0
M           !              '    !2@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !2@    !29VAT;&]N9P   <     &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   4H     4F=H=&QO;F<   '      W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    $.$))300,     !*(     0
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MC3;1FXL,W%]CW[=P=L=4'0UKO:6V,=^>K7V/ _T;_P#MQ_\ Z42^QX'^C?\
M]N/_ /2B2F>1A;,>U[;[]S6.+?TCN0#"LXKG.QJGN,N<QI)\20%2=@].<"TU
M/((@CU'Z@_VU;;=6T!K6PT: #L DI?,>YF)<]AVN;6]S3X$-*R7VVU7FEU&?
M8V&[+JGES7>UCK-VYS/3VNL_ZY[_ -Q:CKJ[&%KV2UX@@P9!'"JC"Z>! K>
M-/YQ_;_KB2FG]L YQ>J2!+A#M-7-V_3VN^C_ (/_ $G]=)V:*VES\?J0EXK8
MR27N);9;N:S?]!K:?WE=^QX'^C?_ -N/_P#2B0Q,$<5V>?Z5_P#Z424U/M/M
ML(Q^I LB =T'<2UNW:Y_]=_^C4&YCBW7%ZDVR"2/?MD#W-W_ $_ZGZ+WJ]]D
MP/\ 1O\ ^W'_ /I1+['@_P"C?_VX_P#]*)*:U5]=E5]GI]0:<?1U3B=Y.SUH
M8QKW;OW?ZZJ_;\O=_0.H;  7'>^?^$VLV>_9_P""?]!:?V/!T_1OTX_2/_\
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M:UP>UIK:X!P_.;O_ .J24M1G85];K:;FNK80USC+0"1N:
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!/0&N P$1  (1 0,1 ?_$ !X    & P$!               ! @4&!P,$
M" D*_\0 ;A   0,# P(#! 4$"0P+"P<- 0(#! 4&$0 2(0<Q"!-!%")1814R
M<8&1%B.AL0D7&#-"5,'1X20U4E-8<G23E++2\"4T-D-$8G."DJ+6)B@X1F.6
ME\+3U_$G-T=(@[/&&4579FAV=X:(F*:TXO_$ !T! 0 # 0$! 0$!
M   ! @,$!@4'" G_Q !"$0 ! P(#!@0% P0! P,#!0$!  (1(3$#05$$$F%Q
MD? %@:&Q$R+!T>$&,O$'%$)2(Q9BHC-RDA<D4P@50X+2PO_:  P# 0 "$0,1
M #\ ^_C1$AQ6U"B.^.,?'1%R/U3Z[7U;G56G](>F_3"M]0;G=Z>HZCU-V+5;
M+I%+I]%G7&Y;,*.^]<]WVJ5R9,NF5(_U$Y+4A)"E!/?1%HM]6?%-@E?ABK&1
MWV7QT?#()YX2>K9YSVSD?9C&HKJ.A^Z)?[;OBC_N8+@_\]^C'PS_ /I8^'.H
MAW^WH%,#4>OV03U:\4JB0?#%<'8_^._1A/&#SQU8W?'ZO(QG2'?[#IQ^W\YI
MYSRGZPE#JMXH@>?#%<)QW'Y=='S]O ZLYXSJ?FU'0_=0L:^K/BC )'ABN  \
M#%[]'<$GD ;^K"QD@$\A7Q].'S<.-#]Z^B+77U;\4^1M\,-Q'U_W;]&#C/Q_
M^6B-QC/^]X]>=/FX'C4<Z:^:+,GJSXI<A9\,-PG(R!^6W1C;@CCG]MM\^H./
M./)SR,ZCYM0.0GW^WX+)^V[XH_[F"X/_ #WZ,_\ O8TAW^W_ (A3 U'K]D1Z
MN>*,\?N8;@&"/_'?HT.3@ ';U9!&=PQG@D@=R-(=_L#S$>R1Q!Z_4!+/5CQ1
MA)'[F&X-W;/Y<='4GTXROJPH9Y' "3VYQP9KJ.<?2?KU4+63U9\5!5_X,-P$
M X(%Z]&2 >,9/[=:?CS^;^[D A,5@GI]_;[HLG[;'BH2%']S%<&,#&+XZ+KQ
MQD@ ]7$;>.<[UDC.-N,F/FI!!UD1YT[^A(3U8\5!('[F*X..^Z]NCB>3QV1U
M=7P#CZQ&,C&<G4_-F1T)^H1!SJUXITG \,5?S\4WQT;/R.0OJ\V< \9 (SCG
M.H^;4<:'[_9%D3U<\4H'O>&*X%'_ /?3HPC  &>W5QS./4Y'V>I0[4#D)GG*
MF!J!SGZ I7[;GBD_N8+@_P#/;HSZ=_\ Z6/32'?[?^(2!J/7[(#JQXHG,']S
M%< SP +YZ.#/PP$]6<'/Q]=3#M1T_*CSGK]0$K]MGQ1(3QX8K@/?O?'1D^F<
M[E]62?AGCMVTKPY_C\HB_;;\4O\ <OW#]U[=&3^G]MC40[_;T"F.(]?LDCJS
MXH]V3X8+AY]#>W1_:/N1U: _#CXC3YM1&L&>DJ%B7U:\4B7/=\,-<*N5X3>?
M2%;BCR-J0>K6 $H<S@ =N_',UU$\C]^24[/X5G]!NJ\[K%8)O"9;E3M.="O+
MJ18E9H53E46;(A5OIE?]Q]/:TLR:!5:S370Y5K8FNM%NKR<MN)!V+W,HGL]R
MBOILDH2223@Y)QD\GG@ ?H_GT1+T1#1%I25J04$)/O*V#!/(/<_(>GST1<J=
M3NN-]6UU2IG27ISTNK'4:Y95@2.HE4?I]8M*C0:?23<C=LQ$)_*R[K61*EF6
MB6K%+5+4D,I,T10_%,H9IPX7[[HG???U3*.K7BG)('ACKZDY]UU%[=&7-^5/
M#D_MPQ",XP" ,$ \G@17*/4??IZTJ69OJQXI0.?#%<(QCDWOT>(YY&<]890_
M2D=N1I6<HZGZ1ZHLO[;OBC[_ +F&OX')/Y;]&.!QS_\ .Q\Q^(U$._V_\0I@
M:CU^R!ZN^*+!)\,%?V^I-[=&,8^9_;8Q^.D._P!O_$) U'K]EC7U8\5 22/#
M'7MH]!?'19)QG@9'5M!'_2'WC3YO^WH?NH2&^K7BH.1^YBN,CYWIT95V^*T=
M7U+&3G&$JR1M..2)^;4=#]T64=6_%$#G]S%<)(SD&]^CN!W[A75K:/O&H^;4
M#D"?=$O]MWQ1GMX8+@/_ /._1C_WL:0[_;_Q"F!J/7[(OVWO%%_<PU_T_P#'
M?HQZ]O\ Z6/7TTAW^W_B$@:CU^R,]7?%&!D^&"X .^3>_1C&/C_\[&D._P!O
M_$) U'K]D/VW?%'_ ',%P?\ GOT9_P#>QI#O]O\ Q"0-1Z_9%^VUXHU__5BN
M 8__ %WZ-\\9Q[G5GX GGT!/;.D._P!@>8^Q"'F#U^H"PJZL^*=)5_WL5Q =
MP?RUZ-G@=R=_5YO Y&,9'//S?-JWH5'??967]MCQ3G;GPQ5X9&03>W1M.1_]
MGU=6#]I(_GGYLR.A^X18#U7\5(5N'ABN @^@O;H^H8S_ /QC;QC/]H6.0=Y^
MJ%>'MZ5XYCZHM@=7/%(,Y\+]P9]?^[3HTGGM_"ZL GX9Y'IDXU!#O]H\@?XY
M5YJ8X@=?H"C_ &W/%'_<P7!_Y[=&?_>QI#O]O_$) U'K]D!U9\4BCG]S#<&#
MZ?EOT>P?E[G5D#GOQ\_7.D.U'.*])COS4><]?J C5U9\4.,CPPU\ <D_EOT?
M[?:>K9&/P[=]/F_[>A^ZDQE/G3[I/[;GBC''[F&X.#C_ ';]&>_PYZLDY^WG
M2'?[1R'W2.(]?LH9?OB&\15A6?=5]5_PUW-%HMH6]6KDK#K%W](I3B:91*7-
MK,Y4>-%ZK*D+>$:GN-Q_+$@F65J$?:=NK"<X-O/7KH.J@]TSU\LIZ2NR[-N)
M%VVQ;MTQF),2-<]&I5=CQ)A9,J(Q5H#%0:CR51G'HYD,M2$-/F.ZZR70KRG%
MH*5DBE^B(:(AHB&B+C-TJ'CNFD("U?N4* =H.T9_;;NC!Y^8/'R/PT1<]WSX
MO^M72[KQU"L_J!9/2Z/TBZ;6.KJM7;KHM6N>=>,CIU+N!RWZ8N#1%LM0'+G=
MEE"Y$-3S<1MM>675)QDEQS5G0O'UT=-=M6BUFV^I]J+O*E5&HV_)NFU6J6S4
M%4VBSKC5"3%%4=J*)S](@29459A&)(\M;'M+;@ )$R4?]D?\/UQT>WJM;R+[
MF2[JONGV%0Z$[;4>+7YU1K=OBZH$T1JG5(L%%(G4%:9D)U4X/2&D.-QF'E*"
M22L\(^ZC)_9#.F%H0ZE^VE,E"K?MB]2+>IE-M2C27'(ML6%6(4-ZO5Y-5J41
MYOZ.$EJGSG82I29,IJ3[/#=2TH:(LM_?LD'1NVZ/U2D6M0;WO*K=-*<[/D0(
MM"=B4ZLOQWZ0S(=I%6??2S)3!B5F#.FA/D%J,\,)2XX4F)T@\<OSW4(KGZG^
M,'IST?Z66!U2OJBWI A=0(#\NEV_%HC<BYF40+=>NJK+J$!VHQ(\6)2Z+$F2
MI>^4Y)5'#:8C+L@!HRBJ6N?LFGAQMJ4_%JCUZQWH-O?3<T?DVPM-/J0M$WZN
MU94=NJHF)K\>VD>?)BHC.0_/=B1$SD/E:$Q/=^=)RSS3OVX]^[Q+_9&>@5-M
M%=VSF+ZB%JZIMG2+4GT"/ NJ/5(-*3<4Q^3 J%3BM,P&J(ZFH*<]L4I392AM
MI2R 916I>7BWZ4VG1^B]86NNUZ)UY?".G3% IT>8_4FD08E1F2IB)E1@)C)@
MP9C+Z4H<DS'WV@W$BN+:5IS,<2H[[R\^7ESG3_'W!MBY[G=ZE(@-V11.D=GW
MG3W+>A2T5ZJ73=O6._NFD&BQ:?4Y:=B&V+3IK23-E)6Y/=E/%:6 0VY)WWP]
M)XJ52_V2?P\,L6LXT;[G,W) ;G/2*5:9FM6]'57T6L^[<,F/-7&@F)6E-1'B
MA<A"_,#C;JD@ E*=*YXY[#7>%G4:V!.7;4CJ!>MH7)7*C;E0-/KK%E=-[\NR
MKBPZQ'E)AS)-'F69(@U)^H-HCI"7HA;0\^R\EW[_ &GLJ*#RUZW*TJ+^R.=!
M;@M"NWE!AW^VQ18-HUJ/3*E:IIE7KU(OJ4JGVS5:-%E5%$>7 JDM#T9B4\^R
MVI"&Y*#M4T24]]]^ZZ5Z5]>+!ZK]/K2ZETF<_;M O>4]!MUF]40[;K-2FQWG
MVS"9AOS'P\\'([ZFFV775NMM^;Y>.=$5%=:/&A:5@U'KO8E#;J4J_>B_3Y=]
MU^;-HYDVK1_:J,W<U!A5%46HL5B2:M3UH\MV' ]C>>0]#?EL.! 41<>77^R=
MW_:_5;J-9$.Q^GE?A6H_6:72Z5&K5R-WK*52>E-.ZA-W/5H"V#2(5J.R9J:6
M5M253FDJ#9\YU"\Q([RSKIYI;EWGGW>:3KIQ^R:1;XL^L7+5K0IMLS[2Z'7'
MU"O.@.S:@:A1K_H-;:HL:S&0ZA"7:?5UOT]^#/(0^Y'FAQI"T\Z$\^AX=_P4
M79'A!\0%5\2'2<75=EO0+/OZWKCKUEWW:=+FN5&G4&Y*/+>:+$>8\2[*CRH;
MT"6A:@/=<.,I3J477K)):03C)&58^J5'E13\4E62D^H(.B+)HBPXPZG^^6?Q
M;3_+HBY4\'A'[6%XGC_PG/&#Z_\ [4/5\9^_&B+K'1$-$0T18UI2L %0&.>X
MT1<>25H'CI64[2M'A+84G*BDE/[;LTE0"/0<>]VR,>NB*A^M7CBG]$O$1&Z9
M7'1[3D=.T,445NH1:S45]1J6BKTNXJQ-N9RWVHRZ>JV*0W0UL/RO/2MN0[Y:
M-%&OIT\^L>R>X/[)!X?*M2J7-I4?J%5YU7NMFS*=;U.M=B=<50J<ND-5Z#(C
M0J=593;E-J%)*I\:1[0EWR(KR7V8SF4AWW]?JD3-:&G+OBM3_P#*6^'9NOQ:
M!-IG4Z&S*K#]!:K\FRI*+>7*A79$L:KN+J*9:DJBT:XYM+@3I7EEEDSFE>8X
MJ,Z [S4J7W7X^.BMDW'U(L^ZH-[4BI=,J:[5ZRP];S+RJO18U?I]J/S*"Q&J
MKSLYMJL5:"P$RFX+[R7Q(::<3@E]436/V1+PZ,4ZWY]1?NVB3:U>E2L==NUN
M@*I]?HU3HPA*G52N4Z7/;5$HK3-3B+,M+DEYUN01'A..H6 0_P =T^BBUT_L
ME?1VD4GJ=,MFV^H-Q5[IW:/4RZ8<9VV13*7=_P"U=4XE"NUBA5I^=Y$D4.IU
M!DSG"PE+4%U,MH%17L)]>_+[\U<UU>+NP[&Z.V!UCO&B7I3J7U,3 70K111H
MYNT2)U)DU?V"93USV&(RFH<"=+<69JD^6A"VU.K=#>AZIS_"K"#^R3>&^J5.
MI4IF=="31[=J%?D/NTB.VA]%&I$>NU&E-LM5,S?IB!2Y3,IUI<5N*M)++3ZU
M)5DBW&OV1KP\M6C.N9]F_J8] O.E62Q:E6MAFE77.JM9MC\N(\B'3JA5&H[M
M&=M-2ZRQ49$V,VF/^9;"W2E!*!&2L2H>-'H^W3^AKM&<KUPK\0E!-Q=.(],I
M;+RI%*9BMS94JHIES8)8:I7M*&I<9A4F6I8Q&8?;RL%/?1<Q6K^R#QV;DJ4[
MJ.]0(M@0.GSEQM5&@4VHM5"9=;O4BH6/2Z'!C5&:%/KEB.E"6Y+C;#DDK>5)
M:82$I(K<B_LBWARG/]/8K<R[ >HCZXU-7^3Z76K9/[8<;I3-5=\J/478]#:@
M7E*9H[LI+DY@JG1$MN*$F.ETHX?CV6S6_&]:%61 G633+@8HIZM1>G<JZ+JM
MF<Q;%R%JMU.A5861/CS$?2RH\RE/-,S'66H:4*\]QMT(*=%*9H?[)-X=9U&N
M:MK;ZBPH=JTRDU=M-4M%4"7<<"M5Q^W8<NU_-FI:JT=54BOQ''2N*E+;14/>
M6!HBZYM#K-8]TV)8%^+K42VZ+U)I]/FVDS=<N%;LV;])0U38$,1)TM+@FR8S
M;SCM/0X_(0ZUL.Y6=$7*7BC\;U'Z*5AOI[:=/J%R=245GIVU5UHHTF;9U!I=
M\W3&I,-%?J[4EE=,G56GB2Y2=[;K+LII/FE+9]YWWWP1<\]6_P!DRDVU7^K+
M?3JV:;6K>Z=TJQ&&ZQ>J*K;]*G7)<E_3+0K$]%0@JD.S;7I CM@2H;2)"IS;
MJ?*6QE6B+0A_LH-PP(70JN71TVH)M/J%?W4BU+ZO6W*M59=OT>U[&K$6V&^I
M%G*EL,29=MN7%4X<2H+JS3"H<<2G4$^5DQ/=M=>\Z"$5GTW]D"GRZ=X=ZY4;
M.M]%'ZOWU=5O7=5XM9D&%9]#IE\/V!;M?@)?"53XU5K,BANOLR  B/*EKCJ*
MV0D3WW=.^_K[A=I=!>I\CJM1+VJ4KZ.<<MKJ1=MD9IS,N,D-V_)8:;6Z)BEK
M5,(=(4XT THC*3@'#OOFB5XKT@>&#Q"'!)_:5ZEGZN%?[CJ]R1S@GC[,=]$4
M\Z+^]TBZ6D\?]P%GG'S_ "<IO&B*T=$0T1#1$61VR,CDC/8?'1%QLXIO]W?)
M"EI!5X4:)M&X GRNK5WES;D\^6%I\S .S(W8R-$3AU5\+%A]6:]?]>N*JW'
MG=1NE,'I)6$4B=$8:BV["N!-Q-R82%Q'5,U<3T!A<A:9<5<7&V*A/.G>B*HK
ME_8_>F]R]5HW5FH7?>PJ,-N.[&H3=0HRZ0BHQ;.FV0*@V^_2'IC*GJ/.<<5!
M2X8#<U'M3+"?WLL_+[1]?I<J*\^^]/O&JC^QM]*I-HRK&A7GU"B6_5)/3Y5;
M2S/MMQ^93NGMITZS*+&C/2:#)?ITANG4MJ0Y5*,NEUJ+->=EP)):**>'?+DE
M?Q^=/+[)TJW['-TCDU"!6J'<5YVY7X=Y77=+U4A3J#5G9$.]78K];MB3'NB@
MU>#)HZ)=.BNQI:XJZX,*?34G"\\I]&67D:=Y437V-/I/OP4@J7@(Z5U*)?D.
M16;M,>^TWJ9S;%1IT7V!R]44-+XIX12E(":4[;\!^E)E"2S'=\U3J76UAI+O
MOJI43\5'@?N'Q!].^AUETGJTND53HI47IK5S7I;T>[)5R^?;R[?5+GQZ7/MQ
MOZ5CH=2^)(0B&ZIM212)3>]#B,]$6:?^QX]/ZY4;KK%4OR^U3^HE'@,]0!'%
MH,1;AN1JV(UMS[K1%5;KBJ//J+42,\_2Z1+I]#2^UEJFM(;2N0['2%'=.S5/
M5W?L?O3&[IM6K?Y3WC0;@JG4%/49%7IC] D2:?5G;2C6?.A0XU9H=1I[=,J%
M,B1_:H[K4AY+Z MB0T@8T_'I52K#ZS>%"V>M=A6)T[KUSW53*#9<FFKDIHSE
M$9D7*S3EPG61-EO4U,FDN..PD^;-MM="JT9EV8S!F->?'=015G<O[';T<N2F
MU6!*K%XM/5*U;8M>-46I],>G4I=G=4+FZLT:N0T2*:NG*J)N2[JLW*C2H\FF
M& B%!CQ_(845D3M)\!U@U"!4X]6NV\*C/J=AT^P)U11(MZD/R*?3+NCWC&FH
M%&H4* Q+3-BHC+,:EH8>B.*:4PM_:^@G?-8(?@&Z90ZE"?C73?<6@T6YK_N^
MW+-36J>[:]"K'4>S+NM.YW(=/<IRW4QYZ;OJD]4-R3+\R<B(ZXH-*DQY!1Y7
MH>5>OY5:=7/V-BVKRZ<QK-L/J%5;8K%-Z;]%>E$"K7-$3<U*=M3H=/7/MA=4
M@TF7;%1DSYZEJ9JB&JHW""MKD5B,E(*2GGZ<Z?E=?=).B/Y$]+^G-BWY5J?U
M(K%@,I7"N67;E,I:&)Z$O-LRJ72HP>8ICD5E[V>.\D2)H92H2IDM2U+43O*O
MUIY*GNL7@7Z>];[]NR^KZNJ]7)ESV3<5BL4JG3:!"I=$I%RVW#MJJJI[Z:3]
M)2'WV87MT$5N358]-EOOF&S$#B$)1W]$4?NC]CPZ.72NXY<JK7;"JUSWE-O&
M97J=,I?TM&>J-B0>GU2HS3CT-P"@SZ/#0ZY 6)1:F)3(C&,,H23W[[_A,]U?
ML:G0:[;OJ]V3)%SP7+HMJQ;7O2D1YL$46ZZ78<N-)A1ZQ$5&?4Z:R]#B_3RH
MJVURV8S ;D1R%Z(ND.BOAFZ;^'VM=2:ITKA+MJE=2*G2JW4K/8DH<M:F56FP
M(]*>F4:$ECSXSM898$FLD/N+=?0A;:UE2SH*=_;10:]W&BZ;CK0EEM)6D;04
MX4I 5@*(3NVK4DK( *BE12I62G ( *5F\QO^V(_Z2?Y]$6,*2I8.4\%92$J"
MRL82G< G)P.0H <'&>Y.B+D[P?.H/2V\5<A)\37B\6,I*1L7XI.L&Q8SCW5@
M90>R@04DC1%UN#D CUT1'HB&B+0>6$K!7E0_X@*C_![[1D#(QSCU&B+CYYU*
M_'2H9)C_ +D^*'-B4AQ#KO5ZH!E8<]X!3ODNI0R2'G"VX$,JV+*2=]]?96%<
MO0"P+JG=3JA<%+-2>ZIVW M.OO.-QO:H])IT.I4YJ-1IZ&&9E-1(;JDE3ZF7
MD(+B$/J\M+@"G???-1Z<J=Z<K%47TV\#%C]-IO3R5&O&\[B_:SO!^\+8^FE6
MM&6PM5LO6LS1IDBE4&$Y)@LT]XN)>.^?(DH0N55"E"D*)Y>V65TBI> SI=6+
M9HUM3:[=ACT5^^)$1X5.EHE>;?\ U3IG5JME3S=*2TI N&AP84-?D(=8HKDF
M*XVM]U#RG??JD?GIP%[74#E?L9G1Z=7[UN"9>?4.2Y>B*ZR]!FU&C/(HT&X[
MWI=^U&!2I2J4]4%,N5RB0VXRZC49[\2FJ+"76'2EQ(U(X5]_2#QYH)S,^4*>
MW#X"NEUPWPCJ(BX+GI%TJZ@56_GY<211)*'7:Y I<&I4%Z-,HLR&[2I3=+CJ
M4M+"JA&>"G(]1:"BE13]//NB6[X#.D$VGM4*;4+I>IGY/=>+<D1G*A!4U(@^
M(&8Q+NE#KC5)0[YD!UGS*&\A38@.H;=FM2%M,*5$#S-].ZG\RFOI7WIR47\0
M?@<JW6/HGT:Z14GJS.AR.CMQ0:S"O"]:8+CJM=@TZBU.A18=39HTZUXYE(BS
MT+2XEE,1QN,F/-IRBXI:Y[[[Y*/2_=*]UJL=*_8\K#@"\0Y?MXNQ^HE FTR]
M:7'C6G'I<VL5:APZ%6;AHZ?H%ZJ49V6S!9<:IS,Y=&8*MJ:8K*WA$=^O'Z4Y
M!3WWR]4ZWG^QZ]*[RJ4BO+N2\*3<8KMCW%2:W"F45UV@U2QK#<Z9L*IT6IT>
MI4]^%4[;D%ZI0*I3IL=^<REV"FGMH2=3GPT_*B/3W[XUK*E_4+P:6MU)MSI!
M;5RWQ=WT+TE8IB6H5--NPW+JD4Q, Q9U5E(H;$ZD3!["&5"VYE(2W$6[&"G$
M.E!*57KW[&[T0FTF?1YU9O)QJ3144J/*^D*0F9!D,WG(O>/6(;C%-2P9T6I2
MG8C;4EE4-^GJ6U(AO+7YI(GZ3X!>F55CVZ:W=EZUJ;0+:CVHJ;(>M^G+J-)A
M]=;0Z_-F;&HM$BQTOOW/9-"HSJ8+$1M5NIEQDI8FGVP$/?>?)9:7X%[,IU*C
MVXN_NI4^T:;?B>HEM6=4:W35T*S:NJM3[@>I]M,(ALO1:8].JLOSF'9LUXLN
M+C"H+4MUS11WS'3CEUNJJZL?L:%D7ETXIMFV5?5P6M6*!;=!M.D5FM)8N&FF
MC42Z*K=*6)M*C.460XX[4*JX%JA2H#26V(_E>8I"BJ(XGK][>4*<[>?T7==L
M=**2Q8M@6K?_ -&=0JO8D"CML7#5J)2(Y?K=*A&(*[!I\6-$@TN05*D+2W#B
MM,@+VI!"MRIC+WK[HN>>KG@@L+JOU(J/4B;>-^6U,N+\C%7;;UK5F%!MJ\)-
M@5?Z7M>H7'!DTV:I<FGOGR$(C*7&<C$I5&"@7 3OOORUA2?V-SHV*E=4M5SW
MXN'=D^VYBJ,*K3'J10H5KW@N]8M!H4>13'%0Z1.JTE\5*))=E"1'<6E"D+)*
M"C,>_/+T&GNI?"\!G1^%/J>^7<LRVJHSU;C"RGID VU3876EJ(S>4"E1O9/:
M8$9+T!FJ4MEN8EJ%.7(<27%.H043W[<4%./\^7IHJVB?L7?AY9LBGV/+5<U8
M:MRUXUK657:K4*=-K5C>SW;5KO<KEL/KI[3$2LR*O5WWW9LJ-)!0B*D17/9
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M@/\  ^HD_N._"J/LZ ]*!^NT2<_?\-3!-@>B%S1F/?V0_<&^!_\ N//"M_Z
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MC[1J2P6@"<P,N%%!+IR(USL@;OK0Y,M'^(&H&&"8$]1]E*+\KZTK@2VR>_+
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MK)O$DP"9O:AJB06U#)QD#'8YSN&1C'?TSCL3C5M\<>GO[_FB(>6K)'&1WYX
MXY)] <C'QU.^#:3PBO81&6G "2DI &<JX!RHI !.,GW5''?:DJQ@9TWV]]]Y
M(L@*4C:XKE/\$ Y!^!('I]OV^HUF0YQ+A8VJ*Y342.%42O*;<0I26%+"FUH)
M24MK0 '"A(7YB6P \5.E>?-VKVGD$"ID$ZB:FTZ]Z3=$V4-*44:DQBTIAJ+
M@ P"ZB3["E,""VTH2T*<'F.!:MZ_.DIDJ)<6&\D)BHK?+*:WTO;34U2(]UMJ
M^LK/?<<\ >OP' ^P<#TXUT"PY!$G4HAHB&B)2?K)YQ[PY[XY[\?#0]<_,5"3
M%=%L("4\CW">5*.2#\<X[9R/0?;K#$> 2)DP<J3I_.<D111.]4YF>F>4:4F.
M2Q E:#O* &@4N*^NE+N<[2$D_P ')['&,GC4,9O .#0XZ"Q-*1;7/GQTEH80
M7!L@UF+\8ZWHH_7KKMNV&FW[AKM+I+"@2V:C.BLN/IVDA;+#CB'%HX)"MFWC
MA6<#70W8\?%$,V<UF74 $:&2)J*2>*X\3'P<*7.QQ2(#IGC03:8] HM3>KG3
M6M2$PZ3>5NRI;I"66&JC#2\M9R AM/G;BL]@E()/;'H)/AVU81G$PB,,\6D'
M28-*Q7HC/$]D<"SX[=Z)L[+B!?GPD%6"WDH+N/<V-K8=*U!MT+*>0L!0^'K@
M9SGD$\6TMQ<(.AI ;R$#/."<APXKHPML.)#6-#VDP".-JZ>F7*.W9>5OVC!9
MJ5UU.%1*>N<N(94Q]T-&2N/N3'"DH(+Y#B"49R 25#&['F/%O&/#_#,'X_B>
M*UF#O"K@8#_FW?V@R8#J18<H^YL7AFT;>[<V)Q_N8^9@(_9(! )T<65N+75?
M#K[TF2D(5?5*"@$I.9"5(21D@'W24$ $\X( YXQKSSOUS^D,(R[:<,$7,/TF
MAW+TF\ZWK]8?I7]2.!: ZE#\V'GE1TTK42,M%L)Z^=)6UX<ONBH(6EPI*Y"C
MY>PK5EI+)4IPH(4PE*2DDY7[I&<C_5/]'X8#&XN$\BXW<4Q:_P G'4B]+1 _
M0_ZF+BZ<0@B8WF0?_*_J?,I'[?W2-9;5^7%+ 44E"G2]'0IIV#-F1EJ2XTE0
M6H,.I=6@>S!;7E(/G(<2 _JM^D@2=[#I>&8P,"8/[.)L"?*2+C]$_J2WS\8+
M"=*_-7\W2D=?^DI0H)O:E*+*DA24N2@XMQL!#OE%,=84R'2O<Z#Y9VY"B,ZE
MW]6OTE2'X?\ \,47/%D5M&60"/\ TA^I,$M:&.?O S1AW30YNF*QEJ:T1GK]
MTE6M3:;XH+A*04I$QPNH5DE:7$N(0H% ][.W&T9[ ZYW?U8_2CW#YL(@0)W<
M6!U:<Z7KDLS^E?U0 1\'$BYIA^TZVIEE9 >(#I$E+CPOFC[$ %!4Z[L7A*?-
MPH-D$(3[Y)/U>0#KIP?ZI_I/7#N?\,4"V?RUM[T("#]+_J@@CX3KTD,)-1EO
M =]"<Z_])$DA-]4EUG\X0\U[0MO+8*E\I9/&$K*2,!:02C< =3C_ -5?TJVQ
MPP"!'RXN9,@2VL:]+*W_ $K^I\\%]9K#)&EG"];2L8Z_=)@@K%]4537U@52G
MD%U21D (+)(&.RU#"N<'C6&#_5G]+[P+6X1;,20\5F;%LW[N%1WZ4_44[V)A
M8D0)(+?+Y09CC.?3,OKYTE2M2%7[1FW%)+FQ;TU(  1YB4.*BAE>TG"2A:MR
M<K!/<=COZL?I@"1\'*DNK$V^6^MYRD46C?TQXKNC?PL4F222 ;DD36D B! -
MAP.!7B Z2)"E.7W1PE0#+84\X"IY2PA*05-)X<4H!"U<+R E1].=_P#5[],&
M6-9A$BY >?4,@$Q_M JJ?]+>(-(<<+%@D1# ;4KGZ#+C+M0.L/3BXZC'I5%N
MZDRZE-)9C,,/^<IQQ(RIH!M!(('JHCG@9UU^%?U!\&\9VD8&"<.) :((-A$$
MM&O07-%;'\"Q]CPQC8F Z2)<322/;H*5U5H; HN$*""SA)(W>]DG:0%#<<Y!
MY&1ZXQC7O&O9B#>PR"VD1:#:*F>8)7EI(QL>@:?B/H*Q4ZZ4!TM>JR!M36[)
M)4K)(SP"<Y [XSS\NVM6-!F<LN'?<D1D9^+!H 0#K-LLA<Z]0GV@$?3-./P=
M3G_H*_G&K/L.?W4&CB='?57VCZH^_P#6=9+1G[1Y^Y46NS(HU1'."R<^N#O;
M.?LP?CWXU9O[AWQ5'--:#]PCS)F9\OI%2J/<2KS%X'&]6.WQ.NH/$"]AI]TW
M#P[\EBUH*@'54-"1HEAM15MQ@]^?0?/52YHSFL4UO[%$?E'!)*0$[MQ)^J$X
MY/' .1C4;XX^GW1&&BDG) V+2E?<8W J!Y &"!P<^H^.H<X$$5J".H2ZR)&_
M:E020I?E[E<H;R"4*= "E!M2@&@H)4$NJ2E:4@@C(- (O1H%Z<>-#Y6A7W'<
M.7=/5<!7YXK;UMWJK5.GL*@6VE-(ZB691(50CU-ZJR)EM5YN>FH2JLRU):8H
ME6BS8PC+86G/D!#B%!M:E!-^%YIW_&4*-QW \N'<\KJE+/\ &9UQN"U[H55*
M):E#KS\6Q%V W,CR4HK3=T]46[&E3F6VGRY-H-,86\%K?<8FLU0%I:#3U-/E
M73UYZ#ERDZ*2P@Y'NOD-<Z*0J\;O49^%U5H3]A1X?4NR;EL2P(MF4^F.5A<F
M\97Y356\7HK"I34B;1(M+H<FI4B:PO<(<QH+9VM$F3RX&>?VR4AA!K!'XXBO
MI][SN;Q1U-CI[X>>H-#A4"+2.KMS4JB7*NXY4]DV].FP9GM\0*BMN RH=7A2
M*8\P^&BA\-#)/F+$3 SRF9S\JUB8LKP!8#HJ$C^/?J)(@W7/7TRM:FPK=K%'
MH4B=,K]1<-"55+Y19[E9NJ#$:54:;0J=!4Q6I$IML Q5/)"G&5K5JOQ!0UH>
M'EWV8<"1 B^??8E2V)XO.J%/NJYXTZ@V'<MH#J[-L"WZK1W*Q%ER(D3HW2>H
M4&H,K<2EBJ4BH.U5UB.M7L\IN-*9\YE#S!:5(<"8KYQEUYY66>X[AUU-!SUO
MPE:7[MGJ+%A6Z+BL:PZ0NY(=AU=5PN56XOR6MVC7G&J<M<NY)?LAJ3;-/7 1
M&3(CM!#KKP;&$I)5:?>O#NG*ZG<=PMZZ'OS39!\<]]OV];=Q52V;,MR-=-5J
M,634[B>N"!9]NBB]*(MZ4Y2YD>,Y4WA>\\-QZ2_(;:;=0XTVT5RU)8=KO "3
MZ5F-.%[VSA"PC0]]VE:<+Q[W[7ZH[1(O3VU;;JAZ=4^_)3-R5U\52BTVM=.Y
M5TLMJIQ<:3*KB*DA,-JE-L_F(#C,A]T/EQ(C?'8Z@=+\IT$@;L@B9-(K:M1Y
M\;%;D3QR=4GW:[3V.G=GJJ5"LRW*\9-QW*NUTUM^JTVDRGI#+$E: B')$^2B
MG*92IIR1%\EQYI3IV@\>O3SKKYTD"ZCX9)B@YYWOE8 &I\[+NCHMU/1U=Z76
MCU'BPT,)NBEO3F83<:0PMMS?4(2D!N6$.J8$QM/EO$N!31"DDI&!CB.>3&'6
M ">-[#6V2T9@.PV.<\L$$S+A:!Y??G11L^)7IFDR N34FDL,/R'\16WD--QG
M4L+4I2)'YL(<;+1;4 I*RD']\2#1S=J%=UY BH!CSK'/GTYG[9@L=NEXGGQ(
M]PB:\1?3Q]301(G;GE*0VDLLH]Y+B6B2%2 4X><;94?[<M+?<C.&]M;GD-9B
M 7D@U(X9^O19OVK9I:XO ),4,Y:4N,Z"BM"TKPIMZ4IBJTIB:S%?;:?C3)C"
M&XTZ/()++L1UI;A<24X2I04 % C''&V%M.*"&/'"IJ),UFQ%3($"D+9D8D[A
M! %3WP!Y1Q6O>74:U+!%*_*BJQX3]<K=#MJDPT+"ZC(J5P3HT""M,0N)?5"7
M*F,1U2P@M-K*@HD-J([09J1H>!GB/6W"D(.'+I11?J-U^Z2]+(4:IWE>=.I\
M*94DT>.N(ERL/*J@BOONQ%1Z,)SB%M,,N.K!3N0EIPD#8<ICS[[X3E*D NM7
M\K1JGB*Z,T^BW/6W+]HK=.M2@6E<M7FJ>=4S3:%>\NGQ+7J4KRFRLQZT]-+4
M94;<&G5):E+2XK:1-1-SK[=_93N.%;^OHGZ-UHZ=R;WM?ITQ<\!R\KPM07Q;
M-%"%B55K32T_*378@>VMAEUB*^\VW)"9FUD[FTEM[:559BVU%2B$D J/"E9*
M<'G<22?Q)P-:-<  )M^:=TXHLRT(,=27DH6/*4G*LE'EJ22XE9W#.U"PH).$
M$$8)R!JA,D\Y]43/04QS1J0(J?9X1IL5R,PXTME]E2XD-6U,90W12M*RI\+R
M!D#(R!JHCE-<]1?/2GE9%NJ!"B",$$@CX'/;C(X[<'70+#D$2_+5\4_CJN^V
M)KRBJ(>6KXI_'3?;QY=T]46/5T1I[C[1^O4&@/(HL^\@$#ZQYX3D_+Y?'O\
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MG:XXHG;S;7LW@@9O86.=T GYL0;Q%*4F#,S'"25A@>(^/83XQ<-CR7-_:"X
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M95/#,%ME<,%P+W*VI5CM?A^(W$ AP)&3C_L1 RK$5H8$C-;M\3)D? ; $[P
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MQM%D>Q(2O(;6I24I<2L$^=M65)4ZXI2G%% 5^;[;,*'O!PD3OMT/G''CK89
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MXMU&%0GR&5NNN/)8RI#;JBX@I["O_P!&_&<)F(PM<_><-US2^M!,$-B9F@D
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M:A,+4':I'2I).4-J4I>!QW2E0.X<IP<$'G0 3,5X7MRMJB9W>H% 8^H\\\%
M^]Y*EI(&1P>,8Y&2!\OB1;%QH!(&5]9KQB,E(!,Q6-,YT6D[U(I+8!1#E+R,
M)^KM)^.2?=!/?//QQW,;K8B!W>_DD'($\@5HO=364' I;Z3_  27D!)''<)5
MWQV^T?= 94FEZ5@B;V^GHD&T92M-[JB[E(:@,$\!8+R@KG@8(20<#D;3SVT(
M+3O330Q6 /+7+AK$0=#W?I1#]LIXCW::PI?8)6X[C_-'!Y(X[8[G4AXR,4K6
M/KWPD)!S%^]$%]1YZ4N%-+B-K"%*+J=ZRV %K)"%%7F @\-E(3\L9PEM*@G+
MSIQ3O[^BU:5U*F"EP%F!'D!<5I"R-\8R0EB* IQM",1?(&0E#8 <"2%*.=);
MD1J),'@3F#ZJ2")X<*?2GNG)/4PI.%TM)(/O@.K/_.(7@<]P >/NY2-1U'=%
M'D:_>.^16S^V5$.W?39 XS[B@KL0<C[,?,#'?D'5@8,I/<'CI(R]M5O,=0Z2
MO >C26QW5LPO.<@CA7;'Q^[MS'=:IYSW=.#5\VTX<)E.L'_R[9('SSZ =SGY
MXXYU$"9  CNOXCWD1%T[QZ_1I"DB/4XCA<&02^VGDC  2H\$J[9]>^.XD@ 3
MP) CC.G#*:B94EI,CF/8?6>2<"\VZDEN0VZC'O!M8/'&1E&>XY'.N5[7/<*Y
M^=<AZ"OY6N&T- !M>.%.5=?/SUW&FWFG&G6VW&W4.MN-.("D+0ZV&U-E"QM6
MA:  M*@0H;LC&NW"VEVS#XG^EHD&I'+,YB51^RLV@EAIOR#G-SWE['E6^?"1
M8=TU%^L463/M.;()<=9@H9?IZ3M2H!B,XVI#"2XV%.EE+?G))2HI*4K3Z+8O
M%\-S <1H) U:+P3>A)J2")FDKSVV^#.:\[A( -@#8FM :&H))RX44(IG@II:
M)"5UV]YTN&M27%1XD-N*\Z@Y"TM*6\XVG<G.-X*4Y).1QK3'\<P<&7L820#N
M@13>IK)&M_6F0\ ?CX>YO5-:[V4.O:+CEU77MH6E;UFT>!2+7A1H=.A(\EGR
M0AQTI2$A3LA\H2EU\[0<C*3VW$  >:VO;,;:W[X<X"08G*MB/3\+Z^Q;#@;
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MDJOP-G;1QDZD.)ZBB+WAP <?:D?KR?TG53_93_EY;_THI^#LQS^GH02C SW
M_E^\C'Z-:MQ@QH;A/ PP/E:9)@WD'B3=(+?EPP"P?M)-P;R.!I;HE8X/X8W$
M9^T)VY^94%?:=9G:\1A)EI!-(;;@#D3J**/^4B)@: TSI>HKPF$%I(0D G
M(&>000<#L-H' &!_-#7_ !27&YJ9UK]1_*J28@W&>=*1UXE&WD@YP#@C _ ^
MI]1J'M!@ U !K8SIG3L*$\T3^O4#_E-8HK\1]4??^LZ+9G[1Y^Y47NW^LE5_
MP=/^>UJS?W!21/4'H95)'N?3DZV4K6UNVPY#V6#KGF?=#4J$-$0T1#1$!\^-
M#,4$G28]:HL@:61D))_#MVR>>.<?CWU3?!S'K]K:'/U1*\DXY4 H]D_''?G/
MZL^GQTWQH8UZQUO_  B(-9"2%?6&>1CC[<G)^0_5SH702"+:'\<0B46,=UI
M^)R"3SP!SDGT&>>>V-1\3AQO^/-$MM&PD^]S@<IV\8SN]XYVXQSC'(^.JN=.
M40)N#?ZTLB44>9P!N.<)"!G/I@$*P3\N._XP2X3!@\@;\#Z^7!%BD2X<(?U2
M\B-CZQ?*&TH&/X1W$\<C@$]^!ZQY\43(_=UN1P2NK15$9VI8<+JEGU 2E//S
M)QCTT\N^_;1%%IW4FGI<2B+"<<<'"521[*TIO.-[:E'+RB<#RT J.3CL02LU
MLY^DZWZ**SNH=9"'"2S3D;BD+#+VQ*@-^U;JD$).PH6-R!W VXY*08KT M]?
MQ=-PZZ&Q$C,<#Y'D;J#S>H8>WMR;I#B24J\E$Q*#@;U92A"$*6 4%+B-I*@$
M^\!ITX\^S.6:@@M,'T58QKRI4&OUE+U4;?8J/LLF%$;BMAYMSE$Z07E/-ETN
MDH+8<!P$X&XGBXW8DD4/O%Q%8X<5'S9-)O6:<!:_W"W7^H5(;6OV5B?(4T%8
M3N#95M)3D I0 DX)!(!(.2D$ZT&[%P!/EKE/,::*P8X@?*9Y\2+4O_$)O1?=
M4EJ,>F6[47UDC:&F)<MQ8QG"@QO23DD90>P'8YQ4N;)$MRF3(F*4B-,Q;@M0
MT@5$&].-1:ELC/HGN+^VG.;+L#I]7B@<9:H%55NSR3A;9!Y[*!^SMJF^V+@T
MC2XM,^D :0I&G\P,^_-;!MSKG( 4Q8MPL)/("[>6V><=URT, C^]4KMW(QK%
MSZNBP)@MTY$&G*:TU*KN@W%^)-AG6_GR1BQ^O;@_-V97 <Y)53H9YSQ@H?*1
MZ\<XSR,@@9%Q=63&A!.6@ X&1>J$<#:*1.6IX<5E/3WQ O)2DVG7@H'@^S0T
M$8^/)/W_ &#.DGSN:$#Z\*<U,>=,S?6ENXH$#TYZ_H5[]KUU)3L62E$-;HWD
MIRE"2=S2,_G2K86R<%)3E6HJ)G@<XM49P*7XZJ>SWT')8V^GO7YOWA:MQ!2D
MD)!8@^_EM*2%!"EMK""K+:FEE.$#"E)PK4VY5U)OZ_34S*(W;,Z\I&'K0N-Y
M!(VI^AFUJW#OEQ"0%#CT..."<C04X^4'Z9ZQ<J.?F*1]^'T6$T/K8SN+M@7,
ML-Y^M;T]S=]@1L(QD_+]&MPX1,BVM?N?JH@$Q4<9,9=F/=:$FH]0J9CZ5L>M
ML!/),FWZM%X[YRMI)&.0#V')S\(WQJ/,D<XD5R@"Z;HDFM=(CEQFYI"T!U%\
MM?E3**N.I(&<O%MP ]\-R%H*B./=2E9)P$@YQK8.:,K B\CU%/2A-%, \]9@
MT&MRG2-?]%=7M4);*MIWJ]G+P2WQN]U(0=P3N. HD_/4 B9B^D9@SKK0:1E"
M@T$U,"3,S!%*"V65I4C9ORD(0EMFLJ944Y2%FH0^/^/O"62?E[Z3CYC0%H),
M3H9GC343GIE><W8DCY?EFU8.E)BV@K[J0TWJ,_YBD0[CBRDD#$=<QJ2XO'/N
MMI!<&,' ('8^NH(:X$.;(.4\;&>L^5EF#B""U\$6,"!-XS] I[%Z@SV2?:8L
M:66TJ*_+*DNH2, J4WN0XWD+PD*2 I6$C.1K,L'^-!76.OOSMK</Q"3ON#B;
M&(/"E;&O"RE$>_:)*!1(9EPPY')>+V0A*"#E9+16Z$)')##>X 9PK!&IW&$0
MX$G.I%;Z:Y_5&XF,UP<U^ZX2(+<J@TX_5,=AW!26I%6M@;8#-.FJ=HZWYZ'G
M*G2YP$MV<!(4E^.T)+JT)"D-^B"G:D#5@ VC1 YS3C.F2N'M=_ZK"\UKO176
M(MV-5:J%H< +7O(]%%2%G R.4H"BD*X4@YPI.3\M0&80EP80X_Y!T2*2#3.\
MY\H63JDQ^W)KA-<C-,J667"C_"([<D$=_B$Y/_5U!:#F\<G'\)!R#/\ X#ZD
ME$4_%62/@%XY] 5A.2?EJI ;:73_ +$D#J:$_1!'^36G0 !OG2\6\^*24D8X
M//8D#G&,XP3VSSVU$G_4?_'2_16_X_\ 0=4A9*,9'?Y__'5V-+Y@,$1<:S]D
MAD_M+?\ VFAOR2/,^7Z?Z-7^$?\ L_\ B?ND,_[^OY1AQ/J#]Q'\HU'P2;C#
M/_\ 51 %ICB9*R)*%#/O#Y9'Z\<?Z_9JCF!I@M9P^45RS(\T2MA/(X^TY_4,
M:!K2/V-GD*Z6E-YXL0!RZR>\D,$<!7/P[>GV_9_J-3#! ^&PGD)]P.YR5M_$
M_P!F_P#P"+:>YX'J>#]_?_7[=0 T&2WY=* #H=>O%-]V9'D /18E+P2,9QZ]
ML_=C6QPF/:( $UI7ZP4WW:^@^R474G;E)X]/Z?\ 4ZI\ @T<!%J*IK/%8]Y!
M)3P"20/AG6I8"&AUV@"08-H->*)_HG]>H'_*:XS<\S[HK\1]4??^LZA;,_:/
M/W*C-T#=2*FD^K 'Q]6SG&I;<<Q[JRH]1&3R.Y]1\=;HL.$_V7_5.KAV+ A@
M(BGS"W4+$Q)D&9,U'V21R0/CK4T!.BJLWE8&5J"<_+/Z<C67Q";-/*"?.EAS
M4TXGS ](/ND[6_[9_P!0_P ^K2__ %'?FE-#U'V1AHJY2<C..?=.?LR=5^(X
M4+#P@BOJ1Y@GT2G$=#]D/+2D^^HCXX&<?#)!..?ES^H'O-FQ-I(__P!":Z)3
MCSGZ1]5D"QV\TD'T"",COC@9]/LX''&H+#$0&\0;5XN\E"+W.Z3C_C*) R>"
M#QDY^>/M YU1SG-,.WH@9- @6B!$"8H15$94!AI22"0<%6 #_>X)43SP,#(S
MR/6/B F;$1!BQ BG\0BT9TV'3FW%S)28^WDGS ',8X&W"^_/I_!'PT.("1E0
MB($<8$$UIG2+B8( FPRE0&J]1X[:@W3X0DC&TR92R4JR<<%*?>[ ;<)XR<\
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M'^VU5)!R4C?[145H*20V@.;0=-\<K#K>PR,4I/-"QTG,5M21%*Y&=)BM#0F
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M&\X/<XR#D@>O;MK$$R;?*3D*PZ-*:HDEL-[%+]S.2?,( )_@@)[C./X7;O\
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ME.=;45=RW"_&OGDN9ZCTGZYV,J6MRC2*[2V%*5[53G4SXSL5.2EP)?#=0]U
M)7YS"7,E.U3O)3HPQ,TT@3E8^9R/F<ZEAFD&XKH?XJ+5SR9J3U'BH=0W*>D4
M6:RYM<04OH"5H.TDQUH#R$)4"%..(2CCCCG5P]I[MV/>Z@L=7\?@TC@:].@+
M>ZD,+0@U$MSHCNU+=4AK#S2@0 %+",YVD$*4D*2#E))4-HL'3:H$F+&8&O+[
M9INF*TBE?,Y3Z:\"K+IE9I569"X$QF1OR$MA90X5 ^\ TXE#A"4A.3R"<@$D
M'$SQJ:WB\GAY1H;W3<=IW7WCU"="&U$@$C;PI)!&#]BLG[^0?30 T()OPCE,
M::GBJD$71Y01MR#CG!//Q^7Z.V@^42! &9%*TN:9QZ(L*U[%$)2D=L$9QC''
M?.>/_CJX;O!KMXZTM6^<03:E$20 HDKW95R-N,']>IWHD-J&T,S(/IZ(E>6V
MKZBCG_C>@^> .=07N! ('*HD<#47(1%L;!VY42,@XQZ=_0X^PG.IWW1, ":3
MGRK7HB?+?*?IB !G/M+9Y]?=<'I\,^NL8W=XC.ONI%>A] 2KZ9SY:<]\'/XG
M6*V @1Q/N5&+L&:+4_E&4?P=1H*$'19'_+_W#_\ Z5%J[G[3^O7>VPY#V54O
MS/\ B-_]'^G4;O\ W.ZHC"\D#8WR<?5_IT(@$[SJ";HE^4V#A:E)']ED8/R'
M&<_+GX\ZION@F!0\;:G((L,J7"B1S(DOH9BM@E3BU=@$G)40 K:!DG:G=ZI!
MP :3>E_J9/K&?DBJ*X^H*WTN)IY13J?M6AV0Y[\@A (*T^8[Y00OA23O0L \
M)';42-1K?NE>7HG6LY=WRU7/=1N:;6:BQ2;3I\FHU62XIIUYAA]Y]Q:@%)#3
M;2UA0*N\H*3% ]Q3@6<&'.@$ U^YTH:<H,7*EL2+169M29[R5U]/_"?6:^$U
M?J=5I5/1*/FKH<!Q'TB2E0*$/3DH?%/2H!)4VRM;Y'YL.-[BI&,S4W[UTY"U
MEOW'\_2.B[9M*P+3LR,(5NT*!2DI:;:<?9C-JG2PVD;7)DY:5/RG<@+\Q]:W
M"KNHXXJ6@F9/7S13<- #:%*">>$D) R!\ /AG[<^AQJR();"?4G@C!">QQD9
M"03V_A$^NB+)HB&B(:(DJW\;=OKG=G[L8^_.B)!4X.Y:'VE0_7HB(J601M2L
M$$90K@9[CD'GU_#1%A4PE:3G<E0"@D$H/<$;@2G([G&TISCDD8 B0+D#S10J
M]+@AV30:E=%08F28E*A*>E-P&3*EF.V-SJT)*TH4E">2PM2&E^BD=M(+J#=(
M,93K.<1;H:J+29/F:#OG^.7>@/B&M"_[GK=K4>/<CM1J->KURQ539DF;#C4%
M*(RF9+T@,MJIZ'U.-,-T:,W+CH?4$F4IM()#!BI@YZ#2#/WROKH7EPB +B<X
MF:U^@GG;M2,V0TT>64>6@E(V-95M2"HAO&"2,[5$A(.TISD 03F?*/>#[J@
M%@.?TI3TGBMQ*$A. >#ZC'QSD8&.3WU*B()-:]T2@,  >@ _#12CT1#1$USD
M(<:D,EII2%MNK6'T-J9WX'O.I4DY:4%J\Q9.4CL,9R11NW,(MVAJ0F&@(H]-
M2407%N04+$%D;8J4EM98) #>U8'EXW9T1< O6+T3M_K,BOW-UAA5*JQ;QGWI
M!MFHTIUR*B; IM1;49,Q=5FQC5*<RU*<CU*)"ICR8<1494:66"I+OV[\U%)
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M!_'2^8E3B8HQ&@!N1N*S03:*"+<0#"NQF-EH#>H Y]W*O="5DI2,* 1MX&U
M2D8VI&T :NLVB )%:]))^JVPV/4E2L8W;E9^[WO=/S&#^)T5DD,-CZH4GDGW
M7'$Y)[YVJ&[/SS^@:(E%M)SD$Y3M.2HY3G.._P ?7O\ /1$>Q/N^Z/=[?+T^
M_P"_1$VS$)+;X(:PIMYLEQ2DM*;5Y:UI=4#NP1EL;5#83E&PC((F.U@PJ@6^
MN,AIEA5#I"F&@N0^VTRY"CAMEMZ0XMYU:&T--[WEK6H(WK4I:W%*"H"1]N'2
MREJ4)VIRD9P,Y2,YQZ_/XZ(C"4I[#'V9&?M^/RSG'IC1$%)3CL/=!QCC''RT
M1:!C-D@YRH A)))V@YX R0!R=VT#/8]M%0/=$%I@P#QZB/*BRB,RT"<)RHJ*
MMJ4H*RXH*65% !)4K"BKONP<YU6'$B#2^60/4$<U;>#:")N!&>611+0G!!W>
M_@$;CG;SC:"2$YS@[0D'@=L 0YIG>!@BNEN/>0LC7!T@BD$&1(KJ1!)KQ@5"
M:W*7$PC\TE(PHX*2ML*4?1&"E*>20E*0A))5M!*B=0\Q&MB0 :#(?@<K%4^$
MR3347,<Q7HJCE=9.FM&OZ3TSJM;:H]R1X\*6S$J"3$B2T3$J4EF#,6$PVUJ<
MV+"&_++CB?+.0LC4%Q-SSM:]>$^JNUK181?CKQ\[CCHKIC/%\IVC>D8SG:H%
M!3N0I#J'5(([$%!6E0[  YU"E.>3D#'&#D_/T&-$1Z(M.:$*:VN'"5$@C<4D
MI*2%!*DC<#C. %)W?5.0HI)%3EI29]LWO<%J52JS:LFL%VZJ$GZ$,:FT:F9;
MC2**B=&"&79+4@>>$NI4X4.J5N*1@$5TLN*<*\XP" G ."!P22?7>%#'P2#Z
MYT19M$0T1#1$",\?J)'Z1SHB06T*&"">XR5*R,\'"LY&?D1HBUW66^2H ;L!
M.$\ @[]RL=R%DJ23N4E1*D\]B+DOKGT"<N:2W=EBMQ8EV1RI<^,E3<7Z;"?>
M2$N%HMHF;MJ5/.)(=2I142YE01]]$[[^OU7-5I7Q4:/6S3*@PNGW PXJ+/IK
MREI1-D((2ZVA1 #7DD'#[N4ND>Z<$ 0?;SI[UCJ,[(NIJ168E8C%Z$I"TI==
M1(8(6AYI:!YBV_?401D^3N &2G*2%9)T:^@O(@B@IF*</.3-1EF622014GOW
M[LZAL>\=R5 $=C[P ^MG!VY)[@ 8[#5AC.$5GWZ_<3J2:J-P\/5/U  35X.W
M@>8#\?JI(3WSV"C]N>?35G5:3J)^JJ+CF/=7LR24G)SA1 ^S /\ +K!;-MYG
MW*C-V?UDJ_\ R"?ULZ*5SG<==CT*"M]:TKE/MGV.-D!2@%E*WUDX"6T8P?4X
M/QT3Z+F)FG5_JM<R;<M]MUV%(EM?E/6V MMFF07'Q&=:2L'WG%-*+GL[9<60
M,[AC&HL('O6N9[\LE&O/4]CL\5Z,VA9U$LJA4^@4* Q#A16VD8:&77WRD9DN
M+!!+BA]96[GX<'4J5,VFL [BO.<\GL>_&.P^7 ^6B+8T1#1$-$0T1#1$-$0T
M1#1%B=*@$[<Y)]-$5->(.NS[6Z,=2:_37EM5*EV5<LR#(3C=%E-TB5Y$I!PH
M!<=Y3;Z3@_O9!RDJ!Z]B8'[0P&OS-IK+A?AJN/;G%NSXC@*ACHX4B5XO6E5N
MG\ZTZ!1YMFS+@J%#BU=NNNPXRMK,J55%LLU<RVUH?2Z2HJ1O6I 0MT--;U Z
M_2B/@[-A%L-^2D7#@ #>F8.1%:T,_EN\';3C;Q!^>LF!%>6D5MU4T51^ET"
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MTHWE2B22NBFH[#TX[=L?=Z:(AHB&B(:(AHB&B(E)"@0H @]P>0=$6L\PV&7
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M713WC'G4ZBN^P.(V99FOJ#$=X)*5#+2W<@K"QG!"0<G73X?LK<?;<+#D'>,
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MD>XEA$Q)4X!)0 I3C+6[W<^\>0#S]-PELD F"32H$_8<\H)J/,?W#6/.ZUH
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M'Q[<_#102!<@<UDR.^>/CJ) N0/-2H/7^*Y;9/&)3WR/[TOXZE%,6P0ZLD$
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M^%VS].[3AO=C;(":R&M(!%IFN9K'*LK[VP^*?!PPS&,2(!/S;SB8@@3K&4Q
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M^^.VK' @20!.674"1Z7(,PK "M- 1PL3[:\9A4'>?2FZ*?<35]=)JE H=>>
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MG<@H4<*6$Z^RW?#0'DF-8RIER-%RN:UI&[0$;Q$1!)(^G3("BQ*=4#C:/O4
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M (+"_P P:A2I!HB&B(:(L+C+:P2I"5'(4,C/O)Y3W/Q]. ?71%KF$V0$EM!
M]X<;<*^/!Y^?'ZM$1H84C 2 $9Y1G S@#/'&P\DIQN).B+(IA/!V))   !4,
M *![Y]/U#&B)/LK>591NRLJ)W$CD'L%9'&<=NP^[1$I4=*L92#C&"<#;WSC:
M,Y^'IHB CI!Y&[!)0I:BI23C (/;&>P]-$69(()R#G&"<Y!QV./0D?9ZZ(EZ
M(@0",'D'1$0  P!QVQHB 2$]AC.B(9YQ\LZ*)$@9FRU)<=+[;B%I"VUI 4E>
M"D@9S[I&#G.%)5[JAC/;5&.=AN$7X$\>(YJ'M#VD',$6D5UGW_*X_P"I?@_Z
M3=0)[]5=I<B@U9\+6].H,I44/K5N#9=BN!Z&A25J*CY+"%+)P5$XQ]S8_',;
M AH=:L&<[VJ:#\P%\+:_!,#'>7P034[L$>8(RS UFTA5'9/@EZ-S)4N>]6+I
MN.+2*LNESJ9+EB#"<E0'<NPI34=EA<QH(>*"M:@I82 G*=HUW[1^I-IQ<+<D
M 00#)L3D.)FD'0YQRX'@. QTQ-;  $&F9$Q'2]87?%M6W2K6I,"B4>G1J;3*
M=&8BQ(D1M#+33##:&T)"$)3^<]PE:U>\I1*EDK*B?.XV,['+G.)+B3.G(29T
MTTE??V?9Q@ -: &MH!3LF:DFI]%*DMI"=Q2"<>F<<9[9^7?Y_'7,UL&3Y=@G
MW7428@96'\7[LLJ>PP,<#@:NH!D Q$H]%*&B)ME[4(=/YQ 2%K*T@*VJ2&UE
MS;C)4CNA'*5JP"#VT0V/TOY)@MET2*/1G_/D/*?I=/>4])8$>2ZEV&TXEV5'
M2E(CNN@[W&T@):6LM@#&-% L.7-3 8P,=L#'V:*4>B('L?7Y?'1%K^2#[Q]T
MCG'! ^PGT^W1%2U;Z16E/N:OWW'IL6'>\Z+3&(=S/Q4OR:5*H[$KZ,J$0;P0
M&''D(DLJ"FI#38#B2CC11'?2>L0LMFW;/<J?Y"75(<=O:@T>#4*S4HE+DP:)
M65/E32Y=&4L$+;;6$LRV%.A3,@G:V4D'3OFI5QM.IVI1DE6<<@CGG(&>3C&?
MLT1975)2A04L(W)*03Z%7N@_B1WX^.B*ENK]RR*70T4:G2%(J]??;AQR.7&X
MJ]B7' @<C(W\Y)]>!J"X-J=0!S)[S'-7P]W>^:H@]8IV:*KGF4TN@O1P-K<>
ME3%+5C)4\N.Z''5J"5+2O>0H;!YN]*4I.%:[,5^S8.SE^*!(@FT6)G3NXA<F
M^Y^.& G<,B@K0Q81K4KS5Z05*CM]-[90ZZTR\45="BA):6XIN9.D[W00"I2G
M%K4%* 4M2BE7O(QK\D\7_J+LWA>U.8T-AKMWY@#E:) )^6E*Y4F?TKPK].?W
M& W$+?FW 3)C06OG]:+J#IDQ8M65/FUJ2PQ(IR83\9R;,;9@NJ*T%:%(=2H.
M!Q(4,@$<I((X&M-A_JEX=CD%XPQ2]A)UK2]M+VA9^(_IU^& 6-_RBDR!4SK6
M+4IZ6)4('1N7*G51V0THS9KS:Z?'J<)II/D-NO.R&6E,*4E+Q9"$;=HRKDX!
M&OLN_J5X2QK:X<N_[0<KWYZ\+A?$PO ,=[\0.!AH!%9N=14FX/E%4ZTE_I93
MO864?14F%+:F.):GJIDR6AV2U:P886\PF,8R(B)DP!U7F^Z@E32^-98W]2?"
M6,#_ ) 8) 'E<DF <[&UBF%X+CC%W=TP2))K 'RR*5$Q210Y5!Y6=J=%0\\P
MZAAQ++RD/,,*2IAMS&Y;2>5H?;,C"4/[VR0G*&4<[OB8']4]CQMI& -QN^[=
M%+UI!DQ$Z5FR].[]--=L>)\@DMDUK($G21SA6IX7HD>K]&J4S/98G,,U^M26
M&Y3/M+;"XU7D+B+;+ZEE(0K*7$(0 I(3@<'7Z)L9?XGA-VEK@YH =\KII -1
MD<XI>XF5^<;1@.V+:',@[DG2:$Y7M UX&ZM"K1Y=A59VZ("W%6K,?:7=L54L
MC\FX\6.EB'+MZ$RPI&R;@)JB%A0=VG8D*YUWG':UC6U#@ T "#0DUBY.JD-F
M'.-'01'$]?+C=6E'FQYL-B?'4%Q)##,IMT.K2E$9UHNLY5L2EII;20YL6-S:
MUK0L@8&K[+LN-M#IDBM!(%+S&8CG*YMJQF8+/DB;DQ(DY36U!%ERO?GBQL6T
MJQ+HM/A5&YZC"W-O&F.1D06%[BA"'9[RDJ&%#!]G"L\GOP?08'@3W$;]#0P3
M%*1IQY'R7F\;QMS-YI$D$#.LD01$^RC%!\;%GS)+;5=MZL45MEQI;TIIM$N.
MPE*MBGWRE8DO,I4XD*;BK:4L[E+2LA1/9C>!,#/DQ)=F*>58&?$ZT6>S^/[S
MRUS3 K:M];6@5GRRZWMBXZ/=E,CUFWZBU5:;+0IYM]A:/+;0XAC<AY39#D=:
M7%+2J%M3(06UAQW*5#7G_$MEQMCPV%K3&L&LDB\6IYGA5?>\,VS VW&Q&N<#
M% W.PO6A,&!F:\%(?SH(4I&$J*L*3C;M&,'OPD\$9SD$9.<ZI@!IV??=_P"J
M6SY\[TL;1$@25T8_R[1\)M&!U*Y2.%2?R<H"G,Y 4$CL-H/(XP<\'\,?/(U5
M@):UQ$DB22<ZTL?,](4O:&O<T6!(')+&0 I65C (P.1V^)QR/CDYU! WLA4B
M23 -K6&EAE2Y54\T CZ5@8])(./7!3Q^HZEQF#PC*I%XZHKX8_>D?8?UG7*M
MQ;S=[E1:\5!%OU4^I87C'?A*>_PSY:B/D0>QT4K<HW-*II^,.#_]V-$4BT1#
M1$.VB))4!C@\^GKHJEP! K)0"L^BOO'].BF>!]/H2E:*4@K X(/Z/Y]%3?''
MOS2MP^8/P]3]WW:@F!)5@9$P1S1!6?0IYQS@9^S!.HWQQ/(?>%*5J-\<?3[]
M]40U(<"8$HB*@GO]I^0^)'?]&I)C6M*(D%Q(&><< '& <_:0>._V<C.@(,QE
M>:*"8R)Y"486E7 (S\,CG[.=2@,Y$<Q"-*TJSCT[YT4H%:4G!(!QG4$QD3R$
MPB2' <\%0&>0,C'P^WY:3:AJ=/=5^?\ [?50>^YM=IMN5N;:L2-.K\2G.3:?
M F%Q$>48Y\Q3+A;!4%.E!2A7<*. #Z0</>,R 2(XDY=T'&5.\0(+9Y F/.A'
M*?=<->$[J_U&Z@7?=E-FT&%&M]FKUFX+@J05*]JB524]'\JAQ$N)+94VZTI"
MEK4A26TDIW#!+<+8!,\OVU!UYFT PK[S2T0 '&XB".Z'SJO15I"U-H40@D@D
M'TP5$I&>"<)."<#*@58YQJP &L3YUSSKW*Q<:FH\Q.0_[3'D86TD$#!].VB!
M\4)GB/S"2'4E12 K<#@C'V\CY<=]5#@21608[X<?*ZN+"-$86",@*QSZ? X/
MZ=64H%P)&2#\/3.?AC.A,(F^6I7E.J"D)+8<4A3I);&"VH+="2GW6S@;<J)3
MD?+5-]M;T[[E3'??\>54PVPIR12*/,>>:E.R:9 >4\SQ'?6J&VMQ<09W):4M
M!(*\921@<ZEKIR-KD1V:J/.>7Y4O21A/<=@,@_=Z:LB&]. <XSV^/KZ#[#J)
MX$]/NB!4!CUS\,?IYU&]!@@R>1]B42B,@@]CP=618%-@<[$8P=YYR!\0.Q('
MQ^S1%%:K0(E6$?VN.W(,%U$F$5.2&ELR&,^0\%,.-;E-#E(7N03@N(6H9T15
MS;%;N&UJQ#LZ[IU<N-ZI&KU.FW8JEL-4]BGA]*X=(J<F($($]AI10PX&LR6@
MV%%3IQHH!OP-.7<_57/Y@=2&R%'@[E;5 [$J;W G! "TK !'H5 E*DJ *5R>
MB<Y=EWUVN2U&5$IDF13: R?WN&J.I3;RT=O? WDY*N <8(TE@/\ R3N4L),F
M8SUB>!XJ'20=TP><7\CD<O9/5192]#E;R,>3)4H*W'>GR'"I"$@I)=7R4CM[
MN-?$_4F*X[#C?!)!#/\ (00 UW'@/3BM/#<*=J87 .K:IBHJ-9M,&+KQGI/A
MRH5>1%F1[AJU-;K=4N=V'%IJ)\R+$9HKE3D3*>T42$"=6)2(+KT6D-A4E494
MN8VT6H3BT?QGXP7[9XOCX&TXT@.=B"7&-X$"*Q7YC36N2_>/#\3^VV)FZP[Q
M:/\ XNBN4"@FATE2EOPIT*,IPR[XK$]3;]=AN0J5/DR)+CM,^EEQ I::BXT[
M-4BDK>?B ;H8=+*T)6@#5&^&X;'#X>T,#0":8D$1,4M&I-=+PN@[0[%H<!QM
M1U#!$&H MY#JBG>%JW79,<L7I58:Y+T$MMRIDE+#2)"2E29$M53V)F/2ML9N
M*2E3BUE*$'G5W8; 8./O9 !Y( S,@@4,9#S"RQ6!HWALY@BL SF1 W9ZF>0*
MR6QX6*:Y4EKN>O5>-'8G4-$^$9]0C/2953HU.JBJ,4)F.>4MF=6*6PY 0L2Z
MDW&#,1#I0L#1NSA_R_&$&/\ ,S) I2:BT5)$CE\LEL/Q&X#P!ODN(,;H+@#:
MQ@FIIJ2H=>?06W*1095T4R[9RX#+M)A&E&K3Y$I%;JM*I55?9<?8?\LEIJ?(
MD(0L[F&([+13M"7%\6V8.S["_!VD8L.89C>DDT) J!0F8RXKZ7AVTG:L1^SO
MPG-IN@$.:TBM;DY 23GE9>D7A@H\"D=%;2CP\M0S%D+*ENAU:I#DEQ3A6K<I
M?F+5E:M^.3P2.=?U;_3/;]I\0\,:YCVMP?A@075/RM ,$2#!K76M5^7?J[ 9
MA;;B,#2'21(&<G/G2T"W$7\Y'2XC8\69 4VYM:=3N:"\-#<M)_-K46E*2V7
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M^R2E2ENRG]PD^:#O_.H.Y(4 5)"MP2-2U@<0TVGZ457&&DBIRROG(][2G>>
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MS&4Q%9I_%.7DI$R(O-%?+0PGY$DC[#@#/SXUSK5MAY^Y47O/_<Q7,?Q=6?\
MH-_R?IT5EO6^/]A:1\X4,_\ 1:Q^LZ(G[1$AQ)4A0'?^8@_R:(FR2A2FR@()
M!*2<J*3E/S&./3OP.?319.D$37/UM'3[F%P#XH?%Y5O#Y>5"MZ-T]DW!%JMO
MT^M,S9,Z?#16I,^YX]NKMRW'(L61'D5R$W)%9EQ9[D9SZ.0LQ''9!;;,:S%,
MSE$'SJ.6MEZ7PKP]FVX;@[&9AD_+69$B\ 5.AD5@V*8;>\?D6N52K48]'.H<
M&31+QG67-;DBD)<9J5.?N-E4AR,W*+@IJD6ZN9$F@*$B//A!2?-4XA$Z^G0>
MYGK2%])WZ8P[C;,*;@22)F23$FN8BEKJ<=-?&3%ZFSKRI['2^]+?_(NQ:=>T
MB1<"Z;3FZBS5:8:E#BTW?)"@A1#D1^6^A#,:6PXEPA*,FK@2" 0"=5Q8G@)P
MWM']Q@U= J\9&M08RX:BZI-/[(4_<)M>H6CTAO"HTZN-T5%1BS(\]BH0Q*J-
MS4VHTNG-L-.094YIVBMJ@R%J1"D+GM-R7VXJPX*M86D&130=!&E:_=?2P/TQ
MA8C#O;5@M,3,F!NR9)@^=;4,*06/^R&4V[(5NS$=&NHT;\I/I$L*4FE/N0GZ
M3$MMV7%GHBR2NFR]UQQXK4%\ J=B30A10IA2[CSM6@OUZQ02;PJXGZ6P<,F-
MLPG0; DD@T$]#6*4%TYS?V0ZUBQ8BJ'TPOFNNWJBJ1GVXR(,1=NUVDR!%DVK
M6'ITEM KJGE(4W'B^:A2 HAW .9IZ]SIDL#^FV-&]_=8="+@FE*QEI4^2EW0
MGQAP.LE<ZB+DVK4[3M2P[?MROS9%4CS'*RQ4*DY/A5BAS8K;*H7M]+F14H<9
MIKT@E#C3BB0L8JXAHFLSIP,&AK8<>B^7XCL&'LV&U[,9CCO[I !J-USIL3EU
MNKMI?4"\>HM-J2K-M&30(^"*)<%[I?@1*G'.TIFQ*9#4Y6 T 2ILN,L;RC8L
MI0HG7*\8CIW8)DZ^HIPX>B^"<3YMW=(L>8R@7FU[\92[(Z'0J/6%W?>E3=O^
M^Y>X"X*M&;;CTB.3N,"@4UG;&IL=!)2F1^=J*T</.J'NC+#V8N>XXE0:C0&H
MH.MHSUK9S&N@N ,&@,7K77/DKEJ=L4VI0'Z74(,69 E1W([T1^.V[%>9<2 X
MR['6/SC:DGWTESWUI2M7;&MCLK"(AL10:7X?FE2<H.&T@\9R%.45XG4U,FJH
M>B])KHZ95=]_IM6V5V=)4'';%N!Z48=.=PLK-OU)E#KL%MPK/EP7MD-M24C=
MMSK [._"/R&AN()M0><"YF+<Z!CL/]I)!K46CEPF\R>4)+OB(HUO2)-+O:UK
MMM*HM.N(83*IKE1@U I!PN#.I2I,=PO8)0DAM1XR HDZ@XCV"'-=)B ,^@UU
MB?()OD'Z12DY7]>&B<*/U%O;J+#DO6?9$RAQ $"%7K\"Z=3Y;:E*2IV-3(HE
M5)Y3)5O:1(CL-O%*D^<T/?U#7'$)<0X08^:Y@SQI7K"MO.># CB=14>M[]*K
M:L?H9!HU:>O6\:H]?74"2IY2:]48Z&Z?2&WU95#MNDDO?1<5*2M <>E39:BM
M1\]("$(Z</ PZR).M-!!O,P"-*F +F!AW+C+IH>$#\Y\8S31U4\/_P"5=9=O
M*S[CDVE>2H3--GA]IVL6M=5%BA810[KMN5),:9%0'%^54:>:=68RE;D3G&QY
M"NW"9@ANZ6UGA)&0DVC( RN7'V;>=O7@ 6D$#(C.LY]950)GU?PP0VC6*//>
MLNNN)=K%7A3I55Z?].G%/!,I!*::U<M(I-5+RGG'7X;]-B3"EHS&V_>35^!A
MDS&7(3(J8X3TG59%V)@DEN[NT$;Q F*Q%9)H01< S-%9\#Q06<TR!<%,NB@/
MN,KE1BJE2:C$JT16QQJ=2IU/,N/+C2T.!V+Y;I462DA(3@:Y,9QPI:&N#6Q$
M<0#GS.IGH=\+:7/ !:YKM8D'.E\B+4%E(J)U&N_J"W.59EI5"AP@DIA7%>WF
MPH<M*DI+;L2EQ"[4MJ O=^>:B9Y2MY0PG7(W&=BF UP(N71D( B_(Q&MUV"2
M =1,Y5]:2-*P)S6[8O1Y%&GS[JNBHINR^JIYC<NXY$1I"Z=#4M"FZ50DK"5T
MRGM!/DK1&\LRTCS).Y95K5FSEQEQ!WA6YXVB@GJ;DPJG";)),DP9&9MF*:JX
M'*5'DL+9>0AQI0<20M 6%)( ]Y*T^\H[3O!]PDY(<.2K?^U:8F#K^/6G*JDL
M:1!%)MEW0=WH-CHO-L>Y7KFZ751%$BU!QQ=Q6/,+GY*UAQQ2G#-@,MI<71JL
MXOAY<<^R2B27V1P4YOP3ACY2 #-#WYYR1866?PW DM-+Q%>/I]5K3?$%$MN1
M+I%_6C=MH3FPI$:<_3?I.D55325ADPIT%<ED!Q8PTAX-JX_.!(&N9^T.PP9:
M[3Y1I1N?=S&=AB08+72!<1Z5&6N4\"<%F]6;FOR!3V+0LBN&&NDQBJ[KJ9;H
MU >E&)&5^;::6[.EA0RE8IL M!.W$E(W$7P\5^*!#7-I_D+R*B3-*UY"(@E1
MO.=($T)R@Q)/<7ZJ16AT,IU/KK]YWC*<O*])JB$5B<D*@49LJW&%1*<O>U'C
MH/NB1)]IFK2 4NLY"1N-E)^9SFDFMSY"UAD0>LE6#<S4TO.E;W_&LJYGJ1'=
M87$>C-.L.M%E3+K0>9<;5G<VMAQ6PH/8[MYR<\=M6&RM&0[,V@Y^JL,-D5(R
MD00 )FPO6-8US5)1NE5<Z?5N14>F<RDPK7G2%R*G9-13*C4N+*>&7Y]",-J0
MF,^Z<!R&XVTPZKWU2&@=NL7X)9\S329BX\KZ:U,3G(8 %6D1?=RS.8D?XZ:6
MOFIO7:/'N)JTKJM&Z+7J4N88E+F2X;<NE5;*MK3L2? <?:(=(7AI[RWFPE1<
M2$@'3#<^UK7YQ<6\ZF:Z*V>OI,+HAIS>AM65)*MJ@D@I)!)!R#\^X]3]VNUK
M7#,<;\)BBA;9^P'[?]3K1%A<22A6#[Q&-P2-W)P,8(/'V\X[Z(J4ZV4EF38-
MQ.(;CMUAN"[%I-75':?=H[E3=3"6_%#X);<4E *@DX4LC@DC4'APSC/N45-4
M2HRK7CVU;E41*JBI+,.EPJLRAYYU:8M/ ]LK.&TL10ZZ5 !M2DA12<#&-&28
MJ ;R=)D1])TA2&[\MF 0:UOE83>%+YZ"]%E-@()7%D-I#@(25K:6E.T^N,YW
M [?@<Z^1X[A8FV[+B86&X$EA $FL!PF@GCZ9RMO#L<['M+)D@FI%!>LR1$1,
M4$3.:\TQX:NL=&N'\H*"W28<Z/59,V!,^EVFWXX=>EIWJ0H+9?0J/*2%,OI<
M:45 K1E"1K^3?%OZ;?J!_B^/MFP83'.<72 ,2=PN#G']M1OM:+D\Z+]RV/\
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M*5-8\WC^&X_BWB&R[6YP:,)X<X/F201 &Z#8"U(B19>FZ,!1 65A"TJ"<J6
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M)!DVM,<+&)\XE?09L6%@N=\H#1$ ?*1(O6:SGY%94(0G!00K@#C/PP,<<8[
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M-P(.0K:G<,*& =2N9IF3-\M._*<^&XG.!GOCGC'Z/]3HK(]5<)$3'?-$-2!
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M1[VS^QT $<8YGRC-1A[N$[>#&ET$23-#E2>.=S*2M0)92E*LM(V@G>HC*<*
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MX-Z%@A2%8*3E15G&.X)P#\ /7G1%I"D0.Y823SC"EC ^& KTT1+^C(7]J/\
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3HI6^A.U(3G.,\]NY)^?QT1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g549728g15g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g15g03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2"F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ((J^@S X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R-C S
M-S(X' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !#)UP7-OLM%:8MBYS];
M(!5-.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/T       2 #4    ! "T    &       !.$))30/W       <  #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      -!    !@
M        \    9X    & &< ,0 U &< ,  S     0
M       !              &>    \                      !
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M;&]N9P   /      4F=H=&QO;F<   &>     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    ".$))300,     !:-     0   *
M  !=   !X   KF   !9Q !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" != * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M,MML?576YT%SZ_YUC0[]R4E(,?H/2<',%^+CBJVX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_   L( .8!C0$!$0#_Q  ?   ! P4! 0$
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M.GB?[ZEOMBY^UOQ3X"&E+]:>)_ON6]?_ +3]7V>OBOP$-*7ZT\3_ 'W+??/
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M/'T70GI0'J7%$0;;;P=RQO$-PW#RD?$.H?%L/K#CZ^ AI1_6GBMO_M4OOO\
M)Y3X?'P? 0TI>/O3Q/\ ?<M\O^R?P^7@^ AI2_6GB?[[EOM^4_AX<4^ AI2Z
M?G3Q/L_DN6^^>G%?@(:4M]O>GB=A_P#*I;[YZ?5Z\4^ AI2$?T)HG?;_ &5+
M!T^7RGBOP$-*7ZT\3_?<M]\]/W^#X".E'U8GBOG=2_WR/X=>#X"&E(?U)XG^
M^Y8/_P"3Q3X".E+]:>*_OJ7^^>#X"&E+]:>*_ON7^^>GS\5#0AI2\/>FB?#_
M &5+!_\ R?C^4/FX T(:4?UIXGQ_V7+?ON>O3Y?9P? 0THAX8GB?9_)4MO\
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M#@X./@RA";<YRDW 1](0 -@#<1W'H  'B(].*)JIJ\W(;FY#<INA@V'QV](
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M8>@C^C9$ /3_ )%_O\'OD:AMOYW*'W_;KB-OJ^9?A[>GJ'QX/?(U#>(Z<8<
M'P_/KB/5X_ZB_M;_ &^*>^1J'Z_PN,/X;_HV0_\ \E^/R;]?BZ\ 9(U#C_K<
M8??]NR(^+Q_,7\>W@/7@]\C4/^QQA_7^K9$>'M_F+^7ZG%??(U#_ +'&'VV#
M81S7$!OO\?F7M\XC]CKP#DC4/ZM.,,/_ .-D1\XC^8OP^,-_\A[Y&H;]CE#[
M?MUQ'_R6'V_9Q3WR-0_['&'VZ_JV0^_3_D7XC[ $>#WR-0_['&']?ZMD1\?A
M^8OY^NWCQ7WR-0W['*'_ ':XC_Y+_P V_KX/?(U#;_SN4/\ NUQ&_P!3S*_?
MXI[Y&H?]CC#_ !_GUQ&WQ=?,OU_)]GIP>^1J'_8XP_SYLB/J?S%#U]OJ^/CT
ML\BY[5=LTW^GV)8LE72*3UVEF!B^69-3F %79&B-)(#H42[F\G!RB8^VW.7<
M!X<&F?G(4XAL)@ 1 !Y@\/4;8.8/8;8-PZ[!Q]&'8!$=P  $1$/'P]7Q^SC\
M]_*>$[1J)U3:O*CI>PCVE=YPI*ZJE([.TC2]2%.QOBLV2492)5=V)3&YJJLF
M]:5Q+N9.,5EB*2#DC-$4MQ*54.W'29IY7TVX5JV)W64\PYJ<Q3J2DCWC/EM&
M_P!_3+-N5),(B2GE6S0%V\45=.-CD2(E!*/0203%(H@)7,A$\I0(5TH4A?0*
M"92I&!N40,FWYDQ)R)$$-A(@"*9DP(04]RB8WV>+34!,IECF!(H%1$2E*=(P
M& P'3.EW0D-N&WH 7F*/(?F()BFMJQB)3%5 2]X3N@(J"#<JY2H)*;I]\FF0
M_=*@ E.4O*8I#K$3.0J@@&C,!MRJGS68QMBAGN_ !0(F(B(M*^8QCB<IRF'<
MP@00*02$]$1.(B87 ^2)?@FA]QX/(TOP30^X\4\C2]H_W-O]QXKY&E[1\?\
MP:'U/XSX?9^/@\C2_!-#[CQ'/VIY )HLRT)!$#"K7 ,(E1$##[NQ8B<0[D!$
MP[["(B/KVV$0V9O8BE'LL;V!2@3\M<<B(D'8W-YUU+T@'8=A\-_4(;^WCW:B
M@(/95V$1('2^TP@\HB03;Y5KB@F$0$0W[Q-(_A_H8  ]1X7N5T2&[+W+(& I
MS"DH8YSAS&,H=> ,8X".W*83#N !N ; 'Q\8J% ANS"S@)B%$34D0.(\WIB<
M80IA$-^7J( .VW3;;< X9ED42F[$774)B$Z:;G!3 4H%YR)T02)D$0$>A#%
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M'W'BGD:7M'^YM_N/!Y&E[1_N;?[CP T(4PF#E P!L4W=E Q=^AMQ)R 8!#H
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M$( %*&XB(CL  &XB(CZQ$>O%[@X.#@X.#@X.#@X.#@X.#@X\_DR)1.8I.43
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M_'C+0V<EV=67;2XL=S8NHVA$1&)C)YTT@7'*M"'$SB"0$X+'WV+NH1,PEZ"
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M=X5<QC"!@VY]C;B( 41$1$?!&9,H,VFL:)N]7D$B.2M%O(K##.&Q'ZIA[AB
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MCX8OV^.7\H5G4SHTQ5 W:?A\=9"K%R=7&F,GQBP-H6B^Z5C%IA@ )IN#M%"
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M6^HV7#4,FM-U!O65XBN)JL91(CJP&F;-"O$&P ISC[GLY!4"%,/=;@ &D>T
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MYN\64*/05C /AX8;0 8QM8NI)0P\QPS3D@@"(F 1(8HBMS" @)C[I!W8CN
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M!REN++E*)0#E$ #<1VVW-ZN)/NQL0.?1)41[P2E):K>FGL)QW(65. F,4IR
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M^?+T]8="^'7U[#X;1M_P0@.VM;0%[1J&0-O[F7?\/BZ\=5V#?T',8?UCUO\
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MT@3030 X[F(F1%-,.0VY@.!^<5@./?"H)4Q)[T44T"=VF'*0!$0#8 VW'<?
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M)#;\C;$( $(41C:<F( 0@%*("5RKT.!NH[@(=0XO=H& #I^TCE]MXKX;^/\
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M>&;6XO5PDF;[)U7;H4Y^Z;J5B(.>?<&,JR9 P;/$EB"JH8AA5Y .<W>E,!A
M&M]KE2Y4_9-N;AY[W$D<;,6*&PTL7D1YKD47MC1(CH69">6 JD;\?(9-7O2F
M](2@'$AO928LL%OTAU>7CLQY0I+92P65,(2J2<.UB$U$I$Y%%DD9!F[=%4<&
M**B@J"0#&-S%#8=^'$ZRL27.J:9,RV!'/V9I96*IKQRBRD9Z'*U<*=^@7NUP
MCXDCCNP*(CS$,4=QZ#X\,@J<19+CV?F5K"^R-?&J=<QA%G=0Z$CWD3/J+QK
MX^Z"+J,5?KDYQ WH'[@QB@*>VQMU)IUHDM9=$^195C?;M56T1A]51U 5TZ+:
M,G2*U=TH"<NE)Q J.$BE(= Q6@@/=G$H#S=.+&@RB2]PTBV%RRR'=J82,Q9)
MJ.&50?1S-K- K7IAT5&50D8@9$R2!2]R0K<_*!5%"$'81-Q%G_ WM)E+C"Y
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MM #:<[$4Q2B'F@[Z" "&QF;WF* #_0F]8;;&]?"#[* A0Q;?MB@!?-"Y;@
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MIB:0/A_"N>\8:NZS5=/^AMCHUIDS%9NH,C88A!6W*V%U29.0>N)=HX=R*<S
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MR/D,5;<3%%4^P]?#?K;2JE$,*B2=4KI@(42<QJ_#\G. B4$@3!F G.!M]B%
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M8XE;E$PB.R:IBK 8  "$4VVYTK'VA^J&AP>K*KS>HK'$M<DLNX;@\99,@:;
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M59HL$CF))^YQ'?.(/.[$#Q^I]M1;3R^&6EKTR-*I'YQ:5Z:J-;L=SN".39*
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MH"H(B_!! 'XLDVQ'W=%,Y(J?J&U?<ECL)1 3)>CRHG1*9),2&YDA(46_7NC
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M6T9,Q[2")8Y)C'LT9=JJ9VNVCHQ9R]]-UWBA!+QTJ4](R-8@B&$PB$6R$.<
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LE%4W.$CD,T)'QK6/3W,1@D5F50P@)U0:E!'OC[%* '5Y.<P  @ CXCQ__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g549728g15h04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g15h04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %E:^5Q@X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R-C S
M-S(X' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !#)UP7-OLM%:8MBYS];
M(!5-.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/T       2 #4    ! "T    &       !.$))30/W       <  #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      -!    !@
M        X0   ?4    & &< ,0 U &@ ,  T     0
M       !              'U    X0                     !
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M;&]N9P   .$     4F=H=&QO;F<   'U     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
M  =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L
M;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U
M='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT
M3W5T<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M       ! 0 X0DE-!!0       0    ".$))300,      Q:     0   *
M  !(   !X   AP    P^ !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !( * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MZCO]&[[V_P#DTE,TE#U'_P"C=_T?_)I>H_\ T;O^C_Y-)3-)0]1_^C=_T?\
MR:7J/_T;O^C_ .324S24/4?_ *-W_1_\FG:XGEI;\8_[Z7)*:6!:]_4.HL=8
MYXKMK#*W @,!JK=^C=]%^]^YZOK&IS,NO)ZC7BX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MN940#8JZAN[[X=S" [B&J]3(J?\ 5%V#2CW8";LRY+E$I3%$ %1MN("!AY3
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M'+ZA^(OSZT%  ]!3#^ J0_\ .'^S6XJ)=AW+U]SF*GN'^;N _P ^N4A ('*
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M<#M6YSLU_#"$ 0$RY"ID$1  #<=>CWRKS5[F+X'^>^-1_P#\K6TUKS8/HQ?
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M471A<'1311-R%5*B42HD'E( FW$>DX<H?[ 7Z.G*'^P%^CIRA_L!?HZ<H?[
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MI-7"?J6C&J2\9&*G!0#G8-#B*A$2*EYT"',42$;HIH&YS 90C=%N45"ANF4
MY-?69BB4B@^<)@W4(8P)B9,P>=NF;DYB"([CS%$# 8YCE$IQ P0+A0@>6?$7
MZ0Y<U'V$-@-L..<<B(&.  <X"/I YC>YZ@U8C8/A^,?GTV#X?C'Y]-@^'XQ^
M?7P2+Y".;+.EU 31;H+.5U#=X8$D$$SK*JB4O4P$33.82@(".W3<1 !QA<7N
M2:;E_&W!YD&D2*4_5YGC3P:M&NUVBH-ES1$_/%W/'R*8DYTW;11(ZAT.<R?,
M4AP*8HA^"8A#\7':!@<H'*;AWHQ3 8 #<GB^5'DYR\J@$YC'-R@< YCF'TB
MABXXE!$N.NP?5+R@;VWRIB^8F)2<]0G$Q*0@D$I2@41  V$?=$1'<1]5Y2@!
M2@&^P 'NC\^M1#8!'J.P".W,(;_!N([?'TU\*CONDCJ' VY W'8IS (B &Y
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M=D^%@C#HQ81ABN%UCE54.Z<3#($BI"!4%]Q$MEP/SD.8.O+L=,W()=BJ)B8
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M>(X7[CQ?R>T_0Z#!P@^F'BQ_#'M/T.OTBE*0H%(4I"E  *4H 4H '0
M #H !T#W-;M1'F6@2.4L97O'<=99FE.[?7).!;6N (4)B&.]; DD]8BKRMS
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MEWJ.7_\ R!=K3_E@V;_I5$ZKO/?]T7X+_P#-D27_ #V^IDEO\#K@P_R_:O\
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M%GZO_P![6/\ SK,Q \<G!JX+*QQF[:N9H.X7*];&20*:"8<IE5 5$B8&Y#@
MF$-Q*(!Z-5 [$23C656[2@KN08M3*]K3QD*) X=H(]ZD=Y1S$52[Q0O>)'#J
M14G,F<.I3"&K"V67B3\?N4W!)./,W]ITY3!<KQN*0J#)26R8* IR"<?M $3?
M!J7>SQF8AIP@X?0=2L:W6&,E2@DN^:I*;C-R:H!R'5*;JD0Z@=.I"F-Z '4!
M4:4C$\A=J,<\BP(1Q8*J9 QGC< 7+[&A YD=U/WTNY#!N3F#<!#??IK)7B5Z
MT<XUH@MG*#@"U6!2,*"I%0*H$8W,)#"F8P ?;KRB.^W74C ("&X=0'6!7CEX
M-..'/O$C.V.$B>#O,. D&#5OC*'X@6:*ESPD_FJI%PMKF*>*6%K8LC)A9(EK
M;8R4+:A?JN2FAB'B62ZJ@YVF3/DBFC!T"*W)'H,W)0*!D%>5L1%8 +RD R*F
MQ@ O(0!(.W*4.@4!<]F'P5KP<]6_81!O$V;("64)I)E<;TU<.KRU72/'RC=R
MWMA#,V<>#=,\="E5&NQX"(H12+HP+!V_$F,*A:+OQ(*S[.2=+1N:6L5'BA:+
M=&@G#QV,<;IQ8G.VGVZB[A%),W.\!4%')B"<QC")MIQ]A/%G.9+P>:%4A!4.
MF&1<ABH0@&Y1.9,+ESE)S>;S" !OTWWT)A+%JA 43;3:B8F$@')D3(AR"8!V
M$ ,6XB'0>@]>@^GT:IQQHRT#PXU/'\Y4ZRC*+7#)-=HKY>T9'R,E'Q:-A.HU
M:NC&"Z$ O?/S-6IE#&Y4BKBJ8! @ZE3%?#UB24)/7&:KTB\N*\C/U9W:)*VW
M9:=7KC5]RA NYD;(NHI$)%$R0QQC^#G1 IE2['VUW-'A2X9F\)#09<?PB5=J
M\FE/P$0E8K(VB:])1YWCII)1C,D\5M'KMC.WKLRJ'=EW.L[V$W,;7[*/#'@@
MLC-V)I3DQFK:Q;1<],M;/;T']BC6J9D4&,N_:SW?2$84G>&(W7,HV JIAV$#
MB.L<?$K0,4U3/W#_ ($A\#8_D*D-6OV0:;89>V6%I*8VL==A91,TUB]BK.D\
M2VMCSHF*_B4EW[YJNLF8A2)'UD @N&/ SJ%?23JD("]OL-&$O+@T_;0);2A$
MD3.2PE-.;ORBW%0FZWI,(\WG"(:^D.%WAS1"HE+08])''2*P43DLMG2)0TG+
M7P4YJX49X"5P3-2$044C2HJF[W8X\QQ,/*KPF<.C]C98Q;',<ZB[TL63N35>
MP6E5G;W/*3NI"?:FGC(33LA4TA3>/^\7#NP#F+T'6)WB&\FH/BOF\71.%*7$
M.,184863%N84;I8ARO4(6S6BI1\PRH+IW8 DJ[6Y5VLM"SD#76RS0P&)(+JI
M)J* .4QIPB\-B$/+026-(9O$VF6)9[-$-9RS1Z,]8WBR,H\L,J@RL*2<C+/I
M)NU=J/'@ X%=J"P&.JF4!_<2X9>'=2U%M1:3'K7!.%/$!8/*2SN)]&#.H &C
M$Y)6?-)$BE52AWC?<6YS%V-N(:QX\>&-.'K%$7PNX^:\.V';]6LA\25-CHNN
M91DIQ[7H.WJ6FOI)350&2LK>.KF1$F$W9I6LVDQA=L9%D9@S16=S!$SW!X6\
M7U*XX(H5CMWE++V.6:S99266R!?D7,J*%EF63-RMW-F:G'^#FK-NBDY3%TS;
MMTF*HD.U,4)2L?#!@"P>)S6>GIV$]=D0FZ\-AMEQF#P$PBDH0LS"+25C>KQ#
M])(3\SYF<BH$#T@ :_)2X4N'%16WOT,=PX'R,V0+=Y%&<L*:M[;M2%(B%FD$
M[ +R;18MC*HF+(\R3ALH5H<IVY 2UC=X@X7"]$XL>'S!$%@[&C)"(QM9[+BR
MX/).TIV_'B;&-DR2[7$Q0L[5.D/F;=%LHLT@6;A[*,E5D"I%(W$H9-*)A['D
MG1JH\DBV!W)/:_&.GBRV1,ABLX77;)G57. 6U'J<YC<P\A0 P\O00V#M(86Q
M0=<I!:S8NT45#D0]D?(8*BD4PHG/W87 1[HBH]V<QR&*0P"41 0';']QMML?
M\*&'F5JQ]C"NR[&]919P]X0G+S=(VMM7=O(LKY3S,:RL[5K/2#V9:14>X?+J
MI'307![S%*U-O:C#F):;/Q$](3K&><O6EGEXQ!V.0KZJ=I&)IQ[A*+;.RVX'
M)HQHHL?P5J?9$I# 9/8 #>6E\,8G;@H+E"83*FD957GR3D%'D2+]DH<Q[EL0
MA?=$VVWKZ:(X1Q.)@.BTFP$Q"G WLDY#. IG*0Y3 'ECL)3E.0Q3AN40,781
MW#5!^-VVN>'F:P?#XZIS&4+EFZ.*5)R=IRYD*$48\[47";2)75O3-N+]VDFN
MHV*X45(HX;I(&:K]YRZR+X65<K8SIZCUP[=NAA6G?.GZZ3EZJ(%$ \*731;=
MZJ4H 05#(%,<"@(G5'=0TIZ::C3+^*JAFS'EBQI>FCMW7+&DS*Y&/D'45)L7
MD=(-92)EXJ39*)NF$K#2K)E*1SM$X'0>-$5  W+RC73'_#IA6 GK%6$<?P"L
M)C*#QW7*6,DS))NH* 85Z12139N5"'>E<JG4=.7S@%!7>.G"JRQC\P@'1,L9
MKX$L&75:B9:D*!1K E 1]E[V>8JM(YXU?"Z)'I,WQC=VYD5",G!B-$@$1*38
MYRJ'3(;Z\2Y'[/C-\Y$)8RFL,VNYS\<_)#Q+$K(UP5CHUN5U*MTF+@HR*;5D
MBH)G9 )W)![Q/<PD, 5/[2*A1- +PSP6(JNO3VMRS5 U^?&G5A8T(V9JR<>]
M"1F$HB'? !D7#<$D >J,8[NW;URZ7 Z28A9FHP'#MCW ,!D3)5$@W#>3D5H*
M4F&55&8?R2DQ<92&C&KIND1P\<,3*JIM *X[TB"!B@ <H;:C<>*CLRFMZ88S
M9+4$;]$7&-QY#UMG5#DD(BRV*55@F35F"J:*$<CX0@Z7<+]X@5*/04>B H@!
MCS*RLW 5)Y$C</P\9CF6N%XDB)LXF+K!WT-9I1]3)&_LSJ3B,>I R;B0ID(^
MFF3KQDN+ELT,":AG1%$28[LAP]65X\<Y4LD)$FBJ9BO&#VO-&M;AF'B9.8M:
M#9TDTFE85&SF,HD)R+!&V!: %%?N';$BH ;63?*L5P?83B<=ER51:7!1U]R/
M4\?TH#55%ZQ/DBV**-8 I$F:!PCW+IR90!E#@D1 3&5453*43EJK3>,GLML@
MW&*J]=>4-_9;DJZ@2%?TYS$IO6<,5\=R26DYM!BS+$131F#YR+Y4%&C!]&N%
MFR:3H@EL74I;@LRA)RM3Q?%XVG[/4(V7<Q9HNLE?,H,\4@DF=[$.D6I(]XU:
M*O&ITRQ3PP.B& 6YS@8#ZQJ<%!\3,L?WS,.=8.K2-&C$N*NVWAPYH\4Q04BL
M:W*BF.\>0$;"QL@^6BV"$DE'FG(Y:<72*BT*Y='*51>S-JXXNRDI#]LO+SM"
M)9'%1JEA208T]T]G$:S;F#%] MRKMV!D4$3I/V;9RQ!X0K)TH+1R4BR:I22-
M9<[]FM5WU*K$DKBOPRUK0\C7HJ)K[2?28NIN70B6[AX$4SD(F(DDY-VU;R N
M5TW\>9VD+DJ*:G/JM?#Q7*Y:..SB<@)6*@I*&J.3*I6F:):C$Q#9.+=4VR33
M*.*Y"+9V.4,S*DFS/(2<G,P#MLU*I&>"F#ND[JYAO? S@Q_+IY=1HE>D*35H
MK(+L\G7'CM6,K=BL"=*C)5B](U524\/F"!&%:L72KQ)%$5W*)$"]YJ*J%Q+=
MF7E**ODK67V,UH&G-F<U;GDE74XUE)#)-G<DQ2;-7[<CV?DWD9'GF&[-DS>/
MCL2HKID'FY"]IK5UX0L^8CS-D;A^\BI5]0Z=<&C:V,Z0]D96LR:-3?S$<X"+
M69DD)=BW$/#DH=),X/3(BT00[XZ9!J[P2.L%0W!W6<V9NK-:4J\;CV,M[IZ\
MJ,2#:(4?Y'RPP7?(5^#AHUJS<D;^+(\ZOBF.F>X8H!(E!Z@X$96MO'?V8E2L
M;^G2-AJSRQ,I:*@'$9&566=G"7G0:C%QXK]TDW*Y=D>HG(FHL01#O"CYZ9R!
MWHG$OV<#_-E+PNVGL9O\MV1^VB:2DWAQE4%Y:5CCR:<?'3B*3B*,\,2/53=Q
MZ;M3E>,'4>[3(8JI#5G[-B'K>3*D,M:XB"G)%?->;821D"U-&H)/0K=8J2!%
M5*N,;#R3-11VLJ\5),MWDRU<J*(+2;QD#!0EB<I\3/9LX<M=QB+Y(T")M]&E
MHRIVYNUK#N1D63J1C59>.C5UFB"PF9+ME!()A5\%!RLFW4,10X 'RUWBM[,^
M4QI9\@Q<WCB(Q[1I%>#?NW,.,4)RIOXF!>NX:#*8)9_',GMICT7[EK';MO#@
M553[K=48DXT+]@KVC-QXD>&PU9383<ZRAD;?7*JNH^F%&-C\D7I 5&&D'4>X
M(9NIW3^7BUVI&HHBNW(1QWA;P\&K06=:N2"0@1IXXKCQ!N42=V@9[2*\Z<J$
M(B4C1-59=0ZRJ;)-)L"IU!333W$@723#8A0]70!]8 /3?U#Z_3KR%]K)>LBP
MO'S;*+0,TR[E]D*HX=KS+&+BVYJH-2Q<HZD%RSE_D++68=Q47)YB-<)E\0-T
M90[U9LF+MTR<.%$R>N6&3.E#Q22BA5E$XUBF=8IA.54Y&J13*%.8 ,8IS )@
M,8 $P" B ".OT3?8FW'E#8=S;[<O3T[CT#;T[CK&MD?B1C>%^!XA\BR=.FKB
MQ/Q)0]=6C(5$=V7C6DXU8KO7"A&[LS=%..4.Z3$K58[IR)$2]T*I3!A_XH\L
M83XC<N0V3*9FGC_PG(6%.,Q]+,\9X:>EBI!JR16D# )Y&6)S+J',DDY<)(MQ
M3ZH'6%5%3E^[ MCA,%7?A\SQ&YJX]\J8[E\L6G"'L9V:D^#P;M=6%*T)?+I$
MD(]D64!X[G:Q6&IRJ%1\9+)2(N2HHOU3V9XV,[6?B,X4(3*<3BK(-":TG-'"
MK::XPE)&(;/;8RR/"42]NXN3B'<>DNSD*G%W^,B)"/,JBH$\3P=!V!V3LI<B
M5_N\+3>&'*=AN[>\M:_,KVN*F2T*O*6.YUPEG+X #R-BV"S=19>&<.R'YFRB
M@BZ(58_[V)Q+YY<SCPV98B'%[C.(KCRK]#LV-!Q417'F)):3CH!U76SBONIQ
MXDA:P.G/^*Z?*M7,B07:)XMQ.,UTDW,H91O(UPR[@%**\0QV?./*Z+8_L!6-
M86C<92T7&P]0)'PD.5O6_%S]LK88,4X92R,U7:;J35<R"R*W@K54J.KV<4UT
M5F^(+@*S?18>Y3,#D/'62ZKXBGFC:*<,8V?JCJ0;3TA /$RRD3.LE&H*KF))
M'3*DHJT.S!4R:H7<XP<@5*H\-9JK;Y2_P*66H)3'+"QXVJ#NXSE9<R=1DY=[
M.2#%A(PX1[*-CHQ^[+)NY1@V:.?!14<"8P@?SP724X;LUJ-K\XXI^T%A:G=2
MU-^U<U3#LDG398C"NQ+%K(',RL*ZB?CR-@DI"PIE(HQ6726%$R*RHG4M43B_
MP1&6,!6NW&_>XTDY#U\I7.(I>#0Q^VAY.KRS)I'-&#]J2=CGB\0+!47)S%;H
M3+\KUR8Y2-QG;BT9O(;M :7:(=K.R4+FOA3D(YTWDU&I(JK+5_(M">1Z[%N#
M=M(1 2";@C6734<.FZZ[DY0\'53+RQ!Q4<0. \BY6S+54LP<7V/+19*:QITE
M4*=B)ZLJBRP->'1K58:0LK/QKV4<#/0TLP4E(Y!O'RZ35V@DZ<(K)G- V%KS
MP\X?M<[(1G$SV@*DO)/V;&UQL]@J2<KC"-X=RV&IG7=R,NJQAI%5P,JY58'2
M=A)%4<D>MB*F L1WC*-=G&^+;GC::XF[/-U#C]X=+B]JV:*T9C ,(Q:4BJM&
MP]87EG3]22&84K",GSME6+N*<RKAP/AJ3H#%S]1.:*!@3@CJ-JR2RN1ZY+)6
M&HKA0JU)6.:C7LU;;'&).#(Q3@CA@5D8-W[T'39HU5!0152*4-\$MKD.'O)"
M<!)GXH.T!;5*(QDE58J>K6,9%_ R,*]<R@(6-W(1EN!0D\V</A;%564DCID:
M$!P @<Q2=@LF4\%*XUK,0CQ%\>]BK..K/6H]FS;8B?QR-9A:W1YJC3B;E@VE
M6#FSUJTRC1A:+ S>2+MP9VHV2;2$8BJX$]N,U0CVM<4G9<V"LRE^ML;+\,[J
MF/'UT39%E)=J7&+4L59;1!*IA(PMVE?,?V9X$NZ3%X*D:JBH*7?C'G$)Q 8$
MSA+R\*QRGQ:X_GZKB5ICZPUK&V+)-M)MV4!968S-LKIU)]BO.#XV7;,$C-H]
M%H[8"H=!^/=GYJ[45+ N+IV=;1W&%VB$/D&UPT%4'4J;!<C(S%=85)\RDWY3
M)RDI.L$!NB**J$BY0[XSY1R\?\S590>7J;BL4F=X9>*ZPX]RAQ>W6U4:PX8L
MRE/S-$)UNGM"L;Z>(:OJN:7<R[.91L+"26?R<&Q%FL)V[0S)Z!O,#-[Q'9AH
M]*X/[PWRC(Y@QC%95E9JG.+3A^NGL=SHDL^KL<_5>G<L7::4:=NFQ=D-)*NC
M()"!DC/"'*4=82K)7N'G(#>8>3_%KV@32I3]3I[<+RRQ8]=5Y_#QH09D95:4
M86A5D"DVO5GD/* BU6YB/7R:KHIGI5P_=N-CPI=UQL"/%=VBCV-J61H6*\1,
M,2# FJ-:"=7:1E=B4&TDW"7J+-RW 3I+F>/3MW31=Q([I%04RL=K,9S'X\X1
M<N0"-@EWM8S[C[N*^D5FD$['V>,=-UAE8YVBHN2112[LR9T'**K5850,"I=]
M99,.;FQS5%!(5,RD,R$Z8%.!T3]T',@?G(4PBB/F=-R[AY@\NVI/TTUL4$ *
M(COMT]!3&'TA[A0,.WK';8 ZCL ".J$<04YF^"0R@XP)#*3MJ5L.,6\GXLAJ
M_:YF/@2Q4H=X^B:[8;#6XF0=@Y3;-C$D)5H5%LNN[2 ZB! '%7DLW:!9EL4'
M;,E]E!@/(\O$MRQ SE[>QCZ=7;Q\L5>.V([O+\C!@U;JG?'41!T=1\)D(YFJ
MWY5$I,JE:XO*14,>Y,QGV>&%*#G<;?>X9[&P490&04>D/\?.&\=9D7SN_1UA
M40L.3%TE7$>P-(.35T7#=XQ(NF0CKZ^-8_$?:,'8+0RV>099%E^,>@HTZ+H3
M,$E8Z#&%!P5&>0@EYSQRW;.C3"R+A!1!^H"$>(-$'8' DZ9FRIGK"O"+3+)B
MKAV:\12*#:\^5D1(@9=6O%C;%,.H*7D()NLQGI5DLLW%!PTK\6_FP5%H"$6D
M<JZR=%ZVWXMYD].MK7LA,%OZ3:!J-O92*!8:*N[&TJ.HZ>,^G8>U6UH_AV+.
M3>NU6CMT#>PL%VZ9W34I"+,SV,H%_P"T!6R?B%U,]G'0*51HF'I+&:79S%$0
M?U:45:P,#*SD3*IV]^I&P=4J=@NT)"L&R1Y3P91X9^B5-0(]MP9YE[6KVA-^
MKZ=FLQJ4A@.D/Y*'<-VIZD,HK?6"469L<Z#P6+DW,LNDN^&/5=*<Q&KU^7F1
M1E?M*\EY=H492SLN#BI<4&,(B5HT]&R4RU>6)]6L@O9]6$8H)5:'=%G22+EL
M<S6NS4?%/HUI(2#,\H_C$.^53I:2B<5M)<3CESV/G#98):-LLP:AV&I.*PDH
M^3CY2Q>&V6<8R5R1=Q"EE"8=2\<V;E35\%D'J+MJBB#=)&VG"_>^.%#/-(C[
MSP'4'#>&[) /&<];*[*UI"6HJ[5- Z;5T:/N$JY=A(*I-VXM6Z"K B::1&ZQ
MS%,4*D8;M6>76.LTR,%CA]Q*MG^0^)FII8YR8=.%BI##3VS8W8V0T8N5-DQF
M6<;(R*S^0CVDY*D(R3E&:#-*R,7$,3\*IQG$+D.GXXNZ?9%</4]B6V4R#=/X
MU2'C(2[0KA![(UXL(TK%ELD(\0AF;!HQ>,T; +:2(T=]X4RB)$CCVUE)\;L@
MZK+I[V0^&VD;7+S%F19J&@%)!BU;V!F5I:8Y9*].C"$*S;A([LFB[H'X)K*,
M18H&<'MUBV:N$OVF_$!&+S5L-1HN%PXZ80ZS8).LL;2^QV\7>*1+UJUD2^&)
M12JICK'?L05\)>G<L5TRM%$X"S=E?C/R'E6WX>F>SMQ!DB\5^AR4W5I"X+C+
M5FTUECD8(J+63LZUD+'I1$G'+#/HQ#]\RGVT@U=^&17*()&Z=5D^,2K/!;0_
M9"X1@9Z9B%S6&:BG%3/ *6!B^75@CI/5<B+*N846DS,+$4.@D_(Z=]P0B: K
M@.1SL[V>:V6/;PUS?PJT_A<FD;:55K$T=O#BRO3;Q6V\+LSME!2<PEX8HNB=
MDDB)A4%!)($69E=UCXL*3EWB.@>#0\@SX?WO%]0;;5[N>TL,DL3/7,!!5W-.
M36N-XZ5K4*9C9+E7IZ!8O2,7M79WIP::-$A&/"UHJCB,_=E*+Q-O%Y:6F^R'
MX=;[&RD'&NJO)1Q*ZPLDD_-&QTPQ2LT5)VV.6CFL:L9O'BHIRR0+1:ABHIF$
M0&1<,0'%;'<4.([1+=E[AS'5*4F(J+EL@QIJ,G:<<MBQLZVEK81TSMSY4JS1
M%K',6S1HW '$8X>@9/QB[3=$LUP<3MMEK]Q#OD;%9K0O%<8G%3"U-K<F231E
M&Q\/7J_W<.DLBP;2!(5M,.$XJ+!VY9J,(UDW;EC(XRO*O0[(=]XQ<V99R14%
M>RKP9;LA4]>#>2SV]LW:K2;://#8]J_7R(2P(UZ3Y6QR.FC.-E7,FG'*N$'S
M- 2<Q.VQ<'Q-LWSZL5WL><-0,=;&<06PS;E:CEB'%J>3=-5M#I^"%Z,HI7EW
M-=![ K@U.N*\'6W,FFB#%3OYDOUAS-$=D=E-WE_$*?"?E&$9O&[BEXM\G$5$
M%WEGA7Y[9'-64^Y@HA*V3,I*/I5JZFQ;-U'3E0RZ*2B;9/(3P6J2ZU,LJL\[
M=/9A4U.5DEWR::+T[Q2@UTS@7;=-LR*@X%03&53\#;^>(F*4Q3%4-=0GV(?S
M_P!HZ\>7:&7//&/.V)=94P9>D;A*TBIT>+FZE-XRR%:JA2ZBE192PW6AS<FO
M9J9C)PF^@G092.U9NI*YHNPAS1*[I<0@C^P&+<%=QD<Z(J@L5RQ:+E6;#NW5
M!5!-0%$!YU-T3@;F2_?#^8)=SF^R'[%-@(?<.8.0VY>GG!L/3SA*7KZ.I@#U
MB ==5IP^V:O;5Q&(.44W2:N;U5N1TW1<$$A,?4%--0>_263.W!5LHBBKW0B@
M9,2@?S ,$W!78PBB(I,XA%%$%#))I,F1.X46.9182&,@IN54QS&..P'$XB;?
M8P@'UIQ;-%MX,DWCTVX<PE9I)-B(@43E4%$!!'8I%#D(=0Y2<_.4@D G(&J!
M=H5B?*63L2T"E8EI$;<EB9AQK8+ CX1$1Y(.!ITTTFR28(2,S%I.6[):-:-!
M3:BY>D8B(]TMR*'&V>*D&K^M3(E.GW*EMLI!*<R*Y! 7A"B!1,"J/0A0('_9
MP+L(E,(["$@-JO7V;8&C*,B634ZACK-FS5L@@8%#"*@E2;$;I]Z<IC$%0Q3;
MD47*<I_"%N;>6N091W".B2"4#BD9-HR+W/>ARJ)D*+80,00$P )]Q*40(4
MH"&-CBPQCE^U<4?#[;:MCJ*F,/XTI.3G%ON0R44FXK$O*UU^T8MVK9>4:2'?
MI@9,[5)G&K$W74$73;H Y$H&/;O:Q!"<&2Z:D)'E,@IW"S95(\:5NH@<#)K%
M,DL1=8%5$A*<Z8]P)C)F$=?8UK$.S8(1S6*@6S)LFDDBQ09MD62**9C;HMFZ
M"**;8O=[%)W8"D4H@041*41/](5Z%3#<D=# <!$_>> M.81$P&-T,3EV$"$
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M7:(P?X8Q-C6_L+9=0>P0>+WD]$2"/@HM%)=K*).X]5./78I,X91H8CA05'2
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M/G =]%)GB$.D4@XWQF)B*&4*)LF3(B D$>Z."IJ*=8JQB^:=8#"*6XF3*80
M=5PXA.''(/$P-$-?J;#,$L<VE&Y0#&L9A?,&#J?9KMW3%Y+(O<5S)SK-E4.1
M%['JQTBW1<.B(.R@L8-2;CNN<05"I413S8_Q7(%B3R0 NGD*7:I.$9.4?2*I
M3$/C\SHAR^%D*<XN5%'"J7>G7*)M@D0LYQ#E(4!QSC03E3*4VV3)@"+=0**:
MG^\01*D1(3=V(<Q^;E PCU-KE"=X@B'$28WQH!14.H #DF6 "B<1$_*3R%$.
M93<PJ*<W,8RJAA >@:I%<>$'-%ESE=>(!JE7VMKN=3K=-4K3K)$JXJ,=&5Z9
M1F2.$&OL?F4,\<*I"0IVY6/<F.=159X!P(G=9"6X@TBH)#C['0I% "*\N3)T
MIN00#O#%'R.[PZHB79(>^0(B!Q$"")  VI9KB&V**F.,8F/R(]X 9'EP3.J#
M9$JR@B>C'6,852JI$.HL?=J"0J$%3F*7@>2/$,];.6Y,>8W:++ME6Y';;)4L
M+AL!R&(15OWN/720'1,)54"J-UD2+$(=1-8A13-4+AQX5,U\-#I)2OIPET2.
M[R7-/G5QR;++/E9S)-CJT\]2CB^02J,7#-$ZP1B5J55TN8KYPNV.S J:!+DI
MSO$(F3D#'6.#<H@!!-DV;-N0 Y@W[VDK'*;G$2^<HJ($ !*8O_8PT4G.(138
M38WQMS_8B8,H3Q!(41 ^Z9DJ2F8!*<NP_8BJF(IF.!!$HU!HW##FNAY_R-Q!
MMDHJQV'*-D@YJ;KUFRM*.ZY"-X&!EX6/0K[5&C)\KMD24%NS=+%3*2*;M&!T
MC>"@JM;@DOQ!)F4$F-<8")A-^^CD>4*H<>_%0JBI$Z$5$5C<RBIE"%+RJF !
M!7;O-?1Y0<0Q@V/C?&@@4P<I R9+\IB_:G'R##8";CR@4O7H B'IUU^Q^V$L
M->L,$E3*575K##2<0I8:UE.1C;-%GDFB[ DQ"R_L=K!'S40BL5U#OSLW7@KU
M))0R1P3 1@?AKX?\U<-%#AL=0$16+="1, WBQE[9D>4=6)=YY276QO%SNRX_
M."C85K:#=@BZ6<J-&;862JSHA4W!K)%F^(<@@)<=8UZ;[@;)<R8IQW\TZG>4
M918ZA   *87&W4=R] WY59WB#.F9$N-L8@14!*J!\CRZI3@(B!BG2/1A*HF<
MFQ54Q$@G()R <@B50M0^'GAGSAP[)+-HA*'OPO\ (60LC2LYD#*DC*6F2F,@
M1,7&2!I"62H)$Y%^NK$HR\S,+MDUYJ=>2LFLV0!XBT9VX0FN()'8/8VQIR@4
M2 0N2Y<A"%'[+8B=#3(83"([F$H& !'80WUR&GN(40/OC;&8@9/E!,<F3  '
M.(%4(54M$ Y$P3*!@Y0YCJCL82E*!A@'B;PQFWBCPY8L-V*$JE/A;*>-"0?U
MG(\R=V=%D[0=F;&#R+:F!#G1 4P1<-G/>E17*Z0,ERC-G#AC"XXT@+(QN!HT
MB\C)1H1+6/G'T^#:)AZ]%P;7PI\]B8;^ZW L#N7!$&)4N]5.?F.<YC#9 H;
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MN!TRB6**44C$,(&2$O*83#OZ=;2X1Q"4H%+BK&A"E#8"DHM4 I0#T 4/$O0
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633333333333333333333333337__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g549728g16p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g16p01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2&84&AO=&]S:&]P(#,N,  X0DE-! 0
M    (7R^A7(X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R,S<W
M.34R' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !"&GOX\P 2!;[Q_9P7A
MAEFI.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/T       2 #4    ! "T    &       !.$))30/W       <  #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!$0      !     "   "0    D      .$))300>
M   $     #A"24T$&@     #00    8              2H   #/    !@!G
M #$ -@!P #  ,0    $                          0
MSP   2H                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   2H     4F=H=&QO;F<   #/    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG    SP    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
M A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R
M@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]4:UK6AK0 T" !H
M G2224I,G3.24T+/K#T&JQ]5O4L1EE;BQ['7UAS7-.US'M+_ &N:Y4>J_63
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M&O\ 3L:W81NZ<VQFZG:W^I^C24]0DL3_ )N9O_E_U/[\7_WA2_YN9O\ Y?\
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MY_@EI_\ -"G_ ,M>K?\ L;;_ 'K)^S_4;_YVK_\ W$Y'_O.E]G^HW_SM7_\
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MDDDE/__3[O-Z_;B]?QNCC&]0930]MP=9(;+A:[TZ\:VK93^CW.MR:OYQ%?\
M5KH=F<>HOPV?:K'MLLL!<-SF?S9M8UWIV;7!C_>S^=JHM_G**5A_6;#QJOK-
MTWJ-73W]0Z@X?H]MWIAHH0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;R''=_(O7+D!$.>! 6OOY#7P?I .+P\#L?ZAP?\ Z7+G_P#Y?[FM)_I N+P
MI2[(.H9W&3/V<[8KF3E;O J?>461@[/B* @ @(\A]^G-[9\Y16Y'#-&S3"U.
MZT6-O,>[?-ZEDFJO:9>H?ZG)/XM5&>KL@4KN-5668J.6R:P *K)9NN4.U8NN
M_M&C1HT:-&C1HT:-&M"@"8A@#D!$!XX]^?N]P]_;W#6RR952+)G3%("B0I0*
M=0WJ',!R@!$T^2E$Z@?J9 $3 8YNTQ1 ?%G'$;F22 %G*!03[2(B4Z!R"40
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M?UR@H+ER(" =H]P  E$ , @'IE^_W /?GSJDK&"<2\'%0OJ)F."YSF^%,P*
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M%?V/:?P.J:$$P;CW)(I)F])%(QDR&**GH$ I#K"=145U0XX]983JG)P18ZW
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M<%73)=4"*\]PFX-IL;),2I\\_  F!(H!P $$0'P' ?<''' !Y#M 0Y&\ .
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MQ^A?B80\^1$"A$<\??[^?NY\VJ?2_P"I =7TAZV>YTIA#X?XU^*O/ A[=T.
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M[I)DNX5*L[,0@&5,DD50Q! 1.J''&L1;1U8.G),5V=C8/?[MNKTN^AI1E$6
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M/K9B [DYH0$. Z0>^0HCSX P,6 B41^0@'GCWX\^VG?=,_\ H?.SG]CCBO\
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M='S>^_BI*.=%<LG49*L&+^/59K$!%1=B9D5HHT,=L" IKF.DNHH':#W>F?\
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M(AU9*'P'(_BF4?\ ?OD#Y:C/<"''N'W\>_Y ]_G\N?VN>-3X_H[?^E\-[?\
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MO0?I:F2PE98UV/C8B%9HQT5$-&,?&1S=)NFR8,(YNDS9M&R"92%21:LTB-T
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'-&C1HU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g549728g16p02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g16p02.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1TD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '0B^=#(X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R,S<W
M.34R' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !"&GOX\P 2!;[Q_9P7A
MAEFI.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!$0      !     "   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              .H   &>
M!@!G #$ -@!P #  ,@    $                          0
M   !G@   .H                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   .H     4F=H=&QO;F<   &>    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   #J     %)G
M:'1L;VYG   !G@    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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ML!K>)-C6]N[A]%: 1M5/_]'T[,RJ\3'=D6!SF,C<&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%!1VAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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MZ 3@!SE<MU"*$()2F(4W!N!]2+-Z(C1$:(C1$:(C1$:(C1$:(C1$:(N.0 0
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MAJ) BYS>'+MJ:SF4ZYH;CCK*)##R'H4IN +V PB/0!@+P!@3]P#<@ \\ZS)
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MZ1X^?KSHB1ZVY<Q%1)-.'O.4<=TZ470([1B[;=*U67SAN"H^6X38S$BQ772
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MO(>=PT[6(7@MH29,[!S*^1;(KLBA-G (I@Q0F*$EIB3]R[$,[UH[@68@8A1
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M"=#\QAZNY@!/J,;I @)J 8>G7_F</'9VA$<($(%QO?)Y7ROFL[+@N)BM+/\
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MAJ<J8H]!A$?=5*F/483&Y 3 (=@&![_#;CNT@BR>5$^/ !V0&, % DGL'('
M%$"%3S%CL@)< !1.F0INP@8AS"80$>.>:B:\\\L5EA @%/YYB&,7CK4X6/U'
M,?CJ YN@16-W!0>X GSV(I'O!#(B-MWU% HF <Q4X3"(]/<M$BQ$!.(CP0.Y
M@'GN/'8-$4IFY#>CAK:HBW>Y?/D=A".(Q:2<S]3P_E'(%<@V23H6(K6*;I%3
MGF,&LJ\ R#1M)J-EGBJB)6R:OFDY(^_;%+!AW+M;S+3V&0*HUN3*#EEG"#1G
M>*1:\>6 /93E(9PO6;M$P4ZS07$W6U5=L4"N2& Z0&#1$K8.4QX$ ,(" CR
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MJ[GVY9!\S2!R":1D55"@OK2+&$&(@!S^N,S.@=VZ5:B\[A.(XB.WCAM!^,R
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M;)1P#>.FF,"]=HQQW<8LB@H@L1::IX-.W&8M)K9>[QF')3RU66%MV6HNVO\
M'J\!F.9K4L^F*V2W1K"@-@BXJ"6?JI$CZ:O6#/V#=DPE5GB15E%R+1?#MPQC
M/!7B"^(QC[$--KF/J-%HX1<1M3J\<G&PC)62K[QT[619H 5(%%#E$XG("92G
M$"%2 A0'1%.:F<I"=(B( F ]S"')BE'@3B(\!SZB(>OKQR' B18"U#S6;$H'
M'2,'*\=R\\#'J\#V$0X_/SW#MHK#4:CS7QDLMCU96RSQ^RR;D$ '[KA-"/YN
M![:Y(SRVA-SGV\P%V0!H80:C6LP<,PO3)_8D(<[Y-P_V;:FH?_F%#%_[Y?S
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M^035=4Z79ATF$"'KE.8"5(1,)/,4F<R-GZ \#]=6'!8G<3)%[@&P1VY_V="
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M#"02%3,0RG&\V4980\N!]!3(W+&P^X8R8A(TJ,7FT\YD,,9I#/"RDJJ_LN\
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M>^?(>7F>4Y=!Y@J1,')JPG?.8\W3E]H_/]TBV*%YZS?JBV\>I0??4,:BRIQ
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MMEN019L: AI2'XM3&LP]QFMO-S0PEB*N[5EAME)\5VBD4!,(>]TAU\@4G(\
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MX/E51W9#IN)#1%9%-H0A2,4"_BZTHV3-T,(,B:ZOLNS8B*QQY$P(N%WPB0O
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M#_2Y^\B?'Y^"%'] @/VZB+D$^! >H>QN?CR(?(P\^\(#Z"(<@';1%4$ $.!
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MT8P\NE(-SLK3((+I>V32I#N&SN#0.5>2<BG'-F1DS'27;>A8\&1]0'&<LVE
MS @NQ=B95H9FEZ^&X:RXKB(FM(C#9"*(P@B3&E2&9Q=6N"?CM!VMVNP3$ON
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MD 1]XP%[CE]F.U_4$\LRPDQ<3=I2\%B3*K7/A)\7=J+;D+U5GM:<VF,E&T[
MLX]Q)JOH=5*6 S=L@#A<B";)58ZC@B0]0MORX" @)2CVU@.'((!A(+BH9R1V
M8W , ;Z-88H9&(@L"SXWRSI3!W6HN\V42/4*V>2:[=R:(B)PK7V-9-8K.;5*
ME&ATG*4Q'2RQBI':F 54.H16*'8=;OM1$?B ]'H)/D[!IFF&!R/*3^)?%IMA
MOQ6YA>ZVFG%&4> 3Z9.*;0.D#G*=-F=^*3@"=1$U/94S*\'$.1^J(CVUB8(H
M0\09O'3+519>OST398EK-12P.XY[YAFKD .0%2$4,D<P%$ '@%2*%*(@')0
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M(I3IM2=9UC)XAJ[E02D*LY%58Q.1!,[@3)'*0@B53DI2M=[ZJ,+9=8!8[4,
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MT-SE<&^ M;6U/U>&QF(+6.(L]QB/1FI1Q-@&7U7#VG#V?TCB!+G@!@A>3D
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MF3 ?E"@(D'GT$/CP B #SK5'4_\ K_\ I52<[L&S<OB:;@5Y%^JFR9;?\#'
MY&,I(2#ARO(SY'(J0< NVE !NP1="F_=(FARF,W@XY!K:K'#RZ&M2Z=^DO/U
M[)HV[1%]([4=P3V44;P#QUB*UBP36L%?21(W<,(]V^72=MA91<8^/(.7B*;&
M3 \])D9-9)@#BMRE23;M[WY).6\1W.;B6A3_ /?JN^9>$[LI?1#8TI(LY[:
M:/;&=0##VI<C:$(;SWMKC7<&Q3X,/XR6B%44A+PX9)F*9$D%,*X;W.:N]U48
MF0+GF_\ !NKK+8ZKC-=9JV$Z3C*NTP4SD!C7@,HDH&*F#<$#@5-5<RY7*2AE
MDRE=('!<%[/278^JC;KYX7*2WP<EYI[M$WSN9M@A'2:N9\C LP:SU?F$C"7%
M%5*F*4C4F\?7TO-Z2]3F+2;(J*J&<JBL].4QPZ[EV]*M,@0;F)E7)S_*3O,E
M'QL>0BPV>;<SKY&&,=ACZ=Z:^X/'G2:'&@MB!%>S3%8<-%X"QIF,_2A L@PS
MJXMC62.M47;BKXL5A'S?(89X)OYWA+-;\+I-">+EL<!"[*64XXOS815!5=BJ
MNB 5.N\R;U9.L5][(R,KZ2$R]:Q(R"B'6YJU><E5;FNWN5WO%>MMISTG]X3%
M P%*(D O2!0^H40'I,0O/NB0O1W'I,;G@I%=Z(C1%35,!"B(\#VX$O?J,'IP
M' \]N1^ _FT1-6W:93M&'L/6"]TA../.1QVB+;Z2I-PR&V04<BJ"0*5"B.V%
MGDS.G!$&(+LWB*4>+D'BHG!/R%"*("O^)=O97G+,VN&V!?&M9A6I7$K=9; &
MXFPHTI,!M@P!Y.K1KZ/7OSC(!X2';1A**]*XJ;FQ1Y;"VE46BJ8T@&!Q,EQ4
M,X'GW[R6)+4UO'5Q(9OW"47%>3K-D?Q@*8I=<4W3%%@KGAO]$BG:D(9&"LLK
M9[W1K3-KX[?1\W*S3^ JDE*+U*<=6J/J<PWGXYXS+&*HH(NE]5G$6Y6 $W+$
M$EWD[B_!KRZIC) /X@ #%BP+.]U,ZAR4J66Y&L(;_",)W'T]D1TIB^*<,(2"
MJZTR[>J^T/VYDRR4G]$UE(1\PSH2/["FV!LDHL?K7%-$?G.)X"UB^H1VL$,H
MHX6)_P#4>=;@PO(9>]#]?_QN!L^%@!BC$)<"$E@22&/-<#@2'.:D20D'D54#
M.JS0X6MR*:)SHUVXSD/36R1BE,*OTA+U5E?8]J+<"% 3)-7QE.#E B0'-U>S
M#8VL5B!$ !#"U"#XD@]6\5X)XN/B(R\,4))_&1&5)@&9K.YA#-0/YJW'5VH;
MXE)#*T3=[+$KUN/;H8KV^.F62D+U8DUE1CDV8R$]"3<^Q5>+N0=1Q:;58]U(
MH+ME6L\H5ZW=?/VGTL'ZC!Q1YC:6430PPD<A8M.3S <M$*M(+T[,VL-A%9@D
MV=J!$3$6(DX,-!>\Q>]&2C5O;C;<]^(;&9,W!8%EZO1VU"A)RM0["NRCZEDD
M(Q!=6%A<AS#FN(U26F8]LNV6D&-<EG4>UE")-E')D&8)#[<5G:6EK#:Q?B8)
M"$2#72F;Y%PTYE9P_P"'9\/R3-HP=S""X,V/+6_22GR85^*;G([;1\>W5*E[
M/YQ6:!%B(<<>0"J90,9$!X$$Q,9/J IA >DHAWQQ11@.07% Y-,W&1E=V\QP
M!RPB4[_YA-W-9K9 2*7IY4,(AV#J\OO^;H /T=_OUF &:HS^&6#?D8G+FN"K
MZJJ-$1HB-$1HB-$1HB-$5BL8QC<!P' B3GD0[<B'KP/<>>!$!+Z^H>@P@'T(
MJ%<=._B/71-QSI?K#1(F,>US#-ES(X?3T-$.X:O/X-LO',WKHI5II<TR^,0[
M2, !741(F01 INI9 !!0/.XOZ?!Q,4,44,48!>H(!D/^)(.O22Y(_J-IPD0Y
M;,Q\TOQ=P31P"9&@+"K%UN%KF'4?1)>00J[B2<IQ2*Q*PK&N958ZBARI&(+*
MMISKHYNDY@12CFDB\570\E@D]66!(G;9\/9V=D+, !H6#,'#8#![ZNS7+=_E
M1VGY\EH8I$B9'6IQ#DLPZI'K5>7K28291V*W4A&FB8]PK//X*2$K,R\B@'E&
MC&S)=99HT.X,5--N]%W[2S7(X*BDFFX4\^W^FFUB'+"(@"23$ \+F@E(&<FN
MN*QB^HVT##[?*"TR(YFCAHC1YD]1);^SM$BLW358T.0 I%5$EGTDBW@S.SDB
MEGQ'S2,=*/Y\B2BY"1JS6P)0TLW$X_WHL D$VRR^GFS80P\N+8M6CW2G24S5
M#QL<; P!GF2X+RD [@>6:WW'$X^L%.AY61ASUM^[2.L[B%DWB2C58QQ Q13?
M-F#PI1 H&*+A@U%3J%1-,Z)TU3]D(BLP(3$^',]TB P?5[Z8#H?F8L3(4.N7
M9YXNE1UM6*LG)0]P ,<!#GI'ZP (\EY$..X" CSR/'IVYX'1%!KO6S3EVK[M
M(NB8HLFX:(DBXN?SSES$X]D+/@=LS&N6]HVKD>A#5Z3<3>2YB7&.FB.9)ZBC
M7XZ'$6A'#I86#^7W-XO_ !3WO^/!^JC1QSGCQ0Y:6PS7Z:MEN4L$K.MH_'LQ
M<JO9$<2Y1,TN%H9Y"MF6BVBL,;72ZRZIZ,<$#!22D<G"NFJ;FNIJ**-/+K[\
M6]54D*ZV?!\05^.Y1'')<K%WO[1PFS8G7G75(]D#&]\"*!BYL224D+L6O_2$
MER@)C%ZP-P/)B>';Y7M8 .I,@CZG4 AA] $.L Y+S\!Z $!^_P"'8"AH="H)
M?"S'G)OC/B/J/B$Y;']-"J6BME_MZ^J^:CEK_&QEC]\_(G]+YG7':_N>OF5W
M0?J.OF5Z9?[$@_7R;B/X-;7^L2!UWP?Z46@\X%SVW[;P"GMWR?Y5:I?P&)#^
MN*#U@M!K#KZ%(SN-_6[YY_>>R1_165U#6'7T*JV3+'^;^;)/];[!/ZXL<:J)
MJKS\LK^ZJ_[=?1%)7X(G^%^^7]]ZE_T#B]$7FLQ.4%*:(FYY/;LA"/'8.1O-
MI3[?]EN3\XF'X@ =%G^I%P]8"2A#$]NQ*<MM%$?[I+L5-[W)\C7$1Z1,4>34
MJ9'L)># '/R'GCD-:[241&1$\B3Z*/(G!_ E2@;M$$C^)CN!>R*7M3-E@; *
MY(_K;G4.^<.[*U5<)M'9GB*@%BDG<.X*WB7JZX2Q3/%/H])Q%2FM#GO=>FB:
M%NW&2DMK&X22+*&06=X?MZ2:*,BJS4CD5VHNU@.U4L%>]E(]DG\B+CV=A")*
M&.*CI)?VMVW.HDJTK<Q/K<_0)_\ OJ=K,/"@V0O(TQ2*(3FSH[(W+@@$!-C
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M6(HY[7*!"1;^?;VATD#DYYAHY*\:N"*K&.F1!P510%"H%'R3"!S!U$'@0#@
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MZ4S&$H&#RS56>_&5W=.[\+'=1MCINVC>Q#V?/>"J.]L.7;[(5>)L>5:' O;
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M>FB+N,FT$0*#QL4W8WY9  Z1#D._FJ=Q_3\^-$74LLS,8O\ ?;4H&$WUG2
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MBQC&#:.C&3>.8,4$6K1DT1!NV:MD$RI((()% ")HHI$*FDDF $23*4A  H
M$HLIHB-$1HBMUR%4 Q3#^Q] Y((\]N.OGCX>G'/RT1-[SS@R SM5XJNS\S;*
MJM79\EJK-AI,HRC;%"V%*#GJN"K1^^CI9MY4E VB;AG158Y90&LDN*#QLN5
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MM5FL*L!NGW7-):BGA2JIQ<:\";R2VCK;]*N$#,7,O5GCR(9 F9\NH5,WE!5
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MA1O)/&LJR.D@K[*Z6<L'S"31;/FY%M&WS;U4,-UFLOEJ)C!AF-+'=8IE_O\
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M@W0,@5XDV5<-4#J%(=,%C:;WONKO?F/1;]&4"O1MIF[>TBVJ-@L@L5)=V J
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M29+I#Y)/-OJ['2UO]KCT8R$>2CQ-&4A)1Y*LZ] QS!\SG#I3ZZ:!6I.FGK[
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M(\\?8(?R@&B+MHB-$0/8!'Y:(J15BB'O#P/(]N!'M\/0!T1<^:G_ *7\1O\
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M9HBQSST3_=C_ ,U31%?-O^CH?N@?RCHBM)/T4^Y#^1QHBL4/RA_W=#^9HBV
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D 'W^[1%CTOJ%_<T/]HMHBRI?0/N#^31%C5ORAOO'^<.B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g549728g18p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g18p03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1TJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '0Z^=#@X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R,S<W
M.34R' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !"&GOX\P 2!;[Q_9P7A
MAEFI.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!$0      !     "   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              3@   'X
M!@!G #$ . !P #  ,P    $                          0
M   !^    3@                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   3@     4F=H=&QO;F<   'X    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $X     %)G
M:'1L;VYG   !^     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M"0L4#20:Z6Q;F.=:UAK+ \'1Q]_!?)KV_P#?DUE^77>_;47U-'L ').S\_\
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M_MU__DTOL5?[]O\ VZ__ ,FHU[825?[%7^_;_P!NO_\ )@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MLS=%1U-C9'.#HK(H*38Y2%=WA8:CI*6FQ,7_Q  < 0$  @,! 0$
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M>/GR<:N_.97"+!CX^#@XF("W#9BN(WYN0 #8ZF8I6RQX@Q&%I9@XV*QQJ[#
MAL4@SJ9^7@H5)4MH^VM*_#)(/#P^XXQSP<Y(.3UQJ W'C<&-@N.(3N%A<7?%
M8DNK)TB8T60/:3B#<<T@3#P 1$3NP.O.;TO ,M)0MR0\,(05$/*Q@EPDJ"E<
M('+F2,G&#TY0[$=D\ OQ'!P:=UQ?#C-#())T-IO)LC&,=#G%^\1\(:X[L&Q(
MXW!IY)L-0B3$!J/4VW"IQ2<-3T=[QA6"G];>"P4CF4\/B/'.*9;:&2KB,S6#
MB[Y(#'8@)WA< $F(I$?%6\+([*EPW,5F.QM7#$82V> ! DQ%:D!.<=U4-!)4
M\ZE'+VW'',YYG)623S&,=!X'KG,_&Q6C%QL5C&83:M:RCW C74S((-. LL);
MAX<,PQBNB9<\DS,W,D4B)]"H4/O!M2UN#V"M9;#CG>@%1("DE6,8QA.>GCDG
M3WC6X6&]P>TN:XD&:2ZE9X 4J!,"@4R3.\"0(W?=P"08B8BO4UU2=%0[\%[O
M5LD*(PZM2$A(Z\24J ).,YP3^75,KF/?LQPTA^$V12#B- T)_$#>#((%+0JN
M.7WF/Q/?8;C$ DAAK I:+&@F3$W"G,2WG0>)P\!4.Y<0M12M)'7.22,XYGKC
M'F-1AN&&UH8Y[P^N]B.<YS0;2YQ)IQGYE6:[??BR & $X9 'Q4H8 UK40!%%
M E<A*%J>=6<+5D)=4"I'%^M\/M@CA'Q\8.2?(:NQAPAC-WW/+GN<S>).Z'$F
M!- (B!8*-[$?@@>[%# <T /CFYM3U)N9HIHXUJ;4)3B5(3[1+J^Z7GIP^U@G
M& ?/GCWQA/;B83L!P>'L^(N!(=>8WP9@S0<!Y2[#+'X6*2=V/B:3X01QF\\9
M/-2%=R@I[YTCJI;CBE9'7V,*Y $CH<\]9'XSY#P<+W+8!-)@"+W)O-($=% 8
MP$@%Y<235QBIH.[P/!,MY:%.X+Q#@]DE:^7,CD,DIR3S( ^7EC1N%@X8]Z<7
M$(U#GO( I4#>C36@NH&)B3O-P=X7J):=* @R.[!-+5<@&IFCJJ+:JB8ZI@@I
ME*,H1&W1'4YW16%%D/JP'P,D#!SK59G=G8F:?EL#.M?FG-+SA>\LP5^%NA-C
M %3RE9AA9EN$[,8V7<,'?#1B,;#=Z> I'*@\#"<ITM,2.XMR:F,E2DI4Z]("
M$>V0$)0IU8X5*) !SG)!\-3B9O(Y08;\UF?<-+FQ[QY&\Z1?>TXUY7*H<'&Q
MFXC,NPO>[>= !W@T5($3 @Z<- DB)T>:OBBU(/+9*$.H8E\:$E:A@8;6H$D8
MZ\\JP!K6R6>V9F<QFAE=ILQWD.&X,4.#20=W=!<0TU%@"%?,9;'9@X&)B83\
M,C=:Z YN]!$DD$228XTKTGN55A#YC.SXZ'4D)4DRFPM"\>R"DO(7S'4!)^?G
MK*-IY08IP<;,83'L,B7 ;QTFM:B@H)BDJQP,<1[O >YKV0#$N$P212AYB2)/
M.%R)"U !3B.$Y XE.@J!Z*[Q*U) \<<\X..IUN8>(,;"=B$;P!EIPR0#&LBG
M&Q\!I0M+!#BUKM Z"9&D&LTXSRJI%0J3$5LK?G,1D)2E'?/OH:9Y'*OCN(SR
MR.+((&<$E.#I9O/9;!&$,3.86#)J"\!QW:S>8D=5;#P<;$/\/".(XU;0[L@$
MFE16#0<N-(&9@D-I>9DM+:X26ULOK+3O+XQ6IQ7L8.4J"P"?$8UD9F&YP#$R
M69PGX(H7@@R12A -];*3@9AA<<7"(>T4PPV*<2( F>4V\4-+K+%0?=1%FL2$
MM*<2Z(\M#RFBA605I[YU0Y*(()P2 ,#EJ,OM#!S.)C8)Q\%N+@DL<UL-=H=Z
M),1%R :F"%7&RF<P!AXN+EL5F#B#?:]P(:;P* "")^'E(XIZ,YI#C#*I' [(
M4I3:''$I<=X ?80@JZ'FHD<^7OQK+[[+9=PP\3,[^)B$[K=Z:U UH*1?AR*J
M!C8K2]F 6L:T[QC@>-*GK,=2ILIUSA"D]X.^/#PA9"D8!Z '',^1^<YP<YQ-
MX[HL0"'"A )Y5,UBQ 6,$X9:\-WR3\32 6P9T,\A:P%X"IV55(D%81-J2(^%
M8Q(F)C@<6.:E+?9*R!C "_/((UYV:VEL_*#]RQ<PYN,27EQ>0\-J:$NFQM84
M,'3)AY3./_S?NG'"W@(8#NB2 );!%3:+\+PJCU5F8DRH<P2FA["BP^'6BA!
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M#P"VJ1+6$@D>UW3P221S5P$'DGGXCKK9V]C8#,EGP_$]XX9/&Q6L:Z*2UK2
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M6T8Q;;<7ZPMY*6X18=3(2DG P9K]HN39B[-Q<ELK/Y[,Y_,8+1E<+%9.$Y^
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MJ6M5+2J=/VQ<8DTVJEA];B5UEMQMR/-BJ4S,:6D'"TI;3DDA/EPVP-L9G/\
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M#:/=[(Q,P^&M;AXF*QKB):!!),&LUUXW/J=E4O9;<7:BI6BB7!B7A77+.N"
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M7LADLP_*9?*N&:S>9#W-Q<PPM!W ]IWZ \;CR]S8>%E\EDLSM-X:_%9#<-I
M(DD P(@$6TI:*E591MAMOK:KE$N.WX,ZVZI1W3(DKI=2G);K37 J/ZK5FGWW
MF)L8*E!8<=0'TJ /'DJ+789;V-RF4VOD\;]XQ\(Y9CW-W,3$8[,""2,:"/>P
M#!W]ZPH0:>1F=LYG./.&'X>*#0!K6TBI@@7N2.-!,2F2M[_-0ZE<+=MV)<-X
M4:UGG(EP5NES(3<&'/BMM.3(L)B2X':@]!;4%OIC 87WC75//PMI?M'R6QLQ
MM/"V5LO.[59ELQ@-S+\#%8T83G,^(@8CK $2!<UB+;N#[+,S;,#$SF?P,KC8
MWQ,P\5N)\4F6B (;)$21"H&LW!3;K[0^SE>@Y73ZSM9=\R.]GD67I]*4V2I)
MX>+B*D*;5E22A?#@Y.N1VAMC+[3VQD\WC;.=@_OV0Q7-.,P.W2Y^[O$$&TF1
M6@-2O2RF6S.5V1M-K'8;A@;1PL-T@&F[03%IK%!QY,O8 446-?G#A2/LIUL
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MYPBI/I:>=0VGO$\>=>][";&=L?96+EG^\;O8SRUC\=V8>QKG.(8<9T[PJ)%
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MUA9A'?)QJC3[TGA$TXQJK,Q,5M6F)@G2;&D4'I?A00 % [LL!*,G"T)?).?
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MZOPF+]3TIS5P&M#B6AP(_#6\CR(TI!TLFH=ZIY2%1W5MH;P%+0#CP '7FH>
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MC5J"W#<9I?@12NAZK2;M# EP+V BA&\V1ZF#\N*F(](KV$4*!_5:=G[(Z?\
M.A:8/M# YFJ'KD8Y<\^_4'9>?_\ (Q__ /%P]15/\0RW_FLU_K;I?R[N%&KT
MCO80*<GM;]G](XB,C=.TLY&<CE4P1C'/_?J/\+V@/_A\?E_#?KU$*PSV7)_F
M,XT<TTXT*DJ](]V#$_&[7O9_1T)*MU+22 #XDJJOT>>-!LW/F^7QR!>,,CS(
MK"M^^Y:8&*PG@7-'E,U]55MC=N3L>[E7;0[$V^[3&S5ZWI<DAZ+0+5MG<.VJ
MU7:S(8A2I[[%/I<&HO2Y;K,*))EK2PVLI8CNN$!"%*&+$RN8P:XF#BL%OB:Z
M]]=('#Q65F-A/-',D\""2*?<+*>.^'B<$\24D+2H *2204\21TRDY&>NL*R
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M2L@@V!B16+5,FP6%[MH8;ZA]!6@ISOPK2:TZ9W>B(<6?23=DD%9*$WU=G"L
M^TI.T^X:RI2%,K2EQ(26P IM2D*6LJ24\*N.]J<MA-RI?AX>Z?>-^*!7^'B4
M)F:F.AY+I-CX^(7MWW[P+=V)D[Q>R"10@4@@0*G65T2H2>$GV> % PG(/"0H
MCD0.)7$.%1*B2,\(.-?+WU<(G\4VI$]_71=FS\(^Y/SY)PU:1::\$ ,N/&(\
M C162 RUA124MCV@ 05JY*^(24I*05?L<G"B.6=$2-VIH2@IRT2!E67$)4DD
M\(*D<04$J5[() 220D$DC1$(G-.)/ 6U*P<Y2.#"72T^L.)<4V2RX"EQOB+B
M"4!2 74!1$I9E*4H!WA.,+6I (0A/[!2ED!*DJ'M)*204Y5GA!T1+^-!/"#D
M\N0!.,\P3@' (Y@G (\=$4>B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(
MT1&B(T1&B)*I00"59&$\70YQTR!X_)UT6".G6X])202T!1'&DI22D\1"%!0P
M<%*\*!YC (\<#57,=< U,D"W6T:7\8*R>\9_J"F]\T$DDM>S^V6E!& 2>1(Y
M>/,>//.IAY!&Z1(,:B8CP-:?DA+*$N;(J:B0!Q4/?H/((3G .,@G!Z*X0GB*
M?XP&.O/D=8_=O'])"D/8:2#RXCQTYV7H=3G![H^) .3@#//'3ESYXY<QINXG
M^[SZF>E"I!P]($:R*4Z#Y^(4HS6DYX%H.1R*5I(Y<U$D'("0#GE@'&<$ZDX>
M)$D$CG!$CD3:.(\%'O,.@WA>\Z=!]SPE*VG6G.Z</):T\0)'#D84.(I.%)!P
MH!2DI!/($DC-Q8:?3DK3;G9*@I)Q@@YZ<QJ47NB(T1&B(T1&B(T1&B(T1&B(
MT1&B(T1&B(T1&B(T1&B(T10+!/#@9]M)^;/71%"[TQXX/X^0_'J")! X'Y*A
M_&WI]UJ+]-XM*_1W;R\"@K-0M8 I.1DUB/U(Y#H<YQC'/&O6]G0?\2PCH74_
M^@K4VB(RN(30;CCX6E? F",)',A0*"$@E6%G!X0/C'A"B!R"B,$@'.OM.*TO
MRF$UI@D7!@ZZR+V\5\WRY;OXN];WSI'*3IW:BSGW"WPVTOO9>Q-MKEOW<V[Y
M$>IVB]'JUQ6+:;DG9BBVO9LJBR+6M.K0+CB2K^3<=0:I[$2FRA;CE&MZ&'4L
MU&3&2I?BC*XN$[&<UOXR#(?+G$DR7 MAL!QK)GE0'V'8N"<%D.%HX 5 '60(
MT*O-2>V+LY!HNSGPK3+CN2+MC#V_I-*VZG6=;L6B[752U ^Y7[RM>\6IRE7)
M.N2I29%5?MRN4*E-KDRR9DB6[';D-:6:PLP]F(UK2-^),_BBAD7  %(-9Y&=
MG)XF%!J"03$4C6 1P,3?CR&'?:BW3LW=6Y[8JUO5"KW-5Z=1)[-W;@W#:\&R
MZON)69M:EU2/5Y=L4JK5R#!738DM-)7*16JE(J1BB:](CN.%C6WD<#,L8T.D
M"@:)WMT P "*FTP12HB 2M7,N9O.$@$DW,2;U!)M,Q-H5^O1%+2?25=D=/57
MU]7?E2NI_P":+<90PH$)*0$E.5)2I*L)XE$ZT_:5F(W(.W@8#VD\CNOGIY5G
MF0K;((&8 M2@I)^-L&9D@3K!$ZPNBK&.5#'3NP<^!!X2"/,=<XZ'D>>OE&OA
M3SKRX=E=V*-;S@>/=M."5J4E RH@#.,GI\Y\![S@>_GJH_&[I]E90]ZWXJ ^
M7(S[QD#(]XR.HSD'5T6,?:I9KDW8R_J;:=YTBP+DJ$-F%2+FJ]ZUK;N'%E3:
MRPCN57G08-0K=O.3PEV$U4Z3!DSVW%\,%@</$$_3OT44Z7/#63W;P6%3^]RZ
M;V5;SIEMS;EL&[J+N(+'N.5)WRW$WOJ]-I#5S4>GW3=-D[I;C2S>E7IS$"<U
M'9JCD2!\!/3'.YAQ)C;,A(3RGS'C,(8K>/6.-)_)6]:FTV5?=<V=K':!W1C;
M*6G6-^*]:5SN[WWE3:_5+DM#;'9BX:=:E6W9D5YV\KGH]D5&^=TZA%MVKUJ;
M"JL:V$LU^#5:3;;L)Z+UX:"3![Y20>9EQ&OS]/E]%LI[,]RW'=O9[V+NR[Y+
M\R[;FVHL"MU^I3&T1YM4JU1M.ER9U4F1!WZ8,VJEP3:@PT^CN9KRXJD1GBZT
MB>_LIX>'G%>FO@EE\[SR[#KK=(8VEW@OQ#D)B>*I85G1*_26 \5I]4>FNUF*
M^9K12HE. .%SD?(BI3]5#4/X-O:=_HQB_P")=$1^JAJ'\&WM._T8Q?\ $NB(
M_50U#^#;VG?Z,8O^)=$1^JAJ'\&WM._T8Q?\2Z(C]5#4/X-O:=_HQB_XET1'
MZJ&H?P;>T[_1C%_Q+HB/U4-0_@V]IW^C&+_B71$?JH:A_!M[3O\ 1C%_Q+HB
M/U4-0_@V]IW^C&+_ (ET1'ZJ&H?P;>T[_1C%_P 2Z(C]5#4/X-O:=_HQB_XE
MT1'ZJ&H?P;>T[_1C%_Q+HB/U4-0_@V]IW^C&+_B71$?JH:A_!M[3O]&,7_$N
MB(_50U#^#;VG?Z,8O^)=$1^JAJ'\&WM._P!&,7_$NB(_50U#^#;VG?Z,8O\
MB71$?JH:A_!M[3O]&,7_ !+HB]_5/U#^#=VH/Z-('^(3HHD<_(_9-L_M-SGH
M[X3V<>TNTLLO)2X=N8;24("%847/KC/!P]>+!X>H! U9H!<T?[@(BA!/=*+"
MZ0TF'?A)/6YYZ>E=%\(6Y_;D[9L?<_<J)3>U;VG*-3VMP;[:I]%3O?N?2Q1H
ML:[*Q'@47U&#=9CT]N!$[B$F%!;;9'JX*(C2,*U];V1[-9+-8'[QC-9[L_U;
MK#)T %2-1436:+@LYM+,L=NX;WAP@#XC3D9,6T&NERJ(/;N[;A*PWVO.U(X@
M,A0X-^]SW4H4E7 H%DWH7TJ!R4I?:2E:058+>3K9Q_9G9+'MW,-NZ7"2(M(D
MD"21!J(.DK&W:.T=PR[$@M,?%!MJ 9K6*B/!25]NSMO]V"GM?=IT)*$//._9
MYW4[ME+BPTR7UM74MYA"GU!@J+?<I?)9*N\!3J3[-;*:TO+&%@&]1@F!SB;3
MI=6P]HY_X1O/KN_]PTDQ6MYH#!M&A257;Q[;Z4%:^V!VH$)&5 *[0.ZC20@.
M. $(^N9$M38]B*%<."Y@JRC(.)NP]AN(C"! -?A!!D\ TDZVGGRV?W[:&X8<
M9(D$N$3KK$1RYF]'>U^W9VV';JMQB3VMNU!4&S7J0A^"YOINC-$IIRHQA*IL
MB!(NXP)S<B.'$)CO%P/-/MMI#:'"RO4VKL#(8&7?B86"UHW9! 9(!-Q%23TB
MM95,KM'-8V.S#<]Q,D$%SHH#0U@ZUF. NOOIIO:8J3$9A*NSQVE92VVFFWI#
M&WL.0U*<# 4N6RH7&AM3#_>)6EU/=/K6HJ=XL*S\JQA&,0*M!,$4$QYQ2EK\
MX7=X)G#:7 @D4!$F]9B0#4UUXIT':@J. ?U-W:<(QR_YLHI/T_7.HG55DG2O
MD?G$+W]5#4/X-O:=_HQB_P")=%*/U4-0_@V]IW^C&+_B71$?JH:A_!M[3O\
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M@MB/H@R'/2:=D!/LJ(O^[RD*Z)4-G]RO:R 2"!G!3[0)'09US_M2=W9S^)<
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MA@-)M$#A/&U(7SG#PW!^.71NET#SY_,=$G=<!. 2,^/R8)Q\O/\ WYU236)
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M/A/EPX+JOT7 IU/62 E<&*1DX^*PA!SX9)YC!/+KCIKXAB#^(3P<[U7T?#_
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M&8G^&!'$!L<^-8U\0OGK/YSZ$#>UI20/IQ\BI+SI  PG/T\O?G\GAG4M$@W
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M#0=%9UQP\:LD<RH>XC&#TY:WQ_*8/]))U,D<M!7ZK!B EK9I+P/6Z1K.<\\
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M0_Y//_1-$1]F+;7[:H?\GG_HFB(^S%MK]M4/^3S_ -$T1'V8MM?MJA_R>?\
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MFCS_  R8'X;:57*]WV<_YZ]Z#Q$XWAW4/$K!*3]?UQ("$JQD(2E.$H!X1D@
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M;E"$Q%21:]"+@J7KA95"!C%D//AWCO:39^!LS$#, .:#(.^0X@P";!M =(T
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MM'0+Z.?J7!\*J_;?Y\Q3NS8<\CR5.WWR/'/_ $BCR]WD-<3[<@>_P^L'C4-
MF+5G@O?]GW!S3$$@$>.\01\IK"^O-L)P2DYSUYYYZX4#>: >X/Y+I5,U=$E6
M 5.D]4J: ^17"#^72Z@T!/ %:=/3P CT:N]R@/:,NT1]-<84>7N(Y?UZWMB.
M'[_A?W $G0"HX="?):6U*95\11A\8=?Q7.Q?<X4D@X5D<7S\9)'7Q'+\6OLC
MG_@,FK 1/"!2./+7Y\'A 3B-K$[W0S%#K:(YQK5G=?)]HJ))R,>>.?0Y/T _
MBQJLFQB!7AYTY7DVFDK* 0:5','3E:;P)O>"FEUT\*CD9Y<OE/C_ )\NG+5
M^712#(\ .]%=I)_$/A/ ?<^I38\ZH@C.>7OZ@_Y\/'6!_P"(5IO4YUOPX>:R
ML/Q=0?O]%LO]"FH_^5:[$P_;;C7F3_0MN?X?/\WSZ\'VC'^1GAB-_P#PQ?NO
M3V?_ -0/[?\ ]V+IU-=?_J$_E.OFO]?_ !^JZMO\L=1_^*4(Z'Y?ZAI_7_Q^
MJHS\(\?F5'JRLK;[AWQ4[&M:LW)3[.NF^Y=,8#D.U[.@L3K@KDAY;;46-2VI
M#\:$E*I#P1+D5&="3%89=D%"@DA1%CU2^U]1I.T5W[G5ZTJ_;-6L6Z56'7[
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M KZX[P&0#ANX)"&QD9PA"6>%*/VJ1R P!TU\L-SU7:ML.@^2A^L-@];@N_\
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M/_&0+;[O*OFNRPS+&D\ G[4*Z@6%$>P<'/XN>JN)$1JX#P3OOY*2\G( .#@
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MY:QO?:!% .G+74R>1OJI%.)K74\IOI'A6BIJ9*/3*>I'7KS\<'Y/'GK%4ZF
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MMJQDCPP.A'+GG'+EX>.L!^+0] +:Z<YZ^@AY,M D7DB9-C30QX*CY<HJ<.%
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MG0137EXC46'RB3I7""D+^*.?+'7P'+PZ=.?4YUWDD\1)G[SH)'V7.,AS -8
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MG/J%$5G6WR[\2OB\^JKI 3?79(.0VE5J;DX42#[1J]NC(QDI'ADX&?F&NO\
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M#SI:@UYC0=%]3--HU7;C1&D7-+;"&6FVRFFT9( :9X&DJ"X?'Q/,$.A*UE2
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MELQ-SKCM.#N'?-S75<E,::M^?!N5FZ8=,C56WU4NK1WV7NZC4AF1"J<0-U"
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M5WM3V,[;V^M>V*//N&IURMT&=:U?FU@,16Q.K=L5:I5=*FF74A;,>5)JTKO
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M@D1F'Y3$;AE..(<98E2TH*VT*?*4-E12JX=0V4E*D@A12IS(/Q\Y2 0#G/0
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M])=BS7IDEII45UU*DA)X%E/=^]=.'DJ@KG9!V5J;SMO-UN[[>-=H]>I%=HM
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041?GW]AX=4HT4HT1&B+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g549728g19p04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g19p04.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1F^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &:*^96(X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R,S<W
M.34R' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !"&GOX\P 2!;[Q_9P7A
MAEFI.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!$0      !     "   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              1(   'X
M!@!G #$ .0!P #  -     $                          0
M   !^    1(                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   1(     4F=H=&QO;F<   'X    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $2     %)G
M:'1L;VYG   !^     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MI0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!!P'D P$1  (1 0,1 ?_$ !\  0
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MX9@ M#C)DT /722LV<R#<AF<3":?K:=TR(,D @5IKZ\SVJM2;A0Y\MI#U55
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M(ML"20;8]-^-D&N+<+& .*-_&(,DN F;F#SYCC7RVY;'<6'$;.)A@M((T-M
M2-*W/8J@AV$/M;3[*U%I2TV4E0&VQX0HW%QRMON!?%F9K+YG$P\(9EKPT N
M>"#Q;0D3R/0VA6_#N:"1@ECC02TB";5(T-1V6LK8@5PS*Y5H+M-J,5JC.0.K
MJ$IEM$2IB7!4\IR!("BN0U!-X<WK ."004WL3C69G\CB;0Q\"WX;#)+G4:
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M]VW?L-\4PV%N\TUF:P*SSTZ=I4F@)ORK/DHG#;^B/^D?[L7W!H2#[Z*@<?\
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M(+L?LE?2U  /1BU&] SWELG_ /IAM[,6/P=G 3_%PZ<R!;26FIX22K#;F&3
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M-1_VDP1/@:H'RLU:_+!J/^TF")\#5 ^5FK7Y8-1_VDP1/@:H'RLU:_+!J/\
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M/LB_-++OZJP@<!W!$^"S3G\'V1?FEEW]580. [@B?!9IS^#[(OS2R[^JL('
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M A6\_)45*/"BP M<FXV'/<@=I%NSGOC$TD-$DD[QX $ D:#D!7Q6PUH+N>I
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M7-1 ^TH Q*E>Y'Y,IIL*ALMR5*-PWUR&TJ!WOQE*B"K=7Q;"]O/@BE$U&OD
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M4ETI"B;D;$'=6P]HW[MNWNM?'^(: 2<-O$"!4C6W'7E2LJD@&YM6Y YZQ-.
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MM<)*U.(B]>$EWP9+RUNAHJX.L45</%O@BGVXK6RB$EP7NM)"B;@ ^4I/%N
M1>VPP1<"'';\E+(*5V%@$A*+$J"@   >(DWL-R>=S@BFTH2D6"0.78+[=YP1
M=@ -AL-_IWP1,$3!$P1,$3!$P1,$3!%T<^(KT8(L =*< ='#7RP MHYJ,18
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MN9!_%.YN%*#72]9I4K&<F0+]]P1SOS[#Y[WY[7QG!&Z8  DU CW>>,RCP=X
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M^/(VUB'\)B-K-*W.AB=)X7["M[(",8NO0D#HVXI'ODML*V;H)YFY(/FXS?\
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MO8[W%^6Y-NT\R13) /, [6W .W=OV8(N.%)M=*3;EL-K"PMMMMMZ-L$3@0
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M(SB,FT _^H'S%S/9=;6:.$%('#<@;D@6)ON0#??M)\^^^.>?U&+0.IO[L>M
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MJ.IFE.H60*3-9I\_-V5*K1H,R27TQ8<R4R?!WY"F.L>ZI+B$H<ZIEQT(6I?
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=6X %?'-C@I5Z)MPIMRL+>BVW=^88(N<$3!%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g549728g20p05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g20p05.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1I&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &BJ^9I@X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R,S<W
M.34R' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !"&GOX\P 2!;[Q_9P7A
MAEFI.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!$0      !     "   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              04   'U
M!@!G #( , !P #  -0    $                          0
M   !]0   04                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   04     4F=H=&QO;F<   'U    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $%     %)G
M:'1L;VYG   !]0    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MR0;>H[B-S(UU $:D^WZ)]_\ K^D3FOJ&A%C),;@1H(\--R-LR_\ 2L_[;/\
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M9G4OK!@=*N91U#/KHML;ZC6FIYEL[=WZ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( /L!X0,!$0 "$0$#$0'_Q  ?  $
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MIG@WQG;XE42J5&JT=RVY%-FK+U,DS$%YNDOM)=I%5=*@@LL38RO+!3B>0*P
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M* 4D*/8V'M.9BL#'CYL!ADQ0S)L;CY0(3%!"Y(W0&AA(!I6[,M>U\!*P&/\
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M6221 ]P\ )\^N>?FLS.FBD)+9E[\.^H*E*A^F%!"2!E(4D\IY21^&"5$\IV
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M!Y\I.""0!N!E/7(0 ,X$36H*#@_=M$WC%5[_ 'X\AY*K;3RMI04X"1R@ )2
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M6?\ P)HB? E5?EPXX?:*S_X$T1/@2JORX<</M%9_\":(GP)57Y<..'VBL_\
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M7AQV*BPD@SC^7@'(=LJ.U;$:NZUU6O;(?:B;"L<"N C@4HJW1Q"!!P ?_MD
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MJA WB&LY%\C3NJ4;CZ-WP_3X+^V&HS+'88HZF6TMA7&RP LM!#;BTB)<!W6
M"<$ X)WY1GH-6SPM##'CX?BC>@EO$SLV0UUU9<7:Y,.'B$/RN.&MZTN*YFKW
M#:23A4I;BU*YEJ<4I*D9/.E("0\^I[)*\*4D<F,Y!Z=?K4F7@8A65"7#&].!
M_6]:U94"?,GB-A&023D&;RX-:A(5(\\""D$@#\+(20,9.-AOG'B/SZPCEX01
M[HE0MTT.I!TZ'DO1*^.!OQ3"=T#1VL[,*#+1LBK2^^I(*4_A;[A)P1CPP0.[
MO'U#?'X>&N)4'DWUIY%;?CSA^69$*7+'I5V\CZ*SON+6%!1YPI)00>3!*LI
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M'M657E>W7QK4-E)[+5>![\ <4^&FP^XXU4O%!B,$!)()?W J#>NI]*+N[+A
M+L YHWD>2WW4@%([\9_.=4B'\HY+O,/)1ZR :@4IHBZYXJN7LBQKE3PXCTN5
M?+E(EMVNU6ICL"E"K.M.-QW9TIF-+=:8:R5K4B,[CE',$IRH$7Q,B69QVMVQ
M[/@\2++XML71;[%;58M?\ZNJ]X-%O9'%:)6JS=]V3;:I"8]L4UVSO=54"X:V
MZQ1W;?:-(;<1+D^YC\=>\^EONG=N\L]?)9%VCF[ZXHS*W?-@V7QQN"X;N:X>
M5VQ;EM.W+TA4=KL\(L50XO6TU5T1X5!MJOU:I(N]HV;5JG%O6NBN45ZV*%5I
MPA0W)KKW7MW\E&K^V6CYZ]:JE9L2]W+FI\V@V5QJC6VN[G7>RZB19O$NGFR*
M?'XKTY^K.7?2ZK#H=5L.E/6<E4V%!XETZUU2;>3(HC?E*G);IKT&CD:6U+4/
MTXJ>^[?IQ7W,IR U$0%.A7*G^44R2IOG2>5?*OE"E96%9Y1L?1VY<"46.5%Z
M^$RW33%6R(&0&7)SD\O8VV4B."G.^,J!.>_&-0=[)NKZ_;U3F3Y?LJ<R.)()
M 9LG'<5/U;TMNH',, ^&!WZ?-P/4CZ%3\O$= ?J%QYSQ)_F;(_+U?]?2N@\S
M]DIJ?(?=/.>)/\S9'Y>K_KZ5T'F?LE-3Y#[IYSQ)_F;(_+U?]?2N@\S]DIJ?
M(?=/.>)/\S9'Y>K_ *^E=!YG[)34^0^Z><\2?YFR/R]7_7TKH/,_9*:GR'W3
MSGB3_,V1^7J_Z^E=!YG[)34^0^Z><\2?YFR/R]7_ %]*Z#S/V2FI\A]T\YXD
M_P S9'Y>K_KZ5T'F?LE-3Y#[KCR_$C&S%D\H&!E^KYQM_M;'IT\?FU$+[H>^
M;D^KAPH(A)K7BV?F''/R6LA[.YVF.T[P&XG\"*5PQXQWAPO9N*Q;HJ-8@<-;
MLN"@0*I*8N!N-'F5!MB2TEZ5'846VGW 5M(.$D8U<O"VSI6/CF"9##& #2("
M*%B+A^!8D6-1FJYMG$QX<"*&.*&H?=)AL32A&FN=31?!EWV1SMV-A01VN>T"
M#R +2CB=="^4H&2I3AGC\/<$]2#TW.KE%X;V>Q>"1F1_+@<<*C@#37@J^-K3
MVK,C+O\ UQ6RS +AZ/49W5N<]DB[>.#CM==H$#!R?A/NCF \1BH=?S>.VL!X
M;P%/Y<@<Y4/J6SYO51_%9U6BCT<1&FKM$?>F:L\CV2GMZ-I 3VO^T(-\<WPH
MW1GY\^Z&00<#(._S:@^&\"36&4URTN%KL'#&E"<J<5NAVMB''S3.%206XZ]F
MM%:W_9,NWV"D#M@]H7 6@A(XH7.2HA:.5.%U'E5S' ](]^WI8QIF>',$(28(
M)+Y?)#U:CFCG6] ML6TYXEQ1DS S.223<#.+V#_7;3]@0XX]H?CUV/+[O;B5
MQ&J?%2XJ?VB;TMJ+<?$VX+AK]>CT*%PZX25"%2F:C)??6W3VIU5J<QJ*E7DD
MR)DEU*0MY9U0-MX>7AL1\*6 " & #0W(-,F:K ,6:CJS;)G&?($<>9/S5=[4
M<4!RUY+[@F3Q([F;)^E^K_K??KA0;['>;A4CW![YKJ,-3P8>[M5<><\2?YFR
M/R]7_7UG70>9^R4U/D/NH52.(Y&%MV4!G_5>JQ'0_A>D2!ZQOX:@NQL*7<GZ
M*"SPU-2QHU&.A+K4]]LF*K";H[,QK9I(DJH-Y<J:9YZ6#BH1^7#DK/0GTA@$
M=<G.KOX,_P!Z==X \KBMPU]+%F5:\1'Y>%6)H30BHRK^O#5G>>4$D*'I# (P
MDCFY4GT5I)RGI@=!OCQU]#B!$<34+FKUI2S<;OZ456DAI4(-JTZL?475GE/D
M(VY <XV&_4>O1XO[HO/]%L8:!AJ!Z5IU"QR6\4KW(QD$8Z>O.XWQK5-B)EQF
MM"SOI8\GI<4-U,,+1@@ $!OKU-&JU[W5CDR$<YR >4%6=@=BA()5TV)R!G(Y
MB1DYUYH'^&6+G(O4 L1Z5;W"T1Q;TT5HX!;.I-JW]ENH>U@GKH/9'[00H7N(
MI([2T@.>ZAFI6%#A5P_40%1AY,H"0V0H^ES Y) 3CYOXE;\:&=_A0EC0$;\3
MDF]'84IR"O6R@?@B@89F]@'MTZ%;,0?XC@G#5CJ\2'ZO].Y(/YQG5<+Y =2?
M9OJNN&S)Z >[_1<^<\2>YFR/[15S_P"\-/FS \R/H4^7(GR!^H3SGB3_ #-D
M?EZO^OI70>9^R4U/D/NGG/$G^9LC\O5_U]*Z#S/V2FI\A]T\YXD_S-D?EZO^
MOI70>9^R4U/D/NGG/$G^9LC\O5_U]*Z#S/V2FI\A]T\YXD_S-D?EZO\ KZ5T
M'F?LE-3Y#[IYSQ)_F;(_+U?]?2N@\S]DIJ?(?=/.>)/\S9'Y>K_KZ5T'F?LE
M-3Y#[IYSQ)_F;(_+U?\ 7TKH/,_9*:GR'W3SGB3_ #-D?0_5R?H]([_0=1%O
M,:"QS.G)2!"2 YJ1E^I0R>).,%BR1L029%6\-S@'/7U=Q'AJ"/DRMQYO;/.F
MKK$-OD/$U*-;W]+Z:?"CVP>Y=0[#5*57DV^S$^&FPE!REJJ#C_E3#N !(3(]
M!1.1D*&,9[\8L/AY_P ;+H7)#D9-GD#5ZNPUH%QMK_[H_P!M6<BG.FE<N%5I
M(+>4EU1PE!*" %*RLJ*W K*!D)RE(R%#&P[QD?7-H_[G#"AI ].->E*5I=GH
M?G^(_.>9?TRY'ZJPR'4E2RHDJ 5@ [#U]=L9SC'^_.(D2X&+!@S6;0'CYVY+
MUR6,#$"]=;VTN.Q>QRWT@E)Q^",C'4^/=_=X]-:#'%<$L0]Q2IN7('"A>UW6
MUA9AR;-8W)D#) ."0H= 0G"2H;G9)Y@-QN#CQUIFQQ&$5+;U*FMZ\O;-RL9C
M"%A6H!Y:?<YY<=E#VL0_5#VDNT6:,:8F8G@*R/)U)4KR8<'$VUTA3KD8>40U
MY,$922,\H\#JE>-/R8=ZFA!J*[D5M1E0&G!6C89H "6W#=\R"+:.-<Z"BW4Q
M(XBC\!NR2<#\)^L#F'>I&<<R">BB2<[8U08'W<B7U+?7Z:JR,'S%*T#OH;6^
MMESYSQ)_F;(_+U?]?65=!YG[)34^0^ZA7(XD%)!9LH[C9+]7W&0>XG!&/O\
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MZR>W)QL% %-5*1V6:YY5%73+;CAL\5.&Q\HA4106Z1L,GP*1D)R*GXJ_)+J
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M8&XWZ8Y3C)TCB&Y+%G XLPHUK'*M='7KE0-"2Y/%^+<>-";U6.S)8.>I./\
M5)!&/6#G'B/7W:T$EC2CT<F@JWD<R:VJU-I#.+'AD>^R%BTR60%@84">4CKD
M9!P1WC(R02<G'>-:8RQ8DLPH^;C+5J ]%&ZX/ !CF"X#N<V?CHMG3VK)(4]V
MI>T4"YS@<"4]1@Y'$.T>F-L#G4, 8&3CJ<TSQF1\.4 &+ N_^2+OGY"T[$A
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MHRM\!X_9<M[B$U2[5M:OIN5=^1[3<E"X&YRO,ETE/#^XPRB-YELYYX0X7?\
M1((/-9MF>&IFTL/\: P@;T4(&X](6O4$"^KEER,;M:7A(S!'"Y$((JP#N7=N
M'Z%>*3[9':9QGL/6?@CFY?AB21OU!*>"Z!GKGT=S_K$[ZZ,/@B?%#\L4&?\
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MM"Y,1F01CA3P+)SY9#B#C).Z">FX.X^:;=B,6.F5+.6&0^:,/S(\[JUX*)I
M!TK49 4&;<,CDZV4T6M;I)'N%1\8Z^Y5.^K_ (KZL[Y^[7$)J*7?0-T[R7K@
M-"./&O/+[=5'[U;;_P"8J/\ ]DTW]TU*S4IVV+=0$\M"HYYC@I]RJ: 1UQD1
MT$8(!V)/JUC$'AB' HM/3VT2S#I5W]E9$2)'B@VS>R6VX[*60A1J+&5-A Y
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M<S, 0ZL^[#D>%.5,RK1A'$,)-]T,=6)IPK6GU6U*FUK=.>:B48D'&U)IX P
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MKPV4"2KX=:&< YY0F@5KF41OA*<@J)V&0<C7=\.D?CS44#9<">H]LFJ.1M@
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MEE6[T7)VK@#B8X&#[I#%JU8O2Q%"VCL]0OBA)]J^]NQ[FY.*/9S3NK?WS7N
M",C?%@$[?-GPWWU9#XJP64F8VCN_ T/G8]0O#_"IE ?4"Q89&W*M>2L<CVK3
MV]7L<G%;LW>D, JN>_-CX_\ )^3C8^'0]^VM47BG!,6P\SJ?<EBPT/"NC^$S
M :>8#>CCU&2L;_M5/M^/'T>+?9FWWWN:^_$CY/\ Q/3&,=<[Z\T?B7"1@CX$
M(LSU]@?TR6Z#99!>($5LPZ7.5JG(%J,K+(]JA>R K/E$\7NS*A0/E-KHOP+]
M A:E(4GA]E*T@<S:DJ2I*PDI<;/II\<6W9$1^67NDO\ ,"Q!(+D'*F8M<,0Z
M]4&"$!WMTDC)F#U%14>N6:VB?83NP/QO]C0[*=X\!^,CUHWS<UQ<=KIXJ0ZQ
MPSK#TRWV*)7K!X9VK#I[R[K8MBH)J;$VS*D[(;337H;<:3$$:6X7'68M>Q<W
MX\R*, ?,11CET<>8#&C+HRP1" S4K45SRS]\E]B$UNID_P#JC5#OC:7;@WQG
M&?=P]VYVZ;ZTBP[^WL%FHC6JF.MH58=W_';;_P"^M$4AVMU-U(2W:E62<@Y3
M.MKI@*!WK"LCHH$#FP,HRK&B+X!^S/>Q:]HCV2*X."]7X15CA_9<;AK2:_3Z
MRCB-7JA$?GNU:8S(CNTT6S1;E*VDH04N&:\RZ",! &,]G8>TAL^9%,CA)B)Z
MBS&WW:BYFT,)^)8:<JY<O?,N,_A8[[5K[>*\A'%;LX)2>9*$KNF^\[*4D8_\
MW_@,Y_P+%#XKDB*,SI1+D;MZ7L3YM1PX?7SC9A,$(<4?,4 8:9U%J4ZVB1[5
M;[>Z\XXL=FH8'?=%]'8^&.'_ $&3UZ=W4ZUQ^*,'$SR0*%MYJUU84Y5KDS(-
MEDT)#6LU*D7;E2VCU5F?]JE]OQ1_Y7.S/@YQ_G1?X\1@\O#XX.>F?FZ=//\
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MK8ALT\Q:9(948DR2[YRMD)CJ:\HZUP,;BCBIIB!)A)<"H 9VH;4/HO7+E;L
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M'5(E3C*9J"%++*U)#S"$D)&0L"]<QH:O6W?!0O;K/\LPP\R$%J0TATKWR4+
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MH5&N IEH7'"V:BXF(F0IM9@+DMS E19"=$7@;C'8':2X6W)Q>HW#_BWQ&J%
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MOX==K+C_ $BKW]5;WL"YD,\3*OP_OCA):-R6E><YRT*-?Z:"Q+L*HU&V*$]
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JR"I(((PT5Q#;:1@(2!N>@.Y))))R22222>I.B*, #8# \!HB:(FB+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g549728g21p06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g21p06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1J"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!9            "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M 0D   '[    !@!G #( ,0!P #  -@    $
M 0             !^P   0D                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   0D     4F=H=&QO;F<   '[    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      /Z     $   "@    5
M >   )V    /S  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 5 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]525+)Z>Z^U]C<J^G>W86UNAH_EL;^8]$^RV[&-;DVLV-#21L)<1^>_U:K7;
MTE-E)5OLN1_W,N^ZG_WG2^RY'_<R[[J?_>=)2K:<HV^I78&M VAA!(\2XJ+*
M\I]5C'NVEQAC]) TUAG]I2^RY'_<R[[J?_>=+[)D?]S+ONI_]YTW@%G4Z[ZI
MXO)&*L\.#18T@#DZQ :!NEN]_P"?_K^C4C3G0"+1/<0(CV_R/<_Z:E]ER/\
MN9=]U/\ [SI?9<C_ +F7?=3_ .\Z'MCO+_&3Q> ^Q84Y@:?TC=Y=,]HV[1IM
M_>]VS_P50^RY9._UO=()$G;#>&^W9])W\Y_Y[1/LN1_W,N^ZG_WG2^RY'_<R
M[[J?_>=+@'<_:KB/A]B-N'D1[KG".-KCXR9E2&/D^DX.LFQP;.K@):27[?\
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MH_D_FHXPZC76
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF5\Z:V:LU_3MFBM97IXKU6G/+J%4@/27^*#EJ MLU>IMI0L*6IIMP!EL7XE
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M@H=1@.WF(Q'9>5M"9*^'M.";#(F8:,]\S8MXEP2#NL& );,9%:W']F1@\?\
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M),,,V.6'(F!R2SO"31MTT-Q2+9\<L1PS,+BCB!&(&AWX9<+LP,))[Q).=:
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M2I03QH6D$"Y3<6N =E'?8'8DWW VQD"*5'#01&&)@1<ZCEKD1FK;\,$4+V)
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M ?=L'L$IP=/Z[EN/IAF>)E&H5^/EV1GQVI9/D5&'/J=..=:C'J3-0@.N>QH
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MK-DX(K7VJ]./BYR)Z'Y?_D,$1[5>G'Q<Y$]#\O\ \A@B/:KTX^+G(GH?E_\
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M$1X*Z6OZ4Z)>CV;_ ,7P:+\W]H10-*Z6MC_K3HER[<NYO.W;MX7WP8YQ4SH
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M^@Z+<?UQ,:,/4MT;*E?+(.GL;6")+J2M3JSD.IQEQX2*.G)]-K%.6TZA4TU
MSS4Y<KK4N!<+V,&0C@+;_6<?$CAE2LMG<'S'!$GEG@LY9(";VOL22-]@>$W
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MM$??@B.L7_5?VB/OP1'6+_JO[1'WX(CK%_U7]HC[\$1UB_ZK^T1]^"(ZQ?\
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MA($(>E[YU6W8Y!^5?1.C*VH^5,YNS&LO3)<M4!$=<HOTJJ4X($DO!D)-1AQ
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M!+5=9M8]*W/Q3MR2=+]%["_:!PDCRJ/9;'S+;O\ QD6IKGQ>X&?KS78;-?\
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MDEONV2I5B1RM?D#W;=^Y[38<N6,<<QA5@?+0/;*VB@EJZ)NOR%!2U"XXD!M
M#IL%&5$2"1>ZSY'"L<[6L+>$S'P>)#AA3BV>K5K0U\U&%8SVRH6;/FV@?G6A
M9=4?H9M@]$;HLFY23T=-$;\-@/%TRRR!M8]@W[3<X^/S@^)G<8HO5Z?3(9,N
M^E?RX;9Y#(D?NOIG@/PU_./X<0LB.#]M?SC^'$16/(^B*522![Y1WL02"#]F
M*1?+#T]"BT)O7":^J]4)S F_$GVK--CPKL4@KI3U[<(2H<_A;6Q]%[(_R9F@
M!;@SA\JOJ>M%RFW0\4/CK0GH/2@<G3PH=40+WN.$)"18 "XY<R-^V_DN<=5+
M)$8/$Y6<'T6H_H;)GXZW9(\J0I)" FW/GW7/R]OGQDGDF.$NY&@X"C=<O.JB
M62)9 H-^K\3]A3G=(;KO&1=)/"3L#;_.]S\V,441#@UZ5/N]*JTZNZ>'6J19
MCV]NK00DA1ZP<2=KGE>W=L;[<QO<8Y#[TS3X,5,[BO6O@%:&'>DPAZ_$'!OF
M]Y-Y+>V]:\CK.@5JN>(@)Z6&?0D)"4I &ENBQV2$@<U'LV 'R_-=O'_.QB[Y
MWM>O-=7LN#^ YM1N&C-U\11;)):"K<2E*MV$C[L:( "@6T4ICMD@GB)%]^(@
MGSVM>W9W7.)13K6&TK6H^*D7-[   ;W)V\I)( 'FO@B9'Y>9:,8SAFC+28**
MB:2N:JNTDPO"G&EI%+$I$DL>$%.+0W[!6ZU+ZXAM+2@J^")0E9FI\&=%ILVJ
M4N+4:@'_  ; D3H3$RH*BH4[+,&(_):D2DQ6QQ/K92XAL)XR2E5@15Z)F.FY
MCC1ZG0ZI3*Q2)BGC"J-*FQJC"EM,NN,N%J7$=>86IMQ"D.(2X'&EM*2XCB0Z
ME!']_?2]DX\$1@B,$1@B,$1@B,$1@B,$1@B,$1BI$3T( ]\"B,0T>H]]$4A7
M8D6Y>7_EB6B_-Y!4,;%F?JI@;@'OQ#1_F'A^BL"X!U4G$.+AX][\N$_-?_GB
M6B_,W(!2JF#1?F_M"(Q9$8(I'/>*\V"@@&^1?JJ#J0$N>2P'F(!_?C$2^ZX'
MIF0WD@ %@M!3U>1PI]49S^"#_P"+73,V*B0/$S(>^W/N\O=CZCV4+85Q0G>K
M2SVLVGA0U7(;6,0G1$-0 .1J+\G\SX>,#\@CB !]Z>WR;;VOY+=O?CJ)>[%&
M7X^K5!-'K4TZ6\ WC##9@0[MU'F<OT0W9'$A0*3M<\^T7[CO_?VWQ,QF=@#8
M</O^N2L(LF>N7#0-2S^-LF[*ED7_ */L(%S8=_?<=_=]M\4,(S+ZTRL,F;AQ
M-*H8S84'B?J/75TAO2E%.]C<B_C7._.WG/\ W=WG:$11@"M=7Y\*79^A8C%%
M5Q0:\GL'YW>AYN-]_P!;5JZSU-^*2+A6NNL!)!^#4*84_P">V]^S'S#M%3'%
MC7=!MF7!^S9,NPV7_P -04+ U_*S#R?-;!R22 3_ )WQHH8B2 33]%LD&^UN
M\7\W;]GVXN3;B6\BBH..*2V2DV5XVY3Q6L+WL+; ?;MVXB*+=\#IDWL\'Z1+
M[URU?M0?JK(RG%\"5)%^$E?BDA*AL4)(223LOLV";D[WP<[H-:T<!ZLYY<?"
MZL3#"2'%J.;C(NW4"GT,4O-A((*!< @+LCOY<?#?EV7[,1#OQ',CE?3(^O54
M,<(O$!U]_HH&4T.?5F_P5(5\_C;8L7A9P:Z!!%"7[T)Y$>=5#V6WV)!\P1_'
MB-[_ $Q>"&(#,'J?H"JJ):+$@A&_(A-SY=E\O\]N#D_F'0?5RHWX0') JUS]
M0%2<F)*B$\*R T.'Q HJ6[P)2/&40E8XMRVH<*%E*@02+[L1%CS;[^[:A0)D
M.KUR(/*P!:_'Z7\=8<0I03PCC4 "E:"0+ $I6A"DD]Q!%K$$@X@ BA+G4-]%
MDNJ^"*B\!PW[0=OEY_NQ!RXGZ%0+Q<_H%C+5_;275(=OM<YV(/=_JS4U?OM\
MV,LJD[#D?^Y >N\6]%CB'\.=PAC/DWU7+&6\.%)/OBVDGLW(N?-SQ]O!)EP'
M6"$$T_*,J FBXB/^9%:^A.8;Q],GHD&3( 7P@GE?MMOY0;#E<[;'%C%$ X(8
M]#GK=QXZ+&S."^>=CX6]NDE]T6*KGB\O/YN7GVN<8LWUOS)<G6Y-'9$A29JK
M*!X2 +@!9&_?S^RUN[%#!";@W<U-<_>?%5-7=FL!6YUTRR)#W3<=EI*K<*38
M=8!RLKV3#L3RVL;$#;G??&MC[N'Q$(H&(YY@AW/BU')HKX.$F=O![M8,;Y :
M6STR75EZ&9MT1.BJKL/1QT14?*5:8Y8.WDN3V\N_'R:<YG32&WC$?^Z(>@"[
MV  0@"S?OYKZ;Q561B(K'D?1%3<-N$=Y/V XJ!O0A_+@X1:#?KALV]4.KP)-
MO:KTS[=__HM[MY\NSNQ]![)Q$8>,PAC%$0=&;VYY].1V^3\2 /1SZ?=>#\A\
M-DA.Y"RFQ/9P\N?,7%CMRL.>_4P]V:&:KT!?(E_9LZU4!>6234,Q'&]R-:9V
M2%+D7420H#A-S<]M^SY/O[\9)Q,,R'++6HL7UL_.VEH&,!I41 "[ER.G#7CH
MA/RN!)()N1<;[;^>UN9Y"YVQ4[IAX^HX-S%370T4S@X;ES+N+W-$C/R2I3G,
MBQ[>5TG<'R$@6)^<G%9  BFZ_#F<KPF@JRRP#^ "+F.$,:AMV+GH^O);Y/K6
M]15T!]62?UL<^_\ ^*]%?\^;'S/;Q'XV+4.,FOEUZ+JMF_R,F?J[#2EM%LI8
MTBV -2-&\PC!2DZHK @2RN,9S1CO=9';2E2GT=6KB8#3ETN%T7;"%$)65<)L
M#<D7AA7=),QU2NZGUI.@M:3IO69.=XN4,JTC1&NY<;BYRK63A2,H5V5D"1&J
M7#5J'62M4C4B&6Z.ZE;4VGRH 95UL9FN>G#+WKT)>Z2^ENI>IM'J)HNG&>:G
MG[,&DV@.7=(LRM9,K\23DC,^GFK$FM:J1Y^9JI"CJTY?JE"2HOU.H3Z#!S=0
MIT:E09E5E"0PF47W5T1LMIH*-5:C1\@U;3'3[,&>:1,T]R76<LR,D/0*;3LC
M9:IM6EG)$BG4D9==EU6,XW)/L5D5:53#4F.M85'L3W[].2^O'Y=:ZP>PX=)D
M-<B7ZE,CN ^9JE2V[6Y7<'/<BVY%3]E9D_-E%^NIOX%B*Z#Q/V1'LK,GYLHO
MUU-_ L*Z#Q/V1'LK,GYLHOUU-_ L*Z#Q/V1'LK,GYLHOUU-_ L*Z#Q/V1'LK
M,GYLHOUU-_ L*Z#Q/V1'LK,GYLHOUU-_ L*Z#Q/V1'LK,GYLHOUU-_ L*Z#Q
M/V1'LK,GYLHOUU-_ L*Z#Q/V1'LK,GYLHOUU-_ L*Z#Q/V11]E9D_-=$/_IR
M:G[#03\^)KGZO] BMGI68>,!=,HZ20D#@K,QP&ZE"Y)H;8"0>$**.M6D*"BU
M:W%CBBB! A -KOJ1TR O=2.-NGOI1\BK=N7F-P%2:71%!'$ES_3DU%E@D (O
M0"5)!!'&I+9)! ;%KF83&16$ N<R*4X$_MDJN-1=A6_Z\/-5T3,SH2 :50AY
M?#E1.Y[-LNV^W$C>.@X,3YN/)6&[1WMD1Y4MQ\E#V3F)9XE4ZA@FUP*W/MMM
MVY?OR YCO^5WN#<OH_U/)-Z5K$_(-XA0]GUU"K>#Z)=//_34_P#?^3UCB#+F
MDFM#J(C]:?;A?&9D#D TXM[\E275LQW6&Z;1%*2H'>M2^!+2;=:5%-$+ZG>
MEQM"(O5J2DW>%[C'N3!4PT>X>HJS#PUS5A$#8N1?WZ_17R9F8RE)-,HH)2"0
M:U-!!(N01X"%B#L=N>,HWF%!;4CZ*QN6U4WLK,GYLHOUU-_ L370>)^RA16_
MF-0MX.H8N-_]-S[_ &9>(\^%<V\7^@16KLK,A"KTVB +-S_IFH7 #I;'_D
M618F^Y5W V&)BX_TT]38D>- U<E-./OU\FXK0B]7E<?3ZHQGOV2VVA:M,],U
M+]C27)*!XF9""+Q67 +\RI M>^V/J/94_P"3%33>8:N=7 >K6T7([4<S39R
M.M;?MP>H7BO*D*"B4D<)N% W/8!?F+=O/OL=^720'O1$ _*<J@@9<;TY<0O
MQ$   O"#:@)RXMHD24^$)LE1-[WN3Y0>1'R?+V#$N8G+<6(SU-31VXA(B(:
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MD1[*S)^;*+]=3?[Z%B"[&@L<S]D4CDC,G#<TRBDI!( K<W<VMOPT%9^9))Y
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M$?K9!>=(/9;EO<>^-CND@CGV';Y[^81 1$MKI<M6K-XYK.21N-[^8WZ9\5T
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MO_B/V['["<1';K]"J2OG'O,+6D]<DJ4-%NC8NQ'%JW60JQ">*^1:U86)L0;
M[6.WR8['LC%NSID50?APY6>,/ED/&MJ!:3;8)BE@?FB+4TKZCQX+40DN >+;
MQ@"2/&N HJ_WB;'EM8[?+8_2]ZC<7Y>7KX4)7+Q!R1Q(HSZ6;T%TA/2%)4JY
MX!RX1O>P[.??L;W[^0Q@BB%&-G+\#T'VXJ\ ()!>K&M=?"UCT3>FR@+[\^+:
M_P#FX!M<@7^P8KO&YX-3Z9<LKFMLH#N]L_L_'0L#FZ:4R41>_'R.Z1<#F+?)
MR\M[]F*C>BGB+2 @59PY/+QJV;VDAY41:C^=#[_5>N7J D@N>JGZ')!5<Y.U
MIN%;DA.F&8R+#L%R=^VUK8X_M3-,4J*$V<4XB*K/PNMML6$".U1%QIW:T]C,
M771+:MP[7[+W[R 3\G+' !FI9=0JF)14GO>'SC$&\//Z%0+Q<_H%BS60_P"R
M+50GD--\\7\ELL5/Y>5^7W8RP!IV';_W)9KQB)/U94/\N=_MC^BY1DEXV!3[
MW@!&XO[WL&_;<^3R8^T.1!#_ +8 "=-P'R-!P7#S*1Q-1R7#\33][IN2I!*B
M5*()&X!/G[_NWWVMC'$0*UR<\<\O>3N%BBA<D5I0E\GK3CZ7LFU*DGC)2KO!
M(OY>7;?NY]^*.2:#*A8$^K9C/BU:6K;Q%A3RRSS2))D6*A<W/,W^?S=A\GE[
M9WB2P%LSY^'AY YH*0C5J=<^;6Y\$@N20JZ2;\1-P;#8K0JW/M4VGS6-A8X\
M$\_Y?$\ >;Z5R9BXT;-EFDP_Q012H=P#6N6O'A:JZT_0K6H=#OHGC;?HU:$D
M[#_>TNRLI7FN5'[,?*Y]<1.?*/ZDOXKL)?R0\O4E?4N**Z,1%8\CZ(I$DJO?
M?_G?NQ!I#3)O4%5!.\1D _HN?EZXW<X?5&*\GGP:4::E(-_]ZE/$^??>Y[K<
MB,?0NR(!EQUOO968C6A.M#GHN8VW"!%#=[7YA_=-%X!RGCO=)WLH[VN2-N6_
M=W;#OQOIT7PY_=M6[Z<?U#ZW6N,/<  KNVO5R_ 4SRR2$Z^0%7%KCG???E;]
MW_+%XXG(?=R<EAJ:7J'KQOJ(@!^'%JX>@<&FM.=4C/R%%.RC>Q%KVOSVW[O-
M\N (W3S<-Q&>67/3-7AE@NP%&K6_5_;)$><)2LD*( 6" K>W"01;MVMR![._
M"01\68/_ *<7!N] 'ZE^?-98(:@.Q,0+'FU\N=FR(6_EZU3/%ZGSJX2"![KW
M4,I!Y[:5:)C^\'_)Q\XV[_QL3W[WKQ]E=)@H!\.W=8-Z_=ULTJXK73O;>W?Y
M+]GVXTJ]ZBDA0!%['OY[&V")+JAFKITU%/$-R<Y'>3#;F*6(9>+:@T)!0VI9
M9*[=:$I4> JLA1'"2+RHB]%7I&3F*QF+,DW2:7J=F!S.] K%5:SSGB7E=S*&
M>*,_0FG:334Z64PY7.3J>L"B99C1IM/JLQQ^3-S1 6^HJBKW#=7OST_4(EW5
MSH<:G:J4"J9->S#DBD4K4#3S1_(V>*JY4\SU.3E:-HIJ#-SC1:CDZAIR_2X]
M:_*AIZ)$G1*IF'+(I%0;F5!E=5#@;C2FNK4_7@OK/H_Z=YZRA*U&S5J1,RR<
M[:G9OBYHK5(R9*FU/+5"\'Y:H>7&(U-K-2H>7ZO56I#M(D3DHJ]+8?@L2D06
MGY*8*YTTBS_*@RY,CB9JU1AA-@H1FX%E=]C*ARK?_=G!%0<I4]*%*&9:[L/@
M4(^2^^7T@6[R>%/OE!0!23@5B (S!=N%F-]$8F@+'6C]'H^GH4W:K4XE$0T[
M7<Y.4V(\ZAM$BLS<OT^*IYSK7&&"ZJFQD$J:;6YPHFA]P,E26@@JQC@@,418
M1$/0"^6E?4N1<.IC: .8A"69V/6IIP(8!NA*,UG_ "5PV5JQ15+0;* S%DQ/
M#XB>04PI26S8E/6<2S?WUN64X>:"###'""- <VSAJ:#/.U0L7Q98A),3E[VS
MT_5CT4RM0,C'8ZMT(;7 .8LE*[__ ,TM<=][;<K' X><<YC\(0*<F\U!G06>
MO3+Q^]1J%#VP,CBY]MVB'F-\R9&(';>PCH.W*Y)%NPG? X>:U1,(&3 GRA<^
M^@387()'B[>%M:_HJ9U"R(D$KUCH(M<D_E'DJR0!O>S*N7>;@?!7RP_#1_EC
M\!]D^+"]Z5T-,C9ZGEX.DVGZCY#J^9X63Z5JW2:IFN;!EU:'1*=7\J5"JR:7
M!?:8F5!-.AQ2\J/%=F06WY!;;;1[(9NTDJ!(R8H(26B%:.-.+6UY+,(H2 0Q
MZ$'+CF+,]0]R6R:W3JB2H+S)62.( $MT5%R$I"^$"A*NV5 E"B5'=0)( Q2$
MDBM\_4>1"6R!MK]".JK>"*AVYDK@\PH1_P#^>Q(SJ_A3P"'D!X_4E2+I-1&P
MS%75 C<A%"^;_L^!_?C'& X+FUJ-]QZ(,S2F1+>%0OGGI60)C'1MUTZRMU=]
M!TISW=M]-&"46RU4O''4TF,X2>1'$4BP(%SCU;/+8J2#;?A+-FX9_"F3BKAU
MY\5_)C-FA-N1.;KFFQW2F!"X2I7_ $*-_2**>)?]$GQE!)X!\@2.=@,?<<#$
M/PT)('RTI:@=O,C3R7!3C_$-<R"><18EO.E7=)<F20; ;BY-M^=S;?;EY#OB
MN\0'&9B;QZV+Z5U5XAUH*$<,N/#0<4UY\M00KAV)) /R[G_/,G?NQCWBS$N,
MG ''3TRZO !B'>>EQ9W-';G:G-PFC-E$(43?B[2#\VW_ "/?SN<6AW8A$X<P
MCND^)H&_?HKPL!$&%!2MC>A-<WO6U4Y=%9!5K]H#QEUH.Z[Z, %*FG$JOJ;E
ME(NCAXD["V^X._.^-1M&,3,#/WF.[O"&C,&;UI5>K9T1^,[@5\FM:IZO2K+J
MZ,4V<]&:=%>JS8+$=26T)HX0V%MI/ A+M%=<"4WLD..N+  "EJ-SCY$1WYE2
M.\: V#G/-]2[WS7:P_+"6%NAH-&L]&97G@B?^DE='D":%8>;_5[EBR*FY3)X
M01^4=9MWVH9^?_0 \]K 8QDG? !(%*=UCK</YOIDGOW7IRR=4ETZ:$JOF&LJ
M&UTVH'F&PI /;WX10@5#W%LAP_7-3P89Z_3E3+5<_'UP*E3'JE>?4+DKD*&E
M>F XUI3UMPG,MW"ED(;WL![VP)Y<\?2^R_\ PH-OF!8\+!R=:\&(7';9I.&>
M1HQ=F_>W$+P]>?!*@#:QMS[#<\[;6^<>3ECI(1WHB0Y BOUT+6)\-%Y)@/PY
M;:PO]!]>*;SSQ/'?X1WXCYKVN0>5_FORQYINYHU'(\&%[V>V2A^\;  N3?7/
M+1LC9(4EQ7";*!%[@7Y\]CO]G+R7Q2@#Y4:I_4Z<M%$+&A#DN_DWN[\$WI3P
M3[Z^UE !2A<BQYD*/C'8WOL2<8H#"-^*K@&KU!&60.EFSO?/"\44(+'( TRS
MZC]%T&O6RD66_P"IG0SX3FQ&DZ]ZQBT?P:;+%0H[80"_3I"BD*0XY<I427;7
M"0GA^=;9BW\9%$]:VX$CD<\GO5=1@01+:@AT_P"D9FKAQF!J[+8>%)G$ C,=
M< [+)HAV_P#.R]C4]3Y?9>_H//[J!I$\6_UCK:KFUE)H0&_E&7Q_GLQ$7]/^
MX*-7#N&]LJ*J5/2%*_*&L!(!.R*(I1(%Q9)H8NJX[^0O;NB949L!EPSL]GK6
MK4TQ2PQB+GJ=;M:E+:%:U7KD1IV-HOT;U.5";+0=7*N@B8U"!2/R&K)!NQ 9
MX=@1=-E;[;;XZ_LJPF3!8B7#7G'5WH[FC#6BT>VRP@()!WFHUMUS3Z4>HH&6
MHE)?XEJL;I *19Q2T#M %TI((N;F^XVMV8^D.##<NP-2VNKZ6;3ISH$="_B.
M'[ YARU+M^2\$\9[@-R3SWOO<B_+RD[7Y#&%KZ.YT]<\\FR>J0 N1F6I>[F_
MU)YII2Y/$I2B"=K  CN/VD\KW.XL<20_O('ZB_U5R6#"H#\SY\$S:A,OQ;J3
M;F.(C;MY?O-L5,>[,A#M0Y#EI3Q 5H#O"* T?)^'C7S J!9>N_K?EU;_ *JM
MH>AM]37^I6MG$4A)='%I?F0!U!=2MNS9!(2I"A?G>^./[40P_#WA#D[UOO'B
M,BVCFP8K;[*<3=W72E6J10EQQOD* 'HF,TR:ZCC3F.N)!)\4(H( (LFPM05]
MU]U=O=8G@(0PYDG[>2Z@\W_6OUKQ57P1/_22N_1H7^'L64*1=)FVL<R5P\KW
M10]O+_V?&X_R,/H@SI[85O7W18OUCIDMO2+551K]:<"=.,\J4E35&4VL?DO4
M_%46Z*A201MXI2H#D03?&261\7#BG\R \?F-/3V5BB+2IS4)$=79N5P_1URB
M94@$ DJ'B@6*[D6 !_W4 G;X"1OR Q]I;N0FC[D#L#7NB[,:W-2%PT58XFH\
M1H>?NG0) ER"$D@"]K DD6[MN9'/<]N]K[XPQ;AN+9N:\6>CTHQYV4,PK<'2
MA/-VHUJ^J07G%6OPDGG?;M[M_P#/V8IO 4NS_4@6Z:9NC.Y):M:5J?#4L[T2
M!(=%SR-[@^,?*0+7(O\ Y&XP!A U=W>[Y T-_"A*]$.5/;&C:G+T-D@NKXUK
M NCD2M!"76]]RA+O$VJ_E2J^W($8\4V)\/B0=.+LPZ%@:94KD%Z<.Y))))>E
M.)RH&J/!Q9=:#H6P9LCH>]$U::U5HX]S-H,HH8112W?VK,K>,5/TQU6Y -@H
MCR<P?E,]_P 1'4]XEQ1J/4'7D+9BBZF2^[4DAJ MY,'HX9SSJOJ/P1/_ $DK
MOT:%_A[$+*CP1/\ TDKOT:%_AX?O'GQ$5CR/HBD51Z@$G@S)7 H]I;H2AYRD
MT%%QY.,>?%2>Z.77458UXMU#5!@26#GG]US_ #UQMQQ_5&*WULEZ2X=(M-;%
MX-)"RW2WDEYTL,M!)5?9*. <K#'T#LE$1+C9@.]7W1BSOPL'#<YMF$&(.*4:
M]W!H;6J? +P#=>XKGE<[W)VMRX-_,#Q7V[N9WLPF*>-ZH!+%M8=6'"UEJB2)
M8.;"MWR+GE869^B&^]LK<WO87/\ =?8_:>?9C)$*PO8@G3W;P5P (#D'XG/3
M[?HD9]X\!O86O8@DD>6]S>VV+1$"$E@&H "7];6LCD"AS8"A8<Q>X"1'Y'"@
M@%)XFW$GB40+E)-[@[V[KV/,C&'#Q#XL=;RX@1:CPORM<LLLIOB Q Y,6.3&
MM >-FR?);]OK5J)(E^I^ZMJ8JU1A@=+G4/B$1$"Q/M6:)[$RX$X6O?8)2KQ0
M>,>,%<#M[=_&1,/6EZ#AX\UTF#/<#E^Z-*Z/Y@ %@-7#;,2Z54$ $9DKJCQ#
M;JZ$;B^^W@!/(>7&C->')>Q7D&)+C]:7:G.G\:]E268*"E(Y!(C0HB38@A1)
M5V6 WN1*W"D7L.>]O+ORN=N?9;!%02F,$J"$-^*;E( /"KF +C90))%N1)-K
MDG!%+P,EQ8#:$J 3=0'C%2]AQ]YNH@E5S8D<B<$4R6F>,D!))(*>?$-@%64=
MQ<) V.PVV!."*OPIN#;<<CV[8(J;YLD=Q/?;EN/F(!PIG9C?E]5!X:CU#^2\
M#_7# (Z&&3Q;AMK;D\<M[&DYBXMSR*@!<G<V )YXWW9Z5+F8S=C9OAEG_I(B
MA&=WA)'[.-9M";,ADQ&%PQ!S#78%ARXV//2Q=<;X=B+\";J  43PI&ZK<1Y"
MP-P+; ;8^HG 83X<)W9=0[L"VE/NUV+M7D?Q<_O,8A74\;'QRKR=(<F0E-SL
M-K7L;D><;]G=M^^AP&#+M#+!U #&AIH.?U=KPXJ>"[QO;O$U>@N/K3U:M0E
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M[V(N4D\_*>[M'*V.@B;X[EOUK];%@*W=@M9&!\*@JP'*H/G5AT%V+?E/**K
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M'CD;$[%I!V(5]J>?:,?)HOGB+GYHGOJ6_;S&75B@ T R]:.>O@E .H  /%L
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M#C6S7'(GT*0GG+W!X"=^T#ESO]OD-^S?%9LR$10PZO7)FX<N.;ZJTL P%QF
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MO\_4 _+VXI%0$^]$5-66<O@*M1*+M_\ HF#W@'_ZC:U\8:9UH7YU4N:@/XY
M9ZT'!4UY;H20"F@T,+(! %+@FW;<?T&W+SXL68MXF_V'G3,60G4DWY<&?[!<
M[?UQ(&8WJG6?4-H;:'M4:5_]7=+9/^M%R&4@)!MMNG8"VPV'T+LW_(BN2U<J
M-7[OF38B_,;5@[[L'!8. ^IKQT=@Z\(Y#R E5E *OL1VD@W!Y&P-K\^6^-_!
M$3'$ ]<JYMXNQT\&6NW2(8;ERP!]M9O)-V3(4A"O&3<D@?+:VUNS?LQY<2+U
MK4CZ>O%V+"BS0PEO6M!?5F^_%-F3)<3?<<[V!L3S\VYY]PQY!O0]YS0N*U'7
M/EF0&5Q!O VOG7+]O,\T)YXJ6 H7)/?8 ]NY[][]G9VG%#$8HLW+M4FNZ6SX
M9!9)<OO"K,.7AI?QKSZ,'K7F'#J'J7T-R1"A3%^Z UE6I4N.TLEQ<[+_ !N+
M4M"BXXI"4)*S=1"4))(2+<3M/^?'S/\ W%='AJRX;L1"V;"WHMB_\FJ"I22J
MBT8D@WO2H"P#W74P5'R7/?W8UL#/0$4K;[#/FL^5^GU4QRQE^US0Z(;;V\$4
M\7MV7#&,A+-1W('K502PBY'V>"H?DWE\*OX$HO.P'@J"!<%(L;,7-P;?>!BL
MQB+4>W(&OC55E%B6<$"I!JSOP - %K%^N:H<"GZ']&-46!$C*5K#7$_]%B16
MK Z?U\DW#:; V )'C<@;@XZOLP2)D8#@;D-!KOC3WGDZTFV "(28?S EG/RW
M?DY8D!:9D^2 %CB2 +\RHVO>X(/BCSC[.WZ',)W '< $7/EDY<M0UUJ^@.Z(
M0& -+,]LP+#S>INF5/G *4D*01WV! MR\@Y\]]QV'%(H@)<NYI%30=W[_LK2
MP 22,ANTY^V&6;&K,FR]UW4!YK7M\G+<_-V8P117J6LQBX6/-9"QL!E6F6C"
ME;\:T3.F2TW6.L%B#_DBWDVV\N/'',(G0Z[N5,VIKG0TJLTN#>A)(:H()Y9^
M^-C7V=];G.,RO5<-!V7D)?;.1->$A+MEM$JTDS62E3:@4FX':DWOO:PQS7:*
M(Q2X6K06R.\Y>H>YH*,:&I6VV=#NQ$4N+>6E*>K!=*AO+5"6"I=$HA5Q*YTF
M KM[RQ?G>_EOCBY8:'J30-I^RW:G_)?+_P"9*)]3T_\ ^!C(BI+RSEX$ T.B
MW!/*D0!<$"W)C8@GGY;=N*Q?*>+>M/#) 2Y -P' SO?6WDL7ZT9>H;6CNK:D
M4>DH4C3+/CB%)ID)*D%.5:H04D,@I(.X(L03VG?&:72=AR+_ !(6R_J*Q'^5
M-A&<,0;I<C2EC;B0N1M(?1PHLJ_BI'#OMPI %QV =@MRMR&/KT =G=MV'@]!
MY#Z!<ANDYT<TR8&@X:6(%3P2+)D*)-E"P'+]W;RMMVVW/(XK-! H"Q.=;7Y,
MP%>JG<M=G\0WHX8:5UHWY<DI)\8#<WM;GV#S?]PL+X\<9-:AFIK?Z$6TXAUE
M 8#FSEJ4#&O-R?3-NR)7$I9*D\CML0.8W';R'R\\83&19B V8<$$]<UE8:#6
MV>J1EK%@E7!P)+ETV'5F[$DV*2+$?(?LQX9D3X>?IF]L_0@WSJO1(@+PFY<"
MM:%F+&AL]_&RZ]W0AH-&E=#+HBNR*1275'HP: #C>ID-Q6^DV4#[Y;)) -^9
M\F/GTXO./&)BY=VB:NMA["Z"!H8!J:T+5NYN]VO6M5]2_DOE_P#,E$^IZ?\
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M>IV0JF,E5VCYBK65:3)TNH<6/7*)I1&SG6\R/4*E&0(CC&0ZG0*\TXW+3#7
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M9<V?4)^85S\S5B1F.N5)S,,V4_6I%3J5=E.5F34WZB9BZB$OEPJ0PI@: G1
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L:)";IU-CM1($5IF-%CLH2A#+,9L-,M(2D );;:2AMM'C<"4\*2$A*01?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g549728g22p07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g22p07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Q44&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!9            "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M 2T   'T    !@!G #( ,@!P #  -P    $
M 0             !]    2T                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   2T     4F=H=&QO;F<   'T    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $M     %)G:'1L;VYG   !]     -U<FQ415A4     0       &YU;&Q4
M15A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F
M875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D
M969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP
M90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L
M;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E
M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !#A"24T$#      1N0    $   "?    8
M >   +0    1G0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 8 "? P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M_<9_GG_TFD79'[C/\\_^DUX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MRZH@>&YL!S'V[XR(.\@[BB00?XBE%0%/J!)-BU0:UL\54 &.\7WF84KR.5-
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M*5M,K_[FR' !QFQ@AM]]\ZQ+K:&[ @NI"^.W;2I3:C<CEQ#376^/AESY>*E
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M>B<VYA6561-#Y9T[,(V15.Y(_EE6,5*XAV%7#PDLAX@0<,MR'=94A4XGK;+
M25@%N'B&BDI4H'ONU6/VUM_ [$DHGXS9>-P^"P<_:0DXDX<KGB2A4Z7,^&M!
M*?BE6\E=K1Q6QL'V>V?M/;./FR/U&S43UR, C=!2H39C)H0?Y:"Z2SA@00PB
MOG:]B*GZ.\\J>&B'H">,TI-&IDXS%+:B)?/I<RY#S"'2ZE27&GF(E"U(4E06
MGC390L#CIL?MU2.P6(5)Q.)1-PN&EA>).(_B[Z5 +*5OO@'G9A:D:W [.P__
M &TPLE$@3I:\8#+DS$B8@R5)WD)*5 I-" 014US>/,T!.:,95E"Y0N955OY@
MS*IJ6:FLNF-1SZ)D\;*XE^'%3MQ3,Y<3 +ZJ!4^$"'>7$B*"1"-.K!&/(MG[
M0[-&;L.9LOM7M2;V@FS=[%2IV,Q<[" 74#\0I0*T^O*EGCO]JX/;:1MO^T.S
M&S<-LE$M6XI."PJ)J'9*52UR775P;BX) BZ>;TQIH9URZ6UI6<^IZFQ0\;&I
M1 3^<REI<T3.(9#;;C,L<25-I0J*2V5MA=FD)ZU256'7?\1\=@<-VR[,8?:&
MW<?A,).P^*5BD2L1B),M4Q).[O(EA25!PP"@0Q8$/&C[.2=I#LMB)VS=B;/Q
MR?U@3/Q&(PV'GS):=WZ4KF,I(-"2DM0T>AIJ43BH(O)S.>&ET^JI^F436$@J
M-J"9Q,?#SQF"B8B ;BER^/B'&I@XRTZZ50SQ4E:P5MI586Q?"[5VO/V/VHPZ
M#BUX039:=CSU%:EJEJEFH42%!R7+<7BVUL!LV5MC8*IZ<)+F39*%XR1A @R4
MKWOI*4C=R<EC1S9S%VLI*^G*))/<N*PB'37%*R1V+9F+I63/Y*\TZ99.H?CX
ME*<X3#IC1Q*4S%)6V2;G&;LWVDQFSNS6.V/M-<S]>-E8J?)FK6I2]X)F%("U
M$DE]VCU (U?0;3V3AIFU\'BY"$G!3L8F44@,D#XB4J2PIJQR)H<R,KGZUJGH
MM4$J25.N7U)'4E+51D^F"HJ9QCB$A:XE:7GG%OO1KR;_ -<O.*X%645$7MU^
MR,;M':O_  ]5B,+B'QR,-68HE2P0HD@K?>MD#:C4CY-HHV9L_M=-E3L/O8*7
MBPTM( 24;J00$@;K4L14ZWBH>BY%S1.6,&W.IK,IS%L3ZH(-R/FD2Y&1[YA9
MFZP''WW5N%0'"0DH46THX4(MJ#F_X<SMHS.SD[$[3F&=,3CEH"RHJ8.*@E1+
M5H!2IM&/MJC HV^B5LV4F3(7A94S<2D( )0]DM4M6CDT8QZI:(NFYN3<I'=I
MS[M-AX^&/4[D$43NBFM.%.-_..,2#5[N0YNU/"%.+1:!A"!A"!A"!A"!A"!A
M"!A"!A"!A"!A"!B"'#0B!-A<XH0$U#OD_O1X0WQ"2OCX>$['M@J%@;Z)XDW4
MHV [2=3N-;@LEZ6!/</?+I$%C0Y^_;/'E&L<G*CS!S174DWG<VINGZ7@$P=*
M.4W.%0DQB8V.ZI4RF<8ZTEHP2P+0K37"X5MH4/.!\U7E6UNQ.(VUVED[6ESY
MDHX96^DI40Y20"6&922U#8M:.PP&W9.S-E3<*9$F:N<"%&< HI2H$!(L7+!V
M4P%6,-L!DI/*(S#AJLD<^FU4RBI8!RFZY8J>9/Q,>F!!ZR!F,OB5,N$J@7VG
M@J$=86XZU'*4F*92@JQK)G83%[+[1JQ>#F*FX#:B3A-JI<T3.JN=NA_F!0 Y
M!(W@Y=S'U'M+A\?V?F;-G2I4N=@YGZS"39;A?Q$)4E4K>)*@E29BC1DD@$@W
M@BBLF:BDM<M-S&)AHK+^E(R:3:D(6SRE^>3Y25N,O-K46X42R[H@DEE94AY7
M"MK5"L6SNPFT9/:*5@9F/([,[.FS,;*03\TS$3DG>022VZ@ '=8BVACZ=I=I
M\/.V A6'EC^T\<G#R,4=T;R)&%2R2%;H(,Q9=>N<%4U+ZAH%RMI=3D+1U;2B
M95//YM&1_P IVY''R-Z8N+B7Y5,6VY3.DO1,&5MH0KBESC:$@O,,(2AY6-"9
M&PI6V$SILC:",1\=>'6R#N)4J8 @EOZ2  P!#$DI!>/CF8A>T9VS9LU:\)N#
M#H"4)4/B;A 40D$ D79B5$L-Y0:%^0LPG R?ED3)99+9]%1M5U,_>'F D4&9
M?'5?'NQ$S@@J'CFU-JAUF8)A ^^J*0\F)3&!#R$-]!V,Q*IO9U$L2&2<2% I
M)%%34GA0 95 =F!85[5+DKV_.(F_#2C#H0$D.%E*&+"S@NY(&5'<GU Y!<:G
M!K90L!=6A-APGB*PM(N3H3V3Q=G;'H^-PJ<5A9N&0H($Q)"T:N&KENY$:D]>
M,P_\/%?$4/E 44G@_.A#$LV5@8\>'H_SEK+:%@4+ETIS D5?3>LZ;FZ&VGF_
M.Q/IK,)3"1T1PE3LOC8&*;@HM*A$)82_Q%E0"1CQ[;/_  ]DXC#[,^%AI<G$
M;-VYA=K8?=ERT_'Q$D+$M,PAMZ7,*0X4X4$@,+QWNRNUV(P\R;*G3IR\'B\"
MO9TV4I:URT)FN/B)2Y 6E@4J2 2]P0T+\P\J*BK.H:4S"^+XOXYDE+/26;4A
M*JOC:>4E^.B(=]<9*ZGEL.FRH1MAT+8?EY:BX=332'X4M+4YF[2]@\/M'%[,
M[3+_ %IVGAY,GX^'PV)FR)::%:@E$H$ A<U8>E $UI&/L]VE5A%8_8XGX?"X
M.;/*TXF?@I>.HE02!\-9>NX^\'J7:I$4/7N73=*9)YI3EZ21$BG-2,REJ/1-
M:NFE:N+1#S.!0RN,C(R%;4'"T1V(:$=#7$BSKHUQI=I[$P6QMD[1VO\ V9B%
M+QI0ZY\Y4Y17OH!"M]E$ L&W:5 8QM\#M<[0[38&3B<7*Q>$P94)2I&%3@@/
MD621)0: %JEB:N!%>5!3V9&9-(0U!/TC3U/2N*;D?G54/3MN=(7"0+\+&/F"
MD3$J@'$O.MLI+:GYBPY!+(=ZB(2CA5N\3L[&]J<!LK8\["_IY*)F'FIF@52A
M20L@$!TL%!02"D@!F8QJ).+P& VAB\<<:K$($R?\.2L*))WE;H))(8%Q8C)X
M?$T=7= 5M552TK()/6<+6:Y*ZY"S&>JD,?)WY9*VI<X?/7)=.6YFR^EMMQD^
M;R_S="D% >2E"$UD]G]I]C]M;2Q>S)']JIVB,(A FE*E2/@RI2%L5&A="B6;
M*A%\.+VSAMI[.P."6DX<X->,)7+<)4F?-6M(W4U9(6P!)L?FJXI2;9*59'R2
M=*B#*F9U56:5/5O&RIIY;D'+)?+E0@BH%J*?9AU1;A;A>L6\8=D/+45!M*;#
M&FV[V&VEC\&C&8D&5C,7VEV?M)<M"RD(D2E'?EBH=+#YDB[<8W>$[68"2<%A
M#48+86-V<9A _BS)Q*DK+.2H;WRJ))&H:+IYQTG4<S% 3JDI=*YK,J,K.#J%
MR33*.^*6H]DR^9RIY#$P2Q&"$4S#S%:@7(-T.\   -CCO^UW9R;M&?V<QN%0
M C [5V?,FA/R[R$364"0&((N#0A@*4CFM@;5PV 7M/#3YZ@-HX>=ADK/S[GQ
M?F2JNCY/E5HMC6^5E:3FK'LQ&)5$Q,PG%/225S&FI57\TI5<IBX%<1&Q+D/.
MX*5O_'$,I<<8577RV7MI,.'$\"K)',;9[([5Q6W,;M>3(GKPN+EJ0E(QFZ$E
M9)"DRRZ4@AF JFB<GC:[/[0X3!X+^RQ/E8;X,U4Y.)F808HS$V2"DI< ABSD
M.*L[%.G(9]%+03LK83+)_#5I!UW%0,VJ&<51"S&,E[#B&Y?&3B(=0\X7FN)"
MXEEL,-.EA:I:[U12[A7_ ,.%IP> QPPDW]1@YWQE)5C LJ!K\RE/O!RU5$,P
M8127VI0G&3PK%(QR<;A9F#0424R@C?/RJ2E@$$$ V< L[B'Z?4UFCF-4.6LP
MF=#R&EY;1-:P50Q[ORE5.8^,E[<!%P[B(5$-)98TQU)B?-U-..1AC20 B$4V
M58^O:VP-K=J,;V:GS\#+EIV+B)\TJ4$. P"6)W;!G:[ G,#Y<'M&3LW";5D?
MJ5*./ER9:0%$ '>!5<D"QK05+FK1ZK<8#+;/9*N%);5Q)XM]_P EN#8[JTV[
MKGUB5*$C 2\*H. &-'!<<0S6OD:@9<?/4^)1.!(!T)+ BFKUTTH(\F5WE%76
M8<=4<W=\VD45" 2FE)2]$K6V_*FHMF)F,8[,I8[P049/6D^9!28=Z(E\+QEQ
ME[K0,>5=H>PLS:LU4Y)W=T'< (9P#;=L7-6X/9QV>R.T:-G2A+*$J2I1WR4I
M+$A@0[NUZN-:UA[R2RUJ.DJJG<\BY# 4;)(^30,M%-2Z</SQN83&#B8I;M11
M*C+X"'@GW&HIF!\T1#OONI:3$Q,5>[$/]78CL_CMD8F8F=,FJ04[NZN85BYJ
MEU$)+V# N3T^3;FUI..22D)=U$*2D @&FZ<RS."&#.PAEZ3.756UE5>2DTIJ
M4JFK%+UU!S.<DQ4/#B$ERB2_$E$3$L+46D J3U+3CEQV4$Z8T7_%'LYBMN;?
M['XJ7+*I6S-I2\2O=N?A2BJM16Y< C.U8Z#L3VBP^Q=G=J,/-(2K:6RIN&0^
M:ES D,16Q+N^;4I%QJ1HF:2>MJ_G$Q9A%0-4QD"[+U*LZI3#$%U+B(L@*(6E
M=U)&Q0H"Q %^P[+; ^!.VU.QV'"SB!.$I<T"80"I@'4Y89:5;0<MM':Y7@-C
MX>6LH_28A9.Z6)"DOO.#<6!BW$@R@J*%A<AX.+;@W54#4TYF\Z*EKX1#1,/,
MFX0-!25!?Y9]A+H(4$-J<( .N.+V3V5Q<O:79%.)3ORMF;2VIBE)6"H%,^9.
M$MPH,I*-\!+V%& I'38SM,A2.T"I)*5;1PV PZ0@E-94D)4HE+:5+EV>Y>+C
M167\U.8M65(RS")@)S0D)3K"DN);B%S&%B)DL)=/5HM#%A]HH<N57)([L=EC
M=@3CV@FXV3A2N7.1-2$)(2%5(2:?Y:&N0CGD;3DJV7@<+-4YP<[?*E.:*4"1
M4N^@%*'B8MA%96UU+97DN]*);)9M-<NF(Q4UE4;&N0\,^X_+O-VV(*8(@I@M
MI2UW+<4N$>+:!\VRKC0;;[*XZ1B-C[61@_URL+.F?P $NA)<T(R%A0N7J"8W
MDK;VSILW;N'4I21C!)2A:"04L$C>/T_*% N SCG%3RRE:YJ^OZ:KFII#+:08
MIN1SJ6IE$).55+,8]^<>;H>Z^.9ETM8@X9E$.EQ$.E+[BE*2ZX6%("3EQ&QM
MK[:[1X;;*<+_ &?+3L8X0X8@$J4N9)6%\_X3DEB H]?@D[3V=L[8V*V=)F*Q
M.)G;1ESAB%!PF6@U0')5?=<@BC"&.<915@K(N HN#AI?$U++:B<J-J#\X0W!
MQJVZW>JEN"3%?,8$2RXVRXZHJ#:W >%RW K8;6[-;7Q&S,#("T%<N8%%@'9U
M7-=.\4(HWS8';,O^U,5B)AW4S1."0*!P @6X'.P.9K%;Q%*5A/JMHZJ9I*X*
M2-P%.3N63.%$T1'1,&_,.J::#<4VPRAX@!2DQ!ADI0H!/5*-E88GLSMF?BMG
M3?B) E2522 U"N64N^KU!W:4M$2=H861@\;*4LE2IR)J&WB/E4Y!%!NFC@'-
MZ5$4'3M*YET!2JJ!E=+T_/X)PS%F!JDSMZ%2VU-8Q[B,RD$1)YA%JBH,1"WU
MA$P2W, VMM,1!^<)0-/A.S.W-B=GYVQS+3C,3CL1B)B)ZPE:Y25S%L-Y0*A]
M8%#0 @:1MINTMG[:VJ-I_'_2RL/(DIF2@-U,PR98"CN@I2YW7J [U!^8PLIS
M)>;TW4&2+K<;"S:39<TA.J>G$;$<2(F)CXF5P\#"1$,T\8EQ++D2P%I07G>H
M3PM<94TJWW;'[#XC"XW8DW'*$XH&),U*F4$J,LE-"[NHDAP:AC6L:_%]II<_
M9>V9.&24'%8C!JEE*F.[(4K>^:G &E7-ZQ=BBZ.C9+7^8E01"8=$'4*I1YD&
M3=1\TA5MO*=2$(X5\1 N0;I%L;CLSL:;@.T6WIZQ_!7B$&0*;NZ$!V  %P06
M 9W:,&UMJ2L9L+8^#EEYV'E3DSE?U%6\5!RX)#*S<\07AFS1H^IX^K*'KFF(
M>73B+HU,W0_3\TB/B]N9,SF%:'70LV\WCQ Q<(()8X5R^(1$(B WQPME.JCM
M/L+&8K;>"VQATIFHPFXCX2]TIW@5K!"5. 1O"H#UH:EOEV3M##2</BL)/"DF
M9(834N%#Z0Q(JH$_-D!5Z%HI:3T/6-1YCP&9E42V7T@9524TIJ"IZ$FAGA<5
M,XEJ)\XCYDQ P,.VJ%2VAIJ%99>0R5*)B%K<6VUK?^RVU<;MM>T9B42I4W"+
ME%"2 [JWAO!.3KH#4$4%3'TIVML_"[-&&0M4R8O%IFK6:;@1NG=U)+'.U#9H
MK_)6D9A15$HDDX2VJ/,XGD:2TX7>-$;,WHEM:EG8EMP*X#\U)M?EC;=BME3]
MC8/$8+$RTH5.Q\^:DI"0R5K&ZS6HEN.08@P[0[5D;4QJ<3ARI2!A9""%.P4A
M*@H!R:6;+/G;;/#*&?UO/)3-J6BX:$5-9--*$JQR)+B2W3$W4W$1$6R4*2'(
MJ"=A2AAD\9(C;VU&-%VV[%S=LXR3,PJU(.-5^DG;JBFGT[Q(T"7\ +F/K[/=
MH).!PV*1/0%*1_%PP(<(F $;PNROF+$!R02XK#5)\D)K+\V95,VW8(9?22;1
MU52N7*#B8A%0S&2HDKT(83YK;, XAR:^=!/"%1PA4I:6QUZ]3@>PN.P7:+8%
M'V-L<8J7.J!O39\LU6S[S+4X=QQ!C8S.UDG$; QN'7*!VKC%)E">I.\?@)7O
M?46(*@=T &]6O%8R2F:QDF8=?DR2"C*9K9R!CX>=)FW5NR]R ERX PXE7F3S
MD0HK!=4Z(UL(;6!U:BDJ5O\  ;%Q\K:6VI'Z0?V1CIA5(FI"17<2E)+!R0H'
M2PUC63]I2Y^"V45S1O;+EB00S$_Q_C',W=B3QHYAWR6RO50E"P$HG4ME:JB8
M=FJWXIEJ'B'"8N/C8F&"(DMK=)4(A"BX4-]6+]A( &/M[/=D,%LJ1COC8.0O
M%S3-6E:T2UK"E.4[JBE12H9*NVH9_AVCM?%8W%+F)Q<TRPI@GXB]W<-&*=X)
MW68;O]6;5$6UE61-05%5565[5M35'3$_GTR>AX* I.?/0PE]+2Y;K,BE;T3"
ML,^?.J*G9E%O+;+++D6I@J44%:N<P'8;&8W';3QF)Q,Q")RYR4HWS\B-]0EI
M<[P=([JYLWWCM,B1L^7L\X3#+W5;Y6M+E:Z#?-:;P!) S+!@(;X/)6KJ2D.;
M%&RV.5/:=K&41D=*(V;QZG(Z#J*-AU0L=#NI +CL/&\*(I40VAH-KXCU3QU.
MHQ'_  ]QFSMA[:V.B;,Q<C:6XH$K)4DS)J%LBH(#)+,.#1M)7:7#X[;>Q\?-
MEHPAP7PDK5+3NA0E@ *(JY9@05.PZ!+/LNJ_K'+6&RY>H2DZ3<8ELHAVZX;G
MYG,RES\ _#'SN6RB'IZ61*8]0;4I+R9PGS,N!;GG8ND?3MCL6G:_9@=G,#L^
M3LO%I1A$C:29<I$U*I"G44K2E*W)J2[LHN[QEP?:16![4*VDK&S<;AU3,6I4
ME:UJD+3/0I(3,EK)00-X$.P"DI(;.[[V7KTPSH@*TCH& C) Q0CU/*$2VB(B
M#-/C6%C#=IR' ZL N#KNMBPK8+A=4Q/6XSLK+QW:SLYMC%X=$R7LW9V)E+3,
M0E:5+5*8%:% A1WRX-35R79^<D[:5_8F*V?)FS99.+WV0M2$FA%DJL&%@P.6
ME7YI4;$5/04[I^0PL$U'3!$"W#,!*(2';+$QA8HJ4E*4A"TM,*5PBU]=^?2[
M8V5*Q&%F2<-ATH"DE(2@)0E)((!(2P<49ARL8UF"QJI<Z6N<M2BD.%*45&Q8
M DFCMQ<-%OLTLIIC4TOD,XI.+AY17=*,D048XTHPTVET1#.-S&FYJIK@<;ED
M?P(<25*XX.*8AHML7[*N'[4=A5[8V/+1A6EXR5LR;)WD_(I14% I*@4EG=J@
M,[EBXW>Q-OR,)CE'%I^))4M)4%?-N_,#OI!H5./J8',5#&ILF:*F=%91TM1<
MU+8FDDD0ET4&W%.L]:5O+LVXL K;2'&PVK^*G0Z8W'8_8,[9?8[^RY])R<)\
M,YNL[P!*A>K5>PU,?)MO:,G&]H\7BY;*E*Q1F2[53NAK@ <1=Q5B\'9*T;,J
M*HM,DFZ(<1IGD\CP(=7&WU$;,78AHDZ]LM.(*AS))MN!]_9+9,W [ FX1;C>
MQDR810EMX$'.V5S34Q\NV\<C&8Y$]#.F2B6&<&B;/>GXYWP:18(5?<I%M=-4
M[<@+::6WM:V.V2P 2!]*0#9M *<HT82Q)U/OW]X6XM%H&$(&$(&$(&$(&$()
MZUCYO&G<"W($G3EI<D$=]P1A" '&219P$\ORBN_^^[\(0:%).Q!]1!\/OTPA
M$<(0,(0,02P>$#%=X*I6O[ZPA-$ D6 -S8^[]QBK;I-:$-Q8YMP9O;09\P,Z
MEK%VA.XE2D<)! W'@;:V)!%['^C%DN@ )S<=&MSIYVO$+ 6'(?='?QJ,]?&L
M(%A02WPH<2I#FI0+$CA4.=[\CK:^G?C%-,U"1,2ROAG>4@76G0"UV-!7.$L2
MSNE5&+-J:U\#P#W+-!7F;B'5O.=I"VR2E04"%#4*'""H+U-B-CN+:8P[B5K7
M,F2Q+EF4"9;5"B6*BQN12G5KQD6$A86BSA^34 %6=GJ-7XV4J'H]Y75?,XR>
MSFEENS&8)"(]R!FM1R-N9(2M+W#,H:13*7P<R2M;"/.&HAM],8G@3$"R.$\?
MB?\ A_L/&K5/,D$3%JF%*G2')%6<-6G4FA<QN97:+:.'E"3*G*1*11(H:$6&
M\#EXDWM%VY/*(*10,%*93!LRZ703;<+!P#$(VVS#PL,D,P[;24$EEM#3:0A!
M4I8%RH\1..KV?L[9VS,,G"8?"I2D  TT# V-+FIK4F[G48B?B,1,5-5/4ZG*
MG^;>)+N]*4LP&C  "I@DI2KA%N.P!O>Y O?PL=".[<\L?>A* ^Z@)>NI(J+9
M<AK&$DAFR4,LNO3EWPBBF$K1VD<:@HN7";VL.&W@;)O:V^]\%E!W)A3O*E$&
M6<PLCY3R95N'*(6A0WBA7]6\6;_3HQRJS7(M2"6F VA2FFK.$=KLVTL-!IKH
M "/&YT &,"),IYT^:"%3!_$ODP8 VI:F0#5BRC,2A*D %2ZY.'X>0!>HTK1=
M=T5*:UI>:TK.!%LRV=,M-Q;DO=5"Q* U%,1*.J>2;E:G6$7&R6^(<\:W:.S)
M>,P@PX25X92@L2RP.^[DU+EW%"&I7AEPV(1AEB;67. HH F[U!:X<TNUA8Q5
M\'#-PL/"0S:'0TTRAA!<_*\2&FPVVI2K FZ0E6O(\\;"5NR9*$2Y/P5;@E!@
M[)0-T/F00'R.KY1.._,EJ4L30Y45"A&\Y8@ ,SL*5N7,*QV5<!;47+$EP(L;
M<1L+; $6'JVWQED2URPK?:8L5WS=3U N*!PF^5:1B44?%^449JBCW^[UNSWA
M.AH$AQ;"T$A159%SQ7-B;WU\;\QXXHI$W%**9HW?A_* *"@#$&CW-AEP>)2)
M<I(FD.I=2+N26M5J!W # ]3)$L%]V%4&5DH)4DA&EKFQ<[]#<ZW.Q)Q]*%A
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M+N- QT9-QZ0Y0[ ;; ( LK9(X0!N!]IO;PQ?$2P0@I#D;KW<FKEORQ-6O%Y
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M]8J_SEOL V'&2DW4+)-R "=-38Z:6L<(F)3$,:ZI*K$*3Q:\*+6T/?< ;7)
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M<OKRB9Q'-R^4593<UCGTN*:@)=/)9&QCJ64A3JD0T+%./J2TD<;A2V0E(N2
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MAO(CHX62I"3GE,"1QD\2O1Q6WY;8E;ITOQ%"=>8T/6]C_P#Q%GJIW%<AKH'
MZ6C0;?#R4VL6H6<W% 26;7B>.I$-$DCNOZ]+_P W*]KX]:Q#>!?NKZ>WCC<.
M24J+4U9ZU!I?0^MH*#O%< 7TVVY<CZ[7WUVYX^4;H!(-6/WHXJS?C0@K*U."
MP'"K\7!/H:ME!2K+0M/S201?>Q.EP1S'\PTQ0DFIK'T)N'%B]2]KUJ;?8/"-
M1ZNP)!(*=2-]1<FQ%M[WOH=;&UCCW3OC-R>.M&O8<NZ,UTT33(>^+\2W&,M/
MD,UV\I!E:H.$I71>9Z+$@@\-,/*.[?$5:$E86W?5/5:WQRW:DO@IJLF2!SWT
M\O+PC9[(!,Y #5)X599/W\1&^GP**4BW^I=X_DG'FB:)4#<FG_J)\HZX_4D<
M_+\0>A-[$BX*$@;;@:Z8B+0;8=P]PPA L.X>X80@6'</<,(0+#N'N&$(%AW#
MW#"$"P[A[AA"!8=P]PPA L.X>X80@6'</<,(0+#N'N&$(%AW#W#"$"P[A[AA
M"!8=P]PPA L.X>X80@6'</<,(0+#N'N&$(%AW#W#"$"P[A[AA""W GL:#YZ1
M["=??A"$_"$\:0+]H@W)[[ Z:[]VN$4/UIY>I?P]UC7(^$9I'H+R!2K0#-6>
M%0X0L=FF4'^.0>0\?#3'6]B0%;1FC((#W<!PQ(ZY'SC2[=_PXO8^]1Q[WI&H
MB#L"!>Y5V1PV/$L7(&BK@CGI[,>I+)^/, %-T5TM2M<LL[4MQJ?H5S+/S2^0
M%VU&0+""UK((M8#BM]][_O\ KQ69]!8.:<[]8ND %-*ES?)BU/?V)=/;[.QL
M38VL>^W?]N/E);Z;5T.=JY>!+U,9(2/#3BN=P #M?>X]@W^W%A1)J[INQZ!S
M<:#6+)%0>)S&AROUC+3Y#<ASRD63J-;FG<VB!Q=FPRPJOB*TV!4DB]DA2>U8
MDD)L>2[6UPDC-EH.G]*A^/&-QL0'X\_7YO%22+'3OL6>-\^&92GB1P)0D)3;
MA-S;< FP-M;V[5OY9QYHOZ@,]ZU+$\F=[-SI2.L1](]YP>ZP%J2H)!.@-R!8
M#;^*J_\ -OB\0DU4-#ZF&&:U'**?ET3-9_,I;)97"-)5%3.:1;,!+8=LN%"7
M'G(AQM#2%+-DN*4E))%C;7"+Q1PS>RV=EC=0HKJCW) )@Y*C.S/Y<96)BDH"
M8 1R8D0JHP]8V1#J<+X2H+*0-0A%Q(28-1:&UH<;4VO@4AQA86VM"[EIP*25
M!3+PMU2P>!RZ>%1N,(0O#K9( 5?BV(O8WY7VOX80@S"$#"$#"$#"$#"$#"$#
M"$#"$#"$"XO;G:_LP]^^^%H;HX.?.;M<) 4 5!9!XT73PZW:2ZIT)"5EPI">
MP.WBH4-XBM&?O8Y?<<LX)8/E[R<?G*-=7I5^7:F_1LZ1N<&0L%T;)363.5U3
MLTY\IG\WWZ??G:WJ?DD^<CS(TY;3GXN;)G'4AH32.2I3*EA\E10CJ]F=FIFT
MI(F"8$%2F"#4E.XE6\^\ 'WB&+&AH(TF+VI^GF;@+@)!46-]Y5J: &G)S%@A
M\)&J A)/1"DBN( @G/2(UY?QLGEG[=\; ]B)@+*G2W%*IWN502/&/E.W-033
M(L&',=_.)A\)(GP%CT0I,+7VSVB@/<,G0![!XXO_ -AL0!\N(E-<  #P*TUZ
M Q8;<%F4#Q2_CN^L$N?"39XFY'1"DQTO8YZ1A/O]#X[N[;OQ4]B)P-9TLG4
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MDN'IX6&0M7-XRU>0P<(\H[E2+$H-&YIK"[$IL*6B"JR@+<0U 1OK<"V.4[4
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M\JV,G=,0U9P$))HZ,53$7)6:@:G,1",=9 0:)=$0\7#Q*U1' >%]I?"H7%B
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ML;$GPOO;%/?VC(!1@ ['/4&_D 6\VRF^18C*HAO*"9;Q%&RF73NH6Z*S+,-
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M.6:X< T8Y9FNF25M-,U82EJTTL^KZZQF;15/2<3Q%.5.7BTA7"A?I!B IQ"
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MV.U_6.XFV*"<'66(.X;#@U*Y>#PF,3+:PMWM][?B-W+X/,HJZ!S]U$VS;S
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MD"V*GY4EJ-;W[ZPB"G4BU@238Z; :W)/<D D^&*!9</4: "!=J%O'PB01""
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MG>,0;MR.(J5Q:#M7!)YZ>JW(6[\=<M(4I2MY3DDEB"!PYDVKTSC1)FJ W0D
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MY>//7NQB]^[18(S);)SY-3J?M1O?<',V',^O[=??;EKBR0;B^7J?3F8$NV@
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M4PXDP,(FPTA8=PV %U*9:OQ<(3<#;7QUOM[/A%/A93V#B]?I]TS/..#Q1:8
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MUF<J1Z)LS3_]'U6K.O,R"/O]^,N##3Y8TF_:,6)_DKY'R(CE8L/_ -90I_\
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M3>]M18[D;;;'[-L(1-A"+2Y\)!R5S<L!?T89@7Y:?)*;DBXUV&)DD_J90_\
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M@I!OO<#GC2=I6_2FU0BG_4G@(V^ 2!,2R1F^;'=55_#\VZ1[:4V6>%)(N 2
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MSK']J+- \DY?5>HZ7T$@F!.,N"_GRO\ S!Z1AQ(>3,_VD/HX/XCDY-ODR^"
M(/'!M.<)Y?DT)&QW[_NQZ])($B4XHW,.0+/IG4^$<-B'$Q0+W5RH6I0:=S0U
MQ3MD*!4D%() YDD: ^'J\;^&3>2"  *D.!IK^''2,B10Y ^0OYWRBGW'KK7<
M"Q!/+6^IXAM< C7U>R)A?=ZMX0%7%&2PS)>E1GD*!J&&:(<)"K$<]U6-O#OV
M]GCC"== ??A$EG :S94>K!LG?K0.*F):><(JBFR56_A%3H000>T:@E@T[NRH
MI/@3WXU^TW_23!D7)&5C7WG'U8-1^* 31ZC-P&<_?[1V*6C8A-D6))-A<[:
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MG5#WHS_<WR-'CI.,$=HD@ @%-S_%UO\ ;C@E73H_VSC>PH!!V(/J(/W8O"+
M=(&/G4LRDK>(D65C><TP;E*FX++R-A)?-86H(EQ]/4-14%-8>+9CX.'<*8F/
M:5#Q[RULDP\,5!*@A&,&F\F:QDU)R*J_ZG6LLP7I@QF=!UW0U44W2LB<:S#K
MF70K,#65-41/7VI/+Z0@DM-TVS$P[C$U@I7"F.B8)X1"R(U]Y97\,WA&4W(.
MDZCHC*7+>E*KB8J.J6GZ3E$FG47%1+,;$*C89I*HA*XMEEAMU#2QYJVM$*GB
M0E+B'W+!S$PBZLU8F$6PIJ7S)<L>Z]/]<"&:C>)(-RA++H* +:&XL3OX(13W
MQ)5@U^6+I_X/R]'_ #@W<>)&$(MAGA*ZG9R7S>=?JYQ]E&5N816P9' )X[TC
M.  '0CC195E7203PV/9OB<.",5*(--\4I4W%JW;GSK&.>?X$P!P=TDD9MT+/
M9\KAHY4,&_\ V&EEE 'XNA>(J 25E*" 0@62@ )M8"P  %L>OJ+83#-D$^)\
M+YBX%"&CA)_S3B,P2U]>'73*MA#?$OD(XB4G=0 W]>FW+E[L9)JG*&_RVRO=
M^ZY'4Q?=(-232]+L7%;B_KK#!%Q 4@*L JQ&AO?U?T':U[:8D$ />@:C/]ZF
MK$_>"*[H-/J<Y4S]B]8IR*B5 %*5"W,FVYTMRY']QCYBKYAHXU!#$O3K6EB
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M/?ZF/N&ZYO:V]8M3AX!^,1$DJRX_AB[N-J>EP/OZL6]=QBT1$3):L-R:R<)
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M]V\OA^['FRR\Q=,].)?Q'C'5R_H3RBHL5B\%G^Z)'+A.G+W80@MX$JT&O H
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M^8NPRCF=J#>F"STJ:L<^_P <XU_XM_B42%!1L-"-1J>?,\]SKZL=("R0X!-
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M2$EH%/#Q7N-<(1X^7TQQ,,O,O*NHO*>J:FJ>NI#4-7.9?OSN34[,Z:IFEE1
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M YTSXALW>G,,\LNH0WE2.F^@./=4,V9. 'GHV*45#+.@;DH?>=7;AMVBJW(
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MD\-L2Y<*&IT)-M=?T^'A?POC=R02&L],\N]B*O\ +JYCZ)1.=+T+?85-RU_
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M5KQIV(?*G+@=YW/,'WZ:D^ONOC',)!9S2E1>G<P(\3Q>2U'SJ6KIJ278E[5
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M'7& 4 &D93<O$_RMIJU_E!(+=_QW+;>_SC"$2NU13"T@HJ*1*619*43>7J)
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MLX;QLV<;"4EF#6U=C0:YAQW7K&Q7\K::M?Y02"W?\=RT??$8^-- ![UC,IG
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M2EV8P@'QI LOQ,;*@7%D.1DO88B(AYKA4ZI*'$.) ;)$A154@@Y@^=*<VB0
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M"9,R(!U&HH3ETTJYRAN@Y<?;914U/5'(*PDT%4--3>53N23!"G)=-93&0\3
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M%H<=@'8ILO0[<6VESCAUO-7<:0M*.) XDBP.,F_,R!MGO5/3V("6EGWA3)_
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MK;$1%O1U?3-TB'3#]1 -P3+S;Q;(4A'I4\0:-AP*"0.(<.H%AH4@6[_F@#8
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M9@0<UG<<RW%V6Y+WY,'8]EJ,(2UQ0IBN7CYT\J0YQD=Z-^5%1Y6TU4,MJ1V
M7,9M5<SFS*)?,9E,X=J6K2B"ERGXF8MLN/35V!AF7IE$ML,]?%N.%PO.)4^Y
M,(])E%^$FUTGBL-N+F=K[_JPA$>$G17"1W!)'_6/W80B(OW &]A8GYMQX#6W
M+:X&O<A$<(1(L:7TL!J.$$GP!.WN^W"$>4>DYT;4=(RF)%3[M2S.DH^EYK.Z
M@INH91"MF922I(ZC*BIB45!+77'@(:8R&,J!R;0KB4?E'64-+LDE00CS6YT
M9O)H7XBHS,B E%-S&IW)_4,MB*:G#T?%,0];3:N(&&E4?!59+TRR(BIG.I@)
M_%EF(,>EQ*X)N7.I4MQK7\>^</;YGGEW-%.PWD[:L32<GI9W-*G(MN$332(R
M<32A)C%U#)V*7JH5#!MT).(JL(B.DKD:T5PTSB)X]4;L9%!F,XF^I#10BY?1
MVZ%E2Y'US(YN]6;=3R:4Q=63]^91D75+LVCYO/)= R*&AG(.?S^H89@NR]AR
M/FLQES\##/S)#8A9/#,60B*]-<^H9O=H1D32RM/%J2=;'B ![:N$</"0GA18
M73N>0L,3"#.!7^Y'>">(>/\ %%C[\(1,A'#Q=Q.FI-@-AK[?LPA$^$(&$(&$
M(&$(&$(&$(&$(&$(&$(&$(&$(&$(&$(&$(&$(&$()7\X^S[AA"!_L_L_^Z3A
M")#M_P#4)^\80A0G8>H?=A"(X0@80@80@80@IW9/]^G[CA")'-O]\O\ Z.$(
M#?SC_P#M!_\ ='"$*,(06OYS?]]^C"$!7]T;_P!__P!$80@S"$#"$#"$#"$#
M"$#"$#"$#"$#"$#"$#"$#"$#"$2_Q_\ >_IPA$V$(D'S%>MS_I*PA$R=AZA]
MV$(CA"!A"!A"!A"!A"!A")5;#^^1_P!-.$(B=O:G[QA""%;)]G_3.$(480@8
(0@80@80C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g549728g23p08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g23p08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %NB^6&0X0DE-! 0      %H< 5H  QLE1QP"   "   < E  "')R-C S
M-S(X' (% #E-:6-R;W-O9G0@5V]R9" M(#$P+4L@1')A9G0@=VET:"!*0B!E
M9&ET<R!-4R P.3 W,C,Q+F1O8W@X0DE-!"4      !#)UP7-OLM%:8MBYS];
M(!5-.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE- _(       H  /_______P  .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))300>       $
M     #A"24T$&@     #00    8              1@   'T    !@!G #(
M,P!P #  .     $                          0             !]
M 1@                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M 1@     4F=H=&QO;F<   'T    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M5E6LKK:^&M:UT-8WV_1:JK?K-]9?_+7*_P __P Q0_K QQ^L75G!I+1F72X
MD"'=W*DT)*=0?67ZR?\ EIE?YX_\BKN-U;ZR9+:]G7"VRUVT567ACF^YE3'.
M]A;^D<]S_P#BJO56
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         /_A0?-H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC,# R(#<Y+C$V
M-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM
M;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \
M9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C
M.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M
M(#$P+4L@1')A9G0@=VET:"!*0B!E9&ET<R!-4R P.3 W,C,Q+F1O8W@\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I
M=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(V,#,W,C@\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^
M"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(S+3 Y+3 X5# X.C U.C$X
M*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R
M5&]O;#Y04V-R:7!T-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,RTP.2TP.%0P.3HQ
M-#HS,RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T
M861A=&%$871E/C(P,C,M,#DM,#A4,#DZ,30Z,S,K,#4Z,S \+WAM<#I-971A
M9&%T841A=&4^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T
M:6QL97(@,C N," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @
M/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.F9F-F(Y
M93!B+3DQ-V,M9&8T,2TX.6$W+3-C8S0S,CAA9&1B,3PO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IB-S9B
M8C$U-"TX8V(Y+30Q-&,M.64X-2TR8C4X9F$T864S,C@\+WAM<$U-.DEN<W1A
M;F-E240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO<&1F('1O(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C(V,6(X-C1A
M+39D8C,M,F(T8RUB,S)D+3AB8F$P9C%D-6-B8CPO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP.2TP.%0P
M.3HQ,SHT,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C @*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW-S@T,CDP,RTS.6,R+3 X-# M
M.6)A92TS-#DQ,C(R,3$W-# \+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#DM,#A4,#DZ,3,Z-3$K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E
M<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#IC,V1C830S,"TT,S@S+65F-&0M8C=B,RTU,V1A9#0X-34Q860\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C,M,#DM,#A4,#DZ,3,Z-3$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z8C<V8F(Q-30M
M.&-B.2TT,31C+3EE.#4M,F(U.&9A-&%E,S(X/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 Y+3 X5# Y
M.C$T.C,S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.F$T,F4U-&0S+61B-#<M-&,Y."UB,SAC+3@V.#9B-&(R
M,S5A8SPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C<W.#0R.3 S+3,Y
M8S(M,#@T,"TY8F%E+3,T.3$R,C(Q,3<T,#PO<W12968Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HR-C%B.#8T
M82TV9&(S+3)B-&,M8C,R9"TX8F)A,&8Q9#5C8F(\+W-T4F5F.F1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I
M9#IA-#)E-31D,RUD8C0W+31C.3@M8C,X8RTX-C@V8C1B,C,U86,\+W-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S
M:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO
M<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- > # 1$
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MX3-"\105(U)B<H*R%R4T-4-SDB0V4V.BL\+2%B9%9/_:  P# 0 "$0,1 #\
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M!]=AR^[AQ;BBX;KKL64E!BN_[EP84(Q/4W7<*FD.U/Y)4%K<ASO"REI02I9
M!%UC=PQB2CNFCOYZX+]:N*\JAVFH+\?NNN1=]55,O55.[=]->ZF$T-94M_-U
M.%EAPN2Z\"%Y%.*(L[SPQB>Y&J-Z_,.WY<U-7!*;M?O6Z:^[VJ]89:=+5$[5
MT[+=6I'>A*$L*62WW:AZJDDD31W &.Z>OH;H=P?BJGO2\Z%%Z4EU/8?O9F\;
MPNXS_?M%0.4::JJI <JC4L-.,@&<^MB+F]Z\#.*V'N'(XJ8@P-B&[L$#%5Y8
M/<OFMNVLITLXCNB[J>^*Z[[Q9=IT5- TBB<8IVGGPVAZNJDTB27DA%B+A]=@
MG%EV7A0W+>6%,47;?-?24]1==TWC<=\TM\7Y2U$,M&CHWZ-NIO(NJ24)?I6G
M45*T+<;4HDV(OL7&;L]\1N M)PS>QTS1,5'%'!-+C?#](DU3=Y7;=57>M1=#
M=%>S-0PRJ[ZSOZ10<2XTZ6T*02H$P"+ZCC_L,=H3AKA56*<07=A.LNQC%/#K
M"-X*N'%]+>MXX4Q+Q/5=HPC08LH4M(J:-^]FKTI'*124O,EM84\THZ6(D_'#
ML<<>. &&E8MQY0X5>PU0XZK.%U]7IA+$E'B)BX^)%W7&F_:W"E^,4[#%327Q
M17$U3"HH$A++,H==2@*2;$0'!GLL\4./=T7Q?'#NIP6\[<=!?==^;MZXRNJY
ML6WVQ<%$N\;Y=N6XZA+U344M'1)6^XZ]D2MY(13.YX%B)C<'9"XX7]P2K./M
MUT&'GL"7;@^]N(JJ%[$-'3XMK<!X:Q!^;=]8HIL.J;74O7%27R%79453CJ(E
M54'$MC,"+@W$G@'Q.X0X5X8XNQW=]!=MT\8;A?Q)@1-/>"*^OJ;CI*>X*AZJ
MO1JF=<%TU(8ON[JAV[*U;U0P+SIJ5Q"7*8I21?/:6X+YKKJKKYH[HO>JNJZ
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M;1B1F^S?]7<SSSU:S?SI2IBM?NRB2"\J6+Q33(*!&[?+O)%U[[37:@X><9.
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MGBRTTP\IEUU,D0MR=A;M3XBXG8MX0W?PLO5SB#A&ANROQ#=-3?>&Z.DHJ:]
MHW4VU?5?>)N^J?O)I&:@;HZI^IJ,CB&$ M+38BZMXDPQ>>%\07UAV_Z15WWW
M<-X5%U7G2A]NJ%/742NXJFDU#3CK=0&WT.(SH5!B$B #8B0*:;*@77%%;>8M
M@C+(4,H ! C8SUT )BQ$(6S&V4:Q.Y,^_:-]A%B*!QL.*"EI!<01W9S$!) B
M5@$ G3;QW%B*)37>9D5"67T+&514R5(?(U2Y64YAI]#0(:;!(= ;2I(*0+$5
MR"E "E5!2 4]V%MO QHDI9>2FD2T! 2E:N_2F$B0+$25Q2E%;424N9D!*<H
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M,Y'(\3.03)\M]K4,)+D"1);&N%>2U ( >[ODC4)2@-ISM$ID&0[KI$D9=#M
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M=+$3EM ",I!'+W=)GQ]\6(I -DB>6I\3]EM()R+$3.;R6<<I@D&FZ:SU5 D
MC2#/+V6T6:8TK)2E1400HB()Y<YTME'7=YK6"AV^ 196 L(UE0)'2!UM171+
M9*)(W(@R-A8BE1E5ZL J&^@YG3Z[$15.DH4M1C+!T\1MIII.GP-B+/>3(&Y@
M_9R\M9L1$L)RA69/TAI(ZDGGY\O;%B*8)!.@ )L19Y#U'Q^ZQ%( $B +4!U
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M!"V4J49_I6<S)6>L,A6>+4!PZO6;NR175>@^</D'P;Y^200?AISVM[B#)IN
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M9Z$D=19[RT$]4@"=29D/@V+F>=574G\S3,]5M\IS3&E0O,,Y5 2<OKK@"1(
MS:[002KRT-ACC+?"3M-.(\."K'"(0&B?<V^I?PRHF$*,9E&!L 2".9&8E4ZS
MR ZS;: !YF<FSG^%)K/OOZ$(AM*2%2)A.FL$: DDZDZ]=HMH6;&1<<:G9?GB
MJVDA"1FV-3V9>+R)2/5"4F 0(DGG,[&=Q \#KK;*(ZQ=FDRI 9\=I[PGLO#%
M36< *5]&,N5*.4;A251ST'JQR$FU5JBT !$$3(&IB8&WT0D==@#KX18B(:B0
M8Z)Y>&NT_;XVLSPO@>K(BYVF=-H,>/0VJBD#.8H7J9U.B('CJ@GXSM$[ B,
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MNI1(2.'-7$'8_EIV9V&\_@6ZW]B _J*U#.UG%_,VV>ZLERC[:A_7D#T]X [
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M#209(MW+8?+ !(>[AGA(N+LZ<5Q'I,(_2%IZ\6<[I7^&%$4S>%>4E0J4E*@
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M-_?8B6NTS@)(;<,Z@$'377W:^ FQ$H6P[F40ROR@Z[R/9\=K$2UYA[DRO?\
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M#4<HK\+S, ;[CS&VUA+!\*J 'DO)X$J4I922M!5H9&G0P9/2-->0M*)A3N"
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MG[,Z49:&F!&IIVCIT+85/GZWPCE;@+TB0=-TABX]['Q<]+MJ[NT0#\BT9O\
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M1YP]NA)&C R)B#2H\(!\G>^3+HSV%@$:4Y 815?]87W2.[9-;JEA25%*E%1
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MTC0$Z%0G0 G:9,?5:]H1J1.6%"=\UG"XBA(D7!$Q>>^J^A<)E)_2CPQ02/\
MO\PLT0"#HB]&E$$ S(R*D@:0?"WY#URA;T!I$4,_T$4YX@";.9<&)FZ_5^J-
MI%^?]&J_O1,R:1>4S>X%%[5KNE5%3YA(%,RC*#)]5  !(G8  &?MMP)Z0^+3
M-)!?[6.1E>]!396[)=Y:$3^1:,6/V,%;WA KB=CXTE.M)"1I GW;[S]?QMX_
M=C#F?PW5R4QDQ1,820 'N:5TQ*9OOXP$@1J!Y_V_&TBR%6!N9[\ZC=54-K!
MVMD&(,O#=/8JWV(GF1!ZVGW?[ /#P(6D.D6!J0<F(#[@K92="9)VT @_CGRY
M$6:DP=02G(_4\J$J_O[ $:NK.5"1=4M+MY+."F.H@G;70\@3SZ<AMK:T7P0D
ML 2\JMOWL<29%8QDVEK#J L"78U??.ANGN717TBBO^Q?QH2=%5]RE)@ZD5;0
M/NZ:;Z6^C^RN**+U@L\HH:83/#A?BOQ7M+ABA]7;41/,%M\$;L!Q;%[W7G I
MW$*2E6:8IF5'78%#B4D\SJH#;F"?'N>S^2#.S\UQ-:DZT0$C[PCQZIE3U"6T
MY5 SW38RR-2E"1S@:S_$VI#][]X^"RC#:G[@/$E,6G4N)E.D0")F#R$[&UE1
M9^L5?M%(V !B?8(TUF3]MK:Q9AF^;JNK\1BY-W-2A(T.:#T,>S32U59&-@Y4
M@I)S;&#&^^FFNOV&UQ"6=G)I=+C?]7HHU@'G1'@I3"1.FD *4?@#_;:AD6S9
M1K0X\C=N60//4>\'[QY6*U5EG5U^ ^ZQ%*%H4(*/.5 :^9(,?"Q%GF5UWZ0?
MB+$5BE6H@[> ]Q.GQM40@#%ZJ8HGF>0,N\5,R4@N<Q"-9! CG() CV 6NQ/
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M16HH8J2J) 3HQF+BMB_HQ@VCC#Q$?+F4HP;1BH</=)IRX*]K*6X=<(400"
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M'6-[F3M-JJ#Z$](1  V%H(<=6$-L)B#N]Y#\6%><<:4H%I!"@EQ*D_.2HP0
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MC])'=MH05E+:$MPVB$)(3F!@0,07IEWW-T)) !N[[QDLSZ"CT9!!"N =\$[
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0N.[UE2J,JAHI)*5$$B__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g549728g28p24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g549728g28p24.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1Y44&AO=&]S:&]P(#,N,  X0DE-! 0
M    'CB^=S8X0DE-! 0      #L< 5H  QLE1QP"   "   < E  #U)A9&EK
M82!&97)N86YD;QP"-P (,C R,C X,3D< CP !C$R-3,T,@ X0DE-!"4
M !#T3^6<_N04M7-7]D;5Q#2%.$))300Z      #O    $     $       MP
M<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN
M=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R
M3F%M951%6%0    & $$ 4 !$ "T ,@      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!8            "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,
MS  !  ( E,S,  $  CA"24T$)@      #@             _@   .$))300-
M       $    'CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))301$
M   0     @   D    )      #A"24T$'@      !      X0DE-!!H
M T$    &               7    %0    8 9P R #@ <  R #0    !
M                      $              !4    7
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<    7     %)G:'1L;VYG
M    %0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    %P    !29VAT;&]N9P   !4    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
M J(    !    $    !$    P   #,    H8 &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( !$ $ ,!(@ "$0$#$0'_W0 $  '_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MV3A"24T$(0      5P    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R
M #  ,@ R     0 X0DE-!"(     $DY-30 J    "  / 0   P    $ %0
M 0$  P    $ %P   0(  P    ,   #" 08  P    $  @   1(  P    $
M 0   14  P    $  P   1H !0    $   #( 1L !0    $   #0 2@  P
M  $  @   3$  @   !\   #8 3(  @   !0   #W 3L  @   !    $+G)T
M 0   "    $;ZAP !P  " P   $[AVD !     $   E(   1\  (  @ "  .
MI@   "<0  ZF    )Q!!9&]B92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W<RD
M,C R,SHP.3HP." P-#HP,SHR-@!2861I:V$@1F5R;F%N9&\ 4@!A &0 :0!K
M &$ ( !& &4 <@!N &$ ;@!D &\    <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  7 !4# 1$
M A$! Q$!_\0 &    P$!                !@@)! K_Q  N$  ! P,# @,'
M!0         ! @,%! 81!Q(A #$(%"()%18C)3)!$T)18='_Q  9 0 " P$
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371702352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 16, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Benitec Biopharma Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-4620206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001808898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3940 Trust Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">780-0819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,547,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,756,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BAKER TILLY US, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Mountain View, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371408816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,477<span></span>
</td>
<td class="nump">$ 4,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other assets</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,729<span></span>
</td>
<td class="nump">4,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid and other assets</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,464<span></span>
</td>
<td class="nump">5,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Trade and other payables</a></td>
<td class="nump">3,231<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,978<span></span>
</td>
<td class="nump">2,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, less current portion</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,262<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value&#8212;160,000,000 shares authorized; 1,645,951 and 480,688 shares issued and outstanding at June 30, 2023 and 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">168,921<span></span>
</td>
<td class="nump">152,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(167,889)<span></span>
</td>
<td class="num">(148,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(830)<span></span>
</td>
<td class="num">(1,245)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 4,464<span></span>
</td>
<td class="nump">$ 5,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371587296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="nump">160,000,000<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">1,645,951<span></span>
</td>
<td class="nump">480,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="nump">1,645,951<span></span>
</td>
<td class="nump">480,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371395024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_RoyaltiesAndLicenseFees', window );">Royalties and license fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,774<span></span>
</td>
<td class="nump">11,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,382<span></span>
</td>
<td class="nump">6,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,156<span></span>
</td>
<td class="nump">17,927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,081)<span></span>
</td>
<td class="num">(17,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction loss</a></td>
<td class="num">(415)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other loss, net</a></td>
<td class="num">(481)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,562)<span></span>
</td>
<td class="num">(18,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized foreign currency translation gain</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (19,147)<span></span>
</td>
<td class="num">$ (17,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (14.12)<span></span>
</td>
<td class="num">$ (37.88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (14.12)<span></span>
</td>
<td class="num">$ (37.88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_BasicAndDilutedEarningsPerShareAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">1,385,818<span></span>
</td>
<td class="nump">480,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">1,385,818<span></span>
</td>
<td class="nump">480,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_BasicAndDilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_BasicAndDilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RoyaltiesAndLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties and license fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RoyaltiesAndLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038365225520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2021</a></td>
<td class="nump">$ 20,010<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 151,584<span></span>
</td>
<td class="num">$ (130,119)<span></span>
</td>
<td class="num">$ (1,455)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Jun. 30, 2022</a></td>
<td class="nump">2,882<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">152,454<span></span>
</td>
<td class="num">(148,327)<span></span>
</td>
<td class="num">(1,245)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts', window );">Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $1,869</a></td>
<td class="nump">16,015<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants', window );">Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $1,869, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WarrantsExercisedDuringThePeriod', window );">Exercise of&#160;pre-funded&#160;warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation gain</a></td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Jun. 30, 2023</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 168,921<span></span>
</td>
<td class="num">$ (167,889)<span></span>
</td>
<td class="num">$ (830)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,645,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance and exercise of pre-funded and common warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance and exercise of pre-funded and common warrants, net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WarrantsExercisedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WarrantsExercisedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374094944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments For Stock Issuance Costs</a></td>
<td class="nump">$ 1,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038364695328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,562)<span></span>
</td>
<td class="num">$ (18,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AmortizationOfRightOfUseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_UnrealizedGainLossOnInvestment', window );">Unrealized loss on investment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(414)<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncreasedecreaseInAccountsAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued employee benefit payable</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncreaseDecreaseInLeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,012)<span></span>
</td>
<td class="num">(15,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issues of shares and pre-funded warrants</a></td>
<td class="nump">17,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issue transaction costs</a></td>
<td class="num">(1,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">16,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(1,586)<span></span>
</td>
<td class="num">(15,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of year</a></td>
<td class="nump">4,076<span></span>
</td>
<td class="nump">19,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">4,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,477<span></span>
</td>
<td class="nump">4,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">4,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Re-measurement of operating lease right-of-use assets and liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreasedecreaseInAccountsAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreasedecreaseInAccountsAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_UnrealizedGainLossOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized (gain) loss on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_UnrealizedGainLossOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038365220848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business</a></td>
<td class="text"> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Business </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (the &#8220;Company&#8221;) is a corporation incorporated in the state of Delaware on November 22, 2019 and listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BNTC&#8221;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#8220;BBL&#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April&#160;15, 2020. On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#8217;s business focuses on the development of novel genetic medicines. Our proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;27, 2019, BBL announced its intention to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domicile</div> from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of effecting the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> (&#8220;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-</div> domiciliation&#8221;), acquired all BBL shares and BBL became a wholly owned subsidiary of Benitec Biopharma Inc. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms used herein refer (i), prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> to BBL, an Australian corporation, and its subsidiaries, and (ii), following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL). On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June&#160;30, 2021, the Company completed an organization restructure as part of the commercial desire to provide a more efficient structure for the future as the Company continues to transition its operations to the US. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s fiscal year end is June 30. References to a particular &#8220;fiscal year&#8221; and the &#8220;year ended June 30&#8221; are to our fiscal year end June&#160;30 of that calendar year. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and the following wholly owned subsidiaries: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal&#160;place&#160;of<br/>business/country&#160;of<br/>incorporation</div></div></div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Australia</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Australia Proprietary Limited</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Australia</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Limited</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">United Kingdom</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec LLC</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">RNAi Therapeutics, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tacere Therapeutics, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec IP Holdings, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374086304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div>  <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">consummation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation.</div> As a result, the financial statements included in this report reflect (i)&#160;the historical operating results of BBL and subsidiaries prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> (ii)&#160;the combined results of the Company, BBL, and subsidiaries following the completion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> and (iii)&#160;the Company&#8217;s equity structure for all periods presented. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;26, 2023, the Company effected a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-17</div></div> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its common stock. In accordance with the Reverse Stock Split, 17 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-split</div> shares of the Company&#8217;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#8217;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. All share and earnings per share amounts presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">10-K</div> reflect the impact of this reverse split<div style="null;text-indent: 0px;;display:inline;">&#160;as if it had taken effect on June 30, 2021.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and any similar events, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the Company&#8217;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#8217;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#8217;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exchange rate on balance sheet dates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">USD: AUD Exchange Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Average exchange rate for the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">USD: AUD Exchange Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, the carrying amounts approximate fair value due to their short maturities. ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;1:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;2:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;3:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions, which reflect those that a market participant would use. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023 and 2022, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash balances of $13&#160;thousand and $14&#160;thousand as of June&#160;30, 2023 and June&#160;30, 2022, respectively, secure the Company&#8217;s credit cards. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Trade and Other Receivables </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">3 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">4 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Computer hardware</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">3 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">shorter of the lease term or estimated useful lives</td> </tr> </table>   <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and other payables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and Diluted Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted- average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of June&#160;30, 2023 and 2022, there were 2,456,032 and 49,716 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue by applying the following steps: </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Services revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-</div> clinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-based Compensation Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based employee compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the related requisite service period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is governed by Australia and United States income tax laws. The Company follows ASC 740, Accounting for Income Taxes, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div>  <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>  <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive income (loss). </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">No</div>.&#160;2016-13:</div> Financial Instruments&#8212;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> Financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Instruments-Credit</div> Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> effective July 1, 2023. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038471018368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_LiquidityDisclosureTextBlock', window );">Liquidity</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Liquidity </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in conformity with US&#160;GAAP, which contemplate continuation of the Company as a going concern. For the fiscal years ended June 30, 2023 and 2022, the Company had a net loss of $19.6&#160;million and $18.2&#160;million, respectively, and net cash used in operations of $18.0&#160;million and $15.9&#160;million, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, the Company had $2.5&#160;million in cash and cash equivalents. The Company has incurred operating losses and negative cash flows from operations since inception, except for the year ended June 30, 2019. On August&#160;11, 2023 we closed an underwritten public offering. Net proceeds from the offering, including the impact of the underwriter&#8217;s partial exercise of its option and net of underwriting discounts, commissions, and other offering expenses, totaled $28.6&#160;million. We estimate that our cash and cash equivalents will be sufficient to fund the Company&#8217;s operations for at least the next twelve months after the date that this Annual Report is filed. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038375223184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Revenue </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues from customers (US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/> ended<br/> June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/> ended<br/> June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized licensing revenue over time as the performance obligations were satisfied. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038375290736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents, and restricted cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Cash, cash equivalents, and restricted cash </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at bank</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Restricted cash</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,490</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038375316576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and other assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Prepaid and other assets</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Prepaid and other assets </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038471767408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Property and equipment, net </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,318</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $136,000 and $167,000 for the years ended June 30, 2023 and 2022, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038368326384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and other payables</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Trade and other payables </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued OPMD project costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued consultant fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374219872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July 1, 2019, the Company adopted ASC 842, Leases (&#8220;ASC 842&#8221;). ASC 842 requires lessees to recognize at the lease commencement date a lease liability, which is the lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis, and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into an operating lease for office space under an agreement that expires in 2025. The lease requires the Company to pay utilities, insurance, taxes, and other operating expenses. The Company&#8217;s lease does not contain any residual value guarantees or material restrictive covenants. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below show the changes during the years ended June 30, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> right-of-<br/> use assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Initial measurement at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(245</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Initial measurement at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, the Company&#8217;s operating lease has a remaining lease term of 1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="null;text-indent: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">586</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the fiscal years ended June 30, 2023 and 2022, total lease expense under operating leases was approximately $277,000 and $260,000, respectively, and was recorded in general and administrative expenses. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038375320096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Stockholders&#8217; equity </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 6, 2019, the Investors were issued 4 Purchase Warrants that were exercisable into 12,600 fully paid shares of common stock should the Purchase Warrants be exercised in full (&#8220;Purchase Warrants&#8221;). The exercise price for the Purchase Warrants is US$178.50 per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (December 6, 2024). On April 22, 2020, the Company issued 2,201 shares of common stock in connection with a cashless exercise of Purchase Warrants exercisable for 6,300 shares of common stock. The Company did not have an effective registration statement registering the resale of the Warrant Shares by the Holder at the time the Holder wanted to exercise the warrant; therefore, the Holder carried out a cashless exercise. The formula for conducting a cashless exercise was outlined in the Warrant agreement. Based on this formula, the Holder would have been entitled to receive 6,300 shares of common stock if they had exercised the Purchase Warrants for cash. Because of the cashless exercise, the holder received 2,201 shares. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 15, 2022, we closed an underwritten public offering in which we issued and sold (i) 1,037,521 shares of the Company&#8217;s common stock, (ii) 715,978 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, with each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant immediately exercisable for one share of common stock at an exercise price of $0.0017 per share until exercised in full and (iii) 29,809,471 outstanding&#160;Series 2 warrants (the &#8220;Series 2 Warrants&#8221;) which are currently exercisable into 1,753,503&#160;shares of common stock after giving effect to the Reverse Stock Split at an exercise price of $11.22 per share. The Series 2 warrants sold in the offering became exercisable commencing December 9, 2022, the date on which the Company had both (a)&#160;received approval from its stockholders to increase the number of shares of common stock it is authorized to issue and (b)&#160;effected such stockholder approval by filing with the Secretary of State of the State of Delaware a certificate of amendment to its Amended and Restated Certificate of Incorporation, and will expire on the fifth anniversary of such initial exercise date. The combined purchase price for each share of common stock and accompanying common warrant was $10.20, which was allocated as $10.03 per share of common stock and $0.17 per common warrant. The Series 2 Warrants contain an exercise price adjustment mechanism providing that certain issuances of common stock (or common stock equivalents), if made at a price lower than the then existing exercise price of such Series 2 Warrants, would reset the exercise price to such lower price. As a result of the August&#160;11, 2023 public offering, the exercise price of the Series 2 Warrants has been automatically reset as of the closing time of such public offering to $1.9299. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October 17, 2022 and October 27, 2022, investors exercised 117,939 and 9,804 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, respectively, at an exercise price of $0.0017 per share. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, there were 2,348,039 warrants outstanding. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The activity related to warrants during for the fiscal years ended June 30, 2023 and 2022, is summarized as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common<br/> Stock from<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price&#160;(per<br/> share)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pre-funded warrants issued September 15, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">715,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series 2 warrants issued September 16, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,753,503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pre-funded warrants exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,348,039</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,348,039</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;">Effective as of the closing of the August 2023 underwritten public offering conducted by the Company, the exercise price of the Series </div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">2 warrants issued</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"> September 16, 2022 was automatically adjusted to $1.9299 as required by the terms of such warrants. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-style:italic;display:inline;"><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">Equity Incentive Plan</div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Employee Share Option Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> the Company assumed BBL&#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-</div> domiciliation pursuant to the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (the &#8220;Plan&#8221;). This includes the Company&#8217;s assumptions of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances . Employee options vest one third <div style="letter-spacing: 0px; top: 0px;;display:inline;">on</div> each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the organization, and certain other conditions have been satisfied, generally the employee has 12 months to exercise their options, or the options are cancelled. After the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation,</div> no new options have been or will be issued under the Plan. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Equity and Incentive Compensation Plan </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On December 9, 2020, the Company&#8217;s stockholders approved the Company&#8217;s 2020 Equity and Incentive Compensation Plan (the &#8220;2020 Plan&#8221;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#8217;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on each anniversary of the applicable grant date over three years. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-employee</div> director options vest in increments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> on the day prior to each of the Company&#8217;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan), the option holder generally has 12 months to exercise their vested options, or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan), the option holder generally has 90 days to exercise their vested options, or the options are cancelled. The maximum contractual term of options granted under the 2020 Plan is ten years. Upon the consummation of a Change in Control (as defined in the 2020 Plan), all unvested stock options will immediately vest as of immediately prior to the Change in Control. </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December 8, 2021, the Company&#8217;s stockholders approved an amendment to the 2020 Plan, which increased the number of shares of the Company&#8217;s common stock reserved under the 2020 Plan to 1,850,000. For the fiscal year ended June 30, 2023, our named executive officers (&#8220;NEO&#8217;s&#8221;) were each granted equity incentive awards under the 2020 Plan. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;">Equity Awards</div></div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activity related equity awards, which are comprised of stock options, during the fiscal years ended June&#160;30, 2023 and 2022, respectively, is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.07&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.45 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.18 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.94 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,291</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">848.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.96 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88.79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.22 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Equity-based Compensation Expense </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of stock options granted during the years ended June 30, 2023 and June 30, 2022 was $3.34 and $44.20, respectively. </div>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.96</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.36</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected Volatility. Due to the lack of Company-specific historical or implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies in the life sciences industry. The Company selected the peer group based on comparable characteristics, including development stage, product pipeline and enterprise value. The Company computed historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the equity-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own share price becomes available. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected Term. The expected term represents the period that the equity awards are expected to be outstanding. For stock options with service conditions, it is based on the &#8220;simplified method&#8221; for developing the estimate of the expected life. Under this approach, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free</div> Interest Rate. The Company bases the risk-free interest rate assumption on U.S. Treasury constant maturities with maturities similar to those of the expected term of the equity award being valued. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Expected Dividend Yield. The Company bases the expected dividend yield assumption on the fact that it has never paid dividends and does not expect to pay dividends in the foreseeable future. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">In addition to assumptions used in the Black-Scholes option-pricing model, the Company estimates a forfeiture rate to calculate the equity-based compensation expense for equity awards. The forfeiture rate is based on an analysis of actual and estimated forfeitures. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based</div> Compensation Expense </div></div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The classification of share-based compensation expense for the years ended: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">As of June 30, 2023 and 2022, there was $350,000 and $522,000, <div style="letter-spacing: 0px; top: 0px;;display:inline;">respectively, of unrecognized share-based compensation expense related to stock options granted under the Plan and 2020 Plan. Unrecognized expense as of June 30, 2023 is expected to be recognized over a weighted average period of 2.11 years.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Employee option awards-related stock-based compensation expense for the years ended June&#160;30, 2021 and 2022, and the nine months ended March&#160;31, 2023 was understated by a total of<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$34&#160;thousand. The Company determined that this understatement is immaterial to the previously issued consolidated financial statements for the years ended June&#160;30, 2021 and 2022, and the nine months ended March&#160;31, 2023, and corrected it as of June&#160;30, 2023. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374249328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">11. Income taxes </div></div>  <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Loss before provision for income taxes consisted of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18,953</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,369</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">International</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(609</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(839</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,562</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax effects of significant items comprising the Company&#8217;s deferred taxes are as follows: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Section&#160;174 Capitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,923</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,965</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(111</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(162</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(244</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(356</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. As of June 30, 2023 and 2022, the Company established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The valuation allowance increased $3.958 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million&#160;</div>during the year ended June 30, 2023. Net operating losses and tax credit carryforwards as of June 30, 2023 are as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration<br/> Years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses, federal (post-December 31, 2017)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Do&#160;not&#160;expire</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net operating losses, state</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031-2042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses, Australia</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,640</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Do not expire</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effective rate of the Company&#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.01</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.22</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.19</td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.36</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.92</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign tax rate differential</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the U.S., various state jurisdictions and Australia. The Company&#8217;s tax returns for the tax years 2014, 2016, and 2019 through 2022 are open and are subject to examination by federal taxing authorities and the Company&#8217;s tax returns for tax years 2011 through 2022 are subject to examination by state taxing authorities. The Company is not currently undergoing a tax audit in any federal, state, or Australian jurisdiction. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The entire amount of the Company&#8217;s unrecognized tax benefits would not impact its effective tax rate if recognized. The Company has elected to include interest and penalties as a component of tax expense. During the year ended June&#160;30, 2023, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&#160;382 places a limitation (&#8220;Section&#160;382 Limitation&#8221;) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section&#160;382 Limitation. Due to these &#8220;change in ownership&#8221; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Australian income tax legislation, losses can be utilized by the Company if it satisfies firstly the Continuity of Ownership Test (&#8220;COT&#8221;) or if failing that, the Similar Business Test (&#8220;SBT&#8221;). Broadly, the COT requires a company to show that it maintained continuity of majority beneficial ownership from the beginning of the year in which a loss is incurred to the end of an income year in which a tax loss is sought to be recouped. The SBT requires a company to demonstrate that a &#8220;similar business&#8221; has been maintained from the time when the COT is failed and throughout the period until the end of the income year that the losses are being recouped. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act was enacted and signed into law and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities, and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses in the CARES Act include a five-year net operating loss carryback for certain net operating losses, suspension of the annual deduction limitation of 80% of taxable income for certain net operating losses, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CARES Act also provides other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-tax</div> benefits to assist those impacted by the pandemic. The Company evaluated the impact of the CARES Act and determined that there is no material impact to the income tax provision for the fiscal year ended June 30, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of net operating losses and limits the use of research tax credits for 2020, 2021 and 2022, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February 9, 2022, Governor Gavin Newsom signed CA SB 113 (SB 113) into law. The legislation shortens the suspension period for deducting net operating losses (NOL) The suspension of deductions of California NOLs applied to California taxpayers with net business income of $1&#160;million or more for tax years beginning on or after January 1, 2020, and before January 1, 2023. SB 113 decreases that suspension period by one year, making the suspension applicable for tax years beginning on or after January 1, 2020, and before January 1, 2022. The Company evaluated the impact of SB 113 and determined that the legislation did not materially impact the Company&#8217;s income tax provision for the fiscal year ended June 30, 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371632448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Commitments and contingencies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract commitments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contingencies </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no contingent liabilities as of June 30, 2023 and 2022, respectively. See Note 9 above for lease commitments. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038369663328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Related party transactions </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended June 30, 2023, the Company did not enter into any related party transactions. During the year ended June&#160;30, 2022, the Company had entered into related party transactions with Francis Abourizk Lightowlers for legal fees totaling $1&#160;thousand. Peter Francis, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> director of the Company is a partner at Francis Abourizk Lightowlers. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374086848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per share</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Loss per share </div></div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders (US$&#8217;000)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,562</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares used in calculating basic and diluted earnings per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,385,818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">480,688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14.12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37.88</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Outstanding warrants and options amounting to 2,456,032 and 49,716 to acquire common stock are considered anti-dilutive for the fiscal years ended June 30, 2023 and June 30, 2022, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038370286944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15. Subsequent events</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On July&#160;26, 2023, the Company effected a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-17</div></div> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its common stock. In accordance with the Reverse Stock Split, 17 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-split</div> shares of the Company&#8217;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#8217;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">All share and earnings per share amounts presented in this Form 10-K reflect the impact of the Reverse Stock Split.&#160;</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">On August&#160;11, 2023 we closed an underwritten public offering in which we sold 875,949 shares of common stock, 15,126,226 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase 15,126,226 shares of common stock, and 16,002,175 common warrants to purchase up to 16,002,175 shares of common stock. The combined purchase price for each share of common stock and accompanying common warrant was $1.93, which was allocated as $1.9299 per share of common stock and $0.0001 per common warrant. Each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant was sold together with one common warrant at a combined price of $1.9299, which was allocated as $1.9298 per <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant and $0.0001 per common warrant. In addition, the Company granted the underwriter an option to purchase up to 2,331,606 additional shares of common stock and/or up to 2,331,606 additional common warrants. As of August&#160;15, 2023 the underwriter had partially exercised this option and purchased 458,134 additional shares of common stock and 458,134 additional common warrants. Net proceeds from the offering, including the impact of the underwriter&#8217;s partial exercise of its option and net of underwriting discounts, commissions, and other offering expenses, totaled $28.6&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The Company has 29,809,471 outstanding&#160;Series 2 warrants (the &#8220;Series 2 Warrants&#8221;) which are currently exercisable into 1,753,503&#160;shares of common stock after giving effect to the Reverse Stock Split. The Series 2 Warrants contain an exercise price adjustment mechanism providing that certain issuances of common stock (or common stock equivalents) if made at a price lower than the existing exercise price of $11.22 of such Series 2 Warrants, would reset the exercise price to such lower price. As a result of the August&#160;11, 2023 public offering, the exercise price of the Series 2 Warrants has been automatically reset as of the closing time of such public offering to $1.9299.<br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September 13, 2023, the Compensation Committee (the &#8220;Compensation Committee&#8221;) of the Company&#8217;s Board of Directors approved increases of the base salaries of Dr. Jerel Banks, the Company&#8217;s Executive Chairman and Chief Executive Officer, and Megan Boston, the Company&#8217;s Executive Director, to $655,200 and $350,784 (Ms.&#160;Boston&#8217;s salary as noted has been converted from AUD $1.00 to USD $0.64, which was the conversion rate as of September 13, 2023) respectively, each adjustment being effective as of October 1, 2023. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371469680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>    <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">consummation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation.</div> As a result, the financial statements included in this report reflect (i)&#160;the historical operating results of BBL and subsidiaries prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> (ii)&#160;the combined results of the Company, BBL, and subsidiaries following the completion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-domiciliation;</div> and (iii)&#160;the Company&#8217;s equity structure for all periods presented. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;26, 2023, the Company effected a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-for-17</div></div> reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its common stock. In accordance with the Reverse Stock Split, 17 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-split</div> shares of the Company&#8217;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#8217;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. All share and earnings per share amounts presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">10-K</div> reflect the impact of this reverse split<div style="null;text-indent: 0px;;display:inline;">&#160;as if it had taken effect on June 30, 2021.</div> </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_RisksAndUncertainitiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#8217;s products and processes and clinical efficacy and safety of the Company&#8217;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and any similar events, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the Company&#8217;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#8217;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#8217;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s functional currency and reporting currency is the United States dollar. BBL&#8217;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive loss.&#8221; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exchange rate on balance sheet dates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">USD: AUD Exchange Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Average exchange rate for the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">USD: AUD Exchange Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, the carrying amounts approximate fair value due to their short maturities. ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;1:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;2:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div></td></tr></table> <div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left;">Level&#160;3:</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions, which reflect those that a market participant would use. </div></td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023 and 2022, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash balances of $13&#160;thousand and $14&#160;thousand as of June&#160;30, 2023 and June&#160;30, 2022, respectively, secure the Company&#8217;s credit cards. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Risk </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Trade and Other Receivables</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Trade and Other Receivables </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>   <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">3 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">4 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Computer hardware</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">3 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">shorter of the lease term or estimated useful lives</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_TradeAndOtherPayablesPolicyTextBlock', window );">Trade and other payables</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade and other payables </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and Diluted Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted- average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>    <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of June&#160;30, 2023 and 2022, there were 2,456,032 and 49,716 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue by applying the following steps: </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing revenues </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of products occur. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>   <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Services revenue </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-</div> clinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation Expense</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity-based Compensation Expense </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based employee compensation awarded to employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> to be recorded as an expense over the related requisite service period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is governed by Australia and United States income tax laws. The Company follows ASC 740, Accounting for Income Taxes, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive income (loss). </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">No</div>.&#160;2016-13:</div> Financial Instruments&#8212;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November 15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> Financial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Instruments-Credit</div> Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> effective July 1, 2023. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RisksAndUncertainitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RisksAndUncertainitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_TradeAndOtherPayablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_TradeAndOtherPayablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374110576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlTableTextBlock', window );">Summary of entities in control</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and the following wholly owned subsidiaries: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal&#160;place&#160;of<br/>business/country&#160;of<br/>incorporation</div></div></div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Australia</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Australia Proprietary Limited</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Australia</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec Limited</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">United Kingdom</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec LLC</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">RNAi Therapeutics, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tacere Therapeutics, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Benitec IP Holdings, Inc.</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">USA</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of entities in control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374094944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock', window );">Summary of foreign currency translation and other comprehensive income (loss)</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&#160;30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exchange rate on balance sheet dates</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">USD: AUD Exchange Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6639</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Average exchange rate for the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">USD: AUD Exchange Rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.6730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.7254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Software</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">3 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">4 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Computer hardware</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">3 years</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">shorter of the lease term or estimated useful lives</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of foreign currency translation rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038370286944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of revenue from customers</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenues from customers (US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/> ended<br/> June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year<br/> ended<br/> June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Licensing revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371723664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents, and restricted cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash at bank</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,062</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Restricted cash</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,490</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038367425408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and other assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Summary of other current assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">(US$&#8217;000)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">871</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Market value of listed shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(97</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(135</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038367418048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment net</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:75%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,318</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,182</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374260192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of trade and other payables</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trade payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued license fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued OPMD project costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued consultant fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other payables</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374119456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Summary of supplemental balance sheet information related to leases</a></td>
<td class="text"> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below show the changes during the years ended June 30, 2023 and 2022: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> right-of-<br/> use assets</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Initial measurement at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(225</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(245</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/> lease<br/> liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Initial measurement at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal payments on operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(252</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of the operating lease liabilities</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June 30, 2023, the Company&#8217;s operating lease has a remaining lease term of 1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="null;text-indent: 0px;;display:inline;">$</div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">586</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(27</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">559</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371406160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants or rights</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The activity related to warrants during for the fiscal years ended June 30, 2023 and 2022, is summarized as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common<br/> Stock from<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price&#160;(per<br/> share)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pre-funded warrants issued September 15, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">715,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series 2 warrants issued September 16, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,753,503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pre-funded warrants exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,348,039</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &quot;Times New Roman&quot;; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,348,039</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of equity awards</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The activity related equity awards, which are comprised of stock options, during the fiscal years ended June&#160;30, 2023 and 2022, respectively, is summarized as follows: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at July 1, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">41,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.07&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">50.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.45 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.18 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.94 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,291</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">848.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">107,993</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.96 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at June 30, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">88.79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.22 years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6&#160;years</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.96</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.36</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of equity-based compensation expense</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">The classification of share-based compensation expense for the years ended: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:82%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">870</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371631472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of income (loss) before provision for income taxes</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;">Loss before provision for income taxes consisted of the following: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18,953</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,369</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">International</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(609</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(839</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19,562</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(18,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of company's deferred taxes</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax effects of significant items comprising the Company&#8217;s deferred taxes are as follows: <br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangible assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Section&#160;174 Capitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,070</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,923</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,965</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(111</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(162</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(43</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(244</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(356</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock', window );">Summary of net operating losses and tax credit carryforwards</a></td>
<td class="text">Net operating losses and tax credit carryforwards as of June 30, 2023 are as follows: <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration<br/> Years</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses, federal (post-December 31, 2017)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Do&#160;not&#160;expire</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Net operating losses, state</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2031-2042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating losses, Australia</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,640</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Do not expire</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary reconciliation of effective rate of the company's provision (benefit) for income taxes</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effective rate of the Company&#8217;s provision (benefit) for income taxes differs from the federal statutory rate as follows: </div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Permanent differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.01</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.22</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.19</td>
<td style="white-space:nowrap;vertical-align:bottom">%<div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.36</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.92</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(20.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign tax rate differential</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure details of operating loss carry forwards and tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374264912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Loss per share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders (US$&#8217;000)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,562</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="display:inline;">)</div>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average number of shares used in calculating basic and diluted earnings per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,385,818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">480,688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14.12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">($</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37.88</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038365289104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Summary of entities in control (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember', window );">Benitec Biopharma Proprietary Limited ("BBL") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember', window );">Benitec Australia Proprietary Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember', window );">Benitec Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember', window );">Benitec, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember', window );">Benitec LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember', window );">RNAi Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember', window );">Tacere Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIpHoldingsIncMember', window );">Benitec IP Holdings, Inc.[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIpHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIpHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038374313120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation Date Of Incorporation</a></td>
<td class="text">Nov. 22,  2019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371487280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">shorter of the lease term or estimated useful lives<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of Property, Plant and Equipment, Estimated Useful Lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038471777888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,456,032<span></span>
</td>
<td class="nump">49,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">On July&#160;26, 2023, the Company effected a 1-for-17 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its common stock. In accordance with the Reverse Stock Split, 17 pre-split shares of the Company&#8217;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, pre-funded warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#8217;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038373708064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Exchange rate on balance sheet dates, USD: AUD Exchange Rate</a></td>
<td class="nump">0.6639<span></span>
</td>
<td class="nump">0.6891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AverageForeignExchangeRateForThePeriod', window );">Average exchange rate for the period, USD: AUD Exchange Rate</a></td>
<td class="nump">0.673<span></span>
</td>
<td class="nump">0.7254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AverageForeignExchangeRateForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average foreign exchange rate for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AverageForeignExchangeRateForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038367387616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,562)<span></span>
</td>
<td class="num">$ (18,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in provided by operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,012)<span></span>
</td>
<td class="num">(15,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,477<span></span>
</td>
<td class="nump">$ 4,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from public offering</a></td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371687872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of revenue from customers (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038506107184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromBanks', window );">Cash at bank</a></td>
<td class="nump">$ 2,477<span></span>
</td>
<td class="nump">$ 4,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total</a></td>
<td class="nump">$ 2,490<span></span>
</td>
<td class="nump">$ 4,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A bank's noninterest bearing demand deposits in other banks (such as correspondents).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371579728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid and other assets - Summary of other current assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 1,280<span></span>
</td>
<td class="nump">$ 871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_MarketValueOfListedShares', window );">Market value of listed shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Total other assets</a></td>
<td class="nump">1,281<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Less:&#160;non-current&#160;portion</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Current portion</a></td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_MarketValueOfListedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market value of listed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_MarketValueOfListedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371764128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Summary  of property and equipment net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="nump">$ 1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(1,182)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371699040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038471814032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other payables- Summary of trade and other payables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payable</a></td>
<td class="nump">$ 1,140<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AccruedLicenceFeesCurrent', window );">Accrued license fees</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AccruedOpmdProjectCostsCurrent', window );">Accrued OPMD project costs</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AccruedConsultantFeesCurrent', window );">Accrued consultant fees</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other payables</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,231<span></span>
</td>
<td class="nump">$ 1,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedConsultantFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued offering costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedConsultantFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedLicenceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued licence fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedLicenceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedOpmdProjectCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Opmd Project Costs Current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedOpmdProjectCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038364192768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of supplemental balance sheet information related to leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Initial measurement at July 1, 2021</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">$ 771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod', window );">Re-measurement during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use asset</a></td>
<td class="num">(245)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset at June 30, 2023</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Initial measurement at July 1, 2021</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod', window );">Re-measurement during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Principal payments on operating lease liabilities</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities at June 30, 2023</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less: non-current portion</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion at June 30, 2023</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Initial measurement at July 1, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Initial measurement at July 1, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset remasurement during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of lease liabilities during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038367566640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease has a remaining lease term</a></td>
<td class="text">1 year 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 277,000<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038364228800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of maturities of the operating lease liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371392832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of warrants or rights (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period | shares</a></td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsExercised', window );">Pre-funded warrants exercised | shares</a></td>
<td class="nump">127,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, ending of period | shares</a></td>
<td class="nump">2,348,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsExcercisable', window );">Exercisable at June 30, 2023 | shares</a></td>
<td class="nump">2,348,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding | $ / shares</a></td>
<td class="nump">$ 178.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised', window );">Pre-funded warrants exercised | $ / shares</a></td>
<td class="nump">0.0017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding | $ / shares</a></td>
<td class="nump">8.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable', window );">Exercisable at June 30, 2023 | $ / shares</a></td>
<td class="nump">$ 8.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_SeriesTwoWarrantsMember', window );">Series 2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Series 2 Warrants issued September 16, 2022 | shares</a></td>
<td class="nump">1,753,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod', window );">Series 2 Warrants issued September 16, 2022 | $ / shares</a></td>
<td class="nump">$ 11.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Pre-funded warrants issued | shares</a></td>
<td class="nump">715,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued', window );">Pre-funded warrants issued | $ / shares</a></td>
<td class="nump">$ 0.0017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantOrRightsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsExcercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights excercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsExcercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrants or rights excercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of pre funded warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_SeriesTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_SeriesTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371762608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of equity awards (Detail) - Employee stock option [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options,Outstanding, beginning of period</a></td>
<td class="nump">41,298<span></span>
</td>
<td class="nump">43,416<span></span>
</td>
<td class="nump">41,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,868<span></span>
</td>
<td class="nump">2,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Stock Options, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,993<span></span>
</td>
<td class="nump">43,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise price, beginning of period</a></td>
<td class="nump">$ 121.72<span></span>
</td>
<td class="nump">$ 118.15<span></span>
</td>
<td class="nump">$ 121.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.88<span></span>
</td>
<td class="nump">50.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">848.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercise price, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.88<span></span>
</td>
<td class="nump">$ 118.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercisable, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Term, Outstanding</a></td>
<td class="text">8 years 25 days<span></span>
</td>
<td class="text">8 years 11 months 15 days<span></span>
</td>
<td class="text">7 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm', window );">Weighted-average Remaining Contractual Term, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 11 months 8 days<span></span>
</td>
<td class="text">9 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Term, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at June 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options granted during period weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038364684096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Summary of equity-based compensation expense (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">115.60%<span></span>
</td>
<td class="nump">122.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">3.96%<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038369043216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Summary of share-based compensation expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038362282944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 11, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 27, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 17, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 09, 2020</div></th>
<th class="th">
<div>Apr. 22, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 08, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 06, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognised share based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="nump">$ 522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,039<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Employee option awards related stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="nump">$ 44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 1.9299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bntc_TwoThousandAndTwentyEquityIncentivePlanMember', window );">Two Thousand And Twenty Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bntc_TwoThousandAndTwentyEquityIncentivePlanMember', window );">Two Thousand And Twenty Equity Incentive Plan [Member] | Employee stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation by share based award unrecognized expense remaining period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation by share based award contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_CashlessExerciseOfPurchaseWarrants', window );">Cashless exercise of purchase warrants (In shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="nump">2,331,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember', window );">Purchase warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_NumberOfSeriesWarrantsIssued', window );">Number of series of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_Series2WarrantsMember', window );">Series 2 Warrants [Member] | Subsequent Event [Member] | Revision In The Exercise Price Of Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod', window );">Class of warrants or rights weighted average exercise price of class of warrants or rights issued during the period | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod', window );">Class Of Warrants Or Rights Excercised During The Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,804<span></span>
</td>
<td class="nump">117,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="nump">15,126,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 1.9298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 1.9299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssueOfCommonStockAndWarrantPricePerShare', window );">Issue of common stock and warrant price per share</a></td>
<td class="nump">1.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit', window );">Class of warrants or rights issue price per unit | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="nump">875,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="nump">16,002,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Class of warrant or rights issued during period</a></td>
<td class="nump">16,002,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Series 2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,809,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,809,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Series 2 Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="nump">$ 1.9299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Class of warrant or rights issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Pre-funded warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="nump">15,126,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Class of warrant or rights issued during period</a></td>
<td class="nump">15,126,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CashlessExerciseOfPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CashlessExerciseOfPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantOrRightsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights excercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights issue price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsIssuePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssueOfCommonStockAndWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of common stock and warrant price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssueOfCommonStockAndWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_NumberOfSeriesWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of series warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_NumberOfSeriesWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of class of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bntc_TwoThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bntc_TwoThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_Series2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_Series2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_EventAxis=bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_EventAxis=bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371637232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary of income (loss) before provision for income taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (18,953)<span></span>
</td>
<td class="num">$ (17,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="num">(609)<span></span>
</td>
<td class="num">(839)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,562)<span></span>
</td>
<td class="num">$ (18,208)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038364583504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Summary of company's deferred taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 18,388<span></span>
</td>
<td class="nump">$ 17,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Section&#160;174 Capitalization</a></td>
<td class="nump">3,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">22,293<span></span>
</td>
<td class="nump">18,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(21,923)<span></span>
</td>
<td class="num">(17,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(111)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(370)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371531280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 46,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, expiration years</a></td>
<td class="text">Do not expire<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodAxis=bntc_NolFromTwoThousandEighteenMember', window );">NOL From Two Thousand Eighteen [Member] | Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 30,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, expiration years</a></td>
<td class="text">Do&#160;not&#160;expire<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodAxis=bntc_NOLpreJanuaryOneTwoThousandEighteenMember', window );">NOL pre January One Two Thousand Eighteen [Member] | State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 4,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodAxis=bntc_NOLpreJanuaryOneTwoThousandEighteenMember', window );">NOL pre January One Two Thousand Eighteen [Member] | State and Local Jurisdiction [Member] | Year Two Thousand And Thirty Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_YearOfExpiryOfOperatingLossesCarryForwards', window );">Year of expiry of operating losses carry forwards</a></td>
<td class="text">2042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodAxis=bntc_NOLpreJanuaryOneTwoThousandEighteenMember', window );">NOL pre January One Two Thousand Eighteen [Member] | State and Local Jurisdiction [Member] | Year Two Thousand And Thirty One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems', window );"><strong>Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_YearOfExpiryOfOperatingLossesCarryForwards', window );">Year of expiry of operating losses carry forwards</a></td>
<td class="text">2031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure details of operating loss carry forwards and tax credits [Line Items].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_YearOfExpiryOfOperatingLossesCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year of expiry of operating losses carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_YearOfExpiryOfOperatingLossesCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PeriodAxis=bntc_NolFromTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PeriodAxis=bntc_NolFromTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PeriodAxis=bntc_NOLpreJanuaryOneTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PeriodAxis=bntc_NOLpreJanuaryOneTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bntc_YearTwoThousandAndThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371670960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(0.01%)<span></span>
</td>
<td class="num">(0.22%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based payments</a></td>
<td class="num">(0.19%)<span></span>
</td>
<td class="num">(0.36%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.92%)<span></span>
</td>
<td class="num">(20.55%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="nump">0.12%<span></span>
</td>
<td class="nump">0.13%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation percentage permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038362260864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets increase in valuation allowance during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,958,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, accrued interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_UnexpectedEventAxis=bntc_CoronavirusAidReliefAndEconomicSecurityActMember', window );">Coronavirus Aid Relief And Economic Security Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack', window );">Number of years of certain operating losses that can be carried back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_UnexpectedEventAxis=bntc_CaliforniaAssemblyBillEightyFiveMember', window );">California Assembly Bill Eighty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_EventAxis=bntc_SuspensionOfAnnualDeductionLimitationMember', window );">Suspension Of Annual Deduction Limitation [Member] | Coronavirus Aid Relief And Economic Security Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction', window );">Percentage of annual Taxable income eligible for deduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards', window );">Percentage of total owneship control to be maintained by the current shareholders for availing operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards', window );">Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member', window );">Beginning on or After January 1, 2020, and Before January 1, 2023 [Member] | California Franchise Tax Board [Member] | Applicability of Suspension of Deductions of California NOLs [Member] | SB 113 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_MinimumNetBusinessIncome', window );">Minimum net business income</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Year 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Year 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Year 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Year 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Tax Year 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Tax Year 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax year subject to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_MinimumNetBusinessIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum net business income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_MinimumNetBusinessIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of years of certain operating losses that can be carried back.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual taxable income eligible for deduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total ownership control to be maintained by the current shareholders for availing operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_UnexpectedEventAxis=bntc_CoronavirusAidReliefAndEconomicSecurityActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_UnexpectedEventAxis=bntc_CoronavirusAidReliefAndEconomicSecurityActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_UnexpectedEventAxis=bntc_CaliforniaAssemblyBillEightyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_UnexpectedEventAxis=bntc_CaliforniaAssemblyBillEightyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_EventAxis=bntc_SuspensionOfAnnualDeductionLimitationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_EventAxis=bntc_SuspensionOfAnnualDeductionLimitationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_EventAxis=bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_EventAxis=bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_LegislationAxis=bntc_SB113Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_LegislationAxis=bntc_SB113Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038373749648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingent liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038373752432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Additional information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember', window );">Francis Abourizk Lightowlers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_FrancisAbourizkLightowlersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038364187872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share - Summary of Loss per share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="nump">$ 19,562<span></span>
</td>
<td class="nump">$ 18,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in calculating basic earnings per share</a></td>
<td class="nump">1,385,818<span></span>
</td>
<td class="nump">480,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in calculating diluted earnings per share</a></td>
<td class="nump">1,385,818<span></span>
</td>
<td class="nump">480,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="nump">$ 14.12<span></span>
</td>
<td class="nump">$ 37.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="nump">$ 14.12<span></span>
</td>
<td class="nump">$ 37.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038371673744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">2,456,032<span></span>
</td>
<td class="nump">49,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">2,456,032<span></span>
</td>
<td class="nump">2,456,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">49,716<span></span>
</td>
<td class="nump">49,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140038361621280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Aug. 11, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 26, 2023</div></th>
<th class="th">
<div>Sep. 15, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>$ / per_unit</div>
</th>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>$ / per_unit</div>
</th>
<th class="th">
<div>Sep. 13, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 22, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants or rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,039<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 1.9299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from public offering | $</a></td>
<td class="nump">$ 28,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ForeignCurrencyExchangeRateConversion', window );">Conversion Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On July&#160;26, 2023, the Company effected a 1-for-17 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of its common stock. In accordance with the Reverse Stock Split, 17 pre-split shares of the Company&#8217;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, pre-funded warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#8217;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Dr. Jerel Banks [Member] | Executive Chairman and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AnnualBaseSalaryCompensation', window );">Annual base salary compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 655,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Megan Boston [Member] | Executive Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_AnnualBaseSalaryCompensation', window );">Annual base salary compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="nump">2,331,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="nump">2,331,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 1.9298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="nump">15,126,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 1.9299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit', window );">Class of warrants or rights issue price per unit | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_IssueOfCommonStockAndWarrantPricePerShare', window );">Issue of common stock and warrant price per share</a></td>
<td class="nump">1.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,037,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Class of warrant or rights issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Series 2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants or rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,809,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,809,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="nump">16,002,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Class of warrant or rights issued during period</a></td>
<td class="nump">16,002,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in the transaction</a></td>
<td class="nump">875,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Subsequent Event [Member] | Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants convertible into shares of common stock on exercise</a></td>
<td class="nump">15,126,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod', window );">Class of warrant or rights issued during period</a></td>
<td class="nump">15,126,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Subsequent Event [Member] | Series 2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights | $ / shares</a></td>
<td class="nump">$ 1.9299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AnnualBaseSalaryCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual base salary compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AnnualBaseSalaryCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantOrRightsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantOrRightsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsIssuePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights issue price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsIssuePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ForeignCurrencyExchangeRateConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency exchange rate conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ForeignCurrencyExchangeRateConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssueOfCommonStockAndWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of common stock and warrant price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssueOfCommonStockAndWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_Dr.JerelBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_Dr.JerelBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_MeganBostonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bntc_MeganBostonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntc_ExecutiveDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntc_ExecutiveDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=bntc_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=bntc_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bntc_Series2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bntc_Series2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>d549728d10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bntc="http://www.benitecbiopharmainc.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bntc-20230630.xsd" xlink:type="simple"/>
    <context id="PAsOn06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn08_16_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2023-08-16</instant>
        </period>
    </context>
    <context id="PAsOn09_15_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P07_01_2020To06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P07_02_2022To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NOLpreJanuaryOneTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NolFromTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:Series2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_BenitecIpHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIpHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_LicenseMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NolFromTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyOneMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bntc:YearTwoThousandAndThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NOLpreJanuaryOneTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyFourMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bntc:YearTwoThousandAndThirtyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:PeriodAxis">bntc:NOLpreJanuaryOneTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2022MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2016MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2019MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2014MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2011MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2022MemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:SeriesTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis">bntc:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis_SuspensionOfAnnualDeductionLimitationMemberBNTCEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntc:EventAxis">bntc:SuspensionOfAnnualDeductionLimitationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis">bntc:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_CaliforniaAssemblyBillEightyFiveMemberBNTCUnexpectedEventAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntc:UnexpectedEventAxis">bntc:CaliforniaAssemblyBillEightyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:FrancisAbourizkLightowlersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bntc:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-06</instant>
        </period>
    </context>
    <context id="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:Series2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="P10_17_2022To10_17_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="P10_27_2022To10_27_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-27</startDate>
            <endDate>2022-10-27</endDate>
        </period>
    </context>
    <context id="PAsOn10_27_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-27</instant>
        </period>
    </context>
    <context id="P07_26_2023To07_26_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-26</startDate>
            <endDate>2023-07-26</endDate>
        </period>
    </context>
    <context id="P08_11_2023To08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="P08_11_2023To08_11_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:Series2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2023_CommonWarrantsMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bntc:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_15_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-15</instant>
        </period>
    </context>
    <context id="PAsOn08_15_2023_CommonWarrantsMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bntc:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-15</instant>
        </period>
    </context>
    <context id="P02_09_2022To02_09_2022_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMemberBNTCEventAxis_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023MemberusgaapTaxPeriodAxis_CaliforniaFranchiseTaxBoardMemberusgaapIncomeTaxAuthorityNameAxis_SB113MemberBNTCLegislationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bntc:BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:EventAxis">bntc:ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:LegislationAxis">bntc:SB113Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="P07_01_2021To07_01_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_31_2023_RevisionInTheExercisePriceOfPrefundedWarrantsMemberBNTCEventAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bntc:Series2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntc:EventAxis">bntc:RevisionInTheExercisePriceOfPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_08_2021_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bntc:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-08</instant>
        </period>
    </context>
    <context id="P12_09_2020To12_09_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bntc:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-09</startDate>
            <endDate>2020-12-09</endDate>
        </period>
    </context>
    <context id="PAsOn09_13_2023_Dr.JerelBanksMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ExecutiveChairmanAndChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntc:ExecutiveChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:Dr.JerelBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-13</instant>
        </period>
    </context>
    <context id="PAsOn09_13_2023_ExecutiveDirectorMembersrtTitleOfIndividualAxis_MeganBostonMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntc:ExecutiveDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bntc:MeganBostonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-13</instant>
        </period>
    </context>
    <context id="PAsOn10_01_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001808898</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_USD_per_unit">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>bntc:per_unit</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_AUD_per_unit">
        <divide>
            <unitNumerator>
                <measure>iso4217:AUD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>bntc:per_unit</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P07_01_2022To06_30_2023">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber contextRef="P07_01_2022To06_30_2023" id="hidden88517285">84-4620206</dei:EntityTaxIdentificationNumber>
    <dei:DocumentFiscalPeriodFocus contextRef="P07_01_2022To06_30_2023">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P07_01_2022To06_30_2023">0001808898</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P07_01_2022To06_30_2023">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="P07_01_2022To06_30_2023">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P07_01_2022To06_30_2023">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P07_01_2022To06_30_2023">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P07_01_2022To06_30_2023">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P07_01_2022To06_30_2023">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P07_01_2022To06_30_2023">001-39267</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P07_01_2022To06_30_2023">Benitec Biopharma Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="P07_01_2022To06_30_2023">3940 Trust Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P07_01_2022To06_30_2023">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P07_01_2022To06_30_2023">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P07_01_2022To06_30_2023">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P07_01_2022To06_30_2023">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P07_01_2022To06_30_2023">780-0819</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P07_01_2022To06_30_2023">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P07_01_2022To06_30_2023">BNTC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P07_01_2022To06_30_2023">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P07_01_2022To06_30_2023">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P07_01_2022To06_30_2023">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P07_01_2022To06_30_2023">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P07_01_2022To06_30_2023">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P07_01_2022To06_30_2023">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P07_01_2022To06_30_2023">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P07_01_2022To06_30_2023">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P07_01_2022To06_30_2023">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="P07_01_2022To06_30_2023">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="P07_01_2022To06_30_2023">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_USD">4756798</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn08_16_2023"
      decimals="INF"
      unitRef="Unit_shares">2547434</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="P07_01_2022To06_30_2023">23</dei:AuditorFirmId>
    <dei:AuditorName contextRef="P07_01_2022To06_30_2023">BAKER TILLY US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P07_01_2022To06_30_2023">Mountain View, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2477000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">55000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1184000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">741000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3729000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4820000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">87000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositAssets
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:DepositAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">97000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">526000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">771000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">4464000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5973000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3231000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1880000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">472000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">275000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">252000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3978000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2532000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">284000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">559000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">4262000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3091000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn06_30_2023"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn06_30_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn06_30_2023"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">160000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">160000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">1645951</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">1645951</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">480688</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">480688</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">168921000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">152454000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-167889000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-148327000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-830000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1245000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">202000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2882000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">4464000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5973000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">73000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <bntc:RoyaltiesAndLicenseFees
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</bntc:RoyaltiesAndLicenseFees>
    <bntc:RoyaltiesAndLicenseFees
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">9000</bntc:RoyaltiesAndLicenseFees>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">12774000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">11272000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">6382000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6646000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">19156000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">17927000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-19081000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-17854000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-415000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-232000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-33000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-32000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-30000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-79000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-3000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-11000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-481000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-354000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-19562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18208000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">415000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">210000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">415000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">210000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-19147000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-17998000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-19562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18208000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To06_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-14.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To06_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-14.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-37.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-37.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">1385818</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">1385818</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">480688</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">480688</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">480688</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">151584000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-130119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">20010000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2021To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">870000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">870000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">210000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">210000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-18208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18208000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">480688</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">152454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-148327000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2882000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1869000</us-gaap:PaymentsOfStockIssuanceCosts>
    <bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrants
      contextRef="P07_01_2022To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1037520</bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrants>
    <bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
      contextRef="P07_01_2022To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts>
    <bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
      contextRef="P07_01_2022To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">16015000</bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts>
    <bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">16015000</bntc:IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts>
    <bntc:WarrantsExercisedDuringThePeriod
      contextRef="P07_01_2022To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">127743</bntc:WarrantsExercisedDuringThePeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2022To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">415000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">415000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-19562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-19562000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1645951</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">168921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-167889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-830000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">202000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-19562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18208000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">136000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">167000</us-gaap:DepreciationDepletionAndAmortization>
    <bntc:AmortizationOfRightOfUseAssets
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">245000</bntc:AmortizationOfRightOfUseAssets>
    <bntc:AmortizationOfRightOfUseAssets
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">225000</bntc:AmortizationOfRightOfUseAssets>
    <bntc:UnrealizedGainLossOnInvestment
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-3000</bntc:UnrealizedGainLossOnInvestment>
    <bntc:UnrealizedGainLossOnInvestment
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-10000</bntc:UnrealizedGainLossOnInvestment>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">452000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">870000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">414000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-62000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <bntc:IncreasedecreaseInAccountsAndOtherPayables
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1357000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
    <bntc:IncreasedecreaseInAccountsAndOtherPayables
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1090000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">73000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">80000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <bntc:IncreaseDecreaseInLeaseLiabilities
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-252000</bntc:IncreaseDecreaseInLeaseLiabilities>
    <bntc:IncreaseDecreaseInLeaseLiabilities
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-196000</bntc:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-18012000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-15899000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-13000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">17884000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1869000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">16015000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">412000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">204000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-1586000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-15708000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19784000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2477000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">794000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Business &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Benitec Biopharma Inc. (the &#x201c;Company&#x201d;) is a corporation incorporated in the state of Delaware on November 22, 2019 and listed on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) under the symbol &#x201c;BNTC&#x201d;. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#x201c;BBL&#x201d;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April&#160;15, 2020. On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#x2019;s business focuses on the development of novel genetic medicines. Our proprietary platform, called &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DNA-directed&lt;/div&gt; RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;27, 2019, BBL announced its intention to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domicile&lt;/div&gt; from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of effecting the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; (&#x201c;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-&lt;/div&gt; domiciliation&#x201d;), acquired all BBL shares and BBL became a wholly owned subsidiary of Benitec Biopharma Inc. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The terms the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; and similar terms used herein refer (i), prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; to BBL, an Australian corporation, and its subsidiaries, and (ii), following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation,&lt;/div&gt; to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL). On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the year ended June&#160;30, 2021, the Company completed an organization restructure as part of the commercial desire to provide a more efficient structure for the future as the Company continues to transition its operations to the US. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s fiscal year end is June 30. References to a particular &#x201c;fiscal year&#x201d; and the &#x201c;year ended June 30&#x201d; are to our fiscal year end June&#160;30 of that calendar year. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and the following wholly owned subsidiaries: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principal&#160;place&#160;of&lt;br/&gt;business/country&#160;of&lt;br/&gt;incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Biopharma Proprietary Limited (&#x201c;BBL&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Australia&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Australia&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;United Kingdom&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec LLC&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec IP Holdings, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P07_01_2022To06_30_2023">2019-11-22</dei:EntityIncorporationDateOfIncorporation>
    <bntc:ScheduleOfEntitiesInControlTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and the following wholly owned subsidiaries: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principal&#160;place&#160;of&lt;br/&gt;business/country&#160;of&lt;br/&gt;incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Biopharma Proprietary Limited (&#x201c;BBL&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Australia&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Australia&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;United Kingdom&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec LLC&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Benitec IP Holdings, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;USA&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </bntc:ScheduleOfEntitiesInControlTableTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityIncorporationStateCountryCode contextRef="P07_01_2022To06_30_2023_BenitecIpHoldingsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;consummation of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation.&lt;/div&gt; As a result, the financial statements included in this report reflect (i)&#160;the historical operating results of BBL and subsidiaries prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation;&lt;/div&gt; (ii)&#160;the combined results of the Company, BBL, and subsidiaries following the completion of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation;&lt;/div&gt; and (iii)&#160;the Company&#x2019;s equity structure for all periods presented. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;26, 2023, the Company effected a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-17&lt;/div&gt;&lt;/div&gt; reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of its common stock. In accordance with the Reverse Stock Split, 17 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-split&lt;/div&gt; shares of the Company&#x2019;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#x2019;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. All share and earnings per share amounts presented in this Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;10-K&lt;/div&gt; reflect the impact of this reverse split&lt;div style="null;text-indent: 0px;;display:inline;"&gt;&#160;as if it had taken effect on June 30, 2021.&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the Company&#x2019;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#x2019;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected. &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#x2019;s products and processes and clinical efficacy and safety of the Company&#x2019;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Moreover, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and any similar events, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the Company&#x2019;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#x2019;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#x2019;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s functional currency and reporting currency is the United States dollar. BBL&#x2019;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#x2019; equity as &#x201c;Accumulated other comprehensive loss.&#x201d; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June&#160;30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exchange rate on balance sheet dates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6639&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Average exchange rate for the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6730&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.7254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company measures its financial assets and liabilities in accordance with ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, the carrying amounts approximate fair value due to their short maturities. ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions, which reflect those that a market participant would use. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June&#160;30, 2023 and 2022, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash balances of $13&#160;thousand and $14&#160;thousand as of June&#160;30, 2023 and June&#160;30, 2022, respectively, secure the Company&#x2019;s credit cards. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentrations of Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade and Other Receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&#x2019;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:47%"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;4 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Computer hardware&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;   &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and Diluted Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted- average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of June&#160;30, 2023 and 2022, there were 2,456,032 and 49,716 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue by applying the following steps: &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 3: Determine the transaction price. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing revenues &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#x2019;s subsequent sales of products occur. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Services revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Research and development expenses relate primarily to the cost of conducting clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-&lt;/div&gt; clinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based employee compensation awarded to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; to be recorded as an expense over the related requisite service period. The Company values employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation at fair value using the Black-Scholes Option Pricing Model. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is governed by Australia and United States income tax laws. The Company follows ASC 740, Accounting for Income Taxes, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. &lt;/div&gt;  &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive income (loss). &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;No&lt;/div&gt;.&#160;2016-13:&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#x2019;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#x201c;SRC&#x201d;) as of November 15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; Financial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Instruments-Credit&lt;/div&gt; Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; effective July 1, 2023. &lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;15, 2020, the Company implemented the transaction to redomicile from Australia to the United States and became the parent company of BBL and the wholly owned subsidiaries listed in Note 1. The historical financial statements of BBL became the historical financial statements of the combined company upon &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;    &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;consummation of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation.&lt;/div&gt; As a result, the financial statements included in this report reflect (i)&#160;the historical operating results of BBL and subsidiaries prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation;&lt;/div&gt; (ii)&#160;the combined results of the Company, BBL, and subsidiaries following the completion of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation;&lt;/div&gt; and (iii)&#160;the Company&#x2019;s equity structure for all periods presented. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;26, 2023, the Company effected a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-17&lt;/div&gt;&lt;/div&gt; reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of its common stock. In accordance with the Reverse Stock Split, 17 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-split&lt;/div&gt; shares of the Company&#x2019;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#x2019;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. All share and earnings per share amounts presented in this Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;10-K&lt;/div&gt; reflect the impact of this reverse split&lt;div style="null;text-indent: 0px;;display:inline;"&gt;&#160;as if it had taken effect on June 30, 2021.&lt;/div&gt; &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities. &lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="P07_26_2023To07_26_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">On July&#160;26, 2023, the Company effected a 1-for-17 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of its common stock. In accordance with the Reverse Stock Split, 17 pre-split shares of the Company&#x2019;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, pre-funded warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#x2019;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include the Company&#x2019;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt; </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt; </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The preparation of financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#x2019;s consolidated financial statements include the estimates of useful lives of property and equipment, valuation of the operating lease liability and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, valuation of equity-based instruments issued for other than cash, the valuation allowance on deferred tax assets, and accrued research and development expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#x2019;s future results of operations will be affected. &lt;/div&gt; </us-gaap:UseOfEstimates>
    <bntc:RisksAndUncertainitiesPolicyTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, reliance on single-source vendors and collaborators, availability of raw materials, patentability of the Company&#x2019;s products and processes and clinical efficacy and safety of the Company&#x2019;s products under development, compliance with government regulations and the need to obtain additional financing to fund operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Moreover, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and any similar events, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time which may delay the Company&#x2019;s clinical trials, and negatively impact manufacturing and testing activities performed by third parties. Any significant delays may impact the use and sufficiency of the Company&#x2019;s existing cash reserves, and the Company may be required to raise additional capital earlier than it had previously planned. The Company may be unable to raise additional capital if and when needed, which may result in delays or suspension of its development plans. The extent to which the pandemic will impact the Company&#x2019;s business will depend on future developments that are highly uncertain and cannot be predicted at this time. &lt;/div&gt;</bntc:RisksAndUncertainitiesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s functional currency and reporting currency is the United States dollar. BBL&#x2019;s functional currency is the Australian dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#x2019; equity as &#x201c;Accumulated other comprehensive loss.&#x201d; Gains and losses resulting from foreign currency translation are included in the consolidated statements of operations and comprehensive loss as other comprehensive income (loss). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June&#160;30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exchange rate on balance sheet dates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6639&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Average exchange rate for the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6730&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.7254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June&#160;30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exchange rate on balance sheet dates&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6639&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Average exchange rate for the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;USD: AUD Exchange Rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.6730&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.7254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="PAsOn06_30_2023"
      decimals="4"
      unitRef="Unit_pure">0.6639</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="PAsOn06_30_2022"
      decimals="4"
      unitRef="Unit_pure">0.6891</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <bntc:AverageForeignExchangeRateForThePeriod
      contextRef="P07_01_2022To06_30_2023"
      decimals="4"
      unitRef="Unit_pure">0.673</bntc:AverageForeignExchangeRateForThePeriod>
    <bntc:AverageForeignExchangeRateForThePeriod
      contextRef="P07_01_2021To06_30_2022"
      decimals="4"
      unitRef="Unit_pure">0.7254</bntc:AverageForeignExchangeRateForThePeriod>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company measures its financial assets and liabilities in accordance with ASC 820, Fair Value Measurements. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, the carrying amounts approximate fair value due to their short maturities. ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%;vertical-align:top;text-align:left;"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions, which reflect those that a market participant would use. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June&#160;30, 2023 and 2022, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <bntc:FinancialAssetsAtFairValue
      contextRef="PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="INF"
      unitRef="Unit_USD">0</bntc:FinancialAssetsAtFairValue>
    <bntc:FinancialAssetsAtFairValue
      contextRef="PAsOn06_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="INF"
      unitRef="Unit_USD">0</bntc:FinancialAssetsAtFairValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn06_30_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Restricted cash balances of $13&#160;thousand and $14&#160;thousand as of June&#160;30, 2023 and June&#160;30, 2022, respectively, secure the Company&#x2019;s credit cards. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentrations of Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade and Other Receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&#x2019;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. &lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;   &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:47%"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;4 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Computer hardware&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td style="width:47%"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Software&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;4 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Computer hardware&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;3 years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn06_30_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn06_30_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="PAsOn06_30_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <bntc:DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P07_01_2022To06_30_2023_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">shorter of the lease term or estimated useful lives</bntc:DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#x2019;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt; </us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <bntc:TradeAndOtherPayablesPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. &lt;/div&gt; </bntc:TradeAndOtherPayablesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. &lt;/div&gt; </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and Diluted Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted- average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;    &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of June&#160;30, 2023 and 2022, there were 2,456,032 and 49,716 potential common shares, respectively, that were excluded from the calculation of diluted net loss per share because their effect was anti-dilutive. &lt;/div&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2022To06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">2456032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2021To06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">49716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue by applying the following steps: &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 3: Determine the transaction price. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licensing revenues &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue from licensees of the Company&#x2019;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#x2019;s subsequent sales of products occur. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;   &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Services revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. &lt;/div&gt; </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Research and development expenses relate primarily to the cost of conducting clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-&lt;/div&gt; clinical and clinical development costs are a significant component of research and development expenses. The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in trade and other payables on the consolidated balance sheets and within research and development expenses on the consolidated statements of operations and comprehensive loss. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance at the end of each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. &lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company records share-based compensation in accordance with ASC 718, Stock Compensation. ASC 718 requires the fair value of all share-based employee compensation awarded to employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employees&lt;/div&gt; to be recorded as an expense over the related requisite service period. The Company values employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation at fair value using the Black-Scholes Option Pricing Model. &lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is governed by Australia and United States income tax laws. The Company follows ASC 740, Accounting for Income Taxes, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For uncertain tax positions that meet a &#x201c;more likely than not&#x201d; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#x2019;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. &lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive income (loss). &lt;/div&gt; </us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;No&lt;/div&gt;.&#160;2016-13:&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#x2019;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred. The Company has determined that it has met the criteria of a smaller reporting company (&#x201c;SRC&#x201d;) as of November 15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; Financial &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Instruments-Credit&lt;/div&gt; Losses, Derivatives and Hedging, and Leases: Effective Dates amended the effective date for the Company to be for reporting periods beginning after December 15, 2022. The Company will adopt this ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; effective July 1, 2023. &lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <bntc:LiquidityDisclosureTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Liquidity &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements have been prepared in conformity with US&#160;GAAP, which contemplate continuation of the Company as a going concern. For the fiscal years ended June 30, 2023 and 2022, the Company had a net loss of $19.6&#160;million and $18.2&#160;million, respectively, and net cash used in operations of $18.0&#160;million and $15.9&#160;million, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June 30, 2023, the Company had $2.5&#160;million in cash and cash equivalents. The Company has incurred operating losses and negative cash flows from operations since inception, except for the year ended June 30, 2019. On August&#160;11, 2023 we closed an underwritten public offering. Net proceeds from the offering, including the impact of the underwriter&#x2019;s partial exercise of its option and net of underwriting discounts, commissions, and other offering expenses, totaled $28.6&#160;million. We estimate that our cash and cash equivalents will be sufficient to fund the Company&#x2019;s operations for at least the next twelve months after the date that this Annual Report is filed. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s ability to continue as a going concern is dependent upon its ability to generate revenue and obtain adequate financing. While the Company believes in its ability to generate revenue and raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern due to unsuccessful product development or commercialization, or the inability to obtain adequate financing in the future. &lt;/div&gt; </bntc:LiquidityDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To06_30_2023"
      decimals="-5"
      unitRef="Unit_USD">-19600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To06_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-18200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2022To06_30_2023"
      decimals="-5"
      unitRef="Unit_USD">-18000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P07_01_2021To06_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-15900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2023"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P08_11_2023To08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">28600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Revenue &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenues from customers (US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;br/&gt; ended&lt;br/&gt; June&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;br/&gt; ended&lt;br/&gt; June&#160;30,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licensing revenue&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized licensing revenue over time as the performance obligations were satisfied. &lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="P07_01_2022To06_30_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenues from customers (US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;br/&gt; ended&lt;br/&gt; June&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;br/&gt; ended&lt;br/&gt; June&#160;30,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Licensing revenue&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2022To06_30_2023_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2021To06_30_2022_LicenseMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">73000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">73000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Cash, cash equivalents, and restricted cash &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash at bank&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,062&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Restricted cash&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,490&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P07_01_2022To06_30_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash at bank&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,062&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Restricted cash&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,490&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,076&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:DueFromBanks
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2477000</us-gaap:DueFromBanks>
    <us-gaap:DueFromBanks
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4062000</us-gaap:DueFromBanks>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">2490000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Prepaid and other assets &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Market value of listed shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="P07_01_2022To06_30_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;(US$&#x2019;000)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;871&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Market value of listed shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;876&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(97&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1280000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">871000</us-gaap:PrepaidExpenseCurrent>
    <bntc:MarketValueOfListedShares
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1000</bntc:MarketValueOfListedShares>
    <bntc:MarketValueOfListedShares
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5000</bntc:MarketValueOfListedShares>
    <us-gaap:OtherAssets
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1281000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">876000</us-gaap:OtherAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">97000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1184000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">741000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:75%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer hardware&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,404&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,318&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Depreciation and amortization expense was $136,000 and $167,000 for the years ended June 30, 2023 and 2022, respectively. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P07_01_2022To06_30_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:75%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer hardware&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,405&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,404&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,318&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,182&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2023_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2023_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1343000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1343000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2023_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1405000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1404000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1318000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1182000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">87000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">136000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">167000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trade payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;422&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued license fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued OPMD project costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued consultant fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P07_01_2022To06_30_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trade payable&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;422&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued license fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;120&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued OPMD project costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued consultant fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other payables&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">1140000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">422000</us-gaap:AccountsPayableTradeCurrent>
    <bntc:AccruedLicenceFeesCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">109000</bntc:AccruedLicenceFeesCurrent>
    <bntc:AccruedLicenceFeesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">120000</bntc:AccruedLicenceFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">131000</us-gaap:AccruedProfessionalFeesCurrent>
    <bntc:AccruedOpmdProjectCostsCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-1750000</bntc:AccruedOpmdProjectCostsCurrent>
    <bntc:AccruedOpmdProjectCostsCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1089000</bntc:AccruedOpmdProjectCostsCurrent>
    <bntc:AccruedConsultantFeesCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">88000</bntc:AccruedConsultantFeesCurrent>
    <bntc:AccruedConsultantFeesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">47000</bntc:AccruedConsultantFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">69000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3231000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1880000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Leases &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July 1, 2019, the Company adopted ASC 842, Leases (&#x201c;ASC 842&#x201d;). ASC 842 requires lessees to recognize at the lease commencement date a lease liability, which is the lessee&#x2019;s obligation to make lease payments arising from a lease, measured on a discounted basis, and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, which is an asset that represents the lessee&#x2019;s right to use, or control the use of, a specified asset for the lease term. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has entered into an operating lease for office space under an agreement that expires in 2025. The lease requires the Company to pay utilities, insurance, taxes, and other operating expenses. The Company&#x2019;s lease does not contain any residual value guarantees or material restrictive covenants. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The tables below show the changes during the years ended June 30, 2023 and 2022: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; right-of-&lt;br/&gt; use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Initial measurement at July 1, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; during the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization of right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(225&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at June 30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;771&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization of right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;526&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Initial measurement at July 1, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; during the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Principal payments on operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities at June 30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;811&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Principal payments on operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June 30, 2023, the Company&#x2019;s operating lease has a remaining lease term of 1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="null;text-indent: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;295&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;586&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For the fiscal years ended June 30, 2023 and 2022, total lease expense under operating leases was approximately $277,000 and $260,000, respectively, and was recorded in general and administrative expenses. &lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The tables below show the changes during the years ended June 30, 2023 and 2022: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; right-of-&lt;br/&gt; use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Initial measurement at July 1, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; during the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization of right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(225&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at June 30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;771&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Amortization of right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(245&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;526&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt; lease&lt;br/&gt; liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Initial measurement at July 1, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; during the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Principal payments on operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities at June 30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;811&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Principal payments on operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(252&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current portion at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2021_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-3"
      unitRef="Unit_USD">202000</us-gaap:OperatingLeaseRightOfUseAsset>
    <bntc:OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">794000</bntc:OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">225000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">771000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">245000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">526000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn06_30_2021_AccountingStandardsUpdate201602MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:OperatingLeaseLiability>
    <bntc:RemeasurementOfLeaseLiabilitiesDuringThePeriod
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">794000</bntc:RemeasurementOfLeaseLiabilitiesDuringThePeriod>
    <us-gaap:OperatingLeasePayments
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">196000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">811000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">252000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">559000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">284000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">275000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June 30, 2023, the Company&#x2019;s operating lease has a remaining lease term of 1.96 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="null;text-indent: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;295&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;586&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn06_30_2023">P1Y11M15D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="PAsOn06_30_2023"
      decimals="4"
      unitRef="Unit_pure">0.0467</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">295000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">291000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">586000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">559000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2022To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">277000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P07_01_2021To06_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      unitRef="Unit_USD">260000</us-gaap:OperatingLeaseExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Stockholders&#x2019; equity &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December 6, 2019, the Investors were issued 4 Purchase Warrants that were exercisable into 12,600 fully paid shares of common stock should the Purchase Warrants be exercised in full (&#x201c;Purchase Warrants&#x201d;). The exercise price for the Purchase Warrants is US$178.50 per share issued on exercise of a Purchase Warrant. The Purchase Warrants are exercisable, in whole or in part, any time from the date of issue until the fifth anniversary of the date of issue (December 6, 2024). On April 22, 2020, the Company issued 2,201 shares of common stock in connection with a cashless exercise of Purchase Warrants exercisable for 6,300 shares of common stock. The Company did not have an effective registration statement registering the resale of the Warrant Shares by the Holder at the time the Holder wanted to exercise the warrant; therefore, the Holder carried out a cashless exercise. The formula for conducting a cashless exercise was outlined in the Warrant agreement. Based on this formula, the Holder would have been entitled to receive 6,300 shares of common stock if they had exercised the Purchase Warrants for cash. Because of the cashless exercise, the holder received 2,201 shares. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On September 15, 2022, we closed an underwritten public offering in which we issued and sold (i) 1,037,521 shares of the Company&#x2019;s common stock, (ii) 715,978 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants, with each &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrant immediately exercisable for one share of common stock at an exercise price of $0.0017 per share until exercised in full and (iii) 29,809,471 outstanding&#160;Series 2 warrants (the &#x201c;Series 2 Warrants&#x201d;) which are currently exercisable into 1,753,503&#160;shares of common stock after giving effect to the Reverse Stock Split at an exercise price of $11.22 per share. The Series 2 warrants sold in the offering became exercisable commencing December 9, 2022, the date on which the Company had both (a)&#160;received approval from its stockholders to increase the number of shares of common stock it is authorized to issue and (b)&#160;effected such stockholder approval by filing with the Secretary of State of the State of Delaware a certificate of amendment to its Amended and Restated Certificate of Incorporation, and will expire on the fifth anniversary of such initial exercise date. The combined purchase price for each share of common stock and accompanying common warrant was $10.20, which was allocated as $10.03 per share of common stock and $0.17 per common warrant. The Series 2 Warrants contain an exercise price adjustment mechanism providing that certain issuances of common stock (or common stock equivalents), if made at a price lower than the then existing exercise price of such Series 2 Warrants, would reset the exercise price to such lower price. As a result of the August&#160;11, 2023 public offering, the exercise price of the Series 2 Warrants has been automatically reset as of the closing time of such public offering to $1.9299. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On October 17, 2022 and October 27, 2022, investors exercised 117,939 and 9,804 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants, respectively, at an exercise price of $0.0017 per share. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of June 30, 2023, there were 2,348,039 warrants outstanding. &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The activity related to warrants during for the fiscal years ended June 30, 2023 and 2022, is summarized as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&lt;br/&gt; Stock from&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&#160;(per&lt;br/&gt; share)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at July 1, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Pre-funded warrants issued September 15, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;715,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0017&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series 2 warrants issued September 16, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,753,503&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Pre-funded warrants exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127,743&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0017&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,348,039&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,348,039&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective as of the closing of the August 2023 underwritten public offering conducted by the Company, the exercise price of the Series &lt;/div&gt; &lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;2 warrants issued&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt; September 16, 2022 was automatically adjusted to $1.9299 as required by the terms of such warrants. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;Equity Incentive Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Share Option Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Upon the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation,&lt;/div&gt; the Company assumed BBL&#x2019;s obligations with respect to the settlement of options that were issued by BBL prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-&lt;/div&gt; domiciliation pursuant to the Benitec Officers&#x2019; and Employees&#x2019; Share Option Plan (the &#x201c;Plan&#x201d;). This includes the Company&#x2019;s assumptions of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances . Employee options vest one third &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;on&lt;/div&gt; each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the organization, and certain other conditions have been satisfied, generally the employee has 12 months to exercise their options, or the options are cancelled. After the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-domiciliation,&lt;/div&gt; no new options have been or will be issued under the Plan. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity and Incentive Compensation Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 9, 2020, the Company&#x2019;s stockholders approved the Company&#x2019;s 2020 Equity and Incentive Compensation Plan (the &#x201c;2020 Plan&#x201d;). The 2020 Plan provides for the grant of various equity awards. Currently, only stock options are outstanding under the 2020 Plan. Each option when exercised entitles the option holder to one share of the Company&#x2019;s common stock. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights, and are not transferable except on death of the option holder or in certain other limited circumstances. Employee stock options vest in increments of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; on each anniversary of the applicable grant date over three years. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-employee&lt;/div&gt; director options vest in increments of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; on the day prior to each of the Company&#x2019;s next three annual stockholder meetings following the grant date. If an option holder dies or terminates employment or service due to Disability (as defined in the 2020 Plan), the option holder generally has 12 months to exercise their vested options, or the options are cancelled. If an option holder otherwise leaves the Company, other than for a termination by the Company for Cause (as defined in the 2020 Plan), the option holder generally has 90 days to exercise their vested options, or the options are cancelled. The maximum contractual term of options granted under the 2020 Plan is ten years. Upon the consummation of a Change in Control (as defined in the 2020 Plan), all unvested stock options will immediately vest as of immediately prior to the Change in Control. &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 8, 2021, the Company&#x2019;s stockholders approved an amendment to the 2020 Plan, which increased the number of shares of the Company&#x2019;s common stock reserved under the 2020 Plan to 1,850,000. For the fiscal year ended June 30, 2023, our named executive officers (&#x201c;NEO&#x2019;s&#x201d;) were each granted equity incentive awards under the 2020 Plan. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;Equity Awards&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The activity related equity awards, which are comprised of stock options, during the fiscal years ended June&#160;30, 2023 and 2022, respectively, is summarized as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at July 1, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.07&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.45 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June 30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,416&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;118.15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.18 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66,868&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.94 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;848.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,993&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.96 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88.79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.22 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity-based Compensation Expense &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average grant-date fair value of stock options granted during the years ended June 30, 2023 and June 30, 2022 was $3.34 and $44.20, respectively. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;115.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Expected Volatility. Due to the lack of Company-specific historical or implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies in the life sciences industry. The Company selected the peer group based on comparable characteristics, including development stage, product pipeline and enterprise value. The Company computed historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the equity-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own share price becomes available. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Expected Term. The expected term represents the period that the equity awards are expected to be outstanding. For stock options with service conditions, it is based on the &#x201c;simplified method&#x201d; for developing the estimate of the expected life. Under this approach, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free&lt;/div&gt; Interest Rate. The Company bases the risk-free interest rate assumption on U.S. Treasury constant maturities with maturities similar to those of the expected term of the equity award being valued. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Expected Dividend Yield. The Company bases the expected dividend yield assumption on the fact that it has never paid dividends and does not expect to pay dividends in the foreseeable future. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;In addition to assumptions used in the Black-Scholes option-pricing model, the Company estimates a forfeiture rate to calculate the equity-based compensation expense for equity awards. The forfeiture rate is based on an analysis of actual and estimated forfeitures. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-Based&lt;/div&gt; Compensation Expense &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The classification of share-based compensation expense for the years ended: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;613&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;452&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;As of June 30, 2023 and 2022, there was $350,000 and $522,000, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;respectively, of unrecognized share-based compensation expense related to stock options granted under the Plan and 2020 Plan. Unrecognized expense as of June 30, 2023 is expected to be recognized over a weighted average period of 2.11 years.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Employee option awards-related stock-based compensation expense for the years ended June&#160;30, 2021 and 2022, and the nine months ended March&#160;31, 2023 was understated by a total of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$34&#160;thousand. The Company determined that this understatement is immaterial to the previously issued consolidated financial statements for the years ended June&#160;30, 2021 and 2022, and the nine months ended March&#160;31, 2023, and corrected it as of June&#160;30, 2023. &lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bntc:NumberOfSeriesWarrantsIssued
      contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">4</bntc:NumberOfSeriesWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">12600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">178.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn12_06_2019_PurchaseWarrantsMemberusgaapClassOfWarrantOrRightAxis">2024-12-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <bntc:CashlessExerciseOfPurchaseWarrants
      contextRef="P04_22_2020To04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">2201</bntc:CashlessExerciseOfPurchaseWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn04_22_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">6300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1037521</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <bntc:ClassOfWarrantOrRightsIssuedDuringPeriod
      contextRef="P09_15_2022To09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">715978</bntc:ClassOfWarrantOrRightsIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0017</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">29809471</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1753503</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_15_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">11.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bntc:IssueOfCommonStockAndWarrantPricePerShare
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_pure">0.102</bntc:IssueOfCommonStockAndWarrantPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.03</us-gaap:SaleOfStockPricePerShare>
    <bntc:ClassOfWarrantsOrRightsIssuePricePerUnit
      contextRef="PAsOn09_15_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.17</bntc:ClassOfWarrantsOrRightsIssuePricePerUnit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">1.9299</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod
      contextRef="P10_17_2022To10_17_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">117939</bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod>
    <bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod
      contextRef="P10_27_2022To10_27_2022_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">9804</bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn10_27_2022_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0017</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">2348039</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The activity related to warrants during for the fiscal years ended June 30, 2023 and 2022, is summarized as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&lt;br/&gt; Stock from&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&#160;(per&lt;br/&gt; share)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at July 1, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Pre-funded warrants issued September 15, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;715,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0017&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series 2 warrants issued September 16, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,753,503&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Pre-funded warrants exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127,743&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0017&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,348,039&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,348,039&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_30_2022"
      decimals="INF"
      unitRef="Unit_shares">6300</us-gaap:ClassOfWarrantOrRightOutstanding>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
      contextRef="PAsOn06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">178.5</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P07_01_2022To06_30_2023_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">715979</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <bntc:WeightedAverageExercisePriceOfPreFundedWarrantsIssued
      contextRef="P07_01_2022To06_30_2023_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0017</bntc:WeightedAverageExercisePriceOfPreFundedWarrantsIssued>
    <bntc:ClassOfWarrantOrRightsIssuedDuringPeriod
      contextRef="P07_01_2022To06_30_2023_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">1753503</bntc:ClassOfWarrantOrRightsIssuedDuringPeriod>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod
      contextRef="P07_01_2022To06_30_2023_SeriesTwoWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.22</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod>
    <bntc:ClassOfWarrantOrRightsExercised
      contextRef="P07_01_2022To06_30_2023"
      decimals="0"
      unitRef="Unit_shares">127743</bntc:ClassOfWarrantOrRightsExercised>
    <bntc:Weightedaverageexercisepriceofclassofwarrantsorrightsexercised
      contextRef="P07_01_2022To06_30_2023"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0017</bntc:Weightedaverageexercisepriceofclassofwarrantsorrightsexercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">2348039</us-gaap:ClassOfWarrantOrRightOutstanding>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
      contextRef="PAsOn06_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.86</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
    <bntc:ClassOfWarrantsOrRightsExcercisable
      contextRef="P07_01_2022To06_30_2023"
      decimals="INF"
      unitRef="Unit_shares">2348039</bntc:ClassOfWarrantsOrRightsExcercisable>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable
      contextRef="P07_01_2022To06_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.86</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable>
    <bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod
      contextRef="P08_01_2023To08_31_2023_RevisionInTheExercisePriceOfPrefundedWarrantsMemberBNTCEventAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">1.9299</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P12_09_2020To12_09_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_08_2021_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1850000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The activity related equity awards, which are comprised of stock options, during the fiscal years ended June&#160;30, 2023 and 2022, respectively, is summarized as follows: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at July 1, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;41,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.07&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,118&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;50.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.45 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June 30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,416&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;118.15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.18 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66,868&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.94 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;848.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;107,993&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.96 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at June 30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;88.79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.22 years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">41298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">121.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2021To07_01_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">50.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">P9Y5M12D</bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">43416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">118.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">P7Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">66868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">P9Y11M8D</bntc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">848.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">107993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">31.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">P8Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">11888000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">27135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">88.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">P7Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P07_01_2022To06_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P07_01_2021To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">44.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company estimated the fair value of each employee equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fiscal Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;115.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6&#160;years&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P07_01_2022To06_30_2023"
      decimals="3"
      unitRef="Unit_pure">1.156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P07_01_2021To06_30_2022"
      decimals="3"
      unitRef="Unit_pure">1.221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2022To06_30_2023">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2021To06_30_2022">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P07_01_2022To06_30_2023"
      decimals="4"
      unitRef="Unit_pure">0.0396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P07_01_2021To06_30_2022"
      decimals="4"
      unitRef="Unit_pure">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The classification of share-based compensation expense for the years ended: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:82%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;613&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;452&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To06_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">161000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To06_30_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">257000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To06_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To06_30_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">613000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">452000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">870000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn06_30_2023"
      decimals="0"
      unitRef="Unit_USD">350000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn06_30_2022"
      decimals="0"
      unitRef="Unit_USD">522000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandAndTwentyEquityIncentivePlanMemberusgaapPlanNameAxis">P2Y1M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P07_01_2020To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P07_02_2022To03_31_2023"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Income taxes &lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Loss before provision for income taxes consisted of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18,953&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,369&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;International&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(609&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(839&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18,208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"&gt; &lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The tax effects of significant items comprising the Company&#x2019;s deferred taxes are as follows: &lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;117&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;263&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Section&#160;174 Capitalization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,070&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,321&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,923&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(162&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(356&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. As of June 30, 2023 and 2022, the Company established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The valuation allowance increased $3.958 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million&#160;&lt;/div&gt;during the year ended June 30, 2023. Net operating losses and tax credit carryforwards as of June 30, 2023 are as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration&lt;br/&gt; Years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating losses, federal (post-December 31, 2017)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Do&#160;not&#160;expire&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Net operating losses, state&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,632&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2031-2042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating losses, Australia&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46,640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Do not expire&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The effective rate of the Company&#x2019;s provision (benefit) for income taxes differs from the federal statutory rate as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Share-based payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20.55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign tax rate differential&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to taxation in the U.S., various state jurisdictions and Australia. The Company&#x2019;s tax returns for the tax years 2014, 2016, and 2019 through 2022 are open and are subject to examination by federal taxing authorities and the Company&#x2019;s tax returns for tax years 2011 through 2022 are subject to examination by state taxing authorities. The Company is not currently undergoing a tax audit in any federal, state, or Australian jurisdiction. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The entire amount of the Company&#x2019;s unrecognized tax benefits would not impact its effective tax rate if recognized. The Company has elected to include interest and penalties as a component of tax expense. During the year ended June&#160;30, 2023, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Internal Revenue Code Section&#160;382 places a limitation (&#x201c;Section&#160;382 Limitation&#x201d;) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a change in control, a loss corporation cannot deduct NOL carryforwards in excess of the Section&#160;382 Limitation. Due to these &#x201c;change in ownership&#x201d; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Under Australian income tax legislation, losses can be utilized by the Company if it satisfies firstly the Continuity of Ownership Test (&#x201c;COT&#x201d;) or if failing that, the Similar Business Test (&#x201c;SBT&#x201d;). Broadly, the COT requires a company to show that it maintained continuity of majority beneficial ownership from the beginning of the year in which a loss is incurred to the end of an income year in which a tax loss is sought to be recouped. The SBT requires a company to demonstrate that a &#x201c;similar business&#x201d; has been maintained from the time when the COT is failed and throughout the period until the end of the income year that the losses are being recouped. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#x201c;CARES&#x201d;) Act was enacted and signed into law and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities, and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses in the CARES Act include a five-year net operating loss carryback for certain net operating losses, suspension of the annual deduction limitation of 80% of taxable income for certain net operating losses, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;background-color:white;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The CARES Act also provides other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-tax&lt;/div&gt; benefits to assist those impacted by the pandemic. The Company evaluated the impact of the CARES Act and determined that there is no material impact to the income tax provision for the fiscal year ended June 30, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June 29, 2020, California Assembly Bill 85 (AB 85) was signed into law, which suspends the use of net operating losses and limits the use of research tax credits for 2020, 2021 and 2022, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On February 9, 2022, Governor Gavin Newsom signed CA SB 113 (SB 113) into law. The legislation shortens the suspension period for deducting net operating losses (NOL) The suspension of deductions of California NOLs applied to California taxpayers with net business income of $1&#160;million or more for tax years beginning on or after January 1, 2020, and before January 1, 2023. SB 113 decreases that suspension period by one year, making the suspension applicable for tax years beginning on or after January 1, 2020, and before January 1, 2022. The Company evaluated the impact of SB 113 and determined that the legislation did not materially impact the Company&#x2019;s income tax provision for the fiscal year ended June 30, 2023. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Loss before provision for income taxes consisted of the following: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18,953&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,369&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;International&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(609&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(839&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(18,208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-18953000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-17369000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-609000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-839000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-19562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18208000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The tax effects of significant items comprising the Company&#x2019;s deferred taxes are as follows: &lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="width: 6%; vertical-align: bottom;"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating losses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;117&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;170&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;263&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Section&#160;174 Capitalization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,070&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,293&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,321&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,923&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(162&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(356&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">18388000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">17348000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">221000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">348000</us-gaap:DeferredTaxAssetsOther>
    <bntc:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">117000</bntc:DeferredTaxAssetsLeaseLiabilities>
    <bntc:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">170000</bntc:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">263000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">205000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">234000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">250000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <bntc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3070000</bntc:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">22293000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">18321000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">21923000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">17965000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">111000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">162000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">43000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">244000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">151000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">370000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">356000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">3958000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <bntc:DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock contextRef="P07_01_2022To06_30_2023">Net operating losses and tax credit carryforwards as of June 30, 2023 are as follows: &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&#x2019;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration&lt;br/&gt; Years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating losses, federal (post-December 31, 2017)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Do&#160;not&#160;expire&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Net operating losses, state&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,632&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2031-2042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating losses, Australia&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46,640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Do not expire&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis"
      decimals="-3"
      unitRef="Unit_USD">30496000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_NolFromTwoThousandEighteenMemberBNTCPeriodAxis">Do&#160;not&#160;expire</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">4632000</us-gaap:OperatingLossCarryforwards>
    <bntc:YearOfExpiryOfOperatingLossesCarryForwards contextRef="P07_01_2022To06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyOneMemberusgaapTaxPeriodAxis">2031</bntc:YearOfExpiryOfOperatingLossesCarryForwards>
    <bntc:YearOfExpiryOfOperatingLossesCarryForwards contextRef="P07_01_2022To06_30_2023_NOLpreJanuaryOneTwoThousandEighteenMemberBNTCPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_YearTwoThousandAndThirtyFourMemberusgaapTaxPeriodAxis">2042</bntc:YearOfExpiryOfOperatingLossesCarryForwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-3"
      unitRef="Unit_USD">46640000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="P07_01_2022To06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">Do not expire</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P07_01_2022To06_30_2023"> &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The effective rate of the Company&#x2019;s provision (benefit) for income taxes differs from the federal statutory rate as follows: &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Share-based payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(20.55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign tax rate differential&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P07_01_2022To06_30_2023"
      decimals="INF"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P07_01_2021To06_30_2022"
      decimals="INF"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences
      contextRef="P07_01_2022To06_30_2023"
      decimals="4"
      unitRef="Unit_pure">-0.0001</bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences>
    <bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences
      contextRef="P07_01_2021To06_30_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0022</bntc:EffectiveIncomeTaxReconciliationPercentagePermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="P07_01_2022To06_30_2023"
      decimals="4"
      unitRef="Unit_pure">-0.0019</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="P07_01_2021To06_30_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0036</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P07_01_2022To06_30_2023"
      decimals="4"
      unitRef="Unit_pure">-0.2092</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P07_01_2021To06_30_2022"
      decimals="4"
      unitRef="Unit_pure">-0.2055</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P07_01_2022To06_30_2023"
      decimals="4"
      unitRef="Unit_pure">0.0012</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P07_01_2021To06_30_2022"
      decimals="4"
      unitRef="Unit_pure">0.0013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P07_01_2022To06_30_2023"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P07_01_2021To06_30_2022"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OpenTaxYear contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2014MemberusgaapTaxPeriodAxis">2014</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2016MemberusgaapTaxPeriodAxis">2016</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2019MemberusgaapTaxPeriodAxis">2019</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear contextRef="P07_01_2022To06_30_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_TaxYear2022MemberusgaapTaxPeriodAxis">2022</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear contextRef="P07_01_2022To06_30_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2011MemberusgaapTaxPeriodAxis">2011</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear contextRef="P07_01_2022To06_30_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis_TaxYear2022MemberusgaapTaxPeriodAxis">2022</us-gaap:OpenTaxYear>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="PAsOn06_30_2023"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <bntc:PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards
      contextRef="PAsOn06_30_2023_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</bntc:PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards>
    <bntc:PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards contextRef="P07_01_2022To06_30_2023_InternalRevenueServiceIRSMemberusgaapIncomeTaxAuthorityNameAxis_MinimumMembersrtRangeAxis">P3Y</bntc:PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards>
    <bntc:NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack contextRef="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis">P5Y</bntc:NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack>
    <bntc:PercentageOfAnnualTaxableIncomeEligibleForDeduction
      contextRef="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis_SuspensionOfAnnualDeductionLimitationMemberBNTCEventAxis"
      decimals="2"
      unitRef="Unit_pure">0.80</bntc:PercentageOfAnnualTaxableIncomeEligibleForDeduction>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2022To06_30_2023_CoronavirusAidReliefAndEconomicSecurityActMemberBNTCUnexpectedEventAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <bntc:MinimumNetBusinessIncome
      contextRef="P02_09_2022To02_09_2022_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMemberBNTCEventAxis_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023MemberusgaapTaxPeriodAxis_CaliforniaFranchiseTaxBoardMemberusgaapIncomeTaxAuthorityNameAxis_SB113MemberBNTCLegislationAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</bntc:MinimumNetBusinessIncome>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2022To06_30_2023_CaliforniaAssemblyBillEightyFiveMemberBNTCUnexpectedEventAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There are no contingent liabilities as of June 30, 2023 and 2022, respectively. See Note 9 above for lease commitments. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn06_30_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn06_30_2023"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Related party transactions &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the year ended June 30, 2023, the Company did not enter into any related party transactions. During the year ended June&#160;30, 2022, the Company had entered into related party transactions with Francis Abourizk Lightowlers for legal fees totaling $1&#160;thousand. Peter Francis, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-executive&lt;/div&gt; director of the Company is a partner at Francis Abourizk Lightowlers. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LegalFees
      contextRef="P07_01_2022To06_30_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:LegalFees>
    <us-gaap:EarningsPerShareTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. Loss per share &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss attributable to common stockholders (US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;($&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;($&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares used in calculating basic and diluted earnings per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,385,818&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;480,688&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted loss per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;($&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;($&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;Outstanding warrants and options amounting to 2,456,032 and 49,716 to acquire common stock are considered anti-dilutive for the fiscal years ended June 30, 2023 and June 30, 2022, respectively. &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P07_01_2022To06_30_2023">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss attributable to common stockholders (US$&#x2019;000)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;($&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="display:inline;"&gt;)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;($&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average number of shares used in calculating basic and diluted earnings per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,385,818&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;480,688&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted loss per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;($&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;($&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To06_30_2023"
      decimals="-3"
      unitRef="Unit_USD">-19562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To06_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-18208000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To06_30_2023"
      decimals="0"
      unitRef="Unit_shares">1385818</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To06_30_2023"
      decimals="0"
      unitRef="Unit_shares">1385818</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To06_30_2022"
      decimals="0"
      unitRef="Unit_shares">480688</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To06_30_2022"
      decimals="0"
      unitRef="Unit_shares">480688</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To06_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-14.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To06_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">-14.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-37.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To06_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-37.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2022To06_30_2023_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">2456032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2021To06_30_2022_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">2456032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">49716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P07_01_2021To06_30_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">49716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P07_01_2022To06_30_2023">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15. Subsequent events&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On July&#160;26, 2023, the Company effected a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-for-17&lt;/div&gt;&lt;/div&gt; reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of its common stock. In accordance with the Reverse Stock Split, 17 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-split&lt;/div&gt; shares of the Company&#x2019;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#x2019;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;All share and earnings per share amounts presented in this Form 10-K reflect the impact of the Reverse Stock Split.&#160;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;On August&#160;11, 2023 we closed an underwritten public offering in which we sold 875,949 shares of common stock, 15,126,226 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase 15,126,226 shares of common stock, and 16,002,175 common warrants to purchase up to 16,002,175 shares of common stock. The combined purchase price for each share of common stock and accompanying common warrant was $1.93, which was allocated as $1.9299 per share of common stock and $0.0001 per common warrant. Each &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrant was sold together with one common warrant at a combined price of $1.9299, which was allocated as $1.9298 per &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrant and $0.0001 per common warrant. In addition, the Company granted the underwriter an option to purchase up to 2,331,606 additional shares of common stock and/or up to 2,331,606 additional common warrants. As of August&#160;15, 2023 the underwriter had partially exercised this option and purchased 458,134 additional shares of common stock and 458,134 additional common warrants. Net proceeds from the offering, including the impact of the underwriter&#x2019;s partial exercise of its option and net of underwriting discounts, commissions, and other offering expenses, totaled $28.6&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;The Company has 29,809,471 outstanding&#160;Series 2 warrants (the &#x201c;Series 2 Warrants&#x201d;) which are currently exercisable into 1,753,503&#160;shares of common stock after giving effect to the Reverse Stock Split. The Series 2 Warrants contain an exercise price adjustment mechanism providing that certain issuances of common stock (or common stock equivalents) if made at a price lower than the existing exercise price of $11.22 of such Series 2 Warrants, would reset the exercise price to such lower price. As a result of the August&#160;11, 2023 public offering, the exercise price of the Series 2 Warrants has been automatically reset as of the closing time of such public offering to $1.9299.&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 13, 2023, the Compensation Committee (the &#x201c;Compensation Committee&#x201d;) of the Company&#x2019;s Board of Directors approved increases of the base salaries of Dr. Jerel Banks, the Company&#x2019;s Executive Chairman and Chief Executive Officer, and Megan Boston, the Company&#x2019;s Executive Director, to $655,200 and $350,784 (Ms.&#160;Boston&#x2019;s salary as noted has been converted from AUD $1.00 to USD $0.64, which was the conversion rate as of September 13, 2023) respectively, each adjustment being effective as of October 1, 2023. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="P07_26_2023To07_26_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">On July&#160;26, 2023, the Company effected a 1-for-17 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of its common stock. In accordance with the Reverse Stock Split, 17 pre-split shares of the Company&#x2019;s common were automatically converted into one issued and outstanding post-split share. Proportional adjustments were also made to all outstanding stock options, pre-funded warrants, and common warrants in accordance with their respective terms. The Reverse Stock Split did not change the par value of the Company&#x2019;s common stock or the authorized number of shares. No fractional shares were issued in connection with the Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">875949</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <bntc:ClassOfWarrantOrRightsIssuedDuringPeriod
      contextRef="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">15126226</bntc:ClassOfWarrantOrRightsIssuedDuringPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P08_11_2023To08_11_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">15126226</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">15126226</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <bntc:ClassOfWarrantOrRightsIssuedDuringPeriod
      contextRef="P08_11_2023To08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">16002175</bntc:ClassOfWarrantOrRightsIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">16002175</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <bntc:IssueOfCommonStockAndWarrantPricePerShare
      contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      unitRef="Unit_pure">0.0193</bntc:IssueOfCommonStockAndWarrantPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">1.9299</us-gaap:SaleOfStockPricePerShare>
    <bntc:ClassOfWarrantsOrRightsIssuePricePerUnit
      contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</bntc:ClassOfWarrantsOrRightsIssuePricePerUnit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">1.9299</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_11_2023_PreFundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">1.9298</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_11_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2331606</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_11_2023_CommonWarrantsMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2331606</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_15_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">458134</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_15_2023_CommonWarrantsMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">458134</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P08_11_2023To08_11_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">28600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn06_30_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">29809471</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn06_30_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">1753503</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn06_30_2023"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn08_11_2023_IPOMemberusgaapSubsidiarySaleOfStockAxis_Series2WarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">1.9299</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <bntc:AnnualBaseSalaryCompensation
      contextRef="PAsOn09_13_2023_Dr.JerelBanksMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ExecutiveChairmanAndChiefExecutiveOfficerMembersrtTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">655200</bntc:AnnualBaseSalaryCompensation>
    <bntc:AnnualBaseSalaryCompensation
      contextRef="PAsOn09_13_2023_ExecutiveDirectorMembersrtTitleOfIndividualAxis_MeganBostonMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">350784</bntc:AnnualBaseSalaryCompensation>
    <bntc:ForeignCurrencyExchangeRateConversion
      contextRef="PAsOn10_01_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_AUD_per_unit">1</bntc:ForeignCurrencyExchangeRateConversion>
    <bntc:ForeignCurrencyExchangeRateConversion
      contextRef="PAsOn10_01_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_unit">0.64</bntc:ForeignCurrencyExchangeRateConversion>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M%T U5SHV,ZJ1!P  X3$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MFVMSXC@:A?^*BIW:FJD*P3<(Z4FH(B;,L)W.,"'=7;U3^T&Q!;C:EEA9SN7?
MCV2,'??(+W:5^-+!QN_!?EJ7<X2X>F'\>[HE1*#7)*;I=6\KQ.[#8) &6Y+@
M])SM")7OK!E/L)"'?#-(=YS@,"]*XH%C6:-!@B/:FUSEYY9\<L4R$4>4+#E*
MLR3!_.V&Q.SENF?W#B<>HLU6J!.#R=4.;\B*B,^[)9='@U(EC!)"TXA1Q,GZ
MNC>U/\P\2Q7D5WR)R$OZ[C52C_+$V'=UL BO>Y:Z(Q*30"@)+/\\$Y_$L5*2
M]_'_0K17?J8J?/_ZH#[/'UX^S!-.B<_BKU$HMM>]<0^%9(VS6#RPE]])\4!#
MI1>P.,W_12_[:X=N#P59*EA2%,L[2"*Z_XM?"Q#O"ERGH< I"IP?"FROH< M
M"MRV!5Y1X.5D]H^2<YAA@2=7G+T@KJZ6:NI%#C.OEH\?4?7_OA)<OAO).C'Q
MV3/A:"G_BU$??5[-T,\__7(U$%)9O3\("I6;O8K3H&([Z!.C8INB6QJ2L"XP
MD+=4WI=SN*\;!U3\3T;/D6N=(<=R7,T-^7#Y--N<(WO46#Z#RV<DD)]NY^4.
M\#1N2=G-]5R0\E_3IU1PV=+_IR.\5_#T"JK[?TAW."#7/=F_4\*?26_R[W_9
M(^M7'1V38C-#8C5R7DG.@]0G,Q9D<I@1Z/%M1W38X'+;ZG_4\0&KNO(Q)%;C
M,RSY#,$'G$HX80YH'N.-#A!<O\9QJN/J@V5="1D2JQ$:E81&[5K0E-(,Q^B!
M[!@7.E*PCN"9%A18U164(;$:J(L2U$7+KL:QG-?S:;D9%JS5V*S LJZT#(G5
M:(U+6F/P"6^IB,0;FD<Q0?=9\D2XCA*L85EVW[UT1A<Z4F!I5U*&Q&JD+DM2
MEVU(/9!-I*8_V<#N<:(=RV&=&T(C00)T$['=%DO/AQ8T.->A W6ZHC,D5D-G
M6Y4]L]K >\2O:!'*SAFMHP#G7;.YT1V1''M];R2-C372L8.+N\(SI5:G]\[<
MVNV&M"7A$0N5.T72)FL;WQ&ITI V.E)8H#,Y0VIU<DY%SFE';AZE@9PUOQ',
MT5R>3+7L8+%&8F!99V*&U.K$*HMO@S[X'\2*)M?,#):;?],2,VKL3:G5B576
MWH;->3&V^1(:E\ 6,CJ^HH_D34L+EK+D5#JVQN/+L9::4;MO2JU.K3+\-NS8
M_8SS'SLF.*[!<OV^->J[EA:;T0Q@2JV.K4H!-FS?B\;VE<1Q_SME+Q2M"$X9
M)2%:I&G6,)/"FO=,B\UH(C"E5L=690(;-O(%MB\LSJC ?&]XN7Y @Y4:8!D-
M!*;4ZK"J2&"WR@2''KH/3Q'=H)7 HF$6@!6_$5V5#U=UIG:*=&!7\<!NE0\6
M5!"^7P968QD^8-12@Q6;J!G-!:;4ZLNC53!P6@6#O#LB7X[]&\:U,^<1G7M&
M^S@(B)21(N%>4+O@:C08F%*KTZN"@0.[^8+>*L%QC&ZR5+Z=:OOG$9VF12&X
MK#.L4V0!I\H"#FS?"UBW">$;-9K])A7$%ODLV6&J;W.P8./J$%S7&=LI H%3
M!0('=O"'-K:5E@.$!<LTPS*:!4RIU6%56<!IE046-&!<SIKY$L=9/F\2Q.0
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M)MHI:]/ZB"7>;CA[!%Q;JVCZHJU-ZZVRH95^C;>2JU^I\I/;':L$*VB&)<G
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MMBRW'2-K5]E6TF"==,T2;S)0-@#GUU*:?<<6R_YNS'X#4$L#!!0    ( !=
M-5?$8[:H&04  "T6   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5AM
M;]LV$/XKA%<,+=#$(B5+<N88:)QUZ[!N0=*LGQGK; N52(^D[62_?J0D2Y9$
ML2G@+Y8HWQV?>^$])&<'+K[)#8!"SWG&Y/5HH]3V:CR6RPWD5%[R+3#]SXJ+
MG"H]%.NQW J@2:&49V/B>>$XIRD;S6?%MSLQG_&=RE(&=P+)79Y3\7(#&3]<
MC_#H^.$^76^4^3">S[9T#0^@'K=W0H_&M94DS8')E#,D8'4]^H"O%B0R"H7$
M/RD<Y,D[,JX\<?[-##XEUR//(((,ELJ8H/JQAP5DF;&D<?Q;&1W5<QK%T_>C
M]8^%\]J9)RIAP;.O::(VUZ-XA!)8T5VF[OGA=Z@<FAA[2Y[)XA<=*EEOA)8[
MJ7A>*6L$><K*)WVN G&B@,,!!5(ID*Y",*#@5PI^X6B)K'#KEBHZGPE^0,)(
M:VOFI8A-H:V]29E)XX,2^M]4ZZGY@C/)LS2A"A+TH/1#YTA)Q%?H[RT(:F(M
M$64)6O!<%\K&9' /Z$\N);I CP^WZ.V;=^@-2AGZLN$[J47E;*PT-#/!>%G!
MN"EAD $8F*#/G*F-1+^R!)*V@;'VJ7:,'!V[(4Z+?^S8)?*]]XAXQ+< 6KQ>
MG3C@^'6<_<*>/V#O'O; =G!E"TVI&=@US3J^DENZA.N1CK\$L8?1_.>?<.C]
M8G/K3,9:3@:UDX'+^M%)B5:"YU7U@K"60VDH+ R95K.?1Y/9>'_JB47$KT5:
M^"8UOHDS"55%LS6"9]T')5BA3<Z9CC,9:[D;UNZ&[G3P%YJI%,KUFZ5+XS):
M@=WMTM;D)-Q>)R%]B:D]'U$-,/I.O4B@8KDI\"6Z>#*^->W'!B_J38Y)% 4=
MB!8I+4;L,.,:9NR$^1LP73=9@9(FN@FG4IDZVH,-:-R#$/HQZ>"T"(5!:(<Y
MK6%.G3"_<*5!\E?5^+0?IRF>A!V4%JEH2B([3.PUE.,Y@1;<4;0(7E.,E3*\
MWOP7>.K%N /3*A?%DV  Z DW8G>_4!L0*--PK7V[TCY3ISB7M;:OI/&5.).B
M-T5ZR\-TUQ8"V/(%Z1)GDI:;+1,":P1(/_(![C9RFQ3Q!Q8E;A@5.[EL_HDI
MT)%0QT)_CQA86T=EIS6_[W=!VH2&,#:$B-V,6%;0=P$&EKF[W=<F% TT8-PP
M(G8RT/R1Z<U_EOZG=W\FR4@G.V5['=6A/ES9:V/M0K7(8#P M6$S[*:SJK_5
M:W(XG'VBN@CZ7<,BY0_VC(;2L)O3_M)'K\'ETJ<GW= F89<=K'(Q\>(!< V1
MX?@5#6W9VLFG3(\!O36@W]G[G),>?[C/G<E:.P0-26(W2YX4_,K:\K*"D-!:
M'X&MP>B3HJ7C]84(]NS9(PUO$C=OGBX 6PYM<$F?&_MP+4+#<!OV)$[&JN"V
M@0ZMC,I4V%X9.(BZ2&URT70ZL#)(0W^$.%?&<=DBO2-!<D.%_:A&G"3ZHTOA
M7-;:/C<$2MP$>D-ENK1Z6>K%K2@'E[C;IVQR?G09#V6CH4WBILW;--NI[C5
MA2UX)3:+G M;PYC$?8C\6MP,07)!]WKSNH:R6C1S[I14^HB@M][VTCGKN?)<
MUMI!:+B8N+EXN'3ZK(K]>!+CN)N?OF 0>^%@?AH")FX"=M6.Y7AH!]<7M((;
MGUR\Y2#6Q7VDU#UOQU1Y555_K>\\/Q0W?9WO-_AJ4=Y<-F;*B]3/5*Q3)E$&
M*VW2NXPT*%'>398#Q;?%]=X35XKGQ>L&: +"".C_5YRKX\!,4-\0S_\'4$L#
M!!0    ( != -5>"7\']*@4  +X<   8    >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&ULQ5EM;]LV$/XKA!9L+1!'HMXL9[:!UI'0#.L6-.WV8=@'1J(M(9+H
MDG2<_/N1LB);+V;L@L"^6*)\]YQXSY''.TVWA#ZR%&,.GHN\9#,CY7Q];9HL
M3G&!V!59XU+\LR2T0%P,Z<ID:XI14BD5N6E;EF\6*"N-^;1Z=D?G4[+A>5;B
M.PK8IB@0??F(<[*=&=!X?? E6Z5</C#GTS5:X7O,OZWOJ!B9#4J2%;AD&2D!
MQ<N9\0%>1]"7"I7$7QG>LH-[(*?R0,BC'-PF,\.2;X1S'',)@<3E"2]PGDLD
M\1[?:U"CL2D5#^]?T:-J\F(R#XCA!<G_SA*>SHS   E>HDW.OY#M)UQ/R)-X
M,<E9]0NVM:QE@'C#."EJ9?$&15;NKNBY=L2! G2.*-BU@MU1L.TC"DZMX'04
M'/^(@ELKN%T+DR,*7JW@=13<8Q;\6J$BT]PYJ_+T#>)H/J5D"ZB4%FCRIJ*K
MTA8.SDH96?><BG\SH<?G"U(RDF<)XC@!]UQ<1-AP!LA2C$C\F)(\P93] L+O
MFXR_@!'X=G\#WEV\!Q<@*\'7E&P8*A,V-;EX&XEIQK7ECSO+]A'+7PE'^8#:
M0JVV($4A(I+)EP/_?,;% Z;_#L#<J&$^)$DF0QOEX YER4C,98'6F7@E%6CX
M!F@<;XI-7OGR!B^S..,JM.ATM#]YBBD0<Q?;1RK7]1,&OQ/&CL";(@J:4+";
M4+ K>^X1>Q]1CLH8 \2!L 8>\"HKRZQ<R0>_;<HKX%B7P+9L.,3U#MJOH.5N
M]C07>QNTIN;3(;5]J8[$35\">M +W+98V!<;0<>"<-*6BX;D7,]KI%J.<AI'
M.3_FJ'>W(C!31#%[?Y+3E&9D3KEF:Q3CF2%89Y@^86/^\T_0MWX=6C8[,.]@
MJFY@^4'0<;!.FZ%.L$@36(M2MZ'455)Z+UD;R125@%BL,K'$D-P>AEAS>XX.
MQMU 5UH[TS$W)Q@,=1J,-(&UF/ :)CPE$^*\($X#I<A]E.(R?@&<HI+E%1M@
M)8Y*0Y1X/0_9O;U':?9<2G2"A3K!(K4K6I3X#26^DI(_Q $W%\EFR/-^S]P(
M!K;5V7462@/G.E\G6'C:!")--EO^'S?^'Y^:;W"9=#.+/43+N!\%06!W2!F_
MF8W[,-"S7:^;C?MB(LL&CCWN.'%(3L -1V?0>"<XQSN*'#SH*27XN3DX."T'
MZ[09Z@2+-(&UB)PT1$Z41-XRMJF8%+5'?'C*%_4%$/9&RTV9B/R\152D!%&C
MB,(E :*X!C%BZ24HQ38E5,ERB:D\C<6$[0J9"W@9^),A\B?]^/8MZ'76R>3-
M=7(23JB<_KE,:0)K,06M?=5H_9]<78+J0#9<52K?[-P56Z.UJ+.<L6=W*=9J
M-M2*%NE":P?#00L!*H,A?,8TSI@,AAWJ/@!VX]<H4-*JM'$VK;!/JST>NTZ7
M59U60ZUHD2ZT-JO[;@!4MP/.*8EJJ%;B\[K'#;6]<P^!IY@,M9J,=*&U"=EW
M':"Z[?!#E1$<: OT$IS:\-G,:&TQ:$6+WG!'FYE]\P"JNP>J @GVJ_<1G'A^
M;W5H;1EH10M/G$.DRVJ;AGWG *I;!^HZR1EDQQOH6_:HZ0OU3@=]$>@'$]GV
M:V](?;D1],=!T&U<#@D&SI%"'NXK>:@NY4\OEH;=I;/T7L!^[0U]UYMXL.M=
MK16_5K1(%]J.4//@2X[\LO<9T556,I#CI8"WKL;"673WL6PWX&1=?=QY()R3
MHKI-,4HPE0+B_R4A_'4@OQ<UGRSG_P%02P,$%     @ %T U5P5U,%%( @
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MKOPAV<;<8BV9E"PS7]= $N!:0/U_Q9@\_- OJ"]"Y_\!4$L#!!0    ( !=
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M]K?$0=*!I74X\$X3<^E P@F2Y2=@%ZXB*"1/T\X'=N((E"'U\NI&-YK4AGA
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M#RD3!2BMR7*BZ3KT*= $Z=WP?>@$'YYQML%("<^!*QV,6)*"&:I7-M=2Q@S
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M"RO+:]WVZZ<\ANPI?)=1^%YF!,,'!EN9<7U-6O?9R"XE%KX-"_)0.EX6B?O
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M?#_']9OHVC0[K5W$)):6-49?]O( ]Y5S<;<1!>,PO?P74$L#!!0    ( !=
M-5>N_"'E8 (  %$%   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;'U4
M[V_3,!#]OK_BE$T32*A)T^Z'MC;2.D" F#1M#(00']SDDEAS[& [S<9?S]E)
M0Q%=OC@^^][S>X[O%JW2CZ9$M/!4"6F606EM?1&&)BVQ8F:B:I2TDRM=,4NA
M+D)3:V29!U4BC*/H-*P8ET&R\&NW.EFHQ@HN\5:#::J*Z><5"M4N@VFP7;CC
M16G=0I@L:E;@/=J'^E93% XL&:]0&JXD:,R7P=7T8C5W^3[A*\?6[,S!.5DK
M]>B"C]DRB)P@%)A:Q\#HL\%K%,(1D8Q?/6<P'.F N_,M^WOOG;RLF<%K);[Q
MS);+X#R #'/6"'NGV@_8^SEQ?*D2QH_0=KEQ%$#:&*NJ'DP**BZ[+WOJ[V$'
M</X2(.X!L=?='>15OF66)0NM6M NF]C<Q%OU:!+'I?LI]U;3+B><3>YP@[+!
M16B)S"V%:0]<=<#X!> TAALE;6G@G<PP^Y<@)!6#E'@K916/,GYJY 1FT1N(
MHW@VPC<;K,T\WVS<FH$?5VMC-?W_G_ML=B3S_22N)BY,S5)<!O3H#>H-!LGQ
MX?0TNAR1.!\DSL?8QVY_%+A?%LPGT#,>#.9SK:K^(:$V\.KA_NCX\#R>GEU&
M4?0:OB/3?CCXS%-7:[*@6O-8.(*S$S?,#KXHR\1N7")<JZIF\IFR4U5(_ALS
M$/]1J UJL%3%P Q80M6H?2>1*6VN!2^8*TX#+6H$0X').683V'>YX<XS)S.%
M+V8#J6JD[5[\L#KTBZNN3/ZF=\WFANF"T[$"<X)&D[.3 '17P%U@5>V+9JTL
MW9R?EM3S4+L$VL^5LMO '3!TT>0/4$L#!!0    ( != -5>DJBI15@(  '@%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*54WT_;,!!^[U]Q"@AM
M4M4X:6@9M)$H VV3D!",[6':@YM<&PO'#K;3LO]^_M&&(I5*TU[B._N^[[X[
MYSQ92_6D*T0#+S47>AI5QC3G<:R+"FNJ![)!84\64M746%<M8]THI*4'U3Q.
M"1G%-64BRB=^[T[E$]D:S@3>*=!M75/U9X9<KJ=1$FTW[MFR,FXCSB<-7>(#
MFL?F3EDO[EA*5J/03 I0N)A&E\GY+'/Q/N 'P[7>L<%5,I?RR3E?RVE$G"#D
M6!C'0.VRPBODW!%9&<\;SJA+Z8"[]I;]QM=N:YE3C5>2_V2EJ:;1600E+FC+
MS;U<?\%-/:>.KY!<^R^L0VR615"TVLAZ [8*:B;"2E\V?=@!G)%W .D&D'K=
M(9%7^9D:FD^47(-RT9;-&;Y4C[;BF'"7\F"4/6469_(KJJL^%/8+^-RR%>4H
MC.X#%:7MN3:*%09+'S")C4WH8'&Q(9\%\O0=\B2%6RE,I>%:E%B^)8BMTDYN
MNI4[2P\R?FO% (:D#RE)AP?XAEWY0\\W/%"^K]4;UZ\=@%^7<UN]_6E^[ZL[
ML&;[6=T@G>N&%CB-[*1H5"N,\I.C9$0N#FC..LW9(?;_O;*#Y/NEP^D _B%K
M[\/CP_')T5F:C"\((1_!WAKZ6]L:O=!W8P=*/,$QI/UL/+9KUB>CM'?_E@Z2
M(219[[LTE(?83R3$CD?[VAGO3$.-:NEG7D,A6V'"8'2[W;-R&:;I-3R\2;=4
M+9G0P'%AH60P/HU A3D/CI&-GZVY-'92O5G9IQ&5"[#G"RG-UG$)NL<V_PM0
M2P,$%     @ %T U5]T]FE1] @  C@4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&ULE93;;MLP#(;O\Q2$6Q0MT,6'')<F!I)NPS:L6-"NV\6P"\5F
M8J.RY$ERT[W]*-GQ4B )L)M(E,B//ZV0TZU43SI#-/!2<*%G7F9,.?%]G618
M,-V5)0JZ64M5,$.FVOBZ5,A2%U1P/PJ"H5^P7'CQU)TM53R5E>&YP*4"714%
M4W\6R.5VYH7>[N ^WV3&'OCQM&0;?$#S6"X567Y+2?,"A<ZE (7KF3</)XN^
M]7<.WW/<ZKT]V$I64CY9XU,Z\P(K"#DFQA(8+<]XBYQ;$,GXW3"]-J4-W-_O
MZ!]<[53+BFF\E?Q'GIILYHT]2''-*F[NY?8C-O4,+"^17+M?V-:^T<"#I-)&
M%DTP*2AR4:_LI?D.>P'CX$A U 1$3G>=R*E\QPR+ITIN05EOHMF-*]5%D[A<
MV$=Y,(IN<XHS\5)AR?(4F$A!F@P5,*W1Z*EOB&Y]_*0A+6I2=(041G GA<DT
MO!<IIJ\!/LEJM44[;8OH)/%S);K0"ZXA"J+>"5ZOK;7G>+TCO*^NOKFK#W[.
M5]HH^E/\.E1J#>H?!ME&F>B2)3CSJ!,TJF?TXHNS<!C<G)#9;V7V3]'_ZTE.
MD@[KA&$7CJ7H7#X^G%^<C:-P=!,$P170$V#[!*^LJ+.#X M-"(T:SB&\CL8!
MK>-1V+ECZHF&RC/C%8)< \^UP11TQD@*A##H?).&\5?Y'2"D\&'G"VH] 2'%
MFZ12"H6!R[<CN(++L#> J\YM<UA*Y;K;Y@['?5I'_?#0(_A[/5*@VKA)H"&1
ME3!UN[2G[;"9USWVS[V>5%39)A<:.*XI-.B.J+=5W?VU863I.FXE#?6OVV8T
M,%%9![I?2VEVADW0CN#X+U!+ P04    "  70#57]-%CZ=X"  "&!@  &0
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MAD1J0XSN<,#HR^*+UBV10E,U<F%J2AQ#?]BY>Y<9G%_ ,.@\2D-GG4+4#:/
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MRA*J4T#!Y,B;'0&&(VL9SJ"96)"QW$XE<B61.KL#W5?E@X)QLZ?B+6Z)&P'
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MM;0 [S?&U.T74M#];G_Y?U!+ P04    "  70#577W6?0^,+   ''@  &0
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M.IA#H? OD)":19?WDH(TX<U&AY6.C+J&$+"CML5 7*NYI/A(0CW>#+8BIBN
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MC;8,B\9!;EI-W33VUGZ7S;H1_N/>+<(;84O)6A2N.#09O#F-P';+I;N0:<)
M+PWQ>@C'BO<Q6N_ [RMC:'?Q"?H-G_T&4$L#!!0    ( != -5?AEVJY#P,
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MM7<NOS#7/2X_U/=35E\CTRGU@EX]/GKQ_$ RGO"EL6O^O;FY;2C?XH]+G5&
MBP?H_L+:)GS! O$7"-_]'U!+ P04    "  80#57MJ\F$.D"  "7!@  &0
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MG+14K?G^"W1^IH8OY53:$>U=;CC!*&VEXG4'U@KJBKF9O'3?X0APZ[\#"#I
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MDP3").CSG'-U",P%_2.7_ =02P,$%     @ &$ U5[C$*[)A @  : 4  !D
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M#BUF).GV,.R!ELX648K42"JN]]?OCG(4)W&,=GN12.KNN_N.]XF<;+7Y8@L
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MLXG16V;(&M%HX*EZ;TQ.*-J46V?PJT _-_L(2,FR\SN^DF O)J%#4/H49GN
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MAN1FN::O$M1.@/:72MG=@S/0?^<L_@-02P,$%     @ &$ U5]D(L=D;!0
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MIKI]5QNG2W_CG6F']V>_7.(?%F%( +_/M7;;#1G8_06:_ ]02P,$%     @
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M4DKAPY1J.AI(L2;21".;*11F%FB4S[A9]IF6V,L0IT??V7W.(J8?R1D91UC
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M-%VMF2A>V<8PYTK3M<-"_PB , 9Z/^=<;28F0/=KD?P&4$L#!!0    ( !A
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M" M.9\BBFC[83(RL7"M928.-R0T+_'6 L@FXOI;2/$UL=^I^1ND_4$L#!!0
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M+/0]"L($Z/DEYVK;,:6ZNYG3?U!+ P04    "  80#57A;IW+)$#  !P$0
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M,RQP&#"Z14Q%RVRJ4=6F4DLW6:%F<2&8?)M)G0B?&8X!X2)&5*3 4(G?\9(
MOT:+>EX139#H"4*7,Q X(U?H&KTL9NCRX@I=H*Q SRE=<QG/ U-(2#64&35
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M6'V'UAU!R^H:6E(A+[6JF<K/#F J0+Y/*!6[CKK9V@^9\!]02P,$%     @
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MV#T16\JDW@0W&M*[&FM>HAANBAO%,SL?K+G2TX:]W.F!$(0QT.\WG*O7&[-
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M/$QNV/'1"3MB(F7WL<H-3^=FX"()M=NYLTK4=2G*?T74USP]8UWO _,]O]L
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M_F.T#UFTFMRIEVZZ,C9JV-F+T6FYY>Q99]:Q6JYS@,1>G8E_C80FJ>JE&Y/
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M#Q50XIKJ1['Y#*V>D>7+!57NBS:-[]65A_)::<%:L(F $=[\\;;-PQX@3$X
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M6Z13=,T6$M-)S" QD\0L$K-)S"$Q=X-=[T50?]@K_FEET.'-AIIV<#.?W+2
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MI,*Q3S+X(E<[AQ!:)D<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(LJK7%$[$0
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MU6LA--9"V\SQM0)I G!^*83>=<P"[?N7_ %02P,$%     @ &$ U5\2/V-+
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M_[RZVC;#JR\$=U1.&5>0X\1,C8Y.S/:7U:6[ZF@Q<Q?=!Z'-M=DU,Z0I2CO
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M5H/03 JBH)P'E_'%8FKC7<!7!AN]UR;6R5+*G[;SOI@'D14$'')C&2B^UK
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MKEGA30F4#<#OI91FU[$_Z.Y>V6]02P,$%     @ &$ U5YB,/C;_!@  /RL
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ME#7 _8649CNQ![2?.>EO4$L#!!0    ( !A -5>[-E)RM (  (<(   9
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M1@!S.PA##(&[$4<P!^ !0\*P?@_NO8_\]7O*W_Q.._H#4$L#!!0    ( !A
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %T U5YE<G",0!@  G"<  !,
M             ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  70#57.C8SJI$'  #A,0  &               @($,"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %T U5TDJ5BQJ!0  &Q8  !@
M             ("!TP\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( != -5<NF^HLC0(  "<'   8              " @7,5  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  70#57Q&.VJ!D%   M
M%@  &               @($V&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ %T U5X)?P?TJ!0  OAP  !@              ("!A1T
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( != -5<%=3!1
M2 (  ,H$   8              " @>4B  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    "  70#57I8L23GH&   4'0  &
M@(%C)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ %T U
M5[38:M0^!0  8 P  !@              ("!$RP  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( != -5<'R[EZ41<  #Y$   8
M      " @8<Q  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( != -5?TT6/IW@(  (8&   9              "
M@056  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ %T U
M5S]A-]B3 @  Q@4  !D              ("!&ED  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    "  70#57RQB H>L$  #("P  &0
M        @('D6P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( != -5?)G1/,_ L  ,,?   9              " @09A  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ %T U5U]UGT/C"P  !QX
M !D              ("!.6T  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    "  70#57*']#6'4#  #Z!P  &0              @(%3>0
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( != -5=XR2DS
M@ (  .T%   9              " @?]\  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ %T U5^&7:KD/ P  B08  !D
M ("!MG\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  7
M0#57%YW1B\H$  #L"@  &0              @('\@@  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( != -5?,Q%8YX!@  (U0   9
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M970R-RYX;6Q02P$"% ,4    "  80#57_Y^X>X4"  !L!0  &0
M    @('^K   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M !A -5<;KLSFL0(  .D%   9              " @;JO  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ &$ U5X-75]68 @  J 4  !D
M             ("!HK(  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    "  80#57XNDWGK,#  "3"0  &0              @(%QM0  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !A -5?GJ7.D$04
M /,,   9              " @5NY  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ &$ U5]D(L=D;!0  #@T  !D              ("!
MH[X  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  80#57
M.&3+]K "  "R!0  &0              @('UPP  >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( !A -5>,Q:V'PP,  -X5   9
M      " @=S&  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ &$ U5W0.Z,(U @  VP0  !D              ("!ULH  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  80#57<K[KV!H#   B#
M&0              @(%"S0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( !A -5=>OBC2(P4  +83   9              " @9/0  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ &$ U5XBOJSW+
M @  ! <  !D              ("![=4  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    "  80#57M 7,.PD#  #+"0  &0
M@('OV   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !A
M-5?'BM..GP(  &8(   9              " @2_<  !X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ &$ U5[<OHU%R @  F 8  !D
M         ("!!=\  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M    "  80#57EQ[\<[("  "E!P  &0              @(&NX0  >&PO=V]R
M:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !A -5>%NG<LD0,  ' 1
M   9              " @9?D  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
M4$L! A0#%     @ &$ U5^-,'L-Y @  X@4  !D              ("!7^@
M 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  80#57&Z_I
M:M\"  #4"   &0              @($/ZP  >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;%!+ 0(4 Q0    ( !A -5<O\7G,XP,  &X.   9
M  " @27N  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M&$ U5_%O*!BQ @  C0<  !D              ("!/_(  'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    "  80#57N\P<NJ@"  ! "   &0
M            @($G]0  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( !A -5<HF?:4<@,  $0,   9              " @0;X  !X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ &$ U5SGSP,G:!
M3Q8  !D              ("!K_L  'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    "  80#57+YZ#7*<"   N!P  &0              @('
M  $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !A -5?:
MR#M0,0,  -8+   9              " @9X# 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ &$ U5U,E)LS)$   \_X  !D
M     ("!!@<! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !A -5>8C#XV_P8  #\K   9              "
M@58F 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ &$ U
M5_HS_]DE @  <04  !D              ("!C"T! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    "  80#57L-]W7V "  !W!0  &0
M        @('H+P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( !A -5?[#[-E$P,  /((   9              " @7\R 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ &$ U5[LV4G*T @  AP@
M !D              ("!R34! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    "  80#57X?C;V&,.  "VQ   &0              @(&T. $
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( !A -5?@HG/\
M30,  +05   -              "  4Y' 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ &$ U5Y>*NQS     $P(   L              ( !QDH! %]R96QS
M+RYR96QS4$L! A0#%     @ &$ U5P\?2O?>!   -RH   \
M ( !KTL! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !A -5?22;QM$0(
M !<F   :              "  ;I0 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( !A -5? B&UTZ0$  'XE   3              "
M 0-3 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !( $@ KQ,  !U5 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>276</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Cash, cash equivalents, and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash</Role>
      <ShortName>Cash, cash equivalents, and restricted cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Prepaid and other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets</Role>
      <ShortName>Prepaid and other assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure -  Loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LossPerShare</Role>
      <ShortName>Loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessTables</Role>
      <ShortName>Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Business</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Revenue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Cash, cash equivalents, and restricted cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables</Role>
      <ShortName>Cash, cash equivalents, and restricted cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Prepaid and other assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables</Role>
      <ShortName>Prepaid and other assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/StockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LossPerShareTables</Role>
      <ShortName>Loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/LossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Business - Summary of entities in control (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail</Role>
      <ShortName>Business - Summary of entities in control (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Business - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail</Role>
      <ShortName>Business - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Liquidity - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail</Role>
      <ShortName>Liquidity - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Revenue - Summary of revenue from customers (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail</Role>
      <ShortName>Revenue - Summary of revenue from customers (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail</Role>
      <ShortName>Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid and other assets - Summary of other current assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and equipment, net - Summary  of property and equipment net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Property and equipment, net - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and equipment, net - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail</Role>
      <ShortName>Trade and other payables- Summary of trade and other payables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail</Role>
      <ShortName>Leases - Summary of supplemental balance sheet information related to leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Leases - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of maturities of the operating lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of warrants or rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of equity awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Stockholders' equity - Summary of equity-based compensation expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders' equity - Summary of equity-based compensation expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders' equity - Summary of share-based compensation expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Stockholders' equity - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' equity - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Income taxes - Summary of income (loss) before provision for income taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail</Role>
      <ShortName>Income taxes - Summary of income (loss) before provision for income taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Income taxes - Summary of company's deferred taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail</Role>
      <ShortName>Income taxes - Summary of company's deferred taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail</Role>
      <ShortName>Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail</Role>
      <ShortName>Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Income taxes - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income taxes - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Commitments and contingencies - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and contingencies - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Related party transactions - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related party transactions - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Loss per share - Summary of Loss per share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail</Role>
      <ShortName>Loss per share - Summary of Loss per share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Loss per share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail</Role>
      <ShortName>Loss per share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d549728d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bntc-20230630.xsd</File>
    <File>bntc-20230630_cal.xml</File>
    <File>bntc-20230630_def.xml</File>
    <File>bntc-20230630_lab.xml</File>
    <File>bntc-20230630_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="d549728d10k.htm">d549728d10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g549728g07a03.jpg</File>
    <File>g549728g09b03.jpg</File>
    <File>g549728g11c03.jpg</File>
    <File>g549728g12d03.jpg</File>
    <File>g549728g13e03.jpg</File>
    <File>g549728g14f03.jpg</File>
    <File>g549728g15g03.jpg</File>
    <File>g549728g15h04.jpg</File>
    <File>g549728g16p01.jpg</File>
    <File>g549728g16p02.jpg</File>
    <File>g549728g18p03.jpg</File>
    <File>g549728g19p04.jpg</File>
    <File>g549728g20p05.jpg</File>
    <File>g549728g21p06.jpg</File>
    <File>g549728g22p07.jpg</File>
    <File>g549728g23p08.jpg</File>
    <File>g549728g28p24.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="433">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d549728d10k.htm": {
   "nsprefix": "bntc",
   "nsuri": "http://www.benitecbiopharmainc.com/20230630",
   "dts": {
    "schema": {
     "local": [
      "bntc-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bntc-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bntc-20230630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bntc-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bntc-20230630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d549728d10k.htm"
     ]
    }
   },
   "keyStandard": 226,
   "keyCustom": 50,
   "axisStandard": 19,
   "axisCustom": 4,
   "memberStandard": 30,
   "memberCustom": 31,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 123,
   "entityCount": 1,
   "segmentCount": 63,
   "elementCount": 454,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 433,
    "http://xbrl.sec.gov/dei/2023": 46
   },
   "report": {
    "R1": {
     "role": "http://www.benitecbiopharmainc.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:RoyaltiesAndLicenseFees",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "longName": "1005 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2021",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2021",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "1007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:AmortizationOfRightOfUseAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.benitecbiopharmainc.com/role/Business",
     "longName": "1008 - Disclosure - Business",
     "shortName": "Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.benitecbiopharmainc.com/role/Liquidity",
     "longName": "1010 - Disclosure - Liquidity",
     "shortName": "Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.benitecbiopharmainc.com/role/Revenue",
     "longName": "1011 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash",
     "longName": "1012 - Disclosure - Cash, cash equivalents, and restricted cash",
     "shortName": "Cash, cash equivalents, and restricted cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets",
     "longName": "1013 - Disclosure - Prepaid and other assets",
     "shortName": "Prepaid and other assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet",
     "longName": "1014 - Disclosure - Property and equipment, net",
     "shortName": "Property and equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables",
     "longName": "1015 - Disclosure - Trade and other payables",
     "shortName": "Trade and other payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.benitecbiopharmainc.com/role/Leases",
     "longName": "1016 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquity",
     "longName": "1017 - Disclosure - Stockholders' equity",
     "shortName": "Stockholders' equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxes",
     "longName": "1018 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies",
     "longName": "1019 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions",
     "longName": "1020 - Disclosure - Related party transactions",
     "shortName": "Related party transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.benitecbiopharmainc.com/role/LossPerShare",
     "longName": "1021 - Disclosure -  Loss per share",
     "shortName": "Loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.benitecbiopharmainc.com/role/SubsequentEvents",
     "longName": "1022 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.benitecbiopharmainc.com/role/BusinessTables",
     "longName": "1024 - Disclosure - Business (Tables)",
     "shortName": "Business (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:ScheduleOfEntitiesInControlTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:ScheduleOfEntitiesInControlTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "1025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.benitecbiopharmainc.com/role/RevenueTables",
     "longName": "1026 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables",
     "longName": "1027 - Disclosure - Cash, cash equivalents, and restricted cash (Tables)",
     "shortName": "Cash, cash equivalents, and restricted cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables",
     "longName": "1028 - Disclosure - Prepaid and other assets (Tables)",
     "shortName": "Prepaid and other assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables",
     "longName": "1029 - Disclosure - Property and equipment, net (Tables)",
     "shortName": "Property and equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables",
     "longName": "1030 - Disclosure - Trade and other payables (Tables)",
     "shortName": "Trade and other payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.benitecbiopharmainc.com/role/LeasesTables",
     "longName": "1031 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables",
     "longName": "1032 - Disclosure - Stockholders' equity (Tables)",
     "shortName": "Stockholders' equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxesTables",
     "longName": "1033 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.benitecbiopharmainc.com/role/LossPerShareTables",
     "longName": "1034 - Disclosure - Loss per share (Tables)",
     "shortName": "Loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail",
     "longName": "1035 - Disclosure - Business - Summary of entities in control (Detail)",
     "shortName": "Business - Summary of entities in control (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "dei:EntityIncorporationStateCountryCode",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
      "name": "dei:EntityIncorporationStateCountryCode",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfEntitiesInControlTableTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail",
     "longName": "1036 - Disclosure - Business - Additional information (Detail)",
     "shortName": "Business - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
     "longName": "1037 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "1038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "bntc:FinancialAssetsAtFairValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail",
     "longName": "1039 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of foreign currency translation and other comprehensive income (loss) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfForeignCurrencyTranslationRatesTableTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail",
     "longName": "1040 - Disclosure - Liquidity - Additional information (Detail)",
     "shortName": "Liquidity - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail",
     "longName": "1041 - Disclosure - Revenue - Summary of revenue from customers (Detail)",
     "shortName": "Revenue - Summary of revenue from customers (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023_LicenseMembersrtProductOrServiceAxis",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail",
     "longName": "1042 - Disclosure - Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)",
     "shortName": "Cash, cash equivalents, and restricted cash - Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:DueFromBanks",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:DueFromBanks",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail",
     "longName": "1043 - Disclosure - Prepaid and other assets - Summary of other current assets (Detail)",
     "shortName": "Prepaid and other assets - Summary of other current assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
     "longName": "1044 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)",
     "shortName": "Property and equipment, net - Summary  of property and equipment net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail",
     "longName": "1045 - Disclosure - Property and equipment, net - Additional information (Detail)",
     "shortName": "Property and equipment, net - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail",
     "longName": "1046 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)",
     "shortName": "Trade and other payables- Summary of trade and other payables (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
     "longName": "1047 - Disclosure - Leases - Summary of supplemental balance sheet information related to leases (Detail)",
     "shortName": "Leases - Summary of supplemental balance sheet information related to leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2022",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2021",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "bntc:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
     "longName": "1048 - Disclosure - Leases - Additional information (Detail)",
     "shortName": "Leases - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail",
     "longName": "1049 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)",
     "shortName": "Leases - Summary of maturities of the operating lease liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
     "longName": "1050 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)",
     "shortName": "Stockholders' equity - Schedule of warrants or rights (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2022",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "bntc:ClassOfWarrantOrRightsExercised",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail",
     "longName": "1051 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)",
     "shortName": "Stockholders' equity - Schedule of equity awards (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail",
     "longName": "1052 - Disclosure - Stockholders' equity - Summary of equity-based compensation expense (Detail)",
     "shortName": "Stockholders' equity - Summary of equity-based compensation expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail",
     "longName": "1053 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)",
     "shortName": "Stockholders' equity - Summary of share-based compensation expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
     "longName": "1054 - Disclosure - Stockholders' equity - Additional information (Detail)",
     "shortName": "Stockholders' equity - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "PAsOn09_15_2022",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail",
     "longName": "1055 - Disclosure - Income taxes - Summary of income (loss) before provision for income taxes (Detail)",
     "shortName": "Income taxes - Summary of income (loss) before provision for income taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail",
     "longName": "1056 - Disclosure - Income taxes - Summary of company's deferred taxes (Detail)",
     "shortName": "Income taxes - Summary of company's deferred taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail",
     "longName": "1057 - Disclosure - Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)",
     "shortName": "Income taxes - Summary of net operating losses and tax credit carryforwards (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2023_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail",
     "longName": "1058 - Disclosure - Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)",
     "shortName": "Income taxes - Summary reconciliation of effective rate of the company's provision (benefit) for income taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "1059 - Disclosure - Income taxes - Additional information (Detail)",
     "shortName": "Income taxes - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "1060 - Disclosure - Commitments and contingencies - Additional information (Detail)",
     "shortName": "Commitments and contingencies - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2023",
      "name": "us-gaap:CommitmentsAndContingencies",
      "unitRef": "Unit_USD",
      "xsiNil": "true",
      "lang": null,
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "longName": "1061 - Disclosure - Related party transactions - Additional information (Detail)",
     "shortName": "Related party transactions - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "us-gaap:LegalFees",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023_FrancisAbourizkLightowlersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "name": "us-gaap:LegalFees",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail",
     "longName": "1062 - Disclosure - Loss per share - Summary of Loss per share (Detail)",
     "shortName": "Loss per share - Summary of Loss per share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail",
     "longName": "1063 - Disclosure - Loss per share - Additional Information (Detail)",
     "shortName": "Loss per share - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "P07_01_2022To06_30_2023",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2022To06_30_2023_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail",
     "longName": "1064 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "PAsOn09_15_2022",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn10_01_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "bntc:ForeignCurrencyExchangeRateConversion",
      "unitRef": "Unit_AUD_per_unit",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d549728d10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "presentationGuidance": "Commitments and contingencies (Note 12)",
        "verboseLabel": "Contingent liabilities",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r51",
      "r452",
      "r520"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r197",
      "r612"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share based compensation by share based award contractual term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r714"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r96",
      "r97",
      "r100",
      "r101"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "negatedLabel": "Principal payments on operating lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r89",
      "r115",
      "r139",
      "r453"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r180"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of revenue from customers",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease has a remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive income",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r11",
      "r88",
      "r128",
      "r131"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid and other assets",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r376"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "periodEndLabel": "Operating lease liabilities at June 30, 2023",
        "periodStartLabel": "Initial measurement at July 1, 2021",
        "verboseLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Re-measurement of operating lease right-of-use assets and liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r621"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end (In shares)",
        "periodStartLabel": "Balance at the beginning (In shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic",
        "negatedLabel": "Basic loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r162",
      "r164",
      "r167",
      "r168",
      "r169",
      "r173",
      "r368",
      "r369",
      "r448",
      "r463",
      "r609"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current portion",
        "periodEndLabel": "Current portion at June 30, 2023",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r640"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "verboseLabel": "Entity Incorporation Date Of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of company's deferred taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of income (loss) before provision for income taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary reconciliation of effective rate of the company's provision (benefit) for income taxes",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance at the beginning",
        "periodEndLabel": "Balance at end",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r76",
      "r523",
      "r539",
      "r566",
      "r567",
      "r622",
      "r634",
      "r658",
      "r666",
      "r709",
      "r727"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "negatedLabel": "Less:\u00a0non-current\u00a0portion",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "bntc_RoyaltiesAndLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "RoyaltiesAndLicenseFees",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalties And License Fees",
        "terseLabel": "Royalties and license fees",
        "documentation": "Royalties and license fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "verboseLabel": "Cash, cash equivalents, and restricted cash",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r453"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r449",
      "r460",
      "r622"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_BenitecBiopharmaProprietaryLimitedBblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "BenitecBiopharmaProprietaryLimitedBblMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Biopharma Proprietary Limited BBL [Member]",
        "verboseLabel": "Benitec Biopharma Proprietary Limited (\"BBL\") [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_BenitecIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "BenitecIncMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Inc [Member]",
        "verboseLabel": "Benitec, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r98"
     ]
    },
    "bntc_RnaiTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "RnaiTherapeuticsIncMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RNAi Therapeutics Inc [Member]",
        "verboseLabel": "RNAi Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "terseLabel": "Licensing revenue [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r705"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Summary of other current assets",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r99",
      "r102",
      "r458"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_WarrantsExercisedDuringThePeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "WarrantsExercisedDuringThePeriod",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercised During The Period",
        "terseLabel": "Exercise of\u00a0pre-funded\u00a0warrants, Shares",
        "documentation": "Warrants exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "IssuanceAndExerciseOfPrefundedAndCommonWarrants",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and exercise of prefunded and common warrants",
        "terseLabel": "Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $1,869, Shares",
        "documentation": "Issuance and exercise of pre-funded and common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "IssuanceAndExerciseOfPrefundedAndCommonWarrantsNetOfTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance And Exercise Of Prefunded and Common Warrants Net Of Transaction Costs",
        "terseLabel": "Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $1,869",
        "documentation": "Issuance and exercise of pre-funded and common warrants, net of transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_IncreasedecreaseInAccountsAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "IncreasedecreaseInAccountsAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease in Accounts and Other Payables",
        "verboseLabel": "Trade and other payables",
        "documentation": "Increase (decrease) in accounts and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ClassOfWarrantsOrRightsExcercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ClassOfWarrantsOrRightsExcercisable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrants Or Rights Excercisable",
        "verboseLabel": "Exercisable at June 30, 2023",
        "documentation": "Class of warrants or rights excercisable."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Lease Liabilities",
        "verboseLabel": "Lease liability",
        "documentation": "Increase decrease In lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_Weightedaverageexercisepriceofclassofwarrantsorrightsexercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "Weightedaverageexercisepriceofclassofwarrantsorrightsexercised",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExercised",
        "terseLabel": "Pre-funded warrants exercised",
        "documentation": "Weighted average exercise price of class of warrants or rights exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_AmortizationOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "AmortizationOfRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Right of Use Assets",
        "verboseLabel": "Amortization of right-of-use assets",
        "documentation": "Amortization of right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Class of warrant or right, exercise price of warrants or rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "bntc_UnrealizedGainLossOnInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "UnrealizedGainLossOnInvestment",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain Loss On Investment",
        "negatedLabel": "Unrealized loss on investment",
        "documentation": "Unrealized (gain) loss on investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted",
        "negatedLabel": "Diluted loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r164",
      "r167",
      "r168",
      "r169",
      "r173",
      "r368",
      "r369",
      "r448",
      "r463",
      "r609"
     ]
    },
    "bntc_LiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "LiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Abstract]",
        "documentation": "Liquidity."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ScheduleOfEntitiesInControlAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ScheduleOfEntitiesInControlAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r607"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Tax Year",
        "terseLabel": "Tax year subject to examination",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "bntc_LiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "LiquidityDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Liquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity Disclosure [Text Block]",
        "terseLabel": "Liquidity",
        "documentation": "Liquidity disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail",
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Principal place of business/country of incorporation",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_RisksAndUncertainitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "RisksAndUncertainitiesPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks And Uncertainities [Policy Text Block]",
        "verboseLabel": "Risks and Uncertainties",
        "documentation": "Risks and uncertainities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15"
     ]
    },
    "bntc_TradeAndOtherPayablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "TradeAndOtherPayablesPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables [Policy Text Block]",
        "verboseLabel": "Trade and other payables",
        "documentation": "Trade and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "bntc_ScheduleOfEntitiesInControlTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ScheduleOfEntitiesInControlTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Table Text Block]",
        "verboseLabel": "Summary of entities in control",
        "documentation": "Schedule of entities in control."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Summary of property and equipment",
        "documentation": "Schedule of property plant and equipment useful lives."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ScheduleOfForeignCurrencyTranslationRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ScheduleOfForeignCurrencyTranslationRatesTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Foreign Currency Translation Rates [Table Text Block]",
        "terseLabel": "Summary of foreign currency translation and other comprehensive income (loss)",
        "documentation": "Schedule of foreign currency translation rates."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_NumberOfSeriesWarrantsIssued": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "NumberOfSeriesWarrantsIssued",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Series Warrants Issued",
        "terseLabel": "Number of series of warrants issued",
        "documentation": "Number of series warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Summary of supplemental balance sheet information related to leases",
        "documentation": "Schedule of supplemental balance sheet information related to leases."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Table Text Block]",
        "terseLabel": "Summary of net operating losses and tax credit carryforwards",
        "documentation": "Disclosure details of operating loss carry forwards and tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r170",
      "r171",
      "r172"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "bntc_ScheduleOfEntitiesInControlTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ScheduleOfEntitiesInControlTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_BenitecLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "BenitecLimitedMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Limited [Member]",
        "verboseLabel": "Benitec Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_TacereTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "TacereTherapeuticsIncMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tacere Therapeutics Inc [Member]",
        "verboseLabel": "Tacere Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_SeriesTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "SeriesTwoWarrantsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Two Warrants [Member]",
        "terseLabel": "Series 2 Warrants [Member]",
        "documentation": "Series 2 Warrants [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_BenitecLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "BenitecLlcMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec LLC [Member]",
        "verboseLabel": "Benitec LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "bntc_BenitecAustraliaProprietaryLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "BenitecAustraliaProprietaryLimitedMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec Australia Proprietary Limited [Member]",
        "verboseLabel": "Benitec Australia Proprietary Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r705"
     ]
    },
    "bntc_BasicAndDilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Earnings Per Share [Abstract]",
        "terseLabel": "Weighted-average shares outstanding:",
        "documentation": "Basic and diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r217",
      "r218",
      "r606"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Investments",
        "verboseLabel": "Unrealized loss on investment",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r148",
      "r149",
      "r150",
      "r151",
      "r160",
      "r201",
      "r202",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r220",
      "r302",
      "r303",
      "r304",
      "r329",
      "r330",
      "r331",
      "r332",
      "r340",
      "r341",
      "r342",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r432",
      "r433",
      "r434",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r705"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r129",
      "r131",
      "r136",
      "r447",
      "r462"
     ]
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r148",
      "r149",
      "r150",
      "r151",
      "r160",
      "r201",
      "r202",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r220",
      "r302",
      "r303",
      "r304",
      "r329",
      "r330",
      "r331",
      "r332",
      "r340",
      "r341",
      "r342",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r432",
      "r433",
      "r434",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_TaxYear2011Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2011Member",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2011 [Member]",
        "terseLabel": "Tax Year 2011 [Member]",
        "documentation": "Identified as tax year 2011."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r174",
      "r431",
      "r485",
      "r507",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r543",
      "r544",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r565",
      "r628"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "verboseLabel": "Current portion",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r622"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r115",
      "r605"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "bntc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedDuringPeriodWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted During Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term, Granted",
        "documentation": "Share based compensation arrangement by share based payment award options granted during period weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Trade and other payables",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_IssueOfCommonStockAndWarrantPricePerShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "IssueOfCommonStockAndWarrantPricePerShare",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Of Common Stock And Warrant Price Per Share",
        "terseLabel": "Issue of common stock and warrant price per share",
        "documentation": "Issue of common stock and warrant price per share."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ClassOfWarrantsOrRightsIssuePricePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ClassOfWarrantsOrRightsIssuePricePerUnit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrants Or Rights Issue Price Per Unit",
        "terseLabel": "Class of warrants or rights issue price per unit",
        "documentation": "Class of warrants or rights issue price per unit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock Par Value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "verboseLabel": "Accrued employee benefit payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "bntc_PurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "PurchaseWarrantsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants [Member]",
        "terseLabel": "Purchase warrants [Member]",
        "documentation": "Purchase warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r120",
      "r121",
      "r122",
      "r142",
      "r164",
      "r165",
      "r167",
      "r169",
      "r175",
      "r176",
      "r206",
      "r228",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r238",
      "r239",
      "r241",
      "r244",
      "r250",
      "r379",
      "r487",
      "r488",
      "r489",
      "r490",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r521",
      "r542",
      "r565",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r645",
      "r657",
      "r663"
     ]
    },
    "bntc_CashlessExerciseOfPurchaseWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "CashlessExerciseOfPurchaseWarrants",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of purchase warrants",
        "terseLabel": "Cashless exercise of purchase warrants (In shares)",
        "documentation": "Cashless exercise of purchase warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "terseLabel": "Prepaid and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r650"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r109",
      "r133",
      "r134",
      "r135",
      "r145",
      "r146",
      "r147",
      "r149",
      "r157",
      "r159",
      "r174",
      "r210",
      "r216",
      "r252",
      "r302",
      "r303",
      "r304",
      "r331",
      "r332",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r367",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r419",
      "r474",
      "r475",
      "r476",
      "r496",
      "r565"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Unrealized foreign currency translation gain",
        "verboseLabel": "Foreign currency translation gain",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r63",
      "r386",
      "r388",
      "r391"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r428"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, less current portion",
        "verboseLabel": "Less: non-current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r222",
      "r223",
      "r590",
      "r668"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-based Compensation Expense",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r274",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r221",
      "r549"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r508",
      "r509",
      "r510",
      "r574",
      "r576",
      "r579",
      "r581",
      "r588",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r604",
      "r616",
      "r627",
      "r674",
      "r725"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Expiry date of warrants",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Payments For Stock Issuance Costs",
        "negatedLabel": "Share issue transaction costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r549"
     ]
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California Franchise Tax Board [Member]",
        "documentation": "Designated tax department of the government of the state of California."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Stock Options, Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r427"
     ]
    },
    "us-gaap_TaxYear2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2016Member",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2016 [Member]",
        "documentation": "Identified as tax year 2016."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "periodStartLabel": "Initial measurement at July 1, 2021",
        "periodEndLabel": "Operating lease right-of-use asset at June 30, 2023",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/Business"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r74",
      "r75"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding at June 30, 2023",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock Options, Outstanding, end of period",
        "periodStartLabel": "Stock Options,Outstanding, beginning of period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "periodStartLabel": "Outstanding, beginning of period",
        "periodEndLabel": "Outstanding, ending of period",
        "terseLabel": "Warrants outstanding",
        "verboseLabel": "Number of warrants or rights outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted-average Exercise price, beginning of period",
        "periodEndLabel": "Weighted-average Exercise Price, Exercise price, end of period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Stock Options, Exercisable, end of period",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average Exercise Price, Exercisable, end of period",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r640"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Amortization of right of use asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r508",
      "r509",
      "r510",
      "r574",
      "r576",
      "r579",
      "r581",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r604",
      "r616",
      "r627",
      "r674",
      "r725"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share based compensation by share based award unrecognized expense remaining period of recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_TaxYear2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2019Member",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2019 [Member]",
        "terseLabel": "Tax Year 2019 [Member]",
        "documentation": "Identified as tax year 2019."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee stock option [Member]",
        "verboseLabel": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Warrants convertible into shares of common stock on exercise",
        "terseLabel": "Warrants convertible into shares of common stock on exercise",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r141",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r252",
      "r358",
      "r568",
      "r570",
      "r587"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issues of shares and pre-funded warrants",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Stockholders' equity, reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r431",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r603",
      "r615",
      "r623",
      "r647",
      "r669",
      "r670",
      "r674",
      "r725"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenues from customers",
        "exampleGuidance": "Revenues from customers",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r188",
      "r191",
      "r192",
      "r196",
      "r197",
      "r199",
      "r261",
      "r262",
      "r431"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Net proceeds from public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r423",
      "r424",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r538",
      "r540",
      "r572",
      "r715"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r431",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r603",
      "r615",
      "r623",
      "r647",
      "r669",
      "r670",
      "r674",
      "r725"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r423",
      "r424",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r538",
      "r540",
      "r572"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r660",
      "r661",
      "r707",
      "r726",
      "r727"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsExcercisable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Of Class Of Warrants Or Rights Excercisable",
        "verboseLabel": "Exercisable at June 30, 2023",
        "documentation": "Weighted average exercise price of class of warrants or rights excercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "bntc_Series2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "Series2WarrantsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series 2 Warrants [Member]",
        "documentation": "Series 2 warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets",
        "totalLabel": "Total other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r118",
      "r450",
      "r634"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of trade and other payables",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r99",
      "r102",
      "r103"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Schedule of cash, cash equivalents, and restricted cash and Restricted cash equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_BenitecIpHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "BenitecIpHoldingsIncMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benitec IP Holdings Inc [Member]",
        "terseLabel": "Benitec IP Holdings, Inc.[Member]",
        "documentation": "Benitec IP Holdings, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "verboseLabel": "Weighted average number of shares used in calculating diluted earnings per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r169"
     ]
    },
    "bntc_ClassOfWarrantOrRightsIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ClassOfWarrantOrRightsIssuedDuringPeriod",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Rights Issued During Period",
        "verboseLabel": "Series 2 Warrants issued September 16, 2022",
        "terseLabel": "Class of warrant or rights issued during period",
        "documentation": "Class of warrant or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average Exercise Price Of Class Of Warrants Or Rights Outstanding",
        "periodStartLabel": "Exercise price of class of warrants or rights outstanding",
        "periodEndLabel": "Exercise price of class of warrants or rights outstanding",
        "documentation": "Weighted-average exercise price of class of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab equipment [Member]",
        "documentation": "Lab equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r674"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "bntc_ScheduleOfEntitiesInControlLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ScheduleOfEntitiesInControlLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Entities In Control [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r674"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r376"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average number of shares used in calculating basic earnings per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r169"
     ]
    },
    "bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "WeightedAverageExercisePriceOfClassOfWarrantsOrRightsIssuedDuringThePeriod",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Of Class Of Warrants Or Rights Issued During The Period",
        "terseLabel": "Series 2 Warrants issued September 16, 2022",
        "verboseLabel": "Class of warrants or rights weighted average exercise price of class of warrants or rights issued during the period",
        "documentation": "Weighted average exercise price of class of warrants or rights issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "DescriptionOfPropertyPlantAndEquipmentEstimatedUsefulLives",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives",
        "documentation": "Description of Property, Plant and Equipment, Estimated Useful Lives."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "bntc_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies [Line Items]."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_FinancialAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "FinancialAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Assets At Fair Value",
        "terseLabel": "Financial assets at fair value",
        "documentation": "Financial assets at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_MarketValueOfListedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "MarketValueOfListedShares",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PrepaidAndOtherAssetsSummaryOfOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market value Of listed shares",
        "terseLabel": "Market value of listed shares",
        "documentation": "Market value of listed shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r545",
      "r546",
      "r549"
     ]
    },
    "bntc_AverageForeignExchangeRateForThePeriod": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "AverageForeignExchangeRateForThePeriod",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Foreign Exchange Rate For The Period",
        "terseLabel": "Average exchange rate for the period, USD: AUD Exchange Rate",
        "documentation": "Average foreign exchange rate for the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r493",
      "r494",
      "r495",
      "r547",
      "r548",
      "r549",
      "r569",
      "r571"
     ]
    },
    "bntc_AccruedOpmdProjectCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "AccruedOpmdProjectCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Opmd Project Costs Current",
        "negatedLabel": "Accrued OPMD project costs",
        "documentation": "Accrued Opmd Project Costs Current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r549"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_AccruedConsultantFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "AccruedConsultantFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Consultant Fees Current",
        "terseLabel": "Accrued consultant fees",
        "documentation": "Accrued offering costs current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_AccruedLicenceFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "AccruedLicenceFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Licence Fees Current",
        "terseLabel": "Accrued license fees",
        "documentation": "Accrued licence fees current."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxYear2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2014Member",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2014 [Member]",
        "terseLabel": "Tax Year 2014 [Member]",
        "documentation": "Identified as tax year 2014."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "bntc_OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "OperatingLeaseRightOfUseAssetRemasurementDuringThePeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Right Of Use Asset Remasurement During The Period",
        "verboseLabel": "Re-measurement during the period",
        "documentation": "Operating lease right of use asset remasurement during the period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "bntc_RemeasurementOfLeaseLiabilitiesDuringThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "RemeasurementOfLeaseLiabilitiesDuringThePeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remeasurement Of Lease Liabilities During The Period",
        "verboseLabel": "Re-measurement during the period",
        "documentation": "Remeasurement of lease liabilities during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognised share based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ClassOfWarrantOrRightsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ClassOfWarrantOrRightsExercised",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Rights Exercised",
        "terseLabel": "Pre-funded warrants exercised",
        "documentation": "Class of warrant or rights exercised."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre funded Warrants [Member]",
        "terseLabel": "Pre-funded warrants [Member]",
        "documentation": "Pre funded warrants ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      },
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail",
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LossPerShareSummaryOfLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss attributable to common stockholders",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r73",
      "r94",
      "r112",
      "r127",
      "r130",
      "r135",
      "r142",
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r166",
      "r177",
      "r189",
      "r193",
      "r195",
      "r206",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r369",
      "r379",
      "r461",
      "r541",
      "r563",
      "r564",
      "r611",
      "r633",
      "r671"
     ]
    },
    "bntc_WeightedAverageExercisePriceOfPreFundedWarrantsIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "WeightedAverageExercisePriceOfPreFundedWarrantsIssued",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Of Pre Funded Warrants Issued",
        "terseLabel": "Pre-funded warrants issued",
        "documentation": "Weighted average exercise price of pre funded warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]",
        "verboseLabel": "Trade and Other Receivables",
        "documentation": "Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DueFromBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DueFromBanks",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from Banks",
        "verboseLabel": "Cash at bank",
        "documentation": "A bank's noninterest bearing demand deposits in other banks (such as correspondents)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r46",
      "r47",
      "r199",
      "r589"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r79"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property and equipment net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Foreign Currency Translation and Other Comprehensive Income (Loss)",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value\u2014160,000,000 shares authorized; 1,645,951 and 480,688 shares issued and outstanding at June 30, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r454",
      "r622"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r46",
      "r47",
      "r199",
      "r484",
      "r589"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r521"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      },
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Trade and other payables",
        "totalLabel": "Total",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r57",
      "r521",
      "r539",
      "r727",
      "r728"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r82",
      "r456",
      "r478",
      "r483",
      "r491",
      "r522",
      "r622"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashAndRestrictedCashEquivalentsDetail",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r648",
      "r656"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r126",
      "r142",
      "r206",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r343",
      "r345",
      "r379",
      "r622",
      "r671",
      "r672",
      "r716"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of equity-based compensation expense",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r629",
      "r630",
      "r631",
      "r632"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Share-based payments",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r702"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities at fair value",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of equity awards",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other loss:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Trade and other receivables",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r119",
      "r142",
      "r177",
      "r190",
      "r194",
      "r206",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r343",
      "r345",
      "r379",
      "r451",
      "r533",
      "r622",
      "r634",
      "r671",
      "r672",
      "r716"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r71"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other loss, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "verboseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r71",
      "r139"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r116",
      "r460"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Operating loss carryforwards, expiration years",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ClassOfWarrantsOrRightsExcercisedDuringThePeriod",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrants Or Rights Excercised During The Period",
        "documentation": "Class of warrants or rights excercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r544"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r312",
      "r317",
      "r320",
      "r327",
      "r333",
      "r337",
      "r338",
      "r339",
      "r492"
     ]
    },
    "bntc_RevisionInTheExercisePriceOfPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "RevisionInTheExercisePriceOfPrefundedWarrantsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision In The Exercise Price Of Prefunded Warrants [Member]",
        "terseLabel": "Revision In The Exercise Price Of Prefunded Warrants [Member]",
        "documentation": "Revision in the exercise price of prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "bntc_NolFromTwoThousandEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "NolFromTwoThousandEighteenMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL From Two Thousand Eighteen [Member]",
        "terseLabel": "NOL From Two Thousand Eighteen [Member]",
        "documentation": "NOL from two thousand eighteen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r496",
      "r660",
      "r661",
      "r662",
      "r707",
      "r727"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "bntc_MinimumNetBusinessIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "MinimumNetBusinessIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Net Business Income",
        "terseLabel": "Minimum net business income",
        "documentation": "Minimum net business income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash used in provided by operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "bntc_LegislationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "LegislationAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legislation [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r104",
      "r158",
      "r159",
      "r181",
      "r315",
      "r334",
      "r464"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r142",
      "r206",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r344",
      "r345",
      "r346",
      "r379",
      "r519",
      "r610",
      "r634",
      "r671",
      "r716",
      "r717"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, accrued interest and penalties",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "bntc_LegislationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "LegislationDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legislation [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of presentation and summary of significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r140"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r189",
      "r193",
      "r195",
      "r611"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Term, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r313",
      "r314",
      "r320",
      "r321",
      "r326",
      "r328",
      "r486"
     ]
    },
    "bntc_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty Equity Incentive Plan [Member]",
        "terseLabel": "Two Thousand And Twenty Equity Incentive Plan [Member]",
        "documentation": "Two thousand and twenty equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r640",
      "r642"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "bntc_EventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "EventAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Axis]",
        "terseLabel": "Event [Axis]",
        "documentation": "Event"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other payables",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Deferred tax assets increase in valuation allowance during the period",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "bntc_EventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "EventDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Event [Domain]",
        "terseLabel": "Event [Domain]",
        "documentation": "Event"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "bntc_PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "PeriodOfOwnershipControlForWhichTheShareholdersAreToSustainTheirHoldingForAvailingOperatingLossCarryForwards",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period Of Ownership Control For Which The Shareholders Are To Sustain Their Holding For Availing Operating Loss Carry Forwards",
        "terseLabel": "Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards",
        "documentation": "Period of ownership control for which the shareholders are to sustain their holding for availing operating loss carry forwards."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liability",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction loss",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r387",
      "r389",
      "r390",
      "r562"
     ]
    },
    "bntc_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Capitalized Research and Development Costs",
        "terseLabel": "Section\u00a0174 Capitalization",
        "documentation": "Deferred tax assets capitalized research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Table]",
        "documentation": "Disclosure details of operating loss carry forwards and tax credits [Table ]."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "DisclosureDetailsOfOperatingLossCarryForwardsAndTaxCreditsLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]",
        "terseLabel": "Disclosure Details Of Operating Loss Carry Forwards And Tax Credits [Line Items]",
        "documentation": "Disclosure details of operating loss carry forwards and tax credits [Line Items]."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_YearOfExpiryOfOperatingLossesCarryForwards": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "YearOfExpiryOfOperatingLossesCarryForwards",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Of Expiry Of Operating Losses Carry Forwards",
        "terseLabel": "Year of expiry of operating losses carry forwards",
        "documentation": "Year of expiry of operating losses carry forwards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r93",
      "r457",
      "r622",
      "r658",
      "r666",
      "r709"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "bntc_PeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "PeriodAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period [Axis]",
        "terseLabel": "Period [Axis]",
        "documentation": "Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_PeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "PeriodDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period [Domain]",
        "terseLabel": "Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "bntc_NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "NumberOfYearsOfCertainOperatingLossesThatCanBeCarriedBack",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Years Of Certain Operating Losses That Can Be Carried Back",
        "terseLabel": "Number of years of certain operating losses that can be carried back",
        "documentation": "Number of years of certain operating losses that can be carried back."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "bntc_NOLpreJanuaryOneTwoThousandEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "NOLpreJanuaryOneTwoThousandEighteenMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL pre January One Two Thousand Eighteen [Member]",
        "terseLabel": "NOL pre January One Two Thousand Eighteen [Member]",
        "documentation": "NOL pre january one two thousand eighteen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfEquityBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_YearTwoThousandAndThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "YearTwoThousandAndThirtyOneMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty One [Member]",
        "terseLabel": "Year Two Thousand And Thirty One [Member]",
        "documentation": "Year two thousand and thirty one [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r92",
      "r323"
     ]
    },
    "bntc_YearTwoThousandAndThirtyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "YearTwoThousandAndThirtyFourMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfNetOperatingLossesAndTaxCreditCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two Thousand And Thirty Four [Member]",
        "terseLabel": "Year Two Thousand And Thirty Four [Member]",
        "documentation": "Year two thousand and thirty four [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_EffectiveIncomeTaxReconciliationPercentagePermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "EffectiveIncomeTaxReconciliationPercentagePermanentDifferences",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Reconciliation Percentage Permanent Differences",
        "terseLabel": "Permanent differences",
        "documentation": "Effective income tax reconciliation percentage permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfSupplementalBalanceSheetInformationRelatedToLeasesDetail",
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LossPerShareAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r174",
      "r431",
      "r485",
      "r507",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r543",
      "r544",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r565",
      "r628"
     ]
    },
    "bntc_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Table]",
        "documentation": "Income tax disclosure [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r705"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Expense",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "bntc_SuspensionOfAnnualDeductionLimitationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "SuspensionOfAnnualDeductionLimitationMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suspension Of Annual Deduction Limitation [Member]",
        "terseLabel": "Suspension Of Annual Deduction Limitation [Member]",
        "documentation": "Suspension Of Annual Deduction Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "BeginningOnOrAfterJanuary12020AndBeforeJanuary12023Member",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning On Or After January 1, 2020, And Before January 1, 2023 [Member]",
        "terseLabel": "Beginning on or After January 1, 2020, and Before January 1, 2023 [Member]",
        "documentation": "Beginning on or after January 1, 2020, and before January 1, 2023."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ApplicabilityOfSuspensionOfDeductionsOfCaliforniaNolsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Applicability Of Suspension Of Deductions Of California NOLs [Member]",
        "terseLabel": "Applicability of Suspension of Deductions of California NOLs [Member]",
        "documentation": "Applicability of suspension of deductions of California NOLs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average Exercise Price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "bntc_UnexpectedEventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "UnexpectedEventAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unexpected Event [Axis]",
        "terseLabel": "Unexpected Event [Axis]",
        "documentation": "Unexpected Event"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Products and Services [Table]",
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r427"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r22",
      "r109",
      "r133",
      "r134",
      "r135",
      "r145",
      "r146",
      "r147",
      "r149",
      "r157",
      "r159",
      "r174",
      "r210",
      "r216",
      "r252",
      "r302",
      "r303",
      "r304",
      "r331",
      "r332",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r367",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r419",
      "r474",
      "r475",
      "r476",
      "r496",
      "r565"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r705"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r145",
      "r146",
      "r147",
      "r149",
      "r157",
      "r159",
      "r210",
      "r216",
      "r302",
      "r303",
      "r304",
      "r331",
      "r332",
      "r350",
      "r353",
      "r354",
      "r357",
      "r367",
      "r474",
      "r476",
      "r496",
      "r727"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r24",
      "r352",
      "r355",
      "r419",
      "r474",
      "r475",
      "r652",
      "r653",
      "r654",
      "r660",
      "r661",
      "r662"
     ]
    },
    "bntc_UnexpectedEventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "UnexpectedEventDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unexpected Event [Domain]",
        "terseLabel": "Unexpected Event [Domain]",
        "documentation": "Unexpected Event"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "PercentageOfTotalOwneshipControlToBeMaintainedByTheCurrentShareholdersForAvailingOperatingLossCarryForwards",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Total Owneship Control To Be Maintained By The Current Shareholders For Availing Operating Loss Carry Forwards",
        "terseLabel": "Percentage of total owneship control to be maintained by the current shareholders for availing operating loss carry forwards",
        "documentation": "Percentage of total ownership control to be maintained by the current shareholders for availing operating loss carry forwards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/LiquidityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r427"
     ]
    },
    "bntc_CaliforniaAssemblyBillEightyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "CaliforniaAssemblyBillEightyFiveMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Assembly Bill Eighty Five [Member]",
        "terseLabel": "California Assembly Bill Eighty Five [Member]",
        "documentation": "California assembly bill eighty five [member]."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_CoronavirusAidReliefAndEconomicSecurityActMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "CoronavirusAidReliefAndEconomicSecurityActMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coronavirus Aid Relief And Economic Security Act [Member]",
        "terseLabel": "Coronavirus Aid Relief And Economic Security Act [Member]",
        "documentation": "Coronavirus Aid Relief And Economic Security Act"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_PercentageOfAnnualTaxableIncomeEligibleForDeduction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "PercentageOfAnnualTaxableIncomeEligibleForDeduction",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Annual Taxable Income Eligible For Deduction",
        "terseLabel": "Percentage of annual Taxable income eligible for deduction",
        "documentation": "Percentage of annual taxable income eligible for deduction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r427"
     ]
    },
    "bntc_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]",
        "documentation": "Income tax disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Trade and other receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r114",
      "r142",
      "r206",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r344",
      "r345",
      "r346",
      "r379",
      "r622",
      "r671",
      "r716",
      "r717"
     ]
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfForeignCurrencyTranslationAndOtherComprehensiveIncomeLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Exchange rate on balance sheet dates, USD: AUD Exchange Rate",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r311",
      "r724"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r640"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r640"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r309"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r335"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r640"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Employee option awards related stock based compensation expense",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "bntc_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r117",
      "r459"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "bntc_SB113Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "SB113Member",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SB 113 [Member]",
        "terseLabel": "SB 113 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Assets",
        "terseLabel": "Deposits",
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r269"
     ]
    },
    "bntc_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "documentation": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_FrancisAbourizkLightowlersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "FrancisAbourizkLightowlersMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Francis Abourizk Lightowlers [Member]",
        "documentation": "Francis abourizk lightowlers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfIncomeLossBeforeProvisionForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "International",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r335"
     ]
    },
    "bntc_Dr.JerelBanksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "Dr.JerelBanksMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Jerel Banks [Member]",
        "documentation": "Dr. Jerel Banks."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryOfCompanySDeferredTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "bntc_MeganBostonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "MeganBostonMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Megan Boston [Member]",
        "documentation": "Megan Boston."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r63",
      "r123",
      "r455",
      "r479",
      "r483"
     ]
    },
    "bntc_ExecutiveDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ExecutiveDirectorMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Director [Member]",
        "documentation": "Executive director."
       }
      }
     },
     "auth_ref": []
    },
    "bntc_ExecutiveChairmanAndChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ExecutiveChairmanAndChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Chairman and Chief Executive Officer [Member]",
        "documentation": "Executive chairman and chief executive officer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Pre-funded warrants issued",
        "terseLabel": "Sale of stock number of shares issued in the transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxYear2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2022Member",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2022 [Member]",
        "documentation": "Identified as tax year 2022."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r602",
      "r608"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "bntc_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r706"
     ]
    },
    "bntc_AnnualBaseSalaryCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "AnnualBaseSalaryCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Base Salary Compensation",
        "terseLabel": "Annual base salary compensation",
        "documentation": "Annual base salary compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock issue price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r266",
      "r430",
      "r471",
      "r511",
      "r512",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r600",
      "r601",
      "r613",
      "r614",
      "r618",
      "r624",
      "r673",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "bntc_ForeignCurrencyExchangeRateConversion": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.benitecbiopharmainc.com/20230630",
     "localname": "ForeignCurrencyExchangeRateConversion",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Exchange Rate Conversion",
        "terseLabel": "Conversion Rate",
        "documentation": "Foreign currency exchange rate conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants or rights",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r264",
      "r266",
      "r296",
      "r297",
      "r298",
      "r429",
      "r430",
      "r471",
      "r511",
      "r512",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r600",
      "r601",
      "r613",
      "r614",
      "r618",
      "r624",
      "r627",
      "r667",
      "r673",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail",
      "http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of the operating lease liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r706"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail",
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r264",
      "r266",
      "r296",
      "r297",
      "r298",
      "r429",
      "r430",
      "r471",
      "r511",
      "r512",
      "r573",
      "r575",
      "r577",
      "r578",
      "r580",
      "r600",
      "r601",
      "r613",
      "r614",
      "r618",
      "r624",
      "r627",
      "r667",
      "r673",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r120",
      "r121",
      "r122",
      "r142",
      "r164",
      "r165",
      "r167",
      "r169",
      "r175",
      "r176",
      "r206",
      "r228",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r238",
      "r239",
      "r241",
      "r244",
      "r250",
      "r379",
      "r487",
      "r488",
      "r489",
      "r490",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r521",
      "r542",
      "r565",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r645",
      "r657",
      "r663"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.benitecbiopharmainc.com/role/IncomeTaxesSummaryReconciliationOfEffectiveRateOfTheCompanySProvisionBenefitForIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r316",
      "r336"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a-c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310/tableOfContent"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001193125-23-239121-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-239121-xbrl.zip
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M @9)Y[R\% P]OMII* <K^GOJ8NSGCL $#W,/E\368?'(&3%\+1;Z:<ZY"P'
M-(8&A$J!.%B)X^K"'14/\"5T^3)O#)+-^7UZE<("P\R26.]@Q?G@SR1,1,#5
MU1/V[7".VWYK$&O.KTLJ6E37/%C!M@F]=1?$VQ',.\WYAET$\ZPWT:_#78F(
M@M>/*==FZYU!)3D',JIFO0DJ'K!06_2$C"+:PS$H+^>0=M.?#EWQ890VK</L
M*X,Z<CYM6&N0:)5H;EK<-<H;=)'SAFO$@ =]%49\TPHJ*V#02,Z;-@6&!_$;
M@L!9!905,:@@YV:71(L'+13&AA]W!8]+-7"6\[E-(>1!_$% ."WOS!N#@'.N
M=U!I$&<^D)P6K?&K0<QY5[P@V#P(/15D3DL[_]H@YIS#G(Y #^)-Q^(R T7^
MO4' .?<W&Z@;1!R% V)W]0J\105NX@W'R#Z4N:2*,#<;<]A9VJ".O$,;12-&
M:0^6AE MQO7* ,"UW@20!TU-'$>32=P;/O>@%#X4*:FLH$$_.0\WI9\$G,42
M>(->VH1_XE)%YGY&IZ^,Q- ><EYV)P&H3%]?%[HH0[-JH_'=0\0K 3<THWPR
M=C?-:!B27G%(NO8$A8(7X69GO>+L1K"T2YS9J!58KFA>=3YNM:7$T"I?)?4\
M.[C- \JM:,=XL.CN)H"#H("=V?'& A_@#= E?Q@:<YR2OG-4JU2RN#'\9,Z$
M'\:970LI<4<-GZ^%M[KPI8)6+#*C08WR!C69,NZSW4Z$+^< &/I>"'G05Y5E
M%SQ%Q/%=&NQ?VU4Z]R)5.*WYO6 VM*$VVP>PG85D8D.S:]3$=_=;[U*5AM99
MN.84CQ7!/*_G415\2K>OAG4-+:3R'H?LL!-.Y@&>>+%K4&OA2E:I5PK?L]IM
M \*@Y#I;*U)Z+O%9]:K:H.Y"7>PTWAK4,R@V%V0L5^Q@W-58'HV[7.'7M#Z;
M5S>H-1>;-"VM9L9D95Q_/73]!@NGB2ONK]?!R77$39_5D^IV8?[XHQ=4S;A>
M'0$SZ#X7APQ7?3.JEBFDUBP\'T@BVDS'%F$6O/(L-UP['IH"RF&W?[VSF$%]
MN?A?K+YA\*W4.3\3Y0N]) 9#YY*&!R;QA2YVR\B,N?IK29>L"<*@R5S,K*@C
MKF)4>@1>@JL480NZG.4F^ 9=YW,S$D_X;T0(@J?)B'NV6&9]G@;UBK7Z+A?\
M*LSVR+J^SR$&RQ.6T#@&399I)'B>@-B<REHLJ&/08"XN5D&#X4NBP0_**U!$
MG.6@'\]AY-+GWU$N-5U7+_B3[M!F+2 &]59+Q\KF4.AW(SSCU]$+#!%"BP88
M!XV7*$NG%K54>!48!GWG E"[]:WSF09UUU+W3HNW7A6#,G.!)H,R!UMX9Y)E
MW+>2-=YSBHNL=\)[8GCH^[4G4N73NFP/QJ#?7+PID\29Z:39I=V9QHG1Q  I
M+A='1<(,T$'W>:7A:$KXYN&2SJD0U*FDZ;)*!KWF DYFO=H!]#](RPGA#PHT
M*_ +58G["3V!XNH>%+D N3%U 8[%!GI"SE+N!I1!V;D(DUG9&#9..;0:JXXP
M0EG+UH@M.XUY: 5YU=U3V^,V<YFF JSC^9S:BCW1>Z*HCE!$/38>D\\I!SY5
MG1&^8RR&ME-ZCDRJ[8@,-=I(C^BQ\.J3*%J2C";)U/!F%M#UPS!)E+6NG19=
MQ;(&3>?"7UN:'DRXVF<*[=18P[K%&GR?"W65GD0TJ+3V644[]=FDHD&9!=E@
MIA..!DU6VF45&U;IEYE5A8J%#1K+!;*V]F-E#*WMO5J#HA(Q[UZLJUC8H*A<
M!"JGJ%1WNAFZD_D,K-U!IAH5#-K*AYB2D[,"H/_O%8;_8?3SGLXM?5W=1P6?
M/QU)MEJ[>!>=?K<4=/[I"&_?&T4WZ_T=6#I^6;E1$81<<@N=UO&V%$+$$8CP
MBK/RZ_3&8189F!GCB/@C:]P!0R#QN@QEE?1]L>.265UVH IUOS].H&G7Y62K
M-W3,SSAUF]TX>\\=,.,)9?'"6S!-%SX&%VC>>K8&4U(%GT91O1&^&IV<CLY.
MCE^D$])6@X"$JWH$1/5J$E!\@V5%U%$%Q/FN"C;#S99%Z&1$7&&=,765C-[H
M1EF9V>*[,DM)**H2/31$GKUVLQKV=)WXJ1G^U/6<E7#'Y?6O9CC3UWQ60II4
M"'XV0YM<&5H):50<?S1$F%PE6@UC5%[_JHPS?QNI'F0Y7:#;6*T/NT)D:F%'
M_H"#Q\G[5B14'$)2Z%5KU.5WL58E)PWE*@%2DSK#I;F5FD-4'']4;@RF:V];
MC*P:3'T"MJ^KK49!=!]N@#V&T0A]2\2-^E_1?;M&"G;5U,\R14-X#;<F(MB'
M;$^X<\E<'_KL%1&<\47B(,^D$KK-!Z:<ON+Z(^[5XHL;15?H:1Q9)"SUZ4@)
MO"$H* 6F%?.<1UW/\8.++(\LSEP7$\VCLNCHH3'X]\J42'#A%%/Z:O-?A>>O
M([+ ]5P5,GGO;8B+9AZ OV4V9GU<4SPS)\W4RH.!@XA-$5MSXLJF?!F1[^ C
M^!VF:P,F.F.JD+L;*7TL@QM$7JBPF:1Z8_G<YPYU@JM)@;DH\W%+E2A;V37/
MM4FJK].H;@3?N?2Q43XNZ9VFM0\V=]-0GZ^:HL-UWGDJ6GSAR6T5OU;#[H;2
M>KT@6$4N%AR'CYCE18._-SP\A4#F;\#I13PUZ.EL* AQ7L8XM[/8^^6]C(ZN
M>)ZL8$IEOX<+V3JK>SK_*FETD5<?_.ZBH2M>OW(0I\M^I\ZOA'&,/$_Y#7^B
M4J_3]</K+AHZZ]"I=._MP]1Z-$LJ45%_F$^.Y.B/E0*<+0A/PNJ/]$6=NY[]
M+>(!S-# Y/ZHHD]=M\)R,NJS5;CO4I]=L]D'>]7(:6 ),_D-YY^OT/F$(CJT
MO4\^*])3G]&2;JM/MMP'LS5H:L-PM*O[SL73HU*[QF%"FOON+7L*3U_=KPR:
MD-E&+.;#LC#G[7N02$T*VPBC_C[D[T ^[8FN+[)D>@E6@^5TGLFKU9FTUV$^
M:SK%=G\"ZX[D[H?=_1IL(0D&MASU<0E(A.W/Z(V)P?,@P^&6K>"/\YFN9E3D
M=>MXF/O0=8"L$'5]'85P)C[2Y#*" [%@VE?8(UL5R&G,ZJUK[T53"=H&!BD!
MBX@^@OE'UA3JV=",^^6BE(+&NCB/<H/R>CZ?N?M04S6*&C/<M]KR:!NX"9RP
M?3:]$OS-];#^3\]U<$EA7QHI(J#3*?:6<3US;<?X>YYF4V0TB"^06>P)]*JE
M(L0-[$4J;<'602#0Z.)< =05&JHI7Z>JSEJ9ABVH:]!2J]_TUT>#K4--&Q.Q
M&J)>^VI=BNKK^IIQ\,<8<8.0]T1=$R;^2ER?=A"5#O+A5 F'9>@[6VAX@@EI
M04,O_>K%7A*^T!OFX)5AW7$-7ECGBPT5Z:BOQ,]$?*-*BVTZOV42A@"]]M[%
M*LIN'99@[TR%M@TXG>EZY<#H][_45GH5,CP!M1<N=Y'0,:LP)4O?19HPZ6 /
MC!H(Z&R5*$2C,RMLNB<FB[!WQN$]/! ,Y^ [Z!G;YY*5Y3V\6E)+39HZ$T;V
M>+:ME5:@*B9J+V)I3EU7W?Y.T&N=?Q&E7?1J0QNQ-\COH2@]ZH2S791A<B>@
MJ^DTDRPB3$:A3I[-=9@^UGGJ3S/RZLOAPB52QN?61<?6Q1E'?:0Y[22A:^UF
M$<9G]05"-'3L?:N\'LT]26SJ*YS!,.C0D9QV3XGM">U).& YZV)I__,[;459
M4KL:1-)ML[^DR>JTM.6S5-/]L=B9%J.F0X*F0\.FL\:FX\UM1.K-H^-'/1$<
M/DJW9XK^FGA3.AM$FH! *A^?O;U8/4;L#1@I/!IQ@F 7NMSY)BER1S;X2A^#
M.M5!/?DKXL_VHZT!!ZU0AIGU.E@+K/O$?:1BE>T7$=>=+^;OD;^FS>ITCXTJ
MA[L^$W>^L)<@SOTX! ;D]=GXXF/-Z3R02['9'[9=:K,5<3LV:\KQ-\OSI_KX
M/7!&]<&7$QZY"]H8B#:^%([;-@#JF,$:!'4V,6N<$?"OG*G>K-3J!#5@ELBE
M2Z5,[8K8Z@:]&"$5J.C<PMK+-ISZ-#5(QWCV'I>>+\%'P92I9_BR"0Z^O>'8
M&=D3Q76T?A,TZM%4GVE]0LKDA?6Q1I7"95Y\<]@*[P(-[!(SR9=:VCUI(8.Q
M0:H%#0XRO.'0/O-AI/G^@GF-*&NR8AX?/!LLWKW"EJ7=\T$%*CI@[8*LF0HV
MS]Q320F,Q[CCE3Y1U]-+[UUMWVO <%7:NHI4MTQ3[6%(:DUAFRR"YLC[S"SH
MA,KZ'>N_H'E.YU<O:Z9OL<P>=)S!F97! BMV;7[4(::!^Z:)Z6D23B-K,PL'
M<'J=AK,H&_B7GHO7+:=LJBL=5Z#]VG2[R6C VO1V+>A?"/<Q"8C3O?-8G9YF
M0\.68;QD0B&>7IFL0$=WS%U[OO@NN$L3TL#?B$[]C@^CSIY3?A<$/L@"';D5
MX6AX,ZB#VZ42.[%=H*2*Q=^2S ;!H@A1:K=K3T:0&76[;30+QC%*.^53,9DK
M*L+AX 1/KH'F%%P[DGIYUG/*=F/ZFN3)RG4PH4[G$PX0W4OJ^/J0#+T/01/;
M;_"Y#D7U&9ZLURZS ]=*7XJ:8(OQ2+SMWF4@9<X(S(K]^KZM**POD*\<+Z.R
M\=BC'D,NA5C;F'U; 'NU_PRX&T0X/>%Q\L2$+R<,7&&7T3EFQ\,([ZV8_4!M
MO,-S,['[W9Y0GZPF@>NH.6-(8#5S-^= CK;)-M<PW_7+<$5B.IE-^_29R]$W
M\A!#<R,:K $V8@X07;ELP> )G-!XZ.K-5&I$6_/%031+<5@.SI+8<L4?ET1=
M$'Y.T2=GU#DGR;;LUUWU;D%>N^;PZ"GB3I\YE4NVCC9!>^?T,Z!'$@#+!N_Z
M"7*6]3I;>/T>:&3R1&#Z Q/(&-#I:VFR5Y::AFBF<Z1*I,@"F'];,GL)Y*3I
MF( %[8%%@=3")R;";8&U1/ZZ#;9?CAIL5&&<K?S5%ZK.?0DZES(83_K)\C9C
M[RS-_1;\C_#LCYZ,P1S&-H9@"EBO1F !W@;NV/G)2;_>9@9C$XO5>!%4__&"
M.L2TB2!4PM.G65>7H 9[+ 7N<923F0>F_N_?;M$4]IY=&(![;:V[R6BP4BJ.
M_T(%=<\)_]8O-X68&\Q(= &VFR=5SY&: KP-XJXOX#UB0/-B21A&++$!+\'!
MC#],YW-FTWYCS+6I:L'X)1/45MZ>&-S&WFP*2([:[3DP482Z05!0NX>8^/L
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M'U"R+.^FM$&BY32.>--D):H%7,T(]2'E>\B#P1-$#PLF/[;8W^EBK;B>8V-
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M9H MR&6?1;_M+*V2T7R(W<9AGB3F3ES]R4^M>\OM(BAWPR+K+#$_ ?H5,GE
M-0VN420.8L6R5[F(U!!TGZ\]WWFYM:&&;]>N=><&E/E83E'>530,;#N:BF/W
MC&T&/8(];@33F++D3@UZ3&YMB11'V1F<C.,0F>O2C>4EH5O5M6YF-HQNF! <
MCY/+8'PE5N'&H%TEK=^R++*5A^J<74)?/+$D(DYBSL,Z5[BRT!5K[W1<5L>^
M_(YBS3YH)1UJ":<Y+F\A];C) 0^0?UH"S#]/$*<1#W"HY[^ZM?84_D9D=^R<
MT4:5RWV 2;8O3I!:]%3PFJ:C8EL]U:17[!''3CMM)!S+.[E7N%Z,2>,M?0.Z
M5:D_'$L'8B-?^J)4KD1FC1D24M12)W/UWX .F3O!^F2YZ^W,-'@)&+^  9'9
ML9)M2\?[E3H1_.UP^-)L]MYD4<F2'MWN1?XA8LC3R%.KUJ[O+YA?Z*PEGF,N
MFSUD24U'L_AO*GV3\&^DJ^4C&@EVYGQ-^?/_ 5!+ P04    "  80#57%,77
MJ=PQ   (\P( %0   &)N=&,M,C R,S V,S!?9&5F+GAM;.U]:6_DR';E]P'F
M/]34?*XNI78UW#926UL/ZDI!4KVR,1@4*#)223>3S.:B4CYC_OO$PB1SB9VQ
M9=G L[LD103ON2?6&S?N_:=_>9]G']Y 6:5%_MO'T2\''S^ /"Z2-'_][6-3
M3S^=?_R7?_Z?_^.?_M>G3[^#')11#9(/+\L/U[=W7S[\V^7C_8>[O*JC/ 8?
MKHNXF8.\_O#IPZRN%[]^_OSCQX]?DFF:5T76U/ #U2]Q,?\,__YW\L$/CT>_
M', ?X;\.#SX]@44-YB^@_'1X<'CTX?^,1K^.CGX]NOB_'_YS_,?_^_0)B9&E
M^9\O404^0+'SZK>/:Q]Z?RFS7XKR]?/AP<'1YU7!CZ3DK^]5NE'ZQ]&J[.CS
MO_UQ_Q3/P#SZE+98NEJH&5J]T<7%Q6?\5UBT2G^M</W[(HYJK$BA7!^8)=!/
MGU;%/J%??1H=?CH:_?)>)9U<L$Q2=Y]9;^#D,_GC1Z2NLLC (YA^P)+^6B\7
MX+>/53I?9 @A_MVL!-/?/K[D=8RU?G!Z=( ^]+^O"L1:FB"^GVKX_Q&SU60Z
M6: ^@+@<Y\E5,5^48 ;R*GT#]T55??R OOCU\6Y# R\@3VL0OZ3%8A:5\RC-
M8]P14-G/NA_Z; ??4UW$?\Z*+($]].:O)JV7!C'1&A^(X[*ITAQ4U5,SGT?E
M<C*]R>NT3D%UET,I:MCP-:BC--- (=_T4 Q1E4+M/)2@@GK"I$/.N\\^I:]Y
M.DWC**_'<5PT4(K\]0'J-X:R=*4>R@+VF'H):R+5+I#*]:';ELBCQL9)DJ(*
M47:73PN('/W@15-<209JZ#Z%*H?-+\W"E6MVH.R/X WD#>B4V/Y\6Q;SJZ:J
MBSF</K01J#0^$ =M 'P!-7> P+]K0QOXO:$]#L#UNA_]3\T"5D*?B+++*$.[
MBJ<9 /5:=WD$&5HAG@M25;]3FOJR$0T8'G#B-@=*O;LHH\U@TF1@,OT6E66$
MEN[R,7V=U?H4Z7S$(B[R\_A'5"9V,-$^8!Y/U^.A< "N1 !O%.$N$?>/FW?T
M3V 2G]('C>,U.[(4VQ^(Y@X>*N?@.7I?FZC@W-ON\O-7M*D':*L/BUR5  IR
M!8?%$HHQK),:^JXY]&9)E&UX\&EI/D]K?(K!IS&\C0.Y^>VD[H<&[[CP>O@0
MP=W!,YR,JR@F1T^CX+2^,G1-AOW[ 91XPC*\,LNV/'0>;%XJ\%<#N\3-&^X7
M9F=!E=8-VAS6-V9#S29;;5FRC%Q%U>PV*WZ8-/*LM6E+MW"TP6_-0 T/H7HS
MDES#@^5_ ^5#] JT1.SJ.K.*F52KTI<,V<L&V,.,R? <O61@B"2K!@S)8]@R
M)-.J1SN88V.7*:N0OLG'J[8]:=VT]K6'[%;]H?,T7#?1_Z$9\BW*VNWR(ZCJ
M,HWAC(K^IC,I2S7K0'9M-:LT[@!';Q"1*;WSB[7"^B<J+V(.MAR#190F\$L3
MN/*78WA&U]HE,]JQ(9UVE^6V9D/2;N;$O[MJ2K2_(G\:8'K7^Y"=&P9S=P>V
M)!S06[CM&3YK&SA0&[5@##13&)5%FT):(P/E>BZC!*P&WT.TU!6-T8X-Z;35
MQVW-AJ3=-$;]J_:4.>!;1N[IM"_C#'U??_QL5#=[:_M'5#<E=G*!%,Q ?TV
MBMVGT4N:X;^:NJM5_9XE.[=!8[;-NP:S%PHF;W6&7=V8E$1[6%':L'#G1WZ'
MEL!+,"U* /<S;RGR!;TMRK7R1N_[%+]I 36Z)8[RY=,UF *X"T[,8^1^P3BB
M1Q 7< QE*;;&3*8WTRF P_\-/,(Y <]D*WDZ75^"'$S3VAK-ID7R:"O3MPL;
M^&@(OIR0$0 +DA-C3):7;-46.4RN.P3WX]NOP^=@L8U[C!AQ"[$@EW8/9S=E
MS[N(_.C2O4CNBP;/LMV7UW]IQ#. V[(I']\ACKRV+#QF+]-T/H)Q166\@M;^
M<_V[W<.1-*\_)^G\<UOF<Y1E'X6Z8#QA6;U 06]73K"*<&M#Q('_1G-FD7]*
MP#1JLMJ@<)2V#8E:(!+M2-HV/4A0W,:G.7YR95+*S7:'B#B#TI1Q\P(^== -
M"DIM?8BX>5&/C8Z;58-8*-@[TQR/]GO8U,9'P'L-\@0DJ\\@::R_P,+/\8IX
M0Y ,/8 KREVXU4IOTZAZP8";ZM-K%"T^H[GT,\CJ:O4;/+MB^.TOOG="0>#@
M#OZS6GT@BUY AC_[G5WX^]GQV<GA::M&-R)_0>[VJ^T=1]J-<DC0@XN+';['
MY:;(L+^MFFR[GN9HGY;%7%I[K02%#("F@B(5"[(T??Q0E'"3\]O'D5,**'MM
MY/@[A:<\#B&<6@3=Z5[1(P.'3M:AV_%2Y,7*]DG$;#>[XY>J+J.XYHTA45V,
M]'RT5\3)@Z+3=^24OJ]Y":(L_0=(?H?:0%/!)+_+WT!%+*\<\@0U"<H3G]3)
M,T%G4A8AG<=CISS2+!C$KK^2G5A0^7.H0BL$_>$^\ZN#EL[UB5.N[_(:E+ 7
M;F!>5P9V?V"2+%.=X#W:9W:58-)I=;OSQ'9&)FH.H?R*!./Q/E,I"9!.XED8
MVR&=;1!!YG7?.I0Z,38Z:^=.6;N)RAP*V+^*$N]=657(YOQ\K[:L0BQTCBZ\
M<G2=9DW=6TXD*&IK?!^='8Q.C[QN780:ER-J!Q'C^'[@E2ET11<K\(3+MYB\
MGOT,L;2%A\&1DHUE]S(#_>8[_M(X3]I^H3"MJ51OH7C='4K/<7K &!RY-:U\
M RBJ!$C&;W !?05?&J22-H1!-6EJ%/$,A7L3C2^E=EH=>-DOZG%%'X2:H!G$
MNS7*,&1O-;(#09UZ5DNM'KQ8;1R0+X;-H-^M+8?G<+*R 4.-I$4"?U\B?]-K
M0/XKL6\=WCC9N>_7#M<@:D87<6L"8N%AF[10H)3>K6EEX!J7:04'P'53(K<H
MK ")JQ8'7R=;+*][=(-]1JU3VE CH]=ZL'")-%J4&&E=E^E+4R,?L>>"1!(8
M.JNQ6R9J\FHC\];;5%7$Z$ENS6S= H"="&6<"G!!LDK8.;BL.5X96+ 8<A,_
MDU_C(J_!>WU#@@7^]K$"KW,R0-J_9T4%DM\^UB4*'L!@S(")K2KK-;;@3SU3
M\(?O#V61-'$]*9] ^9;&8/R>TFX4644):CNCDN.@Q&%OBXP-YH0H&#08L*+)
MT8"<@5JYJNL-#S<Z%[OE"11+IP.&]UW/AE#!3#XX2!@N% 8,9HY)^;[I VF-
MG$TO3JOL]) 8++EU2^J>^+4W&)7,:8M5!R^G9P?[=8@2@F'PI&0V8Y@V'XME
ME*$'E;"WW,.N K]_"P!M.>$5)Y+Z/58(M4@Q8(K@,!3OUFQ%TDQD4,1Q,H>*
M1;#0.R[Q#:B@)H'I=WNNR)HJ,@:!;@U/CZ "4"\H3LPU> -9@5\KB.GCUB,0
MO5X6Z)(GAXM!G6.#T#9$E46)0/'J9Z!+$1L+@Q;'%H]-WP>!3SFE-(&S7Y[E
M/!@,5MQ:#]J0;C(;N.VB&,CI?KF2,S$PR'#K>[.>Q@(EIX$"?DOKV2JE!>Q#
M68,N:5#X*?B_A&^:UFB-J./,)Z5,AKB$:H%D<+Z:83YO/E;R\GR)\I!YKYXL
MC4[<^MO\E[@,&OG=_W.8]GJY,V(?'MQ:1\;)?S3MPXCGHG_=_!"ER5U^%2W2
M.LKPQ?O+]N/X1P#'> 6GB=8(1$"BJ""OA.:_1UG#.W[8_C31<X#N3ISNYTPG
M!MZ@,2P^=U75H*#MZ.7\.RCCM (XSL>T04L.>=DZ+_)5$AZ6)4BQ&0PLQ"=G
M%+('X0OA]9F**].NUP[N@EYM><K#D@TBA$=DVF^?1WZ?"BG30 <0PMLN6A ?
MSO9SNS#I3OLQ>TF@,/ LB[&XK*;#U929D W6\ZQ=[UBKB:C>]_/1\>C"ZV%2
M;?F0!A3"ZZH!;A^C8SND:+A]<,<"56Z#;A]NC3M765157:+$-D\BPPU$6 =V
MQ:/C<SMWI@/]00A+5$K%<$)X7465DNF0(%&+H+.T$@E]1>25KT#:%K @WEK9
MXLVW.XE] D7>)6H/LLPM;:WD>%<DF"F9=<B49,=%W]Y,*883Q+.L=>ED1]I:
M80+&THV>],0HUC5W7-'P!/%TR@PYH<Q^QED23GIN#0X=/G+N0V;((L<1WR4G
M/EH]LL6V8Q=R,/EQ(07Q^&A+0N$PHY8GD"S=Z:A/@URMTQGCPPKBP8U)IH*;
M$PU3)IP:7?NHU%"V_@GL'QM6'ZKG ZT"!G?J];$F?YS0B1* L?>B1>G&DWJK
M)B2*6X] ]'K5K<.7'"9[+V!4=HCX.@QOC814[90E:MB[X<3&8>_]B\I(BN-F
MWN"L1"RW"?&HDFV#]$:O'I5:(TP9GXE',V:NYHG#2N_I<E54QN[KJ6U#'9P?
M'^_'U;!YT()7."Y=_%:IQ/L$&7F-TZ+!)0)Y+A99F_-@:(_L$^'N?.&>X\@G
M71>1=WBL;VBJ0/S+:_$&=9^2&1'^HY\(X0_?\;>7:"27BX*$;\=]Z HEK2GA
M;)'0+KPD:T+Q+PY/_,5U45+QYOA016C &4Z]C['N(Z7J$>!VKDJHUY-#*5%#
M9?#RTH"A5_ L=PT57J3_ /4,A5Q817W>_2T 7Z(Y[VG[D":)$NTXUTC9LA2I
MWN@FQL!;<U43= :6<-R'VOQ*!),OLY<Q1G:)EH1MS<W-&Y6^[6*^.179S91L
MTZRXEF2/>9_.X7\2YEF069:(ZL4K2V%L4!99+AA[WG'M9\<->HZ4I1%*8E:F
M<*=>+E4X$-8G4+R\IC/"BSQ  ]YS@K&1Q7+C8E4.BW;BQ574S)C8 6+ X8VA
MX^<H!B5XGH$R6H"F3F.X 1*HFU.%".PE]L<PS<M@,N#,QN_HERM#P^Z8NWQA
M6]]5FR!Z\')B-C(\E#":<&7CLR8<+]OEB&Q>+.U&]+\+Q&+<[\<\2I5F)V8%
M(JT7Z_@PM8L1F7 >$W3RQ;\6&7K5(R: 70,'(S[S$UW=3,_G81(XB3FU39O(
M'$Y+[ZMJTAY\?[82XB%#PJY)PC-]RU=&G%\XOA+L3[1,^81O0"2;P/ .[&S'
MN*]#%#1/OQ-41F@R?*AUD\UCE+_R[*K=WS&\D9U3I)K#GS(?.R:775"^+.%8
M$N8BME6"2&O)P")EUMQ5'$.Y6P+[LBWKJ#<$4Z.>GD5&0K=NQ\S1>;E\AI\5
M.!]+U"8#W(YMQ>6,I ,YA%?4;+#PHT(O6(G:!*TE!Q-I[V456A2)I4 -(4>F
M*V)]S[0^&!;-T6[]G^]1:@,4%0"'O%W]<#=?E,4;"10F= F4;8*L45Y];E7&
M(9UG9; A/ ]_*J;U#Y37"9Z[VW^N!5K%7FU"EJ7;^'XX.CX[/H7+G%?'P.%4
MZR&V9YB_CUXZ$'RKUV[)7D2O04OT29'!%<9+\6*^:&I0BJD2U.BA>0U?/WP<
MR>"S:+2_!E5<IKAISO;\IJK3.?+Z_EJ!:9/=IV_LH/?Z+;:8SR\NPAR&(HN8
M2?A!/#)GBK^2>LHS?4K4[B&'.8IE;:"J4'^2"XC^P=5=/BU@R^@'4[[T4A+P
M[A9TFB$\F]B/R'V8[[(MWP21VXZC ,=[6U.YE&E3!VM8%PD*\^IME)8X@.GE
M\@]X2&I*+/EM"?YJ4#A>@>E/HC91D<?+"'U.J?.K"F1K5Q4Z!-.D%5J()&H3
MM+ZN.G1H$1 K 36$6+&NB W%].>2X;"N9VAR5X\@;DH4F5)X;)6I3G![?<>M
M,O[D^64"#>%:YJK(8Y#7Y '?8UK]>;F\A&AG<*D2A3H35<6/7P\]WK@97G:E
M\89P*[,K[$I4<0@N056"T_=%FS0;LF0R0(9P\6*?S%!66#>LBM96QS<NS4N%
MUYCZYJVUE8IBK=%K=%922\FP?$RZ,E!#"-9+D5,X-IEU>G2^$CNKJ%^:. JX
M(*YA;'$7RJ1JE\30@O9NBBR^JZ:5[^'YS7 E-8:DJ*/@LOCXXC;-HSQ.HPRE
MNZNK<=V=BUC6778-O$ <>?$/,&W6E0 91,3>,826I%F#LB(_H<,K#C!Q\XYR
M&(*$Y#A$][01N==;101\ "5.IC.>(^5PQIR1]HG*O(Q/@_W"CDJ"B"3<]?;[
M-'I),PRHZ_#7:85N(IJ2=V<JV0*![>5UEH6>H HZB/C#NPF#4$+4L@+X#T\+
M"(.W!HMK]RO7S\*S*N@@HA<_@JHNT[@&R554S4C&3'ZN9DKY'I87SQ8+7(IA
M"@(8N_1QN$]A;TM@?S/BL. ]N^]*RX[3R&LGYCL\"RU5^;H&Z?V;#B($YP$H
M&1IR#V7QEL(1<;G\6H'D+N_RW8]CN*/":RB?(\E&"':OD6IU"51%&(+G )(9
M15J%_T%+Y%N4H?NT,<12EDLHMB@-L51]C-A2#C.;G*J!"\%? ':_&("D0L>9
M57C=.Z3L*'MH7N"2.YE.0<G/.2O=1J]!KW?*6M3J@0S!44 W'62'(XR4D&**
M./(;],1S?(HS?A-ER0ES2,Z?#::T[IP.F1<7;K>@=NXM#KTG ))0O^YUQ2'3
M..8X:ZXEZO;ERFD8AT'?WP^\<3KTF[9=:@3IW#@=,DU8%QYL(,C4EC>@LP*U
M/V,[>U/5\*1;5LXM(3<XI/XW>$!;L\>L278#(9=0<RL)90PFVFVB@\.QXQN#
M=190+/,HKK^E]6PEVUV.;D/0:;6J /Q?\AR]<VV/RJT1T'X3T0PFC&6BU-=&
M"(:>K8#W"AJJ+I?P/)4T<8W>X3^!\BV-V6^-K'Z/:-1A6@G;O<JNEO8J346+
M9E*V6#AATFA%"6@[;@Z:\8FL4+K1C83*\!4*C(*#FY: 69X@L;2GDXK"QM4O
MDPX.$E_Y(DQSXONL9($<HXD?AL<+@O+EE3A/X$8Y@L1;_@%Q]Z<OA'0,(5B)
MGM,YW-:UN>FFH)Q,?R^*1+1,*=3^/AJ='9Q;2AD1[-*EI: 03$\"@85F**GZ
M+63?3W*5R-'B=QMN" 8IIPS[7D5]42U::GU8M6B1S[^ FAL9'?[]9PR.?GSN
M]OT/4RJH7QTPL!J&<1%F8+Q=73,OLL7X0C OK>5RO@:+$L1IZPVWR$ ;!6@\
M+\HZ_0?^/1,7S^O=T">(WO8@*!BG7QC710C>2DPI?R_Y/H+\B@3C'H0$TYD'
M-A&&X*3D.,W%\;D'<_!@/I41&C3E_H2!Z8_/@S+\RG*J-M0ID$.P4CF)7WY\
M[LL$K$.+(K$4J"$8OEP1&\H)V"7#806FEX^?O!U7&*/QDE%29U3166-A"L$4
M92["-4;E)5VT.:9$V(((9+(;OEXZWO].'8)L'](X<%@3HPLBBLG A!STM!3'
MYUX?3PPG3P:?(&Z)T[>92-P^E>53LUB0HU*47489>@;R- /H,=[:I1:VHCP7
MI.K>/=]$:Y7CQ^K=JS>LLM4S^^67(H^%#YJ%=5&O.O6;AH&C9?H@D0<5@JE6
M]XD1UH&=<[;J\R(^'0RYP_*&4[&M)__15#6>>6^+\@OXL?;0OBQR^,^8S,L"
M8XI2.T1M(3@E,-BDV\6U((9@-D4K\F0Z3H@8PGT'K3C!X]MG0(\"QHTR#V4(
MUDUSK(5B!7%$7UB>=CU&.-OD250FU==% N>=PX/1Z<&AD%>I^@2YU_, =SPQ
M;QH5H(5@M]S<C3VFK[-Z,OU: 1PT3GIKNE4/[>!.+OQ&,QRV+64!,F" 9$0Q
M?(32=E'<)].-S7$*CUH->H'_/ ,/H$R+A,*,1BO$O>@DM @C=*(&X0O!/,DX
M^*B?_TAO]&J>-'7JZZ"$8(WD3@'K'B(W[POD?ZT[/5*:(GKP>C=@=L;D831A
MP63,HER9X.31S1V2\ZEN>^W,$UKP+<[,.AQI$!&9-V$\1$N\_98>J:L*I*^&
M%LM'93SN( DBK25C&1#'=N17)"9#KUZ*IE;$;40!Y:LD1O^?(Y CY.;@U/6=
M&9Q*P2;M*,0N.C$^0@&Y%V?\JKBWG 2X(\0Z9EV626(*X1J )BQ:%--\]=,S
M*.>*#.XV0# '.(\I\LA!%L(=P::PJKOYM>WLZ4F 1@X.5WP@(5CV!]RW'5B:
M #7NVS@4,.3>6Y=E$JJW5P/Z"%(\_W:-4XOHS\ZX&GB71IBBTBH#* 3C/4-.
MH8<JMQY!Z#M]E P%2N1M@0O!7&^3OE NU>SR&)8S\>\@ARMRAEZ@)7.H[@JG
M$WQ;+<W"NS2I^@2Y5UN4W BCLZJ&,01+OS<?%%M)+NRMFWH00[@M,.3-<'!J
MZ=&U/1\43 &=3B[*(#R7S=$6RGKIB#_IU(LN39*[>8WZAX7?HK*,(.Q)B6\S
M]L];>71V,#H\,'$M]@T@#8!D_ 97TE>X<L+9/*W 0YG&^ 4FN&T0!RN-H2P
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MOL&QS" GR]J WY/I(XB+USS]!^0&'S2NBJJN[B5<IPU_"?>R4[<AH]<\W(V
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M%1:F0_,O@G-H\A>]I,@N@@(_IYD:D[V6X%<5;2X5UP 9JMJYO+"8S"S\M86
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M6-6FKV8^*!\_L)K)]U1VYEX9U;):*F7=V;OP/>U$[_N>42VKW[ZG 9@-M=4
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M,E!W"XWYX=:'LV..?O,N8.\33.4:.%T7+/+*P\5J-A'I8N/XUL *@P/W!58
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M?I*X,K6U-MQ]C.\/:A\R06*-)G)%I#N36A%1NT-/MB<S#H"W&Y6IL.YL6;S
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M0@-#S@.B[!?ICJ;?XCDL*8?/O%[)^;%I4SZU/B-&8_,H.>59X!N0T6(SCHR
M@++O.GKLY(F2HG;_J/T!]'3L-"P_@MA7T&_L.VZ?S,Z-(R&4:6X0P:B7CE<9
MJ[=1@F\*O%.F#)BA<TB%FF,L!$TRT!Z-\M#N$>O?K0;-!A5!=6;#B1\Z(]7O
M-2N:1/9J^RAC1/E-PB],5'N^*1HV.RL^Z>/\XSRLO>>F:]^YJ+XTI0_C@.7Z
MK]BAH;R<H172!,PXBF=V/_9"R%AW7,KQ=',>X-H46%O0A>R '_96(UOKL/,F
M*;(HR:/PST&L3/BWX#=]LJ 31FZ,J32UE)U+D?K+B'W:4WLXXTB>/3]G+#EP
M7_3.P'AQ^0VFHK.YC*;Z^2XLV\_L=*8RV#]G:;[(=DSUM7=DS89':_8-6\N.
M_5S&WC7.'OOJ^S1AAL/'7K!U1\!S'VV\DLUME10:]B[L4<NJ\BMU& ^K^M8[
MLD5#([6D)>IX5/R+[L)D0 :O:X?Z83:+1PL9!3_!#X1M[-1[,M12Z[.@\]@U
M/5,NGN=8.KI!V+T-?%W4\R(E'F\0%H<@EM2I=<X1V/6YRU$?M/=(LX,^+^T]
M&MA!5UI>>5W=-RSB06-3H;?%G(,ZO?Y-A7#V*!\JISZN^Y$;"'CX^[ ;9C$5
M/H&6VP7N!X9M^Q%T_<6\U:ZLB8$"9C_2TGX\E_:C\R)'S$?5%,(.6TI!RV$[
MB!.9>@+>W7NYNH^SX<*G[<ZLHSMF(Z2.0%&>R?Q]7L!-&G'MW=M[.->97^-G
MOW:S5W<X8_JD7]:>]!LDP^7LH\ZH0G,#;5S!1QOLM,G;;8=?XV^UY5 \W@,W
MP6[LQ* I=F,D_/!O[0,\%CR<'_R:3_[JJ-%:,N1A,#C,5=%AH.'K'M&_AW"N
M\4HV]QFT0L/>A8O82N-@:&]/%W011W'SCES$<:.]I(O8XNA_ Q=QGO&W<A%;
MGW1N4MW8B;E=Q E&XEVXB'(7>+;CS[DX>$>NI/FHNMN1+WS@Z28B8K8CSST_
M\O0JTXR/XU0_R^B.FS+:YCUY]Y;V<<&H$[\.BB?M8F1+*M228\S!.UIRS$?5
MG8</LN0 &-+Q8VUJ2/D _MU844N5G__<Q$K?WYL573SL>N!;[],R@H1==U3X
MO8==&PU>_TSW[]R$+1MH+%4V$+/$4Y*0#YR]1:IW9;UV@.:@SZ'PDI)%M=$&
MZ#?:!#C1U6QL0BK'X*SW@3TXY7ZLE=*0FX;G9'-'QO]3L,.7*3VX6R2@3_4Y
MGU;,<>.E@C!OY$C7_)'7JQ5M@E;,%_2F5PD0$W*UV\?I$6/FJ_"55IKET8 &
M4)E5G*O<V-H];2:I<E(=Y8 <(U'5MJR2F2[,OV&ZZ5$2M-UDI^DLC76B;P6T
M"N%W%,)U$&4LW\-9GA]V=4@%#@N\62S8P."C[R&FP&3L%MA4T\_R/"BH]6$6
M-\0^_1[# \8,92UO'&W?Y]6^L?+-=H-OK'E^[&%D#M20&/=1_OMUAO%-0J"*
M\^(^*/ O41+M#D,O>^%9\&FO,]^X MHWR@BBG*"*%41Y6:&2&T_W6<N--6U]
MLJ4#$E4#DJD&Q*N-V,RJ/=N)XTB]?G_VLC+[?TYCTDT<%4<'%E/#Q'NUF;JQ
M=>$5-KS\W9E-V^&NQ^2U)OC[,YI&^KVHV312;N#B"?5V'6>O48@E\L:,#?+3
M>GN/P_0YB?Y&Q&7W=1=I7N3FA11F_9Z3H@KSCICUZ1P%44+_&B3$-@;[J AB
MVO<*G>W2 VDMJ:D 9,:@ANGON [% BHIKTFQ@#Z"6+![G&,RPB]GR>82O^(X
MW=/I+)5#>VIO1 UH7<RD$?8[)14S!2VZRD8X/L*?0:A-2R@?3L,M4-=7.0O(
MP5YV35+\6X-J+[-_R<7%VFRCM,""?RNO P-\6;?8*%WB+<XRU6[P2U2\H)MD
M$[U&FT,0K] =Z3/#1925^?%P@K<1+5FF&"XG-VOS*J#T/FY>[8,)-.-LX<TP
MUZ5FJ"+0##N #$TSE6FLH7 4RC:'6)WD='A8'-"0-RO\";%P5N";7)OTXZ\L
MG9]995*A,6Q=4I'7=U/<4S+, Z4]EQQCB\*>%F/]I6PY5]'<.R+6"\&]&3)E
MK:&@*>56J$)=-M1C<UG;.Y+K+]YHE!H?'94" (>13HT?;OC4IT:NWZ<T><4Y
M?>U$3\+RQY1L+]I_I^[?I[3X#UPTCN'4S=ZX;_JV[1LY<M9^7?V=ZFJ+=DQ^
M6Z C+E#3=[4A]'@/.-.0?4XR_F<Z9CG]TE!V8P\<R,4U<-1N;XKZ@1BNBSC(
M\_6VM+'K[)Z^Q^P\PZS_F)=_S56!F2/[ S0X8R7N:P;KAUZ*E(U1FB'6>M5[
M1=QJD]>-YB] 91@K/;OX7QKQ,RX^[F2?:+7)ZT:"^)"F8A+F^V9@$N!!5+SZ
M^EFRX9]O9;'X)2@.650<+\GF6:'5YET *K*%7,*[_PJ/]*"7$W?3\U3TB';@
M9I6?(!Y+3'A$&UJ_LJ5]+G7.%H1]-;-%X(2M-'_FN][RO7KUX9L\/PRZXP8T
M4-MJ#>=]F/#F:+U%Y;%$K1:<Q,$6>YP$!.,YEZ"]UD2#0H#MN$U@U-EW@V'(
M:/<]=29ZTS#7.1=C8+TE/O0N3=C#)V(12N[8:GN',^:*RS35H@,HM;61J3_N
MC):J,*<N7[41^MHMY3XHZ8('Y3A0ZNGR$5B%7#[^[I NVY7?R9W,/9$O'Y(/
M3-^MD=E1?C>P-+($H-,WEYWHNN6UY\WXJ9C^G$2%S$R8TT-9"0N)AO=JZ]8V
M=%UM0_E2WS(2M L'-F*R=(.[3+[XM#!V&) .S$+88K)C()P TL@^ $[=;-8A
MR%]BG%?)?8AUZU\V2.V" 26813"10ACRDJ@YI:'YH/HW*"XLP'+2H*]O$KZ\
MY-^XTWYCS'7U'A9P9AJ_W%3!7]T-'N UNY^0'BV0#<U%$,=X<W[LFSG;LW";
MGEV?BEN-@L7Y>+-9;'I&O&OZ>,#SP_))HU++%M*;H:R(GF+VAC8M[9/@*[/;
M-:XP;LXA_1X#Y_<&]I;"Z ;!WDS O&8+Z$L6M@G4G;;H22#?E,GY%H($@O*M
M$VV\<GM\,H%]KCE])]K9$8DI@(3G4QKTS']$</46<E-3EH1^?,'26FTC^W%\
M9*"2T.;HH.FGJG)/>I*437.]R=;.JLEF&V9*IVRZ[:=V>/.-FZDM"Y 7+[A,
M&^QA8?$I)7[9'^G58?V.7+6807/R'M)0C![E)8LY&M089TW8#7\KA<6[3,(P
M#>=SI\P>"7)_ G4?@[?R#=LUF2.[=U!S?<"W$%R3,5'IL^H=U0J1WE'9O<<Q
MM6/&H,XW6N9*#5@@*,IP3-\KE6[Z.PZI-=:54?&SQHKB=ZK3IE*L6=GG>;[Q
M'A*9#HS, EY!\Y79JSJ#Y"@U':4A0T)&IAVWS^P//7FK:Y46 SE;WT4.4YE6
MS9:R5*92,/<23;Q%F8J ,9G3[!;9*]Y<I]GUH3ADF%ZT!HFR0MN(OB#O'D9(
M*FQF6^%/JRIW S<).:HZ0ENRP^5=H:HO1X?J\XG,/8CRY#QK2[KEDD8224&/
MSL>"63@L'XMD?W878]X$<?M#A"M_1=NIGN% ,^+;;F7.,;;>U9B_(N2?9,K:
M^JC'.Z#%Q]78@SE4#Q/)%ZK-$C%_53%V?E1)3S<S^<!ZMYF:W32 /5I4V@40
MVWMSM]8FHVNU ;18;<Z$ -F[M>/<<6.Y@U0>86[[N!8F%@1R50$E37&^;C-
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M$(']0("=_DS6A<[QD!^*8'1^M"0. CD.G@9QX.2-;FE7?[!8D']PNB#_8+3
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M_)+&&S)?Q#DY>PVBN,EAR/6>*ON1_/%+D&VD9U:@++C8KBP_KNIM#OL^JAA
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M\Q?)2C"Q/\#3H;$2"^Y"V0^]DBO;(T: VGVM:)!)]\\.5XU99KU_(#)IRD%
M;L:7)O&132> <+:2K8_A'C =YD):7 Q(];+'6U^G[,$&KDC:)$E#C1TIAO1
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MGN,O:/&,,M'"8- $DP+0+:<!29S5P0;E,)/#5$C&)5D2\6EL'XD6W\KZ3 Q
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MIY_4EGO*X? <:/8HTR:;@^U//RDF"N 4U'ID:1'-0>:MGU0]P\ENO,2%&R%
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M#(B )-C@(3L=EB^2W,(,'^01029T-4<[* 0L]60G$;!TF6:X.Z]15N;C:/J
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M8YFM!HEBLJ89BEX2ELXU7%V_A31!]$-0H,LTP1_+(W%20*W*S0[)KU7#$J&
MYYYRA'8S3^@%(%-5;6Z1@-V'7$X (GP"-3"VYSD>[ML8ZGF*+()HO2?ZEG#S
M/1K5;Z[[A^6_JS7HK4 *WLK ^HW1+D]F&Q>Z^#1;X5*=!,P::&3AU^K> J6
M<5^2@'*GLSKR9OVP^C*(8Y+S?7<TF"X$^BTW0AZ6$:'5.F$)7Z!CL$G2N #9
M]#B]*LFYB:4;TUM$Q/4;20 [TK1?1#1!"NCN*6V#TV>W6R%\&>S;9,,C0<_V
MI&RF$1^T]V-KFY095H&J>/.\DR">IS'N=<[\U!X0.4ZQ@#^/RUB:<URC=BVL
MDV'=,&LKAB%$@3[T9+L4K!3C)"F#^"+ O0[B(*.^B BKLV "4-9I[F<]M"5H
M Q-0:6QLU M(\Y'T]!GWZI__/U!+ P04    "  80#577+V8SA#5 @ SU1<
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M*44!B&2U6B$\1J'BXQ/+H(%.C1OX(G #685< R2^C]U/Y[]?.]>_G5XY1<C
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M6H +$6(/8.XYK0]1#&PW"K%N&"R< HEID5U0"M!EZ]^,9^P)QGQ0L^D/6#\
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M$$D5!H/X'(5>E+>_/061Z*<98K0Z7\:<28[F_(6(?4:L5E$)/%MU-GHN2+6
MHS!U+*5IVZ<T!OZRZ@0H*R!1+T%'GZ? X"B&9N.U6"<&R4 8XZT/RI=IU>(G
M$\/;=DX8A7H(TH *>C#ADI]&.J*UFC17\G5H_[6GVW?9C3C,S'5( S$U%LH/
M*(EZ?9XL(O"?I)]>WD;00;1F]/^0YI6*;^3[82\=%MX44G.PEBVBDC9>6#[W
M]4:K.(6:RQUZ>/,PG/8-&Y.B' !3)[G1*W*J8D<DO</V(^L[:!_IF.; HGZ
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M#/]SFF)J?J%M!**LZ8(#C/';V8GZ'%]^;>F(BB6G"_H]6 LEDY4"IQ(/\\Q
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MP=<J8G9;"QA@-:?7G+YR3B<H/V9V;M*1LTD)?JY$XJ"1)K($*6-GP&"6BR#
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MJ0,^P6YND@((-_D5,';&*^ ('J8=@QV!1RZ&?$7(!X"Z&,B=U'GN[$1'!4C
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M)Q!>*G"6H*<$/* BKE>_GII*:6"*U9--!D.#EYOQW>&D50BA-=,6TU(SU[5
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M4#QE5+3BEG)0#=U% DILSXC@[)H1IC(ZVMK R>+.;\OT Z]E+]7/L'VJ$EU
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M*ZD08(P:2Y+"H;/)=Q(G93SRJPD*((H8^V\E!(R'&ZI % T?I3$&P$,S4T*
ME+]S5^/4HV,O",EHTEI!-"EF$=%*1=K/Q_T0/M%>[%R1;ZE"-:ZWBU4VTX2S
MKFPH;YAU\\MBT8N8CE,H^,U@C%&8TB>]J9V[[PV^WNS[EDCLN-C.#\9C13AU
M%P1*QH]JMWH;<O8*/')"OF[JQ"38X.R*" %PKW''TSITD$YB%R\0<Y7]M[5M
M7&:34HZ9!O@B;2,H&>?#8?71VEZ5>E*+#ANQLW &&W.MIJ1U0-S^5)+X"W%
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M&K8%6#%R7*=AO/MY<9E7%VS22Y]!BZ)C[('V<F,K4NWG(-P&/&3SC FM0^6
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M\:JIKM =\M)-3^+R*$]R4SB<_;]-3Y2RE(NA] T%Z;<!IDR*F/E)X6S7@KW
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M6HQ!.#=U8R'5Z\9=54+"&,HVE5/7?5OB.[GRZQ[D7=?,2V!_"4^GY+V=/+$
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MZE;)7$ECX!TIN5-&<.+K4D07^NC%6"YPOU9-O61^<BY)9]#:#A:WX0@_?;]
M(F<:."1H0P&"B1B[=QRY ^&3-%39IMDJ,5>6F_AX!2&X;*XQ=?H(M#<6@^CC
MW1]6Z .ZT79]W>8VY-&?B \<@ -!.#BDOXXN@DPO*:VLBO^(\BE<02-TH;FB
M1\UED[?>X<S<_Z!,L"_;LQ)9N/C,57_!G1U!I!>H;K@K)G,T&%X$4RT"0'XG
MU M0;^$H@2RM8X"O<,LI5%^)L/E!;/C3H3"8VYXI_2(>[-A[:%5%2'+U'IB
MW^V >2VI@0 4."X0["$I>A9[0XW-77T "*="/'\#Z +9QI."&X_,&"+)[II,
ML60CTF36)$N"CC-EL/,/-N6F5]IGK+;_C:^\-K^#VK\JW9S/F[Q=0*3/WKT(
M3-/Q9\_+1G8!_=$WFZ+@K[QX"3Q;2>AILAG=KS%YM";!\\4R9/S:8![,V8$6
M'>$JD!L(GQ@V$V#XM;UM<:X3M8WFBC<;,VXUT1GNP5M79)TW"REE#*C_6%0L
M0%\9'_;2UW^]6-U'$U;W86-U&?+O#VZGE0QE1[*\;)M^'<PWBL8L^Y(Z@]0@
M5"MP?%9]M20;#'!85+!8FFKZ$!TCAJER10%0ZP5KM9U,I!&@%NI"S*K,7R*,
MCG4V"75_B9J,:X]*=[&TS T[:#D@C9:J(E^$LPJ%8=ZK<:LN4-8'CE/3$5D]
M,7^JAU>X9P%@PS?MV^I8[!WH1N!$1A\;^>!M=!FZ:P%WK]L[;KI^,\C:=I(A
M!XC,+R6&["+#=K]\9-ZZ5'"T\5^-O/"F&MG(C7B(LN32"O*IR&AW_SNL7$#7
MXUV=JY,MJ@<-&7:I63X)1H9"O6#<>":W3\Q4-I/-'/BV[2+SG8RUC?839T<>
MMR+9UG.EO]HUR%<ZP5$I5<:]Q/Q3(-^#B,-FA[L2L0V?(\SJ?*P&.5'C5P0+
ME8<]$O__\8&(MTDRIB3?Q^[.#V)3)[I>F"8;MO=V'Q#4MR9RN*^0PFA%!IU8
MW,AHC!?<*&HM35'0)^P6:S5NXCFBPTI8@+ZCU.'L%[*]0D,Q,;0'?C4-R1FY
MIJVD\X_ZCLO%A&^=6N50#891W5VQ.<_G'Y-#X/*/(.>I8>]H6 /""71EX5X2
MR>XJUYX7_YS:[K42[N2V5KZOR 5%Q#IWIU!UI Y7-:$??FCH!DN8S.-T/PX[
MX(L2H7/:HD5!WGXU9AFY+EJA(;AF/:)&?FO"/>==T5[Y:L1%D5A-FS=2+P *
MB3;868GDF<6CBQCJ44%+IZYQFT+]X3H2Q%+JCW81G+.<YM6VTPY*JUB6L-KD
MXQ97'/THDR(LQ@OJ=X0]I<&9'TC /G)]BI^[%U0(.;F+07HUAB(L'\E(Q'ML
MF#&^:M?2[BPEG%$-\DW*)AMU[45GP[(NAH;>#0:4^V-']]N^6 XV@\)\K1ON
MNH$84E>3J%LYNBF$,EY];"8W&S4$+98:_>)R7M^^_"%=.&?H?L>R)D9VCJYM
M<7=.&WO3:"BB$UQL/:ZN;I7M/B[\T;S*.$+UY6Z8]S?W(8["E-%:[(I9)CY*
M9IP;*K=&I,R@M%3E7G_#5)+?@94[F<U">BQ:316U9,S,@;UE+T6U!%[]>AHU
M9R11T$Z2B)QP-TD$T6NWT@4N*G1')?O+7WIV]+:](WHTZ<8'>NQ]O@7U&^*4
M(;,T^<6(^DU*%779+AB*4DBC5WY3^COP+GR?Y"BX2G$QM]3]\C+]7;OVIZ?_
M'58^W&_: EG"E70G(%FS*"ZXAP7=44Y1H('Q!ITGN2<*IFX#=TA$:KM-#-H]
M&X(I(UN'[J$@&C<!UVNN<%_W;=?#; _COJDM]5V%!/SDW"C+;F78&->7VTX-
M-YV $T2SH!B\)@PTJ"F62,RN+D],^L)^H=R]VSAOY)JJY/.VS3D&6(K>H\4_
MC-Y.X4\TPG&7TI*<KG*U<F[1C"^#CN6]HZYWRCRL74TH.N'9B+V-1)P;5\9V
M$3I**? W=;E*4I9B6L+-W&V*-:\.93'0 5V?2II7FM @KTZST]LXF6Y6)\$T
M82^]_,)>"4N=5D6(K\+^+.*6M7MTSBTR**(Y9(.\G^['ROV 32-O]B@1*M!(
M[""PRPF.O+W3UM9DJX4E4N%1"WG1^+7<-85!^^>ON;_S;P52+=$9[J"3![TX
M=R75<76X#1%EIIWHC%)#=(H2GADS:T@.B.^'$& TIH8IS^1[=_9[3ZE=JW&8
MVZ4":<>B:#5&']AD)4.W;)K%J+J3: KG!<O)_,=?WF:#V)37"7!.;YLY)=.X
MQ5B:80XOI1DZ#G*8M?^ZX_V/IWC_0X[W_[GFT*3]R)\?)>J+NFV(+E\O3>EQ
MF285Y6O6?Y8]#QNG%1<99[I<Y]JQSJ;:V>G>_09&%<S3T<G;/^B&OJR$6A#=
MH,3L,6S#+0T4$MWS]^4&G9F[GP;IM&4E/_HU)Y_>+R]'4O[=]7!>$8%Z^,-,
MCR4V"6-/-E22NO0$6(/GLB/E\83.MB:;<1-0A&3-26.(?=/0CL6[8IUO]:N>
MG9SL.X$&#9ZU9QG.%6=VX<,#IEI#+$(;?S(=%T/T,)OA,G62&>6A0TPQ-=[\
M*B\KO8!\,&?83PX75;'A:,UP]+B:)=B70'3XYGXA.,/M&;'Z5HXRVS!8 YKD
M(>S#L $:-TPI^ GBL%*$A6U>N&1>U6Q%T7!>PC#=<6-*/-G(AK*3[-E(,F\X
M8A[,N\*DD&RSOTA#T9D?/.QP]G+0M9J[%,X';'*:B5QHZK&KFFOC_T1))1L[
M5N$>(^),^Q(-](08=31VFW\<KT:U:9840&SOQ=8T_J":\\'8UL/.X0I<+S=L
M><9M'FEG)#H@^4 #/II?YF3O.5>NTQ"8^CX+\HTZ.K]([6%),MM@?9\<E<:*
M9YI&?W9E]/!.RDX":XPMX1AO-[$T314+_U;%@N18<%869;ZLF\ZJZ:E^:Y*S
MNRG4)W^^#.@[18FRTUW65W1!+:?.B)/,W9W,:5_:E,5")I/SVYNI!=LD;7>D
MX1ADOYC5.>P\$;NQES1)W"1Q=R)QSL%>EA+M]E512J;-6LXY%[_W=+5.8C>)
MW5U1WQ0MRHX6W#F/H6V^P=Y%U.9EV"J&$$C;21(G2;PK$J8_*,8F_1TXO,GZ
MD!)NL<'7E1O)+2I4"Z'7R=&=9/(N97(DA1Q-Y]@KUX.G\)>3_$WR=S=4KI"K
M,J\[@3!$*5/]'>[P=80!#(D5E/\0+GQTG9\7),@,(UYPG9/T.*>\'1)*(<ED
M^0\"MKIF0AZ?O/&PT_,BD*&H$9N M)E04;V<3LUT:N[&DA OO2TNBK9%>$BP
M/4@3 ;!83ER.D\#=F9E@4&I-76X"0X(S#Q;%[[WSF0@ESD@SF+<H]]FX3=A0
M0G#B+9ND\4Y;Q;Y\\]]GKPZ.GSLY=*[ZJIQ_"3:RWPI/T.7-D1BU3)@+CXYW
MI@X^LDHT3_LTHI9L]C*O\T6>S5[WA$K'Z3KKVKRH0-B2 AS@Y9N"<;H"[_BD
M1+_ DJ7*;C]4@8-]5;$7PI0 9G@HP_GV]OP3VGCR</8F+MX)6'%4E_$"9'[H
M6L(-R,/0 5=<E+R."7&V!&PP#'%NPD7;])W$EOJZ_%UH3 )<R%=@F2[<GEYG
M:EPU*<-_,VT8,&-.P)RSX?:]["ZESY1[1+YD?)J WB[+M=3GD!8@NS%4%S7M
M,J^E\I!11B_?O2'PFR_)+!41.AF9DR1_!DDN@,TE2KM%WBXZ[UHKPG$4*)W$
M;Q*_NQ$_,K\B:M*JF2O'3U$O<Z['J;A8DOY6*85,#DQFT(@2PVHW-;I>39[/
M)*-WZ/D$5^.\=UM4:]B^0N4#DQ$1AT,I['%J<U;Y-=$Q$JT*R!54Q8Z(IT))
MF V%&B8= 5:?E\V-M"$^< JDO48#=E-'?Z5%8$^F(K"'7 3VE_\5E==ZGY0=
M0:ENO5U=$'G6-Y5P"0LE.+TD)!8P+KD["UHC@>KIX#0+2MZ>.D\_.V9Z"8RR
MTF'%N_S_[!?$M F37XA1TJ$%1CD45WG%Y1)<P)2HH1C6NQGV<K,N7"K$#'5)
M7K)Q0137HGJZR8A$"KD67C2:&!%U&686D-/[R .<_36:&$GC:;E_C4X<*"OW
M@%A7,9$-KOZ+OL5#=K-_I&$C1%-6HFJ'"XF2-4')KSY IA6)(SGAHV@%P6$"
MV;26_.RO'B-V?"FF5"Z[8@7B#EJL%->U,+5X8B#E&$BSPX<JY/NJ.7PA[<Q]
MW5<JED?"NZ-86OT9(LJ_D0B5*[7Z;N/='Z=8I>!RN-2#M=W#)9X4OX@B[.6P
M6FK,T.W6Y0#6[PI\'5)'AU;SFSE1392D782&RX<D#9EVD!^)RVGBP+ ,@%UJ
M.$_A*Q *>PVR@5"$*)BC<KA8U2;#QIX\;-% RWRLFVNG6%$;AFU)-.T>L7HQ
MN^02E?"TMDOP6CC1[>:7Q:*OBLP7VX&^D:'>5(HWK">FW#1=&Z2<"A^=7,3/
M\C0/6%B)QR[[O'5GLY &$ZFU4Q9,C80N)!8L',"A1%!#KHEW&Y*&4T_)2!)<
M8] H"QZ^ETI:F_F\;_5F9!HWVA(N]&->;YM>UPIFP_9!)X?#T2HBK!N2%$C"
MKCW%5"<WZT_U?C5A *'L+*RY86CJJ'+RCW+N*U 95P*&/6.4,#R$%1V++93M
M%,R:)/@S%1/I]0K>("Z4KSMWA?>>4FR4/\/M(P7==$%-TCA)X]WHT\#4D5EZ
M!0X*B27=]4(']?^S][8]DAM'UNCW!?8_%"[VN; !SJPDKU\$ Q<8CV1;?E8>
M0=*N/K.K6-W4L,@R6>Q6[:^_&2=>,I),5O=HNUL]N_QB:V:J6&0R,C)>SCEA
M/C&"Y[I^=8VK,3Z9:TQ4U<HM84VCK)I)J1D*GYJB&50T=T=7.UWM])'MU*O,
M"#SFJV__) -GG(#P:0.-P(Q5KD:Y&N6C.T\[QNWDO@#VRFAAK4:Y&N433%MV
M2+Z;K@&2,)/K)"P/'DU I4@^X_E"<Y-UDYM1CEI/_=66'UOA2$JJ-)!M5/R=
M#9U(A<.YTU;N;BH>BW-AD.EJGZM]/JI]NB%D=2N#9TN;DCJ5)88<L9N XY6(
M__+V&VYI9'M\B4(QQ1'I>-+5KE>[?OR2OU/B+M"C*B /7P[4 #N@H$\3>W["
M?_&,]*0]D.IV+X O]'OSZ3ZK4:]&_=C.VHO+9PTRY\9))'XR#WW)3[NAAZN7
M7@WZR<L/ -0Q>J#8W(;/[ 1[UT[G'BQZX-4J5ZM\ JN<3B++'/TZCVQM'ZQ&
M^?1&>5/>)C,1C/,Z&SQ1:IF+L*O!??+X(PQD-NQ^^*NFZ>Y>C<?55%=3?401
MH(GTV:[OCD>><"% >?SK:G2KT3T.W6_+C(\M@*A#U=?$XY\,,RF'H=LR5-;J
M6O/,B0&W(;&BL>A*N#@!:[\AE4G'V!+AR=6*5RM^'-=Y4[;7E31D\T53RH@H
M.T=:#U/5871E^,!.L.W#>'6H3VCGDN#9@OSXLN%^I,2]WZW$O<<@[JT>YW^/
MQWGPH#3F<?! =1L>!J(.C5AMQL$-6#<:#OB5U3:\J6+C*71\.?5<XU D1!^A
M=I9-CH+F&8B9T5-,V"D/P;>%#Z_G\KI+'HFHKT-D"B(!Q^JD#*Q?(J3]$CIF
M?V:Z:S%7P1*ITV$<,/]]-]E/0-?09IS-:R[P=%]]^R=&RM!__^GM0!A%+$TM
ME$.F,-.87$\V9.%68Z;QM4"I$4ZCB!!"7JLK^QU\Q1????VG A6+>#W\PP=I
MB3FRYHZUO.ZA:(/:<Q&!1 M0]8>Z=3.SA6?!O^#Z-.K2,O7!3(-F*>;3"=JQ
MXR[Q6[$96WKJ@8:_RV+*9'%J[4CV0RY INTM.WANVF?2(9X*V6H/2$C5%'@.
M-^'M#G$DHPU4+_P2>!ZKBDNF0\AEB'#NGEQ ?-V%IVEI00"&4>D*>=(XQIPX
MK5O[EZ;<OL<KTE_>CQPD\\LQUO_D[>@<1T]QG?'H"YGS[JK%"9>QR- V+]&#
MY0)"2S>,^GV'\A6-F^P/M+$PQ#(5S3.^FWX;5$RR$'FQRB(>LCQB^8&*QDFV
M2C*U89?B:8@F6E"?QAC).B$0=M)4Y8YW'LL(Q+4ZT,HR4K]?XH$Z18+P_]TF
MQ!?U@05*]<)<IV]E>1=X^DNC59]Z8&1F%+SL9R# 7E'9]CS1F<2 7N)LU43T
M;D_3'EA/ONZ@XBVZ21:5(0KYT;!.YV16:";B8GUM7.RJKW?7O#L.W8Z5DO+M
MCZKLFSJX!TRBI)V'V<H#1 3$/\,@BTLL]M-=MXFB8;_$JWK3GE/-J$1Q,A;:
M(UTTY8WX,'0Z/=4'M30^%3.6X:(H@JC[Z;Y-]2GDO2*P93VJS/)<&N.*K3.$
MLS DF"QQ2B6RW:"*)C:PF,P#TVOIE50_66!/*>+B?4U-@EPRM14DD."1OO '
ML"J,KU<)]DY$%S:<8S-Y/YV$G5^AZ<NY][:>8:_O$]T311V+%HV(RRZ-](6^
MO,NE.DBTG@ 'I7^4K4.?" =A<L(OU#<OZ5"4YY5-O^9"/Q.%A*,&-*9"M"TD
M)$CX3<6'22.O5?350A^G%P0#3$W.#_/HLN/C8]^']%?*(1Q470D9%9:B209R
MK[:ZVNJ3V"K.[9 )5 T7(TH3OQF2A("@QER\">'#U8@\((0=X0\Q]Y6 X:[L
MR1NO_G6UV<>Q6<L>D7<BXKTKSTDWO1ZL)E.M[G(UO<<R/>BM"6G><98N=(R<
M:E.L!O5<!;?!#^[[@,>YP%50R2O];C7GQS=G%%H6VA44">SZ\DZ4&#.IU$3]
MD7G/UR0;2!^K3ZN9KF;ZY&:*7EDUB3W;-#"=&*K4_^&YT3VC<3M.MYA9'S7/
M622Y2C2/KL^H-7S[Y=??%:Q-*25I_AON--! WLN55'<CZ_Y8]\=C124NF" +
MTX""[-NRN8&&?8D2/WK:Y6#)F<[Q(ODTJU2L!KH:Z.,9*&D"!\=Z4S6[X"@5
M,8'>,6NV<TAM,\E7^-1J?H]C?AY%41Y(+%I:U7UU'$\RJ^!_%A+Y]RL2^66/
M$'GC@2_2/^5NLXJ5CPJ1V=[4U:U-X*O;=%B *DP*]62A(ZY0P0<V^G]9E,JQ
MKULB$DXT6ZUWE\/F#%5/R*MA,T T@^K4U)ZN!_HB!S<Z7$N@#SP5A.3Q*6BB
M_V>V-X'?MA6F(I3##:0Y_C'6)P9@5.U@_,9PR5;TO5 V1TQ%]T%B-$!P\=M-
MAR7J1!B=IY)<->(U,*2^ON6N#R%O>$#8OJD%D45=H1YB(H*()$ BM^^I6,_C
M3BC-J=M@&ZS@%.\CXBQ* /.JG8B*AXL& SQ%;"%A-<#L' ED1_"<<V&?O29$
MJN97@%0JWFNGX$PG\)!AYBG ZQ\CO>>NE2"!OAARM\9=?0I?/ U5L]>O_UAU
MX29WP=AV*70C+JB0J7F,3%_]&)79Z!'_].]O"); O!6-H@7B"13=(LP3)1$_
M.H1V-DPA\VOY'>ZW(',4/W@3_C(S7=XM.QO)<PDA@WT;R_'+3^C'_K3H='*
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MKW;<2GE#Y-(N[2Y!@/G\QUTE!'=+@C(T#'C'I9R%QS'K28S4=#V2^E_X625
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MZRYLW]>;/X\]O4?B!8/F7?:[1@;4,X)AP)B63JDE6_EYNY@P^Y/[@!>Z* T
MIR7GU]@;QBE._!!8@[NH[A&,2"5JL'Q3W8ORW^IV-X8<YBSCQ&IKV/HQF>8,
M,I(#79\V6!TMC#T)MZX363#Y./""-285&^A&4&C*MQ.JA-U N!DCPUT)FV!R
MPZ\W;^*4X63K-N78$A4J1K.F0TD=@[)NM?A@KN;4E_7)=>0QIB8!*52;ZZ[;
MT2%^,O++C#/)O U!J?$8M49-/WA$T5:1E;)I3RW/*!5&1_C!D&*0^+A,OK%%
MF;^Q@H/[K<S7/?'-U^TMG>Z,?Z'P0WRI+;[] +N@-PTYDFLL-HCLSF?QO8K
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MMF.XS$W9G\-!$I;IZW$@?>!^\\4YV$/XE_/F5^^^^?J+7RL!F,DGT3$@1IU
MZFQ28S2+VI0N6U*=B37Y7113LX>;F?:SZ!G<E#N.-X*--JBA$I2EZ]^_HI/^
MU0V5-@XA](#^N"XF4DNG;!0%C*ZJTQW)M7Z-M_[9)Y]]@N?_VQ@"_?"G3_5<
ME:D!))%*[UX\L;G2,VZ!CYYPBPW>6MNUKX*!2PQC]G[JPW'?0''UKF+B.I]
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MHKO-W\9=\!#]V#"E_A1C0/3>NBB^ RPRPE&.)T^@T<,5T7?0.O[DC_&E4=V
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M^5;-4-UYD5LO%!76_]7F?;U]3_6=8"%].4JV'BR(1&G##V$,9GU@08IV(!!
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M=#%*7Q7;?^K$JH!$7F7C5OK;SQ_I?M$SZ1$1MO%-?553]297MM5,">>?#OQ
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M#7H>CTR?.KM?;5L7NJ!<^&<780,5>,DIVJ-P=6P$/7THWS.[@_\=/D.[6]@
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MW=$L.9-TB*!]IV:B05$NG7PT7Y3&I3&*NB^:\\CH63B71')Y((*C)7I_#VW
M74VW,_S1M8]FS\E+.LDU4QQ)N)U,=DM=-HG)M\2).A!Z$A'X0>#W?#+Q1"IN
M B*DXT<(7_/8$G(U_(#[4]5:G_O85]5!AYY+1>-T,PYB.%LNI#DK,G6 #U+#
M?!3VPI>1453AI&,;2H89)L=P!+,PTEX%$OU)Y@+W^_ $/(8:"-5$B4R5!#-
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MB=Z3CT:7!?<=U\C:0HN8M:II@B%_DF(;3$]%O65P X11.DG895$#6@H?<_)
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M=)?=P%Z<41[73.GP\!_!3=2EV#R6Y*%)A-[8SM;.7KW,2(KU)],(J>B0:F6
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MN9I@7&]($P#L.RO*A.+YQ&=<Z=+M2C<@\.,MGG<D6=1Q0^B; .OE-5?W0,Z
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MMT8)/\[1]4I$ 0/$MCS !2T\0YKQPL*B[BXBV_4<V!\$D*?;>M=H6%WFH$.
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M<_HNU(>13/_2X>$_:&#R/>] ]B*X+;B.*@+2.AJI3(]YZ/!J<?=$TUD,7@(
MRAQ&5 #7(5338F@V!EV(U\\P HA3G ]SC>7BA\%YN9+W0"=OD!0I[-8G$@&P
M=#<A=V@)!:4T!*JJ=L?4CJN7$1(-ZN7LC=<WYAG;D#*('O%UOV)K$>)_4"I#
M<%!U_:K#*L-77#= R$QZ=_RYM]F*KV/N7;M8A,+GPLD4N3L(8D_3H55(R" &
M>MMK8Z[3]>.T)L^+EA-1:[9FWI(+N:-<%F"O4$32F'4QVAIYR<4 KF.\/<-8
M62A# ^,PQ )6 N"1^V-V\]X2#F37EU&4!%<(R^P%9]D(0,S'67D5'*/DBA/0
M0.(K_L1)"0@9\S7SYRG5*',CYS)*WSA K S4/:96A*Y(JN3YIT@B"C">L#*C
MZPAR&?@0=0J-Y,71#?Y=C+F20FI(5Q2CD0> \IN(G8MX>%DRM]M$&\^^WQ,T
M(1ZT"F*6FSD<I(#3A0=Z]ZF^.EF=P'D-W(&UYW+JY2X/T%=M5?TB?0##;@1U
M$^=L=,DA@R]@^-B!4"6R#.O$87"JN&76%;,T;(6S/J=<C9BG5%ZES!K*:,'&
MV;EGZ25D<S!1P/MMVT C634$"LTQ&0";A3F=J/G,3HB%T<^0(8\H=GIP*"K+
M@Y6&MC#6=6F%6CYK?S$E5L]>ZIJUJR^'7-D;ASWWT$[3O)R<5,0?9HJ_TD*
M->Y>:WF<)*T8^-+X2%)#TS4(< HZG@W1)&9Y9=',QF1\6-@K\N=;TV-N3V;S
M<N;@NE9,$@RG]2!9BMOZCBY/LWDSF"[GT48/NAH8,<0ORXHL!U,.J7AS,@>2
MB=^R-2V6!(XD]=@<$9*E'YZ1V3LY?)^HJ@_L3*ZY%4_,5>)$/84F0/H5(38J
MN&KGSP@2,@ F@ ,U &2B&7SM'8 ,$.HMXDSH0EK;T;S@0[O79K;561^:8QVQ
MVY\W5^Z&.*[_"9,2E-ONEBSC953<PM58&0Z%G>JQIA]:V8XL+7S[G^8(Y>;
MB-[U:YIP$81L NP#NVAP@4C2CRR%ZI OHRYP0V!MP76*]*VWZ/Z5EWG<B\V\
MUSLW\+K-#:QR;H LMA]6.R#Y$3=N !8<6T,38LBS1-A&3L<?XG107,&W#>D?
M>U(2RHFS@B2- 2GR*(LN+95NH][$.KZ^K;!B-:#KI5+@-0<-XFIKJL<0.Q_X
ME#%)= N<7?3(B60I#,,).5, O#)$8=+X\5&8<1N*G[8VM[:VMAVHJH,OCC#B
MLKNU-<O FZ>\&?SF,#Z5K]B<SN'0N#1=<"D<Q.8"7X3[<'A\D0<OD30!HC\(
M5M#=8W;J WS5D=(:8]+>II/Z:[B)$GT ONTZ&O36R+PX.OO'Z?'&]MOEFA7W
M'I;U)"V,"*#A9I[0[XD[)OR99L9B_RT*!^;./E,L-2A9\(1\E#&]<1)AZR3:
M/6K@>=?A7!0<-W?[B1?J^:84LZ-F!G1P@;I$QF,':T$YS.ROVV= ^>%WHY=S
MR[X)'"T$N$&,3-HU#M&=0&RN$=4(U@#;*!,>K>BZ5";!&+]9.2)D&[R?84[L
M: LN:,@MML(L+7GFM["N-&,<,2I'&A79X\:_"(V_"@T;<$5R8K3PP$@6_.3Z
MJLK40,L HQ+&UZ16D<:4,/_4""CSN@65!,L>)<BAY#*)CD0O0LX2H4(5QR&'
MW>;"Z>K D2W+#/PFS&*JT9-]%^HGI@ +.52AOXR-#B)((!:R!'J<CAI$6)^I
M,"0=B2EV8RS..(D<A R?:\8P!!<<LZ=+2,P<^66B8RN!I(B8Z&82X^IAH&20
M7I)#Z<_<S"#%*&&=P[$IDJ&C= \.4LL9N8P"1[6/K% 54D6?W"V+G!</8BC_
MR LSK4@:%E"2VQR.;Q"$-:<GFLU(KZHVJS:$-=/GTUJ=N^0\O3.J%?DJS8,@
M=ID@'-)E_Z7_FS$A<RSMRI=']5<M@0>>S.Q'1MS $P]209_AB%EC"QF)JV(F
M,LSHO>XPA!:\@"[3(+U=_)$6GAS7M!U$%J;T(09;.(?_;_.=(-M'Z68G^%3T
M-LE7ID]U/+L8]2AB2%0G^" 45QA7D&"MQ/E'D;\-K+$ ]Q@2CK#V^37\1$TB
MNJ+\]%&_CB!J5)BK]0.2UOU/::Z(G2T(1=QB'3ZB+9&_:99$"H!@-XR!*0?/
MCMA?$>E7D$#;C<AZN];D]+@MY;H"\$12R!7M!]F]9:H6BILAER/S6:#](<$D
MG >!#"W=@IFBC _5A#/.901\P3HQ1=JI,G+6K)>J6A&=\M'XO\9&88QW]R[X
M"O'R@3/;SO" 0G8TBZ[96CI-$([Q\E.:YZ^6V-#KJ-+33N+<<!9D_*Z9#1)@
MR*_CO"'!T0/)R#:##Q\^37PF?UGYF?3-X.7A'\>O(%241ZS/S%\O=2UJP<L9
M]01 ;J4/:X!C(7J0/YL[G&@&KZ&$ M!>@/!$2<H%+P^Z<MSC0^Y%E7$,SKX.
M:-!",S0P!4K%&R%+173XFP*O]6@WZZ]"E\X8W<;APZM9?1P';4Q]*!;!X7LB
MA=R2K/^S./=.*N=@""N%EHY>JYP^R+3]E&Z%GT),+#"(+<RY]V&::#Y-KE;A
M79;3;3[,^<7#;K<<EC0[1UCH)#YFB1^ Q-O,X]\1_8;;GJ(A7]$^?3Y<5I!J
MBZK!=V@BJS94_2H_]X0A891SZK@7?MU-5Q:H<HU%*-TL72B ER*G@H7FI6,A
MPNZ3-*EHRK26JDPI4K^SM;,='+$[=X[D2$O.%7"0>YOR 8)L 6>NQ Z'NI8/
M65DID'9KG#/H!<H1?^&NJ]'(",#._@*.TTTX0+%]J=!BX]9# & ^\L;>DU>9
MV5@I+F_@+_AI^_7F+L6BS4(,Y*;B"I:Q7]K9W/>_9/6.S'2]H^1OVBCY:D?)
M9U4CKFS4')V=QU(E=A1,'$/YQYU'TRF35N7!"F5_\^W]%<K>YM9L"F45KB:J
MYX8:Y$>[FW (+$W;NJ[\$6^H<<OR4(G:W?H!B=HYV-Q[9(GZ 1[$QAJ=Q\AC
M-(Z-/2=<R*[9:V.+9LL:W:DT\<W!1;J+(*:($1BD3MK=:CH#U/H%0498.VU,
M*#.,6 I&;/EP2+X3HYSB*HP9TA7(R&@?1_*KEP,=#BF@)8@:A#O]-7/Q# S.
MV2Z(P&;)WD63(R/!C\JZ8T>N&*J,4N%^_S&'AUAB*X/#4!OA'>VT-0FI%T+$
MUH:(Q0]4P0$D9J0NHHM1< RTS<(6,#?LHT/M$8T5!A>HEBD,\G(X##/+O>]V
M%'*AG&=%1!\[6*X."D.>[ZHS4*/;<?;M6'/7,V^-<48C1&SL* 2(VB\OME[@
MOT? ",O_YG=].#L_/CG?.#K[].GPR\7)._EALD;R[6NV*??W_O;^$K%D[[9X
ME.^VK!&'IN-_%]FO_$//MQ#W7__-J(Z?BU[M[]BB!(I1R'*D>8L9NRW?HN],
M_GEQ3S;_R>@7U@!7QKKQC..>,=9OTK@7W&=A7_PZPX#=]MM!S?3Y^K>,SP J
M^)<7>R\"_(9Q(\BDEP?2]HKL;6]N@;>%)9#!?VWA_[P?\\[ZK>!=:/]K%#$-
MZ 2T,?T(*GGFI#[='DS6MM6QM\G]%N4I[N;.TG=3#TG_%Z[6<7][R(8]P77:
M6<0Z/0W!GOBM"4ILVFZ\_./B)XY&FRU]]>"%=G?>W!8;K97+L/OM"J$H&QSE
MZ1KOI=^?L@W&?GBAK8S MRN"1D-)AVA \"$,A5HX1N# NPWYY;TLJC$N !@P
M<Q./>K9SW"']Z2'?%AG#D-6+7_??/&@H<SXBC[0&N_-:@T7HJ^VMJ0IKA4[*
MUY2(J>B\M >D/2!-]XSY?^#S+=0+/G8)ZMFB)D"$>)5@GY2?]M_0H*$[1\Y=
M.$7M6^G&>A'TZQFN]-/^;N5K@GZC3Z&?.V8P.Q1[R0>PY%X/EVQ,_ FJS DK
MBI!S]8TZ?D0 CUQ.!V-8Q2B@0+T8!K%T"-J$ 3 5NHJE84$<P] :VK= WT$B
MI\V\IU**W7Y3,(CF&U/!3Z"N:4RVCKP1Q ;T_-CFK\SN\] :IBJWS3X!B#?U
M2>5H T%0EI] @GUC<'N7D>[+S=@GNUA8,LKH8>S7C WR&$1,,)4A8+X[T+#0
MG-\.%7/*4@NE9'IKI5]ZH>-YYE* < # TT(Z/=+W[]0X*2Z99L#*89<#'JJ:
M%2F(H@#/L!5(=(75X*ZO'T-R)=2M6Q,!VROB5C&$RC%5.=3RXDZ]Z6\' (FX
M8P[FB/#%#6)==\@UH& ,<]$7F#8PP@PX&[=J9F(]!YO&%@^E )R1&\F\;%0"
MCH9;P';3'$D]X9]P1,JA+EVUB"@:*<H"$!F%0^R+AZO!JP]8/,53I09=:2K)
M6X N$N,&W4[(D?6!C'KS'< <"4<XYBP;KS&F]<.ZBBI3 [R/%3S[1"!>2]*<
M8X'F,@Y2=$I_LB""!%'R#5'HB+C3R.VI:L>HA WYAJV5!(*L? :N@R\-7_;P
MXGHN,%12"7ZO1P\K-AYRSRM12P>F&="L=KL9%%!I\!_&X_,"<WL]?OND-[A$
MCL+T8V&-TP?8%K4;"=UK9G66G 3:$_PVO.R'EE^#[.U*TI[8QB)%!G4W1GA*
M8%\C8VU<)DH6";&//[8@1 NSSMB<O1:;L]K8G/_\#RQ+\864C!2\/^GDY7+T
MS-$L"TRPWD7$6QAWN8+2XA@+I/$C08^)2J)R,<'RYE+ZZ?$[>BC@G MIC"I(
MIJNHQN?=(\T*Z=7EY#DM[ /5IRV^LHMFN>R%A%H8'F6'+., %@$Y"@%V^JHT
M LJP '* RT%LEI?+,6+DH)R@:GVE!HV\<^\>^6?9NW+FL1LA4",QX;BXM$W7
MA6RX@,2IJS@F=.L0;: F(*^!%XKH$;\9M9Y4$#4(M\YQ>@VO;<8,@"1E<91T
M&35@N_X(,!L.@M GR%/Y?H7:"#TT<QK ;UUX1>X/F%_2-!:Y:!7MBSD#2S;
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MY3(B^JL>$+(A2Y7/9Q/V"Z:PN3>!Q::KV5^R:E/Z:>%%5_=!(UEQ>A9H)%S
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M$^QE('<-P+!SB0MBO4_3?<EN!<K= +NZ..7.L8MUA-J\W6JA-JM=S_V?_]&
M*$9M+=VN5&R0[M94W?K>66?UFM=Z"MW'* )P<!B;0T"_;6R2,2^70(IGR;4T
M=W(40M"S7PYF,O&:[F:FJGF,R_GW23NAC+)LLBE>PU(OWL>=5C%\KEOG'*O
MPXFTSEE.^?#YU!8^Y-/J^GSQ /."/6,(&B)&7O"9,Y?HRC<D)$F(Y,W@B_F;
M_SC[#SU(+B?-0-*U P?NA'%YZ(::VJ6H5DMB3B9>:ADT*!K$5,XJ>%.QE!0\
M9^P;5($S+Q/59^OX5"U^)&T!V9X16P9A%N9E/[2N ICU5I(66^JA.0CF![W&
M]9.21=(>PST7A.I8RE&:5)[B*C!X:7)5V\YU$G?84>LFC;ML:_)BY>S"T4A
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M1RJ-C6>1R5U*]I%E/C*OZ!:Y,O+1 F#.DPHS%;X>/3(F0\DMAXL7HL9"VLU
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MWB/8T.!Y;>S>TF9>RC!X8%.=;.%*8!&I7@&4^+!%]^XZ&/\"E!2Y<Z@V(DP
M3+9@\G1;]!5Y(FB!L(]( Y])@@A-F1+W$CO&"+D5Z1XK_!&(:+(,'1Z!L$!2
MR/8 0,AQ .^ Z(2=1NF<#:,D["A1H^:G(H!.R1"EOD"N4-F!WD&*?9K>&G?K
MDR>S*M/(Q5A&2F94@)'.[!!TO5LNE0N:J45T<^T$98:4*-JO=<FBB:N9_8-Q
MTR\*6H-0*DQ"WVFQ418V;@"UQ(%OX-<R@I79-O=^;'_$^]5)/+!FR,R!4W7E
MHW\J##SR5S5CTM:W4PL]J7-N)Z3M1)COPC;,*R8."$<K%/<@/@;,A7F#R1W-
M1&KY=8E])LOX6#?E=>JDXK7H /@YZZ%'WSPY&6WN>1/+0<GXUW>==_1:2FUZ
M+9]Y=GU[<7E[<'[]Y<OPYN[RH_ICM30+X24\&?SZ200:/G:D*_!C1WD!*^)O
M<@TS<3X:KG_XZ_)1-SF%H_Q/&DPO&2S,JF)R9DQN0[9M[>-)_&GYR-22 U4.
M)X,_\E?==@># R("]$N'_K<XXESJ?7MU7&6NOVG#49T;N%IM=V))RQX^M*6L
M#4;_<Q_^]KLRHG^SP;R*PVGN0U=W#!4#.>K?#2;]I7'MS9)Y*6VJS/U3)&13
ML?GR<[""KY!NDW/!)>>!,UM16WZ1_I"420FCT462Y>S>^X/,_BB,M5L<;+EX
M^@>/'Q$\%1O2XRU8?)?SKS#IX4\WRODD#R)N?^3.@Q6B=B=Y&_V1J84QZX<T
M;)RQ<>;I*&'CM\*R*1&*+&OX=;OX]8UQYOJY4!H4_Q<VT0G&AA4K6;%%1M1;
M8408:9U,>#<TG#='"'XY?RM\]\4S?+=QOL/P(\9E0VO"$YA?]$9DWZUON?JR
MC1#< F;\9MD\Y&^1'<7*#4-N&4.J6_GJAOT]\-#A^5884NF&$[7NK>+'++V_
M\*69O+2YJ91W0%1W!"3WXZ%-3X>5W@0>1@ZC5\6:TFBB,X25XE!WW.-43?1C
M,#CN]KLGA_-R+ >;S['LM1DEE6*424\KI=C273(>RV0+C8@LHR)39%PELU7D
ML,YLQ53\V^QV'/9/YVQ'2?KHNG=CTX*PE!.J@@F-IN%B5D4QRS&?5J!G;>'[
M%,Z7A8EQP$*N,L.6R@E#AI=I1UJBJ<K-P" LI;:)1U7&656&IXLI<C%G79$/
M^0CO!IAOYE4'C+.TIWBY7\@LB7O*#50332;IELW)G"\/[>J</LA%##=0P(-"
MA/_$7!O^^^<#T>Q,O<Z*5N9?##.U+?"A%!$R3]NI%!-S9,EP,N&^DW[U1U?,
M=9F1\3Y8<F3XJAI9K;KFRJ4<1>F%OH1ER%6<[PJ+Z\TL;M4RJ@737WWVO55F
M?YB?_?;4="W8TR*=UEJ;M?JNK'1@CE9]@G9^2[=R!^J-3*78KBYS^4JQWY80
M-2_.X&KN6G_W.^:PH1&A.C@TE6V>2_F5=CL;8L(M:+*)%PO%L521$OF\JE +
M]-^0@U$=8ZHU"@Q,MA;DFM'*,G :\8A(UQ%S*F&SF=JSJU?;BMG6V<13/5&;
MK*9+MU1:]\S4\\G:,H]WG7NI5B/SQ_4ES2;,<O)'S&0"8WW!A-KZ1EG>Y7J2
M>N<[)> J_Q.,"(>'D7"DW/(G^)O3!W<3SRUI+MP[(;,73.#T[Q]WL%VP<O3'
M/,$_PGN31/B0F8^^32?"-X/&U?\FGLP?ZYT(V9.WK411"I7#;#_J4O< MOJ@
MV\\)S5#0$QX$!&414C17Q2GIS8C@C"B>%BH"=V-".*:@ Z_3"&UVY1/H0NA0
M#QFJY<+A2L9IL6Z_?K(!^Q[0,N0"9<E,_B"GIT'._1E=[:A[H0S&6CE*@4<?
M)$D\3//V.7.C**'L?(<%20S"T:<"ATD0Q>*1XF%MRC$"X0@'$R2@Y?P[$:[
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M>17H#XV0ZW:]G%>Y-U+UE#X _GD4U;7$6?>6_R?6QJ*#X@#1_['Z,(@(GI<
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M?@S#B-[;R;W(15.A(9V=""\A>"8<$^%QN^<^'[EQ!CH@9X@URV$&=/)DA6Z
MCD$$PA16ROI9[H]L^8@# YI-(" C<"K9#J:1X ?T3::IJ7"05!"%2#(2GE K
MB@(L[H$=K3T<]2?\\ #H+8DCL&A@!-@G&6:QT^PV.B\L\*N..7Z:YL%@D%US
MJ8KT.W@\Z!\V4#']WB-<]H2H P]5]>W"58NQ<1Q%YO%D?*!V5H%/8 <T]!P
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M+IE,/**+Y9U9'J[G[I'S^,H7YC8<OEM.B%W? BG(:ZACK>*9DK+BE_%,+.J
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MWBE#4)HQH!!"QV(A'UNNG[V+:#XXX,J4NU4#T:MO,,P"H:%)@H.(VQ^=)$0
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M6.R:.OM EI2JL(]6@9B"\D426_D3@RU7V3-<<QQ;H,+?$RN,6]0L-0;Q))H
MXV8Y,D6<GL\0O\Z3>O,H?H3O^Z"6A)$53E7>=?X'[^?J(VIVH+6)#;M.X@B!
M]4"XJP*"B_(,\]=OH[XA..F#,2:VX00/'&MZ@!;! 0?IG!?-O:-9EQHP.PCP
M(?"XQ]!,@.]T\@VB%\OM<RMZQ-["BI^O1[.+FM7(CGZ THN/ HTL_?N'N+KI
MYM:ID.JZ0NG#>05^%?;@Z\10KP5[4F3D"M$#C ?+\H66R)Y=9"EF2V+D.+W(
MT;K\1]&R;O&_560_:1V6"?]RLN?Z)S,';@9LF/QH@8%A@7P9C81] D;)@S0]
MZ)=R,?)MGJ(0PA,LX=S#5Y)R[$X\^GY*[_Z=%&K5TYQ$C/;VLT4MQ>$.3[<<
M/WT60WW"%R$Y@UOZKVSX&)MJ!TE<QC5BE4BUQ+.(0V +G<0F.[V,R] .@[%0
M%Z2K3E]-VO&ZS<ZL2 CB^-&-U/BYB3W3?4KTO.?<QT;;;NR)!8*AQY&VM&&5
MQX)(B5VZ'>WV+;\[:6&P%I@8MRW1=%PT:)Y=H)BC,&W4/!Q&!U9.9"UMR$%8
MWO%)+&1J][@EO2O/,&.P0K%)NB_<*L]P)&,@WR2Y!VT=6Y$+GJ.;"[NU/Z?7
M(IK*$2R,O7<_+! $=Q:UZD8ZI\>?%B^TY"O_&] U$C^=%;JG/[K'R@Q.__YQ
M=7.=._7)?>0Z+ER)VJ,:T/=:G<-^Z[@W5]B6U;'IG-8"@E523-Q,97)3TDI@
M;I8#;KZ.5#]N0OX9F<#9H$;=!^8\[0^*]*T='&(2\H,1+5=&.*3DBUKB3N06
M</O:GLK<\9C#KI#?<O:6A0M,:J2S0@MDN^7/ZOSPI37I]9OCLEHL@$Z[T^D6
ML[HT"T#HWD5C#&4?G.*%@J]T/9K"71--A>NAM\%SVSMM#3JGK:.2=FMXOZOU
MBDB#F"[KI4>.O4>A*0W<]--9 U?>0+@O$KUDYJQLQ".Q/?NUO*>\V^H?'[:.
M.T78<K%!%2J2-0)9QQ[<)]0(A,J*ZA7NW2U'DY1+!^;=Q'/C[1%.S;@/NNU>
M$3 ODQU"%2ZR.JE,4M--U:M[4"/'>?<:4I[[>*MDCLI3I;AE1K_2RW3;%U58
M4!4?V7M+9IFFFB<%R)XL3S@;7)R/YGO'W71].Q15]3"B3R<#-ZU*:X[1D60E
M\6,0@BY*ZK;P0I"(O)?/%\P"'T<)S%5[9#8A,%I&KH?+I>LW)N+!5&+IYR##
M3NE7Z8L+[EG/5%K.;,R,&KFV_ 3HZ3MD.^&48*'#L0@UXL1N.9E6#CO/_PC#
M5.$D$.:7C!2Y'MX $S?DP@"I\,/0RES9YR%E>MPDP0E MGNR<B;*G,@\=*1K
M5-SP&)"R;;&S2!WYJ=(;T("J.%"D2Y+6>#W2K.6AKZY>.DR@2LIS4(=H6P0]
MH)^PA> #W4Z[5Q;.DY8(QGL]#R.)N*N59"@Q0M:P\'ID#&@H11FMZ2=EW#*/
M&_*R-<J9%HHH./TUTZ2W@LI6I;#ES\6,]$TM=UR6!=*W>#%9:>\0-N9P0'TW
M&C.43:XCG"YPG:&(P5^CA,/>OD5Y^#X(\V]@&!/$&WJ@/K30R3"V'.H);,GG
M>L$S1Q^])60+_#].S8W(95*\/$G,%-;5DOX/S)L6[IZ97X(,I%^*I]%[;384
M8"I1XL5*L Z3!Z""$-K=KDS'F'$&M,H>H 1S@>((V4(>&<S&@HW%Y%70V\1,
MK=1B1C\$T1G=5&J=LUX(6,6ZE(?!CVY7Y'HTJM7]P.& 1]!A^03_S#Y)^^C;
M=,*;DS3MT]YI,<U[7<ZI:SL.R#75%QH."3+U9J^OU!XWC<UF)MGJT@YKA\2/
MYS<PZ79^=/O2GY+]W9B;9 7U'<AT>EC<+:):H_3H:?3H;0T]T/8L"62OTV4T
MDV&T6<MGV<U9KS*ST-NR%F%3!3T&RA1E.-3OSZFLR'EMT._P:-#JE(F!U-;4
M/"\+B+L3!1=Z4O;G@^Y@)A$VR\Y[;?'%27_I%/^3_DX57]!T5UC;=A5?T(16
MF/U.%E^P;:Z.(**NL -'II1BNU9D2BFJEE5'\43N9,_-"K<?N9.D2E<A/WQ6
MS6L&S;6V>UJ'6 /9!_8\ZB)/F, =<L^2B2:I7B+;:8Y6KP=Q(Q8E8Y@R.9L;
MP!,M6\^V((SV3ZH01LMFO3+F:+^W,N;HT=*0HPT,N94HIDO6E1L841&1$)BA
M(FJ((2GQ6DF_QM ]S=;,VYI_TH?<$9LQA"G"N1(OE#="O"*?A"#$>S#CQ9MD
MUC8"JFM055[7C2KS!LPTGW\[?2E?X\ IY!$TD3[<!#GW 0J''-A*,$F1-.,:
MK7!OOW1W:XA65I28&#"]M<%(27]]9GK(Y.5B-O2;$8&O2<8NKX:O)\A01^)P
M8T!5;U&>%K:UM*:U49ZHE,%'KPT[;;<,?@/::#$SLBB:3]Z(:'Y5U4?Y^1/D
M_?8<;+(\NC+-V$CENK5<G4^J$C@:994ZU.72E.KMEM3[(Y#+M.4TS>HMBV!U
M )<[3K4F>O7ZK?Z1$9\O$I^6$)^*A2D)*QC9N,7!2'%X$-*($7_5'N^0FCK?
M#PMR:48\S 9SZ77137O8+S9Q:T36O4;4=0I3G!UX5;]Z/OB[FJ^[+C(7UK#Y
M)9=F6U;1(1\D@47B&F64Y-X#.V@)4AF*[#=%]OBLO,$EF\-@*&+$0R4=C$^Q
MM@BWED2V]Q;L3M4H& MV0V'NY6W7Y?UV@_8Z.L89R]6HIMNE=AA%S%#D;:FF
M1CR8PV H8L3#>BW7_3%0+S6 KS=GH"Z#08&4J2G,:@S5[3147[W5NV"Q5G>_
MK$ '*.G$4T<I9MW-72Y3H/(B=%,.0HI$VGQ,:0D-SAT%6"[Q"Y? E]*:$JK5
M"9?F3 ?3Y>6U+NH/VX?POPS\(D\R>N_)"EU@Z@-@ NR9P*.*SVUK,ON1P@TX
MZG2*]%??#,+)H^7#3WOY>FBJ[&>%C1;OQ)BXC7R/X\!VL6?7H=I8&.095*^9
M;8:9W/_IPL_PMU$<!G_R U&#*3Z?463$Q I.9*)X[QBSZ.4_'^1T'.RO1: "
M!_&C:__I\RCZJ" 2B]^19*[\7#XN_7SD!5:L5CK38Y+]?^YX$H2Q0+*O9N="
M]FD)8]5Q;$J26@5^80X334#0B5KI>2A^S24(#J3\/03Y._AQ*!'0;OF3&\$<
MKGSX83%)?%22YWWV]=LYH99M)3+:\FDY%;AHC-K'_2=QPTQZ 4.,HQ2Z3O%5
M-5A$3C;-T8"EZJEKM24=L$BK7>$&J&K'M;#*M#"Q>;>%Z.%VY6,1*UX:-Y[E
M+]WGJW*9K]#+EZ+0W.+8R_'$"Z:<BV8;['I"IQ,7MJ9>=65+^#Z1T+2U8Y[=
M<C@08]=V/5> XDH)J>,-PPD&]<9A9V=?THX'P3U=C?"+2 #Z2H0T!1@=P3P\
MT=L$CDPP$=_,.HW)8@ X6S JZ@"(%1$TMD:YJMQ2$:D7<3[3.9]QD"K<9M>C
M$<B^K%4APE,HMDC?++*'#G*.;^B-N]P(@9<1-R0J;2!!))9$DJH0C4GPP A(
M#_+&R3JF1+FY"[Q< AF6OU7T)E(_A-0*ILTNZ1MBQL\"AU2A+,IV*I'V:]75
M!!Z0-2B0P-9R^FVY_D(K+$12A@T5@%<"*V_BAE."2V[!+E!S'.PU,Z7V6$\!
MH:'"+V"77&!\AXFT3;%^& *_+]0?N!+Q 1RLC$F,SW&X%<\L7$U=M.%2J*X!
MPL"!X3YV\0ZVW=!.QAA20YS7=KK!*>T0BI)6#LH-T/XUY?F!%(IBCTH:?%F3
M"4AK6ACME@#_%O@IL.4".J7-KD9$2S53!RY=A":,78+N#L4*GU&I]KCUI'8S
M?+!\][\:Y'6>(*BFNV+)67N="+X>C5SNM%3K5$_<@NG#$?>UVV/4X"N:;3/D
MAHJ,+29!8 *-4VPD.B+PM]F0,.?7*MI\8#\0MFI"V:)AIH0&?I^*)]&*6)W&
M11A[3;1;K>%"$Y<T;GQV4>,!YGYD+;[<5H:BJ-"PUZL)K3IKO5WH:4F_N510
MY^#T!;B];",U^TT<@RU)?/WJH-_-WA^<I6]+T&H>I?A*0F2 *$&K-$@BU5N7
M+@T0&^>JFP8<1A_.L4"NU@^D!B2I\7SZR%JNCB5:)S5^G[36=:%H]TF>VG2K
M(,0XMF$05SD\J7;9!V0_H'M+'D?L<;G2W0-L/7/YU#['KV#TJ^M$Z6=PD]EQ
M$&X!N40+CFFFFNKZU2P3^R"-)+6 PHGEZ7*"C3E'?E1@9JK'7T9M=;/GF0VO
M=[H]P?!T?0MQ_02YA%8=@HX=/J'OS$D( /X"SPI<=G#RW\/E[/"1WG4O/<P?
M6B6,G5WRB^YUW!'LU;?<]5ZVKE(M)?4-BD-%>/DHWZQT^3A"WI%(7SBG_GRO
M7/!I!_?Z]<M%03VV?KKC9$R>%_0G(#?@&G0[2*KD9;(6(?#F0PNB-+W'AHGZ
M/3)$=\0#'9&S:?:5&XNX98@WP27*3/IR.?QW[T?G5+8_S?[^H>08U? +\:R[
M:FADY:#Y\>TY^/8(-Q!(V:'O?'N&1T_%%9C>?KA&?0!\_1466&@@>Q!Q^Z.3
MA.C9C+!I+/J821;-.MW;++6/846$'TA;3<U\SQ^1+L@4B-0:!MXB7D%S*_'E
MON>%-VF'>B<W$D_"4ZZ_G3-G"Q.H=AFM['8L4;9> OJ\"!1QG3#0I9I='ACZ
MM!(8.@\^O!(T=!'9=@48W./=@H@^7F5M)]L&$7VRRNS[VP01C?AY2^-$Z^Q+
MT\Z+"BW_0$8M"J$;4HT^S81.9@RE+02@7@F<?;#W -2[MJ07(E#OVC*7A:"N
MDC@OQ:!F,Y??:UPU53Z:I2/I+THNFT^=E_F)JIBD;C_1ADBFNZ<&Q&W=5=Q3
M&$C0VR7F5%[5;T\UAG0J.T,N<M]0TZ_PJ<*N6=R[->MA>&Y-,( I<.MNY:B?
M@_!S@LD85[(]6UEK'#!<!FBX=%]OB]0+E30X[K0Z)8"@;?:Y")->AI(.MF<2
M$LFH@;V=D"\QD+$J]EZZ#[]>7JO-R1KK8AB(_!?*\)0>0C?U20I?8;GSKQC1
M74'L:!DE,IEC0Z>J.)'9%)3*^2T0Z"^;[5*1@^4B_MFHGY:.!Y#A'N47-L_M
M< '<Z041'#^))WDVQP4121_$V:P/HID^!S5$W2NZ&N0\Z2V]0S4L/"3_-XI(
MW4O04NT/YK0^J% <9ON,+>J&4+MNL<GN!Z>]JNX'+^AU<-Q9N=?!<?V]#O9M
M2-.1@4;>4=A_TJQR=SGA^:]O C*X9[H^;+;KPP8Y0&:T"BJ7])HPK+%M#4%N
M^=AR?7BF>'F>!;4VR4??>#@VO+(17AD^/(3\ 91CL>=7P ]X\]N;9(=_6%[2
MG.PP>#WU=Z3I[GTU9"Y</\]6KC*5I;:DT5"T<YB'_M)=*5Q?)Y3M4;?5.QV8
M\LK-<<>\JJ'F>*8.6/!>M]UO#!=\3Z1+S;E "]DGU?LTC0^UKEZ5XZ[[+<C^
M7I&E2K)^T&.&=;R=_FRVCR"R3 3:$A:I\QDO^;H!9EB@B?Q-Q#V,UK'DO?(W
MT1!(9@K^+0RB:-[!3YNL;4S_Z+6ZW;U0/[:05RJC.:7,LH(>T@ /U:"/''?:
M@[WHR; V=82JUFL1.?E62$OJ)$UP5:5*<MH^.BZ@?AAM9+XVHJD5DY_SM8IU
M4F3EO&GILQ,Q^\E/Z:[+8Y*4*R!Y1*U=F9_9A6V8G]F%;9C?OLMHX]1^-0C]
M_G>RW(A7>W-6Y=%AZZC;&)*<\6HWY]7>N!79[0[:W>-]8)VW[M6NW83LMS-7
ME3$AC4/;.+2WRJ&=[YZ\*=7CY*0U.#$>[5WU:-?'1#7H(H?M@>&D/7!HOX:I
MYCBT3X^,-F*<)0TU1)@@ANX>J2GOF]53,I">]/K9;CVEU^J==FN]7#[LW^W2
ME)Y2PBT[KZP,C@;MKDD'K& HJNWN?6IZBGMR39NXLXFU;>\JMWU^9A>V87[[
M+J.-8]?T.-]H>'ESME.WTV^=GNY%KNE;BR]OW$PZ[!JG[LZ'EQMQZ [:IR=;
M[M#=?[F2UL53;7JCDD27'P>'J0 Y7)B@TAHT)T&,R]ST$-[@2=2(N,T*8*_?
MZA[N19+83LEIC3MV5O\;#-K]O6AGO7/Z7S7W5.E_W;7J?_UVK[?E^M]6>*'^
M1_;P9LLV\6ZDP=O+VKD=$'/F.XE=_L2_^5*HZK4AIC[+$W!@B2,@$(8/1/]"
M"QOHH/Y; $E-@8@UK-19D%26PT?-U5E0<^6*%LK-9 S.G'3Z\ (6^1G66*;B
MKZW5_6'[\*AP#1#%=H,^N0SK!NAS=-3N%5&W\TB[[11/=^Z]83]R)_&P!;=&
ML/,@BC\'89%46A1_Z'F!3=^NPD[&4:*S*>)M4]N09G"2<[C KSKVJ@,7CV(@
M<RQ!X_,'G@#'TWZA.I*RZJ^F]9M+(B4&SCPP\0Z V $V%13RXF "VX%?& <.
M]T3#87I@VE!-:Z"[E^C(_9,:T9'[_6U 1SXRN,/+($:>[#IBY&>!@?XO[&MP
MB;?[)J$B<^CKNP09N3L,N_,0I[JG;1O19?>5Z+U=.H]OQAN-6C+H=T^!!YHJ
M=I<U3NA%%E)J] PSK501\A\I'6]![_W#];%9[(N,QTF2MXFRT,]!;V'LY[A=
M;UG[KS7Y;@P_S..'N<;R:_BAUVO7F\3_:_/2=P^%;*SAVN^/>*W9#3_O-"WO
M;9_C0"]D3PC:;,:%;O9T[I[.2,1-[JE1,E\J_V[=Z,^#4<BQ2SJ(0&RJ'F*'
MB;V3A.M0+)"8GX&65Y*4=:N91\NK%8=:)IK1,G>$&5;2,5=@AF[[L#EF,"KF
MLBHF3!>(X3MLZG)OGPJS:ZZ,W ]1TR!17I9#44\(,N7FS'INLXN$J^;6&$+$
M$*0,4QY@J-<=@;KZZ$9Q$.+*6! R=SSQW)QO"X.15JZU-GNT(B:R+=PX2@.>
M%. L^L949%-[CO[AB%D,5;D))42XL#@K9)/DWH.IV?0\%Q;JBC$\=\1!NKK<
MM^E-)XGB$-:IQU\C[DG+$=Z<<![*X<6$83(T:BBBEG!K@-B%[8$UV%$+NS][
M"14:.?R)>\&$^H-',4C.%IN$@9/8,9NX$XXBA5(*R"U,?6]%F#<_&7Q6@I,I
M7SV25HOS.A9L+<.>PO@.!G@Y-K@5W:?3=:54D4VM53MR+6\$(\LP&YS[A'(1
M5*]R>+Z=R#Z^NH6M/N=Z*HUH\9M?T+/K>71+NK[@+6LR@3G'L#ZD#TP8.V;#
M\F!;HP0[<;LX"VL,RGJ,3]$(X?KB=L0+'QNHA8Z:?YY!D,F"9U^L4Y"%W7,@
M RS:>@*:X5ZVRT+<S9TRM, $9?)T#/D$6[[[,&7!?T3]^-&*-?JJUN*XG.SG
M 2R*!5F^O&B#GL\1HC _]GY'&L V."Z]#XP;8VODE,?Q6;+[>41'>H2'>LSC
MQ\"1/=")L227IWRC'>587QL>O#;[+ENAPY-@V\/ LA];^>\1#8@5."A<Z:KP
M.V/7F01@S,#K^)ES,4>5(O6$3\93AP_'8T6C^AG?9MF#](Q%NUU=BZJI$8-<
M3&3><"6:RZJ\4XPE":V7_T2)PW__?"!S<M0;Z0KQ37GB+*DA:C&AF0^9Z_SU
M':;*W)&X0#5Y AJS\V,P..[V#T_Z/P;OTO/K#.,%7S[-3[+J;*%^-D,>3F&H
M5.&\Y\!NH'!ZS]8T>I<N01^[N,Z5UW:ZRMJZG9G%/:::LG0JG-+_/DG-\1#8
M1Z1I=#N=7]_]5O_TNYV5YM_-S[\JN:<].(3-R+:+@0+=/NEG[XDMR][6(Y.,
M0I/P((L]AFCS_ +RZ-WOE)$EU E@99!V__.;];O.L-5DR4VS[%!H'PMR#]K'
M;N[\H*'P*6<T8-:/>B<4$Q>)0"_8A'ED7<J<>86EHBV2E4:<%T>-SRZ_7GV[
M/&=G5]<W?Q_>_C%D5U_/VTNEP&[KDKX&,8P,5PEP&X7M28'Y[/J6;[MP(]S%
M\ :E%>[T,G.).%F:+V7W5JZKCBR^F7NGX3M0F?5B(KGCKEE=3)I=;-4<B]1S
M*A>G_#P,'3UY91;5):&GA>7N5BV'$K6J[^T[& #NLR@)4;?W456+@2@QJ-XQ
MVBFDGVFOE4%#1E@0%16KHO(M\T'O.>I#9%(XZ]!MR_8FU78OE(?D7^@AJ2(B
M+W>HS!!19,7:L5"*06]%:]('/13,/LO-?AP1\SL!#.X'L1P<"3FQIMJ7I&6(
MVD7$.5U+HP3HOQ:#H(QH5S[#[!M:+MI'F><1+#TTF?TE<WKS-K=2S8$LN-@1
M=W&1@DOA,:EA5S3C;+TB@LN*"%3^<\:(V-39D76;PL+_L[QI!&^BV2ZT<;*!
MTY3G[/?10A6]B=*111)FL1"N71Z19_J 7-.2($N4J"R7=%_N]-9JI2)T?@MG
M><:&#6;3UU!#4[:#R)FV!R<)'5:";.@L(L(NX/&9*IKZ$N'+YKD#J?%ETUXY
M67[0VX9D^>6'W,K<X_7ED;[_?O<7Z2OL=#H?FD@IW>-<?55EMTN9N"8SWF3&
MOPG2F_SX[8NKWX(A9H7VH[#?LC#:A@+K:X7AD&6MW"E/69'*_G+8!XJ.0]^Y
MR*@HA]!1$*Y\C(6E3K OLK"V9FRDDWJSH=\"*,OKN"'?:&N[N*%WW-\QF*S]
MD:]_XSX/I>?%<L:N[T8Q(MX_O9WLT#K%K"0GG*MACI@;.UHU]X[8/PRC-4C;
M;6.*DVYCD+A%>6M:!!A8].U=Y;;/SQB1=2@YWX(85)Q%+GYC4JZDZ]1W'QT=
M[T4[HAW:R$6@8"_<R$&_B 1F% MSI1G%8NOF]WJTSJ927H:4$%($J$1115DL
M(5\&GC(%>Q7Y[>5B\FO@8[(X=RC7(2(]818V\&L0_XN#>+2#!Q\6-=LN,H]:
MO$"6+H]<?7C<:74Z17&Z#/+D1I:^Z!I9?NG'L,]E2V^]"L9,QZ-L(8<E?I@N
M;''Z1\A%H4L<L'*@U426,W"&().*8SOT"HL=M(>I,:T23G>CV2(.[8<!YK59
M*29L6O"0E>7,S?5IC"\$1.GG()1OX?<:P&3^\>TY^/88)!$0=^@[WYY!:DP%
M7N^5CR%#V%PDMSX OOX*5%B Z=QK=[OEF,[M99* &\N95.B>@MMD=MV!8D;B
MQ!63EE@A,;BKB5=5+>-C1=H8)ONH?O8'Q@OD[[J265$,$]]',<WG?@K<&9.Q
M%8S6%[K-I;O5(1N_63_/N,]';OPY#,8KZ-4=C;>[]>G5&UI23QW7PQ^'W9IM
MODWN4D/63PE.].(WQ(F*I53+)T,['!.Z@<?3FC]7/V]430KON&-,EPVQ=D&6
MYTY"_N3"B-X4/H\2D@Y:K<,HK76(LEJ'9D6%^+H=A*&XVMQ8N_WR90KM.;5J
M\VXWX3H'IKAP(ZQZ3<+7Y:7.*9X2]3U'W</JY-4M34CN=MM,$(K%UD\^6^*R
M7*:P&.",BO RJF,%+9@Z<#&#(@!S:!)HNZ'4X"]!%#%17(CUQT]NA*()3X:K
MTPP/DXLJDJJU2&&R349P'1G!?9,1;#*"WTI&L('M-LG)N\&I)CG9)">;N++N
M6D>#$;1 2M>)]B-\_'Z^82[4?=23A<U-%A+PU_6$AV2C13-F 8^485!_4#F"
MB<-[BW*-!ZW3XWH3GC[L1X1Y_7O]<L_+DGO=;QV>U-NU\4/SDG)_!"+!(_C$
M'):W1PG$]9\4Z2/9E% \Z31W2LQFK[C934O%P>$Z1:+)R]G]C!"S"]NP"\8P
M>U7"[YLPR+[R.+N0-F9BG;:.3^K-X7T;)M92N]>XT31H]3H#HR%L7/9O^_S,
M+FS#_%Z?N;LTGO'"(/0Z$8Y+DQ_RF,?=:LQCC2R%E(?YD*Y9LL>2<+KPU1\S
ML*_KA3I>8E'%^:ZPN-XV01V+":TP^\-M CK&,._R:,>%5-3?TW_2.)0F2:0@
M*:C[=(^G0296&I/:,BQEL7$K[/+1WN,N[]B*7@B[O&.K7!9UN6;0Y;S<6"Z+
M[X*/>!ARYYOU<QA%/(Z&OO/%M>ZQ4X;+FP3VK$$]$#">L?63\=$()$ D&KX\
M^ 3JB7FQP$P1)<6';MH212;6RF2E".PF00*9UX<=-*Q(9O-%'YF4SBON5SE?
M+DK=?'7^@#ZA50?+LU+V[ZHYAC(5$)\B!+]4?L4[=@*T]F.Z@SXQ<8,P3"5<
MX8@63K?4KF%0SYI$\+;Z*_TH1X5:\A-9O_?KI[(,1?DQ+JDB'^-%68KU#5MA
MBRO2SW$<DCW BOY'1@[(63IM*EEQ@XF.]:3EO&8Q>7-[9CXE"9-5<\OE2$F5
M<<9>S7]%\F=7.X_R$WK21V'R?FHTAVH3L*W;LN7:3/;Q@*_DIMF"$]8S)ZR.
MY-)MV>[MF8EAO+6DUF[+=L\5ZR82O%PD^$(S\;!]"MBY'VL-#-<9L&KVZULX
MI9W.JCQ<%P]_Y3$+1':9_\"\ +AX3[+-YT?'"QZJ:T4$#)>?6V$X'04A02*\
M!I1E%=SJ0>MP4&^H?#_R'-:RD376ZF.B^%%C&[EWU_7:1-TUXCOM4>+XJN<"
ME[\F6=;K&6CH->U:K2 CNR:U]D<X?>%6Q.&S_\?>NS8W;B3IPM\W8OX#PFM'
M2&] -*^ZV/,Z@E*K;=G=+1U)ML]\ZH#(HHAI$.#@(C7GUY^\5!4*(,"+1%(D
M&QN[:S4)%JJRLC*S\O(DQ\@F>R^F'ORX-\WM1 4C4+@ITZNQMB81U>YMP-[:
M(#)L96PM)L_N2D /]UZPE6IRQ#&2GTD,,1-6K.OW)>!85(Q(AMB(F[+>CM?6
MPZ':\U7N^0J%:+/>V3$ANC^R\LJ/'?_1Q608]B)_NT+RUR#H/[L>]K-)J<)?
M;4KX%4(M5L)O8WNY2J'6J2S#K9-V=YQ4S;1LG+2M"V?LQK"._WX;!F+QW4D3
M0?2+&RBB+; I&=BRZ^N[4^WZKE*67O/G-4RQJF;<QSJZ:A>V81=V]1*RN6:M
M(0(4]Z=36O9>(9<;L.%TY?SZ(F9V\ZQRNVQHXU;I?3ZU6^N+=N[=-6-C\NR#
M ''VY'BR M3!NBO'[^U3Z^DY "!3Q^(O18VN(L:FA%O#/FON!TSF[NWC:C.;
MSHY7ZR>NT%SVW?*N=F$;=J&Z_RR3S.^E20Q51O_63&D_+>*-.=XS&"N&@K:D
MAEZZM'_E ][BC(^"P5&2=DPG/)J]\T0L;O(9^5287P5T[(:AXS\RGLG&$N16
M>\/]-JWWEV_E*FWX-8)I[JJ1L3$1_-[]BJUU*VD&1^ FQ+JS>()==..NW\=F
MNQ3IW)1,6]]%MMK/1?=SA8*MO3X'4V5SOE3@W81B[+BZ+7DE])@>,AET8\&E
M]FISVBI9M_@VKM)TZZS/"J]\K_OH]:MV81MV85>O19MMJ9'-/3$\L-^>S:#;
M.VV^%+*UXL3/;]!46';W5EG!W3FN+(0WE_W;/K]J%[9A?GL=U-J8Z8#X55FH
M[6\2O<I0-4"1]=@* W1>'_U7A($N@IA2-NM6W]4FOM)D>*--K(R'?51;U2YL
MPR[\TVS4M6B?KDQW"3G5Y1ME=.\NK)-VW0K%?Q(WQ!XL0R>F=AAXAW]@< -L
MG^$7P$S:8"",QD'HA!.K[PY & J_AZTR_+[5 [D(O^R9\'TP'KRHAY3$&"H\
MQY%4;/R"KP11"98&3P%FYW!<G9[!_^4OP*)2E::6&UDH IOUGT=!B.!+7X0W
MP<= 4@=QC;YK_&S=&C^!I>"K!DF<A)E%1CA:7V"C('PI/%K4%$2B.^&,'^%W
M0 YA1<E@X/9<FKKSE5IBN'2#M)[=>.CR0"8A+*"C&_1KUKGH.4DDU*3R+P-:
MX:!#-XH#(#$\-;T#!IT>A.>*IY1.O> 1-(NQZ(+:(,N1'5 &83"BAYR'X$D<
MX8#P2WBVA%*R7P>0&RBM*1_P%CM4!HM\8%M.#S<<7N%-;&L(NSX.@R>7.* H
MN[]F=:E=BP+5S[;)L4TZ62+"(^-&P[+!+.?1 >,;&[X45D99_40HYDO@^3"&
MQV%W(U@<VMRJ-4R89: HZ0WE"+KKTCH/*7:S*5H=<%DH"*#G^]F&RG2^>=YT
MN1AB&LN5WQW!NO.6RVM;Q1[/<WK4SCK3P'49P3?5F67IU#0@K:>KUGG3^DFH
M=G@BG-#"H]_/<E[-*FR8Q"7@;M2#8PBGXYT QO&BZ\$T=.E[*?NZ/M+Z@J3B
M"MHGS6AV)MN<M1K%V,!TEO (%$IHI^CPY3L?%;=,7+17(DYLQ1VN4*,NTXKH
M_/KVW>7MT<7UAP_=F[O+G]0?R]W-&?X>>Q3)1D9UV<ONI[IL8U=B+Y<W#SJI
M_U#4.JCXOL(_:65^L7#;H-4,N0:WQ^F\N,C&^@6]LN?/'(K/74:)W5W0T"'3
M>^&G1JT.W"D-U/^MT__,O_&NO#'#?.JQKED'T2KBSR7^Y=>Q&S)>"S:RL_X%
M"C!:VUY4[M%5POO;UD  SSF>=3 .HOCH'=P31@\BM%H-5-F-D\-OP87Z0KS_
MS^_@9A;!!"Y0^H23CT2Z),(Q=>"OF\3#((2+7O>K&WW^%'COX7IT_QS<#X,D
M @/J$F<HA,\_/O]T?W%#5SI\?(7!P+K=/EMM/'"/@KDS.YF6,\<'=^3&)/B
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M(N4<G%K*3/L!/@(U>ST@4/?KP07/-8<T>0^+O7#\<X'F@ OVF[,@A,AG@XN
MB9B%X *D&$CQ#\PVQ9W\T\?+&C+,)5@0\7S5/X"+9+'FGVY%Q7H.D\F(?&IO
MBGM614F$MT:#$:4*9*6.GQO*$!Y9T$+NTBCWK!C9%+KTW$<7_@6VUCLU^$9)
M_/E.+U9-4$\D-432(8R]69EA?%ID&$_?<.9OG#J[\DC([9(-N6! =<>EGE/"
MDP%"TDH>6:_DFQBQ)6I:2:$8)'X?WC!V)F#X><:YY"/O%!YS,J P\S-]'\A
MS45\E/^3H"'JHG <H:3A5EWP%RPOGLS1!;N(P]=Z 0[?"]'X3I=!'#OCF-0O
M<R:T]"3.EIE$HZYF89:[&%$M&=2:RHNE<+*N?+%2A(5- 0RN#NQOZX'WYG.)
MM=H]W&Y</^+9^6RVK9!O%53?;JYR*Z#ZUHR-EUKU8%0%JC,FW(; O@DSPM%,
M)[)D/M'2+1#!!#L"TT;*,'W/03,FBESTZ@R#2,B03NH?@0LXW+W=7C80(+AN
M3'!$5(:!5" I79>/%A',<D2W;W4[ADNQ&\V)O6AOXB5'>63P9<-7E#7&:8"%
M@#!X8B7UY*W1\&*EL(@JF6/@XOMF]:O<B'.!7MH\4[X%P]N*I5&C!V]BG6-\
MY[1C'73/X3^'Y#/(^0ELZ1WB*UF?;_*R(6[1'8#8B2YGF4?!Z!?D[$AM>C:^
M>7*8#&ATD(6GQQRG].;9WRLCUWOQ$&)W!HLI!K/X%:X"(5@*UJ_ I3X^'H%!
M(^EST;7NSJU&HV4=\'\/-<GX$)I^DF@8A&#0,$6,RZUTE0PHED9W$J!C(54/
M/EU_.*1QLW=CXRJ#=E.ZQ_ \[,5X[+GL #2^@BV 6Q2B=&*<@]ZG_2B2L6&L
MDGZU=*>6H8)/(E8^4I8$^8/?_%P_4P=?__VYB[/JR3;-UP/S_JMOON@2T3/^
M%'A1P07X\[GRA%[[UV$7@P2RPT8#N0IDR3D9S<:'K=)4A,_IZV#%?F_H1BC8
MS@,G["\80+D[!S9(Y_DA98!%6@H<+]R+=QHAA;6C;)^+?FWJM9U-<S'<QO0(
M!U4D;:R&$A-X"/FND?L.Y)9D>!7VE<ZX:7X&I13X[&S%[M=?E(_0>-*1/."M
M>IK-Q52@7$J)[LLZ.>>F(+Q.#6J^4V(9I3)UA9F\!PGX=LHOUMH/X_Y2_Q7D
MH*Q$&1;BRY=F,L$40,.0 0W'G",_CP)L:Q&E+9]?A[I<9HLW3E=OC"]K>#>
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MN.RBM^PX2 =>$++&=%:AO+;!)XABX?-909B+R'H/Q@C<MH_^0%Q?3TA<F2Q
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M@!#"ZVMEJ-<7!E2:',,Y#O&7U@/(!>YE%P$W)IS9F-L.V@)9FCS&V2*G&7R
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M3I??18EU@HLW*&&O9IDE^ K?D/AI;K_XN?)UV;\L'EDD_7XFV#")*RP!":G
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M8((@(5!'V:XL;5YBP&)*A(@:DT&_'>_]W+P(FVH0H;R)@I20W6RN_9SCM+F
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MO0VD31/.,[OM"LT.D8ABAXHHO0EFQCL>MGR!.Z;'E:3PDQ>#@LY% IT+]VF
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M:!::C9LI\S?1]7.P%2:@  MUB11K]=RPEXS0_])#PYD@<"/@[@>$)2AHCK8
M[+D" HI8;VP,:E[=Z4M;*JP,C/Y:@S-(O6):I:'H"6K!A*>]WR>T$FSCY$SD
MK3%4T,F$QY,'SV,H?[-]0 :SC,!+"G\UW6="3[P7O!6*_@TP[E\"]B/"JZ=N
MPF?TB]UTNRVC-RJ(?6QP!AJ^>?!$-LVM>$P\9S%4\;NC/VREH]+^F?"2O@*<
MR1A.9YV683B]"_K]H_? L%^L;B^FWEQ.**&,^@JP+L4:R:#*/2"V$G[/D#W
M^@@O]R#B9_3'R'.:N0RQTD'&=MR^.IZR$13PNH\7+,_H0*00@@[D8#?<'@E=
M2*S(G@1B2B_^+C701?=&#V3XAC.MO]C%ZP.?N'AL#*[)HIIHA,H\WR_65UE-
MB?%EZ+/,&@O:2$[_I*E^8A,T.BZGAUJ]Q[T%8]6U#^;O"]+R"LF*3NW=Y05K
M[=T&,CE],8[)ZO V3M8%Y%$-O"RFR2)#O0A>IKVZ]W?44.M([C&1.,P:ZS!X
MUG\OFWVS&P@="-"U5.ZG29-E$R/F_+:,\C),M:E*=]E-F$O;S7 !?\+.KOL
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MFZ4P.H>B.NX[40U0;GAPADS>],#D0+W'&2OCDQ.&CJPJB3#Y/@DQ04?7F+S
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MTZ)Q$D8)7GK4[_7<2>SSE#.DH7.@;D].*D)]3*[$=<H\4=FD2<5["_LP(8%
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M)FVUUT$Z(L6ZE-6L!;7^>D&MYP#U65!7/@,,QPJX7B>6]YU73;B%$4'_;.3
MF#@S>.!IC3MQ*W'YPOC6);XKA.^*'7#GX^#"7-\X4X=E-Y[ZX[$UB"3C*SS\
ML^7-K&"NT#;GJ+4-D8K(A.,J6&7I.S?B@H<O@WP# Q'S)KGV6D!7[%@]G_@Q
M=:Z>B%#$.L@-9Z.1"#$OKA%3T76#O$$0T^3G]]MH*#-A+<64N7#=KCH1R9:5
M$Y7<I15)Z0ZS!;/G,^,<4CZ^';R,2L)KU7H"R%134X'G:H2P2$4D2HJ,T;5H
M\QOUZ$:+QSFPX\0O\O#=-0_<]<;@V.577*;VZ[7TU2@6?# U,[:1>!%G$##6
MHO'@X9&$;09LS4K"-I=[9BX;18'%#HND+2PBKW.+>-L+OG%(2_//I$N6[UA$
M?2V@UL [4YL-FU+-)&KR>&3-$3#.N=+]9^:&_,087L0NX3]XN5/'FUHO .Q+
MT]$E!C=AL$Y>"PII6]>;X$\1704&:MO./=$MA.&_ O^!OWC7)%@F,@#3LY23
MOCU,(V_,8IF_,;B,7,5!.A,L"^P^*9T-$#YS[EWL P]W[P7^TWS9%$=U+@'.
MG07(XY-'*H^?UV/\U2!<(P8Q6,2 $%5/VMF(/72Q>X0HOL\IQ()2W. ,H<,_
MG5F+4@PYH+^ ?23=25GH[I,SG.$'ID?EFVOIO6V ,GW%4*95@/*5[QU'+%HY
M<P,'+&A0!-;%,O&>A?7KSQ"@,D- 9@@\ER&@RPP!F2$@,P1DAL!/P]0J+ZU>
MS=8DPMGXBK'(1SR8]+YMS-6D+\C5A*O^#SB9\OE++W'^6>C87=;9* 6QE:^N
ML9K)D@^Q(AAMO""-9?]HE1DLST"5PHC^NA^HVKSW$ "-"J!=BA:+V(&,'6R#
M=YILV25G*SU;VB%F*ZY3ZGM3%D"]5TZL[[ #W+K8A?5K'U=P3TY6:K*T0RPM
MC:P4E14Y7;T +*P[L<9*'(",3D678D-]T9-14^-#^[X5#"S/F1Y?/XV=N=(9
M,@Q05:5RTE<GG1Y@TNFSD[YH]R4G?>>33@^QTNFV*YT8RM=ZOWY:CZ>?:$T5
MV[0JENU/0M9M<Q4CIMJ2&'D)1@Y@&.BVAD%BI&2,X*'DQ56_5&1<>*+K\ID_
MG*$O)P>=U/NGGTH>= Q)*O\]N;E4;JTGW_,?YF"00W" 72%! .=8SLAB1DX[
MEX><D5-K/)R-N86\=+WO TP@D/.SF)^S[ODAYR>2],CIR9Z>R\[)(:?GTAHX
M8SDS63/3N^D><F9Z@3.-FR[*"5J9H')#]:?^#^34\ V5"SQ/M$0?*2NT%*;Z
M9N%K\IMH<8T?QN%0W,2',8;/@MJ*[<,0>'ZH6).)8P51G^SL*P^<H36#J<:V
M[@P<H?4->'O@*'B"8]LBKRR^Q@)%M@!'/7D8&:MK=MSA>J<:C%AXD92MI%4?
M*55(/C2F\<5O0'_Y+:NKCCCY1J4*?ND5F5GR_4WH28RULCRZRBX52/PY+SR;
M=2H!C,"U/1@&)I@=PC407(H?8',3+@+S@[DR&5L>[[F>*<'Z6:;WU\I/[#D_
M#PL2#3E&3N"PI-(UTY>M,S-V('Q+2R[P\:(01*S2YA45(ITVDXGWDR=#^&[G
M'DRBR_"Z7KC3VOZ)WWV\\CVGON$FY8R+XMK_?A?Z0Q[.N:.P@5[ Z(@SYE8]
M442M/WN N\\W/>..!H+M/&- ,Z"D'HD57ZG84I-BRUV(+4N;M1SBK/0:T=Y]
M[%_\YZIS^_6FV]^T8NDNED-:4QTX_\S<0!@P7I( 2;=8L1I:8-)\;Q_%L=%%
MR8+NTW!D><#[1("4F)I>2Y>X&%E3Q<8"28S784T"=PHW99V:X!$&#CM*Y]('
M)'T#9V2-[U%-@1=B69'B R':_YD'?\2N!W,Y\@/XUG8MHI1#5(##@X@Z935N
MFQGN8 8 WYYKU?!&^&%*IB&PU#G_THLZCE1;,4E;4$9$;H)8'$#;JZ]*>_D"
M6:ON75YI[4B;6T3N2S;)?4V:DOON7/";S[=*.'JP!G_'GY9F?&G#/^E>7=QV
M3Y63B^O>I\[-EXYR<74*O@;^U58G @BI31XI>[]*+BF,Q?Q#4?\SI^>YE=QV
M\I36VA:RC(UI \MD\>?EM;)8H:Q21;1YA[RD\<[^OF_SNYZ.7.=^]7PY*US
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M7T5=EI8:7C%PO;YP5/NN%?<67"RO._\#4$L#!!0    ( !A -5<U47G9$ @
M &4K   1    9#4T.3<R.&1E>#,Q,2YH=&WM6FUSXC@2_DX5_T'%UFPE51!"
M7N9V":$J!':&/39))=3L[4=AMT$56_)*-H3[]=<MV> 0",E,YBZW2SX0+$NM
M5OMYU$\+MSX/?QNT6Y][%]UVN=0:]H>#7KOWK]IQXZ#1JKM+;*]G'5BK<]W]
M@W4^75X/KF_/*[]_[@][%78W_&/0.Z^$0D)M F(\29I72D<\K- 85BZAB4N0
M">AVJ]O_DO>?"3^9-'\Z.!6RPG@HQA)M0)#84:V;O%O$]5C(6J+BYF&<G+'L
M>J221$6N*5 RJ1GQ;V@VEM<!CT0X;PY%!(9=P8S=JHC+2KO5:?<>)F(D$D;+
M9*UZI]VJW] ZU\UY=/(&D[*+0?_3U7G%LU&P/ER"3D0@/)X()9D*V(T6TA,Q
M#[=Y]!916.-0[P&\-!%38-<!^@6:W:3:I%PF_R.'$L7N>I?L-@V!M7ZYOAHN
M@#,1"=1,S#UH2C73/,;^VSHTCGFM<;+']^N-4]]]:]5I4#O[MVV5C:,-R\R:
M"+K-DP^O1&._RKKZX$<Y,O'9KZ A9!TN[TV5>18?<Y9,>-)DY%>!$\LI/N(,
M*X_BB8N5MK-OC1#-+SJ#7FZJ<WW;[=W6D-&#BYN[7C/_\JS?JXNL,&?FO')8
M89>]P>#FHMOM7WU:7-_=7%SFU[_WN\//YY7&X>&'BO/GEIEDCD_YG%5B/H;:
M2 ._KPEIA ]-/E7"SSIV\\$G'Y:+&G97;IY^J+ O&9XP* MLN<VE<5 <4KSU
M:% QW.QQA-FWHOV,K?C49Q..Q-,P%3 #'Q^Z,(Q+F>)NH"%6.F&X2?R"F^IV
M)C0.:__,(8W;2@<D]O%81ZAXPG%7+I?ZTCM ]S1. VP.7#.0/L[Z:RK!!?7X
ML,J.#H^.SRSP;+SPXY8^"#L[*+X-%(_>(10[W" 4$&W1G-TCID+PQU!UB,R@
MZ"NT(%7"/+3+A42DSEDJ$YT"1H\G$.$F3MCCZ!SNY@)1'' /FS13$>9=W-EM
M/X9@?-Q#@@?&<#VG/A&_!XO1A5&#;3YZ@W.&I#-H$NK@">VE$7:3.!Q=\3%[
M(3>\"3,I?2S'SW"/S8S0"B)A0N"^D&,V$\D$5VAB\*R'9#=&UY2/ZYSB,)^-
MYL4X;")',7_LV/'U[#C^?V('L$!(A!\A>0FW*E(#N^-M7;@O9$#RV H_U'QA
M2ILO0KJ K6JY%'"APSF+$9)$)Z)9&"X)E2'5K,R-E/0%6:Y2CS3$#L@1A4"V
M\QGKD,?-A 6AFIF<0!K&PB2:Q!ZG1N<XNEDM\,#DSCQQ=T>%[TN%DW=(A>$C
MV/SX0^/DXYG)L)Z)5]I6E2LF]LR^A52?<0T6O A&,<( DA !I,PH%&9"(ZA;
MA&F%4@M>ETN^,%ZH3(H#*>-H%3H8QUIYX&.S87N(6A^0!@Z:O0=OPN48V 7N
MY51 F!?H)BH03O<@+POL%-M'43%!HQX-$U3$2$='\I=1 BFPU+&&%ON,X^72
MZSP/OLKS8.EY+@F+FP%:(FG:W G!K?S^^3E^GSS+;UN,OC>"=\&(,>'2:JCM
M)*R2OO-X:EX^A'36")#A^51.NJE4HP5,.E-A;"K#;B"M(2J'ETFPF$FQ=N:6
M4IEV6Z*XFF59NBDP(:(S1H7"YXGU=(2/5' M: 7"*4R;VR592@VI/KNK&2L1
M;>)3!M"A!!,M#8HY<ME+0T[Y&M=EG5BJ1QSAM&A10PM3+HV >F).10/@[VJM
M[TNQT;NGV(NSQA.F;1E9+BT3CF4<>P'AD*53?! X*S=*<DK5W" 'J<8B<G'M
MYT!'Z@D^$J%(YB0HU^4YXKWEA$7[XM!SG6AVBN A6U&<ZACI9JP ]CRE?>N
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MO=O_@NW9"ZZ.NW5Z3Q8;[>NU_P%02P,$%     @ &$ U5Y5 T=/Z!P  ,"L
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MC=E!M'B=,M]@TT;@<)F,B[V5/G9Z7_!Z^JZJHVF57GG%B_9-V3\ 4$L#!!0
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M'YS8:XO/3_RP-'OF*Q8W[<?OWU!+ P04    "  80#57%,4!#&?)  !X&0$
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M*.X1?]@?H&'[*V&/L1_L=0]G @!Z#N5$P%D YV#H8 $XH6 %MX#>4-+$\HL
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M<G=WYW47XH4C;/@$)"0D^/@%^00%>; ]>%P\'9'F'CR.+FS?C?RPHPQUL43
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M.YZ,(TGO6=%M+9[$/.G/&SZ U%BX#%E441"\/.;D@/@J/57F*^UQG7=>W'4
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M9VX,Z]Y' ';GI2^"R,"D=?A!TKVIYI>9\YCSV#<^T:;N&S;3MWC#ZX,WKU5
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M!3H7TA]M0PV77L4KY\L7L5);*Q:T.,]0WC7W\:'CCLAYY=&Z-[(?[(48?ND
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M)28[O:I/#T<W3S'IPU?4F:Z[$G2=6A=.$3Y3WB5:+0YA4>_L#.AR)"'P%.<
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M"$YG',[4;H9(B3N>J^B@(ZR@\(9[-OG[T'8N:L[V* :(7JH5J]B])?)XW(R
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M+PO/(UY<$'I <HL]2QB8UT6EQ_@I,-J\>@4)O\D$G"0,5]10F\;<Y"3@ .&
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MA)E:F3WO2U_77$^Y:#"EE7*N-] PY&SOF(/?LFZ-;1D7+P7A)5II:4W?DP>
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MWW9;&-69WL08<##*.6NA89=TKQO;BH/-)N)EV(-HWBL5,E$D5'5U7[&<S>7
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M_3J.%: ?B%(;S'#X6AXWL6* (*57I<?UCTOFKI95=ELJ>*G.$(ZB:(_=\WI
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M%&NSQREY;46*0*?H%1,Q],S.=!#TD5O<(=)\9@H3MV@1;YH"6F>(C*.,+><
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M5[,T<3O\RC>+:C9FI88@]JP.(?,9XI=9Z=]('(%E1=< IV'+$8+G[+6&R?#
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M6NT_*449J>:ZAWT"+J+40.4B1?9,?X)0D*?\VH^?KCEE-A9%"1.@[#_SN[Z
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M"V+5S]]"36:7^-X)@&7//5&"&_P<6]^6/A6$49NQTKJ6,>LEX'JL&>V^,0K
M6P\$0!Q,5F-G"[;7J$1)"XRW7!] '+Q2HTQ>IL]A4P*\.<2,6G)]LI%Z6CQ/
M(I7D/W")I_]O;ZNBHA ]V*G6T[#_8<WM^)H'A5]E=VX.HL7]I0FAA02FP_S
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MTL\B%>?ZV\$>S&1=BK%*X8(4#_^TX_QN@.04_/9SV0)HXLX+_F#O=E77CF!
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MP1_IGM';U,7)K9V[,'%=/73Z:)WDR;;2KXN+VYL_1,I6RFG4>7D%ZVDO%.3
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M0_17WU'F]0Y/A7#7J1?J/@G<:@=KM9<!(@BI+5K5^"*F/*1?,$W/?I7:O^R
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M4[J#K ;Z:^;0(*?UZ2NSXENTPF>45I'P8%/JQ4%.65,;LZ<\?P&,[3#+AW.
MG)G:2H4=M%6L>!OR,[J#SU8$HJ+_JA&7,E8K$QK*0+V\2C/9]Z2\?V"O\:K\
MDU[K>*@GR6G6.-IB)$H/#ZN$%W:1-IMM=.&B97??\ B</=?*:-A][^:\\NNH
M6"&"YPY+U0VXT*F4HJIEYI-=U= ZC+WU&#',;W%>:FU<U0)>KI2LAT>:!M1H
M-V%0@RHZ]=X/(0;/Z@T2:%/'0;KAU^6Y&7\^TFW K?7;%1Q8!V-4J!A$OM#
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MI3:\H3RQD9(\+ZL(K&Q]G>+,L\\^8P8^!HP,O]T[U'&VPO/FI5SW>W)X=CM
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M=EBG? B8C[,P(6 1-F"2:ZJ2XYG"'A@F:\;"P\+]RM>F?S<FS51LM0$"7D.
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MK "250')@BUEP:JR2JIR8,GM;P59-9F_2?[.!A9GB<5Z:9C#=Y>FDK2KEY>
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M:2I1;E-[K2=0CKB(-%%==].]H-V9S\BV9AZRA!]=](WLA''D*G/$AQ>P$GP
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M??V\6"F).;ZBQE6*E1S@*7AR25!%8V)!@:;15$<H'@H-NWS2XE28U@=Y2,<
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M)E\!@L[D$).*<7;1.N>1  H!#F]Y4R7[T!:;,+/U!HT0&0W-6WE4_-A!N<W
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M1(=\5%$B"/S9Z+JT2U:D4%FK3LKH[62Q,09S013,7D4 3"_F\)50,46%.T6
M-O9_NOE\\1CZL+.CQH?[.8+>4Z_QCXI-+G OQ4==RY6%Y?4(W7!)/33F6BO
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MJ&$EB:E1BCF*:6,;,K/P8=9?)7@\ L-E'%/P=(F,F::%V8K'(>6M?#3S;1R
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MJN7;HKROB9M^0Z0-U6A0ZS%I(""(3U1MOU3<L'0"HU4VJ&IU-BBU*/7QXM'
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MC7@>3(I(F;W(\MF+_1VZ):EQ[GQ?X5 NSB')T8!E_I&VO21G^FFCA/"J!U>
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M3(-LM.2,58](%7[SVI([5T,]5X MYPFW)YR;^[T)D$8M.#5IXZC4)2\W^Q]
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MQCVHBW&J,!L-T&CL-2 HB!NH>]R)HX+V+U-<:U^^+8D6FW4VOFOA7.U2#BE
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M>(4ZL=1X.\)>J%2+/.&,M<%/V9M]W_;GV>+0QXPFI[":[K?(2EW*P[ ;IGP
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M1H(@-[>WTW#2.418"@DV*I@:;BA (%AH9D?MC4(F16!B?4OD78\UC<"/H2E
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M=X\(/#Y #HL.&BFE?+JCH%&[]H/H-[':_^@6-$2W+Q U<9"'FL^K!5B4/?<
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MJVB>0PL-+AA@\D1YN]!L :UOJ9(@Y2KP0%<I&<O)Q&(G5O# 5FO[[78C[;V
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M23&W$YH5LZC!,^Z2&^UN3]#8TDGW2 AZ&YQ'N+7_TI83;:HN#30Y[A;H'DU
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M[2*$'WEW89MA9Y)WPYJD:-[E/OZE2R_AO,TB[1#T"Q'H81*H!*SQT2OCW8)
M.GV)1//8FEW5]S_SQZG0(O[I:Z%F3G!?Z>C95T%S]\FFQ '::"*E*)./]W&^
MP@FZ@-.Q3.!8]*$,"Q<ZI_OR.<]7Y2^KJKWW54?EC;)H 04N.*51^01IA9MY
M$!27H(_T:P(]IC@V-]MB_J(GV !2#&"RI,9F"QR2CO[O#Q\ CHO_RZGI6LUR
M3;AW-"U7T-2@:\'*_9TLAT_".@>M[OK)!8_5J\=K%CDC!NO.^5(O6[A@M;9?
MB.2>6YMQ!K!L\3-OXM]8H@FUW6'^BY#"0<D%I'F_LHZ-P(=#4_$,*?H TXL[
M0V$#X/JZM[CW_Z7,K&33M8PC9OFI DQ,:QE]51Y)E[-%VL1,FHD^_U:6#O>W
MI%P/OW X#9RU/UG'-MM8<Z[N.V4L*5+"WN;_1SO<M:(-4BZ1A']C4IAO(0A5
MO N$0)+R.+AQ/R=/(!T=$]/+OD?I#N5O-)%W1)L@J>/'N_M'[2V-U7AUBWPA
MFF8JE3]?6P4<%-1:$T"P6AAIN4W)2T]<^5*\NY<-G?9X/',]^ K?7 [G.ESU
M)V9D;Q"R>I'XQ' 2>JWI^FW%UC6CO.7'T%M%[@2X"5*Q[:N"T_J;KU0<V\LE
M?@SQ*F\PB;71SSLJU;OEFU0WN*1,%,H:L"G;DC*.:C.03_P\<$ YX'PM.X(?
M-J40L^WD?FXC^7*803=LMB<E(%M[E6\538K4!UY*R9VE<Y 4<T^5*M;LTUT#
M?(J^ W>X_C1_XW.5O59Q;MOF.7W\ IR'^X$"0MSR1!49&9'=<9^0X##S-1GW
M)HDZ41XT9B40D' %C4'A7:2$+P-,U8?H.8.#^'B+/;K?,TG^B7RN;2PI<!JE
ME:U;GYMI;"4NQF@]E6Y@>Q,7?RQU,?Y(4M?Z6XUE/-AQ7R9&<OBAV$1QV%N[
M3V5!O^BYF*:5H8\.X#W"=SOQ7(1< 4Q[Y8FB-)U;\::T\8?-33M0%K8&Q&S%
MPB >9P)P%5 ?W!^HQC?'9DGHZ@_J+'?9_ ^P1,]59U.-7ZKX<MFCZ'@-W$.]
M(75^RQMJC *20U(\FZ(LK?&[[$'21[*H"Z]E9,2?Z>ZO<)F><;)8HGA,)*V_
MW2EV^[O\Z-8WM,G%K'OZZ@+'.@$,.I\ Z\4H[EW4R\C/H =@GN=2Q!)(B"$=
M:/^ F0ET;L- 9)  K<:>&M$#D8E$F;B(U)&&45'1K=:OQRU\KYQ;KS>854"N
MF1!AU2H"<;RJ4O9:^1*_H2FR;OW 590)<O/Y/=Z<F*S0FEH%S$N?B;J7!S>V
MH]=I+6JJ)2EXK<*\S[>M]/"FA-L6$*%H^?!Z3.LRUT2QM,()*@NTKLXR_R;[
M)\O1QZ71O!W<::!CE&M0?P<V;>_'(_L@1ISC3<I[H_DV9.N[(=B\^1C+<HV^
MX5:V1/M/E2_2?U-Q6:=G1)I.KC/V[+Q]J?P.HR-\:R+A+TH5-/M&L6;[[=;!
MIB-J_(UWILZ"E!YEF_5^FE#02;'9*UBQK]3U$3.K.21;"__)56-VZ5H-TX?T
MB>Y:-R/=F1D%S)[O3M2R>YG8F[  GOR_W-[Q&L&R?P /2PEU7489?F:IOXG/
MOW%J<<C(?!() (:L.%$;=2 V(4[(R.%N6U"NO@"='L!"7SQL0.^P]%6XF(_Z
MY*7Q WV0T2N1BSF %;4N\0I'$_7OQFCM;@T;[HK;H-L9NKQM\FJTE+!D(?>9
M4G!N+V7-]Q?<VR /F_TT9V4'#J&X^LBBL3KI5%7WZ_#W^<7A*F_,O;S]:PHQ
ML'D65*='OC(ZD'$T+AAWVKK5.; -1U07V86KJQ97IZ7/9'ZS)$R6O=HCSXGH
MS[-M^NBL%I@KDDQ1"=)M; ,1\GCSN+BU=-D('XW&[0A"FD-(<NW?_).!D[H'
M7D\R$<'<]:J9EJ%[YU\2F66S%L>@+VE],ZK'&T6\F/NO6N2[1/&0X*TKW *I
M;/VN#_VJ?@4CI\\0--%B#>..D/>+L!G0S7#,MIHZM=%GA*QMX.B0V4'U?=VQ
M6NEHZ9WL6_K=VLMM*+XW1[D=_A72O5!=$OYY>] _5(84]8VR>9^P""M9(,T\
MHMF&=YA8I^LWVH>(*-5X3UM5VN)-F<TV<I=='G*J\5[L^)L?01<T/D?<]0[N
MQ%*=T8X%'OO7/T[)!7DIC]2*S@87A+Q39ZV:7;%E35,9 %U9APE[H0]$;PRA
MH(5;W*22B9#]NJ.BZ0Q/U5F(9@3OL.I>/_L#HZXN33_^E*F]]RV$UF-7FSQ^
MJS9RD+;8=Y)1/[DQ\49:=X=&UIP0GQFF(_?IWK;/U_TDM\F"7*4&2,8W%97Y
MP'RC6)4O7 2KJH]4(4-%6<[Y&:6*7<ILR/%AX&,3K(LS1HB4YV2"_17Y0_H7
M.*B&DGH%C7)-YN&A16+@D D#/EQ,)06.F9A \^9F<):")/0BN_$L=ERY*%QQ
M@'AV5942G)'_X8ZT#C1V&,S< TYA!4H%?AX%Q!/_&-PT96%>Y>,K1Z'CZ$#J
M5E 7@9[XBA:/;E.-:BS#9<+0J1B_;A/T_TM;L1]#O]@[L.[1EW V&5HU;OT=
MPS@L_@Q05E5D6*W82ILOFE!]O^=>*1,0BK:1YK71O[UFT%3[Z:DC_%;UU9*@
MUK5:M2VF$!6%*\7H-3=B$CK,"PBGVCV<Q>L$;P1^PVC:7E$QV".U4+#MYU>2
M'A&.T/"RD!ZR79D"F05A;J!40L _@R,I"?*7?6J*PG!&8!F_D%-SY+JT;W^^
MTF(LFU%D#TZIFB'7Y$6?L9-?NEFT0T\W&&7 #'JEBG^MK#BM+33;"9.9RA-&
M$G^.:/W:N9^0J(I_ Z>"L@;!;YG!@Z/K<L/'W8YVFP]")G.%FS1R6CM!_VE>
MY%Y?L\_IGB#T@/,PE1>TP;)8"7OGEF?ZMU\Z];K! _#"7H;DS6\V19D=$>ZW
M\4X_*5LS WM^O-><7KGL(SL_Y[38D?OPI.-*&)N!V8%"=0)%LG,N5:8SW[
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M+/C(]M%=5P_D(']<=0U24SMYFUOJ#EPVT V,F6-7A*7L:<2T>D,3 V)EW4W
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MH*3T/^#6[=[;Y_G?]WO>X_^/[_NX8,5]U7G==:U[K37'.A\]_PRXKB2G* =
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M/?LSA'\=P>T_0S@? V A76+B <0!HC7*69@@)'XZ[$V U["[ZYE1V(98YCD
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MW=(<$ZI+.P?TC9^%E\YQ-N$=:_,H["<5(\I3&6P-F6QU/=@)1&)FRW(MX>'
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MQ<H:8O_?&:6_1/FSG:C^=ZOT?SPQ_VN7SJN)^3?NW]>=_VK]\,?"XOM/A"Q
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MOH;-"Y'JF_U/WH5S>M??8F,R>>W,^G''ZT-RS%CPA%=*7NJV+:>D9>K8Z#D
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MPVNTYX!P'THSF+NNT]I(]C.68[>6A'>&A#RM1.ZNS"=E.5FE54'BY"D- 49
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MN<S((2 WGB4U+@V3+:2FD%(]B0YH9$&K.YX&G5:8.LYQML'*S 6IQ5Y,::T
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MT\61)>U=^G)G ?/TBMF<L/UCL[1.KI&!;(+LQV-Y^CW8.MM32TDL)'6L5A0
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M92;=(/9^38?9GD)5<;JTLQ,"QYL[>6EW48A; ;UPCAW2MQIV-SHL)G>KL[D
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M?P/X@SV2-@%;,:V,;DKDB"D[R3=\S*B<<.DJ@G'YN11\3'"Q4-;5S'I6KZ"
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MI\0XN;4PKETSAW['Z!>+IE^G>!EIL(!BXUYD<PZ]7T%C>%A?AQ:,<]U0FTF
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MFJ]IY=JVK<RE7'TJGFP4S6.$'&'$86A3 ET9(]P0AQE(RVIXU,R3JUV@DPO
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M(VR:"D_-BSI 7W!]4PV+"V08Y7WN5@4P[,7T7CQ: S<R(6%CD[![U[63"QM
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MJ9+Z_;:5J6/]VPP43/KT4K83P8V_BM_)D_%C '+;8")<'%BQ1Z>7FX3ITY#
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M_R9SDB;I,MA=6HQ27.LO.Z\A7*]WG1\DZR=F91,)_*OB+G(\.KA)/SE,?%2
MNGCKAK0VYUI3UGD$ED_[VY;5S-Z@%1^I1J[7V3.%_%::=HVR9CL!]>ILO5-
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M>8W)BX=TTG5VPFJU>G54Z<3)8C&FYTTSA 5_K8I3NU[1\7]@S(2WTS$0FW\
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ML(AUY2,S;)JX5^0IE(EL+)9CXQR/;(B_1R74.S+$Z"-:5YN9%7;F'(7\FOI
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M-=*X$R>/9O)ZEUURBP9_?N PZ!4I%GBRY/-Y,CK?;=,E&_;NS^$26+=>MW#
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M':/S2<!/O+5?1AHX6W=D>4'L[.4T&G4F.<R:"7_3\+5K^O.:_CR"B4"58:[
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M09F=F6V[9O!4;:XE."6>3("RSO4]A_W]&LZ]R8'&@9S ;:T(Q]64I:E;8?(
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MKU'F.$"O<W5?'YV7O+?E@3]M<];['U'BX=X^MF_FOCWOL8KT=JF1I;$"0W
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MB2:9$Y\L@L]&\6KW57#Z,Z]HC'2J9*R <741"3]6U3MI :O[C.,G[AW_L&-
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MB0*+52Z605K[$2_V*Z5DXNFYHHU&)\/H,(^V6SD\NZ%:?4Z?D+$H40BV :^
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M&"7R>B=DFK$$-/W=E]YB"<UY(GCSZ]8$'W^U++D>X4R'XN3I3WQXY_((_9<
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M/P;./E^102I0EN_A2LB*Z=QN-RH?($Y$C6YN+_+S/%HXK=\4SSW&[UG5-2Y
M*:P6Y08HD4D,1P*83O5PNPK0V8IU\SV;B'Q^*@>L4%3$LMW;V"O,:A.9-PS%
MN=9JA854KJ[+GA%?G7!M+^N6P/">T<;$2BFP*U>A+7GQLQBG^DZ2 $5 UTJ2
MK86BBXEA@]E;I35INV*I==<BRK?4 1MKW!3H: &W[NBN"@>D/1TW:;01,==:
M+L]%L&<)FLKWM*"\^D$M(U'&C%>Z\4R/K;[E 5R *<EX7K]%642S.NH;(60Z
M=\(!K\IQZ@B#HTSJ(B==<K+6M6Y(4J(C$;5PZ G6D12O<POJ 54*Z.Q )9?H
M&36ZM[$$5C"U\CX--!]X,P.ABY\*@<I38%!WDOIW&AMFP#0"]M0DJ&.PX64V
MB3.?YHALA.0@[J5I-KKT*MF"SUZ\7#')G\315?KV&>2'P,YJ:J/:B5YC$VDQ
M#\O=6D(J%U+3TH/_<4^#A_'MRL#HX2_@FL,;MF-IWS27FR0\Q$_1-_L/7L]8
M8%Y/_%\ 9]+] [G(7X"JF])K /;+OV@0]7X<^%S]%Y 8:W4/EH+Y?[\!$A05
MWGT!/K6?_ 4<BN:_ P+S<]A[\TS^ B9G_M@<+%#=87\L/B-DO2S'B@U2$9F5
M0'U*X[*4,:^A,+]+^_R+R,*;@EQ3SV4$C7J;]Y[U=J"EX<";<T'@1-^^I^WE
M/J+J$P0\4 ==@GJPTLZ6XBQ.Y*6IB4:Y\CW#25SYG)Y^1?9V@V5&FI4B6[LJ
M6;^ O"(E[F5/+!DX[BS:M9!?"+LN\5C;L857'$U8B8/H0-%T'E#K/7R';2)P
M??8FP*<=H/+'IU-R@#1/8[&&^M3PDA]EZ?*>CS4;!KH*=**E/+KNADA>0U^J
MY:&W%#*4VN%^NMD.8A+0:OB!%VYXBZ=80_!AQO'A'O1],>XO@(U[_3-SWE_
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M?!W'CGH$.I7^/RH7R%.&[.@8T0CD3ZS U\"GS*[@+9M;]NEL-+%^83JAJ;\
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MX_+3?*D^YQ(N'NME+6%)U)6ST6!<SNFD^ "K)J5.%*U"6NEH/@-!I(ND=?2
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M OP1].U&'#DJVUL%FL?L/-X_>DI0)VO\!_-G+WER"]D1!D@NC4#[-\)I?EP
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M5KOEU[!Q9M?E.ZOQ]KHYH)LV_'<1T CLFF?56B=@VA8D&5.[>+(,=]3[@X^
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M;FBKAWZ9 +L]\?;$M?EFBPDL?S$YP=I&R7XM(?F47(*3;/7$AB8U)Q0"67D
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M[(Z=B,FZF-P7N95O@+:;UK)=3$4^UB8Y4Y[ ;I[22L#FL\R)B8W):WF'&]\
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MWP/;H[QXWQLU8W%U%CMV1 +:61YW]RQ&8R8*\N>K6O??FAFO/C[8S(;S,!J
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M89:%6P:7ZA@;9.V^XU(=_?C+J!H;)?CRYV58[WC)XQA?=;K,NZHN XR5.K4
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MH_2"D)F,X5@SF1&"!+3MTO9!,D]]&V.-G$KLIJ]=LU*<+?3S72[G(_-C9JC
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M5@TT!^MR;!0=5VVV74Y\4[GYU2'S;O%P#Z?W%Y"S/*CL_KM![#G\M3MH]"^
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MGL=65TO:S*[2\$*3-X@LR5_#JL;X4E>]HMX UBY%VI]MULQ:6=_9T3*TJJ/
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MSA7']>1NCDVDQ=Q?,F,'#3-U$&!EKW<43GA>Q#;(5'30D<^&$F"H,6 \Z:Y
M3MG<I[I1&);'_&S1E%C#SQ+-,HN\,1H;C^PZB@!UW*4G7[J-!GV,F,]I]S,T
MZW'/(*&AU(85^<%H&CPKJ*RLV]/:?U-9;;:14[JV_TW"#A*=J^[TD^U"(Y/@
M3>#K4K@N1JUK-9^5[VE/O=?E7JB-HK_TD3$J"H*YI#,JM&KEMM;9U)Y@@(B7
MM2":MY,6;Q!-I W<+$#3N0Q0E1[#W,A#<,('<LTE[JXG##1]G0=9R^L1@@^#
MH0B=13/,R='C*&R[I'W#ZLX;MH*]-Y[:4TL/4$SD.#IZ,E\)TWA1+-Q?[89R
M6,/DY-@N&5CA;O'3IIZ\[<ON)IW*Y+PP5K$)K$@33,G-#3@D;A]"HTH,HN3H
M7]A\Q:E7KM<=]N(&$G?Y7G=T;*3R1LTK;7Q+:1T'33"KZH70Q+F^Y&U_,WNX
MSFM<19 @MVF*XKY!<9VIK?"AX@WPM$5R!L;?JGC&B_\ 96:G0V9Z,79O8+@*
M.\FV%$NKXU[?Y/J[Q1#>T4R[Z-0O'2UTD1$%NI*9E,J9M,I('>;(?"A4>CA3
M+-7(54=*MFSC6:9N3UG+7C7&#?U@7GC@L;)S]27]K2 G,S1[L&VP\+N@:[NL
M25F,(#L@=F5KV BN:(>[Z4,G0ML-G7U-PRV[VEI!\1?&JVE$=<*/>@-<S/4K
MYK(K&5WX,2-E/"-[[I+X:Z43&6LG+WF6_10+ 0'^R?Y7C!R<F]:P=QZZ ;WQ
M@C-V;9MM"3S1-!0KQ"$SR8SL0@V:-A)WFBPLOHOC=X4JRG!>L6J;A+Z5\HIS
M#HUQ^VMR3_4#]7CQ!7">\\\Z3=*@Z"N""H?9HEK$_^H.X,(5F!$1I48*:*ZS
MR:B[ A-X7[K3R3A,,B3INA0+(G:7N%S.E[:MR9BBZ"Q\=$ZN1U5V "CZ<%G)
M0=-@?LXOG.F3B*[[+P#8V_7C==;Q7>B-_]Q[X#,VZ%TH[N9YYR\@>G='P)<#
M;8BH\;JTBN'7+X$AG+\ M)C?S],?AT^+__^ _R\-2(-X,A-S<\H;"LSJSJ)N
ML\T/9N"TZWI92C;!47YG"7YIC",".\6UQVHXV4M16H&9I0Z#+JZF]1S%'6%]
M<Z6J3O_W^D?_[R):ZR_ ,NK=)G=I%+P;]#+XO&QPE%OY%!GFO!S#6?R?0YXF
MMRW[4RGW4NM8XZ:7\R\ <9U?\O4OP*L<CD[]O_8"]=]1)G=OHNP6;TO8I6GH
M[W\9+!P8 72[HY#J#C%G=(389P,U^Q_-@I.@J315)F;TF;<TXQA.3NI%0)L3
M "RJ#:WBA 4JNGUY_>\_([2(6P,$4*V.8D&'+M&1WGV 1$G$"B26;VLP@$2%
M.DB;:;K?ZW*_FY .E:S4I.=GTH*7+E"JHDE*V$.$,WCH69>#RU;GQ!MKIC3Q
M1,H+U4KIA[V8XSQIM2DZ#?%;B=Y/1_DO^5&>V.:.5TLC&;[ML"9N6*JC@%(W
MW%LK!O*ZW/UQ'&J;JKDRB#27'S<U^V3=W?5?MO1%%I^:<E%WK%M)T>6ZI*%F
M]F M32BAG/K54H5RHC7-[?6FK(-QI;"N?B\.,EVSZ@69K'> ;9SP>N=:Z>(_
MYC<2HBD7TWR)_'*#/+1_\4!]:K&_2+V(0E8IK:M+G*-!@713%&X<7'H?2Y=]
MQ) S):+_X,E9#"EMZVV?W7O^V)@47W:K9O="'A5=N%S:_/64N1)?/!)1K(?$
MQ2MB6G_&:,/>T=T<TM/^X%T::$=F1)<RN"$\CLN4U30G!([IM@D]T;PZV=O2
M)?$33W[(P0XXLO%3;)JU9!LY=,NC[:1/JUO$9CZZJ'3.'^)_5U\(X55O!M-F
M"-4T7QI9ZJ.JP6-$ =&8QUT1B5N)V3ZH]]%P/55&7P5Z>U!6Z=BVN=DU?\/T
M/+L1D.[?\2'I+M1@\8E(="$#H3WJ)/"/"2Y/.OP1?AZP\9$ISY?^\15?OMH.
M-?E!B+ ("&O-1H@U)0Y*L9N 1RW;4A]U.:N<_I^SN/_-[H9S'\-[1]H_9)VK
MGP6R!&+4/J5>>SW+/.@T_WODBO\1J@?M;Q&[Q\#/X1PU/Z3[N)OJI*.XVJ?,
M>.?E_TE/_OSQR+^QQ:U>85$'%'/QV'G42[W5+D]J&\G%/2L+%::TSY&:.'1T
MXFY2T%H$JW&%E2X)P:V:(;81\J-HVK-#Q@C,3G7I''2C:=]2=._[NMNI""WP
MXM_@7+&.[R7)W+(=+:R=;?#_!'UK;AZN#6_>-E%N6C1<NK9OMK'LICZ6T0./
M;"CSY\HN4O[Y+G652FW6K3AS1X- 9Z+F9=%&VQG4[X#L0$-:9"N\!R1(QAVM
MT:O!]J[5::QD&\?[GD=_/&2+9!;XO*2R\O,1&/X2A<!U9'6HS5Y V_Z-L33<
M F"";/W%GU8(F1WPW-O_X[HG+O\Y36*);_%=H>),8X?R9CNT<W^;?G# 7<.=
M6R.4,O6 0$"VI;GN-F1]02PY00%_P_>-HHQ>]DD[3?OQ_'M&K\[-3IJ;EY43
M811,UJWFCHR5&\WV+-ZD9V0,;?%)?50-/G-R*O%<,H0Q"::2@PF??UO$%]7R
M:AY43J,@BR]TI.*CZ)?NL,*1EQF_^1=L8LM'M,,7*]T0[*:J$90=0TXYY?T(
M%YO]7.PD%.L6_^SB/"?:B;\^KLP,X/B@SD^R72W=]EMAR/O(!X 2O<A$C7]A
MIJ-/<!'^Z8#MQ5">I"L.',9P %6Y087$8#360RXE0@9* K)08;SJB!I%:I#P
MY)=2K,]0K&SUD2]X2"9A0DVT]6<AQ7+1 - )!Q58*R"6S/Z%9,-H8#FPN([=
M5?+T0,-41;SU@^2  58@P,WJ8_'Z7>+0 ?Y[R;/\ 8\?YJ]7E-2X?&M]@<6:
M@CEM-/3Q,HKZ SUT&G&_+[\Z_"(?V!?=KGB&GG!CBGK^Z%G?/!=\^-B!J9LK
M+?\$.!3O_O)HU]'93&WO")+/%MOT!H3D-;9916KJ*5@AY&S(:.XY+HXBK8ON
M+G"(7#W)S*J[U7^$6)&XMQ28]]4F-&.9XY'+,2FN:R#&EYO60X3/[V3'[Q-S
M@-6UGR+BV-M="!*83H]X/OX"\B_0#AC0GFV&E#<VU^4.T)">+?3:FYI0Z0P[
M5E@)>)0Z)+'$S35#AJ="OGP)AU<5%2SK#;[ 4CKK&*DL%9VYU;36:%'J2M^9
MW]0=1V?9@VBKB#[D?9WUWMSQ=CO]SUWT_^"RQK-OH@:'NI\E7.KO1#-$(Q5_
M : /@RY5GM0JZ\3B:W2/GUQ.I ]BYVR*="UG<FD-\)@K5^JJRM&J9:0U3>11
M6U$S1F.LI(*_Z&N*-E9*@2DD;3?.1ZE/B3 QF)F6DPV@0.)&["%_YJ,_'5X;
M0OQ^/WLQ,]N-'6/\IXHC9,VD5$8^/D8/WA\$; SG<M$H!H8/<AY^8)3N37$O
MIY,%%$Q'3A1)AX$**,V1T LEA'<3"%87[E%(Y+F#\[EF6)C&<*AC!8<@,0JO
MB1])G-H"/<<(GA_4GNB1['513YT/GYX(Z[>\+RBY)W6PB5F%W;^8%&OF#EG_
ML3H>'8SWEH[?N,5G80:Q[TO<A6GKXP:F;4WHVND;P)1RE:D;#M'$9[7#KPG-
MTCJ%7'X_K"\1%P2A;#<(SLXG3;O-.Y6UTV[!7JF54JK'I]'&Q[MJ'Z]NZC,7
MT1Z93DX.*#8=@H7#2?DQHRVH9YS&-YY5ZF].X=W9\5\?;T]&:X'#' QDSL<_
M%,<F/AUG"6><9@DN:NA?Q#G T%]:I1.\BH$9Q*9,[H)#Y(FQ7*=D\3^@/9/T
MO4T80:P7W_1BP[YBGF19/; W47,R<P=J@13;MK3P8;8GKL<.'?EU#_FKYIAS
MIHJR;N I8]$ IT&CBUHD[MRWX^1&(;P80WW*GX3VQ 5UDE(H E=_ 4N1]5^?
ML@D8'CD$EDM(TGI-##9\"[I(4I(A)R9P[)4G^IAO)Q(9!Q/&9KTA$8B_2%Y#
MP!$QC9K<XSZSV57P.[T.LGO?KVBVVS%75N/B[J]->-,L9LH&P"<E(A^O*>VF
M[N#'9K5CIAE(1,E5>]K9Y3_R#ZX_LB^.X;,S>A$[6B5DF;E<CFU?/%CP%Y[7
M_/38H!FDR+2^4';E7$^4^$J['<\29/@E=.)(-H#=F>*$5JN>K.7PSKCGPJ%N
MTI[[PE(8HTI*"@KF'R.(#F'J.6")#F@%F0;DK+-N=;VD005Z($-=4G+B/)RV
MUG2B;9W=&@?]!*]KQR#.W'^M5-[EI4YOH49/3!DVQ @C+R[X+26<V':%IAO2
ME4(N5ZRISI(Z2NXO0<YE^+6A<&,/4A5UJ Y B,:KV!!MEFP1D(K_@7__8/$8
M&16\V20CM:YV'M&F7@!)SU*V$AQ*3.Y'CMI7(]O N>Y.\36,7=3#9'@(E@ .
M8V!)[+CE4&X8UUISDI=Y)+](.*!02\7]LH/%[FY?^LA9TEP?#CHQK\^-$A H
M@FG[]9C8_O'HC?.0OP>50J@J99.0TKS#A^02*7-OP0M1&T(7E73V:H[R!#J"
M\)2M%M\[P=3;H? OH+S+.1K(2*#%@5SS8+;%EU<'B,MRM!:"XR3>V]L+"KKD
MO+2NH^PZ_UHS1PV!'^.43=%KQBYT/AS8R+ 7MV*OO9+-*B0JPP#+*XSC9SI$
M<>2E4C@IRWA_.!+!FAS.F+ND,V;"S,CD/Y$GF0BY?Y@J.!E""56@P4F<"D<,
M*>8=U6EY[Z6972S/WD -!P+XO!S%#GF0L6/9+TVQ&";\]#7X>FY_'*7R4H<P
MR)96?W@P'; U>0?C<:7V!B07-YC.;7YIG'KD5[7U:9M B4G#=PX"&HT=F5>W
M>]VC<O+&\N=XOE[\;.7^CE-[_&9FEJ7#O&&]4[XO]UZL4FYE9]Q[FA87?;S$
M/[#9]]MK,L*KF&P4E0QLZ](+?UIZ]UY]]/[)VZM/W>YYS_#SZ([KE>OTO(:K
M4P5].^!RL^+9O*A7>NG:%M(7/)EKERL_<-K] MF^%W)*!2J;N)%NW-^//HV)
M.WINYV<Y\B*:'?')\FK[W<KYL.A\?V+ ,''D].=^=%7W4W/)5Q#%IZ+ZM:7E
M0[O1@ #[7$M[T.H[O<;\;WT3NOV4_*TJ=U I"AV]YPMF]'']^ZAINDC8G4#\
MX^#ML0"+X=P7IU!]+T*CV?E9 0WOA+ON<ZMAL)/NQ]#ON^B_ .-9<&_(R^BS
M^OB=Q.K;M"27=?-_I2OY7V$DMTZSG"Z/WD" 9H"_PI)F\9,27I7B)C=;2[=\
MEG& *=KG92)KA&F81J6&<*XG><&<UHA^[.(;[$_MGV.(U%V7/U'U%+;-B)LO
ML)S;/4:O? 5<![H^X6_N+08C-:*X*^L'V$^F*I&J+JJ[34KGA[7+YZXJ5H^"
M%H<V'LEG?$L.Q*?IY^IJ1^UA5-U[3+6!!%0%)FLSQ8J+A/H8OV]^OVEN5'?7
M=&+\(+MY3/.H?LY1P-ZQ\NB(CK?9B$TIV"!@&+@Y4__2#[JD9T.:_3;KODIG
M8TO/^@:UPH%UF?#9?>U%818J7M_=)GF%WD]/%N96Q"PKNAK'6C/1HQJY1C$]
M&Y8T&5J-<B8^!"R9LI]@G(B=[S$>;+2C# S.5X9H0VV;(Y6'S8(EH2Z%K-#-
M#] OEXX?P3CRG$- ??)Y&Y$L)H1[,WS+T7_+UWE+?UXY'>*'ODGFM@ALLL/3
M6.XR.(C18^/3OU</>+#1D_[.HT>CIDGW@/3\+D+0U6F2:=-)\Y![H#Z>>\XW
M\Y#^)ZGJ+,JF?+=I(_B)_4932R?=,!:RY3?ZV+V@UD'XQF_=AN!$TAX7*CR2
MM<]I.;1B=E2B^>X0J-L\Y@NZY!3E8O;T]?I"4@*GHO%V!;NGGU'T(N467XIH
MQC;CO-!#U0\$LKJ'^0;VECZ6> E^?9[G'&KW+SQ\]_76@?>1.$B]&,UO[3$B
M]^1EL)P;N=L4(U+<%L25B/UR?"SJUWA+%'$<)=:+E.<9R]$64/VU&W6,T2;>
M> *N*YX%W,A$P &AEN6/D7#JH<\N*;VK*L;\0&DJWA#9K5T[3\?DUAZA]D:]
MUPG=.1%[-O%FMB^:*-^-.6$$,^V6"M=R?WOW:3(J,_'9^61_T_S9^#F_$>1#
M>?/]V4'YQB'T'9L]R.50CI]/0W">+0[JS ICLN2\NF1K>[#$)DWIN6*#1[(X
M\]63+%V0,FNDAS+$[2<-D4MX=='\PZ_:JP<^$8TXI3C!SM21Q]=5C8P6MNW$
M[6&\60O@(KF5EOJ7J8#'/.O/+-^L[:GSH&RG@@70(YYR:#N3\4;B5L5Z33ZX
M!5^"I^4W)31G CN7\$EGQ$"$4/H,T&SJ&!T]Q$M/>B[W@@%N7?<L!_E&/<WW
M:VO/PCOV/@K]ZU9#I\ZNU0[>(FVMW?I\!C"O/5 S(R$#)Q\\5?3M_?X +[SF
MX</]>OLU]4F[I] %VI\1#?E)>?S;?F##M3@<<L4@)S'N@[]4W6@!JR#0J,20
M/XLZHZ!4C.SKTBDAIXJS,?<]C;S3_2&UOE.6S_/IW&J<%O]_D?_NOT$I2N#J
MJU^,RVOZL<Z-'Z<?;N5[TL./6\5K[?IJ\5D5:_3RGUG?!\X&'L57<KON9I:
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MB\.2M9PC4..=H;!NX!F?-KL^B2,DQL4> 79M9W3=@1[;TM%(];G!;/@@E(D
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M44!V);9_&\>"M >EG+U$VPP W%D<C4K@#4C"U0%)_H4'RY_JC! SL/>3IO8
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MP^6TDT<Z[\I-"V(VEW1;@J4=20,W0R?J+V (,LB0G-"P8C]$,IM:!4+<-"]
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ML5%N699$:T=*,S-5?)B("O&0&E%;SCW0#)E=6[%OC9G0IF\,!P.3SH1^,?$
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M@UIT11H GSD:>HRWGG):C_1!?Y=5_R#2YCM8+;HG(P8685(MXQ<Q.-6S8R$
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M\IWQ%(!H\V=T@YCP(=F'?T(WNYH@-9>-P5/*&C$%D/SIR?7YV 0C'U?H@3*
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M#OT,TK\(K>XF P<3$4OLTMLQ-#>.*1-3M)4OW/YSU'ZL8WP3W]C.)R '9]=
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MR$68!\\S6B***^AE#CAOX9^Z>!>"Q<ORC.6.260$!8@-=@!CBCL[]!5*=/H
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MD=((=A)G,[*9)CW<PJ^T) ^#]4T(-;H.!@C__D$5!^>A6RIFMG0$@KI@W/3
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MO%8$A9Z^4%F^.])1;&KC2K]AD#@:5A?*^JNM-))H=B&]T0EAFAJX[B8%]G"
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ML';7!U&_AQOX8153BI^_.(Y+I/U^C:-99BMFA%RT?!?<,FE@#_N>VH61JCN
M42RKEIM*9,UK[&CA]M?+/4]A%3^-GK5ZJ.<2K]@MG4='$"QKX[H2@%(ADF$@
MK9;ZE9:38V[=G='>:FCJ=<ZIB7&<ALZ/5%-7#%)L9KX^*Z>F/;78DOIK)&)?
M"C-/%S._\<L2I/B77!*%E>6BW&SY<-U9S)0Y]ZT7O3[3BL+!5"?$Y>;0)?O
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M^<NO]\QX_N>@8*O%P@0<<]FZC=9-HIL]XC1;^;G1WUMGC:+!WJ[;6 TU3X?
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M5LQM9.T.>B%:'&+?87'X'P#GS^@_4"CVZAA[_ SAM1D5IEK,V,SU[J)A4ZV
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M([.I7WELA#)VW9A\7T*():6.3^.N0/:A):675I/_:S25P*G=L!MLZ0T!VH,
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M*3,LO9_M[<O3#YN%'V\.V5OJ'Z907(YWP!GZ*(Y)0?0!N?IT.;'(N5*XYRO
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MX6E/$K;QEU\LD'H'++@UL)U(%!*E>, H,D6+ NJZX,K'QX<PNT_*V]CZS3G
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M]+&4J+$AGB.A,0_1U)@>U\DU.)5QP+R:9%'-%XAL=!!C3>$P26?)LF$[QB
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MUB21'D3>L"TPMVC8+EN(P2\8DO$>8)W:BD'JCNG>^I;(H;11&1(M*FI!<>6
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M<+.YY $9,K_5#H&@)HX!;<8X>PZ"K/CW.&NX9H7<*0M:QAOIU%OUZ%#QW,,
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MW9F^<UBA ^TZ?O96^^.CV5+_CY-/F1*I=+P\O[3,GXS5@[+$,*^U)U #8^#
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MSF%B&8I@HQF9GFG[<WQJ;NNT(+R/@G/;CNJ^0U#_,#J0RG5H1VL1G6UU- -
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ME#@5^M3C-Y33/L=B#&9($S$Y ]?W8X9PRWH0G.Q-;Y[JT7+WM_*UF;?*=[P
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MKLZ3-U&N>N(@1^,X?JJP4.^&?G'U=UD11K)B/[#\6T2?:&)CW3.RJQM]/(<
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M_!_X=>Y?^)4,=4LV[L8@<34.F6"23>"^[%+X#_Q*7/&9O18-\!_W59$]JH*
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MF2$GR3GGG(>D@"!AR# PS)"1+!(D2100"4-&@@1!!4$01!3)2LY10"1)DO^
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MGUZA9Z_G^<,KSL[_^%8\-P+8#O8[\8;(H/@=W<#&Y3M=#VKS$RP1,@S<31S
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MWF#&71K?3JHYBBS;+,-&C&12_G(YRDN"ADER"(#_>N_-JI<2:H#0@CHR21T
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MIO=7TAC@E4HR3,I[0:2@1JCLE$?];BA:=F.C*@_43,)+Q">>7-%?UZBJA\(
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M/M2@G A!U-!@H_1Q^JBYM-:V0BVWHK=(73$Y(2).+#!6%I-(YLXL\@Q(P^3
MN75IWRB@D2,WO,RTV%RUZG_5/EL-+5MM-5@Q79)93 J C:2U4=>,$,8_8=4;
M_^H U<U&<8B1BZ#P\GO#YOIU'GJ225-J<$]_5?T^,=\)*JT! 5  2I$G0!:$
MEK;2_*VLSX<CR# 90>TVQS7N#OJOVM%Y3\_06JATF%FZR1LJ73#FV:O623"X
MW^X7\4,\H>[@^YZI+VNO+&JPQ&A6P 6&5M^_%W*W0X;Q-[!.4P6]CN4F7MO'
M'1$X_T_M%' MF@YZ&GE9'M2D%PI$WAP1[/K^7P!UQ0$1C(HLY;A)^86-W<7J
MP%*I*%<N\J ^R^60VIKO+:>)+SQ=X*VL[(=Q&1D:+B\A=>7M^M7ERAK=X*L.
M/4)X>TKVV!ADS[[5(,"OJ_?B:$C[=5I16@=V\/%1^]SD92SIQWCSSU]C!/!H
M@ZY9WB:S#S,U59R^>O[0T+;:*5^[,M/JL/C1K!&]ZNPU*'H$AZ8/02,N4DTB
M.KR/-;03V1>H(X&[92VCHT8PE;:-@B 1L[+1_EHU-F\+DVEDB\U32B@EPN4Z
M],'_##AW]U-(*9H/4_4DGC^[2YR%6Y:@G/%7LN,&,]$+2[<7V$L.3R]AL4JN
MSCSBAGL&=%32RHZ^K! T#W^>RT 5^'9+)=].;)9#LIB4*[LS+2UC.R/P1?\[
M"Q#[;74F'&#C3<,6A5C6*HZ)D#:DW_ST;D-L6YA)D11=[ ;KYZ"9 ;63EF*8
M;"4],K\;2'RW;\EZ UKSWMIXR"))-.S.\'LY(8(".B5CM1[]+%=2C=UN%2=+
M)^O6$%S= ^&!# <ODN!'6$#;10['D6R[9V@7TLW;6,=6Q2-M8-^(NIV5XQ3R
M$,M[NAAAI9YBB"&%IFV%N1K(/EF>:*_U/&IM=@F>Z$N&%YL+V<%-##$E,BT#
M6AH&:_ZO[<5:C5%DA)<O*<%-X%ED])8JSLQO@>=$O9+!I0DFF8H*ZWT^K(]X
MN>$['WJV*CW_ A%F:Z/'X3SC$))))2D.6?KHJBEZO#>6M_NC;T((W1T.N\^?
M=N=?+2BU5<\P:!*>N]1L><-IFY#1]]&*[(G<*8TLH%WQ: Z?*.:&68O\BW&1
M"/+HM ADFOU"2!&)R<I^S5?S >DWQ%F#% ,:/[UX>]E<YD7Q.,U&K, \()[&
MC.4E48/TD\55LTRF*:TRBQ:BU%%>O=IL8G5OU>D?HX:WBFPLTEZ,OT2V,^>X
MG2JY@+IX]-\V@]\_355T4(/0Q?NFC4(CE5QFQAHC\-_76>^/]EM/Q^N1_Q#%
M(_<6[8#W#."0!*GT3?,>H]%7U0P?(^TR<6)10[F'1-&,Z])W?BRV+*Z?1_O+
M-97NW;:F1'CPLZ<)ANWKC.Q96A)MD;=,DPWKIKHP6-#5^=SSHH.KD(XU?*'
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MH9M0.L/"HS_T_U\ =^C$*>Y.&]<KA[0(.-6W:Z:A3K77WK([^V)1D-B7R/P
MWY_S@)YBLCU#;MP(A1&N\[]=MN8]>R<[!,=+>%U:;4XH>GZ8C ^XF1O&!DTJ
MCOF0RLKCK,G/D@320$F4?-"W(B85SR(2-U(2L $29BK0P^%D5CW-#+\7O:6O
MD 7!Q[PN9T/0V9>8!DF;;UI4 EWSZV,N!;K1]/%/?1/L>?*/2*0X*RXQ\^9Q
M:W:Q'!"];L;08-*8545*$L@2>/8LI^9""I*=$^+6[BJ@GEC%L3?*I+R&?W!
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M/ A6V!&Q)!M+[?+H98A9H;,<X7Q)2?$';,=]=>1[.8Z(YQ@6:2>"D" XWS\
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M>R@8NYQWXS<@]<SGE)G!FM#4.\E+LLJJ/%W7F!0>VTU&0&JN/W6O-)67ZRE
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MK"R##,<);<&U'H.T9BU)[TWA$%>5 .H7ASYNN>OS#X/*&V-LOE=K$B(W.A:
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MXA[U#^<#E%?_<E@>YNV+.9T"@ DE#-T-. 5@H4?12P"),@1F#[55U0.PT5\
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MEJ[?0LBFR90.NLS99:8.:GF4<1F4921&?"#?O5??C)V]-2G!G%7V+JO2E&X
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M7YM=C37*JR7=T%1=2\PFFF2ZAY*5)0$@@CDC\&V)O@FUX+O[C%Q)&Z1+H^8
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M:6J(K-0<M-5Y#?LJ=%C?172&Z8B)R;FBURH04O4.HVY2ZV_&$</B.JI5I38
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MH].CN+4TH2ZC#8\THYPF9*=9;D+X!#:&T;<>^VL92<&>$[2[$8(D CY1O.-
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M2:7I6")O;Z>B0;1E*TWNJ+N4AJ P3P%@O*"N>!@A)!P.1M//;0@M.]--#%8
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MD7%U9,:$$Y: #@9%ZH1P-HI$Y:GAQ64]/?$"\E*3:=>"@>#[-#01CX\D_?\
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M<FN$UR,TRI99<*/\(CMR01W^(3D_]74%H.;QR<?PD'(,_P#@/J2413\59(^
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MJ,3K![8L'#+T+4/G,DXW]KJ45@1)$Z?($'B(0%03'1_ES.^Z(EW-BG\Z-I;
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M7@C .N]P?OYRL3\"[\M\++O%;Z:>PF8%KZ$F3!FA%,4*!0%%IH+GQ0A<B<
M]N%1B#[;M<;Q,J'C;2[KP(O6I\BGXI< #\7_<84\GE4O(15EM"MLTK>K]!7,
M=R>&+O,U9"JQ<&64$_4N,BID3AZ6V_7C2\?IZX37ZVK?0=<BOG_) T*>&:0^
M$:0'F'YZH,7:L$J!_=A&#SY".0O4!QY>2G-]\FTPPCD$7$5N1ZO2$ 9BB1TQ
MR5)%*#:&II3L4D\1N,6$)&%]=5P=(&'= HGB]A=#[2)9ZC8'>=:G(+?8@/SM
MH+Q=D;\4CO\&;^K7?"LDI"&^.FK'/93DW;BBAIWL"Z'T@@MCB7U:5&*M7Z4Z
M^\@2I )S_.\A@JC#]?/+.F2286I&+ZJ&(GQLO%!3.W9',8IO!C/$2$XN 9UF
M=B!Q#D!'"4O"#KDMAO-\H"'1K=OZ$<ES+AIU=QNFRWI:M4&F,_LV@^34PU9\
M;K[<?!55+IB#8[THXX*%IH883;$P-97&7MBLAY<B>.$%TR=D5.GGKA/'=5<$
M><VEFV2+!/\][-AKHK/LE14'C98ASY2543LV+#FU2( -. RP_*!2B>YR053H
M%S-E5G0?7ZK;L8"+3\/\*/8[:NPD6[K?20VN)]RNK!CH2-S*NJA[R**.$%75
M.;-$RPG%G);(S]/=J@V-LL\GD-*OFF/P4FV(H_F:>HP:J5ZJ:,<B1 I^BTXP
MJ12WX#F,LVL/ C-8!RF)4(ZBO=?,):'% 6M(Y95=T:/<O*'G(N+B8I&,"N]/
M/MW*__2])2(-4Q+RK.ZNX,M$51P263)@3W6MT/M!Y12^KR!'FW@VIH)C6%BZ
M= %-6JM2?Y! @D#X<%M#[51\/]M0D]CK=VZU1MO+^OIFX42RFVY]%*D;BE>'
M.U9/G2?"OD<OO+%W*>6UK/P4N2.[>,(D*V2TZ-0N6Z!A,@U[5]2N$@J]A/K<
M@)=T^Q7G+$Q^X;S7DZQ=$/*;7 :YZT">;7&EK0B7=^L'EP*O(J@+>NJ#+"#E
MV1>51=$_E;^FKEQF^8HY,1^U<\]:=?[6]JC?TT!TV &5G<7MWR&%#_HT79:2
MFKC414JW0 RGK20#7;R3\:%X@(+VD4Q1Q3+%0T^GV4X_%Y6<!_)+O8\. P1?
M7MN2H%,V7'["#6 ^D8:64V!0_0,P6U5)KDPHG<]KY6@\&?.4\*7E2RH9%Q0A
MA(7C!-'*Q#67E!1"J2-E'L6MN/&9U\\(T5X[1L, HI.'RTQL&]["X68.>(].
M6=29W.W"J/D=NV$*W".R,,VTWQP]O=.@8=?:K7)\<3S_.ASW)5;K\$/$G=)W
MX\!H"T^:P[A_ /1YS9KQ"O(*:MKI]64C<!5-7,:F4*0C<4CSVXK]=\L94,RY
M3SBCXFVSI(Y!/W1Q8W[ [T =:H(<\'M&C<$/H7-&EG91.RN&/UAX*L6C3=ZR
M%ZHHD8+;#"N4!Y#<<*5"\H<"0S+193+U<.M&H^H9<VU.O(6EU6-"=DT2"%R0
M.D(VGO%MJRC!M[!PTKN2!IP%2@27RB\;]Z_\2=0W>4\::VJ^#M+D7K30&O<9
M'OQ<<5QY'3&\3N?"\4!M;9U&W7#G94I/2::2$F&5$&Z\Z3OZG%-\O?-V0I9W
M6::_#O4W7:F22S[D:1&1:\++]I4/=/QMIJJGL^4JYS"R.3!Z.=8KM6F:*Q<(
M%_2=^"E_- (SDO=YF7+ZB1>%7E/2C>MZ+*2\^>ML.2YQM\,VOK T]-[#O=[K
MU2_!:L>3)JJ7L4H+)R2'>]HNJT2DAO !XTR4W3*I0.D8="FWW&7@@N%$TVN=
MP-*N+BA%*$E);CDHAU )9S40!0B,,=EGGT;?*Y@A*>"T50;DDION'9NYC:A7
MX.@#\:47 CI !,!@:.+7#8L1R7A'@I$_ @:,15S*J^(X&'9:#"C_!NN,\J Q
M,#I1OJ;?453L=V-RKGZ5$QP!7ZZO+-.%OMGO,\E-T^YY1AQI:Z\"7\$^V@Q4
MCBOH+1!^\:^8HEB\:$9P)H;Z5*)A4%(OI&*P./)0\R4'>3&RJS]@HG;U)A!0
M,9E5ZZ>=>^#:U<@@%PBW-YO&PB@=+]%C-STG][834]ESB-U6(H![;-_A 5$(
ME,@L;K?O_B"#Q:9.O@E8C5A#2GB(C<=OTE94M^]$_OUGR, =E6L9#P:\H%U,
M*5L!5 U>1[.40T.M]Z[K/$/??+BMR^_R:SWYD#5C E'G7&$@XT5U#_Y=<3)1
MD#/+U8;\A@Q+H!N.&XNXSB6+V+N!28%@T0^_<^(SIY!?;#%W.NAWBA:G6>TT
MM'8*%X1!QZ3ZU>W- Z3?@E(+SH'#!F@C<CK8VG&,[+MQHHO]JWZMYILGKV@_
M#6_/B5#=';WRJWC-A2U(O'X4=Z[B ;8G$"B005'!GO),D$M)* E)2=(1BL92
MJT3/J,^@NGFVRB[E!"/]I[2/OZ)6=UA:I>I9<*,/63B-J)A:XI.A70+F(^5#
M61A%)1"N*$ :U>N*FIT;;Q^E+P]JP[8; ;L+;'+46@S$0E<E"4H$*]7YWQ,"
M!  S"*<^457;BIU*60KE%*)6AMT<DNGA_2=Q&RDM!AG*1.C<0>9PT5M.XT'"
ME!+/7LHAWF'_P_B_8FV.5_:M<4W-3CFR0D@B(* (^F!I%-O6^^*;>Y2P^F5F
M8D0J+R)UO^5K>7'^XV;(89#H D4;(39-)=!9D(*1R,&!MEV+F6&7+O<%7ZK/
MK6++717 FIS/L5S$-NY?=AP!L)::^W&XO.'LZ\]_6FWNY1US>E'ROO .O>HX
MY[?MM#_-7[8/-4'!-!K_Z4U@%:W]6TGK#ZT2(I267/G/]P>"?P#'6G87@?-/
M]YO_R0[K\DS\ XC8>J$_7OC7VZY?E,?P /%B;USN/Y?),9!TG>!TL/Q6"PFK
M@-#_L##Y$TXY/9X?+U;Z7)!!*@&O&&'JYS!B3YR(Y"G,J$'H["RNH.>D$J*V
M!"=YEGE5RO9@)OM^^E=_#06"*SGCRSD#N%GSM-3+S@UH$PZ_,X2BXLX?B.^C
M\X0!+^5Z)(">"^ %^\!C8^/(I<9TKW'=:0_J++A5T2#K?-EH^:)%6VFNSQ=Z
MGP?R M*$>3B7J4Q55T')(-JZ=K U)LT1.MJG]KDO.06#8VD#T8I6<$C>S?M/
M&G_8ENQ_"@:6Z2*U9]E_5Q7VN-"#DU)10R5%V?VUYPJ(==8X#?<"'40V=TK,
M^;4#[^<3FM->AF_OXJ);X)RH\XW,V'KGN!@@D&U+3D#&9*5[W:K2,JNZ@<Z?
M,E?4/\-+K;B=Y;M1:0@KC4\"VLXS:#8PA,]/(/!U\!7:S_Q6J7"J!H:TO@#(
M=@QAWC E)0[ZK[]$4AU,H_^=&P^L^DSM^73H&7AF?CD5D:"S?6% ;ZOYXLO$
MA$Q06J@F5-*LQ?2+DSU<OIHE)WN76G+HJH.*D&67[*4.!HU<N#25B>PE!C')
MM*--DG+<M3'^$*!*G=4TL\A(*8?Z:CM3\B$SSF.G:G XH:0I;$E]"U_2CTH\
MYUZ5"X-Y4TY%!PP+*Z,AR0<VXH>/^YM!CU^:>)[S6NVU=M?C%NP$3^['R;2M
M(-GX@ACL,:46W0Q\JQ5' >H"_>XVD^-QX0O$EJ FA#PFA\EAP=SKEYMO'13I
MV$'<;"*9-8$(G[5F9B%Y-3I]Y;1_=:M@*AS,P=AEDL3?K! :TE0F"I 5S6=_
M"+DH!Y"CY<^EW.5QNK"#U5&VGV+\W1*#XS0"H!$(-?L-XJ >@"] &H^T>)9P
MEL1HCW&HA,_ %FSH6&-Z)U3JM>TWA82(VLK:W9*KP\1?6P.U.MVP6VWLY$P+
MF.+5( H4Y'ND;V4MX%$I:4L?@(#-Q>#]74]WQ1Z>#]TDK4\342^32V]T.:H-
MAP*.,7^4S^6Z<K#VE"X8:B7S>NC7Q\)RQF$Y\;!(W(P;TP$=2Z6T#QPJWQW_
M+,!DIKF<C+]G]=6>=(..]M_R@@L>(W(5HZFNF^S(K&Q)(??H4]TEXD;E6@?#
M%?,<1.F8/ROJC<KF]]J5?*C+9PP%P\84RA-W>^CJ@8',6Y.0K,''%^T%.H3!
MBVPWNXX?276,JMU*K@?3F?]@6E5[Y:)8#2.3 +N=RY>B9F+Y&W.N9?0P15/8
MG*F:0BIX3G;\;>_E>&40IM+B6..=X&TSHT>9LK^D\)Q]9;&;L*=.U0U'$[I6
M:;UHNQJCHS",;U=%5K755,E0ZQ] 1=(XK^8[S[<)2L1\3#YQDI]3A3Y"5Z#4
M.)3H%ON!UZ/W0//Y.-[@LLER,>QIQ@#=5VOF@EV> 4 W"#?)Q;[$+W%U\3\+
M(E.A:5/7:.F?^V)G/EMD468%.UL!XL)C<8>,\:K0B66 .2;TLC%5TM(?=78$
MC(('YI:SO/I.Y $5@G3->RES5Q"&H&:4^\!UM\[X3_(Y+A6;MA,&_JE+(QP;
M")'#'/K.O-4J8PAJXL? (\1,:@E2GN$E?^Q?TX5G$R7N,F>F<\RW#7$4'\T)
M_P"UZHO7C*)Q*=.9VY-/2&ED*3_%<1?8C25+2PCMHF4?):5'-OO<VEC%&M3*
M?UW_E=,*KRHJ5 _=8X_3V>4G-D")>Y'**[405\]43V4ARC1R[WI:4PCW[PH/
M_*["MENM)YI5]0%HT2(BH^'X>QH+N/<7W2;2&"842I," ,A*7=(3\G:R)9$E
M7J'E$IGJZ) Q;T# P.3Z.I>C&"0:#ETHH%;46 2H\P] RY?3W ,E7<TX9L(W
MJZ'%WGW_&4-E$H!LZMK% Y%0*7F!,M5J./\]@8LYY@T*[(T-II-/X%R=%:[V
M3ZV4WLFZ94BHF8"_6-UZI1N*&V-)"GHY+RWOGT'0RV\/&PI3 *&:O1\=$=Q1
M,0A8:F1/@_YF:>=+>$GIFM4_@'C>I>7#RF0=.1EX.[%J[+@>N29+24<:;DJ1
M03QCBUX1%"P7R?'M*HI0=#XO]Z28&?TJ@O^NNT)U<O38S^PN7E->T\Y.7OO7
MA7RM7X1'25F^0-LVRIPWNRQ(@^ZF&VA)Z[XCN.U&EIRG\3(\_D-#;LU /D+>
M$!<U^)5&5Q$?;F#;,'-#_#ID$#DPD/&.6^V2P=:1+4,7LAI.EN]M@3:$52IN
MLNT2=\BVIU1-8\"$CBKS[:-@D[9AKSF0$0J&ZJ#\)1S]J[%8-71'R93YAI;3
M*)'20[D.*MV-;KX_*A'0\;7?8=)[B2V3T'OS*'I"9)]=F@]']%[RQ65*D#%(
ME0*'SZ3H/VU,UPF) <340Y)\8<DC/1?>NT_.P'3'D]?9B8&??4L&O8=%RZ!;
M1=^U8HMIZ^-^GP_5&[:8J-V66!4]F**&Z[(!(Q[IS=)^#*\E_\E*  9OU>MP
M">X$6/0*--&D,L"2(,.N 1JWIR6B,PQ/! VQ_?W?64+.EHH*:&5T!( VC;]M
MP1SOS5?8<NC\\L/IRW2X^5%M:Z:QX\1<%.G;N&T$R","3%UQ42Q#_[KT'9J
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M][I<\2(=-5Q_)$,K0C^3638?"IM:('5K&XE266\OTBM6"2JHF^"7:YQWZ-;
MP,34-A!IUD"OCJ.V21K:=.'G/\#D\D*6+B W#<A5+GY]"?P6WB;GO)@/;CGX
M^J1H-&G'-AH:+59&T;]BM,-K,B-<_*2R4J@)(X>0GZ?WCZQ!@V%*Z-O,6"7W
MI1<09TK?1$ 1P,'NA1VGX/49^<_)C7OQYR (2M?CT,WY69+G4ZEM,:FST^+/
M',&4;RW#.D]^SI.=G8U]VP@A'$&D,<;]'M43"JS]>61-+GC%OLTTB74^DR3C
MX%3CV/OSEO7:7L>8CH=Z!TA56R/_-2EHV$7+=HQVFBAX(NBRO\I;=%E=.^-3
M;'"DLA=_PA+KA^E5%RJJ+7W45LJB83>>QUN_5N7?Q>ER9SPI[PL#71Z6GG81
MA<QJ$]DL_)3S/SFXN'7^GX7[OXLWR3>D\WS()_/F0R"?>O3SQ.,H/S&U5+ZN
M-VW+#;L]0<GC+;R@OJUO_>C$T^;W<G]T6QH[0B[51VV-#I,[O='F%4.11A^>
M+K![%\OB?VZ2=B=,P_VV41'&\LP<*0PA#V4)/62+^66",T,A<:8T),A3@1?O
M [ !4?3,!+^K9W];1H^D-EF%-G.O^C\,^;8Y30W;EX1(,6:=R(U4=9H[3(56
M-ASIJ2DN3?.-.@F>LCP,!E)?#_E!D^X/<E8.3H9_:WAH90KEO!'H-6:07#*6
M+:.O&16H9\$1(\FG<+6Y84*$F:>VR$6=O>93-^Q-*4Y=^ ?X^: I>O-_Q$&#
MO!6HF-^"_@?(]'F84C+QU1"?I(4=_0/XS#[]Z=3Q#V##Q!50_@[+\0\0^O$?
MH+J$#_F_QE?_[[#V:Q)2#NN$L!1F3])0:-*(31V[/&F^?)4@.UP)3Y2>FTYO
MB[R/).7P("4=_ZGES2\5O6$+>,(QEN9-/B4]]:EF)S9\1#F@SBYF;//UC-,X
MM@!UY7J9^1P#.8BDB#4:^JJ:R&/HDMJA6-DE8-F<G;2YU=IECL *0>!=!#Q0
MJ/2\RSF+[<(:+SY)N(88/;=X+YM3]#_ LB>+90 3J*MUJN3#NH7@9N(KQ'YJ
M5CPL#(C/?Y(,CG%OH1>C$J'^7:XL(,"@/_9(QD3W4V^?=#@QYG.=R<22A& %
MD:,C"7,#83C*3L'OJHF >I/R@\\RK:S#LIV%G\#)(BQ=W0[_6^6)5B =S!A&
M1MG\>4"(0YQ5& QUZ<<]K_$LHA;WR6C3?6F\8M5!P96&#HFN:YH5O;4X]%N>
MB1?K,/CZ N[7&J #8T_G^D+5&;.7RB7O(/9K/E?-NG7J32<*TL_W[?E";IUG
M1#!U[YBYTPA'=^\:]X-*Z8&;^20+UW %GPG&=^$P4]'7V0L%RP]6VT]:%N*!
MWZ17 !91(JHQ0V,X\A0B+ ].RH]! )F^-)A^WMSS,0:.LXQP2<^D@+\A1JI+
MAY$?_&?+$;6+I\9H7:3BJA@SJ96PW'N*C_/2[XLZ$IY()8N#9?"/BF]U;<2>
M0#]GS8SHR-I_7L1NV.I3:9:4//RM"MX<<.E.*7OJJ/SJ")W>\I$[D.T?P/K]
MEHLT:>>L@C#]1JV([4\]OTOY71^/YE1.7Q@C:B4*5)*FIYX.)59/;\MRCV8*
M(>8A#B(C@V-4%C)Q0^5Q81,$!)%$/&#6Z(K_LUS_%^91:*&&] 2T(,/6+-E>
MBJ;!]?3"*:1K+ :SO,2R'%P4?YI396_TW:&UQ>T:! _9JPWTZ!"=UDMF.:9A
M#/H.>>5MA,K,5X&.29S*50D*1)A6F+C\=+T:)$;K831LC: 4^8->%1,L*OA>
MW4; XH32\+0$.W4$><3"GKK.A87)GT%I(I06@4#?1$U>LH_<KTJ;Y^P4U BH
MZV.]^D1,\'J)1<OPD%!3MO9<Q0O=9JNL._%O N:9N )&%T86Q.!+8$">RQAW
MQZ[3H'J ;D;C%TR]Q(-FOLV,XG0L;.((!EOR!(-Y^M))XU(^G1&@!8-X@KJQ
MB);_TJ^8(G?!NL+_TISJ*95B3DO:_DN?Y/D[DDG:KOI*HGKYX#]V!R7\3?-_
M]PZYYQ?SM^;_-*0M'^/_"7V04#_3_@=P5OD'P+'[!S!5UUWZOX26B8M+^53Y
M'L)>KZZ5FK"7]/NJOU]=G5@A1LF&Z/K_32/Y^WT!?.RL/>Q)?OAAWD3BQ$4M
M)Z[(SQ[S@E=5L*-9)F.%H0B)P#,>#!T.HUSZL"Y8F+/"*%E4J%:[C680/ O/
MX7=3]I88'C[EU&:>DZP)\!GPM+3;B*CW"8[W79F[<GNZ_XMWQBTS4K=N)&/J
MNVAV7:\K+5&6HZSZT/OH\"7U\L*X3#6XH?L3)R!+IYKZ6 8WC+%";J!(BYB6
MHP!?_QPPGA>A;^VT_@3S%2,@ -4WX,8#G,JE?0:5_BCX#?IQNB?;6"37&:X4
M85#Q!F&R-H,"&E'^P0R (L(BOC .\N5M(?!O//C"PP-<02BD_$G?6L8+O\#P
M<YKG!SI'8JNN+,R(I*QS ?27)%KG:<<.4KU<1G%S,?F8P4*VTNMJG5Q*=1F;
M2O3N]B>)UH;T$(I"FYXEB\M6@ :)"$F!%.V\J/'>&\->J0>N76O@-%>WMO82
M.0-]6,Z.G]*\XD<]A[WB%5,\8>A;J:OL%^-L[D:=CAA&.B+F"*B%^T#I-3"I
M.\?E/111R^A&_MH>^0]@^*CG%S)%<ITZ=_Y#5+D/4]P+#N\+CX"$D[-5K^\8
M*NM0 7Y[DJ)0==/4@OV?@Q-KQ;Y]#AZUOG,E$-L.W"<!E:D91PG]F7036+C+
M%+Y_W_=OG7 #?:/(T UFPV1TT^;'A60A,;*P4&ES4(YFP(N>[E\4%4X];EY6
M[<]L^E*T!SGZBRZM2O,QNM/O4RR@C(#P)D#Z#0<=37KBVJ^K,IGE^AQ0:[;,
M1,R6Z+S@4S6<(E)UXK.754CL,O4^+2^Y$^:O!GW6?QJ@=#YXN'GXL",M9L.#
MI-$VG1X$)S/%MBVMD9H<YS(7UCY,J??.6#J6[D!9Z !O\<-*N&<@4APE3.EJ
MZO\3.FC^P93N90L7OT<\.K)+2Y3%R%H>,E449,-%#H+O)'^>3VWHOZ,RS'0<
M/%QO4O*9=..MAFIGQ2>"5N=(O9CWKY&@;PO:?D)HC&[C J+ "[\Z11*@:7^I
MX8>],S)2-MV=P>D$RU@XFPEHBM&=;;WR"NL<F"F93P,7T7;("/%PDPJ#A<KX
M6A%#<RGE/Q6."033MYI+_FO) <<:N.J'$@,67M6AF:@X^]7%0Z5$<651"FM&
M+NRCF['NK&.SJYKG!Z9$"LDVIX>KIARVOH+F,NX8KLOR[RH_;K?H*'-XF?'8
MN.;UV_XF,*'V35[%!#AEACFF98[%EEL'(S=S8=)(6P#K,I!ARYH8B&.ZN.LW
M2ETUPBCX-$X1/YG_L\-F#'T!Z-S#.=[:2)*[K%QC=XV[J$(W]YO7/%:-^+2C
M/L@ Y/@V::#00,5JJN1R+\/4&+!NS%>^_@NI9IWH:1A0KVCH;5\N>"07!T.L
M-(DUUIPG1B0MX@,U1%SA>B!P$T$X:6-X)N&4+N4VD)@;G\HKD?KIV*O-=Q34
M3*RP&T]#[%:!F$P7.]O*PW\]<W#XF(G)[24G_7=P8!'SMW46]N>Q>F^2S^"W
MAP;:%OBRC2J TRZ.'_<]\^H&7QJH53 L]E$F2G2URDZ[M&DWB=2RTS(57?^_
M1"8T^'=0*6:2^A6TO[U 4XL[]7R22A"F2QHJRX4#54A/NTGXR\3%G-;?+G,R
M<#5)'0G*PR7IDL:G"?5\I\?$I4!M:P;=PGD=Q!VHBW.LI]BA0,W1ADU-+\)5
MAI#B%Z9TG?W<.IUY11++>F-OIE]4!-&=+@@\6\\[+VP/&"L#7FF$S:97_H<A
MIT0*8Y[O'GUJG=4>"+/Q<>\KF)19!-?ZGIE?Z4B21M#^LD+]1E8>-YM<GLIF
MI$R[K!AMQ0L0N5D[J.$#@F0S?G10=X.R 9UBKY0)?MS/D(X%9M5VN_@D GCO
MW(JVB**BDY\^90ZA;]Z> 2>.U%B]4O7RVGV&G,9O_=X+BDX]F06+%-5V1B(1
MS!DJJZ%B?C=2KW"6SM_Z-T@ E +CCNPDYX6?W6;]5?JX(;?Q^9K:68ACQ$E2
M-BRU2/)#L,WF> ]%A'![M<=8NY"6<'"C*SKVPB6UBO9Z $&J?'G0%%>U%,%J
M W<5!Q,C76&TB3_"RI4._K20/XXBHB(_#==VX 5#.LX9%&4:91,#.5"N1T8H
M5T=0(>?TI"#;??/9';Y@U")&W+!TS*;%;M E4 9,H/.?LH=<N& V /O+U1;W
MS1&#M_@V3Z2E<V567\,ME7SC?.@X5O#Z>:Y_(3\\<N89\8'(0*2&4NR#W$2-
M):#"N,K2_7(=X9J!6TJ/^C=J5$K[3%AWZ4_Q BD>/6^ML1C;Q3%&#DXI%EI=
M^YD(RYEGFF)DZ(S.N4H&TI>V>!:F2.E(+FRD24OZAJM(_>")#.D>#CSYGN<%
M?8GS&@2) $8W^$M![1I1?WD6+9DQX('DV.8K;@%$G!DP4C>TD)>%_UB*MEZH
MM=(E:N+ P# )/S3%RJ+*,$[OZP,7;0FP;/;>A+O22F)F.K2#-(;O&9/@QG'@
MDTJ &Y5X7JV\SBV&&<J!FTF57T11O?Q9>BN/W"E95Q(J*BSY66'OVD*9EIZ6
M#/'JB=+GWE"J]L\[&!LP(OQ%MX50ZU:0M*_4D7"IT[ 7**+J"Y54R2-&?-^<
M&S7[H_5@WS:[3SWN%B8KCJ@E9L<PB -%(X@SP\(V9UGGM\YHJL!K[5HY,I)\
M >VO<<IOX:=HV<^4E("!3)+8D9W#$JZ/;^[T9)..Q&Y87K&$ULF=AQ6JUNM]
M,6R79/.]07R,7M&;5P6F*-_=GBW8W^7=)07MR2:CVTBPN84O?I<,[Q90=N)<
MKXF.KXY5L4M07#^ RRN*[FLZ(P9DV*EK:?]WHP_"6/C_VE%F3^D:O/]2F+E5
M(F1:Z.Y^@](/.>ERQ0.DKN*8X6_(WU7B##)Q?0@.\UMZVG!-S^-H!,^1(2DS
MJL1>F3A.[K0=LJQ--W(-Q/34\9 B;6&J5),O-A8.S5?O'0QP@U58ZL2'#!,"
MULQ^MH558%A5:P:"LWI]S;NY6)QU:YN@;YLL7&F?URF8.3XQT^N/)O&#O7<>
M;7;1;H_8C91-Q]18;+2^R/,K][]Z/$3'\G,2EA/GH/*F6H)Q1F@Q??YP2_)P
MU+RN><6D\Z&%LX$%RE&]:(OY+KW(-X(4'GAN2"G2/+'T.!+21723%=N: T2*
M!VOC[ ">+,=I3ZT7&,P?&GH_N<.W1N78<Y5%A]QD/15JJBG3<%$,MO2M/-_Y
MO-><=)A08[^[V]3,\=T!VY)'O>=>0XN"5L;2%M?9RBSKJ18:, DJM6LZRNBU
M$7,&0CK[)H:1I:>DTBX9^GFA^D:T36,,MZ$I%.0,^+T 5Y=:.0&5U1RFHZOR
MS.94C6PA"9^4@<'!]?/^P7:<?IN'MM8>7N<-II:EJH#;X+] JWBZ"<06]1!M
M)%^PN<L8I4HG/QDIPPVT_TVH'T&4[56EA,C; DQ'S_P+F>#?JB[>R\7MH9DN
M'UF[E6%SBY34^T;86@'8Q_49EHC+Y&@FG#Q#:(NC#'B=[6_&O) M_0J3#]8Q
MG=\8ED_A 2S#Q.KJ)>[:G_2:5:'IP%T[X/?G1 *7*5"2_,%PXHA@S[U.\H=B
M(Z7W+A;$3!$5!>]7ERCVWDT5J J05:QZJC9C=,IHLY<#.3(6>P/FDU[S\0'"
M]F^=;J>TA(RB#P&72LK&D=!#JZ^*/KZ8%Y-:536 &&-Z,KE8O$L=1:F&,H\;
M3?JBUQ4<*"ZPN-Z[YE3+T?=5*/(=WC<GI:D^Z/'\E,QWDFA:O/<)=!&)G=8T
M>4 ]6V+24TDM">8I\9:VF>?>I(R>_%4MR+25H0!VI5'!AK](2!&>AH O,3?'
M-KM!"?_WY3_65?\ P867YI,TB8)WJW@/N$J'NC'Y_^W&-6HY?TR11CUJ^Q"1
MFE+@]8N%2J_H'JN!4W_-.]I\^+/R>C@I$59M9 =)(\4?K/FD"*=6'8E.9:CV
M_M#TT48WM655SLC35_U2NY5KEJ,',UVJF8K[AM>5JERLR.XKD^YL?\ H'YOA
M<>LBT@Q0D^>I"<E33"5Q&N4AT34BI;_05]&$C>F*I.#H\T4D4&Z!8%8:I>1@
M]U,+#^GTW[&(&"0G?.F'=(]UI* '1$6P#T>6J\]5YW4T1VG49S(<T.=K54N9
M2Y(AKUT03D%_@@J'%>W;^6^UP[5^]LOH0&,__=W!,N.$QPE1&T9VZ9DVM9U2
MF%]];WK+/ #%300<8-GJ H*B',.P<>$=;;91#T %(Z)L"*Z#<3-1#=GAJ&:A
M19%^5;Y2[&!;&MC" K2?0V@XLL_D'THF)39]9Q&9XU;((T3I;#TT3+_]*=$B
M/+89V6S(94'BF;+\J9"2L]4]+2\S TU%25@EU2[.I?[]_9BYZ;+ D:E"42=G
MKPG1W)\^#36VHZ>&0MM_!-]<U;F3O=GP&"LR^C#/8UB"4:8;_X_)2*?^K&CG
M3D1;(TBTNH47]RM_7ZYT)$+%^4 \A->C0?K,)7S0?;9S&1;B32-5>^Z\EG&R
MIY5HV>*:8(29FB+3^VX.FVJG:@8U0OWECC$\@@X3].&4@2>SD<G1,>32^OT6
MQ&3^TK84N\MRB'5$&1=D6ZI)D*5:FN'JE%"TK\5$??N[> IVCX,E[>?--TN[
M9KEMRFVW9QW>9:4)8\IST24?8@BO5RM>7%P._![?BJC7T3^)]+U;P&A)MIU;
M2%8P^/A<Y1AZ!'D#C:9:Q'GAD=1S4]VP+&&P-)CA>$&4/3:.D(TFOTW%_\0:
MT7+14,,0QRZ^]8U#1"1O8@-D4M3+3'R]X?.<335:!?H^M+O 6HK-9H)L_Q$1
MWBON-?A)8U2N<&A[2BB:CB7A]>[)LN[H)Y&-'T"\*CAHX64HKLM+C=^.\TVV
MF^U?WDA]*:6!IV(Z&#9YXP4],'"+(2\+$]2"IA&VQO^Y3^!**>B/)240(8WO
M=G3[,L[Z!+G:[Q:PR@7!+<H(%7*.W:.UL%9R7GUD%^M1-*$\<YXJ,V+EQQ<I
MW&0<K#<C@)3\+8,5SA[IJM;P<C7T+*V,8LBE0-=$9;PPU $#;,8/(PL0XN?_
M /J!<"]%7M[Q]Q" +("=;XBD*(X!Y%/P=OKJ'R"FR[FWERX%.KXK>3%C(L8;
MOSHS@M. K6U \WGQ@\*-45YYGCY]>H"$+=F'9>?7GBJ4G.6=3(C^LF_#:Y++
MVS(=DL(2\6EEHVV3_R&EQ8;%;/F).<47RV_"%=PD8L[-*_X@87(CEN@JPY?Z
ML7A@HB$/Z.5+:0I0 (O2&H3"+2#Q"4Z9=P5IF#?6)S+'5;=H>D*/DGN,+;AG
M=HC#V&1K?SNJ=CMQR"/1*EZ_E<DMX"P9,9/14I:*VLQ^EX*R<*]PGJ6<C9ER
MP@^%2L2K4T,/9 ERO5@H5,(DJ70D*C$3U1D]A\C:&9BK@-2.!M!HN@R3DD^0
M\Y[1Y>Z\BGJ%.%AL>8O4G.:K&AYWVB>IC/9'620TN)/FK(*=2[@S,G597&[R
M$F6WT(J<?(BG4&;4SG]:2MB$5%MZ&7&0!HNU/)'H!?'82J)OPRM$\Q!:M+;,
M,APPE#%"FF275+HHOOQ]MS*]!92M.%5ESRYI+%1>L4M\'A&#P;?I<$/:0-/+
MIX 54QONM*F506[XVM07_=1]V-0::(&=")^ O=]U_ 6-A?%\AR7R_D5YO&,:
M;LAZH'PH8Y'%,:_%"8$]$=\P3^55WP4Q;%=V3?D'E<H\\Z]0)9<T X@X31;V
M-9Y9U4@K'FZYADS6U1:K<W&R7W0U5F<6GONA<92@H6+5ZHMYO%F-IHVT@+"J
MLDU%@1YI,/.C0<-6Q3%+;J;!>TTA1565B7!W+<X,+[01N:KP A7%4V="F=QQ
M;&[)]T.>+S-,W'[+P479#2MF#C]*O] ;@:D'U+/2%E_0]_;12[4-H0A_>$*8
M3CL#N2R5157M1@JX2IS,8DDZI#9"'@7I.CP?^4:;^J59&7K_^E'A\&^_B7G)
M=6QXG;J5^ZE>_^?.^W<SA_;:.@9L9523_P4@;(K("T7"."X]28-4_4"/SR=
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M4;3D<8(A *M<"49<G(G8#EQ)T92Z*O/.-<>]?#?#]=KW#[SY*J_R(^6 CUO
MS)-H'K4U(L>K4#DZ)X6F*<\<"\8N/!'0]7&ECUH]"]]P7?#+41^KX<GAN/E6
MNN K[P]Z17,.\E:U%I)Z"E]L=Z%>&CV<HN%HW->)&!5)XI/*,X.G$C^7DQZ=
MY,T_%M]!D= PA8L/K-?2VU209\7X*@^E[?([$@F:&]Z[&KM4>0B]JG@\$YS1
M;47;9AD\"O96OEE*-$P6972!X3=<5:8,]3V+^BT[\84NE!C42<5QCOTYY)85
M8W*;5(.K@Z^%)E]8XHO&8V]U] NHO+I-0<+L_LB6ZZ8T'_G%US2L3HQ*9RQY
MM6G0TUQNB-SO&\8[&N6$_Y)AD_V3YV!>_W ;*L;Q&!?*H3_W,;_RR9/4;SY%
M'#1CMA$)J;KV];SM=K[G?_.N"=H4"(#<"L+CD<)"NC5':>NULW9MFWRC&(B7
MQ0[FAG227RI="-M6UJ?J'UE]53^Y3(D#VCQM;>T$32F[AZ7/Y',G$NVQUS#&
M1N'EPHAHU,2TL]II#.$[@/'L%E9Q#*UY#WJO6$[ 6.7'-B9=<B0?[D;!_B3H
M!:(JLO6[*"H#V'/@*H83U$^VH?.W*;;AUE]J2*3'K%U=.78CHWF#$=C!M/2Q
MN2/!?/0"U-J*P,_7N<>"C?&J?Q;8Z)B8HQZS!MW!!(5J4GK[[*1G!C9F.&-_
MVK7%BM-..FL(I*S$C#Y1>W1K]>GJ=#KJQLX]-&? #8)O[O@YIU]@Z'[Y4=P;
M%I$1.R 'S>4KZ:QP_"-&;>56TI]%VN+&FODZB'7M8C:D#(GF'LNOEBU).G[K
MJ&V^00L=;(>D4,>)(*( ^?4[\>]<W46L^Q/IUQ#_GW8Y/S:41($X7"G,^"I4
M8-3U"XHD+_:H7>/2'!I/%DCI&N\Y;^/7+:^_#2^EKBD3/:9'(RD6]!GJ34]Y
ML"<A %4'&AJUTF[+RL&U>E'^7%EO.(SH+O1G[5NGYJ9E37[.4MP+.V5'Z^R1
M0:!?<4J'R:*7*"4S%!^78%2G&BHA(8XK$]MZ]WKJR^N*&4.=DN86UC1.'P%T
M;+58E5]0TO97@3+P5(N]? M4"%BRK).RC)3*PQF/_D3XN1N$J[QE,P:NBYJ[
MPZD-@X="1[+.PAM&"/U3$#@D\F<FGC7OB!W,I$&IH5 93?&":.M7Q&4$8O4I
M\Q"3L"(V%?UGF9"=)DL]_3N7;<33<E6F$$K%5B-X >5Q7:X%LIS5A8Q!P+%D
MQ7A0-91Q2;?Q[XJ8)9CF>:F?Z%10S3"Q3][*P*ZM6(L?NOT?P/@(&W,0[^<[
M=Q$I+W*8EPJ))OP,]>O+]JSU<NJKO#?YGEY+0>0R,G#1;?H1O&<L/=83'RH^
MXT8#(AFAS(R(V0VW7,/%J=%PD=C:]36@]KD6_O7I0$36R4.GR0X:H>/RF$\?
MU#"\KL50RR,&]AT "HA5/\U:5@,Z=9!46/9&FWG9[Y+X<SL2\Q(72 Y=Y9YK
M?AUK2HRED@R3'-=PN[HLNQ+DXDY4BP,9[R+37M1^>S.$M@V>0@LMON)W@,!S
MXY'A5$N>[XL A&5?%$^6X6EZ0GX?6P@J[:QUH-E*@4K?M1E-F+%7 &"&?J&?
M&91A2<_V?0*/]64*# JZWVJN\>2  G3-_'"UR@;$23M)IY6UR&A.ZADC5=9"
MP&W@&QK3>6B5/K_?7JA&SRL]%8V/?A(T3;JZ:A1M52'*4L"LR\WF,FSI1N]7
M5*U^TR@^UB?[\5=I:)TG$?^MC_[*I1+LM2IJ,CC:RJ-8KV3%GW56MU([8/C7
M@NCS:HNNW:EG8,GG*!K.RM[(($>D#)G,33I*C-OI=2]D@EV 1N_\Z^6H=MPT
M&GESLQ7T)5M_"84%$RA71M*QE@DP,G)_%@ $",CSR1]]XZ505TENB\R3CDC@
M9]G"F\_;2OH;W;HU;Z+^E9J"&A@+^!$:(GY^Q?X.2:U^RER5Z]XI7G5AGC3G
MWXRF>I%21'*QZ+RC*Z3"A\<P,'A2 IGU">DQK+TF+%J>2N/*=\-NYL7K^GU_
M)E":#';A]=;WY^-9'95:FI'ZX_F("</'K6JKF?H\;(25.T_%"ZE^ '.J3YG6
M&"T G<:/?:]8'+GZ2^!C=R&H/:I#F&V( 6?D%,WP=%K$E/6G' +;W@>.\KSB
M$3I#4)60IA6L/*)@UF&ESQV9D\E.@UR\?.R^_-%3O=&#X*0;)U:TOFV[0G9\
MWHODIE?N7,PB67)AN3;W,YFPEDT/>=H5;'F-!2E-2B2/2XR(N;.[BF*3<]I\
M1C&?S2ZQ;5U@BYQX*IJ\M7#KP9&6]:>)"7J)6U$)K?6KJ$YQSE2;96AY_YR:
MP\CHZ)I)898M6P"/;JUVNN#79R!X<BF10B)',EKR>BB5*2?3[93SE5CY9N9;
M_\D[$2S[WXT&1^(W>0<A;J+? XY?8D3C;2Z$Q*9X2_7#>+&,@\]>%&DD(_\0
MT.4\+QMN>ADZ$J,G<66H48F861!27(E6+9:>*1]O:E& I4P(<Y;2I;!I]2PI
MP6U))7<V(1S2K-.!7!Z.$^HD98^K%M_X>J0XZQX03/%N1BU%:(<.H?O5ZV1U
M>D<WXQT03DM&@F,ALFM5C_%S-%2:2QIX0F@0-@C\)749UV"Q"H[?D)3IU,&+
M93)C3WEN9@>J9_6&'+TNEIVYFM5-]_YLTVJT4^4K'Q ^V:E^;SFA702DZ^^I
M2I3U81.9 (0*":1+SBM_@-^@.X.FOG'UYP0;--%.P&%@TOMSK0LS%O\5-34^
M2C%?##<>F*\OO:1X#7BKQ'Y Q/$C7-)Z0N-. FV$VE<RXU;B+IS1_-@+DL61
MP#/H&];\%*CSIB,\AA\="@#\>E"4X>X8-W[$H85IZ^B.L)O1,KB!"[A[UFP'
M="D-O'MY.#="*935OJ; ^W$MGH]BGMH9OH3"#==]Q$UZ]BMQO=[0@'M?;K\J
MD4=:'RP#0,ITL23'WGHEK?R:Q?L<9V+-+JJX26V'2*D=]"$=@GF&_)I*>'V
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MX@'R;>6)^#54$"L: R>2BDU.GC1NJKK]A,Z CM2S>+^H6M_O_).OD494![W
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M!D80M$>E1._3<9R9S2128B"\(_C!+&0Q?#^"42D\/16:'L5.F*J0*7W(B<)
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MA<$YEC_?F9EMAACD3+]3C<(7=)_(8;$[:QUTYTK'P&:@H4U>-DC7MK4/0 -
M]BF=FH<\W:,YB[\8\S]$&1"0B@@9:RS5</]VU],8MZF-_^JX!%Y\2UZ622;1
MVF!O-#9^=ZR8V#_*<XMR2.TI%..9BNXX%*,)^P09<G,#A2], \CNI#K)0N8:
MJ(1#:)R3J$J'57#;S=/(#=ZN!N=\]W3@:=_GX65G3FU&59,B:6BW:YR.;NV
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M8\L$?=YC2O)0R]#HK7=IGZ]J/8^U$:AN,+!>Q)$?V)E&<FCZO5IEP69LHQ-
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M(<S#51G]ID2!;RTU=Z;;DR9ZWXWOK/=!S8FV>_B1I410B]5V?^+919^D,!I
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M4/IC*>*_1+]-TA%H&QCEEL6-*)0-%"*_J\ZKCS6,F@RP$.IJ6#@AIYWSDJ1
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M0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y
MSD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y _I=!</_Z2P 0*%B*WIU>1OIX!%
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MN"3Z39(RG-I(G7=79VY6JZ]8^CTRD0\KN$5>S4S ?F',E5V,YAGXZ7/PF'B
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M;J^& J.J;.Z@]^BR6*EB>NYK[S0%9E.OAO >&3]N!]]THY# (LO9H91<8KE
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MSV)+$TBS7X_)<_15T.(]]%9(N7R8LI=O27LA(J)Y(.1;A6 %+3#L"2L"6\=
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MARK6=XO3K_"Q]7'\8O%02C7'8O',]RB=6>@HT,4!''?\+Z->CHMLL@&HL<(
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M![-XI,"YW.ZS>+:Z"RG+#*&,RLV/5>>E=<A]DX@)-:%8DL.EF*,(AZ!?&DD
MP1">'9I=_))?WS*;V,_J*^@H!Y.3QAA95K@,V?F5S3K(02-_2 K$/BN-"1]U
M4<>;03YI*"V6T;:CF3%QWQVWBTLG21=WF%<7J((SAZ0I"348+&%S=M1Q%=6
MS V!B$WA2DG*5<9)'<K1#G%KM*(O/$MC("(L"DV C;$M! L;4\$HH*T770T"
MQDC:'TL?J61ZG#-VBJFDC0(?V!::[C.<ANA[1Q@,LX6$.07$M4;!2$E)R?81
MI8 Y;:MMLKN,Q"GY&:4[8P90MQO(*DW/"8,91RIC!#!)C90FS&$>I*1XWG'1
M)&,[5'W]8!K>J/3KO:RU*7ELM+XHO1C4A-*HXBK#/!6*>0L 42[E6_]YMM$<
M*QK:Q286K9*3J177>"^N:*/3 @P"4]VO2/"-1*S0=HDB62#9V>-4QLT>2="<
M?$0XYQ'/[*;TJN+8*5'(CY<T;OVT2DV#,CKYYK)L':VKYW=J=5I?(R$=*^1,
MC8U-BC'A[[P4[$1 9>T)U77X>(I%&ANEDL&>+P;)RG8?4#0;>QNQ%<U+L%VD
MWF'S2^_":]#W%4 Z'2>TD;/-D:Y@VB"N;!"4272FNFN*E[P7E!P;9M'[@YZU
MVY=71,/MOO]DG5Q)A"M%)W73FS?O7]R#K*]N&:&GCCVHLWV/6MH_PQ[MXUM.
MSIKFO<G^NI[/RQYIZKP!=8_&;T![VB^"-@?XC8PL%3%X+R=3T+-H?"_$\,4P
MP)A7F3TQE"PZ(#L8L2ZK*]"]WV6\D1"R0VE?+"7I'.9>F^T$LJ7;' AXO'_R
M_L]O:O27W(?>H%]&7$&O6>R#F5[:J;+*Z5C (1Z=Z-:G-P#C:2!<UA+C4#_P
MI.= 8O_2\V_[QS,/M+LG$MHG"NA5 #0(,W'$[[G;C?'>8VWIZJ+ZM.H%T\WG
M,7(NU>L-V+E] R )#Q<!>2^>$15D("C77N*#+VOSIK83A9_8$Z+3:[6BV;G:
M\>RI,Q;6X:P'O!A<>13"#LQ??W\O/(<)N:4K0_PPTE2#QF9OYQ6Y#JH?N)_1
MF07RO_Z<Y8^/@<#P#&E$L$4A(4*(;[H/V,A<^?T*,[KYW,K-W3/7D.'R"5*'
MV*7@EEK([(.1$CNN,M?WX8*=:'!2%>"65JE:E#MEE-T6:\8@E? __AI72:$@
M:U4U6SI<L>15[DN,C[Y_1UB"OS(@)54!([9O<)*I:'Z5Q:("@"RK46<"XQ98
M./O0C+E0_:R&9MH0C-BHLI-VJP2T^;5B%QG? +%]AQBL,_4]  LM.))]$/X@
M><U=T1S[Y\_*%[)/-D,-JO*V3X*$&C/2I"[RV9IY(O3A%6!/R3;Z>*0<I0;U
M=ZB4HFPZFR#*K6:[,]+,+Q5PWY.4O43:4%+2,N2Q?UA2K_R5R3E0!2\HAVG'
M36AB?S3!01;2^&6M35SWX;+&"-21Z3Z.:O:ST'R-F;0Z";(AVW!"GH7^4]YT
M>1(E*X8%N4T3"V:[W7I\DK6OB2XYQ79 T^H*KJ1P*T.B>^3XISX)[X'S_EBS
M28&&>CNY6^VI5# QECA[C.JN^0Y"377F; D=)P'AI2ZAU?FOD)T5+$2[ZL0?
M8*;$%@9$E1$B&?G4<$HIB^TQ&?2COA0\CZ^><G)O $N& @I:NPT>#4DW@J,Z
MQ_O6=Y,K--\(1\%9N;CG*//J LK:.')I;![E.:J<3":-YX(9<<6;EA6'BMT,
M%%Y0J]BX;$O:OE4K3:^J44GY1A5<3?A$'VW4><'T2$W85ME.AF)3 D?,G3O\
MYS? *G>JG*U]'XU\\>*;:N.$I-JJGGKYT!HSSB=.[BZ?%''J@\^SZJQ;HS04
MA"LY?CH'YS.^Y,DU0_%VO-\3\.QX:7CS1A\SAN[U$)0%.-Q1=H\= EP1OEW<
MN]'/50MRHEBG-Q]1&<1 &@3^%E1S8G.FQ]N3TE!_QE'Q,3AB_"X)M_LBN^@>
MX:?%'9OFU)B^F253I&-N:).6;K5OY"?GQV^D6OTWBZ=U^SO!/UNM)%?X[:30
M_:E>.6)72<8+S;SUZ6.,(41[*BZ99KLQ_);39+(&F<BY:E"7:7EC+^);&^7&
M(\XL:P&:CC/V@>GJ20_"K:6*)\.1&![N!A%Q@_NG-$]VS2:'K70JF23;8O"M
M;8D(+.Z=]N5"I:5F-?5>< _E.7Z#D@9N8[N2J\H7)1UJ+4Q#Z?C&<@?CE94"
M>93U]YW&578UE61D^R0@EG-?"0F4OQ1DOD/,^S$V"-\7/Q_)\R%EEXL*5,YL
M&_+4->!#" _H*&M1.4 KFS&N:6C^-X+QG-V\/\<L<C+'?HK$LT/"0BO50(T1
MSMB_:%*I%<]"!JDR''6*;[0LDQQ1I&?5UWUNY<&-"@I!_YV!PH]OE.*EF*=0
MIF;OC607&Z;W/F!7,$4W8;W6=X)I=7=L=7X8_%TC9PYG_T>GF>OZ3YG>OK10
M'AD6NV( (]< A?$^^R^-*IX,U6.$M(/X],XZAO!Q/CF$8F<1+'C=*QE*JX,7
MK$K6KX*U6H8\-CX'E0-#_%:#H[FBY'8[-)5[%B;L"I1(U"WTL<2)H2'J?&E*
M40PS'L&$2);\BB;T,8CTHZV$"N^6%55@L'  MS\3(&_TL";I,9AZ(HE$1<IW
M<.>22!"EX#+8J*@$B>MKR*'WSMBDZOE#6RP ^BTNK\)WFG2WKRB'R'<#LUR"
MA0F'A##$%ADU]Q #E\W+AOC[*?#RZ#6ESL]K<V"0%P-STP640\ O6LEZV_=J
MA.X6I&%\%O;<2;+W6MZSAOC@PS_ZHAK4C'%UX9[R6/@&.)#M[_!U:"C"%'8V
MS?/@584*B_GZ=>#"M"S?0Q?F(FU-0!U,SN;'1 Z>S:_UQ)8?!^I^R#H;_Q"2
MC8TLZ)5MK!PA)SX++(FZ]\ (T-MR7MK%O#@9[AO;;;$\T%H70QR%.$+? !#,
M7/G-K0=92BP7$=I])G^GUS)".D <A:@B1)X0]23<+5)+%"_)>HG9M#3- ^(5
M6/9&S\M,<9X+>/QS>K+DC/ZUJKZZ$)2[TC-0BQ^W5OL&S(XF] H'_J)>:JP7
MC1@;%*GCRO7M"I1YRO?S%S:F0T(?@X$9:ME"NT.)F$!TA);K%P=(P/14E7L\
MW '*MY)G^W?,[6=4B<\"D+]R=88#@=\VGH4[&049W@ IDKQ38F553+('H\BG
ML^WM$^#DZC+\]!74]*4";1" X]YS!4&=C+[<GPL#7IL+)SL$UZBTST8@;20D
M"$N-4R3/P)@@G.Y9+[P7&M3ED&HIH-V5PT=^=LPK^G=CJQLM)7]N@UQTJD"X
M''J?64;;'W3AQ1UR1'G**T+9''^^W,.50UGGW'[NC#AW3I)L3VK*["Z''U_@
MEZ0*HW\URDORV4@'0\X5VVU#"R5#_?LE 4OT0FN5G#**9G8Q,518&E*70W*X
M5B0_1$<(= DJNEJ"]J1X"\"0^8ZQ):BLU62[K'NOE2-"$EJ6^@?T! E^L"(A
MA\,%" U'H6_/"U\XP/1\BD5T3HAD7=O-N(JP5A?@&E+AM;WW]TRL(J#3_F!.
M-\R$5F#3?:0S5$H(T&:'_5 )!N>*JZ@MHZI@K?,=M2"XE44V?(8?A&'^T P+
M!)I@C#6_(F""H_P04[N$#1PE23HPBHUA7J.$\\ !]3L43]J#L 7!\%(\+ :6
MK9"2[0\!KY" V_N6'0F7E,$BERYV;Y*>)(8H/E7.S&(<K':SPF $MJO@* <U
MPH$Q!L*2=5F7'39!M=KRC1]YT2Q8M'Z$L^XL<PL.60L"'XN7R7++4J*SR=(\
M8KW&P":_V<5$HN!<-G[9'H7'1F;IEQ#;>2IX?)W<Q/Y).LM]LIP^@90"'59*
MS>8](\'3(*Y$23Q+QTD<!CM0M=97?0MG]#WQS.$TXIPO_J+WZC%WHP^CRW3S
MF*)34>58]V%/WV-B[HNB^6V-&8DFG=XX5]6DE R[Y;YK; [MQIBE2L& ;.,M
MU;&?0,.P$D>\?;ZFY/O=2AG,\" BG<!SJ\"ZT".'$YU?;ERCDRB8+MHMY_L)
MR54GX.WYXH_@ZR3#QG$68)LK:_EG\O5+Q8?N_&K=RB**/:P6HNBQ&H$6*M0O
M'].:L6YL&+E:6*D-L,DP!YL\8O\R? _/$:)^5.!CG%3/<$1^MVQ:V?2KPKK9
M[@KT_A3.(9<XWC%M>2WXXZ)*V]1NM(P:^OZ&'JR,]'1#R43A64-L-H=@'K@X
MJO1KH>."]:G&J!O+I4&$NVKE0%NE\OS^>?<1G64.<Q_AAQN:HMMX_9X&AAF<
M[L:EWTQ@/B7R*T^K>><1LQ@(=L2RD:)++@S8(0^#A5LQ*83#_'<SN&QJ3SMY
M2"I99@5I*(B5$NTD/36/UB=S?[5=B]E"D864G[)0+'4#="0-XI"P)/,0FDML
MM>QLLAU)MXUQM$U3IB8:$9+_\(-!U9:A',YN/R %O#<!=\1B71N<<Z[T?>LW
MW8WTZ[+H>-_DI^,O+_5!&6$Y>0L$3R9O "OB_^9#QE;'5B0DQ&J!>_\<@)RB
MU<??A.+V=IO,H49^.=]JF](Q)566XS3=;G%&1::S)+ES7QR&NI.?>>'$T?8?
MM'DIW9J@I]YLH6<@9 4GOI0)7;>O?U4_%ZF] 8C,8OO'Z.E-:)H#;:R:/!2G
M-<&C28L_2G8RZ6F,\I5N X3'M&PB:W/)"Z=>KO2FRC<\$_ H^R2X$7(Y3O15
MVS(03)^)TUS@F+P=8IM^Q\(DN,&_N\UR;1;)@*YD4RS8-+II(GJ<O'"G\?C6
M3YK,37X;&="WMU*EHGQLG*X 3:&RZAA6M0T0'*,/Q7)-Z0X2Q7-T[W!7$/%5
M&)>>)BS&?.DLR[+ _UIMM)U/W)P_H4VN^S%8.R<WNGB)<AP75]R-@?S)S,FA
M/AVO?>JH0:C-8^PS?EH\W8FOU(BRVU>?^T4?:VR4L;555OE0;]E4SH.N"4=L
MPXTLRVSXD!Q]_M7WUHI6VVOVJWAH,EWR\QY5&B->8^G\II9=WTI"_UH\&^4X
MB]SK>L;%5&7EFU_YQ^:L,JK9I-&83EO227,YIH_)ZV:)\BK,<G?V'XUK$=S8
MX7A)<37DU2BSILO<C=)I9C)X>/@;I)46J"4' .S-V>L6@WH7?_!=-N1::I:\
MALCHE.;#%@9/B/K\63ADGOQ1N<6H3N\$\9Z\UJ[E7RZV0/I[B6^ ;F"Y<-#L
ML_KQ@YOV]LE:V+9SLNR+Y6/!XT9,\QMPQ_AZ!@G$B.B67WL8OQ&_>LJ+:7\#
M7L:6>1ZZ_VT/RZT%A426\]S^V^_*/GND"5!9"[)NB91>Q2EG;/JK0$3:PUAJ
M\")A3EZ,?SON1^+SJWF@+3M.E'.W?Z.41G[3[8IF0Y8!@3^X:",5?MWF?;-L
M5NPTZH&()/ZF)>6!%O23UJCK6=5PD21AL]YLA"UU^RTN7<S%;[DHW!H3@Y)?
MU4KSL-&QQE:%C5++-B@#<:,QSK44)*NV4Q"&XCB_7P\T[Y/RJ86G-/N;N:HC
M_&FD9;KC',XB-BF$\N5HM".L',=Q3KDH$AMF==RINT.2XBFAHQ-K6KA%LKFR
MF%O,OP2,9F,?\"D2]_BH# V%YQ51\L_)C1DG2H2-IUE4"SD'5O#'\=@EY;V)
M8-]U62P@46C*L9T?9"3]D%7"'+FOU,),""\TNXH>R$29_NLEE57G)62W6 XE
M,#ICO^WB[9%_F7R'\I@6HU.D(>@JG"7_'MZCT!:LJ6*(%?4E@Z^T^;=BZ?7[
MLJ</5PX_6<7Y26DY<2WTCWD,N%&_SGDBW*3M,$97#JM2"M1_L/J)<HG0B^*>
MT':ZAP>+.[#A!" DG0&6?J2\<ZLUVVSG"F/(BHN@XILA^#3+F;K4*"&IDX\1
M\7-&JI1 %-B84OXR/(*]#?""D;OUWFNK]HS\O3ELYA^2C/<UO%5:,*ZHP,#M
MMA.A<8R!]4#&#0J[' MG J,:,Y4N\AI*J7JPB[52DTC;<*H4.H01Q]K&/#>Z
M-F"N!;81^^:8R9^KJ\[OIGL"3^W2[&26^VXB)SDF)IP-BS-C=EMV93_5NCSA
MSZ)/CGJB&VY.6@LE=9-$SJ_FKDAF7J]4+<WQ^8/3"]<(Z=#!*[IOGVCW)5HQ
MX>4:)1@N(3-6<EEUUF>21KIF53>%EK?F[>6E_*$2W34S!7M]KE?62GM,JHE2
MFL&9,'^\A2J0A+$U5=>B[*=?;NWHFNVUM(M=TU;U=+@EG9+N6LU28<X+"P\G
M\.0&BDM".@E'N1F""_>8@W_"%_-Z[)NL?8[N]WX(BF3)=\,T)SY.CMX[2"&]
MM2DR4KZW5)@QTIDMK-[.]_^!]NSR[1P/DXXM;>1LC%_/2K\UP6;8MXL;FL6!
M+G5Y[?V)72TR@F9CE6DG0TEGV^G7<).CI4%UP3H71:F:H@(=_SP]M&-'ZTOE
M<ZI[SL?"C4^X0]HFY&Q#^IBHY"XP9/[Y,.P#KCP[CK&",.%PKE&=?8D'=:!\
M=$>U^\G+!..6(4_W$N5V&H2/.(70*3R/$%AQ)459=_D<Y0W(9_),(C42 @YX
M0,7],6:4L^7,P\SVP>%3$#2!LMY%^D?-^G0M;W86=<"DY;T<M.R]98Z9%\MS
M<<V'K+F#<:)15&E,:0[OR-C7-?\BT13NO(*FWRZOTD-EL=5[\!^:>UIJFO4,
M<8IIE>9MM$YO-89:4PM:VS4+.S(+-B JZ,D-/!5NN%9LT,LSKJ *6ZN)2DRT
MI-2XN&&(*;F4>:(BJ)$S)S(LC,?@_2]*1LKD4$D@EQ)#F2"LRB&9G%R =0'1
M*&_L6?/DZ'A4\O(Y +%,F:KJ!S&77J,B"T9,3N_G%+QFV[3,:MWL)STSK$^(
MH^@)22W<;BLF/M9P$[3[NM\M'@#9GG6>7=;R&E,K?\VR3FN<A(9N:>@Q7[O&
ML?*5P;42S0;'*!SEJF;'?68(\DITL*XI_$:+[CRGN3<2D^D^'T$<1<US"C=-
M28YTPN*0+CHZ*0;=XB;'R!6]UA?9>O>?((O5889?_>>>VJ6(D8H*/CJ+Q2J1
MR_ 16#S59_@+I6Z]7=E_U =4/[N#)N*E\H?S>!9QJ@O4U3[T<7R1MP&\#FQU
MSZ_D*\?8W"26%&)RH.1\L E\@D;C+Q(&A^WJM8.RME!^2^KY1CWC&J>BYOP*
MV/8_^YI>'5R?A%W"D]ZI:)J#^I1[*T+'R3I4MEO#(<1:#V1E+%]NI$@%_[(-
M4;5"RD6%0A\?_8,P?9Z?F:]DE:Y-*X$'\TOM-^ Z[^K"G_GJTRGK L;BLP:9
M,PTB8O\F]6O_BTK"*"BF>ZE;ZPW0/HM")#-^;Y U/O&!:8$P%2Y3&:NU6NQ]
MJY,),"IA[MAZKH8+7887*YKV:;KH'"FDA"D2_H0^J/II#U4#EK[4A4YD(%E,
M,D<V,QR4BAV<0"=.RH)0XZ8UA#436 Z7"8@A".(Y"8N2H&>!?0L=8TJ?/-F0
M^0=<,<+L3J@2>U5G(LNE>@WG8:%FW^_,6T-B3%GD,=DR\J/*)@UC0=[K<(>K
M+:-B;IA<AI58.)E(<.>!8#!LSA-))-Q>8Q2*Q8HZH1@.=F8XQ63%6!X,MVO2
MI$:\(9&=O[A'5*-QVGV=)XI'BD:^"DDR+.V*F&(O\163.FU^8A^TEE>3"%U&
MCSLLE]Q.F8C@CVZCEH+2-R[I:E^G#$HZWVO,4046+27^(6U$\90(<0ZR-LIA
M -R%/_Q;*O( QQV19\>M7-CW;$(%C/Z+E+3..('@TS7M&Q JLFGR)/"BW#TI
M*ESST1S$8N$H>5PF!-TF*?VK["'\J:7HV$IIL>&G[!@/4_*QE0"_H++H .Q\
M]Y&,N'"BA8]T,<J.7'EI0Z8;#)*0U\^B#1[S (ZMU5*.(>PV%*=4RBLH[A/8
MH(3E#E3CA,&SE:Q%GPRWCR5O*XVT$5H,B*DYT1-,KX, "21OZY4\'\,8T5BD
M!'!J/N7[O%Q3/D*T"5-,SK@8RUC:3>?O S&;H[ Q8=U/,99L&:D#(QI#4O$>
MP8-8%+<JO? "X?2?%85TU; HB\V0,=F5\_G8(T0T<3VR<#6JP(72'RW5=03[
M^:0J6)=2T57 2$>Q2,$,I?9\A'*F4[R-)%+*YB1RL\#Z,+MBGMCO?<5@8EJ)
M$"EE4W9HT -]\UH7J"LO_F4M^ .A$![9PV;'Y2=JLF?P&S#YO'FXKJ%'Z*])
M&M+RR JY"P1L3"XTO-^ Q9>UO1T!/_4QM\,BYM1ABGB&)1PX0ESL&'%!?'*A
MT/+42B!^O6_>7S8 ZN5L>K3BZ,\NM4=1PKZBH)9]O_QU3N,?98MDL)V_(Y,M
M?7)>BHTOE%):T16AI&57ZYR982/LA[68'7=!>7S'6HC []>8J71ME(G>2]'^
MFZ&@Q0I!!XN]#75YQRQD:GJ,WO"/5 1I'E1<,E$ <$<4!]T/]1,.K$"RV\8T
M ?I02G7"+77D. 1CN7Q!Q\/@^ WOS=J!%M1QRJA 2I8V:);A@%*M6"\B)OS@
MCX%R!,621^9P)-7?EW+Y<,-5IXS[S\KKOVCH*$,BB@!%!$PXMR%%&"FO1RRT
MGH)#D-=F&;;ABI$DL?(B#DQPZ5]A5RQ6<?:1F;N9LQYVM ER4\P#,C(5%\AI
M(1B!L2<5A6)*O8/D-2DLI]N=*89B6M)4$4O?'*$?R'=<RK;X;<'+)]I&T*D2
M[5<6P"^7%,XO+?@^% E7BA<;R('2U667WYST5S4.!C?]I4])Q%%9[,PG+[0#
MJ^,6.-F1=/QI33WX@Z]2-*W%A@&))!9#8&_Z4D&#*@1%G4M&@J4TP:*(H6QA
M"P[.?"H&+<=O 91PS4^7J'K((B\=CPWL8G(N"[GS2 #5&.T5?3^>.H8J%IP#
M)<R<8[#D0'1<7[_I&?94K^F!1EM!A>"DN;N#%2+.N0@E[#LV(  )!E+V?0%G
M3+@FJRP'A5SZLD(RIS!@\ (=/IQEF/[+A*>"N0.LVEU@HF/S7T^+UK[Y)).N
M>&E:^3%YGE@+IS/S-%U>1A3Y4O74'16X:#$ 7@Q)$+@YQ/Q'+!A#'##'XJC:
M,NB7;-<3= TY@#=?#KP<P@%YHB\&RH8-C.0/7F1<0-ED;@"  [LCA8;Y-&(Q
M!XN$AQ;,JAJV9\HYMD<Y$HOVO<,<M=<7RR;IA5,>,:&8-,?@"(?AZ7<&8):1
M3UGZZGTN%Y0Q[+YFNA-D*9?]Q?\!*U21$*YN@EZJJ'0C"]W9M?FB"D8.43TD
M?@,*$X*#CCI%6+.CDL[TP<FYP1 7]H1,7<*GU&$8BB)M,BG4\JN<4DQ,S*/=
M%B/N3S:96<+OCPY+* "EC(8I#Y+?[.K\E$Q2<@,_YZ7$^E$07F$I#:'ABSTC
MGX)%\GKS*3;W8U:B)]R1>)_GY $\-M +-FT>A8+@U2.D_&+AR6!(THM#$.!O
M>Y_#CI1:*(A([\34ID #[&,"Z[*.+;Q5T2*G#F*_9VBD_/KHY>U:2K_UNZY'
MI/$AQZKE!".R#SZ=M2)_]@6"+QF^R8F #L]V7[_L_J?B,^%,=+S^6\_A&X6!
ME+EP@I:Y/E:)"ZUE[C@8\%4D-3J<3D41BWL,_9Y !:TI)CFA)#3R1&?AE:!E
MAIK#TE>MC_YC/)?<!RV1+F[R[\4'VI2HZQQQ)MH8Z[P4\;0>%2HKC18",0YJ
M\3-%[F?:>26_?^JJYQ9%[;DND@V:.D'?<S6!%W\S!AG&U#)>=PAQ7HJ[IC30
MDFK)9::7>G]8X/@FKY;;ASSHO/04Z,EW^>+4P1S=8%J<*PO5<L )K6E  IK7
M:S#R=2V\OJ"@E#[AF,E$MZC3R7,;]LN5MR:U5\38N8T2ORX3/BN5@=CW%#ND
ME-5NRDU&;N;+P+-*JE!QL^'O=MHX/Z#P;2D9?MJ=_&H"=N\(KS-\?R@4FB?X
M9"DZZ@<+NEERD*!Y?;>='7K49N6M&-1C+M*JU]JNM&-O6B;K7RJF(/DIA^>6
M_ZQ?C,+F$<1B0\T)04["(8C\U[RU<*IZQXFK5^I\QUC4&.;07>Q2:>3NEIUH
M^1I5L=P8CS&H*B?X_;O&Q85;S2F_(XW>%!]ETE3Q3'3LM8P4!-$R[DF7,[>'
M^G"LQV)XN;N.J)P$^M752+JZ1)2;WC-$+3J3>?F 10\^BO.*@&TBM%T6Q\VL
M,*J*\@A3++K%*[33@W*#Y8%&*&<K.5QE"Q%,F.^>D8EBB6(85: LB)RZEKF&
M41>;XA&;[ ]A(UP?9KM*19+XB_X<#O;![7ZW6?M+R) W^/X>(_A4A+3@!J/>
M9WM.E:]18*KR1>*@8S*^J.C&76\!0<"[S(%P#K#^R(7O-J1Y-*QD?27=_T<Y
M)'U@EH<H/.-.@7;*I@&*_?V<+VG' HO!^BP&9B"#766\AI!=V:#>:GM=?$%<
MDMW-K5XP%9UYTD-*QST7MS<2-KBD3<$L6D%3&Q%?^Q'S=>HU0ID+/^_9W?CL
M*? -@/L_"0S2!4RR$"N]-V!N2<1Y?"1O<SMK639PG/'7AE<Z5'Q[^Z&JPOD-
M"%+.HR-BECB[3]-R?,VC[^%946L7?"4SAT:\ZKXP3C3T/!'^(GOT0>OQNVOM
M%W]-QW=^;1Q_ ^21!]A'\HHAM0489&%^29LNC_(BKR(U7=_R_W.W&)CAY4)F
MW-GI?%]K[NP,/2&E'F_\T6LHH"/I?$.^)VS4[!PN4KKF$G&:3^J@&\BS!FBP
MT*RM/%0%BHB  KYM0 -Q<A.WOS\EB*'M<6!&;H+B5-<.-B_06K6\-%^C="4?
MC\:$_^GLY.T;$/G:DQU+8/T&_-T^EA/.*J-^,=(F(Q@AX_U>A]F3'_ &$ 1I
MD=;<V'L<]<3_+'T\.\$@P_@2A$XKB$2(O,J8U^[\\^LJ)'XC8,IX_];U+(PM
MP3[=FN6 =:_3<;X#>.0N&42A)!=,]5KN!6 %$?IAB2^Z)U<8;G=_H#$9=:6+
M*^"@#*$,CM6:*LXX[J=G>5FSQ"1%T?W6P $.X((AXJ#;776[\'[A4NI#8@2F
M0K=@CT,>X5L0=*&[;XO8_YF).Z]G)\I4N,=\SVKM#3#^ON$O).J/N+O#VQ.*
MB793D\^2':S!@3&TD^2U>4%FM>%SW(/P&I8Y$%3LNWE?TT.LN"GA?$]UVQIE
MM'"Y6E#V)X&E'H/LCEN9V]JF]0U FOP&+ZP;1.(?B)6.WBT*68'O[E%$F%;^
M)H#^^M@4%N1HE?EDT"WX/#"@?>9&ML/>\=+10+#P=S1C2UC$94?UZ4-/3DS)
MBY=!T/"Q*\,SB0VS4BE5,*=K+ W/?>.QFJ^@6^*TDUB^L!0JC0K\6I0/!AA1
M:9BC@_G,Y3J.D\;T&U<]E#>T@KS I"K]O>1.KK1!$B>\L RED<^+(NAR)DZS
M%9<_5:>O-;*AU3Y#/GU#=?]4-<7EEB##\4L"FC4D0T996'' 9@QM[;.F1 EK
M;(F=2HLV#S$] 5855/I'_6>4\O+PG9K<\FP)=KLWP+$&;]OD)-Y/E+$)AR>X
M25O3WISJZQ/#O.+9I%6)L(5.,M]E9D%X>6\??<YO4U5JS"ADTD.B)+7* J.7
MIQ]W2LN;RJN"HT2L2JIS,!EDAH67BLS2)5J!10:>DH%LCDQ\V[H_"DJHC_&#
M#5.'5.>I^:7/+!3WCK/4N!"_9N-XS>P2^Q&6#S^^&W^__\EEEYI)Y3K2QQ6,
MX493:C@TO[=;>MI":&DPJ-BM&$*X<6(U._-;5;J82H_ +-MHZ':Z?^6J4\F>
MQ*:=Y!KZ6;E%IUU^=86S1I>\J'K%^]-]16QHK<FJ;N$4)UJ26Y.1YG$YW.V^
M<FOR&=)*OZV(^-E.G-DF)W?=1^43 <U!S/<60KGE=@[9]/9ZO]O-J"]>)5K5
M&Y5JZ?\J</K(,N<UA\J(6RMMR-:(LO+\I/Z0B7N52GO )H=$Q#4DSL  8K'D
M.:8&A:,(1EVE'/JF=GFON8#N1RZK&A<-2DR>/WN.K?#8HOR$#4.Y';*IKU[9
M[9<>8/_8Z7(ZH5/:L22\?*["J!'OB5B L^GXL#KRTGV+FI!>3PN>%DET:"L!
M2:PEU4QS#ELENT-<<RJ92(H/5L_KD$7ZWJ,^F&_)7>Y\%/+6D/:FIO+HNPPO
MT2\IGZ(7E*$BUXAYKFBB^O$A$\]A]$CEG6$B!$P;J Y&5$0U+Q<'T[02PHNM
M3*(SU?PW98']GY3%:TU0R]G3,WK'0-A_<B+_N2(+AI/^;"+IBL-H2-I-''ZM
M&_"-&%=D<VB NP&WY+2A\VS+5LC-J7NF:?Y9 /'[P +TNRI<BZ52RFZ/.N#K
M"V'0%O/U>.@,%+\ 0=(%;HWV T,6ZJ\WRR[OT3I]GS=YC=@239\5F39?+"'+
M0G2H Y2.]U%?CT&#/'/N^9N['^1?N@*56FY=*Y]0PNYS5SJ%@OA]MC871=/<
MW@#1[9,=Q0Y&.;@R0:2H^%>;MF6X':M[Q'*(,=E '9+1&(8LOG'8($*!*Z_A
MXZL]-<\%YDV L=,&G[*79.34.<5IXHCIWW=))ACU,+M+$<Z6QH=AJ8AE?S53
M XT/NGH@+;^?S(<1O[\!M?5--',#7'O?>I9K1<VCC*=%WH O/57 &W!B[P&"
M!$"ON)8]R& N+RXQ&@:AV[ P'=+?[Z+<#IHWX)RQ$HSW,1*6_F*0+HMA#+E/
M["X%,0YO_;-[^BR(SQW.QSL'3A@[!;6"@66IZ$5+9>U3+4?'3\*R 5W1+RJ(
MEQ]'FU_8+7%^/\_@BC"WW'@>"C%SYZL\JYS2"GN#A(?C?P%DV0]7US<0B7O/
MFU,18IG-"PFXYJ8?[\X^1(JM/65Y/XNP='H:A@6)3YB^F"^^ 4..]X-60O5S
M1!K4%B]SM3R-K&3D36:4MJ/(YQ-AU _S\4X;]+0G7;J 9ML2HV4*%GFF @T.
M[GO"@.+O\:?WSA^]>(]:Y*^;I2.2W+(EP-EJ+)UFG?OBW&F&:M3$OC0"8X3"
MUJ38 876.(?&RH4F:%#6W=Q'/RJZ5]%8R:73;>ZZAE?,&B&D^#?@6YK^TC\+
M\]6V[JF;^9G//J#6!&9Y>,_[F+\#*RKJ>O.OQ?CO8S+GNJIHZ5.[S2U9M77O
MYX7U0)%O)Q4G-Z\P@U47\>V&)]=(\A^5:G5C07;O$D>4/HKR8]N33E1B<?*Y
M-&20%R=)[:,]I?%B 3#K7MN5QIR.HKQ' RIN\]:25,A$<6>V/!ER,%K)9Z"E
M39:P843Z,42QHU1X]']JA;X/D!+U6'J,:/T88#;5Y!20Z9(VY[*0<Z6"B!,3
MD[]8V8#=8\J_I.F5?Q4LMQH$9UR&>1[(WGIX16CYJ9XN6L_I(#2HE:N%=#47
M+_9[,-UZI;?J>F.9<NTO%Z^RQ2<S6+D2=OBD3V55NK!UZLB),ZV1MJ"4T7>&
M--K!?BQ%*=YH9$0VS$B;SI)* D?G8$I]\=SG>=X"*N0*_$_FJEC4+,*B=!9F
M8C5I=F9=AHI2BS2E0K_:L<OWHQ2'AI-'*U3(_TK-5TO=TIB#]5,-_B(FI>Z@
M\J^M$0-*T-4)%4W0)5(5Q''01U+%89W;;3&EI"1ZI7%SOLEEE//'?+4E'*)/
M84<J<Y,::U##3<'MV"FGS^(@*42D5R10A5B$J%-2<\CGNQ/!S\)/*P%\YV:T
M4NJ*_&AMP5N!KCKHPA?E-(KR?Z1QI^F\,MT2X:7@3-!:0-!>0+:N>BTSP$S(
M<%?VMZ[L]'(9^9C,SAU_P[QEH&H_7UJ]),O.8T$2SX);2SVAV41.(K'[4]'$
M?*\)6C,8D835KN0 7E+W@\T7TO$SM4-G;8+W0UX#L?JV;P"U>2L!1U3LB4I.
M=I!8I,<C'OBJD>H']28/$X,=-,FC#9<]'+%C1?_,#Z2Y0WOU+B3-,[1R@7SB
M-6!,"7T':A4XC(#"K!D,PUU"4Y*;_Y.-/+/,HT"^00W];WC-G>IR O$ZL8J3
M+F69?IMP^93QFA8-:1K1=[7*D?=?F!.KNZB^<A!QD$QF@-H4I'GH0SB1J#UN
MJC?XCT?C0EYS.-$X67Y4"CN367Q6<3G:44DPH-ND7#DRX'$0/JX &$#3.;DK
MX0JFV,'H(D.U();%S%_%3/Q+'P9DS?5/C9B[A#T%Q&B,*92BIV,KY%-,V<;E
M&-3AN++3-!8_96X52'?$'UF6-4E+'H0!0'ZW:[NP4X&R9)H&J+ZV,G0T)]0,
MG#Q*6(EYE#,$_&=0"IWQOQ.<FV<J['&%L;6"]Q5ZFTYYTH*XE!1GRXHB&]VF
MV]DZ2CV6<8>(^?CJ(-QND2K#CXZO <^!+!P?(&#BQM*IGLH'1<R'@!O[D-MP
M?X''>V-+TU>: YV+PW4Q 8]786/2+A'V]< I0AO1V?Z?__H]G:#';3XK?HPR
M,Y;V1X@A;SOHT>-Y,-N9+--G(2 BJ&0S1]369_/2 HIMOZ(#<^'>@%'WD\!X
MRSF0=> W*-$P5=C5\E[*&[-\_<L5H$\MBO'W(N<4\OJI]7KM,VJXH!]O0]6M
M*'JWT/]$%Y@*7CSVR1Y_00A9IMZ W_WS&6<+R;YO@$G/ZI.0)$+(&_#)3XM<
MT.E#4[OCU?O/#1@-/2L[%FS>1U_L$&]/[%]9]"\VZ[XG6) 'X8US^BM?UK_H
M#22055W]V3W;/>%SO"__>+;[QR_A[O'TZ:XG*/RU[ U0[!/IJ3#$."#C^[)T
M]@@9<.H68F[*6_K!B13L@34W;VUX>_0GS.3FQ8C*_IX"> 4%P'ALVL6+WYRU
M[(K?^!QW_->%/D)KWH"8M4ML4)5\"*=(C!JY&S7/<]R_ME,"5X8G)S,8,U@M
M"MF@:GK+J:@5R1.=U2LD&#WO1[RQXTXW\?T;\!'_F??&-?8,#XPC*> %!DZ)
M@DA.100#M3X]&_6T3/,IVI_";1&4!=P>I1[_HMB"L?JZMO,0"*V+;%D]A!6.
M518.RG.B MV] 5.T5">7;P O=O3RPO.>)ME)[>XKK_K=W8Z:01ON//P8#<MH
M3 S)CEH2!Q"%/&%^E0IT.(DD.O<,#<@OH83^ELNZM$3-C)HVOK,->1AQPQLP
M1T(62,DR$L/.%-O'W$ST)B7D258V/X3C!)L>\VD:&;;#(!_H_TP&(_2J)0HX
M$'L^\-5992D("/0X29Q_(_<2(SL,#S'(A<4<.&'P[XY<0T+*] 8]2GM?L.K?
MZ8(!*13,Y& :M&8VM+8_K*+B6/MHP1T)8B"(ZV[]K_^9MB9:;&5UX>N0;P\;
M\?HH_9KQ3@FJ9;OB1TOK/T9'T\_M-+,X67'U1\I\69ED'\SCT?RJ-$%9>@ +
M(1$XVLZY]$34:-P)X+OM[YQ::DXER>4W0Y,UTVUL';RS';8.;M>M.9XE(:JF
MOL3Q*F[ZC*<K0J6Q3M#][%($M=%;FN4\,]X1TE24<$SC@<:YER+]K*[FF%&V
M)N&D9>E>JN5!HIX(GY#EZDJ*U2\OH953AQ)TL54GTJ(0\:W/LUJD%W'S5WQ$
ML!O32X2B%A9/MPR)L569T]LP4H.<F!8/^-Q*>1!Y$%%03<UJ[(J2,>4+ [T[
MO]AM?]>2)KWGS,1IA&IGCA-/E[/>F!L5-15;,M D2ZA_PM-79DMLG;;'3$9E
MPLNVF_6FS_,RDJ^VF>-4]VJ(C<G>91HU=7E')=WF!5A5\)W6AFL57VS16"7%
M!5=^.X* =-8%H/V_F40S&M?VQFW%UY[WPF*+PW1(XE [;6>=#>Z(/-(<:<W*
MV'VUY@+BOTMD%GR?QS>U,W TER1ENJ65Z1Y)1\1=C5!X9T]\H&R^SK*JH#T2
M]?W'8&\68A(FQ["<MN#7N]"6P%&2DYOCIC? _&**6[E4J^_VC$.RUTZ2 9N7
MU2HRE5CO%CGF\$$(I3[YTX([:;D4;AR^O-5H2(;('JD).'(+;J#=,NPTF5G%
M?UR=J&M EOH/IF[GBZ5'?&:F&'QE.&\I2"CH?'?NSSNGEV3^I9,%^U?H3O>%
MU]8;8!#O0?9RH_=R;W)Y<>.?#_(Q$R[2\1W7F161S4W\R:^UNO U48R-1W;&
M:9>TN'C=%LD[6EH*%]WB[C=Y2#NR@LF:4TW_OD*RW\J,=3/VD7.\W>B!L$,-
M=U%J<I4<T4=F0XYV_U&?>2.&!OA]'8BT&R%Z%GP_-?V82(WT' WD>_.0U]^#
MU53KW/G%HQF89S5-;F5^GLZ12>5!=0([/KA*# 6DRO=_J5&BQ?(1\(PL"I7;
M3E]&T_?J6DH;8K/PVE.'OWQG%A'[.8R&Y;)?>/14[M[*EF:>R]W,/X( B^1J
MD:I+KSREV& I\0:X1]MB2<O3<?-E7);4?@11262.]5A5\;).>K8UDU[O_:NA
M,)/-R,^91\X'@D0W84*K^R[A,CUE=':"M<-\\IUXB54+J5A,<]I88F<C^5^#
MHU!H&=T2*V"\5*H<RY_P;6:]#&$MD6FUQP,T$N^=Z#UW&2>3;?H=*F7&<E0S
M%!3H)5B2O+!Q]3/A 2G^-DAQ\JWGC"7SXV<W]BSL&P6DU;E9/H7B5^$&FA"9
M*8S.&+<D4A6+&=@K@%M4+;,W$T-UFV:E23:U:?M$4D8[.XU=[IXQ.T6HFD\I
M]"JZS,Q@V)K:^Y).[O O8;\).(0_5JB@(8;VDY>9AD6-0XW*Y=U'0_8!OW>7
MIEDU@@F6E-OPI4N*^K7?Y^/5J1OF_J3#CVBT39@3I'8 8#^^BL;%"O^(]WA>
M;0NDW*T6:1KUFANRV*[;1*OZW*J(\;FT/KM)*V\ #1AM#@<DCN,$@%SUJ$I&
MQX\_JFK*+-D[$ ^WI9].-R]GG'[0W?3[)OE9LN5C)V5-NI&8!I8+DWQ[L"I:
M\PZQ![^J[UTS5,M3P_&V]2YR :\AB3EV@T-Y4#/%EL,U:!_B4&5,KR&,IVRU
M51 LA03/&SZRS>!^N?@KL#Q]VY;Q<NRG+O;A>Y+%^/N&$^3BB",SQ4%#1%96
M@;[1-LA2O:M5G5*2]:I]MAW*9BVZ1>I?Y$)O:V?"AV7)&H2&SAHZV:@[:BV[
MK^3)0D=I$K!/#I2FF+<6O@9Q03\L;UPW#K8MO7X3JW_Z+74<Q2PR#Y(7@G\J
M4]R1X$.='CP0&Z)C"-ANQ@'.^6+WE?QTSM"T\/;'ENS=NADJ8.BJT3/;LISW
M_^Y\%1X/;;:;+D[ #EGSCO:NR)12-$5K53FVRV#57BH%1P?XM*XM>H:H^Z8.
M)<U9)RS3[IR)],;N:GV)%?5*D8YA74LZC+'0Z T8[P'+E#EYDAIEU8#>4S &
MMANAWC8EXDGKFR__=M)-C+Y1X.8!\ZB,T$]-5^*BFI+CKJ&O>PQ%U6O6_&*"
MQB?/LS@D*/T4Z&XCXDRO*U[(THP7VQ>'7XH6&"U.Q*! *9@T 0/(L<(^<;]F
M2 *8Y2>^"A(II@3VI*NMN/-KM(K&)0JI-%D;4]6;L-?OG8>,I*$_*R <G,L!
M*MBG!#<MLJDA0[Y6>>Z)M;<\C4O+5#PUD\()>AU(YFPZO;%V:(7(E#&6\(/%
M?]K:"15,,0_6\.J^,DT8I;BD5?Q\?>";E&0VOYXN'Q6(]]:)%HS$<4+RV:/<
M0;GDY#WOS.6LA25//F!5P7$-6Y(F5>.4\[%:W+EQ2;9ZHM-<*U ./&I/BPK[
M%M 76T4KUO=],)V\LB#*5#L1W=V[A(U0[,.F?1J+QDN*DQ.IW[H\B<-0##$:
MDY'4YUII@F8NN?B(+.3]X$J99_]():/KTNOP?!(Y9TM:IGK]:XAV1OS$9XGD
ME8_OTMC"*^4'FJ*4I(J5I?'EB1"<-O!D$<#E^>74<(3K0VB00!+EQ@::R8I2
MQ7$365$K6TNSBCJ2PC$97Y(: _K-?*,SEX1HJOA3%$JA0799UT,1(0Z4'.GD
MW96'M&K61N[+2L\)4WQOE4.YNR3.8]8/O;OGH2Q%>(%M_(-HAV2M[#&PW]:(
M/6ES;9(7#7'V=+5XUYHT?\B0:<JJX,T5KG)XQ"QL@)''2^@P&?CD2BBFV?60
M,+Q<P1B\RDPV'-&L+K/,$>-,$*]2;$Y\^?+M-/%K=Y[O8C6^IC.J:1(RY!:*
MR>]8W21:1,%XTDCBRU+KTGD7O#^R/L:RB"7$]ZR#E8FDQE@X\"QG$GSN(UJ$
MX2AOM&?LTB2 X'.U:YA-)X$R5 P7MBA_:DX?@" 3BIR)+O9Q$$(?,'$5S \U
M^PM6%L<"V #GKDT?1J^^9P[^I=HW8*YR:?1U#N$-T @4):7_@_B_9,CZ%?HL
M4H9W%_8?_3OZIW__/%CK&W!P<;GU7TUD.CI[-=3J+M-Q;IE+D$0%V5N]%*4<
MTW%U,?(B"VM^.?IZ%9=;NK[ESFU(>['5'M4*&XT+)C8%1P%(%_LK?[^XH4 $
M(D'0+(FK/%.L9?AWN(CY?NK@YVXA7I#:%B&SRM$;P'JT S5-JA+?'[/XR2#C
M!JIT+J; 2L-)G<4:Z6"P%? R!BN.\>JJ45+" DX2GMN!+4GN3O@+>R^L2I]3
MFO2%"-!UV6\S_A!9DY@Z"E6)NVM#W9.*'16\6K^G&:2-X/_!OX(ZH<B'6%16
M>N<W6HB2Y4<$6))(#V1!_36U8NT:MVZX9OW5HS]4; C)4X8%WBN[APP&DY2Q
M=^231T65B[>_8T?5P*)/0=>80$Y$E;@*X9<C-QPC"89?+H09 XR!M9@' 9*7
MWRX)/D(=>1UTH@4]="7C/P_/A;H"0%#'%E+FVJ_^$>BGV8B?Z]TR3#;>*0AZ
M'+7YHO^J_49BXP^X$V\6HYIBTOKU8 934HT9T]1EI_ZSD0?L<?4.Q%'Q:U%1
MK:24&$V9)?B/']=1A![VU<A<T&(_<>U!4U]G@V^6?8%_+UU2^0;!9J"9UX,!
MQ&P'+P  'K%N_0V<2-&I($URGW_HI@?[0OP,:0?F^0-^Q?"R&CXZ"9Y-\][X
M#F7I!!>M6/K! &3C!FY&)9OY>I7Z!'MK^;[! H[#VBJE9(.5WPFEI.1]2T.D
M_!7@TAC#EPM%8$9,6<6!?2S6X"B7MK%PNAVC_8 H8VF8_76XF6>O;M*H4Y(.
M)T''[1[EHA;"3'&LTX&?S_VTJZDJ:-" 8-SP9;B 1\0J9PQM5"C%]:G4DHKS
MW-;ZB6.XI,D'U5C'YLU%%;9[7S&X'9CFBE-&^B"<%EX(O53WU4SP.VP(*[W9
M_H.D,UK8/&DM]5SC#V#5O0%W" SYBOZ(!$0.6]UEYL.]('>9-@_?7(2=YE-(
MXF\V@V'\I]N< ("4![J]!=.B0B\Y4(Y;<(R6DINXC^'!(HQ"B:V+VC?7*S%8
M[P0K.N,6%?E*"4MQ@KFMOZ(#.$2DW(&)[;54>78 JL7U$.]UR3)QS,MCN)9_
M7=Y+F(Y XC*0;S"3C + U .X55>GI#!C(L0^2$[$#L02KR%WST9H.D@WP$+-
MG MIQ^FJ ]S:=G??4FE?/<*:*P<?'^ G_?>A&6V FP? PI #S!>Q *QC%:QE
M*2%A/V=HX_N9,]>?)%W 9$,KL5,V)-L)E=P9W>3@I/[Q\>9RZ^<1II\J2::<
M*MON&$QXOPH6UIWN(89AL#<H+&#0>UE8C,3$4W3N1V<H,1#)4'#N'.4@?0A+
MC(0$1&'4PP=T,C?EJ&'8>&&NE[QZM\X<PS2_!BV_;[T''BG&WP!X0(@'B*O;
M"A<3^; *Q](+X)&$U/L@2@V8P-[[>&!8@[2VIH$!GUZ !RA:O 6.6O;U W,%
M7+$-JV@P AUQ(X?6IH32@7\']\]FF@='_D+@@&#=1.7LUD>'R[P!-I@P+@A)
M8THQ*MUB)"484L#K05U#,)QC7.O]"X'J;0)A[4PBS/1B[@0YK.D$X1XOYGH
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MP96<8U/(\L[D7%CJEWF9HM1<2?D<@T6"'>)-RRZLX];&0<E(J@V:D434*H4
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MGG!Q7,MJX9F\<Q-=1J5N5LK>_1\X_E'T,28DA.G#A"'310?]^!Q*N\.<B9
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MXN%OK0Z]H9A'I_K>XSP]HY!G^(VOX(0_GV= 7C_,ED#[)"_$/[W3?A[>N_\
MD[L\_P"MD_V:Z?\  >%#V@/63[.3K_I6PC]2$I@^W][Y_5QLCM!@WT_Z20 -
M_P W$#M[?Y6K>KC#]HB AH5TZ (#TR]CD!W ?]JY\/6 ^L/9U^/PX3FOP/X0
MO3Q^VE5_7_YS37B/^?AK/:X[AV,;OQ_1OQ$ ;[[=;BRWVW .@]/WN@\;&QB.
M_8?9&Z[_ )9S77P_U;L/5^'[_#K"?I7.8MOI+-\P>XT+N'S!TXU;AP0_$TL_
M^WWK*][/#W,BM_'KX?-\_&P=) [Z!<R> ![RJFX@'0-Z@^';X@VZ_$ [\7>S
M4$/@=9"V']21\/J\!K]@'?I[>GRA\^\/'\#<CO0<[B/T@77H/_'LK\G3XNFW
MMXE+['$!]RYW8>4>YM/*<"EW*(32?4"B!BB("(#L8H[[;" ATX<?H9U%Y7S-
M=[[#7JQ)RD?#6S(49&(IQ<<T5190%@608IJ+)-P5'D23* =V/,7Q / 0D%QW
ME>B92<6DM(G339J39W51L0"PE&)HR>CP*9Y&F4?LT$WXH<X&.X;'.F4#% 3#
MN <0N:%>;X=>ID2 83ER;>CE*03 ?F)%%/Z!@41* !R^F)S"44N\*4!6,D(.
M0TF9ZM>H34/;;-;8N%B7E3F<E8]9-X$'8,UHNKNY!NS=J@\=NE/*G!%@.L8H
MD(8VPE P" EY^>R) 0[9#5KN A_#$YH\?9R'^7XO\WAQV\\>!W*1S%LX>/'S
M5HU:HK+N'+A4B2""* *"LLLH<Q2D32!)05#&,4"@0PB(;;\?FH:IL'W"VZH-
M0>HYCD/$NH&MH:K?<I'(;[5RSBF=.B5;I5I*!D75"<VPKY:'JJ23JL/ZNT:&
M0D@>)KLSE62(0W<-K0U:Y!TD89T\7>HXOA\FQV1,SZ?\*VF5-96<#"T:#RQ<
M:I30MC=F<IIRQG7>2Y&49#L#IH$3.FO/.46P&*HT77'VM%STK:D)#%E3QQ0K
MKCV K$,SEK*K:W)[FED>X1UV<P"3>#:1SIJXKT(>G WN"BTHC-%!ZFHB5(2
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MRBQP\C* @(@;\<$0*<2CRF,&P\?"E3HR2@F&I5T!'TB_F>B!*J [;@FH+(
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M6>9?'*&8*WB%4L;)R+ U3E;:\9(UR6DDXJ%G.Z@.Y+8'4K)OBM&<8$:W*Y6
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ML%.,[+%1UCCRR;)I.,# =E(%;.4CHG5:J%(JB51,R1%DTU@)WA"&!:%BVA1
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MD147Q?<T_QC^[RC@+T?G5(#8D>+A',;_2;I^=,YX4'Q^V<!SOT4$^=Z/(Q\
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M?U;%.&)<D/)_"N!H:BBY8/[,_2%P<3R,4-H%[F8O!_/E^^UF$DS^__HQC*S
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M@'2SE8/YP!3D]X<!%0#TWVS[C0 Q!!@$38! E,!^,\!\^$-MAS_=]L>O%!!
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MO!:CZ'?-M7U_IKU#7Z4NS)<WQXB^];1&&*Q 54D1YPSHA0<8"(Q:K%U\P>5
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MJ;8KKZ1K[Y%=,MA1V_SR";T5.2GP^EZA)A'H6T@G+XVVX0QW4B/S^';=U['
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M1+I703I*BM,ZX63NXBW<=$LJKLJ^6NP='I-G\G@TC6;N1VL; #P^K8/CV7C
M'!Y +GJG@L8?"RP_C/KYZN*B4\@F09U@R!-X3:)^V'":PI?0\FSIY>(,^"1>
M7H%C^T4IMHO>YH(;9AHP'G?1$D2%95UCX F*/:[3%&A3:JG+'VI%WG"G =@D
ML@^E5DK1!%>"0 F*9"H>N?$QZ4NN(8+U%J_P=?1@-B&OHLEPP-_D4;GN?2F#
MX-B$;N@Z0>0-R2ARRV;$M$;9+@&<<GK;LLWU43__1C)K8L(V08(,.1?= KU&
M$2&1Z.;:P3+,EJ_\"L%^&2BNX 8(#)EOW6PK;Y9QMCRZ/NIC7F8$OEV;3?1Q
M*H8R?!W>L(QR \V!YGL5)5BL:BK]?+(FV%Z;I[EC:M*QQ=B,3LT7ZZROTNDA
MGJGU!A $C6JV)T@5>%[251&@0+^SY<)"WJH@GTGP?#7Q=<&S3SN(S_/_MX(A
M&YIG%1]7$[>^WM7&(PT-#E-550V&)%J%=,M=&"U^U,IG5XF:2)3L=_O(I\/S
M=F.A\T7KMWC\FS=>O1?L?*:F?.I!G13ND@ >#MJWUHZ_.\!0!IDD[91^X]EU
M&S87JVU!VX+!,@2LKO0#$:_71LUBO\)$.15OLQN53OXMR=@[$P6:[R"Q=^RN
M)/3=3Y&3?(0TDGW3[,V)LW7FH>W.90U,JLS-A7NFWO6>FVE#^EU5\>[UMDHZ
MN9LT1MZKM>&YWO/<Q6VZ0EJ"K'T2@^EB ZLC)3R9U6IIL?YA<2:Q%XC;VY9-
MM5YJ+#$I/G$?_2P1S7W7\A':5"K5_(DD.DU*PRU7F*&;;05+]GPE4M_=*]99
M2IOI'OVB39K"HD7%%@!>6B:B?S^[&M_[OG)!)J$LDH*NSDJFX+E>3VJX;&Q]
M>()S>:QL;,OY4\SOO"++7C)159E2^_J[LNOE(DH1G*9 CDT4JM1CK!/^\DE>
MDS6/JJ1;N6L%+\$B)3^<%L\XJZE0* X'ZF; 39,/ +VHZ# U_G8XY4C B=G>
MX.;K_HGLTN/\_5CF;$;K=XI (,!LJOH%Z O* %A&3\!!%""*I1>IP^Z@X?69
M9SU]/07Y\_J?),;; [N7P<78 -!2A@UI _ZH^!?7GC=W9]F RW;;VOX$&SPF
M"J(6K@T5\GQ_OJ-5?/(=3Y:M)*K5LOI\ >_CH7>LFLN@FB?.%_UX?<VJ"OU.
MGHT5/JT%:U7SGM:2*,1<(G H?E$T$DT#D,$'2B0WITL?F'"E.9RY@DYYCWI6
M]_R,*OEIB$:K8DP&KFIC9!@1AS V91:'\-4[04'(YF $P$SC:PLB;?1=M7!G
MOO.V-3M2'ZN(*Z<,R"<->(^WYY./XGE7TQ,!\";&TU'I *!Z5B]ZFI)B <:
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MS7&JHU2N),F]DP37T720UJH%Q97#4&?MA"82P7?@8IV*LCA$W$\=RXXGX.7
MCRSM<*@$SX@D.GHX8L.,W@"\0EJH&CWS@=5YH_1*,4IFC5U1F'WJ'Z"?>K-O
M-[2T8"Q6LI:=U*LUE_[1T/R#N-[UL?PLHAK!-"CHA'N+U >QQF6WX!F- %@C
MZU^J_0-\9(AM^P>(MOX'6.B"XDT)$+:2";&Y7S855UPQ"JU-ZN*6D*1""HSI
M:?@)C^0 19J!X+@H:6-%:MY#&XM!/=(K]70SH:WE20TD7JHGSX?J<'0PM?G@
M!-D'WH S+5UL\5B#/G<3F5LA4I6SWV"$]Q#[<2OD6-R^C16E43&CZU,$)@TB
MF;H$P#X2UGQXQUR44L:U?\^N-]EK[<*G1R+ZT*CG)QGD%1?$;EK:"%.(7VX@
M=8D"A.*8U/#03CO43RFEXU)/)#2ZDGMD#C.*=53B%;.O_+D?S!GIET\, 'Z,
M+9EQY(M:7)#&D'F Y7!7G4S%*QKH<>NI,[&\XK4N $Z_(8SBY;JI.#&Q'[M:
M:+RC?(348:K*#8^B2Q)R[XOX'B^3M']&Y8]X=U2A$N]?KP9&,N^B.I2U[4:G
MA+,KTMLW RU2_[CQJ#:%^\!&M#&QO%;_ 50B'D+<,L.1*,N'&Y]C5=!!;0T8
MJL8#U4X"Q+@!<,4@M (!3O!FZHCM=?#J6V>@/ZW[-(D;276QO;^!O<)0MP//
MU*QLT(<-34D/#HIEI1"(!<M%!#&*&CX@+LS^EL:%-!GS93RAZ^*H7(2UQ'9"
M!\60'N(I0,6>$3@0B CN>>F'N:+6E0P>(E#7X><JFQ1']I3%)-UXR.==1U::
M)]%3%KG:IP@"X_Q,Y//)"N5UYT_NB '^RS'W_#03C4 Z@U=;2&127)"K?EH0
M25P8$(_A@/M]%)5CXNF]5UE@E0C>6*81YX+Y.7A6)&!&>DOH^)*9DX>/DR$S
MZ4S:Z_,D627@]=V=M)<;N9\YJJ_1"<AU9C[Q5!FAJV%D[]ZT)"8J-/UNM7R+
MMZ77K<ZJ53IF%BAZHCT]@(+QFDAHLKG\D%_$+3:]B.G>6=Q_E.)^G?/>;>H:
M:>5U^\1H&,:'Z)1!MNGJE!_6YIEDS"A9+I[W2/:V8AO9-\,5%K[1!K,^[LPF
MC^#JE SC1Q]->FU-O+*_G[-3?DWT#;S64$S'-/?66_DC7)NN?#]M-QB\0=J0
MZHR7=L[V5.\]U,!,-> ?()[[6D8UIX'"]D_.DQ[F:+?DZEJ9CG5G-UJI-3%$
M\ZG2(V^7!23J+Q_?QS=> S-%R2"=-36N/I?AA<K'N@K57&+^[8M)0WU2?UZ1
M^()AN9)YHV:&?K\Q.^;\YU'Z//.?B%/>Y.R'ITII8$S?NRSIL(/:3>2%>T*0
MFKISCPGDFY*9]_@"]%>2U+5X]%"U7\+D[MCTE1JOB\>JOLE83W1@@^L'ER;R
M^Z4=1YY8E+]^!U%L(/E6^T*"UG#:?(GN@^H71LH+O*+71-;E!ZPS]2I")S<A
MAG0UXW+CUB;)^0PG='[/N6>_$MM)8VHXQ6<33G?C>)NZ^ZV\1<CD\1Q\NC1Q
MD%P##?R8.'G])Z-B%&F:<^I\F=REXUMN2(\NF'19ETZ5LDM$IT2VL$2]1'MU
M64;7*?^E0_W-'EZ\0[TPH4(#FN@[S7YA:JB(5C=#/D?WB)S9.$'B["-%Y+W3
M0@5.%6V>Y=,E&,K"-#7B8Z!?,*.+'W=SQ,U^IES4!/53T<.3(47G[:_>W#=\
M!EGIK6[,D*GNSXI1STM^ZAJ8$^K-?E#HSZ5QEG4O:-[2=PZ;U,HMDM3R",;7
M_TZ4//38M&\/19^U>RS\.LNF>=.-[_DTXY']+(K!YKG^3LO.9DG9L\22+C^4
MH1FC_G:O+@JCV0W5,.VX'HD3YA"0?O&B/.GK)K"TC2)E,[!("7\4 M; CHKP
MN40-:=[GT=ZIN <)XE/! =ZWION/4NGI>]]JLH_%WTJZDH7G:@>-EO3V7,)-
M00Q/\"]P;WT91#(:^86S)0Q9P9:ID.T<FC79B,3DT7M#X8BG(T!K118)#1Y6
MFXN^SKU;PZ7RMQS\DS+Z>9>!4(V%507-$]]%'\P\ETU?-'C&(D=0BR<0[+J$
M3.TX*F>IOX7W$ 49>=]DO1#N@4TCNI+7?8I7[?<85J+*3F3%;^D 8W/O-9TN
MN9,[U-<A!,T;@UKTE##EW%LF00C=*/+=;O*PS@"H:K=LBANE"4##\(E\G@7V
M;'->5Z86VW9\$V^=ZWCMQA#P/4E 3!:^M6T5=BO<AKZ#-C=?VKZ#*Q<_H>?8
MOSVK#GEOSW%'UV+PNGZLZ'FI*K4RM\)DY-S:\\B(<?8LC3>-8;G(.HY]<,_"
MG!\1?X8G9NK:LFZ3)F?8]1N XKCF>E+ CY0,S4\K^(39(O+64%TG%_0G+Q5Z
M90=,_@[;]CT_Q<CIT"+C/K\JQ8&2!LAV&FK*D7I *,T D2[MZ&-Y<K.48R T
MC'I'6OW';D___HDWT=AA8S"SQG%I%<J\K+Q.U!6LQ737S4CR"NE@MRQS\&=+
MM[4*T6=B"MX?@#,W_ODDVBF67!#4(UE7_W6LUR^%ON[IZ<]3^:CZ>!C>:*$!
MP^Y9#1B'0)/+C(T45\ \W'CI18F7U-R/QLI2Z'$ZBV.)8KA]1S6V55M%?<6\
ME#%WB<(-Y'90O0DNK:5I7VHNUM-1A.V%<$AIJ>$%W6:&3/U6<+8F.:=W9GL&
M:.:72)P*G;6>D>0MK0<3TI_2Y1J4%A"'UP0UK(0<W\496T6<CC8)N]P1$\'F
MF-OBA9E#;9'/J\%TWKC&U-\<OT6B6GA>2#\517+DRT[*AIUH:4@$(*3@^+#J
MC4^"J?HI/V]$=2Y^S-_EDKA FB6]^]]-J?(J/:+IE!ZQ_KQV'"JXRR]**@'I
M=D4E>+CBAO-RW"C_IWX$1I>@2MA[LC$E!E!3FY%WT+RQ],--G26#%(^[U\S4
M:Q+F) SW1P S(\4(+\Y9ALM@K[_]@#UE'H+!O0IGK$=Y6)R9EL^$:T<V/]>6
MU-2YP-R=<P8"#42G9'B=#L ";L9H!1M] :V*2USQ* !;94]5X$%5%Z3E-$72
MM1O??Y&1:2>2RL[#7)X7)-P#L7 JEG8GK4513__0H"P,>!L1;YJMKH/!3</)
MENCL"J 7R.4)^*WD+O^\SY$WK52N:&#DHZ9-#:<9K__%0O4!]$QMIB^G5D.E
MQ/5\\E'Z\WERDGH/F F-RR#WV&K!X92\Z0P)C6>CN] DE?<\R]I^442Q?+HM
M13GOTA-K<Y\3"23)=+OV!D,<G=45>P>H@G#-X+;9BFC#4("]D,_D28#)^DZV
MV=1]A;0%8[-1G@@*O :HUBTA(OXN6E:LQJR9 %/3=S.WD$ ;VC89' IT;G/M
M(!J_KJ-EO]GEM5; K>X_02&O/<BMIH)TG\B_8NH2AIEI.SU,OS&G\QRY]TXN
MY<_'D/@XZ-DE8"L%A,PF;B*V8M\99Q8&,W@.S#R62%0R)>$/[Z#,]8)_S[05
MO&E8%C8;P\,P$?0O$.*=LY31<=)*3'W'CI4[G2U)>8[W-?5\8).OFH"JPYN]
M@S!%7SC4M$<GIU5L11)H='5*@N2?3"P)BI >+\Y:,';)M,H-0B!4VV)BBAI\
MN1/:#<ZZA%+?C3RHF[>+H#&X.TV]3J[&L%-5]\TY8(1&9TC%JR!3X9(:WDRW
MA3\EJ^$KC>-Y?6UC(MZ:T^L8C/>EP!+BS,^!^/D5![Z9/'$1DO=HM]N?2]3*
MX'=D>;6H'LHK^*S[^L:^U5;NXB (UU*05(^E*E^PH-;S>14M<%.NUWR;=QE\
MT$_<$R:O*2FHVZ645%:&Q>N9UZOV2"A2K+YJ=7Y]+9G(.5=7:(*QJH9(>S8G
M7-R&3F6M9K1L-),L5?%9O^:Q,#4;.R&F3O::6&JCT:)VF.55>WV":62DV2V.
MU!-\$+*)R5B+KY/QD/:+Y',PE$;GS,B$\T[PSS_NY=E\D,W-_53D-Y\OFYTU
M7M]:3%2:\[JV.W2?3 6A-)_;%WLK:/&5LCS <VMC(>>;MF47?Z;![_'@N'2;
M8EZ^C5[@]5'EDO[>_70Z#/@EJYBP]1I^3J 9$&XS7SS096O:QIKM(G+U8JA^
M/-$SF?/H:?M(^+35WGZ5;5>0]E_A;(4WD*SB*Z8*&CZB>CGJ@I:A\&\(\V;_
MTR49EJXY6HAG/1%U;H&-AP=)Y'LO:.#!VY#\H/XPG?HR9'T'ON80^.&T+/X#
M<ORM!][OS4>CEW4=I;][76.W^//R(P(+U".?6!_.U'&RRZ$,01G7X]D6LH&G
M@V8%AT0F5\O<J 8*FU\RW.>1$M42:WUID!GZ.T??I-P<$0.6!".-7NL&+BWS
MI@P?I7QINK#.-GK>N?!\$?MZ#)GND"LY'1]R]JG^-Y_].8=)T ./&K)WL:9*
M,.SDTIORR-5&(3?3TE%!.K2$J[TX[Q)-0Y+\F(!(B']7DUHSCFC.X:"W2\6,
MQ>:6W/Z#7-K4JR?T>Q\'@RFA&D&U?_D)SOL\)8KX7DY)1#_)UOKUO&.[YWK/
MPOQ7RRI3?B;9-])O&3L1N?OMJ^@-@X7.%.V/]HVM5:?)3!N_<Z/4S)VKV77Z
MN$L;=E4+TQT:6%"@P2#JJ0B[L9$F=0_;?JZ<>):(@[X;PF.:<$_F2]#0Z6P2
MB(\'MFH32MG9T&G /]RP0K=L%,CEP#N&H%-V ,0XX2T_,_[Y1^&6<6LF:KI]
MZ.DV^!7YLNCQ-XWZ_:T[8<3!=DF]M+!]50/!G/RSG,XUYQUS^Q<(Z5&W&[P0
M-\JO[C/IO?IE<B824<<I^J>:$[R89!O8H75M*,I9WD*>I=H,;%8$F(1@<9V@
M<?C#7"  3]NB[$9IX#%%:K!_KYB1X>%[F?LKA<D>G0-MV>0?'-RWPN4*7@?C
MOW4UURTSDF'A;H>VAM*(P752ZL$N62VY8\I3J)!%UNET+LUWC09]IF<'V<+.
M*CQ!1S+ZM>XO5*_+DI/EL#'"[YCWZVI0.5XS]-7DN)',B&#12FR>H3UO>J!1
M(Y&UA9;AXT'<C7UQBX^IV!O6DK[OLT57CX5M U([RDOR]Z[]UBWI6DB>#L!R
MLEUMU"*NPCJLO8+JS9^Z=IJ"CNHQ?\PV7\A(=K],6Z#CEB@S%)R6XG]5MCC:
M4MLW:JK-W;7M(IQ- GL]F)Z?%LZ1=W$D&!C^8QI)?">(BE<R(E+?8,_O+ 19
M_1H2D4UAJW,>[!WJ;L.V>:.*14B':K(^V?.5O0%0\2 VA'>U"E,"+E)/?# )
MHFD6V;\VRAY]*I3,IBA&<$]<2::U*C7=*\I(L9EK!9[P/L_/B@MU\#EX<Q9X
M +<=/GWWH_6EX"H62; ED!XH-Q^2'PQV8YU>)Q^,,T7=D(<]/9S]W*/:3I_I
M[+GC)L+(2F7,^Y17WF[MM_V?SAXFJ"'S(QYIA]HS RL),E!O0K=Y_=FW0(,0
M2_\T4=RN& :.8TF\G)NU1XT_4)%5GG7D+AYG6=6L1G U)?W.7,EFM!=I*T*7
M7:(:TT*)I9?P2MXY).(R;U22+FGR1[\=KGE>@9X2%H[8JK@ZE+<)%C#)+XR6
MYYI(RI#3Z<S,RHB]Z/0[9I+Q_#2BI8/K0LSYCF#)+.5BK<K[+@OR2]W9*]QT
MY6-WL/E8I^ZR6]KH(,U$<SQV=G0 ^>-6A@1"1NH&RK!TX$NF!75B0D5,Y-Z.
M4#\7IV_=\?]PJ"M/]1AB?P")D(+^\HQ4&.KBSYUG4O72W?B4/DY&H#6#M?RL
M_U9HG5\>ON/A)\(\E'*)4[/%O;4PHW'RANZ(IUPVWZ0!U#AG=2M"<A1U89<8
MMD2-PU6:(%UHH$-9VCJ8CU9B-Y^; P::C%/B3??;2:R:8MD>N\QIY95,EO,9
MUR$$F@33A2DB0KPM4G(ZNV[:W-C([Z6Z"/AX<OPY1?.M/'E/1X7X@]4V;._&
M%CB[%Z:U R6W<*N'\K_Y^ 9V;0CJSAX2?V"?<VXH#P^2..M(R;48GNVWB%\*
MH]$RF>'H =7BCH=G5#F4^:?[16QY(P>5=C6S/["+BGEM8EZYBY/S,*!13=IC
M:XS/0_[H<A>9MF>\5'2S'D0%"^X/__ RC)MXMV+H6>%D2'PFTYPW>Q1UU&G)
M@MK7:-&U/JERG+?S"43*24 -B??C;9AD8^_993Q7C8VUS%'&'_%[^BDY;C4"
M:#P.$E\1=.OQ,/-9H%ZTN# S7DN(M]G/XC+(!E$_WS/.GR]389BP<./-*F8!
ML@'BL:9A9/QF(WJ'ME@-):V;+XCFPR9E+^52F0WD[R#I(MM=#J],N=+G%#76
M\EUK+1*93+;"Y!_@@P$>7C*ZKY(0@GVTVQFKQ-^Z)P3<YA.Z(+$]DW/7"V=%
M-U\79;30A5[VB)4.2SL834-2ALB6%?:9>P3-53YC0K57?3TD_) CD&2<$'^!
MYO:Z.>@E0]_?V":DK<LYA3<K8D9FR7=3S<8F8[YS(%1@HTU.1<:A"S]C2YDA
M:X,T5?W'=X^3UA7S=E'1\G)?]DE&SR05]>XQ=7-VO5*"Z6FLE;7Y2XG\6#,!
M"$1A!&< A*J']VN^D3QF&WJ&774C*FSH:S;UB' [&!C+#DIE[+6S8!E+$9XU
MNY/2"!V(UNAX\X*[Z:R_9F>NJUA[=%37XS; 1ZMD-.R2?.8S*Y;\PPU[D>=]
M*]47BMN,+*=)J(VEI5?9P7+J>5W'SN>\=TT=[U:CPH4=:M%/MFLG-BEXFZK^
M4X,\R5&V&G9GP1G'_4]<LD61JA-MGK1ZZ#^&+W;$A#M<UBT^7=]4$KJZ6:*=
M/2UR(#*O;8Z4*D"K?@CEIR6M*(\:>]6P0Y?1PM#)X6SZ74RVBY<-"X/0N#Z4
M:[BDRI9D=4O;"F'LR[O#=R:\TXNC\*CX<+DW9#&<1K':G&YVRAM:-G6X0!UT
MA"M#$MZ=\2M[$/53RSW'<&KSD%W6VLVE'(,YRM42O9@I)P(WKCJ;DY,6QKCE
M4_KY!)L;P\VQU9+<"DYF\8NJ(6S3G&7)XBB>DY"=P=0BI4$OHV4#'V,U4I#B
MY?)[,Z88[BLZ<L6H*=\XA:QA7(5*-G5#]Q^\$HD9).35EPUVE%!_@8-IKS^M
M[BKX'?]9])_\@\[M:P>N[(GH;1DH+Y\M/<-<ZR670AJ0B#Y2>+?"YOD$D<],
M#)J)BF=NO%=8;<'QPZ1*N</0TPZKK(VL+V+3(XF69^4W*S!V=IU15Y[BQH\%
ML.K9&N_T62U-CB.LQ^9^,EA^Q_=[GT='NPF:4%VG6G5J@77*)O?IU1]V9Q,R
M2GT'/GN==JG$?"NML? ,^( K3UM;ILL-I^?(A@AY3R2A#</CC"A2J<\#M.*Z
MUI^AR40$VI'$?)^4@G:[JO2%TY/HU'_&)44DPMCCA_-KW6>+STFOT_4[$:WL
M)3=T*(HV%4L8/+[0<LAZFVZL'A))S'\.?5'@VCD_040A=.-_,F+B2:Q5'=3:
M&>+8\S$],G^YI26:6]SNIT&%E\PW4S #B^#5Y%)5_>FA2GEJMYVM:BIBP>"\
MVU8QA.)"F-&O>%<:0MPEN3%+\ _PBL#G99J#_K? ]Q!SSZ*H1\PUFU@3X#-+
MM$4S.7GSD7YCV/<S[9%5P3"R5[Q"A#,<9B/H"(_/!=*XRKV$D87=35NTL6UU
M[ETLZ!2\:M6\U(#=AC--<,O7!!-WG^"*:^M^68FYZL'];(NELG&OKP^1N=I6
MET(SD6')S(\412D%[8U=B)&V4O<^Z#FKYP*KS0G?8JRUP7R6J2$V2_!^GV#I
MUGF="97,)]Q<V-OL0^"7 L/G><@)7[[QPT+E[#(9:[XJGR["R@TO0R$2\(/<
MPR/&E$T/IAG[W'!@#9J?_=&4C)_YZK4-4?V@%XIKE]>WCNS[&SGC=U)IO][A
MK+#)IESD4#&_LQ/J[*[FJV_J-L"K75VLNJ)I=4A*:)#U$[&K:,+E+X'Y=6#-
MZ 2U6;L]"JW/I:9'7%)W]'J>Y?PH;JC)"G)>3D;EC!GY;.QFYBRF%\CHN]M,
M3D\W_]50KCYJ()Z1U_:4U)N>&(>JDM8QCXMJUAVF#\3DVBL;(>S<)"B6?ZQR
M'W*+OF\%1O,X"O/H33R?(;XA=O=A@4;,LP)Z\GAT8O;U,;SPPVT;W9M!KK/.
MTR^N*JQ/6.V')HH9O%AP= E%[#:8"VIJY5W;##.X2>?[X%<SF*OX'_R=&5HH
MPH#HT'3W5IH_M;_5M,6D?:191!DI%9PINYSRFSM>O9GR9XRH?K36XOIH'ZDE
MV)#5\;&#X"G?Z4Z'@\0K$SDR6;=8R5L.B][]TQ<+.^IY8O0_V="[MAI[?7.6
MOM+/Y9E F#7#A>Z<CE.8[I2PY.=QU:>S,:\2K6*9Z6>Y<@=";52@@N\(7JFZ
MBE+'ORA.LU]CKJ^CEQR&."$>0IVR\E>#0+/]R0SYDF34FA7YMPKA.T!DA5#<
M47#7ZQ?>;MG^%,'/2%_]9>3/[2FP[) *NSZ8O=^>\!T2Q5ZBZ<I&'9DPG\OS
MX,AD=77>> 9WJ]#L=%)#AP,%HD3-:<G]/U\85UA]':^B'Y'GC;^S'U:W"C8T
M\,X\K/$VKG5Q[;>JJ_C/AC%VAX77$99(P;651#P;Y3+^;.J)T?HS/G]>>I&Z
MO_:+%4+$<M;&QZ9W3L:;?Z<]I0_5FZ<7\,VRE6_VFO3G$(3,\9)IU2,PQ4EJ
MKO90G F?<#JYK$61S>A4Z"I$-ZV^WR>1Q4LBK"QHHZ.KI:8E*61AY\&T>9&A
M VLGY;F#,^Z26N'Z&W$I"^NR9S/<=FO;T7RC/>'^2HQ^4H!>O%NFEU]7RHV5
MD\JQ[7O J7 ZX1)^LJ_XOEQ]>]AQ20:/C:R?]?2AT.QKRNGP#]!@=YL9>H)H
MP6NW06ZS]<1(X6_?YK=:^+>4KC>^M:U/)[7S..8?^P0I>"[(6&!+ F?[U.^D
M\,O&+SL"GAIT/?W9X7 1.68,79L,)&B?[[?-LDYEJ,L/6?6E?)G 6 6NB0R7
M?A^-VR>M<##$[HLM\4RD5WS(^^.,763/W33X\'@<<OT2[<P\Y'=0F/ZT3 O&
M&.F1'!OM&FQI=N6$H>G1G]53*? Z\[&3-5DN(!^ @$M=;VE'O/+.S80;WRF&
M?',V,RO(<[A]@KG_0E>QKK_GT&O0!:K8,Z=E-O]-\?8%"(&>@)I+KPALI-[]
M WB>3Q5ZNKU3<EG8*+0Q(W3,[=-;$@R)Z!] ?Y"8MFQ,%L44,)B.A5;.S[2Y
MU[H(D+Q)"&&&7]H,Y/5C+KCG:09KQKFR+PA%1APF=11 ]<)6PK:B%J64EZL$
MQ@9J)CB?S$(,"4\>?1][2'!8\._D[#"(2]V13\S9+JPK8Z4RDM-S?)-5"_B:
M1N1@6::RV;1M19TFKR6KVU2Z:I>['&(/A.O'J!M($[W5=5W8H??!@)MVB2M<
MQRN>B9/3!EBY$&- ^7)))C Z"=WJF5S%9 9YM#7<A:OVV'P*FJ6(,W[ _]&%
MF&BMS$[*+D+"X'#9CVW4\@GO1EH\[-C8! <_#$(G3QQ*:1I\ATY0$^#RB@]+
M1CRMR>\0P2U /J'NY4,6!;8D#&<GP73R* G+I99\\IR2,K"VAG:=MM)5Z@;U
M_5':()Y=D>G*R<V#:I:W+?I(PY=!-3VSZA LZ@C(F 2.APTW*A,;<SW;'!XD
M1H\J$L,I&K]^\XVO D\_-S"LS.IRG[?CBH_7)*[GT^U@K?M05@LET*3;SM6:
M#7HYRG#RP?:(62<@"\F%IH0PRV2D[WROG,6X@GN 4'S\8=R8\1H@MQJ@@CLS
M2QB:];@[4&?LLJ<E"U,K_E>J^N@3PZ^<&2W^@PXQ(8?8Q?2PED+T$^Z/M83Z
MEZ8>+!VR#NJ,!@. (SU"Y<&M<6 9LVA)3NZQ!&DXF8P%SV3!0!H;><F$Q"/J
MT'@+&IJRT^P ?@EWZO6-M0[*^03J>42%G81/B2YH@M WUQ4%*=K&; X08TH1
MWZ/IRC=(M<#Q!-00F-%]<A2]^$[N^^$ :M7(/1'Y)-BP2PA4/@S(#?A]X!=,
M%-FOC_.&0ZYUJGCI<;HWH67.I+CG7F,=U:.EBB )&JAHS0=KCS;S&?HM_N$N
MP4>UE98^34Y;@.F(H10);]Q1S4*QS"8@JKFLJ<@S^65Y/:CT^' C';W5I^.6
M*U2IQEY,CVTHL"$H@!K6%^GSRZ%2_E#13 0W5K0C)5 ^(']\=US^(URV Q5*
MHIT]$.<;=D?C#;P ZC4I1<UK2YN9DWVM+/K)]K43J0_@P![8]+"H4,?,U))7
M&)B1IB: A@JQ,*@3B/K/9<B<S@4I9;E:5*WHFH(S:_95E(F&Y%QJ_7-\>+7(
M2/F]/M?+@Q,8R4B,"?+MV6H%V?MJ^UZ6PQ:$_F-<6JW)RU*+/>M7NOE,1=KS
MU."<C$77><)QKC)#2'4"F+J3Y(Y)'U&[ YB\&V :53AAN8<S&Q,":W4?2_9+
M$M9P<;D SS%*-0#J ">@? ]^4C)8, $C0(MH2U=2+6DI\]ICJW/ B#]+@<I(
MOVWO<5"_ $:\/KJ'):B0BM 5>H/S^[Z:93N@]/?1G@@Y8_.0.#H:\DR7LR'<
MKRP^TQ,C)?I>)KY/E;!,I.>RDB'/!8D"B-G?)=)/XR6"2BL@JP!:XC1 :JP4
MOEX*=*+,6M@)AUYOOH+MS'?6 $N"6[D+ - 6&)_@T-03GO%D&RZQ/7E^:T2%
MDQ%@*97ZVLCFR\K11;.6M>>RCN7>"X9)=.(SEIEQ*;/^9W03)?6\G\_X%\-3
M$?%6@EJK+1/4&>QJUOL?>WV<^'K42]?$]%#S:I]AXY@!8AFY!")N<I>:A1)1
MH/&$]:0")E!NUG.UDJ5'3_G54\' M%KMZ<G:D1(1UFY(5ET0BA<.QZ<W6@"7
MU?JQ5>##2M/.RP57:)R<I7PT4HV?/:-&O">M2"O0+"(V!39\3P>BRI)QN.J-
MC0&4(%^7[%>I+)_T,<NI&_8ZF<[^JZ@UNXS7KH6=05"1I[I$CIZ?T&;>$!&F
M7=>%TF1SR++0<9[- )=VY=L(N\O46>,I"TG^R@+8^PQU'A)L &XNEQB8)(L+
M9$)IQD0K)HZ&Z==MEA@LVS+!:L3C8:, $ %%KWB<'P'%.%[@/>$!SMOJT(?F
M#XTW[8*GB?5CQ2[\VE<6:I;B_'ZH8,F #E+-VRL"B3AG,4U&YPUG^?J=7H+0
M'OWE\P)6<NE*A9NXNW"(WMV:WIA4T*;Y;"+I>(F[EK-]'5?ZOD(R)*U2SV3;
MGD=LG&'L'X!(#JO/3TW+R;L >2][S*E0 B"BDAW@>$/.6J 2P'YOZI&F66U*
M*3N)0(#=2/EG\D%<O-176:0EJ%!41_I)N9,XR@Z9#TD"A-K+)>U/<=V(2VD^
M;FC'TDS)H/V,R;V9D^\(*>LV6W>7&?.F7T\$"RC,%VCF,G:<3<%[M<8P7!<5
M'8FF?HJM@00:-3"S^>P;^WB$$2]@()+4H=&0.A\= VK0USR\4^">VW>%+(B:
MFXPVA-?98WP38,*?@,?<:H$+4K0%$NAMUYDXT*X:IN3E%R"L@9I;-HP;&^MG
M+)YMYHT6B$C@'M?-O*F@,U>(P\MSBR,5H*:]S9\VH723%:^ODX5F-*8 .>(;
MM0+WB:1L@@O6TP@;K+:VKD(5=J7UEIMS!0^JV)D=B[5=LX#>%[%NY#>C#22D
M8<<N.T6?3"Q>X PC=UWY^A+A];QRO]A)M0"@H7Z)D-HC(.7U!"?/X%@CR"&/
MXP$71$2-2YP#V'KNG>:+$G3)0+C<\GP N$8&Z)\ENNIU)@A4L;LP60@V ,^$
M8[82-"H)#!&%\4?9P'=V\G[ZD9E;PH-N=KG;/@7"HJPXTPAJRS]7RB$Y[+0D
M%FJ-LC8TPAKLL#5N+4ES4;8(\_FG4@JZ>C\#"F%97_CF54(#9SKG5"R#>3?.
MEM^99HGEZ%4QDB\JC# 5-%B$]*,>1B^SL*0E^/V0A1OB8GD\=I?$H#0<_$T9
MG^T<O"+9+T^$V&H_48N583#X )JBM]_$%W47N.DV##)O>E4WD(E@(R#<!*AR
M6BRHYXX#F6O_D]98A'*7 \*JC#UWQ$\&.)Y-[ZCWZ E..<_*P.4;!KZ6"NDI
MMFK(QL<7)F=KO%EED7C:NDEC;-<5TF$& 96^<@K)W*MH7-O+^ZW.[X9?M,Y$
M7&3PZ_-1I$9]X)<)C?H&VDIZ:NN=64$W8M/;1B<<@K OTO>1ZN/01)?#IYY<
M9D00//Y'MT5OO0)OR65P_90J3+]^QN4^77_<\<M96/J<G,9\UB+4FURJ3.,Y
MRYI9;F:7U@M=S 4)E$SL(JQ=9QX&ZG#0?*LHZTCZE1<MH8,_K$VTWY;Z>W5,
MBY*570UF*?(^5YSB8-)Q,_>8W;HP\IAO;?(F>%!450Z\8=F3&$8\8#.;R=S#
MH-?\.=E@I#G7_4<J5UPANXMCZ17A3# _9.J9U%DXVHU!(0D @"1/[NH$W5,\
M6)0?D)\6TQSZ(/#-\1OC;Y4&:N2(TYCJX/?.@LBR4GKS<;@ 5UE<$'&!QHH*
M1X3' ILB;Y=G4N67T7\ ;E?A3"'Y'(GJC)I:/1<NV,0DG$7#1I"$-C=VH ,\
MA\6*;DJ?U#GJS31O B+2M</V25JY<C>4,SOJP'1P?-%'A=S$)K]$TLHI))CT
M08I%>H0 Z@W-F""6Z#03O"^9'47Q^<?X4_SZ_PV)>'-N"Q$@)6Q$(CX1+9]5
M?^$,T2-D(D(.04LCJL:>"\LBDAK-]GWJ,DF(OI9E2X1[:.6_8B_N2)SNJ<67
M7\31IP[8?!=E;B5435X(GB^3<R'+DHKKA/:Q2*5/SV@G/;)^F%K>V^+G>,U(
MN#[Z4AF9\O<\0)CR> 2(,!]<-8QU*3L1W\1-&<;Y^Z$\4O12H*O*_U(;.7QC
M84CM:WH;L%'R_J':$# B\?11$^6HUF!3NG!ZT8_RJH7#[Y.!:FYR/L[F53,,
M!W&RZN'X!@!XT\]IA/GT3+'I)WS4:K\9'I(\0)^&"TCI^@\031MTB84\)"C>
M1@YZGW%4<)]36:=^HJS\H5GO76& V E%Q Z].J8LD!8\'R22D)2.>&+E7:!R
M44$J_*<JD61$RE2_L;1H D(*8*O!/;_]DW3#^*&+-1:TJFIZ;KJO#\-;IS]T
MIKIAJ%7=)FOY.]J7^J.OBXTQ@";M>:8Y&&GP_GBG?5B1"</%W0?X253;ETB"
MH+DBF+!^7TU+$I>$62/62,MVR)<R38)DGD+3"&BI-@&7;[J_T8X_CL+Z_D@W
M__.HKOT%Z->:B_^X;=V9@_<%!"DK^J.-I6QH*(&PVE*/C^N*$#<(%J]6"[Y
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MP]ZJ.F;GOJ5 ]J _#O]?1GS\MQ&?=T$[(!%N6.[)PW&YH!$_!H$=I WJ9\/
MSDWGEP2%4/W50*!_-;1MG-Q^-G3MT!X_&VK.3I"?#6P<?YE6@3K:?0_$-P<!
M W455>P!]_ <!@;#D.XV2LA)X >IHQ#_X*DX_;.?"@IF9(Q GV4S<$(#OY&*
M$PS\)[Z!FQ/ZD*_GY:1D]I--X@&'HI$HB#7:^F=5Z-GIN?VHBH/S[T?5PR#
M;=%_,F^$G1Q_XAM"G;[Q]5#0WV IL=/ Q=0>CDTN-E\."+L?$2,_$!A@?5)!
MHM%(9R<DPNZ["MD/R8$+O_&/_> ;.-C9_RX@_2' ^O:3?5 YN$O?? #BN[JP
M:0'].!Y6%>>AC/S7"!3]OVGA'3ML'LSTBX?M4S_;3(=6UP_;Q#_T0(=:7)3?
MPOPC_=]0<#<.SX\#XH<=#VJ8X#?IUN$Y W;Q^2/A?OCN$='W<1P6%X[2M\]W
M&>2G#.<?,J:?GG]KGSXXPU7^Z<4W5WBQ?WH/>7: ,""!G;-"V.//0OX+_<[K
M_:[[KQU^T*]I"R#<G9R^N0H0V"#=$3"WO\T:*%KXA\L'I?9;FH&_U0.@\K-N
MOKEA\*LL#H?CYN0 A;N9.&D?%#;H+SCXAS+@(#, 0'C8T(3\9IO0#H5T=_D+
MBP")<K!S^+EFJ1D>*)T_Y&';QZS=T4AU. *.LD;#88?>7W7YL>22?.M\P#F0
M:#K;@?\OC!_7'>7TEX7[,/A_Y>BXV?UU<2>P=D(;6=O]A4<.A6/UX%YH33<-
M(QWM'\L'T0_V7SH3VR-1WLI.#G8_(D7Q;? :/]@'T87!;:W=#]</8@\X"OV'
M[B8_V'_M3FICIXIT0J)^"R[5-P45]9^" S=TD8B#(S$:Z8*]2+C!?P\<B1,V
MD/_@DMD<+D3_X).B#I:;O[$/9Q/W-SWL!T?Q$_"+3W5X"OJV+N#1'+8.$HIS
MV#[H#YS\D7(D]G,?>ZH' 'T'?'6 #@!AAC%+ )DR#&D#MU35P;:7 ?+#%@#S
M/]##C "! !D1$1$Q$1DQ,1D5*0DI%2T%&1D%+1TU-2TU-1T5V2%]/_R90,=(
M28^1'Z,D)Z>D(2<GISGX0T[S387J/V, TPA0$6&=1^*"6 $<*A N%0@SAATH
M(:8%I(CU$A]T2-_#B N </#P"0B)B$E(07\7@@ <W!]"2@"$!\+%P</!)R0@
MPL<E$\4*J7#Q6(X+XROK6U.SN@:($-#$9)2JL+'3&C39B(JA;KQ2)>2(-?ST
M;A7J)GXBL^PF)R3."*;V[ %:XF2?\11\K3RPN=]]>OTL5WQ64$5"R\#,1G;E
M\\'9SR:V'L%W<JI:A]YO2JJ;VGF&W,VM;GL]MT4%X.!@O<4[](F0 %_\T 46
MX>-X6 ]<6:GQ10)B: X\:#)X]4F4W>8=ZD:LJB$MU$ULE8/@P %"3O%G?5@G
M'IR$J1E+H.%3/UWX=P^X?KF >0N0X1YB4@&*P.>SE<7VCDK'<(#3  XZ5E-+
M.U4TUE"EMTB>H)#9^,DYJCLF4VVEKX<87HLMN3'U80#'>[/J!7NP1BGX$\'\
MR;W2WOP(M^7\)2BCLU/GX]>+A@O>="5U>VFY7\3((C->GHIQX_]0:W+Q=8U"
MZ\8+)\<4X@DH B&;[&BQXEFX3P5]/V.RR^]+3JYVC/T>KY]Z366=?KG?@J!;
MTH*HZ!+S._Z<3=/+ QC@II:[-_-0Q$H[(U*4P!^?B[&[[LZ-<XH7\\ZJ[>[Q
M)7]]OW)^(WTUP;@8 T@KE&" V1SF_19C#!!W 0-4[)> ,  +_&N=SL1N5S7]
MJQW9P+T0!K\A,PP0K:E=*M-PKOO18%!R5!ST[)Q(LAGTIAUBZNWH"F+6U:1M
M?IBNBEZXM"!CQEF@I.I13,]8E_TG$P.#6$WV^*Q830Y%S,O/1M@CC["Q3.2Q
MVHJJ@G+!)I:1B)K61VO@*)T)AUR.9/F)FCR_[JZ)KPT+?KZ"^Y^R<AY>*%QD
MUB_HXMI(.?>HN]AE(O'=@D@A?I'S0 K]J3+L6"JY]RR:=YX'),=L/M9*NI5L
M7S5"8%;;Y7;%F3[)_-'\]9(G Z\7$ W]&$#-=.=<^KJ;) 80W$F?N(4!'O-$
M#78U80"?O?,KSS' .$W\1W-'WN*AQTM0D%N*%W"L!Y41]/E6UMS,[4OFEQ9?
MX&=6#\+MK$&3^VEU&$"XR[<W=T<+ _0)H$9+[HTXMY8O,INZO8$/;YI^&)IT
M:GNX)"WNT#?Z>O_ASEF_7+MU\\&/S(52V^[3G[5URU/4!B6Z?)J%3V, W=9J
M:_HZ-R?;!8_JG?0'FN?U8ELP0')2P[;?P/Y7R[UWY_81MMA$80##W56_K2 .
M68<SY[=KDS' W1^.-[Q_C]RW_*S8<!(#>!D85J3"IC;DBJZ%+_N9]78XV^I(
MI%R/W-=)N\-HXI=L,Z1Y'O/J,!5B=>DZ2(.,"EDV+CKA=_LY_#W9[W&32X>,
M-PJW]O"Q &(\&."%!;942JLP@'?EY^"G";;4ZL9-GOIMSA'\&8G+G2R?WM^Z
M3F(&W2MRPP :M1B@?.\L!IB[@@'V6B:P(9[G&<( ]VBP[C\TP0##(WY/C!<L
M31"M+>[#TI<M9<'2&373>4\SE5T<QQ;>>DCVV\W3LD5]9KA9O3 XN<F590'Y
MJM!3EM0G8Y4E/LPR%&S4;_=U["GIXJ.1ZT')BDL6"J-VY>N*J85]FKK=C*1Y
M;U+>\N^5ZHJFNUV.]TYR<>15+!R;%]M)+_&=^\*1^_?Q=.PJ#B#W/1YB@%%=
M]?WU[$V_O(FO2Y88H 8[]*TD#IF)=97TKY4+$[OTR*WLOVOG]M<I#I1D7,UL
M*!P/<SRW-;.Q-5VN,K3D7"LVU&:VO.]LGY[O9Q2* 6(^88"E.WXS!@8LG\_&
M836?F&, J//^9Y_L#5MTLX.MA85I<97O:Y^5D6K/=8N'ZS[5NYM[XO>'@BM
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MZJ9/[!RB,BJJ&J87S-S<K]Y-S'[UCE/RK+JAC9U]V>"0)MSC1FA.>>4 YBU
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M</0!(2+"',N&4=R)=)FL(JN4<TW/57;"$B=K>Y!!HCC^-B!966/<>']#XMN
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MB AP-IZ]O?IUO7=:EIUE+HJ)<FM[_^5Z04/$2M^)U:]%QW*O3N_%E?DI7,<
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M&H4E%V+\R++B)*E6M-\4!V\+GL@,%[K<[V+<SS&(P]?KDGS3H;1,6RM=[BO
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M8*<4[C;*R00A'%50P6VKKHZRGFM,5/ N #4"A(\(F6=;GWY_UG+EU9>PBV?
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M<EVK 8R^<13&NTFWDS4]H6__)9GOP]T(*_9TSK/+MSV<LN_8SW=HC#4%T?0
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M..G=N1=*%/RY*H5EF3ZTA;DA3]>O\B$J+S;!1'_JX?,60T4P;OLUCDURA6O
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M,G39<6ST@G*/)FIU3CY,;V,(<!RY,0:V+\CH)SL2*AZ'9A(FE+Q9%3J!$KI
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M:-="BFH)S-W[!9PT6 OH'*<$U1,0P=IP P<!SX?/Y/S:L7XCZ0D O(' P=W
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MD,!R&'D@&4B.]53JI2F4[+D?:'CNBV>[[0<GTE?",IGK%3-D-O?;GYV[0$+
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M8\O]:W!;ZK57=UFY+'*<;7Z7>':<TXKAZZSKT*[BW60:U;33AKED2CV<)O\
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M /   !P'CV -5@#@. ]@\!HT:-&C7__94$L#!!0    ( !A -5=(Z#Y[AM4
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M,:\HD\A88AOETAOMQ_7)AAG6F4G?R%>2[O;1(-<F5A,ENU@:KGE#&1O?!^Y
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MM33.%*+>I#LJFC@P%DT]+$M=X-P+;H7P1" 7 *;@QF]^WQEHJ1#&$;OB ^2
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M>HOV*Q9/OBQ.S0\,G3LG.DH[LL20^/G$.LE9'/GL^R_*B3^>E_:W@5I2*80
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MWI187]L,JTJO$EDM4:53K1Q-[VV^U6;@]%6Q/B#1(<>_/U@WOE0R0ERY6-=
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M"&%\,L?LI4T4AE)O;;0@AX44\%C&* :IOC.X%Z,;U#:-W<@RC(OWM,5)NB*
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MSXW$Q8#QV F3?9IQ&E'ZXT9,50AC&[36JQ]6;9F^4R*=9^)?(XF23/G^KM;
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M]UP$\O@=7-I[[3U0M5^\=U,33]W"30)CF!6'6Z351(2ZB(UBG7C-U#[IJ?W
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MR]*A&WX*6A<.%@SC0M(@M9L*R4:%&*02."2/B0@F?,J=610X<<V>_ECW5RC
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M3D[FX5\.K7^XGN%STIU2F_3X(-Q1N^G\ YR<5J>RKS.=?X/D1C@M[%R,]1L
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M=;+42VD]6K>;8Q<MB2V!2YF)?M0UI?_-NS$)Z*E$\\F8OCX?5@V,!/&7L[.
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MKDTJJH&IL#'MM.T&&_E1Z+(%#0.#T_ B5@,%6W.?6% #/;=F$_]1]CL$  R
M(H)H?@-1]F7E=9>BZ_) 6.B $,7*6(BX''/?/!GLN=_R=@$%_Y0Y%I%ZPCF
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M5YX%??^?QX+)_R\>"]2]7LT"W#3_=+X!D_O@O][V^?;U_F9^0R(L9.;DZ?K
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M,R0T]]7JF%#\H+E,7XZ44/BY0'5YWQ>,%24WDK:^[):>E*)$ A^KQE#D/7C
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M]U'>>3Y!=/6WT1'ZO!6Z6[TZ?-*9S0S-#3/M=#%:8P-9  >SC@K'P7(0XRM
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M=RK,+1:,+I\&=K2X<[ UL\);N0E.=N6QG<'+H= CE*DL?B9'%IU]LE]F4*"
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MNU[.^,V1B8JI9,-I*5\(Q%0^B6.>B9HPNT[[+B+M$S2>ND'K]DJT;]$:'_O
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M<&(_U_S8=/>>?UAPA;O0:?YKF"_I/0M1 ,(# +.8G4I])KYV(161%-/]"RI
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ME_Q+?[@)C\+I08$YU#JW7VDF5.17,;TWWW-RX_Y:%Q<;DQ!J1,?'8Z/BS>
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M"4;<G!F<L&8#K(BB)Y1[GL36#^A@'>T2&/&9_1,FQYUSH@?7/B^S]J2U[AT
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MXR^=HZ:%HJ$ID$FQ9'UWFM'TIV*@ DZ]'4C=0S^A=JTBP^M"_"^ 3Q/IM1V
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M-7I7S+VU)8]T%J40!I1-E>U9C<.I/Q[N&J^8>CZ:!#E06L."GVC@!9D+7"^
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M@@AH][M2#0(BH;F&@ARF94Q#@NG5U^2AD=1B_+?B**J *97&+*]&7Y]%\N]
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MF7G+T@0FKA@1RF,P2"<'ORE"GVR3R710",XX=#CV03I-HHH5[&CHX&P0L>&
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M+P#I2;S_0RQW_X^%D&4Y_6W*8_LX.M7#FBC(W E2-KH#S^4*1WW+\>LG%;:
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MC],5.Q[:P009)XK$-,66W2$='(-)&;M:"&&@@T&>3$CP WNOH9^#U#*A>6B
M:%S N-Q/1KK<S<V=T5[4DHM)0H__UA7-K#SU)/1F\LT/I!(D^+3[X+VWV2[A
M&P0)+7H%6&TT#;P/!:J2!_Z$@)+KWO?W6/"WF%E2*5"(-/>/"]SDS?"ZSW5
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M&9-2TX." N1(A@5'",NWD79B1IRDN9OBX=S3U#@\/JIL;GOA+O^M78S?^MF
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M.)\E;O6^DQ(N.@KNJ%]PMC[12_PX/^BYBO:#YU#&/ -.!NYKU*V? 3.$A\^
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M^)0HDL"-M88KAZ+!WR^L$Q]7D7=<K;;RC%AWUS[5<0>H#5TJKG::$QE*V%O
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M-GQS@'.=VC]G )^TG!BBN;,C."4U!4[ZI.B-25$KOD2U<HD<[,JFIO'<RF'
M/M4 G8VL[P!.!B6$A*GIW-&TAZ;51=-PII,[;7M_.+/?U.L8KVE_]6@8U2%[
MY6%S8Y$E)06H,M":J;$OC?N"P7,(>2= \I8.A*:FV8UR]LMZY!D@>GKJB0."
MIM50V\G-FV9_K&<DPWRB;\ODZHM6=CE0$YCB&^[5RB$O8T!'\0=C0&EA(;W&
MFX8MF8^ISGTG/)(%<MVB!$Q*1<\ @^C';ROT8:O/@.Y9<[=S"0];<'O8'VE[
MR&95SU?S,Z2IYQ.WOKBA O^.[QYK:OP]FY/!.#,0-_!O]SZ%D8N-!AL3KH-]
M'JX:@20PJ0)'23HAF07%IM\&.!U16T**+)(OCTN8)GKC_K(ZZ, W"H$HBJ7H
M>8(33/\R<MDNH_!!9]$^9C=N)OF.\6N#NZV:8IO3&&M-IB856TEKP9]R?NXQ
M[=.KLRKO;T;APN;-7P#OIA11+S%L/$1';U<6!P<_67I4NSR]CC+ZDHS:W# W
M:Z#?_!)]>;P*4C34ZJ"L1X95.<,\6V,4$$DKPBDF+B@6[C ,G<M*U4F[[Q=6
MBUZ<2ABE=5%2MA?=%XN&#9H1$J&DV 29!>]C=+ )[+M7X[J<4K4K$F.P:1KZ
MJ<H!M5[<ZMA_@74L+9F,+9875GC]033 JRF^8C0[&Q/G+C;MY<VF-T]M7H:-
MIADR&PMZ<9+D],OOC%7.; \&H 1N[<9U1)%^WCKY/;'&?Y-RXSE@;XNA.*F?
MT'S4&JV Y=VO$L#XR/ #O_@;!P.[Z>EOU?%Z"T<QPXZ7S'SPIDM#08(*S2\R
MQ].?/90S:)2*V@=0W;4L]8@U\U3CWG_H%Z,M['>&Q)\K8HC,]RV\ARE(CM5)
M--9[BJJJ3*'P#U@-C%JN-Y^V4Q-A\Z!C'\>\?0GNXOW8*&2L=1,4]9& S7%
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M2:N@17_RRE]*V*279$,)&N@# Y:!@.N.R0 RO61RIO?T]4UN)R-V/"IRO_\
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M$]QW6<YL;T?7ZUV.P][<8HN=G]8YMB9GE8$#=GQED/?:$P@59(W)9KC/M*0
MW,*+@+Y$Z=<:8%2G!9O66MHZ&0824G1WCGX+"T*,3:=*O+5>K?S8?UKTO<BK
MXL@Y!FKJ?E!YB5$&'ZJ'PZ/A8^B/3 81[WH+<:A_B #$;*'ZEN(,GR#\X-:'
M]L3DE)K+LR$:R2#/!2C@YM%5&S/]^D#;ML4O+$V,29OAE:WZSPHA]:?<<Q;/
MWZLU(U_>%CX#_NBL/J(2WSZJ28C!6@==>%D5M)/G/X3=O/HEL5N=ISE$>"_I
M:Z*[.OW8MY_[^X)=)IV-9AA(Y^=QVZC@*R1?2-"L:_NN,*/_(1!IM.>EJ5[H
MUZB)CF=Z=1;P4^(&5(?JOS>>=1,+9:WN[/F;P_#I9X(*!9$@8_%"I-9!R"+H
MXVVD;.1\,*Y;5Q'.G&P8A!U;2Q(''+ ]C7@]UA^$2!7=BR!\-]@ =\*]10AN
M"Q;E!G*,/C646&CS_]P$RWYX+6F^9@EP%QF$ 8;>XENX_9Y"(9<(I@2SJ3-M
M%K)=JT.Y;!GX@"/$VJ/NMR.HD=FI;._-L,0G&$BJ(VA."$/%?@_Q"0:'/KVA
MA=#Y\@\-V-=.V"DK9_G6>ZY76?[0G"ZB(X^^"0359MW+ A2TAPE+*+>S# *5
M[<5)1+':*0L1A,DGN9OK&1J1^ P!XC [L&J;Z!W&2_W=HK_EBL^ [RNFV1+7
M/LN<,"?'X85_$G*W:O<8><R'&+8V-UQJX^PK&5K*QQSFK6*NRS^HY'Y0Z-N*
M(+ZY.1GUJ]#K SK)YQ+BE&\\O?0;VZ$8#IL5+64Y_UL6:[8_N(%$R_$ES_7<
M%!?SN3L6"WGZ8IW;42E&(7A(=</#@4XGJN*%\@M6U+F.GE0!1S^72'UXN+LC
M9H0P^L.G<A,X;M6CS^'5]4S)C)U@5MD^=LD=_ISW/[W^J;\P<KO2R2=7#K W
M9J*2(W]71K9A9Z+.U@E?-V3_;%4PS;:O8-K^X.RK3N<UH%WFS^UE(TK_PUAJ
MN:B!V&R*L_*FW-0>OJ;^8^9A!?"DUN$1WGD"MJ[\@J\WV>?/-A9_#S>CM>4X
M0.RK91]S9+=+29"D__%'/-IVY/,CZ+E*QKK/UWR^,6P*79V7%<%4W-#D#O_R
MGB1Z@?0^?8>3EY'?<]>3D>BT)SA7FQZ94F\NZD4<5>29EJZS,Y4J2D3IR3'[
M7:\^FEW:1"D_(1Q-HU5/@9N1NCGYL)$:WD"7)Y>C^;S:-0<\XESG?[7*+Q#!
M+FP7LPPW\SR*!H<9N@6UKHE#<,':O$]C?'1_(T@_*>*AG:=%X>BQX<9X?S7>
MI#5_-:YA!P7BV^G,';0.\4!))^*WL&EJ)]).N\4?+*5/W@(75L)T-94.\N9W
M,9,F6=ZK5:"AFR/3AB=XW)Z._-WF:/=XY^=8:W)"3/)5]FSR-GU?MNL*@O<8
MSM$PX3A#H>KM 9N)$\7?P.FD@LX4S1S02#H6O3YJEM[<]  U8Q:\FR&J!>X\
M%)AIBF__&W32*YF.9X 5(7]=9B[*,T ,,!_4;+6M0B1_@6]WM+K; 8Y'(\(*
M:A.=)T8X4I_SS[C$2[G3Y;'1T>$7C#T\+*P] RJ>6'?>G9K0!97=?5U+*MB(
M0YQEO_^?[ZZCY#[*F5+$D PVVWTUF=!VA$OF3A?-["=CTRC+&L 37*]142,X
M>I0H<=BU1K5"6V(5R5OB.A>=JQ!1G78MN*^^<L&IFZE+'Q1',MD1?-(6,@[E
M.DG%WAYLB32?WQI@?98M677!>UU]^H'M38Z%QVE3^>_OB^\^&N9+5947^+QC
M]+#8*1"QYVV:3S@VI!FC>VO;K)(9.1(C2T';H5@P7:R][T%=Y?A.8,="E^VL
M;^?M;I$<!PLG1PK\BT;50?EJSJS6:NONS&)HA*YEW.P^648_:'I-Z:.2HE8&
MG/QJ2T#GF)( (RG66)2Q0J<PF>&%ATCWKCS83UB,6/**+^NVT ?XQ"VF^PP(
MOC$J_7NFDWC,!;OE3C8K-]-*+[G2,M"GP+=TA6@ BNAWOZR]D%((1C]G19'U
M'<#5 %SY#@%<3EM@9(+?3;VS[0;<%F'Q<^F\;1Y"+Q+W:.70:Y) @F4S;!<+
M W3*W\H%RC1+IG<47%1&@T2!L:!I(PU%?=]>G80(0I[%RFUEAV;L=0FE\6\@
M 90VBPO@JAFI$:T<,F'TZ*B%6,N*3DO>_Y66K6($![M3Q?U!<R,^-\SV/LR:
MJ\!F>1G!-6L\?ZDY<OI9F+F#?2;I4:^ FMVP>GYOQB@AZ:/QZ>%NC5* <O1F
M57]X*]]'IJ&!;F^II0:B20'RTDBL7].E,].3O8-V-"SX6ZMW51HJLM,!C%>=
M_ SVK<N@V??-@S-_2!(_Z#KZG"_ZI*\J1A]VGBR[-(OFZ=>^C<2_]%J^5F7D
M2!;LJZ\Q&F0\:OM!$#W 1FISL>#1ORC4P,W<J@+3.T[8D'*QJWUAJ,CS]4-Q
M#'-@#/,W;#[C#C.OH3J #0!'* &D9;W!:%?B/S-XO"QH5.#,;9??WO:^4N_H
M<Z.>7<K%K X;7@>+<@*ZUPLI5ZOJ(F6;]N+?V<S([)1IV_AF8X\!4)<3X^2O
MMC4:.8(3#,L8+*'B+!:*S&CEJ"!%@,V4).K<E(_J <<>YK[>5IBWS%7=HUM4
MG*U0HUDM"KO)LN<V6(**?<LU"]UM>$>MY1E@9SJ?Q3.)8IEE\R*7H$T5)LCQ
MY_=ZGY<B(Z",!2O;HS4*OD&QV.M%?Y7Z#%C1:V'C8_>CHB,KD9LF8ED0WB(S
M',WSU,'4OO6(V0ID@*N):7[>G)9L]^+W-B@E'7-2P*:5NC'-'*>3];PXG\^K
MPWZ\Q^B: 9<<24\M$-]7 _<-P1,SFFX.Z:\AAC-\KO(N\V QI;8<TR?K$C&?
M**PXY^7]!WZ68G\-#V,T<[&?M5SBQ8$*\9&2[#G)S%+L5V[^ZFH^?"YG#YU>
M?5P9)  R0":"4A!],(&K"9!&%D2L3,+U:4WOLV5OTO@?+M* L7A6FE:HM03W
MQD%9AGR[JN(I_VKU%P&YDBJUDH-S5CG5,9_Q4A=ZM)G+[C.19X#?1OQ.>"Y0
M%4+JF5?6>L(^D$LBA](NN>F-@WT@M)F]$C'D/:'8]>&IY=6Y] ;F)DD&9T\(
MVK@Y<;R(I0CEO,0A:0F[G:N<^LM.UNZ)\@LA([_8 T@X:JZ40XOS(][_ $U
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MQ^G7A[6=.6$7#W:F9&%B_,F5ZN0 $4K GP+>_!=4QGFKBQU0/R(('XSKCO\
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M;>;)B)@VM!IRU-]%R+6GXN(-N,QZ@T\2J=EOJ.2%X!SR\L#'C_6.>J#\(D2
M3KZ@:^/R5VMDQP-9O'2_ZA4W*>4?V?/F2?'E_D9_W:QO<8-=*4U/3GQ\>"S
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M1RT]!Y?;>U^S_P!K7,8>OA]5Z)OX#Y!3M7-CT*A)W.8='\9&?D*0-8+5[HI
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M+*7 4I)4WW82HA25DDJ)PI/#@X.OHV*]F$6/;4BDF//AIIK-URN78X!X<UP
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M"G.;<5E&'$4-.6O&T^$POLW^H]7 NM>D'RH<J9V6P3RP..5VB GZ<8 )RK!
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M&@CR\=4A=^I?=L'0E9J>QY2>BE4'M-@$'F".'M3MI\<#A2,C)YYYX3M3'/\
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M*7)GNJ<C16(\,%0,:%';(;1ZV7VGB8.$&BAJ8F(DS$3)]":+0Q,H'8DS)&Z
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MMS[(@N_8^C;A2T3*=MO-O<4F15U;J;@[C&+)FQKUD<%/HBJ<(;ZIJ)\Z<ZJ
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M+2X+5U!;U(7TH,=*F$J/IMK"WNE5(Y21_K%0^[<PW&>")0!"E=@6G0 H$60
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MZI335#RRUL+.@N&3!#"W:6F)K)FZLX=G"=LDD8J029[>C@Y3UGK::/DQ?JL
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M^EW[PX" G_2K% *,=)!E\>7[?F.:1>[_^,&SC, WMW\+0N"?4<@(_"'@DTI
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M^ Y?B]]B!_>O-08H<V7:7^@8LF6LBB$FWG=6%G]U(YSNE; RBV57?#GE2\F
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M/9-^BL;V!80>L3)/2/ADO2 R"8"&GCP6$8JV:&J3,2@Y'"']FE23K>\^A5Q
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MS"/?!-SRB0$0\5SVO Q4Q!_NZ0)*^V:ION@EXKIB/D47:LK"6_8X\(7$&@E
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M?'89Y#VIT(K!K996>(-K(.JOOS9F5X,KD2'OB3<JGZT_2=MIC;HWAC9R'\E
M7BQ)'#0$:R$!(DD#OOR /&!VKW;!.$026(WX:R,HV')T;G1(%(8]?-)J#\(2
M3\-@@/7_D7)83$JWOKMA4$=-V6(H=>.X*Y=+D/40BD%$[E0<S"RH!']B;-#9
MX=V>]%[A#[#IX%;__:TXZ0]. K>-K^FKY*+3Z?F>SY7#'4 *>X/TC1_'L $/
M"9M(/%7D- ;O#6>0 UQ^NS_?(Y]^12R-K-3C?SS_17I37NOG/\&*WI8;G"T1
M8 +4Q.ITAV@/X3%Q@,:W-&CZDR1V[Q7LK*]_4,(!\]IP*>RX=NQ@^,0*#_<
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M.<)+/)6F2KZ/<O^'$3$9ONC7K)/_]"K]5R^)/N=^61ST&Y]XB>;/ASG:&Q^
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MP%#&)S%UL.=%QRE^&PUOY1699W\7U_O6'L\@] /&CC<:_1;DER^D-%Z!!YG
MQ/0!\FEY3?35C =2\]K^O]5<M:UGM/7;!RVWUFR'' 4APE29:+ 1P\AHG0N%
M)@4W^1E@LQK*%PD>VTS-M9P_;K?/'HG-WP:!(*AETLX2L(J6&M&"!+,ZIN5M
MHUI%G(=K&\VJZ";4 2C+Z9D-+>U$K@(6.="Y4[8+]RJ*'<!BM#3WLMTNZIX1
MS00-4!["VO;'EU<NHJ];Y>VP#T1DV/?8&5CYF\5D@-<;;Q'((<AV_V=!_(<@
M7OU,S5?6L;DM"RVKI;88<'3H"J2U=E\^9]VG=2?M/_C+1L.36>D' *,D<<03
M8?]?Y#1"]5?2T"8#'93IN@(2$CZ@*D%45,EA<$@^\_.=_S(#Q>^M'MAD>[3O
M?;GTG(K^U"*,C$B<=52%L4$P_0M.O?B"!,I)EX!B8BQH(-(V_19MN!2],(*;
M*D:"&TQM/#^[2W!=O\.@(Y2ZE/1"+%U>.1 $'0&4ZHKN(=Z,S/TD+(>/)=4J
MEY!,E\RX36M4G\1%_BHOPDV1)1J1Z*1O*P)3^]N0?]>1]G_(:_$5H11MH1Y7
M7W@<[PV+>LVWC<;/(PDLBQ6+4YW_]7*<>6BI?/J;H%75+!5S2A$-_[,.O/?A
M-Q3T_"'=G]^6+/K&SUK[@_E9FAL3$A,_<2Q%80K)8]#9*0QKWL6KJWA\B:E2
MNKN] :MM%<AU1)]'M]"(R9QPP$]V7R/<J)20)#0!T)]IK0(F_%G<5G<*C=_Q
MQO>_$D>\<G''4:6*R\NK-&YY)O"^RMK9;&\:9GW=I+!FG0M_*4-^</0! Q)M
M3,87V[AXE8KW5"'ZLLJMMZ@M>]V<H-W3JM%>"J&_1N7/-><GV)SO? %\8*C8
M,3-I(M6'ZV"&BX[\\_@\K"[3\0?BV/W"7ZR&,C76Y?L7>'?;Z+W+2O)]"+12
M5U13?A)V3[\)BY LBB8(N\J\WW#JW]9BG9/IVEU*6?,"IC83?RG_&#ZO+T=8
M=EBR9D/8/&UYA'5X2N:DE+:?T[VLY]HFT2B#'QAQ<4<) ,L53';AO"UO.*.K
M\LK?>LPRG53>$I7(3JW,E"Q_YYC%+EYQDO$L3&U@L2H&,\0IR/].44__U(&G
M-?B-0G BB*GD;U @>GKC.U'OZ&;7)@: YHS7$I&3,EXWY:<5R6R_#OE([??O
M,&)]J_MHN:UX6,+;VVI)4 R,BA<^Y\I *LQQOZ\K"P=_^C]_/0?+2-#!T7,(
M)&4X/RL05U-TU<M9>^3T(.>8+JBTZ=EM[I!C4 ;2+27]MT 1.P2Q3DW-3\'*
MSW4P]$0^J&\TKC^T5![UBD5!^ZPY#'F%SKX],GD=^%^]E!*>?Y9[V,S\3]_J
M"$.UYTOOK[@9VT=II=V,<9N*"4F9O[U.):I8>"!3@>W_"D]YE6^.0FM"Z>H4
MR>Y!!0\;05"K=GX[#02[O]]O=N04\Y9N&57_@AA#M>_24/[96W\*V8"^9%04
M.G*V^/*I3L0GC)-Q_P(DRHVQIW]3$UQ!6QMR\#<^&=+9<5JJS0HF+N=2:,E2
MOU]?N#D'<M\MJ_ZVU&S<J6&!,I?"8%2TDLK(T?ZEJR)@=>V>5(!0AGD(:_,!
M0-?1OOZD>,DZ)]MEE!6F03!#H_]\L\\;+.VS6X:![]2Z2MJ\<G_O:;-FK; 4
MP@!XV_:__I,ME31@'LVKU0[W@E[P6\[U#A'&4?P1&>_T73&[>FKRH!5_.+9)
M[I(-6+3Y#"6PO7:KI8$A:(MK""O"B0V^70@AKVYUD"-QK6F"6)^]'[Z?.KS*
M[7\ VDXNU'T#A<8%=FZ5Q/017%&^Z4=.K#$VT.B//:NHE.TQ7=Y+3)P5#Y=C
MY=-2TI1KQV.&FKH'IK,J%/\8LR^:P'P>[)+'PC&J/W'8*=_+-Z=X\LK@U3V9
M'F?W/H%1H9M[2N:?*?7TXJ-J2CH\Z\"+S#1/]W11TTC:+;"RU_I-D<\N*5ZR
MNV>*-?W-J#I[[D\%MV;WD>\%F6!HN55, 2K[J(:+YJQ$M.H$*<7Q"I!/*U%T
MW-SG-!R&;5[?ZSP &(_G*ANIG*(_>ST741=4U6B%]7RO%;$S6;\3[6?I[B*-
MR<^H(S@.J"PAZV)E9<M.GV1O>_K-/#6^K)E;?+87040T]ZRBQV1JT<#!F>[$
M^%6I#Q>9PR 9;"I9V(*5S,MTCY&>OU3K[G3=9<F\4:!;&'I6%N,;N>Z#^_W=
M>=+VF!3AFZ6QCF9 JM;L<S(KCV2)?/D?0HT&9A[-JKT#I10-TYBBO2=4=@CS
MEY8*S*6<?@ZD^BQI'>67A_X-XQK#7Y7(SK9=#B4_\6O%"1),VFNX+4(6A,](
M!J,O AD,OP<YQLG@<VBOGJ4<%T R4>C]7?%@(4ZMK76]^'8^5Z!R)[7)]MQ'
M;@JOB^BWGQG=-G,?@-Y>[ UONV/M^1O;TG<TQ)R7'3_%_9I,%Z%+>_&'#>+G
M5 YO2/D'X'<@;??CQEQ;Y?Z:W"L)IL##T'OQI![GL=_F9OA%-]<=B^53B]('
M  %6[G^&GI#.+1*<E?",6*%W5)68%Y\)%U>]=((PV.9?(GL#.B)YM*$GIU4:
M54\5_-%D\R&)4A-E2NU6.1EPKUVJ)D@[8W=Z=.4* *F+[O[.2B-O].<JF@@@
M;%K^<\TWQ#<)IKIMPE[OD>=?D:J4&J721XP:_)M)XZD3F#220])Q>9[SV> \
MG 0>C,9B,:^ F*,$H>_T_F;.7&@ &ZX &J3.= [R"!:S-, !&\%^($J%5#70
MAIVC.HRBI:"8^WQH3  2AW@7??;L8-2-^)P-B^W 5I)Q6YML%!K4^Z-15>KT
MKOBVR4!)-RX/U[%8S]88,OEV@!=*$(KYUX4TN\=I1F0-%K"0(,Q!\K>Q2I=%
MA?Z)@7R5["P<K_4"'J+7ZK2!O_9-*.P)MQR_JU"=]Z%2*G:OH:[E@M_H'+^"
M%T[ZIP[',S6WID-?3H(F\P#$IGTG"%4X+X[8II&W!8D8$NHHM3?5!]E]1SVC
MBB,ZI!I-H"F@&.Q;6]2"?&VYTNI!'H3M"2O4_YM8G@Z.-"G4&*)(*"J)SO!.
M@E@WJ< 8]-<QH3:?DS[NF#T-$'8'64W?E+,'J#STQ VEL=O 6J@7OW0DC7LT
M?Q.M_C&)T/@!*$QF6Y[P*76(M/.QM0V4\K<IML2)\/= .B[\M$'4=ZL]/][
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M3*B[W<?,+(?]9EO3>M8Q&D3CE0R_C)^8HF:$ E<$P14E,4T&]-M1H1$REUU
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MHY<=H#9[)O#8<T!(,4="3QG%U -8CIBDRD@'\2V6JAP+.=W-=<R"\NN51>W
M5A+-I'F6<+"1KAM^.K'\[A"]]U@RVFO"N5_"IV_&RY[$'*$'%ZCZ,8T[I;K8
MALUQWWVQ;!SV, ]IWK,'7]^C'&ER:S#D[@@6<L9>U%,:5X3)%V657]PP2E8
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MUF:$3VNU=0&6-GX[6#2\%? D+8>W"9 XJ^W%AR9Q?4VJ1U8ST,?"BL3*RP,
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MZT2:]P%"Z]<K5%YGX%@QZO>$080W>_V]F&M1HKBH@(@\5'OA"A /E+!.UZN
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M)B6>2<8K?W_*C6<*!$F."JW\,Y9-4!,(<)@?$S*>=&/T.N'\#S"Z\89+<_%
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MVC55<"'S(%)^%S#^P+Y.WT=4U>[K"A;5MZ7ACKMAEM$THDK9&EJTTFP[RS=
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M.V'(QI544E[)^(2GXGR;Z-Z*AK@V^6_*]""OUG"R^*N.$T?14$/W@+'29F*
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M:&F-,0!LMH'IHIKM)]72@:N_S@#%M5'/)O(X3P+<9<;SK95<O_.].P*>>%J
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M;AL%M?_YYY<GN8)/2[W%:3*S)38[:E8L9?[J?TS.URX>:!><#'?J0G2_)7*
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M_Z1N3R!PT7%N_>09KNW#;F?,'R3(:>-,7MZ=S?T9>%-@V5RWQBG-Y)<O[Q)
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MO;\\O>CG[E3TD<=N(BC8-3+("5'S@'SH<QO>=]?4Y6GB.GG1!.F%_8,JDZN
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M3WF=_?']&0"-@8Z^#@ (! (R<'^ _356'9BK-];;S]7;!RPI"@7(:>@;$Q
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MV3J-_F0KK)OV]*%$IO"%DYJB#*U,-\RM+I3JO>2^>&;CIB9E<TFA*B4[2)?
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M)*$(=!R2DAU54BAEG$UOG]] 2X(P7+]MS_/JWER]C=M91G;+Y\RY6[Z/AXJ
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M\SU/AFW:N9@;EX*8FH(XF6YTQ:I/R41%$=]WL#J3?4'J]<9.\@M1K67SN=)
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M52T'EQ#'L,T(]_Y=\:(3)_7"&:7%WEZCDB;.;Y0G@/J\/V^L4&(-! B<8A^
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M752*B^-BX?OM&E=DUP3M_2'_$6_RVY>-\%K>,:7-@X<17OP\/=0SN!.-I(=
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MVUNZ%("CB>/)0D2O]#N H.HEK(-;_*EZ;RR]80L;%(SE*C)7E33EI,LJX\C
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M3TP6H7@Y\^S,E2(N2A34KSO9OU3DHH+H$MG$Z-GV?*7Z20Y+"N]K-MH&0'!
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MI%;W"'\EYV?O2M>A]?QB.+PJ?>-=\9COPONFM3D\] [8NI%Z!["M'5]/_2\
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MSX]NNGA5*-8-N1/?K.@77)AK7+KCC%/C^\V7>JD,&._.9AT]Q%2)%['@++C
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M\,>'RW1+C)E!Y7OIE9+XDA65=#G!&P^FD^+""98&9%G)8 D#3(T/-Z*Q;/%
M^3]+.S=.FH!6[A[U;;_YBH__ &33?W35.757"K5MP D4.CY )'_!--Z@;?\
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M=[9!I-+IOL;%==AT^G1''.,G#!"ELP8S!4D*KY()8:;&<YP5 D'Z=6#PN?\
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MU&7LA-P,RQKT#7:[]E\#J$U9)SL/]^,8\3CIX:TQQLXLU#6K>?/B6U<+T00
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M -]SN#@[?5N>@/=J8HWA9]'^O2^M^*RA@S8FY%,N-+CAFL6ER"4CQ"AD=1U
MP/ ;[_/ZM>$3/YK/J"YXB_%K:G@5N,% ,R?4 EN7UKHVU9[4F<4YVM>TRHYS
M_D\1_NXE6< ?FR3@]_7KJG>((C%&"?\ F79LHJ>3=W[^"A:'CN^E"?;T6^X@
M<JEIZ]%9^?\ Q_COK,-K-P_?O.EAUN_)3=2B:(M?GVRNH)]C2K1V_P"6?A?G
M/3 ]\.=^[7=\.EMIRCH#TS7AQS&40<Q]PWD3W?\ .A?<W)V 3@ 9Z[=>_NU]
M$BCWHYA+4BOE4/2O-\KT57$ >(DT!/.E/8=Y61]TJYLG&"0?#_>3OG'JVUJB
MCA!>Y9Z'CP-,ZV&="5D(-?(:<3QK^EE9WG1R?A').PSUP=Q_CZ<:\DV9\U7)
M85U[Y<5E# 7I6E2UNP_'S 5G==/CMZ]NO]V?#U C?;08R=.^_NX7JAASK9_6
MP8,'-VI3-EM%^U,7$*[>G'CKS#LHW#GP&>*O"K&?H 'A].^JSMX[W/=;C7<O
MQ.5+"PLNK@J%J-O#.OY8K.SWKZ!?H/H!#9R,;?W#57@SZ?5=-1-_@)^;6Q%'
MHB:(FB+@D @'P)SX 8S^?[M$5-YRRE3J2I7.CDYDG=9YB4IY49S@G8;#)('7
M )%/0M*T\R3MZ]B/G\-$4>0<@$9'4>'?OX;;Z(J=6SQSME(QZ_1<&WTD#Z1K
M""@K2N=-%C%G_IB]6;S6A%[/\[R^R(7B@*PKX+>&2]CN0EFM=WU[_/KZKX(A
M'X<Q%P#\0.2T)(((8Z@=0YX-2O$!B$VD,180.P)HQI2KKX7U2> I.%D $J.-
M]\[A6-LY..O^ZS00$1SHB  26)H]*-Z =%RH-[X8&[$X%FJY'TXTT6!UJH**
M5E*E9VR1TV2 #X=V^,;C&->9Q#0L&)I:Y<!J&QRIQ6<D1;HN*EQ4&L1:A] 1
M[KK*H5%8'I*4%!1SD[@'?/\ C/AC7GG1[SU'+A]* =U71@@&Z +W(/2Y<GE3
M[KKFJU(\VZE$^462%9QA*5*<Z]<M$-Y^,,>H\Z.<!#-<@ P%G:[6#L#EQM>J
M]>&@_F$&C%C4/>@ZURLYK1?J ^P+.^6]B2[%ZED!8L>]$*[LJ1Q9X@ =<9YL
M'![]\9 U\OQW^)C)SC)Y.0PZ>M5:) _ETJPA8YLQ?Z<N"^P2?P4_,/S:TK:N
M=$4*R.4G.VV_TC6O_A]ZHM*[VTA)\GQN[, 0#D\*KK](8(!]]S2@%8Z$CH.I
M V!&KIX0?XDTB$M2K%K,>!N_JJUM^*$?#A) .\/ZKAP+?5:GTN63G.0>9>Y!
M[\X.3MC?OV/JU?(XF%,APT((S8\M2N((3=C6U*YDCBU6KPXG$)\OE)3S#?.=
MP"=O#.=N@ \,=^=>...Y+MZ#K;S6\4TMK<Y^I]<EB$^: -UG/4)[SG?8=?\
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MXP;GOLXZ@_\ V!&_4'88(/T\O$;9^-&(FIP!.=CF&X$ZAW!'KAP0A#;IR<L
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M^W.$%$ORN381+$.IUT\/K6DW/4&8:'U!$&3,:BKI;#4T*#<T<[H4RE9T8!V
M?G9_9%4WAVK^%]AW Y;M=C70)$2-;#E1GT:WY-5HE)J%W0ZI.M^@3)[*_0K%
M2CTJ2[$ALL*0H.1_*.M!Y(3F ^8!R&ITR;KY)D[]^W['@]TX(=J/@[V@)U3B
M<,:Q/KQI,%JH5%]VE2X<1F+(<;:B/)?DA*5F85E4="!_*):>*<!I0UC5V:C7
MHS]@^?5%Z%E. IRVVK',@)4E)"@5$('*0204J5SJ5T0A"UX5R\IE%Y9XB=JW
MA[PKO.M69<T&L-/T7A]5>(+U1C1G9U.EQ:/4*= >H\$4]F8Z]5TIJ,68_&2T
MVBFQ'6Y$E#:)"%'$F(6&;:TUI;Z( Y <#/E<9_3SNK?0^UM:UYSZA2[,LR\K
MFF,VE2;JI\N/3G*91IS%5@.5$0)E7JS40464PRRXD&I,AB2M(\@I3:PK4Q.P
MW34DOP%17UIR41@:;U,NP:\.565RH_:>H%5JW JB"UZU'E\=5O"E2$R(3\.W
M"Q95R7DXU7)314UYZ6J"B&S3V^1V=[H"J,)7 B2,C:V^:G)Z5)9N.0UZR"-T
M48N?ELSLWF7XV6*5?MY<!:54JC2&U7M5I]#9N&5<+%"M&5,7;*;6J<ZFU[W<
M!?9$)5/:A&HOC*U+I$V%/;06Y3688&XRSI3I^XZI3OOS^RHT]N7AFW&3(DVM
MQ%<B377Q1Y="MHW!"FT[FJPI]0\]B2D(BIJK-"K,N,P]SOB)!=?6M(<:YY
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M9,N:I4/(\F,H*7!AD8C[B"$E:TE?ASO4"E>($S)Y'33&U"S\/KD^)D:@^4[
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M[G>N&=U[]_+ 6#0=\]\QWC&+*V6X\?*?KSS_,^=9]M_Y_P%02P,$%     @
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M!] \^S-A-P_&&7^Z  #D!.'E(P!F ,'^S/X6@%(=@7%"GM,T!A#NOP10'W(
M1-"!WOX\( Q 24I*2D9*249&":(@IP QTE!2TC RT],STM,S@R@/Z<_#[XF
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M$<@1R!'($<@1R!'($<@1R!'($<@1R!'(OQF$_*\W 2#1"&7.\YRJ*OOS $T
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MO]R&^-M=B9]8RYR3;U,<14TSTB)&94Z]7^+D\N,;__K."IQ"8^'W/F\MQ5E
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MO#0NCCMR+)\\%OJCQ?L%1;?#[MU\FJG'?8S@<9#C\?N,\;/6L6@NQM Y:%-
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M;TA<1#*>1627YM36WW5<781LZZ<#:".B<Q^J@_QH0 7K'F../4L%U]7C.?4
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M(%&#M*4@J@]+#I1!RX8TU#F6UPCU*8D>L9XYJS);IJMOM-6GV^+B0/[924-
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M_.=V$3G3BPK3%XH7^*X]7$]!3YT30A]?^O[W*,^Q'+X :?T/S"G;O<<)JT3
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MT_WM$7($RP.SX1>S)@T_SAO-H-5M\')8+C>NNMU*7.H8P3Q]V;5IJ!D)-\P
M>>,HK\8IH(ZZ.*#WJF;@S69Y+EHR!)$19EXEC@U*HFJO7Z@D.YASY$/3C7@K
M.0QF9V7S"ZCOITI]^7K)=;:>.0%$%1AZWF1??,Z=P6;B]2C40N<6OE,NI1=8
M1P_<7V6_Z9J!>J?$"E0D;VOOM#75L6J(V>[=$2- W^1AW+A#)4LE=-LW._@7
M:P1<31K+_Y?!PL$)\AYFCMH3V9!'"3Z :GWQO5K:%'\_&ZGOJGY:U2GO&'X.
MSIH+Y#8H<UZ9>OEE\DD_X,LQ-\('X)%<,V,S55 OCWGQ2\2".^:G!BS_Z4^^
M7L)TD/K'B)]!7O;MJ-9-%D===I\)9\3-(A.)1!-L?(?#N,CUJC=I>477P(2O
M#P(/I+E0B.1G2(L+CIR[SX9(EBW'^>6NPZ$Y)E(VST$[6H/!T&L )ZBNC5RP
M*7L< V_E%4(J,:@9U9XM')E;+Y>"X\I"?H&ZM=[#\+QS\-V_XZEPKHTQT4S^
M+U8EFQ:;1&=).B[>3'F.$:;OJ9 :7BNB=[(IZQML)B&R_H8;L^^_@A#B>3M)
MPT1"1G3D#2WQ[=M2F@(GN@0\&:XG6O*AV-^$-O<[25EBG!^<JSNK4(62EY?!
M<U7-0.>D#X M[U,+6>Z@"H',E_9Y:;OYXP4O=3-H2>C=[P3S?_WCDYZ%_P,"
M;+W$/H&(R<CHX<0[*88S3%GHMS12UD?S1+^ZNSNZ)MU[_T]_CE_T>$#\WTK7
M:3;OO.EOG;Z-K^W?H!4]"+/>S!";1[+MN1\)\M9(-,$ZU^.CO809A'(K(Y5-
M]]_S-\BIRUVK<^]?GJDX1D#.N_A'9*X+^/A(% P)Z&$OV0$D'G8VNSFIE7JM
MEQA4(=".0,B!%XG3E/<HU\ (3&.HAH93BKNR5D.4:0\BTQZA^OGT(E";A3<3
M:QH8R"O4F7GY4A?-^&OYT(ZT,<Z'06I#X+$,98+K+'DCT0DCT&]7(!;4M4P6
MPH?AWW*[]J58<HZR]$[RBSO*4)'&LAH_!C8Z41?9H46/_=Z#0<N/52F3O(N*
M..R?A<7</G5(=<#F\-BK>%X0A*?Y^N9BYK%^9F^G8Y3?WWZLLF;%R5*LFD^_
MR_A">V  W2D3I=KB \#D_M>OL+;<P+KR"J;W_40JWP[X"ZYV[ 6,JUY=VE5"
M,>I;R7BBYS%/SJ""->;8S,Q,15<ZY!*4.#W4,IR#V'$LHVP;*U,^F%Z@EY2;
M56X_P<60)I-H<D6MGIO44*5SN."ND<H$3KOIY%K@^\2?6S);5J,]H[9SLEP>
M1NW']G[F4?AR:UH+O'OF][(#*Q&!B@9/JJHB_MB#Q,.2&W"]IS*B4<2342;*
M%>97]ZI R3.?8H64IB;<]A<*BW'R5>AC9:-/DXP2=BQD%=QB^&SBZCK+9[XJ
M:'54LE);OT;]-AC/*&54J%:__51^4SICFQ&29;%89C:F)2JB5-%0NH"_4$]\
MD$.72$%0J)@DE? 5M?Q?:<#7YN'I5Y:492/2-TG1K.K(3!A3_H2]PA1FB-&G
M+?CR"X/<U^\X\/"X*]8ZL/=*\O_/#2G1T\7T,Q1/EVW:-/V)DM?A@T3G6W!(
M90?5"=J"0;;7')D)?#N?H*1N%C"C98\;.L')A\0B/1.;Z<< ,K<H@FL@P]&"
M3M"E9&^OQ0\N5!77?F4%.5;M838-=UJ5]7.]0OZS2$S.7648ITY,!SS>3&<V
M0OJH^L*.S @HD%38BX/KO?+(,"@4JH?\A"])]V0=U3YFS>H E\_DY -@STJ9
MTKR>Y 1W)A ;>?@OC+\?=A/IP=<XX=^8<A+PS_61(-H:G:+"ZJ_F-C3H1_((
MQ$Y[/M2#S\\.]P:1F!99>&>.I#M:<1(D-N'6C2>&)33&8_ZCV.9%F1P<65Z&
MU#I-7NX).^C<[%O4B%>_5VBH+E%;;K2G^_UN!AO[W,HYM?O2+<.F7+K M0:=
M X5 .=]\P7B1@ACB!TN=S4LB)-&RL B%Z/V4#AF#(_=03L 3*+L I=$-:$J-
MTP7:W7&"\0J5\L_J]E@)X>NYBO+>.6$J"4OXZDF\Z,7N-%LP_Y;8B'=ANFXV
MF&2AVW%E?!:@57@25->==%,K (T5[OSVQVT).1G!7@^@^0- ^Y6==MQ,NKG+
MT&9Q0?,!,OL!F)[S)YCX (1N1?Z_HQG]IQFL**=5.<>4E]]E, EXZJ5,#XYG
M(7F[7 EA<JU8W2^YM$TK8ENPUE]\D)IBYO+KSL#$WLUP\I;WL^/=ADV)X]+K
MG,:<59?F,-NV7?[1/AEDZ]W[S'-6+ZUO3/F3]*V#U*3BH*^Y7*HNL^1(3*!H
M^2HT$$=>>1BD ^P";%!>_$4G"^M/_DS+[FW&=#YP3Y0^.<!*9#W\@_(;5V3:
MD1:>-O3"KN?M!8ESG=]3W2_ I%GU=!BNK!F+?FW?Y."L[VF;[,ZAA7]LT#H$
MXI=I0&(3DT3(O; \^S"U6K6#.WFV8KE0;5N=9!!G6#.@2^ND39F>\P$X=%!(
M8$!B-?X\.*1M_<,=T0R?Z\\PN^%3KF;6<XJ!/G=;RJW<CB#U)^:40%DF>:C'
M_LI3)Y_@Z2\4I'O7U&5]+50NWW9V!;0,L]<5!0F%I!QVXI@@06WJW[46LP5+
MOIL<;4 [ZMNK6QR1Q+*=8*3?8AVCTBISC JRL,N[-E.L7;O&<PLS1['^RA%9
MPMB"BAHFX3::*+B10?2RZZOJ"OI?P;-+,!'OG,WZ^L8S4S7])$S!2"(S@UVY
M%,M&:7>V([;'L?B-ZG99/QYT<3E(02:!O+AJF_E>UI1^[^6N1,EQ=UZY8',!
MHL%L&E>1QVYM)!<6*^GJ$1XH&XJ@@]X??"Y@;J6R.#9*(-TO0&7$EK09 @D)
MC\>O[7;)P?U&K576XT+#V1FOI(<3D\PQI&94B2S&# W S"48O];,-TTTKPSB
M'Q')Q FL@.A_ 'PMFZ]X>LA_-W'QP'AK@5SG__#7^PRBA.\%^:!.38D/G$_]
M2P8FR]]#EE3&!>>/Q>-_;\5$%[ZYY[;_@9=C'56*EB-+< +@$5[(K3W&74RH
M,_Z.E1*UVU?I_'I42?B% ]*8?ZR_<#-ZBT1^&*R*I,:M#K^E6UGM'.14%#Q0
M@VU8T</PL@P3IV61T8<8VQJ/ZC@I"=[O+QV$*M-/_+%'7TWL%'/JRL5(9X7Z
M\T<^#)MFD53:H]S9*7U3O5SE/+J>NR*G U5Z^945&\[W*I?[GRL\YW40+QL5
MR'*!'0_"1.Y2G'WUBLEH1#)8='I'1CC&5,M^\3>:KV%6C5>+_B1QCAW[^H-%
MSL]@Q!_&D 7'Y3W25'^L0D8[8<TIIPE[5L5T9E4,8K>8NXIB7C(Y5GAQ)6DB
MT6.=^@TJKB&UWC<R&4S>FGR!_7YK!R_S47'2N%NG?_-N:12CXT YLGAL[[:Z
MIKIO+QC6A#LN<O7S.?V)  0NW;1=2\MJH#VC,7,NG:JP$AU%:V)PFSW]1_[\
MNSR223)<B"YG7+G4%QXPN%U]I-:N$X]3O^T>_WE3(D+["I:&_NXHE;_%-%?1
M\(N63.7W5BY]S;'&N[9SX5B=9)9"R6"34,T(J73*FF)V#+7=>TN5#:'9CNSB
M>8_]]5@I;'V!I&3>NHI8_5H&PQ2I6!4TI?*ED@6&I(D??KPN!32&2V_QJ%0V
MKC%L*W;\B V,BO2,+)FIRX85 TDL@$]U]+@"0<P/IM$G%Z_8;TP8>%Y;I<>F
MD>W=<"(*L%(;3_3/NA0LE[TJL[T87@&? M(08]JO-.[J)(W (;G%(13_S4;1
M*W*J#=67\1-./NX7:W!J-SFHEQ,;:]5M# SRK89;W;JB.K]\/!WK][LGQ[%_
M-=KM+6[B%A,^^J1(W[)!O4FQ9O/RSU N_%55J2#.(6SK<.2=J\/I=\)).4#7
M)OI$E;P0[ 0;.O8X/-=.:\A]^E>D\L!6_E3#RU![=?/I,*]4R>:-"V MZ.DA
M"H<F(B*\] $0O%Z4P))"+Y9ABLB&XZM%BO#\@O#%;/<'27RQ7Y)A!+:@A2G@
M T"%ENM\0?ME/&FIO7[7W'BB][A8ULK_+_]7 Y8</X6O11'$N/0@ 7# MUS(
MH9^B9' 'F(XY#RCQVV5G [:.6I^WT+2+#  BPT2+<7?RVEPDPZ@_0*FW47[%
MP%(^WDUP-F8D8\*/U9LN9 LP]#"8>-YPHG[.4>M[RMI>/-<E*Y?70?O\[!'R
MJ:8H#H<P)@&^!Z7^QOAO\#LYAE]7/8HWQ-5(>X*58F'ASNRY]@?&L&5"-K".
M@0H9_/K+9G%2\[\=VJ+F<IH!70BVXXWC1O=X)'4P/UDEQ+6TKKZF-OY!JWPJ
ME0ZLXIZ!!,)5=SN7^;FN>R;*W1EOP\,[3M5QQF;GIXOV2SQGQ3P>HAN:$<*V
MGD_]6CGI#B\H9XM;+P@E)6/A@9R\TOD*I,IYZ]I%,0L"0<Q,2<GP;Q=N'/']
M7L6'R!B&F&*S5K<V:YZ#')))]-L1.R&WZYN/-^M^P^ARE4DH<JBBA8!UY'MR
M771$@*$)__Y<=I+[-!V5&W?+DM#:6TMW.C"-TK/:V'%@LPUZ8D7]'T'2OZK)
MXN0+SY.;JC*2Z3#>=.V>C,3 4(BX$XXXM2^03KC1QDUE]C<GT,^L>XS1LQ)T
MO/#&ADD'1S^0&%H4J;-C3I(^1[QIDGW=6^6O)UR.5$A8,%UB,K3F.!@OPY/D
M\LC&X>< [;H(S!Q*&<)6:W\RSK)*[MHJB_^I-+51\O24=;+S3<;X3G)) H-K
M]'6MXF(+A8;H2 9+%%YE?]*?_C^!PU#SG]"IA^6E5!TIUG654R4GPYC:?>DE
M>OU=9=&V&K 9*?12,$.Y!& 6>1)C1-3!D- W*RU'4I>(E.4$+B;%_\@K. E^
M?"!<=@/."I 8*YK.'? TNCH,A[9K=\2!T4BT)Y?U'QH_GT#0.X0-VE%"U,7$
M0[RKAU)=J=#E'LMW@:^ZIV2D@UR@8F_#_:5<G(JTP! Y.T2Q:6Z'B+:C*LOV
M?O? 1Z1N&V"N\ZV]"3Y-['(_EMC?[N[YMN9MO\VEDKR;,M==U<S+5H70\"4
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M1B:YGXQR\\W9I72P"6Y\$0Z]\@]V_3\ !MHUC?/@:-E6[;93*"K24-42[ ]
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MM%]0<@C12WM^$=W E^M##-(H#&Z!OJ#CDF\S9]HVQ1(;54H8S4B?B;B;;W:
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MQ6/"&OW,% :0B>;^Q!A_:"7H \!II==PS._ZA[K'TXJ@6:=R+O<'9UB!A+(
MRF##J6+KJ*/-CN#[VHK;%0=EG%Y$FQG:9[;X$U-D@%$/U0T?W'F/^2](>][O
M?!H&R8,\#"7BL_GJ8-;V*IU&+"58FG0I +TD*8K2=8T3=N!?Q)9%@/<B )4R
MCN/++[&>R0IES9GO9&PPYW<Z)&,3N9ETW49*K\A81@A1+_3J?+3L*4&V*:J?
M0$]VC@] \BU2^@$L702>J9[5%5+LL*C8&W-!0#77 R[[PK%>Z&JN9MN8/SX]
M@5>V>C%-/9<\$I]=67)?ZM]5\24SEZ03*,%YOL\-'X!,2@UNA&IA<SJ#L-_N
MN@6TVTKU%P/THH-17#MZC89-)-[D]." *F0ZMU8\0BQ?=%\5-E_/E^]4?KQ0
M8U^8W_]^K2=I,W*YA0)'TU(4L8W'<PB7HQPZR3^ 9%4N-S=RZ9=1AK;,S2,1
M14=\H$1)OU9^U^2B.DFDDA54<!YL.6QYM]\$FPT)G6#.5VI,IVZN6!\E4 N9
M%@)C@<F.$<Y"89?1SMD(N1N:XA11)_K%K5;F@=]7?+:\GV0P:S!5B\.KP T%
MA.56C/):78/YE&9M8L,ASC>T&X\V*^O7,Q6K<*=](;0)3 ZB+"@&RC09.60Y
M5=DH^TOQDBPQT)R?!,YI_R>JWC(H#B98V%W<W8([!)?@KL&"!)?%(<'=W=V=
M+"[!+<CB[AZ"V^*NB_M]S_F^NG7OOYFIFIKJGIGN9Z2ZBQ,B$>?W?Q@H,@F9
M9O!3_V*M @4[^B _74.M!SS\3.._R71!O/Y]K7FR&6@,BQ]!OP0UZT4_[Q\0
M_?O_3,^GT_\\HF7R_]OR_DQ(U4&"1C:S@I\@/YG#SS/.Q 0?Q.+JR=?RRD.0
MGTV7)^$)=Q%!4 4W<V[)X_M/^QF7,*R[U4BS^"1B28.I/&Y,2.-W-RVN4?)X
MQO4&IDQT<YM>?_%J<&*!AUH@[&>;WA2,V+G$K#K>$?OGR5!&=I)J]V:O!MIX
MM$>1E\%T9_QP!&/S 5=;@XC35H!1G\[YV8@FBX#[;:R!NWYK8)J*!=S"VL#)
M D(*7>1XRLX8Q6?1+8\U6PCA8'V<&W^5UMIF#J&""3$7Y=V OG:3N3Z)NR\=
ML6K(YB*?(L:,_QC-P_ZH_43Z-%<(/$V3[3HDM"6'];>KIWR%LRI/W.E@^IH+
M=BD:'85R]>7@#H 4#90BAG+ ('DYN<O\Y8#\Y-E[P2+X'9UF3SFR-ZIQNS^C
M$H*VV*Y0R5C 5Y6%8_V']$'W<*N0H90^$K>PU(?1/_NW@G*M)_DAQ+YG2ECR
M T", Q/E/"E.993#CAE;N5)WI3\]%/^I'KICL&"707_@(G&EA1Y_H>S@8]^R
MB!CDN$^Y=S0D(9CSY_J-L.\7;>'._=%F8.FZH)8.X7<^7M$4T:-H]F\IRM'4
M1J/A\ R+A$RG7K6.??T".VU@!";=0CK\93W@2"9NS+Q$ KXF;*JS&78MH!9:
M$)1'3W$'+$OQDN2GR9*QY.=KVVY>LH2B$-&5E(/H^=OXM\E;:7Y'Q86'AQ1(
M4N7Q7I,F8*=XIZ'!ID$58*0&0<E =XQPY]C0P]:U:2S(?A_^*USG6[X'<@+,
M9L!,![P<X%+\YT8(;9!G?N/_I$D1GEEY,(G:(C\\>ZF7<<*\N?=?IA% \GX1
M.\,A^S\="Q=*;B '+PT) E$\@DX[L4BW*;5:T+S0D_N?$XUYI4LN]SD'ST,4
M1;WV*GWE?47?DC'5L4_(+!VXJ%LV)-S+<(;#4E(0&O*1T5>@^QDTG\-XYY,@
M':Q?QB* WV&'L>7_/ND>EA7-0ADKNTXBLY*U#Q7M7C7/Y/=M.5V2-6*W&>,5
M!1V&%!G&ZP%!K!PN=67;OFPA((9/.^E=.&&XW_2#])MMCA5O=P_/<S0K(K!-
MJ"<>6 K>"_4%2NU3456>JRG*(PG>YE=N_(/N$56%#1ICV?!&72&C=FQQQ7]T
MX38?OP%G91!JI-#$',;+[,WB*0C%CW^6!I;CE,JA'J0R+IC?R80O"FD<S@IS
MJ(X-VK'5OV:)!5Y"\$73^V D2:_BT!\'BC5FZ%/(BZ-BL+_9?0".2/*$, 7W
M-9,>*E=.8EN2OL^5B<>&FE#MO>BZUK_^ GA WKU*#+/ZX^>H)P[HQ\9?BC<>
M#5Z_NHG/LY(UXJY3=#-Y*KUI&VOR=50+26?:Y#*YKJ^*>NHT=8?KE8G#,=%'
MS_]:])FX'2\ATEP$2A>VU9>*$R_P[9"=K*LI18LTKVF8F%ZU6OWN@S?8(KP4
MH&\FL2[8ZUHF+^:SZT-WENXH1UBVL-4Q=>#Y<^1.6LU5G#NUZC@,[J9'@3C[
M3TW-"%\FYLGBP+=BHL!KL.NW[BW^*R' JM%?]W:[TMF&[7_8?_?E,C6=V$B6
M;YG#E2<-7A<[4V0Q6]6<F_]Z#,"(I.D6O7^4.UC[M&/2EWL\'&_KW_GWO=N-
M)?^PZNSR Q 6*1Y6'OZB>QS_;^<:WNG P&L1E7%:^?XI +2B)HY,EG_"T(;>
MYM*^=]_TE7AX0Z*P0*2NUU]$W7\"P05PLVR<&9BWQ/?IN/3B$OM@)*J\RO!X
MX94HQIJS#^Y+*MH_=1:_9A\=9H;UR/&8Z#V"95^DIU:H =COFX64<.E8\<T+
MQI>N99.>CFOE8W58=2]'W[R)S:W\]8"9M%T<V.E;_!JVOG:CPY#Z,")_4J6,
M9YSG%81#>=&,_:Z1;C[ADA#!>_)NWZ<P"1DEV]()[>I-P>J]Y-;-=_. [&M#
MP)L]TFW>[VH=3=BT7,]%'-<V,EYFLZ\')^OD#Y!6=+^))H)5>%$("./$(.BO
MN[#X$UQ9 8MI6@N(WF ]R)O.E3Q#^7W=>I"*"/]$I^V;.E*@HSB7^$:8\;_W
M[;OO!(FT1S6:R?VUD !6.]D0!?*<R^[EZ/0P49N%O_&B)Q7L#7P]3LVU=Z,2
MC%^%A/2W,/2KJDS$-T;O0MC @=9ML(_GPI0? #S*U\)_G:)W^FSM3*QHCK*I
MOZ2_EM<MV/"\W%_'1^LQMZWG4Q,10NT$'2<H%4*0/17H8G*>G#A4JC)B:+8
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MX^3IN?[C];(,.4,@:>[1N1_#.411'$.E0@B!!8-1X W MBY(C3TH\'YZH1^
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M!)B1'Y8.Y4Z1MZWFK#/$K<A0RT!BFT)O[#\ M)#I0\)(#VJ\2,Z$8S&&X)Z
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MCMX1^OV[F[0?J&"__K8T @;S==5Z&Y-TU7!3]G^+P(;K)4,5=-:>3A<BX0A
M#B0AY&'?THG7M;CP@M89?0ZKI#.W#:40),5KL$8R([@OR[<:&2MZVF$/L,I[
MSGCK'#;4+8"3X+XKSNM&D1 * H@8 $1W/@"1Q B1=.H".ZA:?VH11X)]'SX
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M<T #$X5$-6+.M/,7"U4I]G,?@.\1B]_7E'A4EA0EU<[7@T"0ILNA<[/'U ^
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M^LX5L,)MN'-J^F6*OBTO]LY(R+(XUL_\FDE_]M<<8;5\ <X>1:RM]>%?^WH
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M<5<85\PH*N"X=^4#B_8XB[9>#>$DT*"A6I#>BDKZDG)/TO<A8Q3S&C6W[<#
MD_RJ=M7)*^[![GKIS 1_V1-3<K3=A7=J0!C%TI^-,69Y^3,#*$50 8I+ !O?
MB'J,FG<D/1>^IN%7K153U*:MKE%.L+&!'7.,Z^T3E!R'T:E^W#"OB*"_9]=,
MSSCC$!0&?4EA52"QLK;\^Q<-A8]?1%'X!AP7,-VWX<@@\(B@4BV"EMZN\Y\Y
M#!VO1R$BW=QZ&FI Q^@5Q?%;^X=@_+K0+E67K))P. ]ZG]8O!^53=W\QU37;
MFP/UK>4'GS2H8C&8+"+7V<34:BMF])@,?Z9"^!IGW]J\+/NNW-G#+C83!G=5
MKZ9-5$^L=@.DH'*8<A(O?\2:Y[89S^@00!TAW'D;R T_D[-_X1=M[6601:;I
MJ-5_2KFC6NJMCJ"2IT*V0LAG8*3:=/O+=?(%.X^[%)@ZO02 +N?VMKQ0F*SY
MF25\<2%+$0DU3IK)JZ+C$K8=;LLC<VF,&.-FG.*C9AB#7YMH?LU]V[.?R1#Y
MCOM#RA!B9):#P;,8*R+#B1W!T%0H%C\53SZ$=UK<<6*LH)+0J?@'L_NH;W7G
M W#.P1SL?# ,MNL/Q/ADZP!.KE%Q'.!M6#FCB;B0])P/S>;=WQYHZ&0$!*/(
MD._*(7T VI5G5A+SAUPGGVM#2#&E_QJ;X5<Z?  6ZM[QHDP+KI#+.2!ED_GK
M7%\QR!%V9*<YED@$-$Z*;)#7:5<S%1/N+R<7G_QZ&'\(OT\/O>+91/(PU#G^
M4W$_Y#KL5BA':![] CT@"G44=:H!=T5F'/J^CIQ!.KQQO,-"5C)*P\\$'\/K
M8A@C2&WSM?_&BVB8N>[A)IO)+WN2]QQN"L_\X)S*0JOWBJ+"A6FN&ZH*Y+6B
M&6WXN?<<;^T+5!]K?XE5$)$!0GL>'.UK5O;.1R+8H#;$4)+NC+;ME'&T=X>0
MS"W*Z,:%%*7I]?*\ (W_IZ/S?&3#\;JX#AUJE*(U:Y-8%:+$:&U"C$AL6B-(
M[-F:'6IO$GM+D-B;J&K53&*O&FVI&719+5W/]_?\!??%O?=\SGEUEC>^[!\&
M[7^0R&3FY/)J1]L)P((.I=7[\BQ^/I"#%-S;)ZN'SP?YP0_XBE[3+]0IK_B$
M(63C)PZR#P/X='J5OC\1^!0)F)0]BEDY5W^%\[_GE.LP8HA891S9=H[ZW?5=
M^]9=>&N-S'D96(/WW8Y?RU>*B9E!(R%L7R$5'9)/I>N^"$L6XURTONZ_.PT=
M='XDU,V\=MC1%MF]5?7T$C/F\U>HK%UOL,ZS>N8=<H/NGL9C;_G.]O<1KAM_
M/IB$..8E5H\%VHSR&TPP1GF1MD]H(@!GZJ.$<I?M\/29*;2119'*K%Q8Z(?Y
MT]?+Y ^F*X_ZO3*+E'IZS/_4X[CCKIK[QJ=)3E%;_TBOYF=MV7J1G_;^$+H>
M6>T5_37G7=MH3##+Y-SFFY;N>K_ FV7&UUM5(0I".]+.=KV[^2%7GQ*=5&]V
M<3-<Z'MR>JJPD:_TC\%$*([H%2SRZC,<K_V#F;'PGH@96VV5+OT1\*9DRXG0
MAPWV@Q\'0QW>(Q6IR4QWRL)+.->+6ZU??"F>A'E-FJNY?=CO;3_N]+VI81V=
M3MQB-5WPZ;GW'5S,EG%X8=3_RH9L^;(;OQI[642S E/TL'CGZ[C4E0\393^*
MS^0*]Y.%3JU:_S'4&?QPS<SAY?\""U8FOP=VD0&JN =/!.YUWQH6=(Q.:);K
M*?0<:N3<U\_S^#ST\4\6J60"</H]QU#R!F#W;BR(6["L+LA^;1BJ()E6F\$W
M7G(Q _:3<>QKU-./$8>:3[Z>K2@,"<76"?.^L\-"HF?YL2ZB(.FG1AH K>H+
MJYD$2 :B-D/;;R7RY-5?TS\GFRD!)GE\Y"]*$EO'WY5J<TA-<1S2[&7-U:E>
M?I 72YE266&!GU>>^P2]7PRB1>\_'OCY([F?9^0TDA]M8:#)NBC2Q*!VSHF?
MM:/#B'V;"=OBT^<I4/SRUY,)5'.<:K-53!G70YG^DX6L4;EU"')ON-XVW0**
M7UAI@L+]UOVBE]O^_%Y8^L'WPUY0QN(.]&YM >_U@9L][W]_Z;WUI$C#>['=
M<)*>T;*O.!GBX'@-(B3E,S@55'G6]Q>+TGK2.M$T?!4DD=)T\2O?[ <<3T']
MOE""EZN??)\\^-A)IBZ%'6YQUUJ-0?E,/0YPRU^U,YFD\_CTSP+$S^&EV5^.
MLX.K72<ETX,WHDX(AGV+SA.Y8VG;K0KI\9PW'R=OPD C=SOM-(@7QI[M:,;]
M8S!S]NH#F;%0$H7V&=\T\Z?]2JV?Z-L8^L=P@_UY4]JAVVD.=9"\[?@X]YK@
M=Z$'L;Z7B],Z&.]NO$(8,7"<V[]Y6WC_PU\=:LO9SRJ3A-3MJK)WR)8(_YU&
MYNO]_#?#^8?N<]=$=EDCL(=)(@L,_B<^KWY]7EX\^&06?G-O;>+(]H+-M3"+
M/QI)^&$Y+J^5GS&E<B#LZ:4?^\N"ACW-NJ;^F;Y.N&M*HH\9&+5J[E:6E/;N
MAPN<36\&G!7;=91=N4PXJ;"QZQ^&!FNYO,T5/_%)L_2\[J%7DY N]+L!,.I#
M>.3,O-[#=DUEM,U>;]VI-^$-U]TGNW.+U,^B?7ZEOK_9(^].!SD$;>7/>2(B
MDR6EI^:+*@L4CTTKB]!!54.UKRERPWL'Q0 %#+95L-K*9S."PP5[4 $P,=0%
M,$MU5/=%GXH,VR5/Y\)!K_PSCN6X[?T *(A^?+L-Y1@"0]KVJ2)#.KJ.N75?
M=CI@&FS3;X@2=G!A2D=P8)!3JLZ8'T+0YX5V>(DX*5GVR'QN_YAHT:JG>,^4
M@B01N%.KPEZ)1XB]=5!_M2%K1C%UUV^981BO:=:@U8M UA7MTBU#D';!!9'Y
M=0,Y*DXB9T..O@(0[5M1Y(KBU4\6R3IUL[;G=)?//,W%SY<O9:QV1C7IH425
M9K#3^V.^)^^J 5NOA,Y=)(J^_K1K^/VYUB<Q6T'56QG\G?>@&.*=-LDJ<OPW
M)ZZS/AZ[VEI'MI90^&@K:(/I,'P4M^M<KS76;6_T\-XEV6L*K:+O<.^MZMTH
M,HNR]3NC@1?#"W$,W/#KG9S70Y>O_%9W8]?5WXG # 3-G2Y1W[:5*:Q]ZBU7
M77XLP._XDUXPHUPYQ68WMW!I%W*AA?(8.?V/H>**.AIX[6_LYP".O)OG_XZ<
MT_4M3E,[+82:L!>\TY;7;^Z;/GXHUYVH<BLA2<JG%\H.U>!;7,UK%XPC?]I%
MZ!E75BA_8JZM>J#3IM(BWZ1]/%?&Z=?\J<__2YV]D_XV;8._K7XT8#W;O??Z
M:K7J5,-*X-IK)-6*G@S?L6WTDTP$:Z9AS+F%QPO^7,OX9.E_GC.^_;.PR.I_
M=H,E-D&2]^=)6U>E"%.F=8"O'_&R1<7H3\/5K[K[JTQ\LST/3C;R0EA?0'[3
MF^J"W3#+4H)%O5>OKXI=5\D*UP(W2U"ZU46'.I-3@D*?W;G9ZWDE4-KZ4F4^
M!7M-'<0XV'7OVH/2C/#&1[T^_QCT9+VF[R$DNHFG9.[".1",[7[0!_MZI%*/
M4]L-NRUSTFFCTH;XYL35S3^WYOA_Y5=:[E;%6^EP5=.O5)&[&G/%6^0"J*[?
M+WG%9/>TSN638&]5,!K<U*L,ST881^-%_;_(R&NOY)RE;F$PVM:S\S/^A9('
M#T 9F5[O@2X9ZQ@M<3UQUI>%#O%<@V[T\MAXY;6S7TWVZMTA?S[G+CI4*\TP
MW,6\E'^/.U3^QR#=YI9]P,SX:>XMG0 ,)JG]'1O^&&?HY%$%4 ,[JOW:1)F,
MUPJ&,OFFZ:_ZLO[I:I$O@5@A7.;/E+W:!7DE*E!F4,5>3>DY:)2.''PQ4^Z9
M.:H=(6W[7!R8;9($K=M?PNG+W*(S!MY.>^J@VO2FF:,B0E?Q_)SJ3Z!)7=?K
M<8Z/IJJG#>CU\O$NDACBL4'EE'E"_W/DC'SY^D-\!T>L4F[[FO!\@NG$G<Y%
MZ75O=0>?V;M'CY53[HS$L>R>FUR&,'>!OW2'=5ER!AC,>GH]N,D/VGJ/F^QQ
MQ.*>P7=VL\=WZ;C)=WR%)RPA3F^;& 4ZOURX_;.M^0K[HP0%OB1F8O9/5>>*
M-S]#$V/>V>CMZOG8A;W/MMPQ:^06FH/<%8S^536AO66X^= ^R,F\[2N%#AM.
MD;LBR3S6*-7MSLDECT-O1&*H2AP7M@<ZF1 SQFX%6636O8-I)LQ[WBX??ZZ9
M)^40LVR4UZJFUQ>?S5L')DM\ ]<UO>QP)VR+J#CSA"]S@SNPLSX^\-)QU,X]
M[?JH"J^AN"VND9T?EN[/ZI9L[<)+]>F5DRWE=L2[^A/=H:3?0+ P[^]9RGNX
M?8! HE%EOT_@7@C' !"R-6J1ILYG<,LUZV'MI1GK+DI)BN/SQ36W+^TKYR];
M5Y4?*]?NAM>C7NX,0I_IYVL^*VK9'T6<X"12;:B63J1IO+C4GO-$>%Q2.]=<
MRSHAZS.PVJ):!8][6PQXODS9+-XC+3Y]S<H0%G%DZER SKD]M3#3V:MJ!N8H
M753&9P9070P"WD!S#QJPG!W4D$^$:VS'9N!]PTV_"X)C7X.> Y_@.*>B+WG5
MJGW[QU#+DQ)2JG$[;^EMWN9BROUX&L>20S"GQ+Y#.XE0<^84#TEO+U@(*2NM
M'9W:AH-+YS@GPCZ*T*8E=H S/JKX',5APU?I$-N\O$*3;V?X"E_+.4>+D>Z*
M='X>[[@5TLS#NRHEP,#M,JGUNL5;Z?%R59\-UMV_218^0Q&&1P-92%>$;C8*
MNPP[''0F<Y!9@Y\+2V/\#(PY>N=FK,M=GG8)\;%$KH@5#WX)Z([AD[M5J3:N
M*[;"QTI674.M)6D1E)K -5U^)OM'AB (2_"S3]]W'7DI?7].PKG:(D+7K%Z5
M!78UFS>_6G7X%(\Q3KB.,6Z]%*YXYCXO5\]<L''-_0N$=SEF$X/?)E\Y>FYA
M"+.N-. XN6)M:OH"]OU&%[>U819;7JF$0DHDNQY96'Z8;@_/#<DS8KC=FG'4
M>FE4XMZD&IXIIWS--*7<8!#P(RCXMOG*MXPRB$Y=9C?YL;=>/Q;[75;3VU1H
M2"2V9FQ85C[B+FE,SISE=4]SE#ZBY\.+ _OO9RM%S_+;1&>W"6[%VNXOR+.?
MW><@OVUY+JN@9!TIAVC<U6^6K+K>/_!<+W]D;4'#[I2PWM<+H>#E7?(.U]L'
M7@_+)]3YOB$Y?M@>-N,.=*BOJS&\V#/=;1O+OT X&HG8^>!1=2ZZXF4)M5%Z
M"\'^CX&-Y=;W-/MG(RL_UL<_K,@DN180W5=;G=1/42G3!O\8%B][^/WY.<AI
MIN7:T#C6&ST1?/ #-W<Y2 ^@_:9@U_OJ?R;&_>+%\YMO0I-XOS]^W$<05KXT
M='(KS]-,)F]+22SM 4JLKR\*.O]V00#]UV.^_N;.NM&([^;C;$]RNQ7)%))9
M>B"7_ 9AT"+@JP*#M-<M9IOM'(>]V<Z  5,U@X^&Y8P5+EHY1KV*<7$I[Q\K
MY+=*<OK2_N'%4=G!%G>EYVA2]/X=IGZ'+F47" L 6>/]*BY\8XWQ/\!L^&>N
M']%VPN8COD#_,?A9;4;81X8T?0YC<-J_=H?''>3%O88B)%]04FB^:!DJFB_V
MCJ^/GFWGH5W\")[X+=< \1R6=(8^4D*UA/;Q/'%Z8RV=QI+M@GRH+R%;*P%Z
M*VRIKRSW \P/VX.W&+\=O/95E?;(D.%R^3S>'C%>.IGK9!7>AB K,TKMXX)7
M=JRPI/<U':\<G@5$' RI=*2T>I3]-WK6=I'^ORZK*Y>#*C^4G'OY+J-@.IQY
M[R 'G]2G'RW;]9P<$"SI]^+$^U6&#U_8?5$**_AGBH."'K-YEN=<N>#E2?<]
M&8Y'GR[>O!2[IHI@UV83T#Z)F/\=K+6@H7ALTM:'#&*&2==OU,5G@@--?7%5
M42(0M3UD8#*; OWS(P!<8F24?)?4?0B1XR\:="#,].:-.^!8XL6)9F0*1[4E
M84DQ912I*9:L>^63[6*[*VEY#?_E\LU'8@QR##1_#?!$N;TM*<]<I: ^)J@E
M<,O-G^64L5D_ .=?B#_V,K_(F<7-F5G!<ZBYK_ER,2)],CQ"?:X_"":WL"N]
M7;(.=">D$U;--?>AM1VO+IXQ&MDVY' ^*6NTP2Z=FH%/S@7\8YCLZ/@;]=?3
M0X,/&%.[J?-#VW-MK[^1\E>FV;=EWF7VJ!1!_VY'K-#3,3VL4T9"8FP) \:'
MH#%3-7VD-O$\IY0)%U'\M.6C.Z=^5N>685J_,3&/W\5M[Z6,8\SN-433]U!D
MH:'()B[JIDPGY+K7]@7KTBE:K'()EV!!\;7SRH:"LNW'UA</6G*4%Z'<*F=2
M2UFKSV^QK+VP66GJ*_=7M0AB=ZY,DZK@&V,78V!)Y _!F!<$N $<+X?\8TCX
M4#G5ES3_G>P5+.?M4/HBY-O'<8.HEWFN2]/4)O];MS]6LBE;7F)U[;4'JCK7
MURW:)^D]*<LUY/HY6G/DI5;BJ +A>!!Q(IBQ^G43&C%R.4<E8/I3K?G<1RNP
MTLEKQKS1]^<20MV?S$AX3[N^OPC1$KOQG]R\MOD6>[2V8SC5I[9RE'#W;M<F
M=6L(T+7#X*ZD^3Z=%WQ0*W. [SK4D#^NAM2&AI\_2BJ54#<,(BM#LV5W]H>2
M^:K9M*TW*)G"3L,Z 965> 4'8IQNCDC%>7F57\) EN7(L._9_QAB_)B)\$OA
M-KS;\%X.L026KV]'3U4"JL%S:A5X:$G1D?/.^^KNZ4R'"@_FQ#*R1G804E@I
MJ=CLC6VN-/V+?84U^A)!)]$<;W('@SVU8$Z*7)QTSZ%B=U]TO P:N<5LX:?8
M5-_ZZ!?]+2PA^1'96/7AJBWQ@>1$N5_%/P8@\<G<@@;/V.4?4[*'GQ.MM<80
M+5=V]WY]_L> :N7M_CRJE":Z9?KGW7.;&V7!\%I%2YG'A;3+'?\8LL*(DEXG
M/V]'_2X+\R]O-/Z37GT9F22[TOCDHYW]C 9SKW^\@8#9O!E"KKDH4*E7RC?M
M)(<^<%&A!*)U%#U-HQ&;T/ 88H0XIJ0*)4,7E ("W2LVSW7)M>!H[J[-MJ'&
MCIK] SI"MU(O2HA@+B0KYKJ$N?-@OA]TTF1GTEP&J1<&AQG7=$N>]PJM-.E^
M2:58W _0#5[8<1R.EKM>V#W-,E>?%AI&E-.-BI03,>#587H_MC1=\="N8;/P
MSJ<&[X7*>#%6^OQ?;O?OF*YP#1N'2VRN=ID^<./_-J^SJ#L+ >^S/*/W399)
M1^L\<Q2YLOE$BN]37TKNK8 (!Y5/6JH:3WVX=>*2KF_'^GRB^3Z>(]GE,.WP
M37/IH/_P76EF%*WZH1W]]X-@QF^KSVJAM\5_9RN(#UYIS)Q,1NZ\'4,]1\C[
M;V@8-V.LGO)Y[-;E3DKB1;!0H 9O3@:\767!5/#%IC@ [D<^TZX72O[&TF'!
MJ'?E4P Y?TN%6=9<;A5>_G6FMHM\K"/%L'_"V140<:F!W&'RJ/6XC=>BA*P6
MS#BA^@A!G$TX.'QDY'-__#30]_[8HH%-X)REK%I&<*5T 59]X7^4PW;9TVR=
M>HT1>E8%-5>53C%W+*[>^?@D=_#>@!*FQ/?U;7UU[7=0!B;>.[ZFOK<N'Z*:
M?HX%5W#H@'])!1 >9"VF9)UK?ZWTPJ;T]U<Y]5J@1:QMHH5]ZK">D304CMPG
MH?39[W9SWZC0NR8D,0"R?A,P[_]=-"$QP"$][^\^NZO)6I7M3?-U^)H'K1 7
MA(6"+9(^2VABJ,$.PQSY5DE-^W8X$-B%?[YLW-D0/80:-O937D?#N6,9ZMC%
M)'6/BE73B@M[ZP.9#F%"<R_9\OI$0=OQ-3L-]T0< SC)M4U($;98#,<NU]5!
MP@4 ?8ZKX0LLJSIQ4!5D5>K6JUG=JS^2?P^X4:!X>)L(K=R4Z852CSI)'.1L
M":\,P/55G4"3-"*^!Q# )3S/YPG4&QHP>]%QO0Q^Y?Q"2Y+E0=G'7.QJDGP@
M+(%_WTC(5Y;F>U?HPCO#-W(%ISF($004OV-16 PIAN6#Q&Q-)=0"B],%ANU1
M03IPD]!B^'GN7=L0(VA2UDS2.3&2\V4S-@&6(-+/RCM'([C<0,[(_B\Y[JH\
M^9_O56SG$C?)JZ-3J98@7:JOQ=+$E?(>EF'A7H!9U\%#\/!KT5]<[?5BRX^_
M7;9BHZ\O *]P#'-$:ORLE7D_O0Q!84+<:_X6;E9;FN (N_%758?*NN<*]"-Q
MK"R.E @,57/8MS'W=MB/WP+BL\T03O/U5F'QH6F:W^WY_/=M3VYN.7Y;V:[R
M$'E;G0H\50MQK8HKILMYD=R6/CB,S0'GQ,OE M$9%>UF[GEU-5N!L7 P;VUF
MN?\\?;*5WT[WB5N/'-&6PO.\D%/V9P"M^P/8]=$3,SGFN&L1ZRX_>/J2O!1G
MDA+J)JS+I<T4?;2Q<]I:U.Z"C+AB/(+(_NX>'2V=4^64(E RJ,WK.L3QWJ!)
M3/W3LU5]X'8N.RW3T;,P31K791&S %QL'6FL#4[7')A-R=<95YAB$B&E K;I
M4T"6649-+7C_6H^P%#HJ".UWIDN>=@!>@\>K<;U0:QQLX/O84]>PG$-.T(2D
M_E+Q<8%U_C3HS-A^CO-3[U)!+*5FX;@N9ER%-?C6LG=Q&UI<O1P4R1ZID1O^
M8"RZ5U3.NNV,(.=*[@\F9R)FOMN/V88-R N-3P1XM4/CG](G+//L[\R99@OJ
MBG$;%JNR&J8R+NAD23B9TW.+6QOT*(M$.X^<&I-M 0@M?[[@Z/=71+@XB*!7
M.5EK03P^_\'$>;Y\CK>N5U#]&^5:UBTT2W] 9W'6HM;3@0<9G7/+ZN\U@1J@
MEC3X2+AS?FNH%>W[GETN#K"8P\B:S(*\-1:A[.:IZ-QM$7+'51\F?BHCYTV.
M";!+OY)O6B?,% (245=2>G3/BJJ_5;FV,3B1OD@.F*KGFK&Z2)_-YWEB?!CM
M0>4RZ=;+.8:FD! %J8H@*_'AM +FKG2*KJ2=B[BK/"4P$EJ4@UNKRN!C'L;^
M\MA<E7GL^:D8\5NREAOCWQOY[E[ABYW*HQK\%DQA_"S3I&P8'ECEGZZ5KI/K
ME#:HC^1V*&IF+]@TDA^ UKR'MC)CN]Y.?7 ;P8^@B=-VV-OG-^9/:WZZN1TK
MAS:\L)K0-B-Y+)Q%>GYQ<(]<Q/Y>5"X6[/A\'JR?; Q6QL!M"Q%51.^JDM_Q
MO 'T8&A+I8*Y L$XAATIX=IPHUY]_^MUOA\_/B\E];'B>]08^&2Z2\#1)-7A
M*I-(0AZH78P^Z(*0^0$MWS*I!RNZS3AEYP*?[1QLSXJ-5H%A^(EX2Z1<R5LP
M;]%CN:0V-)@W1:INU!(9:-8768"U%<J]?YG%X4^@5W,[%+WQJJ1;SNI^HX?W
M1[.2V.["D P4"<F;LQ&>:BE#GR_;]JXVKFKGCJ2S4!L;BC.W*'4 7%)@#GZ6
MSU=4OJ7H>IR89Q2W%D5#^4#??U:FODIZ5/4DL5!1K97/N:!(RBOU:@(XJ?Y<
MD#@U7O6$ZXUM!6*53,5D@GAM?(/CV)GLV;H>'>O6UA1+;J)?U<R#O/>SY950
ME&B31TI)<<9@\HD'QHO+,'C.LGHRKZ(\[GJ.>X0J7!CQ,20AE=$0C=6D6.G2
M-.0/Q59&B^E*O7*&^(W]KYD';XIM:6"(G@7%RK,XL\*$!"OOSBG.Y_#ALAW#
M5F'?3CO89Z[W !VN_SIPR92>.GO07^7VQVC\+!&W,8.VBRB5V)240-UVWY(*
MHJ<SDA)M$O*51A3YD7J>=TI\$M+:N2OXG4U[!)A?58B)!6]0YQXWK5!5KX'F
M//1I;04^F*>_L+%(V\JMRZ#WD'2(])1;SSE%"7?^SSBB2RX\DV7KPG$^_+WG
MY,>TH^[5L(6%X5(FH!ZCWI?;#NT/+\!C<LK_,1"*I0_&:]VA+-R%]XF; ]8@
M)Y<Q65$EF$N^+:;2))[07A E3G*5BE9?D.9Q14JUN_Q&$]XUB+]+OV^"ISK8
M4,T>- *#ZQ$)O/\=WA_[&-ZTVDNOCW71S=*3=)X^HU9-6W=W+2?_%,>BG4SQ
M>446[739FB'"^6(H9UZ=I<D\J95TYP%60->P[8>C.M2_]@')%VPSW8&Q85M0
MGS=+GV'O#,R)'C=SPV1SPC2)G=:U$]%VR\G2QB_55DE5_BE5:]20W=CS%P))
MBCLMRWYU+HH58KE975]4K&S2[X:7<2[QUXMP'-3MM]Y5WM6WI(95@;42D>[E
MFS1J3FU^\\XW:B  3C_&1/'8ZM<KMUI5]1@83TMS[@*(LRZ4@!:9QLO5H44F
MV0 3E,S)EG6Z1<UT9M'Z_90_EX*3GCPON/(BX: D;RT<:7=#87;?G;)^G$YT
M&D9YO;DY'7Z7U.;C-JI$^\=P/P91-8T9'W-.F--?;Y9M9OQ"U/-I0Z01!K]#
M^A=#-@! \4&"E6'=PTQ3#YP%JAW/Z7^<9&33='?%:</_W6W>48LO0H+[+CL3
MA M,I>6'EE/+D%]^2BMU'>00Y7++&*X;'F]C9$]$('VN5\=;!7P5>.@/I9JF
MWT,?%TOY@Z-;GX6NW8W;BBM_NW),. V9%_EZ2?5FI>?"NC'WP[<2/[>5@_L*
ML0?[DF)H3=?"0G=TJ^WG !&1FK_&J8!]Z@U97H[#Q IB0U]#CJ!)+I%.AG>\
M95@I>MJ9_A$ZZUG;Q6I0N5T2TA[4#5OY.,,&WDPA% :)%6M28(;4Q7O&0:F\
M.%'5N8M%T^-/3N92K2J'#$?W[NQQ7BUPM79P=V=MJ#3S16EMH^EI;X,VJ1%K
M)X*<L.&.!GOHQ@G#W*MR-Q\$/20C.%NI4=+*T[8!Y2RKG6/!)./YW;X:(4S)
M%0S<Y7#33UH)D>-K@J[XUR&X9\'EIEW3S6I37IL+@WMK%9&2-9>?5;?ZAN/2
M'AX=4:5I7RS%Z%L!F;E )"92IC6?3C/ L3IJEJ&;;R"([>([,R+M^^1$MQ#8
M^.X2:O [VV-2%@SV9Z?Z4<C/[T\:]/[6[A;SSN85O*ENXS]ZRXXFD=I^%ANY
M8X"^TQN=PO-<5T^OHF,E;+7YY#LV0JV6H3X:=C?Z,^"M8@A"U5D3QU,<EG#^
M#8#;+.DI6Z_8Q[_B@K_9S;&M _ L?):RR,I%+/;=BA3Q88#,N3<MWNW^Q2.O
M.#VJ^-_Q+(#=*%^*K8':V:1\+S//D)2G8WZ*K_.O*;VM&TETJI?97+(C2E?_
MY#<H%M"(8"K</](NEN 'R DEWA -'AKOGI';W!_8*D)%MIK1$"^_BW-@%@_P
MKM,>F^'V(4S>82.N4JI2_;4R1NC%E#M5PLIQYCD?0K7061&_)"_W&,M8*$V8
MM Y%4/*?YUK.+NF>8I=D6?JN#NE!4RU#2RV> Q5Y7X@(=WW^J14(]+GOW!5I
M;$RU=-:M[3J;W?@K<+E)*L,C>+M<A) 3R57-\_;.U*&$4SIX@7XM%D@PHIEM
M,TF8>,G24MQ^:LA6^/I2LC80C,@30K.=<\ G%1KZH*+XS/+D^Z[3YLR:W?&O
M]E2G%7ZZ[MD30N0%PEEE37/@C+Y52:]6**LUT;JRO\%*JGT_N7IQ&FQ:]3;3
MS; R;WR[$\UQ_5;-G>4VPI)+,M6GHA4L,PO;'Y[Y:-!2(2T_7[ZE:(J?M30%
MVZE;[1W1DWU>TTKJ*=+3^*89^2IX!M!'#U2ADRG;T9L F=;SJG%4 IS*[J?*
MUL7:EAK,RK3KC?,X_L"!N+2='OAOB19MF%4UX/;MW.H:$G@T(7PU9O%F12=1
ME57EFL4\W4%K7"8M#D^]++2#QW9_A\ BXV>V@0AT0;;]V.RHMR[UK+*@I<24
M *>/IL.S3:G!Q1KNW@!28+EL4KMC6*[B?/(-.B$!S"MZ9W/09X=R@W![\C&*
MOE'*IJPD[^4T[]47\Z%AA3#39]:J7+[) @J2\-@5Q(PS>;S[C"1^L^"5,9(N
M6 G+VAHH%&Y7<NL/!U4:L-WCO]@CG%-@-QI?W[L]^O+ RDP#05>5-FEW+,H6
ME;R7'[B^%)%_Z):XJ+=;_$!5IP[U\XBNG?37/D8_K*W5@H"(*F4* H,AR^8?
MPTW<]%$+A=@?7S_N4FJ/^L92K&KKS(_J$SD+I/,5AL6VH+]7FNU@BDK=IHH2
MXY6JN>[=3#!9\+5VJ.5>MOA]@%9&RXZ(_TRXC>XSPSF'L1)/5EWJ$JJH8M)M
M-C"YG7E\@"( 9\@V:(A#FE9K.CB\'I- /)X2DP##C4T(V_:?0N#7;DYIL5XQ
M&150.VC;=4C,MQ9Q)Q%,<8AR-<ORGM438!*5RXJ4!'YLL:Y^BL$[5*MR:/ V
MD(.QB&1S#Z9PPK!EZB>]K\=>:$?YU0R*2 >FD.$?0_O$?HM[03"I#./D5X%*
M4 TLSWE7.QW$62ZJ.)9H7/,8FC0.S;R$8ST/QQLCX;F%RR7QMPIR\Q7$E//&
M&>N'UFQ>&PK%:*O\?+ 'XV;5K%'G]?6L0JU0"3Q9R8+$G""]4+$9I7++#531
M5S6@RIPL)06(4D!TVL;N;^^!>8L!6/7M)A&#O-U,X6EB;LWXTVL+=M,K7MJ,
MW#J5P2]YDF5VY5#5]&-'DKNV>W*!3;&F<RIK?35KGWYV01!$ )6(2DI#X&&D
M.0F+CSJL,$S&3KSYKILB6%)Y^GUXU$36LVM67[4?3QWNU;_;: X-I?^!_7=Q
MD)PO9L0I=_=>K1D514O0A3GW\HV5/Y:$^>7[+DH%2 MP=? 7 M/+8[V"B%F@
M0!@]/VH!V,X;1,1:\=M$5"\74#/#O=SN[B*M5E$RAW94["2!,LZYY&V$U?NF
MZ] NC&W[A9,LTLNBRN9A6,7R&;7B<O"<;,3#1AQ9ONQ(QUK*;CW+=;NNG:/1
MI%I#N1RF0!IK68F1R%76!;!>X-;Y7H+V53(V&PX9*KIO=$U9!6!;^?]5AO>3
MDP57V!7;+R@QYV8=ZGLC'GB(RIOO@IW9I5GR3?M3UFGZEB2 #LNK WOT\'S9
M,DN]F0J^G.G-S7X>CSF&40IUCG^LIMN]-VOG&^B+4PU@OHQ:\U._T8YGT6>&
MJ&&/'T]5Y5'="29ZIUT]-K!@;(]W0!O%KX;]:LQZH& 6'2;I:%;=$7.?(%>N
MOGW)-IV)GU++5'$_X$P#5,];1+Y(+C29=T![+Q21WF#R!C605V$W5WSK6?-G
M7[9!<[S7>LQ/2ZZ6WZO23'CY\KTAK9LWJ" HIV7Y:@W0R9HPMP06(W=NHP!'
M\[LW &E0X7=^]ZN'0AU4TU\V.?H:&_E=/,6LYC+3PH_^U-5,DFV/',;"(N15
MC68P1WGI24A7T<F9*D2Y"+X&EZU5A@2UH53W+SFDYKD!4\_1Y:<?/$.(X_-V
MX*7BK(\_SF_>.7Y":-36,$S/%=J5O=2=+V):5U OO-72C^*Q;(&[*R!"RX1F
M(\56O N .+PI6-^N^D4W!,6-U!81P+)]_=B:5;S>4'PKF6',;<VK2KG0"K5M
M457@!Z/E/S'UO&H_$A[+40IW=$S9&G<@Z52W/3T*"]8=+!2IYP@.O*$Y7G_-
MSL%"/OKHQ]Q+VU*GN^2TXN ?DTP^;. Y <JPJ+G+%II"F0I\9>LY/IYAK(H;
M6."MU$Z_.C<G\==HH3?S5IM;!UXW8"Z'(&XC9>KP>3>&WF#-&Y+W<,:K-9#;
M=2R$Q!58NW^KA;2J/9.R6"PZ1,6&A_CJ''HH(LIU*F>S-?*^/=]X^4<9T45/
M%N^7KU8RL[&93VF]JVCYGR^)>Q\: CH_-U\>B*YKYS7A^3(<$6=B"[+)P/?Q
M''7.OJ3L$\KP6?*%7AKB@7_UY[P7JV:+A=,VE971,T/T=O4>K50T<F6;6#)G
MFU:;QQS$+0L*#I,;_X:(7S)N'UI!Q^-55@:QF3:;?W$"U[>F-^"@#T;&JE8P
M 2YE$T=-*N=^-R+=(5E6!"C4+<$3%O22Q1)O&.@(+K 3-Y?4*E56C8F\Y_=$
M3RCS[<X_!B=AI=:/QJ9II_\8@+5B_2/'=53C\+HAH]I)W/WJ&;'VW&)#GJSB
MG*AG-CKU9I5W:-:Y++FWGLF!'$RL)5FY$YEU>PH_C#X!!I-WTC/9Y6$'\P]J
M9Z0*W#8EXN$A=46T AAC=^-DF85@I@5(,.ID%Z=Z1$;8HDT2F1&\QC<LN&3*
M?6X\WELSY9$^FX!&)YV&@\-#/$SQ4X-ZB8B5H?<ZIB :XP( (3;]@FAY VC'
M""^$E<+C30-SQ>[!.9[Z%!BA7QC"%PXG?AC<#8H.D5/WVVK^3F^=RK1UL8<8
M55MDV]<8I.:)3-6&!]P FA/N<D3Q9JWC<D6$@!KFYGM5/NR^PY^B;]M0.:YC
M1]RX'+H)K2,_/S04!9QYHM][F!=/TS:KS6UB;BA@K+1H<W8$9762N*+\YB-M
M3\8)#U#7-#VL2HWUIB@$_SJIAJU3'& ,R^0?7H $>M/G=[_E""T6S>!>QH0A
MU4#_&(SDDKN7&OY:CG9S:$"[]7(+;&.YK;2HP3O8N03_[(+:L0;OO&1.520S
ME;78.O]</&J^:@+K/$@<]/FQ7!)B;IP5(O:KQ7AG9CK9*%P/T38=;3_25M7*
M8BFN:%=LE8NSA&;KT!JG[!JM[*F*FT.A")+:#,&J\NJ'D40YG7W#__3/Y/GA
M5''7O6=5E7M9L7GAVKNQ;#HD55#O;:'7M)!ZK89ARG%8$[K9U"WZZ2S9P?9J
MRIZG.\SQY"82_0Y+Y#@ON"K,^(JC7/;KQ,?=.I <H%'T]6*,^7MGNYLFT6G>
MR I:HQM3K"0B"%/+9AQS0V0ZS;D&5=>>[X;ZB3LC!-I/6@*O9^=6M%01$&Z&
MZ595JK!47EVR(1SJY]GNP?@NSH^@>F!I8"*8/'7A%).<*Q"-LY"F&2?#*-V^
M7!Q!?MK5L^]I?DV8C-FER8(BD7VB B])#IJ8SG*0<<(DS"U'VUJCOU[.GVZS
M\8!!S(XLIB$A@K=F,'^=QL,;B]$9UL;5FX_;SW!!=[8 ]1K98B&'&")6:/[V
M"6_+;WJRB^@-WJM9-=GVW@];;L7<>"D[]SNZ:&%2DQZ=8AB8G3>5[91!%G?J
MS%VF79E9,C9SH[2SOTS7JX/C8=A;^?J%QL0M_O8L#,Q2A0K>#<)6=U58"$0K
MN"CP]=)-Q=#UEX+);VR_$K:UWIM56!^,!X\N5C@PN5Y?1594B@U*:_EZ>RR7
M*9A7SCUP"4\LF;/2 _$OY,D %ED)HYY2%R\N'F#H6_E+'C-_,\TG=P5]:G9Z
MSY%-?2-L#DR1Y:@JITS3!BN0A'L-*O4>17%]C(V\'+9U\2JTV*(&\!]$M;0P
M+3,>?=%_N'8</W6K/I69B&:6)@ ?0 SIN"E-$X?LO%9]^WBYWD+0(1C@Y25F
M4<LV26/2\^=U=*D$R/:=&QF#UP8O&;.]7ZS3Q.L\U,G9;69KJ-- ;V]7UB0M
MO#+='P>\/G+WO<:V^:H4$KC5Y,6:(&JX@XT/?-ZBMF0W(--C:F)'4I2P=6FV
ML K*-L6!TK5TK2TX2DUSKZCTKYB$;F%5L"%!U;=#$$X9UHJPR[!@W_+BG?QH
M):C&36!G7CEJU\&P[=T>XMV843J+R0"ZIGGZ*-^')UV)8AXWZV@7J?-</K=&
MX\ZA#T>?;B5F2"=AF<MAL*8;&:1$)Z>B_8&JTDIH4U.\8<&8DYO3%=SO06+T
M:Q]8_5P+[XNO3,LYV^<X6DMJE)\:XA^[@PZQOU^MG[>KE4&]^X1%[W&<C1+#
M'9V 'U-BM7+Z"YUS-^)Y0IH%!BKHHIW[=/(_!I,Q/A*2I(3N!A(4176HZ4,U
MLZ5E4^(1YR,:@+K>W>:Q:];H6JXA'5_S2M &#E905='+JT1X(3/^%_,H82+.
M%O4U"5IQ-+B3[3!SA@HOSB"YBEM[GB:UX]"@8'(\MT9@(H&]M=@/I*%-X#DO
MFN(&*3[_<B:5:@)^34-VZ%XJUO,ARK%3>Q8>O.J%<[<&DW8B2N@IJ,_6E+"J
MED3P35&14FGIRR2?+8=:JY(!6CN@  8+05 (XW@:=L_7(#"A#&?L4BGN=C%S
MK$$]_^WF7!^BW\ ,)D?RLE^"$>R\M.K- ZL-_CC,DEZ>S=LAY>I-:^DQUPGF
M-5@72FDJ,-7*^5$@_#&J8]=>EA.2R_X\7F)SWG+*M @"MJBRWJ6.F@</RRNP
M29/P@+8=\YORED!;-HN@#U'4%I=!WVM^LZ#>NT+ G*0"^"\<9N\&?4%P$.73
M>_;K4PDZO^X52=E@E.>)N'M1,F[W>)>_WK\<[1Z=F4>/RY=+Y:A8&08RE<^(
MS.$L,IU21-LZ*F8K#.(L15,'Q3B%Q1[X[VAV3X7LICK1L$R1E"B14@1&5F%T
M+6!SK,HL*=]<L/3< N=GY0KS3OM\QJGY.^OHM0?7$KMOCB[VX5'V(KM?*C=E
MZO&G%PX\9!5KNAN(5LY7XO.DN5*5*=TZ=^8W>GEOR R$]H##ON0,@B+QW0JP
M*B^S+H)X^\/&:[9+7YVW<3&*LS<K[/'!=3M]5PHN.JK46.PIKBX %Y-E+8\H
MF5S!1Y9+& GO0FLHO\NU^G:P)9%#'$"7KJ%4S_(:9<TP^6?<'*M9&_OR.I>[
MG).WH[YN9GJ[,LZ/<NRH$9-1BWO<M,OLALY'IO08)'5]X$CG6=J\()>D@<BT
M\(V_\TI=L ,M'WMKE"@CU:'7>JAU@_EOODKMK&I#O?[#^H,%8\$X<FA- 2SG
M8!"3:3!RI(^9(2ADVV0:4+J1Y#3K=#@M)(EZ(/9RP*3'AL;C3%J:V2>G,)7'
M[?FG0-&Y @\^M&]6KQS?^AFX-M#[[NFL&20=^BJY"=AJ83%R@[?.&AWHJK[_
M7HV:*>X>_E\8R=VT<J[?Q78UFE6C\I!))G:Q$F7KIB&T7^<S+U4<:2\Q.>%J
MT\>\\V/'0^8[Q%V-BN^& RU;4N*#>\R(.[76[F]C3"K-9O)X?%/A 5QV,''?
MN13WRBXJV[07"&<0JJ,'RA)(N(:Q19O[O!V!_Q"$,MI^(CXZ69QZ(\2N;_K'
MC!Z1#?(E+B@E@]'!O!\W3CRFU0F\\%4#XGVGHMUC26#UO7EKEI^^H#$UB=E6
M"6O\/-'G)B]Q@!;FPEL()V!S8H9>30B_7A!3N%'S::MC8[;'\;.[C884!-!3
MX+K!3\PFMD=.O@<7475\BS,/J)Q2$X@#&L^K$?=6V3-O"V4P>Y(W,+,ZUV,@
MT8RS@>@[,R5P8_OS[)61&6%KU9*[JD?GQ'<>0'L%Y^L6JX+MW NG;"841>?<
MYG:KI9HY))QJ=%.J[:TLZJ I&\2Q+ISF;+?"AY2NUUT.K,IGB H2[;U$N\Z2
M7?8UR*9,(C9(,#13EW8@,=:HM'+URN@BY)DY#>SI6=N$G1-_M3\[G<F1M;QK
M7*<!*:MBAGIW\H@,,='OXFT-U+;)[HUN4-@%]<TSO$-+D/@%206$OJ_SG5O%
M'!>!Y1R8\=[]^6QN#<UPWI3<3"X9<F<.8OECWY-RO88"#5ZIU%\L*X5Y-3!W
M<35K'%3UGFR_;[EP@E?]>,W$BZ1)X_0W51W K*T1[_JC%PG)A;+M+4PZ72XK
MG[]^R>LV>  !H,52EF4_J]>92_,<PF&LKE,@4JWI5L<>LN[KJ6(>+_BJ2T"Y
MX1, (E.<OJ_G6VHK$XMOV4=#I?5N/K[N&*\^T:>'7:;K3)%,=EWW1D.0"- 7
MMVS#G,ZVW1QRFC8-2PEFG)VQ^/XGTS#?N(I:D?0BR;K%B5ULYD]<]:?O(>+I
MD5\5'M7R77-;N8>, ]\F#&O+WB\WHYSN26WQU@,*E+JGA09'ZOLDE"16,&WO
M%2P!BL4^\E:( Z %\9)Q8LEWZ8P7%'X5:3^^OE=6ICK37TV.?@DW%RQD24VV
M/>.MO&F,-WUFDK&>J=2['S?NXMN+Q$-FL@CJ%PNB(-4F+",^[R9D?4&M_$+#
M$B=>7Q%BA;]"]$MG/"J]BV+,9@4L9@;@BC%(GN[0]MQU-W(TJMYBF7*XXZ=E
MM\NJ',LK9M-.X=)6GW!K-\/<SWEKS('V*X/&)A$U:Z*Q0_-1YE/'=#U(C$Z%
MV^_2O+91?Q#^$:8[4S4NZ1CNNI@%9C791;*F+$OI&OJV;;=RS)9)6.[S0Y&_
M4#^^'^CML>;<T\K-JK$\F#M_R;9REMZTFUDSNV-1-IBX=NE/5IN$NKYKT]+/
M(G4T<P=!*B1)4/-*B]Q_:?J6R#/^^S%1@QW;S\4@Q[R77"IG/8\-/QL39E=A
MA-FR5R7-B4V2!J%B71.2@^3;:7NIM5'/&UT?WM%+#.*.04=[X,UW@@+7%>CY
M4;N6LX\1"TZ$(1^**/A6?E1^G9:]PJY_3=HL:KRJGVA0R"U@7$-4O+WHW6&N
MF_1#W^=68?7UHPVW)%WO5E.JV>:9<R*'(A<P!&)RB1Y(,W+4B>UN''X(6'RE
MF*ZRG@3P?K>:^$DIQH1%@/;R@S[E4TH>K8D<5FZID=15#QA>0GN3U.J[YXC;
MT,M,3(A/\]P.%K;N*R\_[C\O$T 2)/7:**E.JL]S<:NZQ3?E!JG-MWP:F)!R
MB=RDS8 [1,ZGK:;5PF>M(N5*;U-Y%K.F5^*=]LPYA7L?C&8J$:.XVT"X(FG5
M[ZK<+ 9W%FR2.G-M,Y5;30DMTY^('8&;$K4B/FIR;6W3]'X=)9M)^#^&F+7+
MB-6T-^X6;DRFV>AZ#H?%8)/,'"((8Q30W3CC^4VH%QSO+N=%HX3E0 ;+%_^X
MM9<1/>6ETU\ H"HB!(NI7KFZ;G9*VGT*%]>P;L<Z,.I\P4$^3%LQ$]4VG8(2
MC\,/V-=!;._#X14?TR@K/KI6C3ONV2IY#88S+PL^50!R\X#464*(::7L;& 2
M]Y)]O,!5<VJ(73W'&N!\H28"(2[;US_+=W/J1H_,1F1CEHMA%2I)":+$$W*5
M2WSHZ3M4I;*+G?%7[#/R" HOEM5PJ= '?[%<6 5KF(Z.,\RTH.&0FS]9YEHC
MCMH6,)E++ CQOES\G6/VHU&#"YDEE;.\Z1:$5V^,)TDP4E5_8=&K=C&8=_?4
M1R-0,H:35FKB;TB]?I#I:-2*S")?9(IU;]M_Y&ZZ]R!0#U[['ZVAM'C./1PF
MA<Y!8LHZC)W4>R#M>2EK@QB2CU7/UXV7Z+7@NDKA_#G!8).0T%RI'S#TMME9
M']7B^A9EA"*0=PQ7D3'*VQL?@Q%[&K>/2LA/Z*J0W!MUQ!EIY.T+RE))=;U0
MXF"M3K(#$BS#.R<+E@H@&%;.0I;<MOF\QU-%B=X<TC[:.^MX<D;!S4U36[8A
M*ABWX/RF"H'A5 %5\[@$?:IGQ1YY'M? 45C9LQ DQVK/P-E[U* *O@:]N67+
ML=0F:NB [MJ&M=@XYZ7=1S??KR)<2=C4 AN(7)20,DPC)]D7V7,;M)CGZJ#A
M'/ZZG9(F2B?X1&_3T>Y UQ#]3;"%;H&ZY V5";;\Q!SNZ3\9B8[>C6XW'\^W
M_"I\VG*.PUN ;WK)TU>=/Q8G+$["8JA2R3J$EKQCI7X,=F">7 -C0T4P9E$V
MZB_IR,H,.T]2>%C8#60\/^2[45(@#>:CJGYRL&K+08ESE?"*F5NI[.RB6MK7
M!]S/VH@U%I7]Z%F\[)UEDZ#0_JP625;G456/N\;EU 9X!6(+14FLG>+/HW 7
M1,&:WIG,,R:P$0::\#7XZC-.F<I$8;%D3G?6%(ATOJ*:+;DG6Q@)9!FI0-BF
MR_KU0IWKNK8PN9=*>5,.TV:<9\;,(%N0C7?F>:F"C?8EI&(8AZ1PMZ&(3=U1
MQ+3#< &]NZ4V\^ W>9/KAYM!QJ:FD(MN*T^5?39(*JGJ8[CB59^N\3KBD/9Y
M.UF)U^PJ$G36/,0N=JGN=R+.;6ZG5=04/UM<_CK041FEZM/#I NXYMTKL),V
MZ#PRH=RT=\T9UX$GMOFSVUH&6YIYGAK9ZH,%ACW_^$3]0(V5FI?F6=]3M!)S
MAVP:T=XJ6QX3N2"X4$M</OCNKH3+KK!\+E-&?Q[O^>#[_,\F);X8[0Q6J/+)
M=F)WR$_T\F&H3M=N404>GJQ&)34P\BZ71?T"?PT2>-%X+:H29-P@/%!V^;XW
M0->TKKW"SCC;DX9*J:Y6O2LW>0NG6<F1KD\]6HH")Z5B*CZ;UBI<7Q_6D<HT
MKP&,!JY<$:=+VX\SYO(;W2W6^%G!-^4(. DGP=!;9C=R*A5&W6-,?39?DH.P
M>ET$"5".$U(Z+2_>.->E^!^#GH]X]0/C%[#88/2DI*0U4.&H4/1^G3MVIK!A
MGM@=6@BKG;MAF#++&^@QN]:R,GHU\:I,OVOJ<CM7.XC3O.+.0OR[VZ24Y:>'
M3UJH[=Z]T+HIB4G,I,M8):Q:CIGD1>OH,K/\X#T4SO$.KF+,Y)F!==IY)S[P
M3HKE' 3 )80I!!T-BT&KF'2P4C[Z,NJSCRJ4\G"W'A'A)!<$$]ZI*OCJ:.V4
MU+'[UAUZUJ!I_ODRZD@^J^)8['U(A6_$?;HV""^34I2M]8U9RF)5&S5B8I@U
M\HS]7:HIXE2F!WR6CA0QXQ^5OR<^]VHO[=Z\^D&.;BN;0?!TJ9:21(N[(Z?N
MFV_A9<!,LX!J$6'@GOE>])"/'.F^''%3I:+:(6RP7K?VHI'"T6WH.A+0[AFF
MG"R \*XO! G(Y<R:#SD\RU6L=X^W&V<7V1R"HDUZ\G95 ^,^.]G9G,"T"H("
M!.U<ZF'G)?9+4@I4%34T:@X/4L(6<Y#BNWK5IJ6:J8+%<O8X6\_8^UD'-4T$
MDQK-H]'L"LMWN2(Z5/MT/@;#7-?@J"G/,+)I>'*5+5 Y,##3MLR(EMFR"2@@
M[QQOMGP.+ !>3=UO?UM#K,H544OG%H2;W0#\A[\I26,0<XW,S,8&K>&S!C'%
M-)V1HG199)#4]OLT@"0#WM>U@XO/51N"$.WJRUEN(1YGCY+C?IV2)5*-*YV>
M6RVE)35DH#?-^QN8!SDG*+./4C!GUN*S5HMV:S(553A:UB<407@6J#,*W6_'
M9=X[F#>B\JCF?V\9Y&6YRL54.0=,1IQ<IX(DJ<SEPX@7EZ;QW$LZSFT=,SYE
M%SN6[J\DT= Y>C#3=FLK.WP/@N8WPF6;_B99G.YG](R;N:%]N,!B%_6FZG4Z
M ' SZGI%O$J,$2#)LEBU^0]BC_)*6/3-5"^D:KZ5U2T]9ZW['L@@G;=,/):6
MM**<;:%=,;,*M9P"!&R0:LU#(\,#1<&:)HN@JLO%06CS[(.39W1]2QI//&CS
M=W8N_3CRM=1GA*![J0#+,:+&1.?I0&C6.Y/00E0<-.8A:[O&8P.;<_*16*_7
M?_N0!J#_)(?_[;4[0Z69-0&F'H0>P\:)BB%.NT'3>,!/#LFI#20]3N9X9C?-
MTEF/I"?/O<LY*\=,4!,85((B7X7O?"?8I?,R,X_F6F.B#/J)V;K$.=#*J%^7
M2_T625&J5812RF&W-N"P W=RL*U-Y('SV>4;730VVS'-Z**R"\YXY^Q[CAHT
M+SV2G^%GQAJE N2$]:4L_(WC.<RE@6N9//$O46U9AD6M( FS&K-PPEU9BRHS
MNW4QD]Q+:M,%EJ# 7U/A^4R>72_NR@-0ITQZLR6O4F%9I8) O@MF\J 1Z>T-
M 26[R6)>U(FQ'2K+-A0T79.FF$,TM(<:IXZL&Y<,2_M@HCQ#(AD(QO>5N;]7
M.CVY_\(^-?(?@VZMUM0?14H[;Y2UG%M1CW:-Y4 YAYY(+O?Y19..9?1?-E?E
M:;E/O% C>V/19AT7<8YQUY'\!THC!"@-Z\F5J9]KG@W%> F?N!J2)DG=T56$
M.ZNR+]]KQ]K46!):Z &=/#;G !9[UW7?TY; U=T5(1 ?+WF]<$?E9L'N^;;U
MYBG-\IM#<<>V"7'22/=WYGOLW.$/TN)?9[[N?.W/+KSEFP[1*MQ3LFOW$S5W
MG]WY#S7.1H@K^[E(F/.[MA/)8UB 62*7/*Z5R39<U%29FJH4JUS$#JE&FQ99
MX?N)B!93&Z)1E:;$F^@0CH+J=2-Y,SM'U%OVZ44.R=E2_G.,<K/B9.C\P5.I
MB]?7E8H-IGPTR]XT6 I/VF44#5HU+) .2(H2"*"BA#5V!BG)3QH+A.D&@&@V
M"K8Z.RZ<M_S7WQHS#Z8+Y/F%6Q"_*I*P4Z-_N)741"?%)NGY3-F:S&VS=H72
M(*"^5QTMW3*, S6(LZ&E(8%P8>)0X97GOX=%E5^\Z'@A=O&J[C^&1$+!(UCU
MV+,;XIMY1\0YJ]U6XOX4FIXJ47-D<[1A%@ZQT?&C(.[3K/$JX7/Z?K7DYS;&
M%XW:66Y,8UXF0FO_(T0-Y+LWQ-T<$*B][%X&)#H;!\K;[,&0_-^RSTT3[BJ@
MG.\KW'YVK+MDK2_ <,,+;-7VQ*QB[A D K:O': JC<QALLW?/@>Z(T6'7-S2
MRG,%== !*"'UMOU8^91D50O =<^,PFI+UW:.BU;YJ=QJ4M#K5(5"%M T1\9Y
M>Q]\><?4NK^X.D!8&'#QP;_%_P-02P,$%     @ &$ U5T@RHS?090$ +;L!
M !$   !G-30Y-S(X9S(R<# W+FIP9^R\!UA3R]<WFM!#DUX4I)< H?>B=.DE
M!*1+0@($ H$0BIW>.Z&)2 T0!*5+L2!-D:(B*""(5 4!Q<*Q\P4\>O0<SWN_
M]_[?>^_S/9>EV9E9,VO]UEHSL_;LO</>GMA^"F Q,S8U!@"!%,#CP., P/8Z
M'\S&!XO'!OM@ P659.4!ZOJFEE14 #+QJ5_'B?Y5!4#Y*   \G\^"AL '0ZG
M*J^DIJC.1T$-T+!$>^*PP5@OO.!1+ XI"!%4D(>8"QKBX&1.&!KO(VBF+XA"
MHO'!@I9V@O(:\FJ*2@JR2*QG^*YVL5WM+#ZWD75")_J:\BLI']<_*A[=;=/<
M;5O::2=_@+LUAD <.@!O'8(/#,&3J]0[/)M@O!T"B\7L]C -P*-0 2'^W\L[
MWP88W$Y]WZZL'3I\IX<^&K\C\Y=.%,X*[H^"&3G"?H!]$[#!8;%>=BA\2* U
MPM>3S&8$V !P "SYGQ= $& '0 'P@!! X*X(?>"/WM_5Z&/P 7]:Q(@(06/P
MZ(!=E>0Z:+>W@:63^;?0:^WTIX#\XC';3QY;!^+1V(!@,I=[UZ] ?,!W)\A.
M(G _*E#O8,N_6G !!G]5 O!_52P0F. ?%2MO?.B/BI$_QO!'A1S'OU3K>_IY
M_QF(;P8"H$?T#<A?E+MEI* @$AN"T,4^!7RG([B ?_#T,?_LIX]#PNP#\,8B
M4 P>\!/I8Y""O^-#@S'X7;Y-.$;7Z0>;/A3EB<?B#.%X^(]98>-M$_Q]5NR4
M__PVV T"R@O_._4P\J+X'=_.$_.-;X/S_ F6A;P, H_ZH,B#2QXO=(#W]X@Q
M[S1 R3;I8_%XK#\&&^#]IPCC]Y8=$W[B,WWG0]'>/C\W,'QO(-OV@[TS<RC7
MO]E >>.K"GF9 K]_[\XJ\=TVYK\\.!SQ38J*:;>ZL\*==^N\/^H'=[6^V:V#
MOLL!=Z4D6+Z%^?OP?T.A?+=;-@'(>7F16S#D(\V?0M\XI07G?G 4=X_.Y.-W
MCLKN$?(79U?G^]TR>25M_Y8HG^\T_\^W[<:"[EM$=^T"4.A^^_S9=O!'G+[5
M]^^4*/5^6/_-!;(WP+>[/&^RQXID/^0!:H ?R^87^HFW([,C^Z\=?M!?20(0
M$(+9F6P4.W (;$@ ,OAO:]03K_#=Y)V)_=.D OQM]@'T?\S2;V9 ?TS";^X$
M8]">J& 'C,7.,@+^@D.]VT8NL)$_M+L54\.?=--ZX[ A@;^P:+ XM#?Z1X8T
MLML1LM[ED>M,\! \]@@J (6#XU'(7>N/!WY/\/3?.N]P=EI,_;T%_U_PGS($
MA_GE-+$;_%\YEL'>OYY*:. 8/ SN_0N/V1-%ED.%XTV#36"6%M^3%=UW]B^=
M03Y8W D]#-K[>Z3V?7/>Y#M[)[I(E!<\9#=;@4)1./QONCM\9__:G0'A;8#%
M8'$_!9?UFX#^D1\-.V9880-VOD%X;"#YE!2,^CEP]!AR(/_!943LIKU_\!EP
M.\GM;^S=U23Y36YG.A]^!?B+S[I;!'[+0E0<N[6= :7:K>_T!["V_QFP8O+'
M@UQ\"@ T[_"+ #P X/;$]CJ 40^)1:".&5@"*+8W ,R[-0 R8D=N^S$@!L!(
M1T<'HF,$@1A9&>@96#GW,3+NX^1A9^=D9^=A9=RE/[]^3T F!@8F9B869F86
M#F9F9HZ= S/'-Q'6_QT%VUT 5CJR\<640&$ !2N0DA6X/4-VE'Z[%WB8;"4U
M<)?^#",E $A!14U#2P>B9P#^O1$(H*#\WL@" %(!*2FH**AI:>BH*1F5R(VL
ME%1"; K4>K9P=N&@2$4:CLS2!GT144[H3822,B[JO@&M6);=J[E-SV 5KK+&
M:''#;!C2J+L<K\H]:C^/>MT4T_,@9.&-L02A(K8YIW=L\2VQI6]\Z9V#5VA<
M;F5K_\/E+;4C1[W#XO.JKMQZ].P/5@ %!=E:JEV;:&FH579-$%)@HR);$"3,
M3JT8F<FQ8\%-Z/U72J*(.5Q4EH$=IV>P\J88S8X!M.(JW:-D(\JYD4;VJGC4
M_ \3_MT"B;],V)X",%+N8K("#@/>P7*LCRE[G3".W,*^_=3R4:O%^]V7A)'6
M>_/4LH%\ZEPO_F@7DQ;:0!D-4=^=*P&-?7*IVJC9!O@W*[J9,@,"9+>:#WXI
M_C!\]N-$^NKTV2ZMS\MG%\=<W;?6SRB=U^9S/#*_.&EL.)$CRCHF<D/X95/C
MG0.RH17&SP^X;@,6OX:.S?J'GWE@7A5$Z6YP-JC3>K38^^LIXW>0A+<"7X,/
MOT9?F3 )NH5/!>9:W9C2[7=)9"GDS]12G&>>LLHR#1($,!Q9;@K=!H2U&TWF
ML3(1A[5:H];QN>GE N9^-]X)-ZRZ?(W<!CQ3VP:(YY&P'VFW >?O?C[GJOCE
MS1:UXY?9/MZ.K:6/5IBQA?5@9POT6_=%A6S"<H;4'U@(\Q@=ET;J5L;+5S)?
M0QS?U6T#=%^^*=@&9)N/7_E"N0T8\?YJ*0LZL_GB_<6$4#IF^\<WS@4R!T0Q
M1E<)W+CRM;5X/0PT8RL_/\$^T8GMQ#XXZ3SK_94N]3?VS.[:\_*F@Y;\)\L+
MA4]\!9L3J%Z#4D>V/JEN V*VKAFU<W_$-H\M;/B@3FDR.(<\^"+=6O8Q=QM0
M<O;#\#9@@/BG4B6RTG3&&R=?&:7=YL\FS*L>;;A:U)7=J&9^:WD;X'TBX<X=
M\7H_&;$G3YW/)*JLO7Q;Z)8^LPT 09M^4O"35>B8&Z>J$LX\]^-+61Z3"8'W
M-G=06D0SOOU2\O7KE[5M@'$=] 6HWNG@HXS;5"?AG<<)3X@WGI,'[>QK-(._
MP%/^G>'SZ:<2R"]68=NGRUX1_<+M:^3L-Y2ZL(^T9W>&XL2C[7MO2[$VG]"U
M8[.-)H\#7N+]BYP.KYQ.6)R5\-M_!.&J]ZF5@XD<>,P^+K6U:R\4VD[BT[V?
MN7R^\?G#1^'.]9-I-]V?C+H=5@>!3T\*M-U]<_=KMGGHD0VESV^V 15C9]U?
M77P9]H>8QA/.TQM?%PF#/YI&9S(_I6P#M+<!*RJL6P,'8FUGCP;](2?\I?V1
MRC8 C'I]MN=P+[F@*3]_S3<#97UYX_:7_K,7SKX]9_0=QQVP1WNT1WNT1WNT
M1WNT1WNT1WNT1_^_I^TY77D?/#Y04TXN(%@6OG-[3=83ZR\7#@^44Y"5EP-H
M'PX/A'OZH?""")0W.D!'^&7G#6%!-%)'^*B*I;QEH '*!VUR H>R.V$%\SSA
MYZF!%#Y\B%X[7#/</] ?A8<+AOMC H(UPW6$=Y5KDLL[;#EAP=TN>#\=X=V;
M>H*.EC:"!E@<2E!55A[B*2^O**BF(:N@JJRLKBXCJ"BO*"\GKR:G( ]15-24
M5]5441+\DX0/T9./VCBDER;4T/A/.')-1_A/O\+"PF3#E&2Q.&\Y!0T-#3EY
M13E%10BY!R3X>  >'@X)"!;YIN2['D-4L"<.O?OT3G"G#D=@0_ ZPL+T@C_1
M-R"DYP^<P! <9A<%Z2F'PJ#\40'X8'(,%>1^)T=V_8?@;P/_.Z' G[SZ18C<
M0!92^C<D2\O_&LO?_[>2P7BC4/Q_+1F\<Z=9#HH*QH;@/%%&H62?17ZO"HKZ
M%]M_KXK<_;>* K\_ ?^70'QO_A;#0W]IT$9Z:GIA<?YP_"&T/]P;)8<*#/;2
MEON+^VM7/!J/01WZQ8#=J:&'P?_*_=Z 0>]8J(F!!WCK"(=#_KQ9+WSH__8#
M=VVY;VK_9H3</ZW8]>+O!N\XX8E#P?%8W&_<L$,%_9L;A[[_7N"_,N!7^5T#
M_@FF39YZF@8[;)0A^7.(O(B5(/(:$'EUF+RZIKR*IH*Z-/FH)*\M][>>O].!
MQ<&P6,PA&[O=I:DBB\1@!!U0N."=1:HBJRBK^).6/_O^38TE%HGV.OX/4S0T
M%11_MN.G;G]70$Y<2#@>_G^MXN>./RDAKU--&QP6&>*)PAW2(T\,!!PO:(@.
MQJ,Q&!2.G.5DY04ECZ(#D-BP8+"VW"_=?[7%TE+3$.L9LI-D3 T/?4NMY%F#
M1OZU0C15/-75%!04%"&*GHHH" *IK #14%/P@B 1\FIJZJI(N(J7TJZ]ORK[
M!Y!I0# >'K#S;/ 0F2&+)H.0-2BHJ6F@(/*>"$^(I[*R"@2.0&I E!!*JNIP
M3R5Y.$KUN^J?Q/^AVH3L.Q9W_+\W0W=S<B <%[S[+%%'^'O.$/Z'P([,;A;3
MA'ON9/-#GMB G4=M**2VW"_\?Q<DX\#))RSR1#ODA</Z"\(# S%H3_B.U,[X
M".*QO[!" Y!_IJ,?X_ =ZB=-_W#LMTOM?\3C8'CH?\-;]#^'VE,!KJBDH:X
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M0/9 ]D#V0/9 ]D#V0/9 ]D#V0/9 ]D#V0/9 ]D#V0/9 ]D#V0/9 ]D#V0/9
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M[))KR3R"U68(69UUC0Y^R _3I1XO?AW/WLW))P3-S;WE?LV*MKYMC=NGE5K
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M%C[!U:*,<&3RZ#Z_IQ%O L2PG%(=['2;\*V1=N+WUR 3%65!;!-@16:-$^J
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MT[&A7PF,C:HJ=6_[M>-$ 8_E9 4%Q(DKV>_M9=N^UA^)GG(CJ,+]#+4 8VO
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M/.&- _Q!C$;CMV4=\C+R.AWSNN+X!$[ 2+AVY8^8F\JW:G_;HKL;& T4(;"
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MP*0:VXGE7*$3SH(TTMKOH1;;EXCG^C%)LQ0W6+?,*Z4-QU>_I%PRMU@ 7R'
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M +?O[L2*D#4B(58M2D:V?PDDI&071YXAIZ5Z@-P0#<4NFQ'][H>ZV.I[&_\
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MPX0AA- 4]8V:F!/_ )>J$?;\;Z80BUV<]$2&%RAS6>2Q'EQO+2O%(4Y/)ZZ
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M&T\J$:W-]!-[#GMH!H-,:-G0!_I2'O8#EI'WH8+53,Y\>+^PT'B@:=4 >JF
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MY4C#0S1JQ\*.1U+$<FK&[/\ !V*=E4]Z!U3Q,<W$N.L=)"OD?UM,YG!@_P
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M\B*M&7#?XA&KI;GO&.LVV+!&M_RE]@-T)WM:_KWQX]_S%<OM'<IL.0A5B\3
MPA"9RX*S<\A;E\U/Z^6,:C\Z!QX\?M]XAK\?LWI&BYY?1?#Y0.9C^5D]EH;V
M!(/65!L;$C;>^_=MCTKLF6E ?_>(8\4"NN8J*MK>.6VM_-3>QRYOTXQA$?<W
MU-M=23??7U]WM.^.L6V\JI-3>Y]_:-6&!S85UN*-D[UKI5F,-KCG(6T[_P!-
MM+_=KB0!<BF0U.3"[:/>]H@DFYL/?YAKBGA8I[5QJ2+6-R.[7EH-M<7L'#U
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M5 8#SO:UF'/BTO/E0X^$DV.Y'@._]._AKBJ5E*)QIR(H*97HWW C',J0=&Y
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M E#;Z7'%'XBC[!*$<2EGG9(O:YY:Y< 0J?+ J1,!9BQJ!GSC%B3_  EC-B?
MQR\X9V\#"@66KS>'7Q-JXVNKZAL))4H-J2YOQ(*-!8\1&F/:Y%,').I8C-V!
M(LS YZT>.&GJ:8:.SL:MZ:Y\.,)UO6)[2;6L0%<1)]F@\==?9;$E9<G=<O0E
M) TN]0&I3KG%TI!''G;6F5-2:0S1D20"E()NHV]7^ZUU/J(Y[WP4I1:@H"[
MG2U<^=A%$@.JHJ0+L*#ES:F8M8L[SVJE$:@#3EMW_O\ KQE9#AA?WUZQ8)=K
MARV7/7T,%R1Y**DIMY:TM(14<D!4X2EJWQI"7NZ0$!6NQ(-K'07./AVD0K!3
M27=E"EJITJ79_=\N&?\ 52F=OENS,":FM&:FM:QUD15U-)44KGDM0MM92I"H
MEKB2I*0"#99VN-3;NTQX^1_$6+$/3)J>/".VWF0"*VK7/VV08=\YK.F;FT_E
M0L2-8EGEZWQ]V+1<6'I;I ^65-?G!*?^4L_]HPA!2JPID\5Y]*R2?XL0V=
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ML9$LP[/R9SB27'W$MI!]$U8*[/$1Q*LF_"-; \@".7[3%\-+K><&H[LA9.?
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MHM-IX$G47"2=2;DI!)[1)WY V\-\>.'^:KB3Y/Z1VZ0Z0#:OF8.X1KH#<WU
MQ>+)+@$P+#N'N&$3"5Q *U62G>YT O=*?5C"M+K3_N27S8>-X9'7+W[OW:)'
MP@=:F_*%3=M-NK&3F5]DFYU7\HB=S;<"VFU\>D=DR\E;G^O@&H*VXFL<MM7^
M:EAD?//[6M>L8/'WQJ-+V(MH+=^E@+^  &W?CM5@ D@GZM[GP>K#B;<,M2JY
MYGVU3RAD?B5)OJG<G47Y_;S^SVU4:!LV+^/IGEU:/;0R/OG55];^S<Z6VO\
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M"4)"G%K9-PYPG@3:ZK '%H02B.4X5)"QQ@VL$%:K7T5PI0>)*K62Z@%M1N$
MJ0H80A8AUU1%[:N<!2;%5@+D@@)*;#YR7$!6]B-,(0KPA PA%J<]/])?-K_T
M9U[_ /XK-<9,.'Q,H'_,C_WB,4ZDJ9_L5Y1RR9<^HRB6%1U,OA;Z"VL,Q>UO
M4+_9CV1'^&PUV*4Z/4AM,GX:O'"H+3)[7U_Z12)8EY/ /7KW?OIMI]V/O70H
M+M\I-!J.M?;1@DT$P#-;FXK7.N1BG(AZZE"X*2=-M-3<7T]I/+UC%"H!R!7B
M]FNWH*F,P#T\_;D]YAGB7T$$$V(%K^ Y::[<N\:V.WS++D9L2<@[\A7AP:X
M>3=@7#]Y8!_?2%5#Q!](N6X21PG,>@DZ@7(-826XO;N'?W::'&'&G^YSJU*"
M^C;IO6O72,LA+SD T((]/?LQUG:6N*?D2>7Q)+#;Q$&P![AIX[X\<F/\68]W
M]5:4CN)?\M!Y^#?>*BQ6+1*OYI]GWC"*K^D]/,02OD!>ZVRG3?8 6D"EOSI]
MN*UWN#!_&+&H;*OC>.;KY7%^WE+.F8VDV4G-:4JU\<LZ!%_^;WV]N/5>S1?
MH -"7<-_].6UWTCCMI?XD\C_ /\ 1<8V(ASB!7<C37EKKRUO?33] QN5++D
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M#6[#13Y<15X01$0HE0XN?(#GOZM-[[>&N/LFMNH;_*U#EEG<5#BV<8T(W7H
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M3X-5&Q37D[WDP\MBY@%9TYD77#ORUH)48Z'' KKXQ) MI=3:%G<A)V\WV_\
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M:(E:&D_P RE6;^<QD,J_$M1M?G:V@QYGVC_QRB0Y9)ZDG@*&H&C%[B.OP/\
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MQ))+4(;O.F5'(MKD:.\9?1(&9F620HZYD9?]P'^C*1^&E]1?])Q\N-.[A9K
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M_@3 '!W221FW0L]GRN&CE0P;_P#8:664 ?BZ%XBH!)64H(!"!9*  FU@+
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M?TK%TI87J6)MK]J>IACB7T@*MXGN&O@>X??OC!,6YX58:EQ3AP#6K%D4W^)
MU:[\":MD>58IJ(B"HW.E[FWZ;?O;G?&%4TBC6MFS\0*V_!C, "=Z[9V<_CW8
MDKJ565572R5$ ?*:1*OLO6;08N%C4> -['4$:X^#'E\,MR11P*:>@HUA'T8=
M/SB]:/0#DWC3/FT=G!$EA'4N.K=F7&IYTGJ9M,X= [1_U*%BF6O6HHXM@56
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M"/$\7DM1\ZEJZ:DEV)>U0*4>&QUWYQ-N^P(/Z?5STMCY]\.SY5KU8:URC(@
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M@! (5_4]YMW(OH1:DM>8T\=>[ K:&%#,4GD4^\M(LC#D&@JU02X/'WJ(0O\
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M'?,\XF*H96(A0<*3Q-J2"2V>/OUXFFB!:VJ0;\QH+S"''"$#"$#"$#"$%.J
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M,*S+8^'@VVE1\$]QH>_#WUBY\%T.YY+X>>H8S?JZ,$[@II+79/-)E,X^F8>
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MBX:)?CTAU;J$)9)T-XN&A<YI#4U4PE64]FE&S^:P$/-H9MY<BFDW9EB8*/\
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M%A$?( &[CK:'GL)5X> 4?<0 A@<=I,T3YVJQ/"JQSA'KQ)JY]4'95UB[D5L
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MEP^,'I>9\SW'+0226P,CNU>$I#+T#F2"[0JFF5-#1-:5!A,!INSV^&1FV_C
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M<%L$LPG<W8:9GUE8B%^36<4=A))XP1#VS!I*S% ;&,*#6=N 64A*2%)$5%C
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M-C09!-#B/V_.H.1&=M0->W^9TF7I[N*H-LP'Q),%IS_'U#>:>Z&HZ&E9/QS
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M@NYS4J-MZ*<REP\/C9Y[#@^]K5I#&CG-(*8G$LE43>L?OW;080++HH4(V^'
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M,"T-2]BWAE".0UP55(X<T71A14\L9+>672\:?XV[?Z?M,$$UYC#$I/.F<(<
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M'QGV?P!!0+Z_% \UAN3&IV:\"8.XL1,6[TK@ GOED!(*M&Y@_1C,US/23IJ
M=B)C35M=*5?/7P?W &@!U,AL3KRY^ZT$B$.4$T8BJO$E12ZHZS*BUMX?JY!\
M2-.6]JB.$X\/)6U2:!]X[X=71Z+PO-)!-4X(/[);.V@^DW_;:PB!H>J@PD5'
M1',7O>("LU6\?6(T2R(@") ;$[^/VVE0B47M>*AK5N#4_2")Y?NMQY:[:ZV(
MIA>=Y((7\Z48Y'NS,^!3,V(C$WK>E0 @5"D$D:A* >F_=QKKI/+6Q$R:K[V:
M !J<P .D(U,^#1(V\!\+$1#=Z7B,TND3S3W2@3S!E$^?U=2*=-[7D$F'W03
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M)RG4[;<I.A/M.OPY6(G;!"XDQ!*=-=AO]FFI/3:T1!P1W52"Q!P1[25JC*1
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MVU7( ,C>VWR4R$@J2 D;[\_+V_CI:8;:.*6J0S7MS8*L4+BM(B.7BY1B0N2
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MA9(1D$"(\M??-O4BSUY&#U@'X*!'O!L15*OWO^HU_P#+M##/B?-%6O-4^&5
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M&_C%B("H@I(F01R0A)!GJE //J!X6(E3A(!!$RI)@Z$0"(D1,S.UB)<^?64
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MT';"A$,8R^T,)WR?"N[E'VU?WW9&<[0$M)O@AOFXPP.:Z%.,H(B/HI !C?*
M-=()T/OM]W@E#" 7EM^DE\0C^:+:\\YY(120-.1'N&HMI$&-7E@V7@JH3( M
M2IU.D>4#[+51!5"#"QK [L3X0G7;?32Q9F-BS2=O-#'2>>5(5YSR_'NMO"7A
M&QN$E1G(.)(Z>:#R23K&O3R/7QM3WF7/Z+34&)5GH[I<B1&WM%LU=<?<V(WD
M:#I$Q'XTL1#*24DC?+$^V//K\-[$6"MCY'ZK$0"C"4G_ #$V(@7E"%"/#?J-
MA[#\+$2PP$D=$D ^W\#SL1)W! (F3N=-N?X\+$2Y[4GSCW"/LL1+WOIGP2/K
M ^VQ$OJ%*0<HW4DDB8@ <_9/U;V(MQGH"5%7I(,'Z:#AGB#69U_2#PKD6AOB
M?)F;/'P3OOOHMF'RJ!93BOL?:"%73Q2]ZZG"SD3YJ(VVCG9*IN\6\D7E$I#F
M"QE5HH@:HZ^"Y,<X'N,3*)E320J.9C*KZ2(D2KP4?H^,;V(BP"A0/72?;8B<
M(^@B/#[9^$V;%:#YAOZ%-Z?*I)RG;5<F#',)(!,D Y9&I(M!+ G"M-LWQIO6
MY B#;*/B";G<!\I"ZO(\-W8B_<08<PZJM%VC$%\T%TJO L&I33(O*I12I>#(
M<IENO-%W.IL5")B -0+?P/6#TO:>BM$_*(!,0.3""2&88@;7<@3D OZ?HK1/
MSCI/Y-!""2=4 3=Q?5H@W');Q:#T*:;RI:2NI^U9A)IIZFIW2V]@:\UOM%U&
M?)4%6(D!"TDQ"92H@_1TM\;MO;5#H-H8(S[PB(PF @EF-XUOF V@8X_N[/V<
MZ;I!E8QPPL""1\).9(G>S%KVHFK?H3<LC^5CA &9A.!ZX".FN)=MOQO$'M[@
M)(]P(I4-G%CE:9SX4$]#[,-,#$69PN,P]'&W$YE$_P RJEM.G:KP:5'0J."+
MQS'W8F5T'(#Q&UM#[>+,!SH\#8>[BENUPA]F&F-*RB?!J?\ 3/CFLFO0LPJ?
MY5N#A&O_ 'CWDJ==H.)![];0/;W9 ?V:$[+..N;1]XR5/Z,-,%;(C-G/$@9W
MIBGT,2D$%/:LP6>H.!;Q /A/YT$^Z/LM']/!C(]U80AOF>SB#@@B^,(?9EI0
M9K$YWAVO83I?-Z--3I]#(D)*7.U)@M<R<J<#7H0HC7UE#$Q"3,QMN3!BVD?M
MUMH("8;'6.0(:M=:.=S7=%M9^S/27 -E43+$TJ)@&>:ZY]IWT=K'9QX9WAQ(
M_3=<N.7Z:HI*(7#=>%JFB6\JI=#:5+JWK^=13-@D2M:%@S$3H?Z?H#VNVOK!
MI4.B6D(LS%&(=6(N2(A]TZ[UR\%X/3'J';^BM&BMS9RA!)(  #8R<-7&4G6M
M]*TI90\E2>[R)AJ7!D6K1Q!;621"I,A2PKZ:3!$?9(=&@U+/287>*&&*(28O
M.NPX"4W)7S2+5$9@F\)((#2(+"3[R#0G:3.A2')*) S :I"3,"= !U\^4FWJ
MB(.JWZH!P>=-S+*%VG<2 <1BBHB2-C'OC4?#QM52B6VU""8B9YD\O9:S_"V)
M<][D4]JHC6_H)\K$1*$Y9*Y (D1OSY'\?;K"X#FC5WDTW^3NK$N \I#-V<98
MGA59I25_1YP1/CM^-K4C+G=EMN?%5(9&-@I$$<A]D_4.5OYT53D_4U6)/Q83
M(XDSYRV*9,S!YZD1U'E\-+ "9 <;N]Z13)O8  [QQOXHMM!RZ_NA4>X'S'\;
M:V<)!F*M7>U)@]X@>@SGMF+R[T,\LI;#< #06]2JKV*#($X JT$Z$C7P_C8L
M]<X#GYJ-304LK*B)!&41&O/S'U6;%(C)(!9B6E^*N$EM 2DDP><<_OT\;>"U
M,0.)=\V,FXRQ=S>M22:JZ\SHU)1J(R^$3H9T,?;KI99ZQ+D2V$7&O@\\E!BU
M02SMF1E<5F-@-_'K\;>F#YAOZ%9FT)N$J5?B_P"%U[U:UJ'@BV/P*UL(C%:
M%F8GEFZNH>KT"@D'?4YDSY:^8TMZ(PUGH[C]5L"[2.'T,E-D!#%I$(I\7Q/6
M9 RG.FY=_O1Q(3^EW'0V!P2UMRBO9B!;G7V[PC6T6@^*&3AS)CO&%;L%]^]A
MY+:7*@)I*KA^.2W)'<^*E'_KJ&_LMRV?[1%E:'H#XKI0C]#8YP0^(5K>>V^;
MO +8_)9_NCH%5L5558BJQ%1.A$P0%$<^0T^'QMM"6L+:4I3P-W&8*VL7][92
MH8@9XL>^JT5>D<'^/G#<CZ. WEF#M_RPL@ =#,]9G6W6GL,B_J6V=F(C_P"Y
M&_9/BW*?MJ_ONQ!H3#2LX83T'%=#G#(,[^N9UYJ5^/9[_OD#:L+49NL_)?#X
MR\1.92]1F#X?:;:1%V.7B55#J^D?QRM5$,Z@N!0023 D';U('0#?Q)V,Q,13
MGY\>JQB$R7!F93QW;V2Y6BU)/- !]G2WHAH-G6:@4? ]?P0PW5Y_8+8+=8N(
M+B2D%(D<P?/34:^>EB)$ZVH.*!C>![2?C-B(1U*DJ.8@E4$QX:"Q%"=C/0V(
MESB@$@<@F/'U3[IC7PVL1+79*@1L9^W^%B)<X(4?QU'V6(EI42M<@;_7[?"Q
M$J</K%/('3KM8B!<$N1R($_7]EB)95*/>I5I(;5Y:D)^V;$6X[T XCTCV$-9
MGAOB/X<0N%:0/A/M-J O$0PD\]A1;,_E4+*U8H['\0I2;KXF0/H@A=7A9O4D
MGD![2=8%K1388D/3;?LSE<G87FHNWL\\6C?ES8>5A,,7EB'!+_$VZF:J\+@H
MFZC!3.9+]^JK:N\&:)JB#GT"]4,OB"DL%4*L%]T\M].1,\4[X)7COA1Q%X7M
M8=&/<,5F'*G%E$;SN=3M5=54U>% "TL+S7?>%8NFJ*=BII'ZB@K$4]6FFJ*>
ML#:J2J8=6?=XU\GV(N&(282E0)(@ @_M<I]4@CPD>=I1-VTJ*4#GL!E)$P=R
MDD\^23RL9Y8R5H2T0?N2:4Z%H08!"C!&C@]9)D:E+>DC]Z=( ,@'.U@_11@Z
MUQ)!>A!8EB&+:I\"MS%JAQ,N QHQ(&->1D[+GG#;O'>)7#Q!+S21CC#F0?KR
MDNNWHD$DE"D$'(F$ESFH:R+?FO7'5C]!6ABA#P6,B&>3";D@O609W,E^P]2(
M;(^FK'6B/Q6L+OJLY<%I7 FKG:5[(:4$4E(%J*S\W:$J0@D*0E(4 "@A*?!(
M3S,FW OI2TB.G6Y!>*&TCA:YG(IB'!K?1@R[9T31M&@L+&#W8,,5F"8HF))9
MPS-0'#9)3J4D)T0B>O=(DZ'>41]7G;P"TM 222 V!:Z0PZ+TQ:+H;3LH:X-C
MBP5DN%.N5&HV[ML?[*1MM:\5O:D"&9 +S!.(Z=WJGN-"AI8P8.7#^"R+P.[;
M9\TI/UBU/>VHI+<5!LM"-;&SXE8A:1_S;>XW0CK_ %#%I]]:N&.H\I CJZD:
M/HD9864!:L@2-CAO-4MR4RE*$D9AZJ4H! 2I4D-A$[1K//76RWM+2T@U8HXB
MQ+,2*SV.X$][S60T31H;6%K*&A=P[,V8>1F#+HNBGI#4A/9GQ<\DA"E7C<R2
M A*DJ(KV2)"B3H=1N 8, V^B>RZS!].001$Q QP%R7(<77<G=YK\;[1]$L;#
MT!:VME"!$8(G$M4?#%< #C]X3:Z2\_3:2MHH4CN@EBG[E12E25$H)4%!&50V
M_:S$2?6RP!W-8P".RLK/7CU!!"6!&%[AKL)9R7$%M#JV]K:WF.*5!,S$AK"K
M5^A3"5%2LF1Q65!(2X4[H!)'ZL@"5*A.8JT$^.PP_58!]@\TB(+$5:>USX-5
M&1F"4A*DJS9E J;&HY0I:%1SDI\O"55,,A"0=- )E31CW.V(L00=4YU@S!2F
M08TT(41$SL3'/6Q$P9$(05'*8/JJ"P1OOZAY=.N]B(M(!"I"E*(A,(4H'3E*
M0?(_"+; R#N7&!/AYUP4[A0\PV>%^.\9-I6@@*;=$@04H4 !!WG7XCG.MLX@
M7<WWS\;Y(2Y?'PE/@]^U&00)*2=-<J5$@[[:Z]1U!&AMYH[$&<)+FXMY#LJF
MI"7<D&XAL;Y<Z[9+)L*6H$-.P2?6R*C69Y$_CSM:&""%ISO!(K>A@#FK$ #8
M&8TR1Y!2,I)S9<L!*@8'\/"+27AD "*N03/BSX=O?<7[R[R6,+_R;G^H;:*%
M8F% $+U('JH4K?V ?&Q1%0[#T5QJ2((C?,%((UCFF#[X\8@DL%8D#F/]9,>\
MD"Q6A!)& -=BH*2?VD^6=!^I1M$-E9VL8$6L"] &!E.L)P>LUMN^O7HKZ03F
M3Y9@2?<;;1Z/9P0$@Q.&9R,0&^42FHCG"6>Z537&II@PZT-3 @^WXZ G>.5L
M!  7GWN6+' \%;4RG*Y.P(0K+)\;(_E/C2JVT?[4;#GEX]U4JVG,D9%$ZG0&
M- / F=#IOX<[>FU^ST?; 7X\BKV)?WSWDL*$WRF9= [KOQZ.(SQ<QLJ5 G!3
M8(((VO%L:Z09CKOYBW.7MW;_ &8!S0XS -\L=M;U]\]B+C\K8R)U2]X,0'$5
MYK<HL95+@S]+ST4HZVY:)_31Q2?7?^4%^)&Z>?31@ L(2'^%H1@0" #PB-]5
M5O/:ER"<_! 28("<!TA56R158BJQ%92<P,1(&YGJ/Q]MK&*(6%L!0B$&N)+C
M9>KV<1%K9 "IB(E6@X]X+1=Z1TJ/'O#(2A;A/#YYQQ24@-M-MWPL*S**P2J1
MH !TUWMUE[#P1Z$M8@'<1BK?XI',-?B^"Y7]M('Y[LL7!&^S',$RI=FNA+I
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MPRU&LZA2=#K^Z.G@=/KK'&TL Q)O.(P\S2B@\<\<]^;W[C/G%>20'&T\I2@
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M+N*D> .$"HTB00.=+\N'@&N8/5Z,Z_%->-*GJ35:%"DN2VKP-V>Z"?V>"_"
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M9Q8TJ2S)25_M0-V>.LF*!9=9@DG.=#"_,\FEWO@G2%PI*?'9SV2"UMQP ?J
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M9G)BF=BXGR6AR3/XQ3C(!6._85O9\Q )2C_&V.^SL/+Z/*30W$R!N$WYG[S
MNT5,2M1",>(FMQ(@KD&FJ+O9=BW,2B*H6[F(^INJ5X'$ O2]C*I\1V? 4*_2
M_S3.6>PH<_EL8N2+[$7IEPPIWS,-8=KF^N4$;-R?UVCK@E#=B(/?VX@W [*U
MP+)UMQ1DH(]JX,3KV>UL6*_LCT?+JQI\&<5$I ^AD0W9S$#:"H['NFC5H\KV
M6@'PQ2LA:-DEA[*_P /E7YI?PXWT>P.<X 5E>K>=9 @+:#\&:K,^J)+#&(^]
M"RUS'>T$_-U_G?< 7,U9C#2E5D7!'52;[Q/<[<&W7FMN]0ET'ZVK_C-;(T:N
MP#[V9B&T66;(;TAZ)ITPYCG6=A^/.Y0(CX^1DL$)UY%[:.TX?X$O:)=^BT3D
M+.P1!7.F:LH,"T^H:F^5 %C@LT)LXE,'EWGR0*'M2^XW1?)*^B-/\**W:O[Q
M%\K>* X71%KZL"U>Q9?!PA<'B5_$]=VQQ3GA^B@/W"\+EC< H5#5ZGO6HXG"
M//.\,R<4'KW241]1<O&7(]<#[/-[%B- K^[FNULE;>)\+(V.[PT<901J4;X/
M))JX<-;28744;&L3I3)Q:,NY$D]!#;7WN5!)MG6;BJ&:EU:2-\#%E0[H.MA$
MP31"/K^FE55I/--!V>7V20!R765*KS&M;@Q^&@#P(.?SZP7MT=Y76<3?N$^^
M <QMV'JW^NT&*(3D>#,3!F94@F@.BLJ;ED8./2'+<.O5U5!": ]&+_?NIE3<
MH0:N-M$B@J?Q%\8-RK5026ZY +Y=A78\B"053S?:R(@K4H0^/*"G-X_@A>I2
M6">LU+FWA(F_P!=;M(@E&@;11R[Y$K -;>(4>#U2 XI*M\AD.AYL&5+C55]2
MJ,$"=D@>$S2(27O$YZ:M4'&Z15)+_LC:H'#P  :N69C \ YD44M^QT>%'?$6
MY3=NC85H(VI!#,$C^@R[#B6KM-4Z*KP%N^##3.FHU@J,#P#6.ZZGG]_]I4+9
MJR@%E[0-$ '/M6W9H[;O*D DV.E.0N@2Q?$E.QL;ME)U=,]5:LI:[ZJA[S]N
M)LO?JLQ7>F/59.X8HBUT7:;K#)8XH6^-0500:9?YY\Q&"62EUCT&A*--\E<Z
MA?9WW1/4,M$G4(7,3JJ_=[*2_P":I$IG=WK--;+(R#2 _DSB(']8]4$3Z&[+
M'G\WZ\(M=X*6[54$IOF^?V+',DQ6J$@8 H:J6KWS1FS?6?.1Q@CRU.\'TRE'
M8/8B5*</QAEE%4H\F7DU32_%F'_VW RZ1UO_YW#$=.]]$7,Y^E??KXX.S-I8
M='(R]Y9Z>AD*Y1+N$I(_LDW=!7YYQ#8M*\I[PGL:'4/8K&E(6E2*84 S:'U
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MVWLOO:GP[-\@M8?"S&-&YDJ*RAO1-X"0>6?2"V>FM6]_/R_G)U/\G^:,M2]
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M@UBOT;I"?Z)6W-OM;08YR.":Z30L')W-WR]2_089DP4J[D3M(/90;A0Q.K7
ML7,DJ%)RQY3W2<KR69'>"I$^G-F*4 (8M!*65@Z#!NGV*IR5F+6&0C,%A-X
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M[U'7ZOOM B!H>JEB*@C<I-]M;2H4@<( 3&@_'L^KPL15WGA\?X6(J[SP^/\
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M"92?TH\,4$C_ +_,+-$ @Z(O1I1! ,R,BI(&D'PM^0]<H6] :1%#/]!%.>(
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M#'LTTM561C8.5(*2<VQ@QOOIIKK]AM<0EG9R:72XW_5Z*-8!YT1X*4PD3II
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M]K'EFAMX(ND@^%PWRJ&9+GUJ"LL@@"!RUV$^/29D>VV,?P5GWRHO4UD06U7
M\)5Y)8K-.:>>I)]6! 5'LU'3?32WBM(HS$X!DS4:OB'YWNL""(6A%TS)^N4Q
M/!#.*2 I6BM=<NLZS]FFYMI96I&J(A(U?"I?AYAUA#!%K.TIEY3[?)!O/)4(
M"8Y;:ZSX>6Y%O0;:R8_*)5PY+75+4%\W'G<Q["3.%+>J0023FS3 DD>X[=9/
MAI6&."(L&)V$4I=<W&]2!-XJ<:["][O,WWNAW#ET*AZP_>TU&FI,;P!)D[#7
M2VD+$AZ3?@K V0,Y\?%*WUA*0H@@ &2KE!ZP.L?4-)M:*$  C9U41161A:
M&M23SN9*%J#CI&:$D"3KKMH.ATCV"U%FE-2VA+ZDISE.4DC<R%;^ B/A;&(
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M$J"7#EU!B3J(,:BUX=4%SXGDWCYJL6L9#P\3R;?<B XD02&QH(*U,SKMJ:@
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M!$<6WQ'<9F2*(D$ >H ""/Z%*H'^=WZP?"0#XB+(OBAB ))(( <F9R(#[RK
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MH2834(40)@N(!@1,&1F(F2!)"05?12HC,^CM,UB18Q!S^PTLM:0\U4VFBQ@
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MXLXYO5B],7WE58AO:[</U54U57OAK#[MY,X;":>]'ZQM"+A0@W3W*JAUQY2
MXM*2I!(W_0>BO5WT)Z&L3#H>A#1HS"!"T>L01,F;F9+U&2_.Z?ZQ>F/3%J3I
M6F16Y,8B-I%" XH'  'PAF:^C%R?FSN+;]21%5<P.P4C#6&5H(  "FU*N):E
M-D =THJ.9O*3!TM_9AH-B_EVP(M(A$7,G./PA#JQ;?V52C4W45:DG\V,,0O?
MG^08'M_ME9H=.,;_  4DNW01^T#AK"W38?\ (%B*WYTXGKG54]"BAJ*E86&V
M*+">&ZEXIRA166D8><7E2EI2EK""E !*BFQ$.[C6_ %J=>NML9U)*%X7PPE:
M8&5:E(3="2B5DB%)&LP(&A$O<QE?8*4#\FA2' ZZAG#&%4NK0%H;U6[<9"2I
M:TH F2H%,F-2/WWUW47*[@XD<9+CI*AK##MXTM&Y7NTSOY+PI="J9^]&"PW4
M43[]/<"DU-0PNH9;4VT4*"UA+"60%)'D.CB(3%9&8V5#&7T7]*Q](>D[)C#I
M$ GB"+V9V<-OZ(S]/7')+E2FGQ-?-6Y3)[NJI6;AN1]=&ZET,K:J*=O#IJ:8
M*<.1+=0$O.20V22+81>C[,N[D7@4(O%+QXT7]6#T_P"E0Y.D6<W>8D'F:\1T
MF$#7<?>/%&U6E[$UZ--TE2BF?54X?N1D4U<67ZM-W5ZW,/(#+ZZ6E?J*:ATK
M5L([PH(,VI#Z.T(?-86@9GD<Y;B^8V24CUA](D#_ &L%W^Z#)LS68G@9EBR!
M<[0O'9A;E*]C2]F'@7P45-S8<8"54[ZZ>I:9;3A_(Z:=]M;+J5GO$N(*%00;
M6_(- 8CW=I?1Y;)D'ZU5?S_Z0?\ M$+M74D2+R3,>,IADE3VD>-\!2<=WJ@J
M#SJBJZL,"4)W4D"X)0!E(/[4I4(D6C\W^CWE96C8$$Y5D>\%;\_>DG_M4#"H
MU36>;B@?=L4-1VF..*5-H&/ZQD I"W#=&&U"F=5E+:W4G#WK'UDK UB4G?2T
M?F_0Y>[@BAC=@2"TS,FYVE08.H/I[TBQUM*@(J9->S5:9:4C/-&'CYVF&W4-
M+O?&+7>-.5#(<P5=I2JE90RI52%_FKD0TPFI;;<[S,@&I2EQ)U ]$'H\0D1!
MI8D4+7UGAR:E(O3FFQ0M^461=V$B;G!G*8GLE4KY'>>,^(6(:Q5[5Y8OFKK@
M:I^\G\&8;>?=%%**ZL;"KA=:33TI4VE_N@ZRDK_65(5#2?7##J@"Z_E265Z_
MC:3I.EVT47O8X(K,S8,[GPQSH5Q)6+<2J=;;[VX5H=;]1JFPAA4L)2@BH"DO
M+P^ Z'DJ3F25E1=_5M)("K2:U;+Q\KGJ]%Y%$YB''2ZN^:=^ZZ1%3A_OZJ_J
M='#_  L7;AI:9X-U%97,JP_G88I!/?/+ 2VX4-+4E3@24^'.7GM\BX3>6(KZ
MO.C[BN7=ZJ=QQM]YJBPYA^[75P0ZRCYU=MW4-0WW2"E4*4M)S@9)U+OO?<Z+
M<O\ )\GU.^DHPFHDC-PRQ 5))5FS'BCP?.N@2?5C4$DG?46"][I#E7FANY\#
M3D.*V7_*PE)&+>QJ04IR7+Q4 *H *U56%4D\Y S&=/V5D2$VE%Y$*4@O+@C*
M5N:$#*H@)_9@! 202D@DDQM.D'?N[XHF:5@*TSJ2I86I*LIS*E?K*_9+A"PE
M2LI!;&4 'UK"#-N?/<68B5YP1-&LX+3DKSH.1#K@*G"VK=I*P?HI!]5/T=1M
M)%L]9@1)FDSC?.9F>15@+[@0[SD=WT-V;:E<=>"\X!R.9P3(]78R ?&-NL:V
ML#K#81L?Z&;;)X5,I)Y3ODE$))R.)6%!91G""%=T5C3N%9<JD !8DD+ZV!(F
M ^$\7F]-@PX*86>=)]#@N_/9\[6/#SA1PUP=@K$?"FLQW?-T8X=ORO?J:BA5
MAVIP]5WK4WP:)5V5K3Z&;R0\^6:6\*D.TK#%.TAUHI6LC/4$<3QNU6E)Z/,'
M"YI3>85G,)> B1D"[/CF!=?U7TG"O;LPI<M!>%TIX;5*J>IJJU5V5%*UAFBK
M:"X;TIKZHKWI70W<[:%U%>]>%%4N-5+24TC]%W[*6D+:)L(0"S P_JYMLF+F
M)$I50QF*%H@-:3D7MP&%W0+AG%'M2<+.(G"S%>#+HX85F$\1WWP_N?#%T5-R
MOW%1T%->%VTB**J5?:#<S=YUMWW@X'JE;"ZMNH7651JF7U(:2E,ZD%-6X5+M
MNZ;YE4X<.\>F 7*KS[9>"<6XXN^^+ZX<7V_AR@NFENN[;LHG\,W9B&DK:K".
M)[MOFOHKP=NNH9>J[TOR^;DO6LJ;S+QIZ>YG:>FR5#;2U-6$3A@!DS$TE6>=
MS7J!K&IA$ZL6X!E\1PMQDP]A*YL3TV&KKJE)O'%2;UNN[[Z8H[Z:H;IJ5W<I
MQ=<Z\I"*J\*=Z@J&F5MT82@OAP+!3:PU9O9@4D_?>]QUKB#<*TGR;9?L7VJ^
M.V377MQ[P1Q<I<-O4MT8(PSB^Z</X31\V=-#>F)L#5>$:VNJWZ@&E?5^5KYH
M<1.M5(<;?8H#=U.V%OK"HCB@@9H6!PF_2CRQP3XFE%JXL\[]U*9UO7/+F[8'
M!BFQ/B&]:G@76-X09P==^"^$V'*"\+I4, 7)<6(<95ERM/NWA1/,WE07?A_%
M+-#4U52^IROQ!=53>E8[\[26C$,<!D8-9V:YNMW08,K 6@K'*1-1,NYFQJ)W
MG"B97UVQ>$EXWG@6MN;A%>]-=^'L=G$M[X>J[PN6INBLH4T-12!^BH:BZ&F_
MGCM4_P!]4N5RG[O^=-E5(A:2+:@0$?JE[C6]R>.6*DQ%Q/69FRI(2E2[Q*ZT
M<>.*.'^*&(<+5^&KLJ;OH,/8'N##58NM:I::KKKQNUIU%;5*9I&VF"$5*UTR
M%-L4Z%ML)+;*6RF9.H TS%C=3;B;KJS41$DW,PD'KG=3>*+X@"3(,R#!D@ZP
M#N-#H1;(/-\2VQ"(0VK*4Y7]L592@F)(WC<#>TJ$TN]814T3Q6V U64+LNJ>
M0@J8O"F="N]80HM+84AM]-0LI2UJ5YDB+$6P:X^V=A6FO7C=BBOX7/OXGXD8
MFI+RPE6%VY7$X6;;NF[+E98O9%X4]X-5:[G5=]97W.J[U=PAR\*YZ\J=L]V0
M1#X([8.':*C-UXPX?TV)*)EB[7J!1H[EIG:1ZDN^G9JZM#CUT*^<U-55%ZLI
MFEYJ5SOU0TN ;%$W+LUW?UQE,-QZC[4.%_TSW+Q <P1>GYI7'P[O["=)AN[7
M+GNR\&KWK'!6HO1=134/S5RGJZFA<%:S54;BRW5=VUD&EBE<@XI]J#AIQ'XY
MX-XIO<.KUH<,730+:OR[$7U1F_G[WJKXO/$3 NZ^:2G:-W4J'ZQBD%*U0K#E
M(QW%YD %((N05':VX77E>%S.5O#S&%+1TSF+ZW$%!08JIQ2U=??]#6T5RMTS
MKM(OYI=S;-6FJO>A 6U4UJ0XT4)@6+/4))=FN:70=>8K\_P%QSX585P[PZH:
M[ .*+RQ%<-_W4YB>\6;\NUEBMNJZ<,8WPY=9N*CJ6'TW1>[:L979?5)6WP%T
M1O*Z&ZYQA33<$IAA(J1N[OOEA.2YGC#M:8$Q3@Q>%[IX=5-VM7E18?:J*^M1
MAI-=5-7/=%71+?<J*:YGJGYS>]=5TU\5;SJZ9\5M*[F4M ;2DK&_-<PNGMB\
M(J$5C*.##[S->[75C=0P<,OU@JG[HI*-BO?JJVZ XS5=]2NTX8[EN@-(^<@6
M^9L[[[\53W8=W.SO?V NNV%N.EW84HKJIZ*Y_P K.MB\_GZ*AFA9(IOG7%N\
MVUW:M04W3WB]08YN]ZH>R(3\WN>OIUY_G#5G??%3[L.[F3=0_%A]77T:Y^UL
MW2\2+\Q+?&%57]A-_ %!P_NS"?>4:4TU&U=.&;NO.J?K%H!O)V]KPN$WI4%1
M6@*=;32-L]VO.5US?"?:_P"&Z55U\8RX3U-\XFK<64]4W?5*_<JF::Z6KOIV
M%4:*&JI7%/E=2RTLE9(;0E32%91%B)K=/;#X6W+>M%7W?PGO5-WNMBCKKEO*
M\\*OW==K/Y3HJVE>N)FJNYMOOG7J%VLJVZY%<\N\Z@BG6AI00DBZE<9^(5W\
M1\775>]R78Y=U'=&!<+X8<:J6$LK<O/#C"J*\:JI82 :=AQ53W5$1J\N%#(V
MH-@B^3EW+)"HF 4EP )YQJ9$\@=8TL1#K=:!U6KQ 4"/=)]X(/CK:0TW>DFQ
M4%Y,U9OA/Q979JVFW&W"E*PVI*UI4I 2XA*@5(450 "-CJ08(@B;0@=IUO6Q
M&^NVMPSOG$5WWTYPJK.XNG"F'\.%VHJ;EO2LJJJZ6Z5^H216TZD?,BXP54RF
M&VGVRJ"XO46J!,ZPUA<'((;//,X.HB!(D6Y)<CMC\/:^Z[KI+PX95E+\VQQ=
MF.ZCYK5W"W17C443U_H>IJN@7=JFU(:IKVHJD IIZ0.W:PBH"T+<*IU;.?P<
MR:3'/9*F<"$NY+R;&_9AC-ZR7 ;V[3.!%8^X6X]N#A[6W)38$I\9T][W8_47
M13T5^JO_ !!?=XW9>C-#142D=[279>5-0W@:I3]&\_3-_,V@TE648;,U@W/L
MOK==7:Y-AKBA!VC:,+P9SKN0&+>T;PHX@\/[YP[?_#.]J?%-6I-==E_71>5U
MW:';SIZ-REHQ>K%+=U,:BB8S%VE9IE,A<K[X*( LU+,@/ [7OY@I\4IC.6=1
MF9/L9V7$;@[1[5P7C=MZ790WI6HNZINJ\*-E=46+JI[V;X/WE@15*F[*9X%V
MBH;\Q!27JY4-MME=3=+BU)+K*(C4@:< PJ95I/9PQ0:TWO?8TF%'W\5RS@[V
MMF,$NXEO''.$T\0L0XDQNUQ)NB^%OT-$NYL6,W>S=AOZ[:%IA*&JE5UN7BS6
M,A"J9+=4TXXP@MH66K#<"!@YP:Z5);)(\63TW<#N)=L,/J">V%P1H*NFKV>"
M->JF?9NVIO2EJ:[#]4S6WU3+K:BNO1BI;HU5-.S4)<0W=C+)<345*"I\Y6PW
M8T0^6(@85NS5_A(8P F<W+SPP0U;VU.&]Y-5O></K^HG475BV[J+YTNX[RJ;
MWH:WAS4X2NN[[[>9H[OJ5T;=\N(K:E=*ZW3D=X\:%]2 %S#%$"1%##&/UC*(
M@W%@["Z=TU35 AUH8C!&[Z@'PAC<1*8\=^L-EE3-*PRX[WJV6&6E.@HAQ3;:
M4E8"2$A*R"I*4A(2"$P(@6B()^$:HDP%TI\T&LWQQ:T5YQPX!@L"3I*CKRG?
MP_A:%*JQ%RK N+G<$8E5B"G8%15BX\27+1I6XI+;-7?=Q55V-52TMK0I2*)=
M<Q5]T3#JVW)VDD7;Q[M<8#I[@X?791<+&6ZW#]-AU[$M>Z+BJ_RT_=1O!=2U
M1MJNUY5-=MXO5%)4]Q4.OU#3R'FE.%!38B?U_;8X;WO>5_7W6\&:+YY7T6%*
M9WYO3X:4IYJX<74=[BZ5TSMSBG;%ZW4IN[KL=HT,5?SGOW*NI4E+61WVZ+C_
M  %[:V&>&F \18:XB8$OC'&*,0<1JO&-X7]=EY4%RMO4[]=<*KR107<*1WN7
M?GMP=ZS77>LT+R:UY+:VTE8<I (H:MC)G?(4P<4#R*6D$)/PQ18%PQ;=PN.
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M&+0SX\2.A18I] OZ+U*LY[/U[N*S!0[[C1QS6)!*O63^DE(()4Z3&4_K#!D
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MF83M7$FZIJECIAR7J:*\QM"G[R5)?9\3%FB6X2%UJ-3#L, HW8'=]7'Q1DN
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M0! F$@S*KB)9/C;"4'Q*_I*"27%9G/1)$PY)F9F()S&#)3=:$A-4Z@X?I$G
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MV44P 4"YC8JB0N@W.FDS[*8,&\DRXJOJZQ@ZB$/ #0#@>+>?8T,Z.647AT%
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M'^$=-7!;DO42Y+1:RJ1(S@FSRPJ=P.2<F#BNUSFUC@X"70"W5RP.!W1L&#"
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M5_[IQ:=^<#KZUO\ 4$L! A0#%     @ &$ U5Z+ERZ$T%   V-H  !$
M         ( !     &)N=&,M,C R,S V,S N>'-D4$L! A0#%     @ &$ U
M5[XFV%ES#0  F+H  !4              ( !8Q0  &)N=&,M,C R,S V,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( !A -5<4Q=>IW#$   CS @ 5
M  "  0DB  !B;G1C+3(P,C,P-C,P7V1E9BYX;6Q02P$"% ,4    "  80#57
M_D3?,_EH  "\! 8 %0              @ $85   8FYT8RTR,#(S,#8S,%]L
M86(N>&UL4$L! A0#%     @ &$ U5\1PS19A3P  G@$% !4
M ( !1+T  &)N=&,M,C R,S V,S!?<')E+GAM;%!+ 0(4 Q0    ( !A -5=<
MO9C.$-4" #/5%P /              "  =@, 0!D-30Y-S(X9#$P:RYH=&U0
M2P$"% ,4    "  80#579T\X'M$"   D$0  $               @ $5X@,
M9#4T.3<R.&1E>#(Q+FAT;5!+ 0(4 Q0    ( !A -5?)&%CF- ,  /4(   1
M              "  13E P!D-30Y-S(X9&5X,C,Q+FAT;5!+ 0(4 Q0    (
M !A -5<U47G9$ @  &4K   1              "  7?H P!D-30Y-S(X9&5X
M,S$Q+FAT;5!+ 0(4 Q0    ( !A -5>50-'3^@<  # K   1
M  "  ;;P P!D-30Y-S(X9&5X,S$R+FAT;5!+ 0(4 Q0    ( !A -5=M%2>
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M8C S+FIP9U!+ 0(4 Q0    ( !A -5?9.51>1\P! )(W @ 1
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M9S S+FIP9U!+ 0(4 Q0    ( !A -5?)P][QHH8   [:   1
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M<# T+FIP9U!+ 0(4 Q0    ( !A -5?*TCR?%/0  -I. 0 1
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=<#(T+FIP9U!+!08     '0 = # '  ":3A0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
